LATUDA helps your patients with bipolar depression experience more of life’s everyday moments

INDICATIONS AND USAGE
LATUDA is indicated for treatment of major depressive episodes associated with bipolar I disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. The efficacy of LATUDA was established in a 6-week monotherapy study and a 6-week adjunctive therapy study with lithium or valproate in adult patients with bipolar depression. The effectiveness of LATUDA for longer-term use, that is, for more than 6 weeks, has not been established in controlled studies. Therefore, the physician who elects to use LATUDA for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. The efficacy of LATUDA in the treatment of mania associated with bipolar disorder has not been established.

IMPORTANT SAFETY INFORMATION FOR LATUDA
Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older. In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber. LATUDA is not approved for use in patients under the age of 18 years.

Please see additional Important Safety Information, including Boxed Warning, and Brief Summary of Prescribing Information on adjacent pages.
Contraindications
LATUDA is contraindicated in the following:
• Known hypersensitivity to lurasidone HCl or any components in the formulation. Angioedema has been observed with lurasidone.
• Strong CYP3A4 inhibitors (e.g., ketoconazole)
• Strong CYP3A4 inducers (e.g., rifampin)

Warnings and Precautions
Cerebrovascular Adverse Reactions, Including Stroke: In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks) including fatalities compared to placebo-treated subjects. LATUDA is not approved for the treatment of patients with dementia-related psychosis.

Neuroleptic Malignant Syndrome (NMS): NMS, a potentially fatal symptom complex, has been reported with administration of antipsychotic drugs, including LATUDA. NMS can cause hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. Management should include immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, intensive symptomatic treatment and medical monitoring, and treatment of any concomitant serious medical problems.

Bipolar depression is different than other types of depression. LATUDA treats bipolar depression so patients can take part in life’s everyday moments.

• Efficacy established in both a monotherapy study and an adjunctive therapy study with lithium or valproate
  – In these studies LATUDA was superior to placebo in reduction of Montgomery-Åsberg Depression Rating Scale (MADRS) scores at Week 6
• Safety and tolerability evaluated in multiple bipolar depression studies for 6 weeks and 24 weeks
• Once-daily dosing, taken with food (at least 350 calories)

Learn more at www.LATUDAhcp.com
**Tardive Dyskinesia (TD):** TD is a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements that can develop in patients with antipsychotic drugs. There is no known treatment for established cases of TD, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. The risk of developing TD and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses. Given these considerations, LATUDA should be prescribed in a manner that is most likely to minimize the occurrence of TD. If signs and symptoms appear in a patient on LATUDA, drug discontinuation should be considered.

**Metabolic Changes**

Hyperglycemia and Diabetes Mellitus: Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.

Dyslipidemia: Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.

Weight Gain: Weight gain has been observed with atypical antipsychotic use. Clinical monitoring of weight is recommended.

Hyperprolactinemia: As with other drugs that antagonize dopamine D₂ receptors, LATUDA elevates prolactin levels. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds.

In the short-term, placebo-controlled monotherapy study, the median change from baseline to endpoint in prolactin levels for LATUDA-treated females was 3.1 ng/mL and was 1.5 ng/mL for males. The proportion of female patients with prolactin elevations ≥5x ULN was 0.6% for LATUDA-treated patients versus 0% for placebo-treated female patients. The proportion of male patients with prolactin elevations ≥5x ULN was 0% for LATUDA-treated patients versus 0% for placebo-treated male patients.

In the short-term, placebo-controlled adjunctive therapy with lithium or valproate study, the median change from baseline to endpoint in prolactin levels for LATUDA-treated females was 3.2 ng/mL and was 2.4 ng/mL for males. The proportion of female patients with prolactin elevations ≥5x ULN was 0% for LATUDA-treated patients versus 0% for placebo-treated female patients. The proportion of male patients with prolactin elevations ≥5x ULN was 0% for LATUDA-treated patients versus 0% for placebo-treated male patients.

Leukopenia, Neutropenia, and Agranulocytosis: Leukopenia/neutropenia has been reported during treatment with antipsychotic agents. Agranulocytosis (including fatal cases) has been reported with other agents in the class. Patients with a preexisting low white blood cell count (WBC) or a history of drug-induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy, and LATUDA should be discontinued at the first sign of a decline in WBC in the absence of other causative factors.

**Orthostatic Hypotension and Syncope:** LATUDA may cause orthostatic hypotension. Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension, in patients with known cardiovascular disease or history of cerebrovascular disease and in patients who are antipsychotic-naïve.

**Seizures:** LATUDA should be used cautiously in patients with a history of seizures or with conditions that lower seizure threshold (e.g., Alzheimer's dementia).

**Potential for Cognitive and Motor Impairment:** Patients should be cautioned about operating hazardous machinery, including motor vehicles, until they are reasonably certain that therapy with LATUDA does not affect them adversely.

**Body Temperature Regulation:** Disruption of the body’s ability to reduce core body temperature has been attributed to antipsychotic agents. Appropriate care is advised when prescribing LATUDA for patients who will be experiencing conditions that may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration.

**Suicide:** The possibility of suicide attempt is inherent in psychotic illness and close supervision of high-risk patients should accompany drug therapy. Prescriptions for LATUDA should be written for the smallest quantity of tablets consistent with good patient management in order to reduce the risk of overdose.

**Dysphagia:** Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer’s dementia. LATUDA and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia.

**ADVERSE REACTIONS**

Commonly observed adverse reactions (≥5% incidence and at least twice the rate of placebo) for LATUDA were akathisia, extrapyramidal symptoms, and somnolence.

**INDICATIONS**

LATUDA is indicated for the treatment of major depressive episodes associated with bipolar I disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate in adults.

Please see Brief Summary of Prescribing Information, including Boxed Warning, on adjacent pages.


©2016 Sunovion Pharmaceuticals Inc. All rights reserved. 4/16 LAT244-16
**WARNINGS**

**INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS, AND SUICIDAL THOUGHTS AND BEHAVIORS**

- Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death [see WARNINGS and Precautions (5.1)].
- LATUDA is not approved for use in patients with dementia-related psychosis [see WARNINGS and Precautions (5.5)].
- Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients aged 24; there was a reduction in risk with antidepressant use in patients aged 65 and older [see WARNINGS and Precautions (5.2)].
- In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber [see WARNINGS and Precautions (5.2)].

**1 INDICATIONS AND USAGE**

**1.1 Schizophrenia**

LATUDA is indicated for the treatment of schizophrenia. The efficacy of LATUDA in schizophrenia was established in five 6-week controlled studies of adult patients with schizophrenia [see Clinical Studies (14.1)].

The effectiveness of LATUDA for longer-term use, that is, for more than 6 weeks, has not been established. Therefore, the physician who elects to use LATUDA for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient [see Dosage and Administration (2)].

**1.2 Depressive Episodes Associated with Bipolar I Disorder**

**Monotherapy:** LATUDA is indicated as monotherapy for the treatment of patients with major depressive episodes associated with bipolar I disorder (bipolar depression). The efficacy of LATUDA was established in a 6-week monotherapy study in adult patients with bipolar depression [see Clinical Studies (14.2)].

**Adjunctive Therapy with Lithium or Valproate:** LATUDA is indicated as adjunctive therapy with either lithium or valproate for the treatment of patients with major depressive episodes associated with bipolar I disorder (bipolar depression). The efficacy of LATUDA as adjunctive therapy was established in a 6-week study in adult patients with bipolar depression who were treated with lithium or valproate [see Clinical Studies (14.2)].

The effectiveness of LATUDA for longer-term use, that is, for more than 6 weeks, has not been established in controlled studies. Therefore, the physician who elects to use LATUDA for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient [see Dosage and Administration (2.2)].

The efficacy of LATUDA in the treatment of mania associated with bipolar disorder has not been established.

**4 CONTRAINDICATIONS**

- Known hypersensitivity to lurasidone HCl or any components in the formulation. Angioedema has been observed with lurasidone [see Adverse Reactions (6.1)].
- Strong CYP2D6 inhibitors (e.g., ketokonazole, clarithromycin, ritonavir, voriconazole, mifepradil, etc.) [see Drug Interactions (7.3)].
- Strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. John’s wort, phenytoin, carbamazepine, etc.) [see Drug Interactions (7.3)].

**5 WARNINGS AND PRECAUTIONS**

**5.1 Increased Mortality in Elderly Patients with Dementia-Related Psychosis**

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (median duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be cardiovascular (e.g., heart failure, sudden death or infections (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to other characteristics of the patients is not clear. LATUDA is not approved for the treatment of patients with dementia-related psychosis [see Boxed Warning].

**5.2 Suicidal Thoughts and Behaviors in Adolescents and Young Adults**

Patients with major depressive disorder (MDD), both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until clinically significant improvement has occurred. Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide. There has been a long-standing concern, however, that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment. Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (SSRIs and others) showed that these trials increased the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18-24) with major depressive disorder (MDD) and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older.

The pooled analyses of placebo-controlled trials in children and adolescents with MDD, obsessive compulsive disorder (OCD), or other psychiatric disorders included a total of 24 short-term trials of 9 antidepressant drugs in over 4400 patients. The pooled analyses of placebo-controlled trials in adults with MDD or other psychiatric disorders included a total of 295 short-term trials (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients. There was considerable variation in suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk of differences (drug vs. placebo), however, were relatively stable within age strata and across indications. These risk differences (drug-placebo difference in the number of cases of suicidality per 1000 patients treated) are provided in Table 1.

<table>
<thead>
<tr>
<th>Age Range</th>
<th>Drug-Placebo Difference in Number of Cases of Suicidality per 1000 Patients Treated</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;18</td>
<td>Increases Compared to Placebo:</td>
</tr>
<tr>
<td>18-24</td>
<td>14 additional cases</td>
</tr>
<tr>
<td>25-64</td>
<td>5 additional cases</td>
</tr>
<tr>
<td>&gt;65</td>
<td>Decreases Compared to Placebo:</td>
</tr>
<tr>
<td></td>
<td>1 fewer case</td>
</tr>
<tr>
<td></td>
<td>6 fewer cases</td>
</tr>
</tbody>
</table>

No suicides occurred in any of the pediatric trials. There were suicides in the adult trials, but the number was not sufficient to reach any conclusion about drug effect on suicide.

It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with depression that the use of antidepressants can delay the recurrence of depression. All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.

The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of depression and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality.

Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient’s presenting symptoms.

Families and caregivers of patients being treated with antidepressants for major depressive disorder or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of agitation, irritability, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidal thoughts and behaviors, and to report such symptoms immediately to health care providers. Such monitoring should include daily observation by families and caregivers. Prescriptions for LATUDA should be written for the smallest quantity of capsules consistent with good patient management, in order to reduce the risk of overdose.

**5.3 Cerebrovascular Adverse Reactions, Including Stroke in Elderly Patients with Dementia-Related Psychosis**

In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks), including fatalities compared to placebo-treated subjects. LATUDA is not approved for the treatment of patients with dementia-related psychosis [see also Boxed Warning and Warnings and Precautions (5.1)].

**5.4 Neuropsychiatric Malignant Syndrome**

A potentially fatal symptom complex sometimes referred to as Neuropsychiatric Malignant Syndrome (NMS) has been reported in association with administration of antipsychotic drugs, including LATUDA.

Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.

The diagnostic evaluation of patients with this syndrome is complicated. It is important to exclude cases where the clinical presentation includes both serious medical illness (e.g., pneumonia, systemic infection) and untreated or inadequately treated extrapyramidal symptoms and acute EPS. Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology.

The management of NMS should include: 1) immediate discontinuation of antipsychotic drugs; 2) careful rehydration; 3) administration of antipsychotic drugs with lower propensity to cause NMS; and 4) management of extrapyramidal symptoms and medical monitoring; and 3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for NMS.

If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. If reintroduced, the patient should be carefully monitored, since recurrences of NMS have been reported.

**5.5 Tardive Dyskinesia**

Tardive dyskinesia is a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements that can develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which
patients are likely to develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown.

The risk of developing tardive dyskinesia and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses.

There is no known treatment for established cases of tardive dyskinesia, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment, itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and thereby may possibly mask the underlying process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown.

Given these considerations, LATUDA should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that (1) is known to respond to antipsychotic drugs, and (2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically.

If signs and symptoms of tardive dyskinesia appear in a patient on LATUDA, drug discontinuation should be considered. However, some patients may require treatment with LATUDA despite the presence of the syndrome.

### 5.6 Metabolic Changes

Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemia, and body weight gain. While all of the drugs in the class have been shown to produce some metabolic changes, each drug has its own specific risk profile.

#### Hyperglycemia and Diabetes Mellitus

Hyperglycemia, in some cases extreme and associated with ketoadiposis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and hyperglycemia-related adverse events is not completely understood. However, epidemiological studies suggest an increased risk of treatment-emergent hyperglycemia-related adverse events in patients treated with the atypical antipsychotics. Because LATUDA was not marketed at the time these studies were performed, it is not known if LATUDA is associated with this increased risk.

Patients with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.

### Schizophrenia

Pooled data from short-term, placebo-controlled schizophrenia studies are presented in Table 2.

#### Table 2: Change in Fasting Glucose in Schizophrenia Studies

<table>
<thead>
<tr>
<th>LATUDA</th>
<th>Placebo</th>
<th>20 mg/day</th>
<th>40 mg/day</th>
<th>80 mg/day</th>
<th>120 mg/day</th>
<th>160 mg/day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean Change from Baseline (mg/dL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum Glucose</td>
<td></td>
<td>-0.0</td>
<td>0.8</td>
<td>2.6</td>
<td>-0.4</td>
<td>2.5</td>
</tr>
<tr>
<td>Proportion of Patients with Shifts to ≥ 126 mg/dL</td>
<td></td>
<td>(43/528)</td>
<td>(71/839)</td>
<td>(12/32)</td>
<td>(32/472)</td>
<td>(10/80)</td>
</tr>
</tbody>
</table>

In the uncontrolled, longer-term schizophrenia studies (primarily open-label extension studies), LATUDA was associated with a mean change in glucose of +1.6 mg/dL at week 24 (n=355), +0.9 mg/dL at week 36 (n=299) and +2.3 mg/dL at week 52 (n=307).

#### Bipolar Depression

Data from the short-term, flexible-dose, placebo-controlled monotherapy bipolar depression study are presented in Table 3.

#### Table 3: Change in Fasting Glucose in the Monotherapy Bipolar Depression Study

<table>
<thead>
<tr>
<th>LATUDA</th>
<th>Placebo</th>
<th>20 to 60 mg/day</th>
<th>80 to 120 mg/day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean Change from Baseline (mg/dL)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum Glucose</td>
<td>+1.6</td>
<td>-0.8</td>
<td>+1.8</td>
</tr>
<tr>
<td>Proportion of Patients with Shifts to ≥ 126 mg/dL</td>
<td></td>
<td>(43/511)</td>
<td>(21/339)</td>
</tr>
</tbody>
</table>

Patients were randomized to flexibly dosed LATUDA 20 to 60 mg/day, LATUDA 80 to 120 mg/day, or placebo.

In the uncontrolled, open-label, longer-term bipolar depression study, patients who received LATUDA as monotherapy in the short-term study and continued in the longer-term study, had a mean change in glucose of +1.2 mg/dL at week 24 (n=129).

#### Adjunctive Therapy with Lithium or Valproate

Data from the short-term, flexible-dose, placebo-controlled adjunctive therapy bipolar depression studies are presented in Table 4.

#### Table 4: Change in Fasting Glucose in the Adjunctive Therapy Bipolar Depression Studies

<table>
<thead>
<tr>
<th>LATUDA</th>
<th>Placebo</th>
<th>20 to 120 mg/day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean Change from Baseline (mg/dL)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum Glucose (≥ 126 mg/dL)</td>
<td>-0.9</td>
<td>+1.2</td>
</tr>
</tbody>
</table>

Proportion of Patients with Shifts to ≥ 126 mg/dL |         | (3/290)         | (4/318)         |

Patients were randomized to flexibly dosed LATUDA 20 to 120 mg/day or placebo as adjunctive therapy with lithium or valproate.

In the uncontrolled, open-label, longer-term bipolar depression study, patients who received LATUDA as adjunctive therapy with either lithium or valproate in the short-term study and continued in the longer-term study, had a mean change in glucose of +1.7 mg/dL at week 24 (n=88).

#### Dyslipidemia

Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.

#### Table 5: Change in Fasting Glucose in Schizophrenia Studies

<table>
<thead>
<tr>
<th>LATUDA</th>
<th>Placebo</th>
<th>20 mg/day</th>
<th>40 mg/day</th>
<th>80 mg/day</th>
<th>120 mg/day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean Change from Baseline (mg/dL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Triglycerides</td>
<td>+0.6</td>
<td>+0.6</td>
<td>+0.8</td>
<td>+0.4</td>
<td></td>
</tr>
</tbody>
</table>

Proportion of Patients with Shifts to ≥ 200 mg/dL |         | (4/138)   | (5/118)   | (8/58)    |            |

### Table 6: Change in Fasting Lipids in the Monotherapy Bipolar Depression Study

<table>
<thead>
<tr>
<th>LATUDA</th>
<th>Placebo</th>
<th>20 mg/day</th>
<th>60 mg/day</th>
<th>80 mg/day</th>
<th>100 mg/day</th>
<th>120 mg/day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean Change from Baseline (mg/dL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum Glucose (≥ 240 mg/dL)</td>
<td>-5.1</td>
<td>-8.2</td>
<td>-3.7</td>
<td>-3.0</td>
<td>-6.4</td>
<td></td>
</tr>
</tbody>
</table>

Proportion of Patients with Shifts to ≥ 240 mg/dL |         | (6/126)   | (7/114)   | (12/119)  | (12/122)  |

In the uncontrolled, longer-term bipolar depression studies (primarily open-label extension studies), LATUDA was associated with a mean change in total cholesterol and triglycerides of -3.8 (n=556) and -15.1 (n=357) mg/dL at week 24, -3.1 (n=503) and -4.8 (n=303) mg/dL at week 36 and -2.6 (n=307) and -6.9 (n=307) mg/dL at week 52, respectively.

### Table 7: Change in Fasting Lipids in the Adjunctive Therapy Bipolar Depression Studies

<table>
<thead>
<tr>
<th>LATUDA</th>
<th>Placebo</th>
<th>20 mg/day</th>
<th>80 mg/day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean Change from Baseline (mg/dL)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Cholesterol (≥ 200 mg/dL)</td>
<td>+1.3</td>
<td>-1.4</td>
<td></td>
</tr>
</tbody>
</table>

Proportion of Patients with Shifts to ≥ 200 mg/dL |         | (4/138)   | (5/118)   |

Patients were randomized to flexibly dosed LATUDA 20 to 120 mg/day, LATUDA 80 to 120 mg/day, or placebo as adjunctive therapy with lithium or valproate.

In the uncontrolled, open-label, longer-term bipolar depression study, patients who received LATUDA as adjunctive therapy with either lithium or valproate in the short-term study and continued in the longer-term study, had a mean change in glucose of +1.7 mg/dL at week 24 (n=88).
In the uncontrolled, open-label, longer-term bipolar depression study, patients who received LATUDA, as adjunctive therapy with either lithium or valproate in the short-term study and continued in the longer-term study had a mean change in weight of -0.02 kg at week 24 (n=88) and 5.3 (n=88) mg/dL at week 24, respectively.

Weight Gain
Weight gain has been observed with atypical antipsychotic use. Clinical monitoring of weight is recommended.

Schizophrenia
Pooled data from short-term, placebo-controlled schizophrenia studies are presented in Table 8. The mean weight gain was +0.43 kg for LATUDA-treated patients compared to -0.02 kg for placebo-treated patients. Changes in weight from baseline for olanzapine was +4.5 kg and for quetiapine extended-release was +2.09 kg in Studies 3 and 5 (see Clinical Studies (14.7)), respectively. The proportion of patients with a ≥ 7% increase in body weight (at Endpoint) was 4.6% for LATUDA-treated patients versus 3.3% for placebo-treated patients.

Table 8: Mean Change in Weight (kg) from Baseline in Schizophrenia Studies

<table>
<thead>
<tr>
<th>Placebo</th>
<th>LATUDA</th>
</tr>
</thead>
<tbody>
<tr>
<td>(n=321)</td>
<td>(n=321)</td>
</tr>
<tr>
<td>20 mg/day</td>
<td>20-to-120 mg/day</td>
</tr>
<tr>
<td>(n=147)</td>
<td>(n=284)</td>
</tr>
<tr>
<td>-0.02</td>
<td>+0.33</td>
</tr>
<tr>
<td>+0.16</td>
<td>+2.09</td>
</tr>
<tr>
<td>+0.22</td>
<td>+0.54</td>
</tr>
<tr>
<td>+0.56</td>
<td>+0.68</td>
</tr>
<tr>
<td>+0.02</td>
<td>+0.60</td>
</tr>
</tbody>
</table>

In the uncontrolled, longer-term schizophrenia studies (primarily open-label extension studies), LATUDA was associated with a mean change in weight of -0.09 kg at week 24 (n=755), +0.59 kg at week 36 (n=443) and -0.73 kg at week 52 (n=577).

Bipolar Depression
Monotherapy
In the uncontrolled, open-label, longer-term bipolar depression study, patients who received LATUDA as monotherapy in the short-term and continued in the longer-term study had a mean change in weight of -0.02 kg at week 24 (n=130).

Table 9: Mean Change in Weight (kg) from Baseline in the Monotherapy Bipolar Depression Study

<table>
<thead>
<tr>
<th>Placebo</th>
<th>LATUDA</th>
</tr>
</thead>
<tbody>
<tr>
<td>(n=151)</td>
<td>(n=291)</td>
</tr>
<tr>
<td>20 mg/day</td>
<td>20-to-120 mg/day</td>
</tr>
<tr>
<td>(n=82)</td>
<td>(n=194)</td>
</tr>
<tr>
<td>-0.04</td>
<td>+0.56</td>
</tr>
<tr>
<td>+0.11</td>
<td>+0.02</td>
</tr>
</tbody>
</table>

In the uncontrolled, open-label, longer-term bipolar depression study, patients who were treated with LATUDA as monotherapy with either lithium or valproate in the short-term and continued in the longer-term study, had a mean change in weight of +1.28 kg at week 24 (n=86).

5.7 Hyperprolactinemia

As with other drugs that antagonize dopamine D2 receptors, LATUDA elevates prolactin levels.

Hyperprolactinemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported with prolactin-elevating compounds. Long-standing hyperprolactinemia, when associated with hypogonadism, may lead to decreased bone density in both female and male patients [see Adverse Reactions (6)].

Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin-dependent in vitro, a factor of potential importance if the prescription of these drugs is considered in a patient with previously detected breast cancer. As is common with compounds which increase prolactin release, an increase in mammary gland neoplasia was observed in a LATUDA carcinogenicity study conducted in rats and mice [see Monoclonal Toxicology (13)]. Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans, but the available evidence is too limited to be conclusive.

Schizophrenia
In short-term, placebo-controlled schizophrenia studies, the median change from baseline to endpoint in prolactin levels for LATUDA-treated patients was +0.4 ng/mL and was -1.9 ng/mL in the placebo-treated patients. The median change from baseline to endpoint for males was +0.5 ng/mL, and for females was -0.2 ng/mL. Median changes for prolactin by dose are shown in Table 11.

Table 10: Median Change in Prolactin (ng/mL) from Baseline in Adjunctive Therapy Bipolar Depression Studies

<table>
<thead>
<tr>
<th>Placebo</th>
<th>LATUDA</th>
</tr>
</thead>
<tbody>
<tr>
<td>(n=130)</td>
<td>(n=147)</td>
</tr>
<tr>
<td>20 mg/day</td>
<td>20-to-120 mg/day</td>
</tr>
<tr>
<td>(n=65)</td>
<td>(n=144)</td>
</tr>
</tbody>
</table>
| 0≤5x upper limit of normal (ULN) was 0.0% for LATUDA-treated patients versus 0.0% for placebo-treated patients. The proportion of female patients with prolactin elevations ≥ 5x ULN was 0.6% for LATUDA-treated patients versus 0.0% for placebo-treated female patients. The proportion of male patients with prolactin elevations ≥ 5x ULN was 0.0% versus 0.0% for placebo-treated male patients.

The proportion of patients with prolactin elevations ≥ 5x upper limit of normal (ULN) was 2.8% for LATUDA-treated patients versus 1.0% for placebo-treated patients. The proportion of female patients with prolactin elevations ≥ 5x ULN was 5.7% for LATUDA-treated patients versus 2.0% for placebo-treated female patients. The proportion of male patients with prolactin elevations ≥ 5x ULN was 1.6% versus 0.6% for placebo-treated male patients.

In the uncontrolled longer-term schizophrenia studies (primarily open-label extension studies), LATUDA was associated with a median change in prolactin of -0.9 ng/mL at week 24 (n=357), -5.3 ng/mL at week 36 (n=130) and -2.2 ng/mL at week 52 (n=307).

Table 11: Median Change in Prolactin (ng/mL) from Baseline in Schizophrenia Studies

<table>
<thead>
<tr>
<th>Placebo</th>
<th>LATUDA</th>
</tr>
</thead>
<tbody>
<tr>
<td>(n=68)</td>
<td>(n=71)</td>
</tr>
<tr>
<td>20 mg/day</td>
<td>20-to-120 mg/day</td>
</tr>
<tr>
<td>(n=82)</td>
<td>(n=194)</td>
</tr>
</tbody>
</table>
| 0≤5x ULN was 0.0% for LATUDA-treated patients versus 0.0% for placebo-treated patients. The proportion of female patients with prolactin elevations ≥ 5x ULN was 0.6% for LATUDA-treated patients versus 0.0% for placebo-treated female patients. The proportion of male patients with prolactin elevations ≥ 5x ULN was 0.0% versus 0.0% for placebo-treated male patients.

The proportion of patients with prolactin elevations ≥ 5x upper limit of normal (ULN) was 0.4% for LATUDA-treated patients versus 0.0% for placebo-treated patients. The proportion of female patients with prolactin elevations ≥ 5x ULN was 0.6% for LATUDA-treated patients versus 0.0% for placebo-treated female patients. The proportion of male patients with prolactin elevations ≥ 5x ULN was 0.0% versus 0.0% for placebo-treated male patients.

In the uncontrolled, open-label, longer-term bipolar depression study, patients who were treated with LATUDA as monotherapy in the short-term and continued in the longer-term study, had a mean change in prolactin of -1.15 mg/dL at week 24 (n=130).

Table 12: Median Change in Prolactin (mg/mL) from Baseline in the Monotherapy Bipolar Depression Study

<table>
<thead>
<tr>
<th>Placebo</th>
<th>LATUDA</th>
</tr>
</thead>
<tbody>
<tr>
<td>(n=140)</td>
<td>(n=147)</td>
</tr>
<tr>
<td>20 mg/day</td>
<td>20-to-120 mg/day</td>
</tr>
<tr>
<td>(n=144)</td>
<td>(n=147)</td>
</tr>
</tbody>
</table>
| 0≤5x ULN was 0.0% for LATUDA-treated patients versus 0.0% for placebo-treated patients. The proportion of female patients with prolactin elevations ≥ 5x ULN was 0.6% for LATUDA-treated patients versus 0.0% for placebo-treated female patients. The proportion of male patients with prolactin elevations ≥ 5x ULN was 0.0% versus 0.0% for placebo-treated male patients.

In the uncontrolled, open-label, longer-term bipolar depression study, patients who were treated with LATUDA as monotherapy in the short-term and continued in the longer-term study, had a mean change in prolactin of -1.15 mg/dL at week 24 (n=130).

Table 13: Median Change in Prolactin (mg/mL) from Baseline in the Adjunctive Therapy Bipolar Depression Studies

<table>
<thead>
<tr>
<th>Placebo</th>
<th>LATUDA</th>
</tr>
</thead>
<tbody>
<tr>
<td>(n=301)</td>
<td>(n=321)</td>
</tr>
<tr>
<td>20 mg/day</td>
<td>20-to-120 mg/day</td>
</tr>
<tr>
<td>(n=156)</td>
<td>(n=159)</td>
</tr>
</tbody>
</table>
| 0≤5x ULN was 0.0% for LATUDA-treated patients versus 0.0% for placebo-treated patients. The proportion of female patients with prolactin elevations ≥ 5x ULN was 0.6% for LATUDA-treated patients versus 0.0% for placebo-treated female patients. The proportion of male patients with prolactin elevations ≥ 5x ULN was 0.0% versus 0.0% for placebo-treated male patients.

In the uncontrolled, open-label, longer-term bipolar depression study, patients who were treated with LATUDA, as adjunctive therapy with either lithium or valproate, in the short-term and continued in the longer-term study, had a mean change in prolactin of -2.9 mg/dL at week 24 (n=88).

5.8 Leukopenia, Neutropenia and Agranulocytosis

Leukopenia/neutropenia has been reported during treatment with antipsychotic agents. Agranulocytosis (including fatal cases) has been reported with other agents in the class. Possible risk factors for leukopenia/neutropenia include pre-existing low white blood cell count (WBC) and history of drug-induced leukopenia/neutropenia. Patients with a pre-existing low WBC or a history of drug-induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the treatment period.
Patients with neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. Patients with severe neutropenia (absolute neutrophil count < 1000/mm³) should discontinue LATUDA and have their WBC followed until recovery.

5.5 Orthostatic Hypotension and Syncope
LATUDA may cause orthostatic hypotension and syncope, perhaps due to its α1-adrenergic receptor antagonism. Associated adverse reactions can include dizziness, lightheadedness, tachycardia, and bradycardia. Generally, these risks are greatest at the beginning of treatment and during dose escalation. Patients at increased risk of these adverse reactions or at increased risk of developing complications from hypotension include those with dehydration, hypovolemia, treatment with antihypertensive medication, history of cardiovascular disease (e.g., heart failure, myocardial infarction, ischemia, or conduction abnormalities), history of cerebrovascular disease, as well as patients who are antipsychotic-naïve. In such patients, consider using a lower starting dose and slower titration, and monitor orthostatic vital signs.

Orthostatic hypotension, as assessed by vital sign measurement, was defined by the following vital sign changes: > 20 mm Hg decrease in systolic blood pressure and > 10 bpm increase in pulse from sitting to standing or supine to standing position.

Schizophrenia
The incidence of orthostatic hypotension and syncope reported as adverse events from short-term, placebo-controlled schizophrenia studies was (LATUDA incidence, placebo incidence): orthostatic hypotension [2.3% (6/1508), 0.1% (1/7708) and syncope [0.1% (2/1508), 0% (0/7708)]. In short-term schizophrenia clinical studies, orthostatic hypotension, as assessed by vital signs, occurred with a frequency of 0.8% with LATUDA 40 mg, 2.1% with LATUDA 80 mg, 1.7% with LATUDA 120 mg and 0.8% with LATUDA 160 mg compared to 0.7% with placebo.

Bipolar Depression
Monotherapy
In the short-term, flexible-dose, placebo-controlled monotherapy bipolar depression study, there were no reported adverse events of orthostatic hypotension and syncope.

Orthostatic hypotension, as assessed by vital signs, occurred with a frequency of 0.6% with LATUDA 20 to 60 mg and 0.6% with LATUDA 80 to 120 mg compared to 0% with placebo.

Adjuvant Therapy with Lithium or Valproate
In the short-term, flexible-dose, placebo-controlled adjunctive therapy bipolar depression therapy studies, there were no reported adverse events of orthostatic hypotension and syncope. Orthostatic hypotension, as assessed by vital signs, occurred with a frequency of 1.1% with LATUDA 0 mg, 2.0% with LATUDA 120 mg compared to 0.9% with placebo.

5.10 Seizures
As with other antipsychotic drugs, LATUDA should be used cautiously in patients with a history of seizures or with conditions that lower the seizure threshold, e.g., Alzheimer’s dementia. Conditions that lower the seizure threshold may be more prevalent in patients 65 years or older.

Schizophrenia
In short-term, placebo-controlled schizophrenia studies, seizures/convulsions occurred in 0.1% (2/1508) of patients treated with LATUDA compared to 0.1% (1/7708) placebo-treated patients.

Bipolar Depression
Monotherapy
In the short-term, flexible-dose, placebo-controlled monotherapy bipolar depression study, no patient experienced seizure/convulsions.

Adjuvant Therapy with Lithium or Valproate
In the short-term, flexible-dose, placebo-controlled adjunctive therapy bipolar depression studies, no patient experienced seizures/convulsions.

5.11 Potential for Cognitive and Motor Impairment
LATUDA, like other antipsychotics, has the potential to impair judgment, thinking or motor skills. Caution patients about operating hazardous machinery, including motor vehicles, until they are reasonably certain that therapy with LATUDA does not affect them adversely.

In clinical studies with LATUDA, somnolence included: hypersomnia, hypersonolence, sedation and somnolence.

Schizophrenia
In short-term, placebo-controlled schizophrenia studies, somnolence was reported by 17.0% (256/1508) of patients treated with LATUDA (15.5% LATUDA 20 mg, 15.6% LATUDA 40 mg, 15.2% LATUDA 80 mg, 26.5% LATUDA 120 mg and 8.3% LATUDA 160 mg/day) compared to 7.1% (50/7708) of placebo patients.

Bipolar Depression
Monotherapy
In the short-term, flexible-dosed, placebo-controlled monotherapy bipolar depression study, somnolence was reported by 7.3% (12/164) and 13.8% (23/170) with LATUDA 20 to 60 mg and 80 to 120 mg, respectively compared to 6.5% (11/168) of placebo patients.

Adjuvant Therapy with Lithium or Valproate
In the short-term, flexible-dosed, placebo-controlled adjunctive therapy bipolar depression studies, somnolence was reported by 11.4% (41/360) of patients treated with LATUDA 20-120 mg compared to 5.1% (17/334) of placebo patients.

5.12 Body Temperature Dysregulation
Disruption of the body’s ability to reduce core body temperature has been attributed to antipsychotic agents. Appropriate advice when prescribing LATUDA for patients who will be experiencing conditions that may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration [see Patient Counseling Information (17.9)].

5.13 Suicide
The possibility of a suicide attempt is inherent in psychotic illness and close supervision of high-risk patients should accompany drug therapy. Prescriptions for LATUDA should be written for the smallest quantity of tablets consistent with good patient management in order to reduce the risk of overdose.

Schizophrenia
In short-term, placebo-controlled schizophrenia studies, the incidence of treatment-emergent suicidal ideation was 0.4% (6/1508) for LATUDA-treated patients compared to 0.8% (6/7708) on placebo. No suicide attempts or completed suicides were reported in these studies.

Bipolar Depression
Monotherapy
In the short-term, flexible-dose, placebo-controlled monotherapy bipolar depression study, the incidence of treatment-emergent suicidal ideation was 0.0% (0/331) with LATUDA-treated patients compared to 0.0% (0/168) with placebo-treated patients. No suicide attempts or completed suicides were reported in this study.

Adjuvant Therapy with Lithium or Valproate
In the short-term, flexible-dose, placebo-controlled adjunctive therapy bipolar depression studies, the incidence of treatment-emergent suicidal ideation was 1.1% (4/360) for LATUDA-treated patients compared to 0.3% (1/334) on placebo. No suicide attempts or completed suicides were reported in these studies.

5.14 Activation of Mania/Hypomania
Antidepressant treatment can increase the risk of developing a manic or hypomanic episode, particularly in patients with bipolar disorder. Monitor patients for the emergence of such episodes.

In the bipolar depression monotherapy and adjunctive therapy (with lithium or valproate) studies, less than 1% of subjects in the LATUDA and placebo groups developed manic or hypomanic episodes.

5.15 Dysphagia
Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer’s dementia. LATUDA and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia.

5.16 Neurological Adverse Reactions in Patients with Parkinson’s Disease or Dementia with Lewy Bodies
Patients with Parkinson’s Disease or Dementia with Lewy Bodies are reported to have an increased sensitivity to antipsychotic medication. Manifestations of this increased sensitivity include confusion, obtundation, postural instability with frequent falls, extrapyramidal symptoms, and clinical features consistent with the neuroleptic malignant syndrome.

6. ADVERSE REACTIONS

The following adverse reactions are discussed in more detail in other sections of the labeling:

- Increased Mortality in Elderly Patients with Dementia-Related Psychosis [see Warnings and Precautions (5.1)]
- Suicidal Thoughts and Behaviors [see Warnings and Precautions (5.2)]
- Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with Dementia-related Psychosis [see Warnings and Precautions (5.23)]
- Neuroleptic Malignant Syndrome [see Warnings and Precautions (5.4)]
- Tardive Dyskinesia [see Warnings and Precautions (5.5)]
- Metabolic Changes (Hyperglycemia and Diabetes Mellitus, Dyslipidemia, and Weight Gain) [see Warnings and Precautions (5.6)]
- Hypertension [see Warnings and Precautions (5.7)]
- Leukopenia, Neutropenia, and Agranulocytosis [see Warnings and Precautions (5.8)]
- Orthostatic Hypotension and Syncope [see Warnings and Precautions (5.9)]
- Seizures [see Warnings and Precautions (5.10)]
- Potential for Cognitive and Motor Impairment [see Warnings and Precautions (5.11)]
- Body Temperature Dysregulation [see Warnings and Precautions (5.12)]
- Suicide [see Warnings and Precautions (5.13)]
- Activation of Mania/Hypomania [see Warnings and Precautions (5.14)]
- Dysphagia [see Warnings and Precautions (5.15)]
- Neurological Adverse Reactions in Patients with Parkinson’s Disease or Dementia with Lewy Bodies [see Warnings and Precautions (5.16)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The information below is derived from an integrated clinical study database for LATUDA consisting of 3799 patients exposed to one or more doses of LATUDA for the treatment of schizophrenia and bipolar depression in placebo-controlled studies. This experience corresponds with a total experience of 12559 patient-years. A total of 1106 LATUDA-treated patients had at least 24 weeks and 371 LATUDA-treated patients had at least 52 weeks of exposure. Adverse events during exposure to study treatment were obtained by general inquiry and from vital signs, ECGs, weights and laboratory investigations. Adverse experiences were recorded by clinical investigators using their own terminology. In order to provide a meaningful estimate of the proportion of individuals experiencing adverse events, events were grouped in standardized categories using MedDRA terminology.

Schizophrenia
The following findings are based on the short-term, placebo-controlled premarketing studies for schizophrenia in which LATUDA was administered at daily doses ranging from 20 to 160 mg (n=1508).

Commonly Observed Adverse Reactions: The most common adverse reactions (incidence ≥ 5% and at least twice the rate of placebo) in patients treated with LATUDA were somnolence, akathisia, extrapyramidal symptoms, and nausea.

Adverse Reactions Associated with Discontinuation of Treatment: A total of 9.5% (143/1508) LATUDA-treated patients and 9.3% (68/7708) of placebo-treated patients discontinued due to
adverse reactions. There were no adverse reactions associated with discontinuation in subjects treated with LATUDA that were at least 2% and at least twice the placebo rate.

Adverse Reactions Occurring at an Incidence of 2% or More in LATUDA-Treated Patients: Adverse reactions associated with the use of LATUDA (incidence of 2% or greater, rounded to the nearest percent and LATUDA incidence greater than placebo) that occurred during acute therapy (up to 3 weeks in patients with schizophrenia) are shown in Table 14.

### Table 14: Adverse Reactions in 2% or More of LATUDA-Treated Patients and That Occurred at Greater Incidence than in the Placebo-Treated Patients in Short-term Schizophrenia Studies

<table>
<thead>
<tr>
<th>Body System or Organ Class</th>
<th>Placebo (N=708) (%)</th>
<th>LATUDA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastrointestinal Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Nausea</td>
<td>5 11 10 9 13 7 10</td>
<td></td>
</tr>
<tr>
<td>- Vomiting</td>
<td>6 7 6 9 9 7 8</td>
<td></td>
</tr>
<tr>
<td>- Diarrhea</td>
<td>5 11 6 5 8 6 6</td>
<td></td>
</tr>
<tr>
<td>- Salivary Hypertension</td>
<td>&lt;1 1 1 2 4 2 2</td>
<td></td>
</tr>
<tr>
<td>Musculoskeletal and Connective Tissue Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Back Pain</td>
<td>2 0 4 3 4 0 3</td>
<td></td>
</tr>
<tr>
<td>Nervous System Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Somnolence*</td>
<td>7 15 16 15 26 8 17</td>
<td></td>
</tr>
<tr>
<td>- Akathisia</td>
<td>3 6 12 11 22 7 13</td>
<td></td>
</tr>
<tr>
<td>- Extrapyramidal Disorder**</td>
<td>6 6 11 12 22 13 14</td>
<td></td>
</tr>
<tr>
<td>- Dizziness</td>
<td>2 6 4 4 5 6 4</td>
<td></td>
</tr>
<tr>
<td>Psychiatric Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Insomnia</td>
<td>8 8 10 11 9 7 10</td>
<td></td>
</tr>
<tr>
<td>- Agitation</td>
<td>4 10 7 3 6 5 5</td>
<td></td>
</tr>
<tr>
<td>- Anxiety</td>
<td>4 3 6 4 7 3 5</td>
<td></td>
</tr>
<tr>
<td>- Restlessness</td>
<td>1 1 3 1 3 2 2</td>
<td></td>
</tr>
</tbody>
</table>

Note: Figures rounded to the nearest integer

*Somnolence includes adverse event terms: hypersomnia, hypsomnolence, sedation, and somnolence

**Extrapyramidal symptoms include adverse event terms: akathisia, cogwheel rigidity, drooling, dystonia, extrapyramidal disorder, hyperkinesia, muscle rigidity, oromandibular dystonia, parkinsonism, psychomotor retardation, tongue spasm, torticollis, tremor, and trismus

Dose-Related Adverse Reactions in the Schizophrenia Studies:

Akathisia and extrapyramidal symptoms were dose-related. The frequency of akathisia increased with dose up to 120 mg/day (5.6% for LATUDA 20 mg, 10.7% for LATUDA 40 mg, 12.3% for LATUDA 80 mg, and 22.0% for LATUDA 120 mg). Akathisia was reported by 7.4% (9/121) of patients receiving 160 mg/day. Akathisia occurred in 3.0% of subjects receiving placebo. The frequency of extrapyramidal symptoms increased with dose up to 120 mg/day (5.6% for LATUDA 20 mg, 11.5% for LATUDA 40 mg, 11.9% for LATUDA 80 mg, and 22.0% for LATUDA 120 mg).

Bipolar Depression (Monotherapy):

The following findings are based on the short-term, placebo-controlled premarketing study in bipolar depression in which LATUDA was administered at daily doses ranging from 20 to 120 mg as adjunctive therapy with lithium or valproate (N=360).

### Table 15: Adverse Reactions in 2% or More of LATUDA-Treated Patients and That Occurred at Greater Incidence than in the Placebo-Treated Patients in a Short-term Monotherapy Bipolar Depression Study

<table>
<thead>
<tr>
<th>Body System or Organ Class</th>
<th>Placebo (N=168) (%)</th>
<th>LATUDA 20-60 mg/day (N=164) (%)</th>
<th>LATUDA 80-120 mg/day (N=167) (%)</th>
<th>All LATUDA (N=331) (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastrointestinal Disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Nausea</td>
<td>10 17 14</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Dry Mouth</td>
<td>6 4 5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Vomiting</td>
<td>2 6 4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Diarrhea</td>
<td>2 5 3</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Table 16: Adverse Reactions in 2% or More of LATUDA-Treated Patients and That Occurred at Greater Incidence than in the Placebo-Treated Patients in the Short-term Adjunctive Therapy Bipolar Depression Studies

<table>
<thead>
<tr>
<th>Body System or Organ Class</th>
<th>Placebo (N=334) (%)</th>
<th>LATUDA 20 to 120 mg/day (N=360) (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastrointestinal Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Nausea</td>
<td>10</td>
<td>14</td>
</tr>
<tr>
<td>- Vomiting</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>General Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Fatigue</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>Infections and Infestations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Nasopharyngitis</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Investigations</td>
<td>Weight Increased</td>
<td>&lt;1</td>
</tr>
<tr>
<td>- Metabolism and Nutrition Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Increased Appetite</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>Nervous System Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Extrapyramidal Symptoms*</td>
<td>9</td>
<td>14</td>
</tr>
<tr>
<td>- Somnolence**</td>
<td>5</td>
<td>11</td>
</tr>
<tr>
<td>- Akathisia</td>
<td>5</td>
<td>11</td>
</tr>
<tr>
<td>Psychiatric Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Restlessness</td>
<td>&lt;1</td>
<td>4</td>
</tr>
</tbody>
</table>

Note: Figures rounded to the nearest integer

*Extrapyramidal symptoms include adverse event terms: akathisia, cogwheel rigidity, drooling, dystonia, extrapyramidal disorder, glabellar reflex abnormal, hyperkinesia, muscle rigidity, oromandibular dystonia, parkinsonism, psychomotor retardation, tongue spasm, torticollis, tremor, and trismus

**Somnolence includes adverse event terms: hypersomnia, hypsomnolence, sedation, and somnolence
### Extrapyramidal Symptoms

#### Schizophrenia
In the short-term, placebo-controlled schizophrenia studies, for LATUDA-treated patients, the incidence of reported events related to extrapyramidal symptoms (EPS), excluding akathisia and restlessness, was 13.5% versus 5.8% for placebo-treated patients. The incidence of akathisia for LATUDA-treated patients was 12.9% versus 3.0% for placebo-treated patients. Incidence of EPS by dose is provided in Table 17.

**Table 17: Incidence of EPS Compared to Placebo in Schizophrenia Studies**

<table>
<thead>
<tr>
<th>Adverse Event Term</th>
<th>Placebo (N=708) (%)</th>
<th>LATUDA (N=168) (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All EPS events</td>
<td>9</td>
<td>10</td>
</tr>
<tr>
<td>All EPS events, excluding Akathisia/ Restlessness</td>
<td>6</td>
<td>11</td>
</tr>
<tr>
<td>Akathisia</td>
<td>3</td>
<td>6</td>
</tr>
<tr>
<td>Dystonia</td>
<td>&lt;1</td>
<td>0</td>
</tr>
<tr>
<td>Parkinsonism**</td>
<td>5</td>
<td>6</td>
</tr>
<tr>
<td>Restlessness</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

Note: Figures rounded to the nearest integer

* Akathisia includes adverse event terms: dystonia, oculogyric crisis, oromandibular dystonia, tongue spasm, torticollis, and trismus

* Parkinsonism includes adverse event terms: bradykinesia, cogwheel rigidity, drooling, extrapyramidal disorder, hypokinesia, muscle rigidity, parkinsonism, psychomotor retardation, and tremor

### Bipolar Depression

#### Monotherapy
In the short-term, placebo-controlled bipolar depression study, for LATUDA-treated patients, the incidence of reported events related to EPS, excluding akathisia and restlessness was 6.9% versus 2.4% for placebo-treated patients. The incidence of akathisia for LATUDA-treated patients was 9.4% versus 2.4% for placebo-treated patients. Incidence of EPS by dose groups is provided in Table 18.

**Table 18: Incidence of EPS Compared to Placebo in the Monotherapy Bipolar Depression Study**

<table>
<thead>
<tr>
<th>Adverse Event Term</th>
<th>Placebo (N=164) (%)</th>
<th>LATUDA (N=164) (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All EPS events</td>
<td>5</td>
<td>12</td>
</tr>
<tr>
<td>All EPS events, excluding Akathisia/ Restlessness</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>Akathisia</td>
<td>2</td>
<td>8</td>
</tr>
<tr>
<td>Dystonia</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Parkinsonism**</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>Restlessness</td>
<td>&lt;1</td>
<td>0</td>
</tr>
</tbody>
</table>

Note: Figures rounded to the nearest integer

* Akathisia includes adverse event terms: dystonia, oculogyric crisis, oromandibular dystonia, tongue spasm, torticollis, and trismus

* Parkinsonism includes adverse event terms: bradykinesia, cogwheel rigidity, drooling, extrapyramidal disorder, glabellar reflex abnormal, hypokinesia, muscle rigidity, parkinsonism, psychomotor retardation, and tremor

#### Adjunctive Therapy with Lithium or Valproate
In the short-term, flexible-dose, placebo-controlled adjunctive therapy bipolar depression studies, dystonia occurred in 1.1% of LATUDA-treated subjects (20 to 120 mg) compared to 0.6% of subjects receiving placebo. No subject discontinued the clinical study due to dystonic events.

### Blood and Lymphatic System Disorders

- Infrequent: anemia

### Cardiac Disorders

- Frequent: tachycardia
- Infrequent: AV block 1st degree, angina pectoris, bradycardia

### Ear and Labyrinth Disorders

- Infrequent: vertigo

### Eye Disorders

- Frequent: blurred vision

### Gastrointestinal Disorders

- Frequent: abdominal pain, diarrhea
- Infrequent: gastritis

### General Disorders and Administrative Site Conditions

- Rare: sudden death

### Investigations

- Frequent: CPK increased

### Metabolism and Nutritional System Disorders

- Frequent: decreased appetite

### Nervous System Disorders

- Infrequent: cerebrovascular accident, dystarthis

### Psychiatric Disorders

- Infrequent: abnormal dreams, panic attack, sleep disorder

### Renal and Urinary Disorders

- Infrequent: dysuria
- Rare: renal failure

### Reproductive System and Breast Disorders

- Infrequent: amenorrhea, dysmenorrhea
- Rare: breast enlargement, breast pain, galactorrhea, erectile dysfunction

### Skin and Subcutaneous Tissue Disorders

- Frequent: rash, pruritus
- Rare: angioedema

### Vascular Disorders

- Frequent: hypertension

### Clinical Laboratory Changes

- Rare: creatinine shift from normal to high occurred in 3.0% (43/1453) of LATUDA-treated subjects (0.0% and 1.8% for LATUDA 20 mg, 0.0% and 1.5% for LATUDA 40 mg, 0.0% and 1.2% for LATUDA 80 mg, 0.0% and 0.7% for LATUDA 120 mg). No subject discontinued the clinical study due to dystonic events.

### Dystonia

Class Effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first-generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups.

### Schizophrenia
In the short-term, placebo-controlled schizophrenia clinical studies, dystonia occurred in 4.2% of LATUDA-treated subjects (0.0% LATUDA 20 mg, 3.5% LATUDA 40 mg, 4.5% LATUDA 60 mg, 6.5% LATUDA 120 mg and 2.5% LATUDA 160 mg) compared to 0.8% of subjects receiving placebo. Seven subjects (0.5%, 7/1508) discontinued clinical trials due to dystonic events – four were receiving LATUDA 60 mg/day and three were receiving LATUDA 120 mg/day.

### Bipolar Depression

#### Monotherapy
In the short-term, flexible-dose, placebo-controlled monotherapy bipolar depression study, dystonia occurred in 0.9% of LATUDA-treated subjects (0.0% and 1.8% for LATUDA 20 to 60 mg/day and LATUDA 60 to 120 mg/day, respectively) compared to 0.0% of subjects receiving placebo. No subject discontinued the clinical study due to dystonic events.

### Adjunctive Therapy with Lithium or Valproate
In the short-term, flexible-dose, placebo-controlled adjunctive therapy bipolar depression studies, dystonia occurred in 1.1% of LATUDA-treated subjects (20 to 120 mg) compared to 0.6% of subjects receiving placebo. No subject discontinued the clinical study due to dystonic events.

### Other Adverse Reactions Observed During the Premarketing Evaluation of LATUDA
Following is a list of adverse reactions reported by patients treated with LATUDA at multiple doses ≤ 20 mg once daily within the premarketing database of 2305 patients with schizophrenia. The reactions listed are those that could be of clinical importance, as well as reactions that are plausibly drug-related on pharmacologic or other grounds. Reactions listed in Table 14 or those that appear elsewhere in the LATUDA label are not included. Although the reactions reported occurred during treatment with LATUDA, they were not necessarily caused by it. Reactions are further categorized by organ class and listed in order of decreasing frequency according to the following definitions: those occurring in at least 1/100 patients (infrequent); those not already listed in the tabulated results from placebo-controlled studies appear in this listing; those occurring in 1/100 to 1/1000 patients (infrequent); and those occurring in fewer than 1/1000 patients (rare).

### Schizophrenia

#### Inpatient

- The mean change from baseline for LATUDA-treated patients for the SAS, BAS and AIMS was comparable to placebo-treated patients, with the exception of the Barnes Akathisia Scale Global score (LATUDA, 0.1; placebo, 0.9). The percentage of patients who shifted from normal to abnormal was greater in LATUDA-treated patients versus placebo for the BAS (LATUDA, 14.4%; placebo, 7.1%), the SAS (LATUDA, 5.0%; placebo, 2.3%) and the AIMS (LATUDA, 7.4%; placebo, 5.8%).

#### Outpatient

- The mean change from baseline for LATUDA-treated patients for the SAS, BAS and AIMS was comparable to placebo-treated patients. The percentage of patients who shifted from normal to abnormal was greater in LATUDA-treated patients versus placebo for the BAS (LATUDA, 8.4%; placebo, 5.6%), the SAS (LATUDA, 3.7%; placebo, 1.9%) and the AIMS (LATUDA, 3.4%; placebo, 1.2%).

#### Adjunctive Therapy with Lithium or Valproate

- The mean change from baseline for LATUDA-treated patients for the SAS, BAS and AIMS was comparable to placebo-treated patients. The percentage of patients who shifted from normal to abnormal was greater in LATUDA-treated patients versus placebo for the BAS (LATUDA, 8.7%; placebo, 2.1%), the SAS (LATUDA, 2.8%; placebo, 2.1%) and the AIMS (LATUDA, 2.8%; placebo, 0.6%).

### Dystonia

Class Effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first-generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups.

### Schizophrenia

- The mean change from baseline for LATUDA-treated patients for the SAS, BAS and AIMS was comparable to placebo-treated patients, with the exception of the Barnes Akathisia Scale Global score (LATUDA, 0.1; placebo, 0.9). The percentage of patients who shifted from normal to abnormal was greater in LATUDA-treated patients versus placebo for the BAS (LATUDA, 14.4%; placebo, 7.1%), the SAS (LATUDA, 5.0%; placebo, 2.3%) and the AIMS (LATUDA, 7.4%; placebo, 5.8%).
treated patients and 1.6% (11/681) on placebo. The threshold for high creatinine value varied from > 0.79 to > 1.3 mg/dL based on the centralized laboratory definition for each study (Table 20).

Table 20: Serum Creatinine Shifts from Normal at Baseline to High at Study End-Point in Schizophrenia Studies

<table>
<thead>
<tr>
<th>Laboratory Parameter</th>
<th>Placebo (N=770)</th>
<th>LATUDA 20 mg/day (N=771)</th>
<th>LATUDA 40 mg/day (N=1487)</th>
<th>LATUDA 80 mg/day (N=538)</th>
<th>LATUDA 120 mg/day (N=291)</th>
<th>LATUDA 160 mg/day (N=121)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum Creatinine Elevated</td>
<td>2%</td>
<td>1%</td>
<td>2%</td>
<td>2%</td>
<td>5%</td>
<td>7%</td>
</tr>
</tbody>
</table>

Bipolar Depression

Monotherapy

Serum Creatinine: In the short-term, flexible-dose, placebo-controlled monotherapy bipolar depression study, the mean change from Baseline in serum creatinine was <0.01 mg/dL for LATUDA-treated patients compared to -0.02 mg/dL, for placebo-treated patients. A creatinine shift from normal to high occurred in 2.8% (9/323) of LATUDA-treated patients and 0.6% (1/162) on placebo (Table 21).

Table 21: Serum Creatinine Shifts from Normal at Baseline to High at Study End-Point in a Monotherapy Bipolar Depression Study

<table>
<thead>
<tr>
<th>Laboratory Parameter</th>
<th>Placebo (N=168)</th>
<th>LATUDA 20 to 60 mg/day (N=164)</th>
<th>LATUDA 80 to 120 mg/day (N=167)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum Creatinine Elevated</td>
<td>&lt;1%</td>
<td>2%</td>
<td>4%</td>
</tr>
</tbody>
</table>

Adjuvant Therapy with Lithium or Valproate

Serum Creatinine: In short-term, placebo-controlled premarketing adjunctive studies for bipolar depression, the mean change from Baseline in serum creatinine was <0.04 mg/dL for LATUDA-treated patients compared to -0.01 mg/dL, for placebo-treated patients. A creatinine shift from normal to high occurred in 4.3% (15/360) of LATUDA-treated patients and 1.6% (5/334) on placebo (Table 22).

Table 22: Serum Creatinine Shifts from Normal at Baseline to High at Study End-Point in the Adjunctive Therapy Bipolar Depression Studies

<table>
<thead>
<tr>
<th>Laboratory Parameter</th>
<th>Placebo (N=334)</th>
<th>LATUDA 20 to 120 mg/day (N=308)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum Creatinine Elevated</td>
<td>2%</td>
<td>4%</td>
</tr>
</tbody>
</table>

7 DRUG INTERACTIONS

7.1 Potential for Other Drugs to Affect LATUDA

LATUDA is predominantly metabolized by CYP3A4. LATUDA should not be used concomitantly with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mifepristone, etc.) or strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. John’s wort, phenoxybenzamine, carbamazepine, etc.) (see Contraindications [6]). The LATUDA dose should be reduced to half of the original level when used concomitantly with moderate inhibitors of CYP3A4 (e.g., diltiazem, azathioprine, erythromycin, fluconazole, verapamil, etc.). If LATUDA is used concomitantly with a moderate CYP3A4 inducer, it may be necessary to increase the LATUDA dose (see Dosage and Administration [2.5]).

Lithium: It is not necessary to adjust the LATUDA dose when used concomitantly with lithium (Figure 1). Valproate: It is not necessary to adjust the LATUDA dose when used concomitantly with valproate. A dedicated drug-drug interaction study has not been conducted with valproate and LATUDA. Based on pharmacokinetic data from the bipolar depression studies valproate levels were not affected by lithium, and valproate levels were not affected by LATUDA.

Grapefruit: Grapefruit and grapefruit juice should be avoided in patients taking LATUDA, since these may inhibit CYP3A4 and alter LATUDA concentrations (see Dosage and Administration [2.5]).

Figure 1: Impact of Other Drugs on LATUDA Pharmacokinetics

<table>
<thead>
<tr>
<th>Interacting drug</th>
<th>PK</th>
<th>Fold Change and 90% CI</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strong CYP3A4 Inhibitor</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ketoconazole 400 mg/day</td>
<td>Cmax</td>
<td>Should not be coadministered</td>
<td></td>
</tr>
<tr>
<td>Moderate CYP3A4 Inhibitor</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diltiazem 240 mg/day</td>
<td>Cmax</td>
<td>Starting dose = 20 mg</td>
<td></td>
</tr>
<tr>
<td>Strong CYP3A4 Inducer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ritonavir 600 mg/day</td>
<td>Cmax</td>
<td>Should not be coadministered</td>
<td></td>
</tr>
<tr>
<td>Lithium 600 mg BID</td>
<td>Cmax</td>
<td>Adjustment not required</td>
<td></td>
</tr>
</tbody>
</table>

7.2 Potential for LATUDA to Affect Other Drugs

No adjustment is needed for lithium, substrates of P-gp, CYP3A4 (Figure 2) or valproate when coadministered with LATUDA.

Figure 2: Impact of LATUDA on Other Drugs

<table>
<thead>
<tr>
<th>Interacting drug</th>
<th>PK</th>
<th>Fold Change and 90% CI</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-gp Substrates</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diphenylhydantoin</td>
<td>Cmax</td>
<td>Adjustment not required</td>
<td></td>
</tr>
<tr>
<td>AUC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP3A4 Substrates</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Midazolam</td>
<td>Cmax</td>
<td>Adjustment not required</td>
<td></td>
</tr>
<tr>
<td>AUC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral Contraceptive</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinyl Estradiol</td>
<td>Cmax</td>
<td>Adjustment not required</td>
<td></td>
</tr>
<tr>
<td>AUC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norgestrel Estradiol</td>
<td>Cmax</td>
<td>Adjustment not required</td>
<td></td>
</tr>
<tr>
<td>AUC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lithium 600mg BID*</td>
<td>Chlorthiazide</td>
<td>Change Relative to Interactive Drug Alone</td>
<td></td>
</tr>
<tr>
<td>0.0</td>
<td>0.5</td>
<td>1.0</td>
<td>1.5</td>
</tr>
</tbody>
</table>

*Steady state lithium Chlorthiazide on Day 4 vs Day 8 when lithium was coadministered with lithium at steady state

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category B

Risk Summary

There are no adequate and well controlled studies of LATUDA use in pregnant women. Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. There have been reports of agitation, hyperreflexia, hypotonia, tremor, somnolence, respiratory distress and feeding disorder in these neonates. These complications have varied in severity; while in some cases symptoms have been self-limited, in other cases neonates have required intensive care unit support and prolonged hospitalization. LATUDA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Human Data

Safe use of LATUDA during pregnancy or lactation has not been established; therefore, use of LATUDA in pregnancy, in nursing mothers, or in women of childbearing potential requires that the benefits of treatment be weighed against the possible risks to mother and child.

8.2 Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

8.3 Geriatric Use

Clinical studies with LATUDA did not include sufficient numbers of patients aged 65 and older to determine whether or not they respond differently from younger patients. In elderly patients with psychosis (65 to 85), LATUDA concentrations (20 mg/day) were similar to those in young subjects. It is unknown whether dose adjustment is necessary on the basis of age alone.

Elderly patients with dementia-related psychosis treated with LATUDA are at an increased risk of death compared to placebo. LATUDA is not approved for the treatment of patients with dementia-related psychosis (see Boxed Warning).
8.6 Other Patient Factors
The effect of intrinsic patient factors on the pharmacokinetics of LATUDA is presented in Figure 3.

Figure 3: Impact of Other Patient Factors on LATUDA Pharmacokinetics

<table>
<thead>
<tr>
<th>Renal impairment</th>
<th>Cmax</th>
<th>AUC</th>
<th>Adjustment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild</td>
<td></td>
<td></td>
<td>not required</td>
</tr>
<tr>
<td>Moderate</td>
<td></td>
<td></td>
<td>Starting dose = 20 mg</td>
</tr>
<tr>
<td>Severe</td>
<td></td>
<td></td>
<td>Maximum dose = 80 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Hepatic impairment</th>
<th>Cmax</th>
<th>AUC</th>
<th>Adjustment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild</td>
<td></td>
<td></td>
<td>not required</td>
</tr>
<tr>
<td>Moderate</td>
<td></td>
<td></td>
<td>Starting dose = 20 mg</td>
</tr>
<tr>
<td>Severe</td>
<td></td>
<td></td>
<td>Maximum dose = 80 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Population description</th>
<th>Cmax</th>
<th>AUC</th>
<th>Adjustment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td>not required</td>
</tr>
<tr>
<td>Females</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td>not required</td>
</tr>
<tr>
<td>Asian*</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Compare to Caucasian

10 OVERDOSAGE

10.1 Human Experience
In premarketing clinical studies, accidental or intentional overdosage of LATUDA was identified in one patient who ingested an estimated 560 mg of LATUDA. This patient recovered without sequelae. This patient resumed LATUDA treatment for an additional two months.

10.2 Management of Overdosage
Consult a Certified Poison Control Center for up-to-date guidance and advice. There is no specific antidote to LATUDA, therefore, appropriate supportive measures should be instituted and close medical supervision and monitoring should continue until the patient recovers. Consider the possibility of multiple-drug overdose.

Cardiovascular monitoring should commence immediately, including continuous electrocardiographic monitoring for possible arrhythmias. If antiarrhythmic therapy is administered, disopyramide, procainamide, and quinidine carry a theoretical hazard of additive QT-prolonging effects when administered in patients with an acute overdose of LATUDA. Similarly, the alpha-blocking properties of bretylium might be additive to those of LATUDA, resulting in problematic hypotension.

Hypotension and circulatory collapse should be treated with appropriate measures. Epinephrine and dopamine should not be used, or other sympathomimetics with beta-agonist activity, since beta stimulation may worsen hypotension in the setting of LATUDA-induced alpha blockade. In case of severe extrapyramidal symptoms, anticholinergic medication should be administered.

Gastric lavage (after intubation if patient is unconscious) and administration of activated charcoal together with a laxative should be considered.

The possibility of obtundation, seizures, or dystonic reaction of the head and neck following overdose may create a risk of aspiration with induced emesis.

SUNOVION
Manufactured for:
Sunovion Pharmaceuticals Inc.
Marlborough, MA 01752 USA

For Customer Service, call 1-888-394-7377.
For Medical Information, call 1-800-739-0565.
To report suspected adverse reactions, call 1-877-737-7226.

Revised: July 2013
901436R10

LATUDA and ® are registered trademarks of Sumitomo Dainippon Pharma Co., Ltd.
Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of
Sumitomo Dainippon Pharma Co., Ltd.

© 2014 Sunovion Pharmaceuticals Inc.
About this Guide

In this book, you will find three main sections: Program, New Research and the Exhibits Guide. Use these sections to navigate the 2016 Annual Meeting and experience all the meeting has to offer.

Located within the Program, you will find a description of the various scientific session formats, along with a log where you can record your daily attendance for the purpose of obtaining CME credit for your activities. The Program is first organized by day, then by session start time, with formats and sessions listed alphabetically under those times. Individual meeting days and program tracks are color-coded to make navigating the Program simple and easy.

New Research lists the posters that will be presented at this meeting, organized numerically by session/day. There is a topic index at the end of the New Research section to assist you in finding the posters most interesting to you.

The Exhibits Guide contains a list of the exhibitors and a floor plan of the Exhibit Hall, along with information about the Product Theaters, Therapeutic Update, Career Fair and Publishers’ Book Fair. Use this guide and the included exhibitor and author/presenter indices to navigate the exhibit hall and find precisely the booth you’re looking for.

If you have any questions about this book or the scientific program, please feel free to stop by the Education Center, Escalator to B3-B4, Level 2, Georgia World Congress Center, and a member of the APA Administration will be happy to assist you. All members of the APA Administration will wear green badges.

Welcome to the Annual Meeting!
You’ll provide care that makes a difference to our Soldiers and their Families. As a psychiatrist in the Army or Army Reserve, you’ll practice in a collaborative environment, with no overhead or concerns about malpractice insurance. You’ll experience the pride of serving your country and helping our Soldiers when they need it most.

Visit the Army Medical Recruiting Booth #716 to talk with an Army Psychiatrist or go to healthcare.goarmy.com/eh79 to learn more.
## Table of Contents

About this Guide ........................................ 1
Welcome from the Scientific Program Committee, Steve H. Koh, M.D., M.B.A., M.P.H. .............. 4
Scientific Program Committee Photo .................... 4
Welcome from the APA President, Renée L. Binder, M.D. .................................................. 5
Welcome from the APA CEO and Medical Director, Saul Levin, M.D., M.P.A. ......................... 6
Georgia Psychiatric Physicians Association ........... 7
General information ........................................ 11
Shuttle Service ............................................. 18
Hotel Locations and City Map .............................. 19
Special Acknowledgments ................................ 21
Disclosure Index ............................................ 23
Program ..................................................... 55
  Format Descriptions ..................................... 56
  Daily Attendance Log .................................... 58
  Saturday’s Program ...................................... 59
  Sunday’s Program ....................................... 73
  Monday’s Program ...................................... 97
  Tuesday’s Program ..................................... 123
  Wednesday’s Program .................................. 141
New Research .............................................. 151
  Saturday’s Poster Sessions ............................ 152
  Sunday’s Poster Sessions .............................. 161
  Monday’s Poster Sessions ............................. 163
  Tuesday’s Poster Sessions ............................ 171
  Topic Index ............................................... 180
Exhibits Guide ............................................. 183
  Exhibitor Sponsorship Acknowledgments ............ 184
  General Information ..................................... 186
  Product Theaters ........................................ 188
  Therapeutic Update ..................................... 197
  Exhibitors with Product/Service Descriptions .... 198
  Exhibitors by Product/Service Listing .............. 240
  Career Fair and Publishers’ Book Fair Exhibitors ......................................................... 244
  Numerical List of Exhibitors by Booth Number .... 246
  Exhibit Hall Floor Plan .................................. 250
Presenters Index ........................................... 259

---

American Psychiatric Association
1000 Wilson Boulevard, Suite 1825
Arlington, VA 22209
1-888-35-PSYCH or 1-703-907-7300
apa@psych.org | psychiatry.org/annualmeeting

Join the conversation: #APAAM16
Welcome from the Scientific Program Committee

Dear Colleagues and Guests,

Welcome to Atlanta and to the 2016 Annual Meeting of the American Psychiatric Association. The meeting offers many opportunities for education, new experiences and connecting with colleagues.

Under the leadership of APA President Renée L. Binder, M.D., the Scientific Program Committee has planned a diverse educational program reflecting the presidential theme, “Psychiatry: Claiming Our Future.” The APA Annual Meeting, the largest psychiatric meeting in the world, offers more than 400 sessions, more than 40 courses and up to 40 CME credits.

The Opening Session for the 2016 meeting will start at 4:30 p.m. on Sunday, May 15, and will feature a presentation by Atul Gawande, M.D., a renowned surgeon and researcher and author of Being Mortal and The Checklist Manifesto. We are honored to have Tom Frieden, M.D., M.P.H., Director of the Centers for Disease Control and Prevention, present the William C. Menninger Lecture at the Convocation of Distinguished Fellows on Monday, May 16, at 5:30 p.m. At 10:30 a.m. on Tuesday, May 17, General Robert B. Neller will address mental health issues in the Marine Corps, and on Tuesday, May 17, at 1:00 p.m. U.S. Supreme Court Justice Stephen Breyer will join the meeting in a special session to discuss connections between U.S. courts and global issues.

This year, the APA has once again partnered with the National Institute on Drug Abuse (NIDA) to present a series of sessions focusing on substance abuse issues. NIDA Director Nora D. Volkow, M.D., will chair the session on assessing marijuana risks in a changing environment, and NIDA Deputy Director Wilson Compton, M.D., will address integrated treatment of both tobacco addiction and psychiatric illness. The Annual Meeting will also feature a symposium addressing important ways that the DSM-5 and the National Institute of Mental Health (NIMH) Research Domain Criteria (RDoC), a new framework for classifying mental disorders in psychiatric research, are highly complementary and mutually necessary for the advancement of the field of psychiatry and its patients.

Several new formats will offer attendees a variety of learning experiences. A series of sessions on integrated behavioral health care will include a unique simulation experience where attendees will be able to simulate working on a collaborative care team. In our new Learning Lab format, interactive session participants will propose ideas for new apps, tools or systems that can improve the quality and delivery of mental health care. A panel of experts will respond to the proposals and hear reaction from the audience. A second learning lab will involve a mock trial with APA President Binder as an expert witness. A debate format will be used to explore the use of the controversial treatments ketamine and marijuana.

If you haven’t already, I encourage you to download and use the APA Meetings app at psychiatry.org/app. The app can help you make the most of your meeting experience: connect with colleagues, get the latest updates, find sessions by speaker and topic, plan your itinerary, and more.

Welcome to Atlanta!

Steve H. Koh, M.D., M.B.A., M.P.H.
Chair, Scientific Program Committee

Sitting Left to Right: Tristan Gorrindo, M.D., Catherine C. Crone, M.D., Saul Levin, M.D., M.P.A., Robert M. McCarron, D.O., Philip R. Muskin, M.D., Linda Worley, M.D., Laura K. Kent, M.D.

Standing Left to Right: Steve H. Koh, M.D., M.B.A., M.P.H., Charles S. Price, M.D., Barry D. Sarvet, M.D., Godfrey D. Pearlson, M.D., Elisabeth B. Guthrie, M.D., Robert J. Boland, M.D., Julio Licinio, M.D., Michael F. Myers, M.D., Uyen-Khanh Quang-Dang, M.D., Lara J. Cox, M.D., Sidney Zisook, M.D., Anna L. Dickerman, M.D.

Not Pictured: Uche Achebe, M.D., Renée L. Binder, M.D., Josepha Cheong, M.D., Donald C. Goff, M.D., John Luo, M.D., Arnaldo Moreno, M.D., Edmond Hsin T. Pi, M.D., Nyapati R. Rao, M.D., Kenneth R. Slik, M.D., Andrea M. Brownridge, M.D., J.D., M.H.A., Kimberly A. Gordon, M.D., Stephen A. McLeod-Bryant, M.D., Daniel S. Pine, M.D., Jerrold F. Rosenbaum, M.D., Alan Schatzberg, M.D.
Welcome from the APA President

Dear Colleagues and Guests,

Welcome to the 2016 APA Annual Meeting. Some of the best minds in psychiatry have gathered here in Atlanta to offer a modern, dynamic meeting for our members and guests.

The theme of this year’s meeting is “Psychiatry: Claiming Our Future.” It’s an exciting time to be a psychiatrist. Our passion for and commitment to providing high-quality, effective treatments for all persons with mental disorders will not change, but we must adapt to meet the demands of an ever more complex, evolving world. This means that education and professional growth are extremely important. At this year’s meeting, many of our sessions will address some of the most pressing issues that face psychiatrists today, such as exploring new models of care and how psychiatry complements them, hearing about the latest research, and meeting the needs of our patients while leading professionally satisfying careers as medical leaders for mind, brain and body.

With that in mind, we are honored to have a group of very distinguished speakers lined up for this year’s meeting. Our Opening Session will be followed by a special lecture by renowned surgeon and author Atul Gawande, M.D. He is the author of the highly praised Complications, Better, and The Checklist Manifesto, as well as his new book, Being Mortal: Medicine and What Matters in the End. Dr. Gawande is a MacArthur “Genius” Fellowship winner and is regarded by many as the definitive voice on improving health care.

U.S. Supreme Court Justice Stephen Breyer will also give a special session on Tuesday, May 17, at the Georgia World Congress Center. Before he was appointed by President Bill Clinton in 1994, Justice Breyer taught law for many years at Harvard Law School and the Kennedy School of Government. His published works include books and articles about administrative law, economic regulation and constitutional law, such as Regulation and Its Reform, Breaking the Vicious Circle: Toward Effective Risk Regulation, Active Liberty, Making Our Democracy Work: A Judge’s View and The Court and the World.

The William Menninger Memorial Lecture will be delivered by Tom Frieden, M.D., M.P.H., Director of the Centers for Disease Control and Prevention, at the Convocation of Distinguished Fellows on Monday, May 16. In his role as CDC Director, Dr. Frieden has worked to control health threats from infectious diseases, to respond to emergencies and to battle the leading causes of suffering and death in our nation and around the world.

We really are lucky to have such a distinguished panel of speakers and exhibitors all converging on Atlanta for our meeting. It is a vibrant, bustling metropolis with a rich history that makes it ripe for exploration. Those with a thirst for culture will be well served in Atlanta, which boasts a diverse palette of art, dining and historical attractions. Many of our members’ hotels are right in the epicenter of Atlanta’s culinary scene, which offers some of the best dining experiences available in all of the South.

I have to thank the Scientific Program Committee, led by chair Steve H. Koh, M.D., M.B.A., M.P.H., for the outstanding work they have done in developing the programs and sessions at the meeting. Between our excellent scientific program and the diverse offering of cultural attractions from our host city, I am certain that the 2016 APA Annual Meeting will be a truly great experience for all who attend.

I look forward to seeing you at the meeting and sharing all of the education and excitement it has to offer.

Renée L. Binder, M.D.
President, American Psychiatric Association
Welcome from the APA CEO and Medical Director

Dear Colleagues and Guests,

Welcome to Atlanta for the 2016 Annual Meeting of the American Psychiatric Association.

The meeting offers an extensive educational program, featuring the latest scientific research, advances in clinical practice, and innovative, interactive sessions that will both enhance knowledge and be enjoyable in the process. In addition, the meeting provides a myriad of special events and networking opportunities.

Please join me in honoring APA distinguished fellows, distinguished life fellows, international fellows, award winners, and others at the Convocation of Distinguished Fellows, as well at the different sessions where awardees will give a synopsis of their careers and their work leading up to an award.

This year we are honored to have Tom Frieden, M.D., M.P.H., Director of the Centers for Disease Control and Prevention (CDC), presenting the William C. Menninger Lecture at the Convocation. The Convocation will take place on Monday, May 16, at 5:30 p.m. at the Georgia World Congress Center.

Other award lectures that will be presented at the meeting include:

- Simon Bolivar Award Lecture — Gabriel de Erausquin, M.D., Ph.D.
- George Tarjan Award Lecture — Emmanuel Cassimatis, M.D.
- Solomon Carter Fuller Award Lecture — Eduardo Bonilla-Silva, Ph.D.
- Oskar Pfister Award Lecture — James W. Lomax, M.D.

This year’s American Psychiatric Association Foundation’s annual benefit to support its public education and research initiatives will be held on Saturday, May 14, from 7 p.m. to 10 p.m. at the famous Georgia Aquarium in downtown Atlanta. This special event at the Oceans Ballroom promises a delightful look at two whale exhibitions through a private window, as well as a program honoring the 2016 recipients of the Awards for Advancing Minority Mental Health. (Ticket required.)

Additionally, we will bid a farewell to Paul Burke, M.A., the executive director of the APA Foundation (APAF), who is retiring at the end of June. Come to the reception to bid him a bon voyage as he moves into his retirement and thank him for his service to the APA, the APAF, and as an amazing professional who has helped increase the visibility of mental health and mental illness in the nation.

A special series of scientific sessions have been developed especially for residents this year. MindGames, the ever-popular Jeopardy-like competition for residents, makes its return. It’s a great way for residents to go head-to-head with each other on patient care, medical knowledge and psychiatric history while earning bragging rights for their program.

If you haven’t done so already, I encourage you to download the APA Meetings app for easy access to program information and the latest updates and alerts during the meeting. The app has been completely revamped from last year’s meeting, and boasts a treasure trove of content in a very user-friendly package. Download the app today at psychiatry.org/app.

If you’re on Twitter or Facebook, be sure to share your thoughts and experiences on the meeting by using #APAAM16.

Thank you, and welcome to Atlanta!

Saul Levin, M.D., M.P.A.
CEO and Medical Director,
American Psychiatric Association
Dear Colleagues and Guests,

On behalf of the Georgia Psychiatric Physicians Association (GPPA), I am thrilled to welcome you to the state of Georgia. A district branch of the APA, our organization envisions a Georgia where quality psychiatric care is accessible to all. GPPA is committed to promoting the advancement of quality psychiatric practice and mental health through education, advocacy and engagement with the Georgia community.

As APA members, we are bound together by our common dedication to lifelong learning, and as you expand your knowledge during our 2016 Annual Meeting, I hope that you find some time to enjoy the city.

Atlanta’s symbol is the Egyptian mythological phoenix, because it rose from the ashes to transform into an international gateway city with a rich cultural history. Atlanta blends traditional Southern charm with a diverse population: more than 5.5 million people live in the Atlanta metro area, and the city is more racially diverse than the nation as a whole and is the fastest-growing city in the United States.

An economic engine of the Southeast, Atlanta has been called the “Silicon Valley of the South” and ranks among fDi’s top 10 “American Cities of the Future.” Considered a national leader in health care technology, more than 300 bioscience companies have operations in Atlanta. We are home to the Centers for Disease Control and Prevention (CDC), and research facilities at Emory University, Georgia State University, Georgia Institute of Technology, Morehouse School of Medicine, University of Georgia and Georgia Health Sciences University are abundant and thriving.

Atlanta’s cultural tapestry is particularly informed by its history as a Civil Rights landmark. The city boasts a wide selection of museums, a thriving theatre scene and three professional sports teams, all within a cityscape that blends seamlessly with nature—Atlanta ranks first among major American cities in tree coverage at 54%. Whether you like to be indoors or outdoors, Atlanta has something for you.

Once again, on behalf of the GPPA, I would like to extend our sincerest welcome, and I wish you an enlightening and memorable experience.

Kevin J. Winders, M.D.
President, Georgia Psychiatric Physicians Association
APA Foundation Annual Benefit
at the Annual Meeting

Join us at one of world’s most magical aquariums in recognition of the fields of psychiatry and mental health. Snap selfies with beluga whales, whale sharks and manta rays as you network with peers and colleagues. Let the atmosphere take you away—all while supporting a very important cause.

Exploring New Depths

> Take delight in our private window to two incredible whale and sea life exhibits

> Enjoy delicious food and beverages

> Help raise funds for the APA Foundation’s public education, fellowships, grants, research and awards programs

Oceans Ballroom at the Georgia Aquarium
Saturday | May 14, 2016 | 7 - 10 p.m.

Tickets:
$125, Purchase at apafdn.org/benefit

Questions?
Email: lmcclenathan@psych.org
Or visit APA Central
How do you sleep?

See how your sleep compares to others

Visit Booth 837
McLean Hospital
Unsurpassed in compassionate care, innovative research, and exceptional education

Discuss the latest advances in psychiatry with McLean’s “Top Docs.”

Brent P. Forester, MD, MSc
Chief of the Division of Geriatric Psychiatry
Sunday, May 15, 2016 ■ Noon

Kerry J. Ressler, MD, PhD
Chief Scientific Officer
Monday, May 16, 2016 ■ 10 am

Roger D. Weiss, MD
Chief of the Division of Alcohol and Drug Abuse
Monday, May 16, 2016 ■ Noon

John Gunderson, MD
Founder of the McLean Borderline Center
Monday, May 16, 2016 ■ Noon
General Information

Key Locations in the Georgia World Congress Center

- 2017 Annual Meeting Booth (San Diego, CA) ........ Main Lobby, International Boulevard Entrance
- APA Art Association Exhibit ......................... Water Feature Wall, Level 2
- APA Bookstore .......................... Exhibit Hall B3-B4, Level 1
- APA Cafés .................. Exhibit Hall B3-B4, Level 1
- APA Central ................... Exhibit Hall B3-B4, Level 1
- APA Daily ...................... Room B317, Level 3
- APA Education Center ......................... Escalator to B3-B4, Level 2
- APA Housing Desk ....................... Main Lobby, International Boulevard Entrance
- APA Information Center ................ Main Lobby, International Boulevard Entrance
- APA JobCentral ................... Exhibit Hall B3-B4, Level 1
- APA Newsroom .................. Room B305, Level 3
- Brain Breaks (in the APA Education Center) ...... Escalator to B3-B4, Level 2
- CME Certificate of Attendance and Evaluation .... Escalator to B3-B4, Level 2
- Exhibitor Registration ............... Exhibit Hall B3-B4, Level 1
- Exhibits/Publishers’ Book Fair ............... Exhibit Hall B3-B4, Level 1
- First Aid Room I .......................... Exhibit Hall B3-B4, Level 1
- First Aid Room II ....................... Room B410, Level 4
- International Housing Desk (in Registration) .... Exhibit Hall B3-B4, Level 1
- Lost and Found ......................... Room B204, Level 2
- Luggage/Coat Check .................. Registration Hall, Main Lobby, International Boulevard Entrance
- Meditation Zone ..................... Room B319, Level 3
- Meetings Office ..................... Room B204, Level 2
- Mothers Room ....................... Room B205, Level 2
- On Demand Sales ...................... Exhibit Hall B3-B4, Level 1 and Escalator to B3-B4, Level 2
- Psychiatric News .................. Room B317, Level 3
- Registration ......................... Exhibit Hall B3-B4, Level 1 and Marquis Fountain, Marquis Level, Marriott Marquis
- Scientific Program Office ...... Room B210, Level 2
- Shuttle Bus Desk ...................... Curbside, Building A/B Entrance
APA Central

All attendees are invited to visit APA Central in the Exhibit Hall to learn how APA provides medical leadership for mind, brain and body. Representatives from the APA are available to answer your questions.

Not an APA Member?

Discover the value of APA membership. Join onsite through the Rebate Program and save up to $640. The Rebate Program is open to fully trained psychiatrists, residents/fellows, and international psychiatrists and residents who paid the full-program or resident non-member Annual Meeting registration fee. Stop by APA Central for more details and to apply.

Find a Psychiatrist/Professional Headshots

APA’s Find a Psychiatrist database helps connect patients to APA members accepting new patients. Visit the Find a Psychiatrist area in APA Central to opt-in to the directory and have your professional headshot taken for your Find a Psychiatrist profile and other professional uses. All are welcome to participate.

APA Foundation

The APA Foundation has two goals: 1) support APA members through grants, fellowships and awards; and 2) embed programs across the nation that reduce stigma and foster early identification and treatment for mental illnesses. This means that the APA Foundation is your foundation and one of the strongest public outreach forums for mental health in the country. Learn about programs that are making a difference in our nation’s most pressing mental health issues and make a donation to invest in the future of psychiatry.

APAPAC & Congressional Advocacy Network

Together, we’re making a difference to boost psychiatry, evidence-based treatments, reimbursement and patient care. Members can get involved through the American Psychiatric Association Political Action Committee (APAPAC) and the Congressional Advocacy Network (CAN). APAPAC identifies and makes political contributions to candidates’ campaigns for federal office who are supportive of mental health issues affecting our specialty and our patients, through the generous contributions of members. The Congressional Advocacy Network helps to develop, train and energize a national network of psychiatrists committed to building personal relationships with members of Congress to help educate them on mental health issues and the profession of psychiatry. Please stop by APA Central to learn how you can get involved.

APA JobCentral

Looking for your next career move, or need to make a hire? Visit the APA JobCentral booth located in APA Central to discover available jobs across the country or post a position. A representative will be available to demonstrate the user-friendly system and assist you. Using the Event Connection tool, candidates and employers can flag their resume and/or posting to show their attendance at this year’s meeting. New this year, be sure to stop by and pick up a copy of the 2016 APA JobCentral Recruitment Guide. Visit online at jobs.psychiatry.org.

Lunch-and-Learn Sessions for Residents and Early Career Psychiatrists

Grab your lunch and join us for daily sessions on emerging topics:

<table>
<thead>
<tr>
<th>Topic:</th>
<th>Date:</th>
<th>Location:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Global Mental Health</td>
<td>Saturday, May 14 Noon - 1:00 p.m.</td>
<td>Resident and Early Career Psychiatrist Hub, APA Central in the Exhibit Hall</td>
</tr>
<tr>
<td>Organized Medicine and Your Career</td>
<td>Saturday, May 14 4:15 p.m. - 5:15 p.m.</td>
<td>Resident Resource Center, Room A310, Level 3</td>
</tr>
<tr>
<td>Managing Personal Finances and Student Loans</td>
<td>Sunday, May 15 Noon - 1:00 p.m.</td>
<td>Resident and Early Career Psychiatrist Hub, APA Central in the Exhibit Hall</td>
</tr>
<tr>
<td>Marketing Yourself and Finding Opportunities in Your Early Career</td>
<td>Monday, May 16 Noon - 1:00 p.m.</td>
<td>Resident and Early Career Psychiatrist Hub, APA Central in the Exhibit Hall</td>
</tr>
<tr>
<td>Tips for Your First Job Out of Residency</td>
<td>Tuesday, May 17 Noon - 1:00 p.m.</td>
<td>Resident and Early Career Psychiatrist Hub, APA Central in the Exhibit Hall</td>
</tr>
</tbody>
</table>

Connect with Your Resident and Fellow Colleagues

The meeting may be over for the day, but the fun is just beginning! The Resident and Fellow Caucus will be hosting nightly happy hours at nearby locations where you can network and mingle with your colleagues. New to the Annual Meeting? Resident and Fellow leaders will be on hand to welcome you. Stop by the Resident Resource Center (Room A310, Level 3) or APA Central for more details.
General Information

APA Art Association Exhibit
Water Feature Wall, Level 2

Sunday 10:00 a.m. – 4:00 p.m.
Monday – Tuesday 10:00 a.m. – 5:00 p.m.
Wednesday 10:00 a.m. – 2:00 p.m.

This exhibit includes paintings, photography, ceramics and crafts created by APA members and/or their significant others. Stop by for information on joining the APA Art Association.

APA Bookstore
Exhibit Hall B3-B4, Level 1

Saturday 9:00 a.m. – 4:00 p.m.
Sunday – Tuesday 10:00 a.m. – 4:00 p.m.

Stop by the APA Bookstore to see the latest books, journals and online content. You’ll find new bestselling titles and classic reference works on every area of psychiatry, including the DSM-5. APA members can take advantage of a 20% discount, and APA resident-fellow members receive a 25% discount on all book purchases. Special member prices are available on subscription products.

Administration from APA’s CME journal Focus will also be available at booth 1528 to answer questions about this publication.

APA Daily and Psychiatric News

The APA Daily is the official Annual Meeting publication that highlights events, news, special sessions, and other meeting attractions, as well as provides information on the host city of Atlanta. Print copies of the APA Daily are available at the Georgia World Congress Center and will be delivered to meeting registrants staying at APA’s official hotels. A digital version will be sent to meeting registrants via the APA Meetings app and email. Psychiatric News will also cover Annual Meeting news, and the latest issue will be available onsite at the Georgia World Congress Center.

APA Foundation Benefit

Saturday, May 14 7:00 p.m. – 10:00 p.m.

Spend an evening with some of the biggest names in psychiatry and fish in the sea! The American Psychiatric Association Foundation will host its annual benefit event at the Georgia Aquarium. Be transported to an underwater world as you dine alongside beluga whales, whale sharks and other sea life, viewing their splendor from the largest aquarium windows in North America.

Tickets are required and are available for purchase at APA Central, or visit apafdn.org for more information.

APA Meetings App

The new APA Meetings app gives you all the information you need to navigate the Annual Meeting.

Search the scientific program by day, format, topic or speaker. Use maps to find meeting spaces and the Exhibit Hall. Receive real-time alerts from APA and provide feedback through surveys.

To download the app for Apple and Android devices, visit the App Store or Google Play and search for “APA Meetings” or visit psychiatry.org/app from your mobile device.

Continuing Medical Education Certificate of Attendance and Evaluation

The general meeting evaluation and CME certificate of attendance are available at the CME Certificate of Attendance Booth located in the Education Center, Escalator to B3-B4, Level 2, Georgia World Congress Center, or online at psychiatry.org/annualmeetingcme. The website will be available during the meeting and for three months afterward. Participants can claim CME certificates on or before August 18, 2016. You will need your badge number to access the evaluation and obtain your certificate.

Educational Objectives

By participating in this meeting, you will

- Describe new research findings in psychiatry and neuroscience and how they may impact practice;
- Apply quality improvement strategies to improve clinical care;
- Provide culturally competent care for diverse populations;
- Describe the utility of psychotherapeutic and pharmacological treatment options;
- Integrate knowledge of current psychiatry into discussions with patients; and
- Identify barriers to care, including health service delivery issues.

Accreditation

The APA is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide
General Information

continuing medical education for physicians. The APA designates this live activity for a maximum of 40 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Unless otherwise specified, scientific sessions on the Annual Meeting program meet the criteria for AMA PRA Category 1 Credit™. Sessions in the following program formats are designated as Category 1: the “advances in...” series, case conferences, courses and master courses, FOCUS Live!, forums, lectures, symposia and presidential symposia, scientific and clinical reports, seminars, interactive sessions and workshops, and media workshops.

Poster sessions are NOT designated for AMA PRA Category 1 Credit™.

Please note that the scientific program schedule is subject to change. Please see the APA Daily or the APA Meetings app for details on changes to the scientific program.

Presenter Changes
We understand that emergencies and unforeseen circumstances can necessitate a last-minute presenter change. If you need to replace, add or remove a presenter for your scientific session, please contact the Office of Scientific Programs, located in the Education Center, Escalator to B3-B4, Level 2, Georgia World Congress Center, no less than two (2) hours in advance of the start of your session.

Attendance
Scientific sessions are open to all Annual Meeting registrants with the exception of case conferences, which are open to APA members only. Courses and master courses require a ticket and an additional fee.

To document CME credit earned at the Annual Meeting, participants should maintain a list of sessions they attend. Credit is earned on an hour-for-hour basis. A daily attendance log is provided in this book for tracking your sessions and credits.

Education Center
Escalator to B3-B4, Level 2
Saturday – Wednesday 8:00 a.m. – 5:30 p.m.

Exhibitor Registration
Exhibit Hall B3-B4, Level 1
Friday 8:00 a.m. – 6:00 p.m.
Saturday – Tuesday 7:30 a.m. – 5:00 p.m.

Registered exhibitors will receive red badges that will permit access only to his/her exhibit booth in the Exhibit Hall and to ride the APA shuttle bus. If an exhibitor wants to attend sessions, he/she must register for the meeting and pay the appropriate fee.

Exhibits (Commercial and Educational)
Exhibit Hall B3-B4, Level 1
Sunday – Tuesday 10:00 a.m. – 4:00 p.m.

All exhibits in the Exhibit Hall close at 4:00 p.m. on Tuesday.

First Aid
First Aid Room I, Exhibit Hall B3-B4, Level 1
Tuesday (May 10) – Wednesday (May 18) 7:00 a.m. – 6:00 p.m.

First Aid Room II, Room B410, Level 4
Friday (May 13) – Wednesday (May 18) 7:00 a.m. – 6:00 p.m.

International Pavilion
Exhibit Hall B3-B4, Level 1
Sunday – Tuesday 10:00 a.m. – 4:00 p.m.

Learning Lab
The Learning Lab introduces an exciting new way to learn at the APA Annual Meeting. Every session in the Learning Lab transforms learning through collaboration, rich discussion around issues impacting psychiatry, and hands-on learning. Sessions include a mock trial on risk management, expert debates on ketamine and cannabis, collaborative care simulation games, a shark tank-style psychiatric innovation lab, a resident leadership boot camp and more.
General Information

Attendees who bring their own devices to the Learning Lab will get the most out of this experience. Please bring your laptops, tablets and smart phones to engage with the facilitators, participate in polling and interact with other attendees through group work.

Learning Lab 1
Room B211-212, Level 2
- Sunday, May 15, at 1:00 p.m. Psychiatry Innovation Lab, Where Quality Improvement Meets Silicon Valley: Pitch and Idea. Build a Team. Design a Venture with Nina Vasan, M.D.
- Monday, May 16, at 9:00 a.m. Mock Trial: Lessons for Psychiatrists From the Bar and Risk Management with Kristen Lambert, J.D., M.S.W.
- Wednesday, May 18, at 9:00 a.m. Collaborative Care Lab: Experience the Newest Way to Practice with Erik Vanderlip, M.D., M.P.H.

Learning Lab 2
Room B207-208, Level 2
- Monday, May 16, at 9:00 a.m. A Leadership Boot Camp for Residents and Fellows with Laura Roberts, M.D., M.A.
- Monday, May 16, at 1:30 p.m. FOCUS Live! OCD and Related Disorders: Diagnosis to Treatment with Michele Pato, M.D., and Katherine Phillips, M.D.
- Monday, May 16, at 3:30 p.m. FOCUS Live! Understanding the Evidence for Off-Label Use of Atypical Antipsychotics with David Fogelson, M.D., and Joel Yager, M.D.

Meetings Office
Room B204, Level 2
- Friday: 8:30 a.m. - 5:00 p.m.
- Saturday: 6:30 a.m. - 5:30 p.m.
- Sunday – Wednesday: 7:00 a.m. - 5:30 p.m.

Members of the APA Administration located in the Meetings Office are in charge of the logistics for the meeting. Lost and found is also located in this office.

Mothers Room
Room B205, Level 2
- Friday: 8:00 a.m. - 5:00 p.m.
- Saturday-Wednesday: 7:30 a.m. - 5:00 p.m.

Please first stop in Room B204 to obtain a key. Private area with changing table and comfortable seating.

Newsroom and Communications Office
Room B305, Level 3
- Friday: 3:00 p.m. - 5:00 p.m.
- Saturday – Tuesday: 8:00 a.m. - 5:00 p.m.
- Wednesday: 8:00 a.m. - 2:00 p.m.

These rooms are for the use of registered press and credentialed public relations representatives only.

Lost and Found
Room B204, Level 2
- Friday: 8:30 a.m. - 5:00 p.m.
- Saturday: 6:30 a.m. - 5:30 p.m.
- Sunday – Wednesday: 7:00 a.m. - 5:30 p.m.

On Demand Sales
Exhibit Hall B3-B4, Level 1
- Friday: Noon - 6:00 p.m.
- Saturday-Tuesday: 7:30 a.m.-5:00 p.m.

Education Center, Escalator to B3-B4, Level 2
- Saturday-Wednesday: 7:30 a.m.-5:30 p.m.

APA Annual Meeting On Demand includes over 300 hours of educational content from the Annual Meeting. Content is available online within 24 hours, on USB drive and through mobile streaming. Additional CME is available.

Meditation Zone
Room B319, Level 3
- Saturday-Wednesday: 7:30 a.m. - 5:00 p.m.

Stop in and refresh and renew. Soft lighting and soft seating provided. Bring your own yoga mat. No talking and please remember to turn off your cell phone before entering.

Publishers’ Book Fair/Career Fair
Exhibit Hall B3-B4, Level 1
- Saturday: 9:00 a.m. - 4:00 p.m.
- Sunday – Tuesday: 10:00 a.m. - 4:00 p.m.
General Information

Registration
Admission to all sessions is by registration badge only. A separate fee and ticket purchase is required for all courses.

Exhibit Hall B3-B4, Level 1
Friday Noon – 6:00 p.m.
Exhibit Hall B3-B4, Level 1
Saturday – Wednesday* 7:30 a.m. – 5:00 p.m.
*Escalator to B3-B4, Level 2 (Wednesday Only)
Marriott Marquis
Marquis Fountain, Marquis Level
Friday Noon – 6:00 p.m.
Saturday – Tuesday 7:30 a.m. – 5:00 p.m.
The registration fee covers admission to all sessions (except courses) and shuttle buses, and includes a badge, $10.00 food voucher (for paid registrants only) and copy of the Guide to the 2016 Annual Meeting. The Syllabus and Proceedings, the Guide and Poster Abstracts will be published online for downloading. Registration badges are required for all sessions and the Exhibit Hall. Only an APA member badge will admit you to the Business Meeting. Badge Color Codes: Blue=Members; Yellow=Nonmembers; Silver=Press; Red=Exhibitors; Green=APA Administration; and Clear=Temporary Personnel.
Course tickets not sold in advance will be available for purchase onsite at Registration beginning at Noon on Friday. You must be registered for the meeting before you can enroll in courses.

Scientific Program Office
Education Center, Escalator to Exhibit Hall B3-B4, Level 2
Friday Noon – 6:00 p.m.
Saturday – Wednesday 7:30 a.m. – 5:00 p.m.
Come to this office if you have questions about 1) scientific sessions listed in the Program or Syllabus; 2) adding audiovisual equipment to scientific sessions; 3) scientific program changes; 4) submitting a scientific session for the 2017 Annual Meeting; or 5) the 2016 IPS: Mental Health Services Conference.

Scientific Session Capacity Guidelines
If overcrowding occurs in a scientific session, we ask for your assistance in abiding by the following guidelines so that all in attendance can benefit.
► Take a seat as close to the front of the room as possible.
► Move to the center of the row and fill all seats so that chairs are available near the aisles for additional attendees.
► Don’t stand or sit in the aisles or lean against walls. The Fire Marshall may shut down an overcrowded session; therefore, please either find a seat or choose another session to attend.

Shuttle Bus Desk and Service
Curbside Building A/B Entrance
Pick up at hotels
Saturday, May 14 – Wednesday, May 18 7:00 a.m.
Last departure from the Georgia World Congress Center
Saturday, May 14 5:30 p.m.
Sunday, May 15 7:30 p.m.
Monday, May 16 7:30 p.m.
Tuesday, May 17 5:30 p.m.
Wednesday, May 18 5:30 p.m.
A 2016 meeting badge is required to ride on the courtesy shuttle bus. The Georgia World Congress Center will serve as the “hub” for all shuttle bus routes. A detailed shuttle bus schedule will be available onsite and will be posted in the lobbies of participating hotels.

Smoking Policy
Smoking is not allowed anywhere in the Georgia World Congress Center.
General Information

Audio and Visual Reproduction Policies

Registrants are not permitted to photograph or video record any session, as the intrusive nature of recording may be disruptive. This includes photographs taken with cell phone cameras. Audio recording is permitted for personal use only. Registrants are welcome to use their own small, portable audio recorders to record any session except case conferences or unless prohibited by the presenters. Larger professional tape recorders are not permitted except for use by registered members of the working press in accordance with APA press policies. Media will be identified with silver badges, and approved equipment will be identified with APA Newsroom stickers. The APA has authorized a professional taping firm, which will be clearly identified, to record sessions.

Wi-Fi

Attendees will have free wireless access in all public spaces and meeting rooms.

There is also free wireless in the two APA Cafés (Exhibit Hall B3-B4, Level 1, open during exhibit hours), which also include free coffee and charging stations for laptops, cell phones and other devices. The Cafés are supported by Takeda Pharmaceuticals USA Inc. and Lundbeck Inc.

Future APA Meetings

**APA Annual Meetings**

- May 20 – 24, 2017  
  San Diego, CA
- May 5 – 9, 2018  
  New York, NY
- May 18 – 22, 2019  
  San Francisco, CA

**IPS: The Mental Health Services Conference**

- October 6 – 9, 2016  
  Washington, DC
- October 19 – 22, 2017  
  New Orleans, LA
- October 4 – 7, 2018  
  Chicago, IL

The Preliminary Program for the 2016 IPS: The Mental Health Services Conference, which includes registration, housing, air travel and program information, will be available in June on the web at psychiatry.org.
Hotel Map

Hotel Names and Locations

1. Aloft, 300 Spring Street, NW
2. Marriot Marquis, 265 Peachtree Center Avenue
3. Courtyard Marriott Downtown, 133 Carnegie Way
4. Doubletree by Hilton Downtown, 160 Spring Street, NW
5. The Ellis Hotel, 176 Peachtree Street
6. Embassy Suites Centennial Park, 267 Marietta Street
7. Glenn Hotel, 110 Marietta Street, NW
8. Hilton, 255 Courtland Street, NE
9. Hilton Garden Inn, 275 Baker Street
10. Holiday Inn Downtown, 101 Andrew Young International Boulevard, NW
11. Holiday Inn Express, 111 Cone Street, NW
12. Hyatt Regency, 265 Peachtree, NE
13. Omni, 100 CNN Center
14. Ritz Carlton, 181 Peachtree Street
15. Sheraton Atlanta, 165 Courtland Street
16. W Downtown, 45 Ivan Allen Boulevard
17. Westin, 210 Peachtree Street, NE
Shuttle Service

The Georgia World Congress Center will operate as the “hub” for the APA shuttle bus system. All routes will begin and end there. The shuttle will operate during the following days and times:

<table>
<thead>
<tr>
<th>Route 1 – Blue</th>
<th>Route 2 – Red</th>
<th>Route 3 – Green</th>
<th>Route 4 – Orange</th>
<th>Route 5 – Purple</th>
</tr>
</thead>
<tbody>
<tr>
<td>Westin</td>
<td>Ritz Carlton</td>
<td>Marriott Marquis</td>
<td>Hilton</td>
<td>Aloft Atlanta Downtown</td>
</tr>
<tr>
<td>Doubletree by Hilton Downtown</td>
<td>Courtyard Marriott Downtown</td>
<td></td>
<td>Hyatt Regency</td>
<td></td>
</tr>
<tr>
<td>Holiday Inn Downtown</td>
<td>Ellis Hotel</td>
<td>Marriott Marquis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Holiday Inn Express</td>
<td>Sheraton Atlanta</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Shuttle information signs will be posted in the lobby of each shuttle hotel. Check the sign in your hotel lobby for additional information and changes. For questions regarding the shuttle or to make an advance reservation for a wheelchair accessible shuttle, please see the shuttle supervisor at the Georgia World Congress Center during shuttle hours.

Hours of Operation:

**Saturday, May 14**
7:00 a.m. – 5:30 p.m.

**Sunday, May 15**
7:00 a.m. – 7:30 p.m.

**Monday, May 16**
7:00 a.m. – 7:30 p.m.

**Tuesday, May 17**
7:00 a.m. – 5:30 p.m.

**Wednesday, May 18**
7:00 a.m. – 5:30 p.m.

Walking Distance Hotels, NOT on shuttle bus routes:

- Embassy Suites
- Centennial Park
- Glenn Hotel
- Hilton Garden Inn
- Omni
American Professional Agency, Inc.
The APA-endorsed Psychiatrists
Medical Liability Insurance Program

Please Visit us at
Booth #1217
to learn more about our Risk Management Services

www.ApaMalpractice.com

(877) 740-1777
Special Acknowledgments

American Association of Chairs of Departments of Psychiatry: support of the APAF/AACDP Research Mentorship Award.

American Psychiatric Association Foundation: support of the Child and Adolescent Psychiatry Fellowship; Public Psychiatry Fellowship; Diversity Leadership Fellowship and Jeanne Spurlock Congressional Fellowship; American Psychiatric Leadership Fellowship; and the David Mrazek Memorial Lecture Endowment.

Association of Women Psychiatrists: co-support of the Alexandra Symonds Award Lecture.

Estate of Agnes Purcell McGavin: support of the Agnes Purcell McGavin Awards for Distinguished Career Achievement in Child and Adolescent Psychiatry, and for Prevention.

Estate of Dorothy C. Kemp: support of Kempf Fund Award for Research Development in Psychobiological Psychiatry Awards.

Estate of Kun-Po Soo, M.D. Ph.D.: support of the Kun-Po Soo Award.

Helen Johnson-Leipold and Assurex Health: principal support of the Mrazek Memorial Lecture.

Lilly USA LLC: co-support of the Simon Bolivar Award.

American College of Neuropsychopharmacology and Society of Biological Psychiatry: the Research Colloquium for Junior Investigators.

Penn/Scattergood Ethics Program: recognized for its collaboration with the 2016 Scientific Program Committee and APA Ethics Committee chairperson in the development of an ethics track for the 2016 Annual Meeting.

Substance Abuse and Mental Health Services Administration (CMHS, CSAP, CSAT): sponsorship of the APA/SAMHSA Minority Fellowship Program and support of the APA’s HIV-related education programs and materials.

The Ittleson Foundation: support of the Blanche F. Ittleson Award for Research in Child Psychiatry.

University of Nebraska: support of the Frank J. Menolascino Award for Psychiatric Services for Persons with Mental Retardation/Developmental Disabilities.
Understanding Parkinson’s Disease Psychosis and Its Treatment

DATE & TIME

Sunday, May 15, 2016 · 1:00 PM-2:00 PM · with Q/A (Box lunch included)

LOCATION

Atlanta, GA · Georgia World Congress Center · Exhibit Hall B3/4, Level 1

PRESENTED BY

Daniel E. Kremens, MD, JD
Associate Professor of Neurology
Co-Director, Parkinson’s Disease and Movement Disorders
Department of Neurology
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, PA

Henry A. Nasrallah, MD
The Sydney W. Souers Endowed Chair
Professor & Chairman
Department of Neurology & Psychiatry
Saint Louis University School of Medicine
St. Louis, MO

PROGRAM OVERVIEW AND LEARNING OBJECTIVES

Parkinson’s disease (PD), a progressive neurodegenerative disease that affects approximately 1 million Americans, is primarily considered to be a movement disorder.1,2 PD psychosis is a common non-motor symptom that affects more than half of patients with PD over the course of their disease.3 Non-motor symptoms are common in PD and may have a greater impact on quality of life than motor symptoms.1,4

Please join us for a program to review:

- What PD psychosis is and its diagnostic criteria
- The prevalence of PD psychosis
- The impact of PD psychosis on both patients and caregivers
- How PD psychosis is treated


SEATING IS AVAILABLE ON A FIRST-COME, FIRST-SERVED BASIS; NO PRE-REGISTRATION REQUIRED.

Learn more about advances in PD Psychosis at booth #1437
Disclosure Index

American Psychiatric Association Continuing Medical Education Policy on Full Disclosure

The American Psychiatric Association requires disclosure by all program planners and presenters at CME activities of any financial or other affiliation with commercial organization(s) that may have a direct or indirect interest in the subject matter of the educational activity. A “financial interest” may include, but is not limited to: being an employee and/or being a shareholder in the organization; being on retainer with the organization; or having research or honoraria paid by the organization. An “affiliation” may include holding a position on an advisory committee, speakers’ bureau or some other role or benefit to a commercial interest.

In compliance with the ACCME’s Standards for Commercial Support, the APA has a management of conflict (MCI) process for all CME activities. This process ensures that all conflicts of interest are identified, managed and resolved prior to the educational activity. Additionally, the prospective audience must be informed of the presenters’ or program planners’ affiliations with every commercial interest by an acknowledgment in the printed program and verbal or visual disclosure to participants at the session (disclosure by slide is required if audiovisual equipment is used for the presentation). Disclosing to learners the relevant financial relationships that were present and resolved assists learners in assessing the potential for bias in the information that is presented. The APA also requires verbal disclosure of discussion of unlabeled uses of a commercial product or investigational use of a product not yet approved for this purpose.

The presenters and planners on the following pages indicated that either they or a spouse/partner have a financial interest or other affiliation with a commercial entity producing, marketing, re-selling or distributing health care goods or services consumed by or used on patients; the company name and affiliation is also listed. Providers of clinical service directly to patients are not considered to be commercial interests. The second group of presenters and planners indicated neither they nor a spouse/partner have any relationship to disclose.

All presenters and planners must complete a disclosure in order to participate in an APA CME activity. This disclosure listing includes both the presenters and planners of the Scientific Program and New Research Poster Sessions.
<table>
<thead>
<tr>
<th>Name</th>
<th>Consultant/Advisory Board</th>
<th>Speakers Bureau/Speaker Honoraria</th>
<th>Employee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbey, Susan.</td>
<td>Pfizer</td>
<td>Purdue Pharma</td>
<td></td>
</tr>
<tr>
<td>Aggarwal, Neil K.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alexopoulos, George S.</td>
<td></td>
<td>AstraZeneca Pharmaceuticals</td>
<td>Otsuka Pharmaceuticals</td>
</tr>
<tr>
<td>Alphas, Larry D.</td>
<td></td>
<td></td>
<td>Janssen</td>
</tr>
<tr>
<td>Amadio, Jordan</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anderson, Karen E</td>
<td>Teva Pharmaceuticals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anthony, James C.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Artigas, Francesc</td>
<td>Lundbeck</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ash, Peter</td>
<td>Forest Laboratories, Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Attia, Evelyn</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baggott, Matthew J.</td>
<td></td>
<td>Genentech</td>
<td></td>
</tr>
<tr>
<td>Bailey, John</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bailey, Rahn</td>
<td>Janssen</td>
<td>Eli Lilly and Company</td>
<td>Sunovion Pharmaceuticals Inc</td>
</tr>
<tr>
<td>Baker, Ross A.</td>
<td></td>
<td>Otsuka Pharmaceuticals</td>
<td></td>
</tr>
<tr>
<td>Benjamin, Sheldon</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bennett, Jeffrey I.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bierut, Laura J.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bisaga, Adam</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blanch, Jordi</td>
<td></td>
<td>Gilead Sciences</td>
<td>Janssen-Cilag</td>
</tr>
<tr>
<td>Blier, Pierre</td>
<td>Bristol-Myers Squibb</td>
<td>Eli Lilly and Company</td>
<td>Actavis</td>
</tr>
<tr>
<td>Brannan, Stephen</td>
<td></td>
<td>Forum Pharmaceuticals</td>
<td></td>
</tr>
<tr>
<td>Bravata, Dena</td>
<td></td>
<td>Lyra Health</td>
<td></td>
</tr>
<tr>
<td>Brock, David G.</td>
<td></td>
<td>Neuronetics Inc.</td>
<td></td>
</tr>
<tr>
<td>Brody, Benjamin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brown, Brianne</td>
<td></td>
<td>Janssen-Ortho</td>
<td></td>
</tr>
<tr>
<td>Brown, Richard P.</td>
<td>Humanetics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brown, Thomas</td>
<td>Lundbeck</td>
<td>Shire</td>
<td></td>
</tr>
<tr>
<td>Buckley, Peter</td>
<td>AstraZeneca Pharmaceuticals</td>
<td>Eli Lilly and Company</td>
<td>Janssen</td>
</tr>
<tr>
<td>Bussing, Regina</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grant/Research Support</td>
<td>Stock/Other Financial Relationship</td>
<td>Other Disclosure</td>
<td></td>
</tr>
<tr>
<td>-------------------------------</td>
<td>---------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>National Institute of Mental Health</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Johnson and Johnson</td>
<td></td>
<td>Founder/Partner at NeuroLaunch, a neuroscience investment firm</td>
<td></td>
</tr>
<tr>
<td>National Institutes of Health</td>
<td>NIDA</td>
<td>CSR</td>
<td>American Association for the Advancement of Science</td>
</tr>
<tr>
<td>Lundbeck</td>
<td></td>
<td>Consults with attorneys to provide expert testimony</td>
<td></td>
</tr>
<tr>
<td>Eli Lilly and Company</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Part owner of TMS Patient Care of Tallahassee. Also employed to do consultation and mapping for this company.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Robert Wood Johnson Pharmaceutical.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Janssen</td>
<td></td>
<td>Author/partner in Brain Educators, LLC</td>
<td></td>
</tr>
<tr>
<td>Alkermes</td>
<td></td>
<td>Inventor on U.S. Patent 8,080,371 “Markers for Addiction” covering the use of certain SNPs in determining the diagnosis, prognosis and treatment of addiction</td>
<td></td>
</tr>
<tr>
<td>Bristol-Myers Squibb</td>
<td>Lundbeck</td>
<td>Takeda Pharmaceuticals</td>
<td>Janssen</td>
</tr>
<tr>
<td>Takeda Pharmaceuticals</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lyra Health</td>
<td>Castlight Health</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pritzker Neuropsychiatric Disorders Research Consortium</td>
<td></td>
<td>Expert witness to the law firm of Wilson, Bowling and McKinney</td>
<td></td>
</tr>
<tr>
<td>Humanetics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pfizer</td>
<td>Janssen</td>
<td>Sunovion Pharmaceuticals Inc.</td>
<td>AstraZeneca Pharmaceuticals</td>
</tr>
<tr>
<td>Pfizer</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Disclosure Index

<table>
<thead>
<tr>
<th>Name</th>
<th>Consultant/Advisory Board</th>
<th>Speakers Bureau/Speaker Honoraria</th>
<th>Employee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Candilis, Philip</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carrothers, Timothy J.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carvalhal, Adriana</td>
<td>AbbVie Pharmaceutical</td>
<td>AbbVie Pharmaceutical</td>
<td></td>
</tr>
<tr>
<td>Castilla-Puentes, Ruby C.</td>
<td></td>
<td>Janssen</td>
<td>Johnsen and Johnson</td>
</tr>
<tr>
<td>Chang, Kiki</td>
<td>GlaxcoSmithKline</td>
<td>Actavis</td>
<td>Sunovion Pharmaceuticals Inc.</td>
</tr>
<tr>
<td>Childress, Ann C.</td>
<td>Shionogi Inc.</td>
<td>ironshore Pharmaceuticals</td>
<td>Next Wave</td>
</tr>
<tr>
<td>Choudhry, Zia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ciotoli, Carlo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clayton, Anita</td>
<td>Lundbeck</td>
<td>Palatin Technologies</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Clemow, David B.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coccaro, Emil</td>
<td>Azevan Pharmaceuticals, Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coghill, David</td>
<td>Shire</td>
<td>Novartis Pharmaceuticals Corporation</td>
<td>Sandoz Pharmaceuticals Corporation</td>
</tr>
<tr>
<td>Craig, Thomas K. J.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cress, Kim K.</td>
<td>Neuronetics Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cubells, Joseph F.</td>
<td>AbbVie Pharmaceutical</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grant/Research Support</td>
<td>Stock/Other Financial Relationship</td>
<td>Other Disclosure</td>
<td></td>
</tr>
<tr>
<td>------------------------</td>
<td>------------------------------------</td>
<td>-----------------</td>
<td></td>
</tr>
<tr>
<td>Abbott Laboratories</td>
<td>AstraZeneca Pharmaceuticals</td>
<td>Bristol-Myers Squibb</td>
<td>Cephalon Inc.</td>
</tr>
<tr>
<td>Dow Chemical</td>
<td>Merck and Co.</td>
<td>Pfizer</td>
<td>Praxair</td>
</tr>
<tr>
<td>Johnson and Johnson</td>
<td>GlaxcoSmithKline</td>
<td>Sanofi Aventis</td>
<td>Merck and Co.</td>
</tr>
<tr>
<td>Bristol-Myers Squibb</td>
<td>Eli Lilly and Company</td>
<td>Johnson and Johnson</td>
<td>Merck and Co.</td>
</tr>
<tr>
<td>Auspex Pharm</td>
<td>Genomind</td>
<td>Palatin Technologies</td>
<td>Forest Laboratories, Inc.</td>
</tr>
<tr>
<td>Euthymics Bioscience Inc.</td>
<td>S1 Biopharmaceuticals Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Azevan Pharmaceuticals, Inc.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sanofi Aventis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Roche</td>
<td>Seaside Therapeutics</td>
<td>SmithKline Beecham</td>
<td>BioMarin</td>
</tr>
<tr>
<td>Pfizer</td>
<td>Lilly USA, LLC</td>
<td>Biotech Holders Trust</td>
<td>Genzyme</td>
</tr>
</tbody>
</table>
## Disclosure Index

<table>
<thead>
<tr>
<th>Name</th>
<th>Consultant/Advisory Board</th>
<th>Speakers Bureau/Speaker Honoraria</th>
<th>Employee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Davine, Jon S.</td>
<td>Lundbeck</td>
<td></td>
<td>Lundbeck</td>
</tr>
<tr>
<td>De Dios, Consuelo</td>
<td>Janssen-Cilag</td>
<td></td>
<td></td>
</tr>
<tr>
<td>De Faria, Ludmila</td>
<td>Alkermes</td>
<td>Sunovion Pharmaceuticals Inc.</td>
<td>Otsuka Pharmaceuticals</td>
</tr>
<tr>
<td>de la Gandara, Jose E.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dell’Oso, Bernardo</td>
<td>Pfizer</td>
<td>Lundbeck</td>
<td></td>
</tr>
<tr>
<td>DeMille, Steven M.</td>
<td>AbbVie Pharmaceutical</td>
<td>Lundbeck</td>
<td>Intracellular Therapies</td>
</tr>
<tr>
<td>Devanand, Davangere P</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Doghramji, Karl</td>
<td>Pfizer</td>
<td>Jazz Pharmaceutical</td>
<td>Teva Pharmaceuticals</td>
</tr>
<tr>
<td>Douaihy, Antoine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Doumas, Stacy J.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duffy, Farifteh F.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Durgam, Suresh</td>
<td>Allergan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Earley, Willie</td>
<td>Allergan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elefant, Erica</td>
<td></td>
<td></td>
<td>Janssen</td>
</tr>
<tr>
<td>El-Mallakh, Rif S.</td>
<td>Aventis Pharmaceuticals</td>
<td>AstraZeneca Pharmaceuticals</td>
<td>Lundbeck</td>
</tr>
<tr>
<td>Eriksson, Hans</td>
<td>Lundbeck</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ernst, Carrie L.</td>
<td>(Spouse/Partner)Sunovion Pharmaceuticals Inc.</td>
<td>(Spouse/Partner)AstraZeneca Pharmaceuticals</td>
<td>(Spouse/Partner)Janssen</td>
</tr>
<tr>
<td>Fallu, Angelo</td>
<td>Janssen-Ortho</td>
<td>Shire</td>
<td>Sunovion Pharmaceuticals Inc.</td>
</tr>
<tr>
<td>Name</td>
<td>Consultant/Advisory Board</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------------------</td>
<td>------------------------------------------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Davine, Jon S.</td>
<td>Lundbeck</td>
<td></td>
<td></td>
</tr>
<tr>
<td>De Dios, Consuelo</td>
<td>Janssen-Cilag</td>
<td></td>
<td></td>
</tr>
<tr>
<td>De Faria, Ludmila</td>
<td>Alkermes</td>
<td>Sunovion Pharmaceuticals Inc.</td>
<td>Otsuka Pharmaceuticals</td>
</tr>
<tr>
<td>Dell’Osso, Bernardo</td>
<td>Pfizer</td>
<td>Lundbeck</td>
<td></td>
</tr>
<tr>
<td>DeMille, Steven M.</td>
<td>RedCliff Ascent</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Devanand, Davangere P</td>
<td>AbbVie Pharmaceutical</td>
<td>Lundbeck</td>
<td>Intracellular Therapies</td>
</tr>
<tr>
<td>Doghramji, Karl</td>
<td>Pfizer</td>
<td>Jazz Pharmaceutical</td>
<td>Teva Pharmaceuticals</td>
</tr>
<tr>
<td>Douaihy, Antoine</td>
<td>Alkermes</td>
<td>Orexo</td>
<td></td>
</tr>
<tr>
<td>Doumas, Stacy J.</td>
<td>Sunovion Pharmaceuticals Inc.</td>
<td>Forest Laboratories, Inc.</td>
<td></td>
</tr>
<tr>
<td>Duffy, Farifteh F.</td>
<td>Forest Laboratories, Inc.</td>
<td>Lundbeck</td>
<td>Takeda Pharmaceuticals</td>
</tr>
<tr>
<td>Durgam, Suresh</td>
<td>Allergan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Earley, Willie</td>
<td>Allergan</td>
<td>AstraZeneca Pharmaceuticals</td>
<td>Lundbeck</td>
</tr>
<tr>
<td>Elefant, Erica</td>
<td>Janssen</td>
<td></td>
<td></td>
</tr>
<tr>
<td>El-Mallakh, Rif S.</td>
<td>Aventis</td>
<td>AstraZeneca Pharmaceuticals</td>
<td>Lundbeck</td>
</tr>
<tr>
<td>Eriksson, Hans</td>
<td>Lundbeck</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ernst, Carrie L.</td>
<td>Sunovion Pharmaceuticals Inc.</td>
<td>(Spouse/Partner)Sunovion Pharmaceuticals Inc.</td>
<td>(Spouse/Partner)AstraZeneca Pharmaceuticals</td>
</tr>
<tr>
<td>Fallu, Angelo</td>
<td>Janssen-Ortho</td>
<td>Shire</td>
<td>Sunovion Pharmaceuticals Inc.</td>
</tr>
<tr>
<td></td>
<td>Perdue Pharmaceuticals</td>
<td>Merck Frosst</td>
<td></td>
</tr>
</tbody>
</table>

**Other Disclosure**

- Supported by the Spanish grant FIS PI13/00352 from Instituto de Salud Carlos III
- Spouse has received an editorial stipend from Frontline Medical Communications
<table>
<thead>
<tr>
<th>Name</th>
<th>Consultant/Advisory Board</th>
<th>Speakers Bureau/Speaker Honoraria</th>
<th>Employee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Faroone, Stephen V.</td>
<td>Adam HealthCare Systems LLC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fayad, Sarah M.</td>
<td>Arbor</td>
<td>Pfizer</td>
<td>Ironshore Pharmaceuticals</td>
</tr>
<tr>
<td>First, Michael B.</td>
<td>Lundbeck</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fisher, Carl</td>
<td>TalkSession</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fogelson, David L.</td>
<td>Roxane Pharmaceuticals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fong, Tim</td>
<td>Reckitt Benckiser Pharmaceuticals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Forester, Brent</td>
<td>Eli Lilly and Company</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Formella, Andrea</td>
<td></td>
<td></td>
<td>Avanir Corporation</td>
</tr>
<tr>
<td>Foster, Norman L.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Frasch, Karel J.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fu, Dong-Jing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gache, Chris</td>
<td></td>
<td></td>
<td>Actavis</td>
</tr>
<tr>
<td>Gao, Keming</td>
<td></td>
<td></td>
<td>Sunovion Pharmaceuticals Inc.</td>
</tr>
<tr>
<td>George, Tony P.</td>
<td>Novartis Pharmaceuticals Corporation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gerbarg, Patricia L.</td>
<td>(Spouse/Partner)Humanetics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gibbs, Ayana</td>
<td></td>
<td></td>
<td>Roche</td>
</tr>
<tr>
<td>Goldberg, Joseph F.</td>
<td>Sunovion Pharmaceuticals Inc.</td>
<td></td>
<td>AstraZeneca Pharmaceuticals</td>
</tr>
<tr>
<td>Gomez-Trigo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baldominos, Jesus</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gopal, Srihari</td>
<td>Janssen</td>
<td></td>
<td>Janssen</td>
</tr>
<tr>
<td>Grace, Anthony A.</td>
<td>Johnson and Johnson</td>
<td>Lundbeck</td>
<td></td>
</tr>
<tr>
<td>Grebla, Regina</td>
<td></td>
<td></td>
<td>Shire</td>
</tr>
<tr>
<td>Green, Alan I.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Harvey, Philip D.</td>
<td>Boehringer Ingelheim Pharmaceuticals</td>
<td>Forum Pharmaceuticals</td>
<td>Genentech</td>
</tr>
<tr>
<td>Hatch, Ainslie</td>
<td></td>
<td></td>
<td>Otsuka Pharmaceuticals</td>
</tr>
<tr>
<td>Herman, Barry K.</td>
<td></td>
<td></td>
<td>Shire</td>
</tr>
<tr>
<td>Hildebrandt, Tom</td>
<td>Noom, Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hilt, Dana</td>
<td></td>
<td></td>
<td>Forum Pharmaceuticals</td>
</tr>
<tr>
<td>Hodgson, Richard E.</td>
<td></td>
<td></td>
<td>Janssen-Cilag</td>
</tr>
<tr>
<td>Holland, Peter J.</td>
<td>Eli Lilly and Company</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hsiung, Robert</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Iosifescu, Dan V.</td>
<td>Lundbeck</td>
<td>Sunovion Pharmaceuticals Inc.</td>
<td>Axsome</td>
</tr>
<tr>
<td>Iyer, Sharat P.</td>
<td>Truven Health Analytics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jacobs, Karen</td>
<td></td>
<td></td>
<td>Takeda Pharmaceuticals</td>
</tr>
<tr>
<td>Jacobson, William</td>
<td></td>
<td></td>
<td>Takeda Pharmaceuticals</td>
</tr>
<tr>
<td>Grant/Research Support</td>
<td>Stock/Other Financial Relationship</td>
<td>Other Disclosure</td>
<td></td>
</tr>
<tr>
<td>------------------------</td>
<td>-----------------------------------</td>
<td>-----------------</td>
<td></td>
</tr>
<tr>
<td>Arbor</td>
<td>Pfizer</td>
<td>Ironshore Pharmaceuticals</td>
<td>Shire</td>
</tr>
<tr>
<td>Biogen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GE Healthcare Inc.</td>
<td>Lundbeck</td>
<td>Stada</td>
<td>Rhoen Klinik</td>
</tr>
<tr>
<td>AstraZeneca Pharmaceuticals</td>
<td>Pfizer</td>
<td>(Spouse/Partner) Humanetics</td>
<td></td>
</tr>
<tr>
<td>Janssen</td>
<td>Janssen</td>
<td>Johnson and Johnson</td>
<td></td>
</tr>
<tr>
<td>Johnson and Johnson</td>
<td>Janssen</td>
<td>Autofony grant pending</td>
<td></td>
</tr>
<tr>
<td>Shire</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alkermes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Takeda Pharmaceuticals</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shire</td>
<td>Equity owner in Noom, Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Forum Pharmaceuticals</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eli Lilly and Company</td>
<td>Biogen</td>
<td>Genentech</td>
<td>Dr. Bob, LLC</td>
</tr>
<tr>
<td>Brainsway Inc</td>
<td>Alkermes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pfizer</td>
<td>Takeda Pharmaceuticals</td>
<td>United Health</td>
<td></td>
</tr>
</tbody>
</table>
# Disclosure Index

<table>
<thead>
<tr>
<th>Name</th>
<th>Consultant/Advisory Board</th>
<th>Speakers Bureau/Speaker Honoraria</th>
<th>Employee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Janicak, Philip G.</td>
<td>Neuronetics Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Joshi, Kruti</td>
<td></td>
<td></td>
<td>Janssen</td>
</tr>
<tr>
<td>Josiassen, Richard C.</td>
<td>Otsuka Pharmaceuticals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kalnik, Matthew W.</td>
<td></td>
<td></td>
<td>Antidote Therapeutics, Inc.</td>
</tr>
<tr>
<td>Ketter, Terence A.</td>
<td>Sunovion Pharmaceuticals Inc.</td>
<td>Teva Pharmaceuticals</td>
<td>Janssen</td>
</tr>
<tr>
<td>Khattak, Sohail</td>
<td>Shire</td>
<td>Janssen</td>
<td>Purdue Pharma</td>
</tr>
<tr>
<td>Kiss, Béla</td>
<td>Gedeon Richter</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kleber, Herbert D.</td>
<td>Alkermes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kleiner, Oliver</td>
<td>Boehringer Ingelheim Pharmaceuticals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Knable, Michael B.</td>
<td>ProPhase LLC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ko, Mancia</td>
<td>Ameritox, Ltd.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kolli, Venkata B.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kott, Alan</td>
<td>Bracket Global, LLC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kramer, Kenneth</td>
<td>Allergan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kratochvil, Christopher</td>
<td>Mapp</td>
<td>Chimerix</td>
<td>NewLink Genetics</td>
</tr>
<tr>
<td>Kung, Simon</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Consultant/Advisory Board</td>
<td>Speakers Bureau/Speaker</td>
<td>Honoraria</td>
</tr>
<tr>
<td>--------------------------</td>
<td>---------------------------</td>
<td>-------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>Joshi, Kruti</td>
<td>Janssen</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Josiassen, Richard C.</td>
<td>Otsuka Pharmaceuticals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Karnik, Niranjan Ho</td>
<td>Hoffmann-LaRoche Pharmaceuticals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Khan, Christina T.</td>
<td>Janssen</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kiss, Béla</td>
<td>Gedeon Richter</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kleber, Herbert D.</td>
<td>Alkermes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kleiner, Oliver</td>
<td>Boehringer Ingelheim Pharmaceuticals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kung, Simon</td>
<td>Employer (Mayo Clinic) receives some royalties from pharmacogenetic technology licensed from Mayo to AssureRx</td>
<td>Medavante NeuroCog Trials, Inc., Sengenix</td>
<td>Medavante NeuroCog Trials, Inc., Sengenix</td>
</tr>
</tbody>
</table>

Employer (Mayo Clinic) receives some royalties from pharmacogenetic technology licensed from Mayo to AssureRx.
## Disclosure Index

<table>
<thead>
<tr>
<th>Name</th>
<th>Consultant/Advisory Board</th>
<th>Speakers Bureau/Speaker Honoraria</th>
<th>Employee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lavretsky, Helen</td>
<td></td>
<td>Forest Laboratories, Inc.</td>
<td></td>
</tr>
<tr>
<td>Lefebvre, Patrick</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lerner, Debra</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Levin, Frances R.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lev-Ran, Shaul</td>
<td>Pfizer</td>
<td>Lundbeck</td>
<td>Reckitt Benckiser Pharmaceuticals</td>
</tr>
<tr>
<td>Lewis-Fernandez, Roberto</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lewy, Alfred J.</td>
<td>Servier</td>
<td>Pfizer</td>
<td></td>
</tr>
<tr>
<td>Lindenmayer, Jean-Pierre</td>
<td>Janssen</td>
<td>Forum Pharmaceuticals</td>
<td>Lundbeck</td>
</tr>
<tr>
<td>Loewen, Gordon R.</td>
<td></td>
<td>Forum Pharmaceuticals</td>
<td></td>
</tr>
<tr>
<td>López-Jaramillo, Carlos</td>
<td>Abbott Laboratories</td>
<td>AstraZeneca Pharmaceuticals</td>
<td>Lundbeck</td>
</tr>
<tr>
<td>Luo, John</td>
<td>Otsuka Pharmaceuticals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lusskin, Shari I.</td>
<td>Pfizer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mago, Rajnish</td>
<td>Actavis</td>
<td>Sunovion Pharmaceuticals Inc.</td>
<td>Otsuka Pharmaceuticals</td>
</tr>
<tr>
<td>Mancevski, Branislav</td>
<td></td>
<td>Janssen</td>
<td></td>
</tr>
<tr>
<td>Mao, Alice R.</td>
<td>Shire</td>
<td>Otsuka Pharmaceuticals</td>
<td>Shire</td>
</tr>
<tr>
<td>Marder, Stephen R.</td>
<td>AbbViePharmaceuticals</td>
<td>Allergan</td>
<td>Lundbeck</td>
</tr>
<tr>
<td>Markovitz, Paul J.</td>
<td>(Spouse/Partner)Avanir Corporation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mayberg, Helen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>McBurnett, Keith</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>McCracken, James T.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>McDonald, William M.</td>
<td>U.S. Food and Drug Administration (FDA)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Grant/Research Support</td>
<td>Stock/Other Financial Relationship</td>
<td>Other Disclosure</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-----------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Lavretsky, Helen</td>
<td>Forest Laboratories, Inc.</td>
<td></td>
<td>Grants from the Alzheimer’s Research and Prevention Foundation; NIH</td>
</tr>
<tr>
<td>Lefebvre, Patrick</td>
<td>Janssen</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lerner, Debra</td>
<td>Janssen</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Levin, Frances R.</td>
<td>US World Med</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lev-Ran, Shaul</td>
<td>Reckitt Benckiser Pharmaceuticals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lewis-Fernandez, Roberto</td>
<td>Eli Lilly and Company</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lewy, Alfred J.</td>
<td>Eli Lilly and Company</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lindenmayer, Jean-Pierre</td>
<td>Forest Pharmaceuticals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>López-Jaramillo, Carlos</td>
<td>Abbott Laboratories</td>
<td>AstraZeneca Pharmaceuticals</td>
<td>Lundbeck</td>
</tr>
<tr>
<td>Luo, John</td>
<td>Otsuka Pharmaceuticals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lusskin, Shari I.</td>
<td>Pfizer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mago, Rajnish</td>
<td>Actavis</td>
<td>Genomind</td>
<td>Alkermes</td>
</tr>
<tr>
<td>Mancevski, Branislav</td>
<td>Janssen</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mao, Alice R.</td>
<td>Shire</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marder, Stephen R.</td>
<td>AbbVie Pharmaceutical</td>
<td>Allergan</td>
<td>Lundbeck</td>
</tr>
<tr>
<td>Markovitz, Paul J.</td>
<td>(Spouse/Partner)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marmar, Charles R.</td>
<td>Eli Lilly and Company</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mattingly, Greg</td>
<td>Alkermes</td>
<td>Forum Pharmaceuticals</td>
<td>Lundbeck</td>
</tr>
<tr>
<td>Mayberg, Helen</td>
<td>IP licensing fees from St. Jude Medical Group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>McBurnett, Keith</td>
<td>Pfizer</td>
<td>Sunovion Pharmaceuticals Inc.</td>
<td></td>
</tr>
<tr>
<td>McCracken, James T.</td>
<td>AstraZeneca Pharmaceuticals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>McDonald, William M.</td>
<td>U.S. Food and Drug Administration (FDA)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mayberg, Helen</td>
<td>Alcobra, Ltd.</td>
<td>Alkermes</td>
<td>Forest Laboratories, Inc.</td>
</tr>
<tr>
<td>McCracken, James T.</td>
<td>AstraZeneca Pharmaceuticals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mayberg, Helen</td>
<td>National Institute of Mental Health</td>
<td>National Institute of Neurological Disease and Stroke</td>
<td>Stanley Foundation</td>
</tr>
<tr>
<td>Name</td>
<td>Consultant/Advisory Board</td>
<td>Speakers Bureau/Speaker Honoraria</td>
<td>Employee</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>------------------------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>Grant/Research Support</td>
<td>Stock/Other Financial Relationship</td>
<td>Other Disclosure</td>
<td></td>
</tr>
<tr>
<td>--------------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Nordic Naturals</td>
<td></td>
<td>Co-owner of COVR, Inc., which owns the intellectual property rights to the Classification of Violence Risk</td>
<td></td>
</tr>
<tr>
<td>Pfizer</td>
<td></td>
<td>Abbott Laboratories</td>
<td></td>
</tr>
<tr>
<td>Alkermes</td>
<td>Forum Pharmaceuticals</td>
<td></td>
<td>Johnson and Johnson</td>
</tr>
<tr>
<td>Xhale</td>
<td>Celgene Corporation</td>
<td>AbbVie Pharmaceuticals</td>
<td>Titan Pharmaceuticals Inc.</td>
</tr>
<tr>
<td>Janssen</td>
<td></td>
<td>Chair of the Board of Governors for the Patient Centered Outcomes Research Institute</td>
<td></td>
</tr>
<tr>
<td>Bristol-Myers Squibb</td>
<td>Royalties for the use of the Columbia Suicide Severity Rating Scale</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intervexion Therapeutic, LLC</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Disclosure Index

<table>
<thead>
<tr>
<th>Name</th>
<th>Consultant/Advisory Board</th>
<th>Speakers Bureau/Speaker Honoraria</th>
<th>Employee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pandey, Ghanshyam N.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pardes, Herbert</td>
<td>W.M. Keck Foundation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parks, Joseph</td>
<td>Otsuka Pharmaceuticals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pasternak, Gavril</td>
<td>AstraZeneca Pharmaceuticals</td>
<td>Cytogel</td>
<td></td>
</tr>
<tr>
<td>Penninx, Brenda W.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Periclo, Antonia</td>
<td></td>
<td>Allergan</td>
<td></td>
</tr>
<tr>
<td>Peters-Strickland, Timothy</td>
<td></td>
<td>Otsuka Pharmaceuticals</td>
<td></td>
</tr>
<tr>
<td>Phillips, Katharine A.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pi, Edmond H. T.</td>
<td>Bracket Pharmaceuticals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pilon, Dominic</td>
<td></td>
<td>Analysis Group, Inc.</td>
<td></td>
</tr>
<tr>
<td>Pogarelli, Oliver</td>
<td>Lundbeck</td>
<td>Lundbeck</td>
<td>Otsuka Pharmaceuticals</td>
</tr>
<tr>
<td>Posner, Jonathan</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Potkin, Steven</td>
<td>Sunovion Pharmaceuticals Inc.</td>
<td>Forum Pharmaceuticals</td>
<td>Alkermes</td>
</tr>
<tr>
<td>Price, Charles S.</td>
<td></td>
<td>Actavis</td>
<td>AstraZeneca Pharmaceuticals</td>
</tr>
<tr>
<td>Primm, Annelle</td>
<td>Johnson and Johnson</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pumariega, Andres J.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rado, Jeffrey T.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Raj, Pritham</td>
<td>AstraZeneca Pharmaceuticals</td>
<td>Allergan, Merck &amp; Co.</td>
<td>AstraZeneca Pharmaceuticals</td>
</tr>
<tr>
<td>Rakofsky, Jeffrey J.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rasgon, Natalie</td>
<td></td>
<td>Magceutics</td>
<td>Corcept Therapeutics, Inc.</td>
</tr>
<tr>
<td>Remington, Gary</td>
<td>Neurocrine Biosciences Inc.</td>
<td>Synchroneroneur</td>
<td>Medicare</td>
</tr>
<tr>
<td>Reynolds, Charles F.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rich, Kelly</td>
<td>Janssen</td>
<td></td>
<td>Alkermes</td>
</tr>
<tr>
<td>Risinger, Robert</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rosenbaum, Jerrold F.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rosenthal, Richard N.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rostain, Anthony</td>
<td>Alcobra, Ltd.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rothbaum, Barbara</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rovner, Barry</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Roy, Alphonse K.</td>
<td>Orexo</td>
<td></td>
<td>Alkermes</td>
</tr>
<tr>
<td>Rush, A. John</td>
<td>Cyberonics Inc.</td>
<td>Brain Resource Ltd.</td>
<td></td>
</tr>
<tr>
<td>Saeed, Aliya</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sajatovic, Martha</td>
<td>Bracket Pharmaceuticals</td>
<td>ProPhase LLC</td>
<td>Otsuka Pharmaceuticals</td>
</tr>
<tr>
<td>Grant/Research Support</td>
<td>Stock/Other Financial Relationship</td>
<td>Other Disclosure</td>
<td></td>
</tr>
<tr>
<td>------------------------</td>
<td>-----------------------------------</td>
<td>------------------</td>
<td></td>
</tr>
<tr>
<td>Reimada</td>
<td>Cytogel</td>
<td>Sarentis</td>
<td></td>
</tr>
<tr>
<td>Janssen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allergan</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Merck and Co.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Janssen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shire</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eli Lilly and Company</td>
<td>Eisai Inc.</td>
<td>Forum Pharmaceuticals</td>
<td>Toyama</td>
</tr>
<tr>
<td>(Spouse/Partner)Actavis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neuronetics Inc.</td>
<td>Otsuka Pharmaceuticals</td>
<td>Alkermes</td>
<td></td>
</tr>
<tr>
<td>Takeda Pharmaceuticals</td>
<td>Assure RX</td>
<td>Magceutics</td>
<td>Corcept Therapeutics, Inc.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depression prevention research supported by P30MH90333</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alkermes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medavante</td>
<td>PsyBrain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Braeburn Pharmaceuticals</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Virtually Better, Inc.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Merck and Co.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>May receive royalty payments from UT Southwestern for rating scales.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pfizer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pfizer</td>
<td>Merck and Co.</td>
<td>Ortho-McNeil Janssen Scientific Affairs, LLC</td>
<td>Janssen</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Work supported by NIMH ROI MH 048153 and NIMH ROI MH 098554</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Consultant/Advisory Board</td>
<td>Speakers Bureau/Speaker Honoraria</td>
<td>Employee</td>
</tr>
<tr>
<td>-----------------------</td>
<td>---------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>Samalin, Ludovic</td>
<td>Janssen</td>
<td>Bristol-Myers Squibb</td>
<td>Bristol-Myers Squibb</td>
</tr>
<tr>
<td>Sánchez-Gómez, Pedro M.</td>
<td>Janssen-Cilag</td>
<td>Ferrer International</td>
<td>Janssen-Cilag</td>
</tr>
<tr>
<td>Saragoussi, Delphine</td>
<td></td>
<td></td>
<td>Lundbeck</td>
</tr>
<tr>
<td>Sauve, William</td>
<td></td>
<td></td>
<td>Otsuka Pharmaceuticals</td>
</tr>
<tr>
<td>Savitz, Adam</td>
<td>Janssen</td>
<td></td>
<td>Janssen</td>
</tr>
<tr>
<td>Schulz, S. Charles</td>
<td>Forum Pharmaceuticals</td>
<td>Myriad Pharmaceuticals</td>
<td></td>
</tr>
<tr>
<td>Seibyl, John</td>
<td>GE Healthcare Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serfaty, Marc A.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shah, Asim</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sheehan, David V.</td>
<td>Actavis</td>
<td>Shire</td>
<td>Janssen</td>
</tr>
<tr>
<td>Sivrioglu, Yusuf</td>
<td>Actavis</td>
<td>Pfizer</td>
<td>Novartis Pharmaceuticals Corporation</td>
</tr>
<tr>
<td>State, Matthew</td>
<td>Pfizer</td>
<td>SynapDx</td>
<td>Blackthorn Therapeutics</td>
</tr>
<tr>
<td>Sudak, Donna M.</td>
<td>Takeda Pharmaceuticals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Summers, Richard F.</td>
<td></td>
<td></td>
<td>(Spouse/Partner)Hummingbird IRB</td>
</tr>
<tr>
<td>Sung, Victor</td>
<td>Lundbeck</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Swann, Alan C.</td>
<td>Teva Pharmaceuticals</td>
<td>Otsuka Pharmaceuticals</td>
<td>Lundbeck</td>
</tr>
<tr>
<td>Tendler, Aron</td>
<td></td>
<td></td>
<td>Brainsway Inc</td>
</tr>
<tr>
<td>Thase, Michael E.</td>
<td>Actavis</td>
<td>Alkermes</td>
<td>Allergan</td>
</tr>
<tr>
<td>Name</td>
<td>Consultant/Advisory Board</td>
<td>Grant/Research Support</td>
<td>Stock/Other Financial Relationship</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>---------------------------</td>
<td>------------------------</td>
<td>-----------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Samalin, Ludovic</td>
<td>Janssen</td>
<td></td>
<td>Amnestic Inc</td>
</tr>
<tr>
<td>Sánchez-Gómez, Pedro M.</td>
<td>Janssen-Cilag</td>
<td>Ferrer International</td>
<td>Myriad Pharmaceuticals</td>
</tr>
<tr>
<td>Saragoussi, Delphine</td>
<td>Lundbeck</td>
<td></td>
<td>Medical Outcomes Systems</td>
</tr>
<tr>
<td>Sauve, William</td>
<td>Otsuka Pharmaceuticals</td>
<td>Avanir Corporation</td>
<td>Sunovion Pharmaceuticals Inc.</td>
</tr>
<tr>
<td>Savitz, Adam</td>
<td>Janssen</td>
<td></td>
<td>TauMark, LLC</td>
</tr>
<tr>
<td>Seibyl, John</td>
<td>GE Healthcare Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serfaty, Marc A.</td>
<td>Chief investigator on all U.K. National Institute of Health Research-funded studies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shah, Asim</td>
<td>Actavis</td>
<td>Pfizer</td>
<td>Novartis Pharmaceuticals Corporation</td>
</tr>
<tr>
<td>Small, Gary W.</td>
<td>Actavis</td>
<td>Pfizer</td>
<td>Novartis Pharmaceuticals Corporation</td>
</tr>
<tr>
<td>Saragoussi, Delphine</td>
<td>Lundbeck</td>
<td></td>
<td>Medical Outcomes Systems</td>
</tr>
<tr>
<td>State, Matthew</td>
<td>Pfizer</td>
<td>SynapDx</td>
<td>Blackthorn Therapeutics</td>
</tr>
<tr>
<td>Sudak, Donna M.</td>
<td>Takeda Pharmaceuticals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Summers, Richard F.</td>
<td>(Spouse/Partner) Peloton Advantage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tendler, Aron</td>
<td>Brainsway Inc</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thase, Michael E.</td>
<td>Actavis</td>
<td>Alkermes</td>
<td>Allergan</td>
</tr>
</tbody>
</table>
## Disclosure Index

<table>
<thead>
<tr>
<th>Name</th>
<th>Consultant/Advisory Board</th>
<th>Speakers Bureau/Speaker Honoraria</th>
<th>Employee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Torres Vilamajo, Imma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trudeau, Kimberlee J.</td>
<td>Janssen-Cilag</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Turkingdon, Douglas</td>
<td>Forest Laboratories, Inc.</td>
<td>Lundbeck</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Vieta, Eduard</td>
<td>(Spouse/Partner)Novartis Pharmaceuticals Corporation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vinogradov, Sophia</td>
<td>Otsuka Pharmaceuticals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Viswanathan, Ramaswamy</td>
<td>Beacon Health Strategies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weiller, Emmanuelle</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weis, Catherine</td>
<td>Otsuka Pharmaceuticals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>West, Joyce C.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wigal, Sharon B.</td>
<td>Eli Lilly and Company</td>
<td>Ironshore Pharmaceuticals</td>
<td>NextWave</td>
</tr>
<tr>
<td>Wilcox, Marsha A.</td>
<td>Janssen</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wilens, Timothy</td>
<td>Ironshore Pharmaceuticals</td>
<td>Sunovion Pharmaceuticals Inc.</td>
<td>Euthymics Bioscience Inc.</td>
</tr>
<tr>
<td>Williams, Jill M.</td>
<td>Pfizer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Winsberg, Mirene</td>
<td>Lyra Health</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wise, Thomas N.</td>
<td>Otsuka Pharmaceuticals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wittenberg, Gayle M.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wong, Donovan</td>
<td>Janssen</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wright, Jesse H.</td>
<td>Doctor on Demand</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zeller, Scott</td>
<td>Teva Pharmaceuticals</td>
<td>Ferrer International</td>
<td></td>
</tr>
</tbody>
</table>

---

© 2016 American Psychiatric Association. All rights reserved.

Find out more at psychiatry.org/annualmeeting
<table>
<thead>
<tr>
<th><strong>Grant/Research Support</strong></th>
<th><strong>Stock/Other Financial Relationship</strong></th>
<th><strong>Other Disclosure</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Janssen</td>
<td>PFIS Contract for IT (FIII/00502), Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation, Spain and the grant FIS PI12/01139 to the ADHD Unit at Vall d’Hebron Hospital, Instituto de Salud Carlos III.</td>
<td>Director of the Insight-CBT partnership</td>
</tr>
<tr>
<td>Janssen-Ortho</td>
<td>Pfizer</td>
<td>Has received research grants, honoraria related to continuing medical education or consulting fees from Centro para la Investigación Biomédica en Red de Salud Mental (CIBERSAM), Grups Consolidsats de Recerca 2014 (SGR 398), the Seventh European Framework Programme (ENBREC) and the Stanley Medical Research Institute. Site investigator on an SBIR multisite grant to PositScience, Inc.</td>
</tr>
<tr>
<td>(Spouse/Partner)Emmaus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Takeda Pharmaceuticals</td>
<td>Forest Laboratories, Inc.</td>
<td>Robert Wood Johnson Foundation</td>
</tr>
<tr>
<td>Eli Lilly and Company</td>
<td>Forest Laboratories, Inc.</td>
<td>Ironshore Pharmaceuticals</td>
</tr>
<tr>
<td>NIDA</td>
<td></td>
<td>Co-owner of Before School Functioning Questionnaire, licensed with Ironshore</td>
</tr>
<tr>
<td>Pfizer</td>
<td></td>
<td>Lyra Health</td>
</tr>
<tr>
<td>Johnson and Johnson</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Doctor on Demand</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Empower Interactive</td>
<td>Mindstreet</td>
<td>Lundbeck</td>
</tr>
<tr>
<td>Lundbeck</td>
<td>Servier</td>
<td>Brainsway Inc</td>
</tr>
</tbody>
</table>
Disclosure Index
The following presenters and planners indicated neither they nor a spouse/partner have any relationship to disclose.

Aaronson, Alexandra L.
Abdel Gawad, Noha
Aboraya, Ahmed
Aboeid, Lila
Acar, Selin
Acharya, Bibhav
Achebe, Uchenna
Acosta-Uribe, Juliana
Adams, Caitlin
Adams, Samantha
Adelsheim, Steven
Adelsky, Sol
Adelson, Stewart L.
Adi, Ahmad
Adelson, Amy B.
Aeschbach-Jachmann, Crispa
Afzal, Saba
Aga, Vimal M.
Agarwal, Vishesh
Agbonyitor, Mawuena
Aguilar, Maria E.
Ah Quin, Dyanna Leolani
Ahmad, Ammar Y.
Ahmed, Iqbal
Ahmed, Mohammed W.
Ahmed, Saeed
Ahmedani, Brian K.
Ahuja, Amir
Aimienwanu, Osarhiemen R.
Akerele, Evaristo
Akhtar, Sameerah
Akki, Mayada
Akinsanya, Adefolake
Akiyama, Tsuyoshi
Akin, Will M.
Akinpar, Abdullah
Aksoy Poyraz, Cana
Alarcon, Renato D.
Alavi, Nazanin
Albassam, Ahmed
Albright, Brittany B.
Alegría, Margarita
Alexander, Ricky
Alhadi, Ahmad
Al-Hassani, Ghanem
Ali, Arshand
Ali, Shahla
Alkis, Andrew R.
Allen, Rebecca M.
Almas, Aysha
Alosaimi, Fahad D.
Alpektin, Koksai
Al-Rubaye, Safa
Alvarez, Kiara
Alwahibi, Abdulrahman
Aly, Tarek
Amin, Abdel F.
Amin, Ritesh
Amin, Rohul
An, Seung-Min
Ananthamoorthy, Renuka
Andersen, Aaron K.
Anderson, Frederick
Anderson, Otis
Anderson, Tyler
Andruskevicius, Sergejus
Anees, Muhammad A.
Anglero Diaz, Yohanis L.
Annamalai, Aniyizhai
Anzia, Joan
Aouin, Elie
Appelbaum, Paul S.
Apter, Gisele
Aragon, Darinka
Arbuckle, Melissa
Ardalan, Firouz
Arditti, Joyce
Arman, Farid
Arroyo, William
Aschbacher, Kirstin
Ash, David M.
Ashley, Kenneth
Asif, Muhammad
Atluru, Aparna
Auchincloss, Elizabeth L.
Auger, R. Robert
Avery, Jonathan
Ayaz, Sumayya B.
Aycocik, Jean E.
Ayub, Shahana
Ayub, Shehzad
Ayuel, Atong
Azam, Mohammed A.
Azizi, Hafizullah
Babatope, Taiwo
Bachem, Rafi C.
Baer, Wendy
Bagwadi Ellur, Mallikarjuna
Baird, Mimi
Baker, Megan E.
Balasundaram, Janooshsheya
Balair, Ruben
Ballestas, Julio
Balon, Richard
Banu, Sophia
Banaroski, Madelon
Barber, Keila D.
Barber, Mary
Barkil-Oteo, Andres
Barnea, Yael
Barnhill, John W.
Barry, Declan
Barry, John
Basalay, Nicholas P.
Baslet, Gaston
Bassi, Bruce
Bassirnia, Anahita
Bateman, Anthony
Bath, Eraka
Batista, Sharon
Batta, Priya
Baum, Antonia L.
Baweja, Raman
Bayner, Jessica S.
Bazzi, Lama
Beahrs, John O.
Bean, Jennifer
Beck Busis, Deborah
Beck, Judith S.
Becker, Anne
Becker, Daniel F.
Begel, Daniel
Belhadi-Tahar, Hafid
Bell, Carl C.
Bell, Holly S.
Bell, Tiffani
Belnap, Barri
Benassi, Paul V.
Benedek, Elissa P.
Benson, R. Scott
Benson, Timothy
Bentman, Adrienne
Bera, Rimal B.
Beresin, Eugene V.
Berlin, Jon
Berman, Ellen
Bermeo-Ovalle, Adriana
Bermudes, Richard A.
Bernardi, Silvia
Bernstein, Carol A.
Bhatia, Subhash C.
Bhugra, Dinesh
Binder, Renée
Biskin, Robert
Blair, Thomas
Blanco, Carlos
Blank, Arthur S.
Blazer, Dan G.
Blevins, Derek
Bloom, Mia M.
Blumenfeld, Michael
Blyta, Afrim A.
Boland, Robert J.
Bonilla-Silva, Eduardo
Bonnie, Richard J.
Borchering, Breck
Bordoloi, Meelie
Borenstein, Jeffrey
Bostwick, J. Michael
Bota, Robert G.
Boursiquot, Philippe
Brenner, Adam
Breur, Jorien G.
Breyer, Stephen
Brichant-Petitjean, Clara
Briggs, Jessica
Brooks, James
Brooks, John
Brown, Adam
Brown, Frank W.
Brown, Gregory K.
Brown, Jordan
Brown, Kevin
Brown, Millard
Brownridge, Andrea M.
Brozyna, Caroline D.
Bubl, Emanuel
Busch, Alisa B.
Busch, Fredric N.
Buwada, Victor J. A.
Byne, William M.
Bysani, Sailaja
Caban-Aleman, Carissa
Cadenhead, Kristin
Cai, Stella
Caligor, Eve
Calkins, Monica E.
Campbell, Marc L.
Camps-Romero, Eduardo
Cano, Miguel Angel
Canton, Ali
Canuso, Amy A.
Capaldi, Vincent F.
Caplan, Rochelle
Carlo, Andrew D.
Carlson, Stephan M.
Carnall, Amy B.
Carter, Arthur T.
Carter, Dakota
Carter, Debbie R.
Caruso, Keith A.
Casey, Patricia R.
Cassimatis, Emmanuel
Cassin, Stephanie
Castellanos, Daniel
Castilla-Puentes, Wilma I.
Castro, Carl
Caudill, Robert
Cazes, Paulette
Disclosure Index

Certa, Kenneth M.
Chae, Jeong-Ho
Chakraburty, Amasha
Champion, Michael
Chan, Stephanie H.
Chaney, Michelle
Chang, Grace
Chang, Sung Man
Charara, Raghid
Charles Malveaux, Wilma M. S.
Charoensook, Janet
Chase, Daria
Chatigny, Ashley H.
Chaudhry, Montika
Cheema, Raminder Pal
Chen, Alexander
Chen, Donna
Chen, Justin
Chen, Pao-Huan
Chen, Wan-Yi
Chen, Pao-Huan
Chen, Donna
Chen, Justin
Chen, Pao-Huan
Chen, Wan-Yi
Cheon, Joah
Cheong, Josepha A.
Cheung, Stephanie
Chi, Su Hyuk
Chien, I-Chia
Chikvashvili, Irina
Chilton, Julie A.
Chiu, Simon
Choi-Kain, Lois W.
Chong, Yon J.
Chopra, Mehak
Chotalia, Jigar K.
Christensen, Aleta
Chudal, Roshan
Chukwu, Ijeoma
Chukwueke, Priscilla N.
Chumley, Frank B.
Chung, In-Won
Chung, Moon Yong
Chung, Sang-Keun
Chung, Seungwon
Chung, Wilson
Chwastiak, Lydia
Clark, Scott
Clarke, Diana E.
Coffin, Philip O.
Cohen, Carl I.
Cohen, Jenna
Cohen, Lisa J.
Cohen, Mary Ann A.
Cohen, Mitchell J.
Cole, Steven
Collins, Ashley D.
Colombo, Francesca
Colom, Omar A.
Colomb, Hector
Compton, Wilson M.
Conant-Norville, David O.
Conrad, Rachel
Conroy, Michelle
Conway, Kevin P.
Correa da Costa, Sabrina
Coreale, Jennifer
Coryell, William
Costello, Caitlin
Cournoys, Francine
Cox, Lara J.
Craig, Thomas J.
Crawford, Allison
Creed, Jamie O.
Cremaschi, Laura Angela
Crone, Catherine
Crumlish, Jennifer A.
Cruz Alvarez, Beatriz
Cukor, Judith
Cullen, Bernadette
Cummings, Hugh
Curseen, Kim
Cyrus, Kali
D’Aquilia, Carolyn
D’Mello, Dale
D’Souza, Deepak Cyril
Dager, Alexis D.
Dakwar, Elias
Danzer, Graham S.
Dar, Syma
Darby, William C.
Das, Smita
Datta, Vivek
Dave, Ananta
Dave, Shalini D.
Dave, Subodh
Davidoff, Donald A.
Davidowitz, Andrew
Davidson, Deepak M.
De Erasquin, Gabriel
De Guzman, Earl
Andrew B.
de Julio, Adriana B.
Deans, Emily C.
Deas, Deborah
DeGraba, Thomas J.
DeJong, Sandra
Delia Cruz, Milania
Dell, Mary Lynn
DeMarco, Austin
DePaolo, Antonio
DePaolo, J. Raymond
Dereczynski, Aimee
Derish, Nicole E.
DeRubeis, Laura
Desai, Pratik Kumar
Desai, Toral
Detweiler, Mark B.
Devassy, Cindy
Devlin, Michael
Dewar, Mantosh
Dhilliwal, Arashinder
Dhillon, Karnaldeep
Di Giacomo, Ester
Di Nicola, Vincenzo
Diamond, Diana
Diaz, Esperanza
Dickman, Anna L.
Dickstein, Leah
Dike, Charles C.
Dilley, James
Dimsdale, Joel E.
Dineen Wagner, Karen
Divakarla, Swati
Dixon, Lisa B.
Do, Linda
Doblin, Rick
Dominguez, Matthew L.
Dong, Hyunseok
Dooley, Erin
Douglas, John
Downing, Laura M.
Dragatsi, Dianna
Dratcu, Luiz
Dress, Erich M.
Dreyer, Benard
Druss, Benjamin G.
Du, Ye B.
Dube, Anish R.
Duckworth, Ken
Duda, Roger
Dumas, Noel B.
Dunlap, Constance E.
Dusad, Asha
Duval, Fabrice
Eilender, Pamela
Eisen, Jane L.
El Sara, Ammar
Elas, Alby
Elkady, Rasha
Ellison, James M.
Elmi, Sarah
Elswick, Daniel
Enomoto, Kana
Epstein, Igor
Epstein, Steve E.
Erb, Alexis
Erickson, Jennifer M.
Erickson-Schroth, Laura
Erlich, Matthew D.
Escamilla, Kristin V.
Espiforcen, Fernando
Esquiva, LeRoy C.
Eterwaroo, Narissa R.
Eun, Tae Kyung
Everett, Anita
Everett, Mia
Evren, Cuneyt
Eyler, Evan
Faggen, Alec
Fairbairn, Jonathan
Fairman, Nathan
Falcone, Tatiana
Famador, Mark
Fan, Qing
Fardeed, Aymen
Farooq, Moebeen
Farrell, Helen
Faulkner, Larry R.
Fauman, Beverly
Fawcett, Jan
Feldman, Jacqueline M.
Feldman, Lara W
Fernandez, Carlos
Ferranti, Jessica
Ferrer, Daphne
Feusner, Jamie
Figue, Martijn
Fils-Aimé, Joseph R.
Fineberg, Naomi A.
Fink, Sabina
Fink, Victoria
Finlayson, A. J. Reid
Fiskin, Anna
Fitelson, Elizabeth
Fjukstad, Katrine K.
Flaherty, Marissa
Flinton, Christopher
Flora, Charles M.
Flynn, David
Fochtmann, Laura J.
Foglesong, Dana
Foidel, Sarah
Foo, Calvin
Ford, Elizabeth
Fore, Peter
Forrester, Anique
Forstein, Marshall
Forster, Janice
Fortuna, Lisa R.
Fournis, Giel
Fowler, J. Christopher
Franco Cadet, Suhey G.
Franco, Kathleen
Frangou, Sophia
Freedman, Robert
Freidlin, Eve Khlyavich
Fritz, Gregory K.
Fromson, John A.
Frueh, B. Christopher
Frye, Elizabeth A.
Fryml, Leah D.
Fu, Emily
Fuehrlein, Brian
Fuller, Linda
Fung, Kenneth P.
Fung, Wai Lun Alan
Funk, Margo
Furuta, Michelle
Gabbard, Glen O.
Gage, Fred H.
Gaianter, Marc
Gallagher, Keith
Galles, Elyse
Galykner, Igor
Gandi, Raghunath
Gandhi, Tapas
Garavan, Hugh
Garrick, Marshall L.
Gatchel, Jennifer
Gaytan, Osvaldo
Genova, Nicholas J.
Gershengoren, Liilia
Gharatmal, Mohammad A.
Ghani, Shareh O.
Ghignone, Erica
Ghimire, Shree R.
Ghiya, Ashik
Gilberti, Mary
Gillihan, Seth J.
Gilmam, Megan L.
Ginory, Almari
Ginory, Laura
<table>
<thead>
<tr>
<th>Disclosure Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gipson, Shih Yee-Marie Tan</td>
</tr>
<tr>
<td>Giri, Aditi</td>
</tr>
<tr>
<td>Gise, Leslie H.</td>
</tr>
<tr>
<td>Glancy, Graham D.</td>
</tr>
<tr>
<td>Glick, Ira</td>
</tr>
<tr>
<td>Glick, Rachel</td>
</tr>
<tr>
<td>Glover, Juliet A.</td>
</tr>
<tr>
<td>Gobbi, Gabriella</td>
</tr>
<tr>
<td>Goddu, Sumana</td>
</tr>
<tr>
<td>Goedken, Rebecca E.</td>
</tr>
<tr>
<td>Goelitz, Melissa</td>
</tr>
<tr>
<td>Goethe, John W.</td>
</tr>
<tr>
<td>Goff, Donald C.</td>
</tr>
<tr>
<td>Gogineni, Rama Rao</td>
</tr>
<tr>
<td>Gold, Liza H.</td>
</tr>
<tr>
<td>Goldbach, Jeremy</td>
</tr>
<tr>
<td>Goldenberg, Matthew N.</td>
</tr>
<tr>
<td>Goldman, Matthew L.</td>
</tr>
<tr>
<td>Goldwaser, Alberto M.</td>
</tr>
<tr>
<td>Gomez Fuentes, Amy C.</td>
</tr>
<tr>
<td>Gomez, Chaska</td>
</tr>
<tr>
<td>Gomez, Juan Carlos</td>
</tr>
<tr>
<td>Goniewicz, Maciej L.</td>
</tr>
<tr>
<td>Goode, Kimberly D.</td>
</tr>
<tr>
<td>Goodman, Marianne</td>
</tr>
<tr>
<td>Goodwin, Ericka</td>
</tr>
<tr>
<td>Gordon, Kimberly</td>
</tr>
<tr>
<td>Gorelick, David</td>
</tr>
<tr>
<td>Gorriondo, Tristan</td>
</tr>
<tr>
<td>Goschin, Simona</td>
</tr>
<tr>
<td>Goswani Banerjee, Arpita</td>
</tr>
<tr>
<td>Goyal, Dharmendra K.</td>
</tr>
<tr>
<td>Graham, Yolanda P.</td>
</tr>
<tr>
<td>Gralnik, Leonard M.</td>
</tr>
<tr>
<td>Grammer, Geoffrey</td>
</tr>
<tr>
<td>Grant, Cynthia</td>
</tr>
<tr>
<td>Grassi, Giacomo</td>
</tr>
<tr>
<td>Gray, Kyle J.</td>
</tr>
<tr>
<td>Gray, Sheila H.</td>
</tr>
<tr>
<td>Greenbaum, Jordan</td>
</tr>
<tr>
<td>Greer, Tracy</td>
</tr>
<tr>
<td>Gregoire, Philip</td>
</tr>
<tr>
<td>Griffith, Ezra</td>
</tr>
<tr>
<td>Griffith, James</td>
</tr>
<tr>
<td>Grob, Charles</td>
</tr>
<tr>
<td>Gross, Raz</td>
</tr>
<tr>
<td>Gruenberg, Linda F.</td>
</tr>
<tr>
<td>Gspandl, Scott</td>
</tr>
<tr>
<td>Guanci, Nicole</td>
</tr>
<tr>
<td>Guerra, Paloma A.</td>
</tr>
<tr>
<td>Gularte, Valeria S.</td>
</tr>
<tr>
<td>Gunderson, John</td>
</tr>
<tr>
<td>Gunturu, Sasidhar</td>
</tr>
<tr>
<td>Guo, Qi</td>
</tr>
<tr>
<td>Gupta, Nandini</td>
</tr>
<tr>
<td>Gupta, Neha</td>
</tr>
<tr>
<td>Gupta, Nitin</td>
</tr>
<tr>
<td>Gurski, John</td>
</tr>
<tr>
<td>Guthrie, Elisabeth B.</td>
</tr>
<tr>
<td>Guttkonda, Sameera</td>
</tr>
<tr>
<td>Guzman, Margarita</td>
</tr>
<tr>
<td>Habi, Samar</td>
</tr>
<tr>
<td>Hackman, Ann</td>
</tr>
<tr>
<td>Hagan, Jarred</td>
</tr>
<tr>
<td>Hagleund, Margaret</td>
</tr>
<tr>
<td>Hah, Jennifer</td>
</tr>
<tr>
<td>Hairston, Danielle</td>
</tr>
<tr>
<td>Hall, Ryan</td>
</tr>
<tr>
<td>Haller, Ellen</td>
</tr>
<tr>
<td>Halperin Rosen, Anna</td>
</tr>
<tr>
<td>Halitzman, Scott</td>
</tr>
<tr>
<td>Hamdani, Najma F.</td>
</tr>
<tr>
<td>Hamidovic, Aija</td>
</tr>
<tr>
<td>Hammamieh, Rasha</td>
</tr>
<tr>
<td>Han, Doug Hyun</td>
</tr>
<tr>
<td>Hanif, Amina</td>
</tr>
<tr>
<td>Hann, Michael</td>
</tr>
<tr>
<td>Hanrahan, Mary</td>
</tr>
<tr>
<td>Haque, Shariq</td>
</tr>
<tr>
<td>Hardaway, Rashad</td>
</tr>
<tr>
<td>Hardeman, Suzanne M.</td>
</tr>
<tr>
<td>Harding, Richard</td>
</tr>
<tr>
<td>Harewood, Meredith</td>
</tr>
<tr>
<td>Harrigan, Michael R.</td>
</tr>
<tr>
<td>Harris, Christopher</td>
</tr>
<tr>
<td>Harris, Gregory G.</td>
</tr>
<tr>
<td>Harris, Patrice</td>
</tr>
<tr>
<td>Harrison, Nzinga</td>
</tr>
<tr>
<td>Hart, Joseph</td>
</tr>
<tr>
<td>Harvey, Margaret</td>
</tr>
<tr>
<td>Hasan, Rabiya</td>
</tr>
<tr>
<td>Hasnain, Mehrul</td>
</tr>
<tr>
<td>Hassan, Tariq</td>
</tr>
<tr>
<td>Hatters-Friedman, Susan J.</td>
</tr>
<tr>
<td>Hawa, Raed</td>
</tr>
<tr>
<td>Hawes, Mariah</td>
</tr>
<tr>
<td>Hazlett, Erin</td>
</tr>
<tr>
<td>Hedrick, Saima</td>
</tr>
<tr>
<td>Heeramon, Vineka</td>
</tr>
<tr>
<td>Hemani, Umair M.</td>
</tr>
<tr>
<td>Hendryx, Travis</td>
</tr>
<tr>
<td>Henein, Fady</td>
</tr>
<tr>
<td>Herr, Christian Y.</td>
</tr>
<tr>
<td>Hernandez, Sergio</td>
</tr>
<tr>
<td>Herrera, Helen</td>
</tr>
<tr>
<td>Hers, Richard</td>
</tr>
<tr>
<td>Hetrick, Benjamin R.</td>
</tr>
<tr>
<td>Heru, Alison M.</td>
</tr>
<tr>
<td>Hidalgo, Marla</td>
</tr>
<tr>
<td>Higgins, Napoleon B.</td>
</tr>
<tr>
<td>Hill, Kevin</td>
</tr>
<tr>
<td>Hill, Wesley</td>
</tr>
<tr>
<td>Hilty, Donald M.</td>
</tr>
<tr>
<td>Ho, Cyrus S. H.</td>
</tr>
<tr>
<td>Hoang, Julia L.</td>
</tr>
<tr>
<td>Hobbs, Jacqueline A.</td>
</tr>
<tr>
<td>Hodson, David S.</td>
</tr>
<tr>
<td>Hoffman, Christopher</td>
</tr>
<tr>
<td>Hoffman, Perry</td>
</tr>
<tr>
<td>Hoge, Charles</td>
</tr>
<tr>
<td>Hoge, Steven</td>
</tr>
<tr>
<td>Hoirisch-Clapauch, Silvia</td>
</tr>
<tr>
<td>Holbert, Richard</td>
</tr>
<tr>
<td>Hollander, Eric</td>
</tr>
<tr>
<td>Holloway, Ian W.</td>
</tr>
<tr>
<td>Holsey, M. D.</td>
</tr>
<tr>
<td>Hong, Victor</td>
</tr>
<tr>
<td>Hooshmand, Farnaz</td>
</tr>
<tr>
<td>Horgan, John</td>
</tr>
<tr>
<td>Horowitz, Mardi</td>
</tr>
<tr>
<td>Horvath, Thomas B.</td>
</tr>
<tr>
<td>Horwitz, Josh</td>
</tr>
<tr>
<td>Howe, Edmund G.</td>
</tr>
<tr>
<td>Hoxha, Avjola</td>
</tr>
<tr>
<td>Hreish, Mark N.</td>
</tr>
<tr>
<td>Hsu, Kean J.</td>
</tr>
<tr>
<td>Hu, Sai</td>
</tr>
<tr>
<td>Huang, Yueqin</td>
</tr>
<tr>
<td>Hughes-Feltenberger, Megan</td>
</tr>
<tr>
<td>Hunzeker, Adam</td>
</tr>
<tr>
<td>Hurucic, Damir</td>
</tr>
<tr>
<td>Hurley, Brian</td>
</tr>
<tr>
<td>Hurwitz, Thomas D.</td>
</tr>
<tr>
<td>Husain, Nusrat</td>
</tr>
<tr>
<td>Hussain, Filza C.</td>
</tr>
<tr>
<td>Hutton, Todd</td>
</tr>
<tr>
<td>Huyhn, Martin K.</td>
</tr>
<tr>
<td>Hwang, Michael</td>
</tr>
<tr>
<td>Hyde, Lee S.</td>
</tr>
<tr>
<td>Hyler, Steven E.</td>
</tr>
<tr>
<td>Iarocci, Doris</td>
</tr>
<tr>
<td>Ibeziako, Patricia</td>
</tr>
<tr>
<td>Ibrahim, Lobna</td>
</tr>
<tr>
<td>Iheagwara, Chioma L.</td>
</tr>
<tr>
<td>Iheanacho, Theddeus</td>
</tr>
<tr>
<td>Ikekwere, Joseph C.</td>
</tr>
<tr>
<td>Iliipila, Geeta S.</td>
</tr>
<tr>
<td>Immanuel, Josepha</td>
</tr>
<tr>
<td>Imran, Sheema</td>
</tr>
<tr>
<td>Ingram, Douglas H.</td>
</tr>
<tr>
<td>Iqbal, Muhammad N.</td>
</tr>
<tr>
<td>Irfan, Muhammad</td>
</tr>
<tr>
<td>Irwin, Scott</td>
</tr>
<tr>
<td>IsHak, Waguih W.</td>
</tr>
<tr>
<td>Isinguzo, Chidinma</td>
</tr>
<tr>
<td>Islam, Zahid</td>
</tr>
<tr>
<td>Ivanova, Daniele</td>
</tr>
<tr>
<td>Ivan, Christopher</td>
</tr>
<tr>
<td>Iyer, Veeraraghavan J.</td>
</tr>
<tr>
<td>Jabeen, Shagufa</td>
</tr>
<tr>
<td>Jabri, Lamis</td>
</tr>
<tr>
<td>Jacob Mathai, Ashwin</td>
</tr>
<tr>
<td>Jacob, Karen L.</td>
</tr>
<tr>
<td>Jahdi, Maryam</td>
</tr>
<tr>
<td>Jain, Abhishek</td>
</tr>
<tr>
<td>Jain, Lakshit</td>
</tr>
<tr>
<td>James, Christopher</td>
</tr>
<tr>
<td>Janda, Kim D.</td>
</tr>
<tr>
<td>Janofsky, Jeffrey S.</td>
</tr>
<tr>
<td>Jayaram, Geetha</td>
</tr>
<tr>
<td>Jenkins, Thomas</td>
</tr>
<tr>
<td>Jennings, Keith W.</td>
</tr>
<tr>
<td>Jeon, Junwon</td>
</tr>
<tr>
<td>Jessica, Moore</td>
</tr>
<tr>
<td>Jeste, Dilip V.</td>
</tr>
<tr>
<td>Jett, Marti</td>
</tr>
<tr>
<td>Jha, Manish K.</td>
</tr>
<tr>
<td>Ji, Ning</td>
</tr>
<tr>
<td>Joe, Soohyun</td>
</tr>
<tr>
<td>Johnson, David</td>
</tr>
<tr>
<td>Johnson, Sarah</td>
</tr>
<tr>
<td>Johnston, Robert J. H.</td>
</tr>
<tr>
<td>Joiner, Thomas</td>
</tr>
<tr>
<td>Jones, Jana</td>
</tr>
<tr>
<td>Jones, Meissa M.</td>
</tr>
<tr>
<td>Jones, Travis W.</td>
</tr>
<tr>
<td>Jordan, Ayana</td>
</tr>
<tr>
<td>Jose, Diviya E.</td>
</tr>
<tr>
<td>Joseph, Courtney</td>
</tr>
<tr>
<td>Joseph, Robert C.</td>
</tr>
<tr>
<td>Josephson, Allan</td>
</tr>
<tr>
<td>Joshi, Astik</td>
</tr>
<tr>
<td>Joshi, Kaustubh G.</td>
</tr>
<tr>
<td>Joshi, Pallavi</td>
</tr>
<tr>
<td>Joshi, Paramjit</td>
</tr>
<tr>
<td>Joy, Michelle</td>
</tr>
<tr>
<td>Judge, Sheila</td>
</tr>
<tr>
<td>Jun, Tae-Youn</td>
</tr>
<tr>
<td>Jung, Chan Hyun</td>
</tr>
<tr>
<td>Kahlon, Ramandeep S.</td>
</tr>
<tr>
<td>Kakhi, Sara</td>
</tr>
<tr>
<td>Kallivayalil, Roy A.</td>
</tr>
<tr>
<td>Kanba, Shigenobu</td>
</tr>
<tr>
<td>Kang, Jee In</td>
</tr>
<tr>
<td>Kang, Suk-Hoon</td>
</tr>
<tr>
<td>Kannal, Rajasekhar</td>
</tr>
<tr>
<td>Kantor, Edward</td>
</tr>
<tr>
<td>Kaplisky, Dheeraj</td>
</tr>
<tr>
<td>Kapoor, Shweta</td>
</tr>
<tr>
<td>Karas, Dan H.</td>
</tr>
<tr>
<td>Karim, Reef</td>
</tr>
<tr>
<td>Karlsson, Per-Axel L.</td>
</tr>
<tr>
<td>Kaster, Tyler</td>
</tr>
<tr>
<td>Kathol, Roger</td>
</tr>
<tr>
<td>Kato, Takahiro A.</td>
</tr>
<tr>
<td>Kaur, Amanjot</td>
</tr>
<tr>
<td>Kazmi, Ajmal</td>
</tr>
<tr>
<td>Keenan, Walker D.</td>
</tr>
<tr>
<td>Keith, Asheena</td>
</tr>
<tr>
<td>Kemble, Stephen B.</td>
</tr>
<tr>
<td>Kendler, Kenneth</td>
</tr>
<tr>
<td>Kennedy, Patrick</td>
</tr>
<tr>
<td>Kennedy, Robert</td>
</tr>
<tr>
<td>Kennedy, Sidney H.</td>
</tr>
<tr>
<td>Kent, Laura K.</td>
</tr>
<tr>
<td>Kern, John</td>
</tr>
<tr>
<td>Kernberg, Otto F.</td>
</tr>
<tr>
<td>Kertzner, Robert M.</td>
</tr>
<tr>
<td>Ketchen, Bethany</td>
</tr>
<tr>
<td>Kethini, Vandana</td>
</tr>
<tr>
<td>Khairalla, Hanan</td>
</tr>
<tr>
<td>Khairey, Nahed</td>
</tr>
<tr>
<td>Khalafian, Andrey</td>
</tr>
<tr>
<td>Khalid-Khan, Sarosh</td>
</tr>
<tr>
<td>Khalil, Afaf H.</td>
</tr>
<tr>
<td>Khan, Jaffar</td>
</tr>
<tr>
<td>Khan, Mohammed A.</td>
</tr>
<tr>
<td>Khan, Mohsin</td>
</tr>
<tr>
<td>Khan, Muhammad</td>
</tr>
<tr>
<td>Khan, Qaiser S.</td>
</tr>
<tr>
<td>K Hanna, Surbhi</td>
</tr>
<tr>
<td>Khaawaja, Imran S.</td>
</tr>
<tr>
<td>Khawam, Elias</td>
</tr>
<tr>
<td>Khosh-Chashm, Darrow</td>
</tr>
<tr>
<td>Khushalani, Sunil</td>
</tr>
<tr>
<td>Name</td>
</tr>
<tr>
<td>---------------------------</td>
</tr>
<tr>
<td>Khusid, Marina</td>
</tr>
<tr>
<td>Kidd, Jeremy D.</td>
</tr>
<tr>
<td>Kilani, Jayotsna</td>
</tr>
<tr>
<td>Kim, Chaeri</td>
</tr>
<tr>
<td>Kim, Chul-Eung</td>
</tr>
<tr>
<td>Kim, Daniel</td>
</tr>
<tr>
<td>Kim, Daseul</td>
</tr>
<tr>
<td>Kim, Eui-Jung</td>
</tr>
<tr>
<td>Kim, Eun Young</td>
</tr>
<tr>
<td>Kim, Han-Joon</td>
</tr>
<tr>
<td>Kim, Helena K.</td>
</tr>
<tr>
<td>Kim, Hyun</td>
</tr>
<tr>
<td>Kim, Jung W.</td>
</tr>
<tr>
<td>Kim, Kahn Hong Seon</td>
</tr>
<tr>
<td>Kim, Keun You</td>
</tr>
<tr>
<td>Kim, Kyungwon</td>
</tr>
<tr>
<td>Kim, Minsu</td>
</tr>
<tr>
<td>Kim, Seong Hwan</td>
</tr>
<tr>
<td>Kim, Siekyeong</td>
</tr>
<tr>
<td>Kim, Taeho</td>
</tr>
<tr>
<td>Kim, Won</td>
</tr>
<tr>
<td>Kim, Yong-Ku</td>
</tr>
<tr>
<td>Kim, Young Hoon</td>
</tr>
<tr>
<td>Kim, Young Shin</td>
</tr>
<tr>
<td>Kimm, Tyler</td>
</tr>
<tr>
<td>Kingdon, David</td>
</tr>
<tr>
<td>Kiong, Timothy</td>
</tr>
<tr>
<td>Kirsch, Daniel</td>
</tr>
<tr>
<td>Kjaer, Jesper N.</td>
</tr>
<tr>
<td>Klass, Benjamin O.</td>
</tr>
<tr>
<td>Kleiman, Mark</td>
</tr>
<tr>
<td>Klin, Ami</td>
</tr>
<tr>
<td>Knoll, James L.</td>
</tr>
<tr>
<td>Koenig, Jessica A.</td>
</tr>
<tr>
<td>Koenigsberg, Harold W.</td>
</tr>
<tr>
<td>Koh, Steve H.</td>
</tr>
<tr>
<td>Kolodner, George</td>
</tr>
<tr>
<td>Komrad, Mark</td>
</tr>
<tr>
<td>Koniaris, Christine</td>
</tr>
<tr>
<td>Kor, Ariel</td>
</tr>
<tr>
<td>Koss, Debra</td>
</tr>
<tr>
<td>Kosten, Thomas</td>
</tr>
<tr>
<td>Kothari, Kavita</td>
</tr>
<tr>
<td>Koyuncu, Ahmet</td>
</tr>
<tr>
<td>Krakowski, Menahem I.</td>
</tr>
<tr>
<td>Kraus, Louis</td>
</tr>
<tr>
<td>Krishna, Swathi</td>
</tr>
<tr>
<td>Kroeber Trakowski, Kristin</td>
</tr>
<tr>
<td>Krueger, Robert</td>
</tr>
<tr>
<td>Kudler, Harold</td>
</tr>
<tr>
<td>Kudva, Ganesh</td>
</tr>
<tr>
<td>Kum, Seon</td>
</tr>
<tr>
<td>Kum, Reena</td>
</tr>
<tr>
<td>Kumari, Meena</td>
</tr>
<tr>
<td>Kurdyak, Paul</td>
</tr>
<tr>
<td>Kurkjian, Natalie</td>
</tr>
<tr>
<td>Kurtz, Kristina E.</td>
</tr>
<tr>
<td>Kuvishansky, Jaime M.</td>
</tr>
<tr>
<td>La Noce, Audrey</td>
</tr>
<tr>
<td>LaChance, Laura R.</td>
</tr>
<tr>
<td>Lackamp, Jeanne</td>
</tr>
<tr>
<td>LaFrance, W. Curt</td>
</tr>
<tr>
<td>Lagman, Jasmin G.</td>
</tr>
<tr>
<td>Lahera, Guilermo</td>
</tr>
<tr>
<td>Lai, Hank</td>
</tr>
<tr>
<td>Lakshmin, Pooja</td>
</tr>
<tr>
<td>Lam, June</td>
</tr>
<tr>
<td>Lambert, Kristen M.</td>
</tr>
<tr>
<td>Lambrese, Jason V.</td>
</tr>
<tr>
<td>Lavender, Ted</td>
</tr>
<tr>
<td>Lazarus, Arthur</td>
</tr>
<tr>
<td>Lazarus, Joash T.</td>
</tr>
<tr>
<td>Le, Hoa</td>
</tr>
<tr>
<td>Leal, Camilo</td>
</tr>
<tr>
<td>Lee, Byeonghee</td>
</tr>
<tr>
<td>Lee, Chuan-Mei</td>
</tr>
<tr>
<td>Lee, Deokjong</td>
</tr>
<tr>
<td>Lee, Elliott K.</td>
</tr>
<tr>
<td>Lee, Hochang B.</td>
</tr>
<tr>
<td>Lee, Hyuk</td>
</tr>
<tr>
<td>Lee, Hyun-Ah</td>
</tr>
<tr>
<td>Lee, Kyoung-UK</td>
</tr>
<tr>
<td>Lee, Li-Wen Grace</td>
</tr>
<tr>
<td>Lee, Sang Kyu</td>
</tr>
<tr>
<td>Lee, Sang Yeol</td>
</tr>
<tr>
<td>Lee, Seung-Hwan</td>
</tr>
<tr>
<td>Lee, Soyoen</td>
</tr>
<tr>
<td>Lee, Woo Hyung</td>
</tr>
<tr>
<td>Lee, Young Sik</td>
</tr>
<tr>
<td>Leistedt, Samuel J.</td>
</tr>
<tr>
<td>Leivent, Jacob</td>
</tr>
<tr>
<td>Lemieux, Anthony</td>
</tr>
<tr>
<td>Levin, Saul</td>
</tr>
<tr>
<td>Levine, Henry S.</td>
</tr>
<tr>
<td>Levine, Stephen B.</td>
</tr>
<tr>
<td>Levitt, William</td>
</tr>
<tr>
<td>Levounis, Petros</td>
</tr>
<tr>
<td>Levy, Sharon</td>
</tr>
<tr>
<td>Lewandowski, Cathleen A.</td>
</tr>
<tr>
<td>Lewis, Edward T.</td>
</tr>
<tr>
<td>Li, Dongmei</td>
</tr>
<tr>
<td>Li, Eun Jung</td>
</tr>
<tr>
<td>Li, Kevin J.</td>
</tr>
<tr>
<td>Li, Luming</td>
</tr>
<tr>
<td>Li, Shuang</td>
</tr>
<tr>
<td>Lichtenstein, Max A.</td>
</tr>
<tr>
<td>Licinio, Julio</td>
</tr>
<tr>
<td>Lim, Jongseok</td>
</tr>
<tr>
<td>Lim, Russell F.</td>
</tr>
<tr>
<td>Lima, Atreaya</td>
</tr>
<tr>
<td>Lin, Joy E.</td>
</tr>
<tr>
<td>Lipsitt, Don</td>
</tr>
<tr>
<td>Lisotto, Maria Jose</td>
</tr>
<tr>
<td>Liu, Lusha</td>
</tr>
<tr>
<td>Liu, Shiyuan</td>
</tr>
<tr>
<td>Liu, Zhaorui</td>
</tr>
<tr>
<td>Lizano, Paulo L.</td>
</tr>
<tr>
<td>Luberes Rincon, Nubia G.</td>
</tr>
<tr>
<td>Lochhead, Jeannie</td>
</tr>
<tr>
<td>Loehr, Colleen</td>
</tr>
<tr>
<td>Lohitsa, Akshay</td>
</tr>
<tr>
<td>Lokko, Hermioni</td>
</tr>
<tr>
<td>Lolak, Sermsak</td>
</tr>
<tr>
<td>Lomax, James W.</td>
</tr>
<tr>
<td>Lowenthal, David</td>
</tr>
<tr>
<td>Lowy, Daniel L.</td>
</tr>
<tr>
<td>Lu, Francis</td>
</tr>
<tr>
<td>Lubarda, Jovana</td>
</tr>
<tr>
<td>Lubin, Molly</td>
</tr>
<tr>
<td>Lynch, Alison</td>
</tr>
<tr>
<td>Lytle, Sarah M.</td>
</tr>
<tr>
<td>MacDonald, Kelly</td>
</tr>
<tr>
<td>MacKenzie, James G.</td>
</tr>
<tr>
<td>Mackey, Sean</td>
</tr>
<tr>
<td>MacLeod, Stephanie</td>
</tr>
<tr>
<td>Madan, Alok</td>
</tr>
<tr>
<td>Madhusoodanan, Subramoniam</td>
</tr>
<tr>
<td>Madsen, Helle</td>
</tr>
<tr>
<td>Maeng, Se-Ri</td>
</tr>
<tr>
<td>Mahadian, Artin</td>
</tr>
<tr>
<td>Mahendran, Rathi</td>
</tr>
<tr>
<td>Maheshwari, Subani</td>
</tr>
<tr>
<td>Mahgoub, Yassir</td>
</tr>
<tr>
<td>Mahoney, Nicholas</td>
</tr>
<tr>
<td>Mai, Mario</td>
</tr>
<tr>
<td>Makani, Ramkrishna D.</td>
</tr>
<tr>
<td>Makanjuola, Titilayo</td>
</tr>
<tr>
<td>Maldonado, Jose R.</td>
</tr>
<tr>
<td>Malik, Arsalan</td>
</tr>
<tr>
<td>Malik, Mahgul</td>
</tr>
<tr>
<td>Maloy, Katherine</td>
</tr>
<tr>
<td>Maltz, Brenda</td>
</tr>
<tr>
<td>Manalai, Partam</td>
</tr>
<tr>
<td>Mangal, Jed P.</td>
</tr>
<tr>
<td>Mangiardi, Mario</td>
</tr>
<tr>
<td>Mann, Gurjot S.</td>
</tr>
<tr>
<td>Manocha, Pankaj</td>
</tr>
<tr>
<td>Marazziti, Donatella</td>
</tr>
<tr>
<td>Marcus, Adeyemi</td>
</tr>
<tr>
<td>Mariani, John J.</td>
</tr>
<tr>
<td>Marino, Leslie</td>
</tr>
<tr>
<td>Marino, Patricia</td>
</tr>
<tr>
<td>Markkula, Niina</td>
</tr>
<tr>
<td>Markowitz, John C.</td>
</tr>
<tr>
<td>Marlin, Robert P.</td>
</tr>
<tr>
<td>Martinez, Richard</td>
</tr>
<tr>
<td>Martino, Steve</td>
</tr>
<tr>
<td>Martz, Gloria</td>
</tr>
<tr>
<td>Marumoto, Megan</td>
</tr>
<tr>
<td>Maruyama, Nancy</td>
</tr>
<tr>
<td>Mashiama, Amnapreet</td>
</tr>
<tr>
<td>Maskel, Lynn</td>
</tr>
<tr>
<td>Mathur, Anu</td>
</tr>
<tr>
<td>Maududi, Syed E.</td>
</tr>
<tr>
<td>Mazhar, Mir N.</td>
</tr>
<tr>
<td>McCabe, Sean E.</td>
</tr>
<tr>
<td>McCarron, Robert M.</td>
</tr>
<tr>
<td>McClure, Deimante</td>
</tr>
<tr>
<td>McDougall, Matthew A.</td>
</tr>
<tr>
<td>McDuff, David R.</td>
</tr>
<tr>
<td>McGinnis, MegAnn K.</td>
</tr>
<tr>
<td>McGlynn, Lawrence</td>
</tr>
<tr>
<td>McGovern, Amanda</td>
</tr>
<tr>
<td>McGraw, Kate</td>
</tr>
<tr>
<td>McHugh, Paul</td>
</tr>
<tr>
<td>McKenzie, Kame</td>
</tr>
<tr>
<td>McLeod, Megan</td>
</tr>
<tr>
<td>McNeill, Shawn E.</td>
</tr>
<tr>
<td>McNeil, Dale</td>
</tr>
<tr>
<td>McVoy, Molly</td>
</tr>
<tr>
<td>Medici, Clara R.</td>
</tr>
<tr>
<td>Medlock, Morgan</td>
</tr>
<tr>
<td>Melcher, Tomas</td>
</tr>
<tr>
<td>Mellon, Synthia H.</td>
</tr>
<tr>
<td>Mendiola, Andrea</td>
</tr>
<tr>
<td>Merlo, Lisa J.</td>
</tr>
<tr>
<td>Merti, Julia</td>
</tr>
<tr>
<td>Metzner, Jeffrey L.</td>
</tr>
<tr>
<td>Meyer, Donald J.</td>
</tr>
<tr>
<td>Meyer, Eric</td>
</tr>
<tr>
<td>Meyer-Bahlburg, Heino F. L.</td>
</tr>
<tr>
<td>Miccio, Steve</td>
</tr>
<tr>
<td>Miday, Karen K.</td>
</tr>
<tr>
<td>Mihajlovic, Aida S.</td>
</tr>
<tr>
<td>Millard, Hun</td>
</tr>
<tr>
<td>Millegan, Jeffrey</td>
</tr>
<tr>
<td>Miller, Adam</td>
</tr>
<tr>
<td>Miller, Andrew</td>
</tr>
<tr>
<td>Miller, Gregory</td>
</tr>
<tr>
<td>Miller, Shefali</td>
</tr>
<tr>
<td>Mills, Jacob</td>
</tr>
<tr>
<td>Milrod, Barbara</td>
</tr>
<tr>
<td>Minhas, Hassan M.</td>
</tr>
<tr>
<td>Mintz, David L.</td>
</tr>
<tr>
<td>Mistry, Amit</td>
</tr>
<tr>
<td>Mitra, Paroma</td>
</tr>
<tr>
<td>Moamai, Javad</td>
</tr>
<tr>
<td>Moffic, H. Steven</td>
</tr>
<tr>
<td>Mogalapu, Raja</td>
</tr>
<tr>
<td>Moghimi, Yavar</td>
</tr>
<tr>
<td>Mohite, Satyajit</td>
</tr>
<tr>
<td>Mohyuddin, Farooq</td>
</tr>
<tr>
<td>Mohyuddin, Hira</td>
</tr>
<tr>
<td>Mokrani, Marie-Claude</td>
</tr>
<tr>
<td>Molaie, Ali M.</td>
</tr>
<tr>
<td>Montalvo, Cristina</td>
</tr>
<tr>
<td>Montano Arteaga, Pamela C.</td>
</tr>
<tr>
<td>Montazeralghaem, Douna</td>
</tr>
<tr>
<td>Montenegro, Roberto E.</td>
</tr>
<tr>
<td>Montoya, Ivan D.</td>
</tr>
<tr>
<td>Money, Larissa</td>
</tr>
<tr>
<td>Moore, Kevin D.</td>
</tr>
<tr>
<td>Moore, Lauren E.</td>
</tr>
<tr>
<td>Moosey, Matthew</td>
</tr>
<tr>
<td>Moreira-Almeida, Alexander</td>
</tr>
<tr>
<td>Moreno, Arnaldo</td>
</tr>
<tr>
<td>Moreno, Maria E.</td>
</tr>
<tr>
<td>Morgan, Theresa A.</td>
</tr>
<tr>
<td>Morris, Sapna B.</td>
</tr>
<tr>
<td>Moscicki, Eve</td>
</tr>
<tr>
<td>Mosier, Jessica</td>
</tr>
<tr>
<td>Moukaddam, Nidal</td>
</tr>
<tr>
<td>Moutier, Christine</td>
</tr>
<tr>
<td>Mruthyunjaya, Pranathi</td>
</tr>
<tr>
<td>Mudgway, Ross J.</td>
</tr>
<tr>
<td>Munjal, Sahil</td>
</tr>
<tr>
<td>Munnangi, Lakshmi P.</td>
</tr>
<tr>
<td>Murphy, Dewey S.</td>
</tr>
<tr>
<td>Murphy, James</td>
</tr>
<tr>
<td>Muskin, Philip R.</td>
</tr>
<tr>
<td>Musselman, Dominique L.</td>
</tr>
<tr>
<td>Muszynski, Irvin L.</td>
</tr>
<tr>
<td>Myers, Michael F.</td>
</tr>
</tbody>
</table>
Disclosure Index

Myers, Trenton
Myers, Wade C.
Nadelson, Carol C.
Naem, Farooq
Nagalla, Madhavi
Nagurney, Michelle
Nam, Yoonmin
Narasingh, Meera
Nardi, Antonio E.
Nascimento, Antonio L.
Nash, Maureen C.
Nasrulla, Insiya
Nassan, Malik
Navarro, Aniceto
Naveen, M. M.
Neff, Daniel
Nebenebor, Nicole
Nelson, Christopher
Nelson, Sally
Nepal, Hiteksha
Neramballi, Malini
Netherton, Elisabeth
Neufeld, Ron
Neufeld, Matthew
Newmark, Thomas
Nguyen, Sarah A.
Ni, Michael
Nicolas, Samuel A.
Nijjar, Gursharon
Nikiforov, Ivan
Nizad, Vahid
Nisar, Mohammad A.
Nissan, David A.
Nissiros, Kalliopi S.
Nitturkar, Abhishek R.
Niu, Grace C.
Niu, Kathy
Nordon, Clementine
Nordstrom, Kimberly D.
Norko, Michael
Notman, Malikah T.
Nowicki, Stephen
Nunes, Edward V.
Nurmi, Erik L.
Nusair, Furqan
Nwankwo, Vincent N.
O’Brien, Virginia
O’Gorman, Cedric
O’Reardon, John P.
Obi Berry, Obianuju
“Uju”
Okoronkwo, Joshua
Okuda, Mayumi
Okwesili, Meredith A.
Olarte, Silvia W.
Oldham, John M.
Olsen, David P.
Olupona, Tolu
Ong, Christopher F.
Orr, Matt
Osher, Fred C.
Osman, Ekatherina
Osman, Ossama T.
Osframesky, Howard J.
Osorio, Flavia L.
Ospina Duque, Jorge
Ouanes, Sami
Ouellette, P. Lynn
Owen, Andrew
Ozbayrak, R. Kaan
Ozdemir, Armagan
Ozel-Kizil, Erguvan T.
Padilla Candelario, Mercedes
Auralyd
Pai, Nagesh
Palazzolo, Jerome
Pallanti, Stefano
Palmer, Brian
Pao, Maryland
Parekh, Ranna
Parikh, Niketa
Parikh, Tapan
Park, Bhinnia P.
Park, Dongchan
Park, Hyemi
Park, Jiyeon (Regina)
Park, Sa Eun
Park, Seon- Cheol
Parmar, Arpit
Parasaik, Ajay
Pary, Robert J.
Pashko, Steven
Pate, R. Jill
Pate, Ankur
Pate, Erin L.
Pate, Mitesh
Pate, Rachit
Pate, Rahul Kumar
Pate, Ronak
Pate, Ruchikumar A.
Pate, Rupal
Pate, Shama
Pate, Shirali S.
Patnaik, Mitali
Pato, Michele T.
Patriquin, Michelle
Paudel, Shreedhar
Pauziunik, Markian
Pearlson, Godfrey D.
Peklo, Bryan M.
Pender, Vivian
Penders, Paul
Penesetti, Deepak
Pengrin, Lauren
Penn, Joseph V.
Penska, Keith
Penumetcha, Varma
Penzner, Julie B.
Pereira, Luis
Perez-Rodriguez, M.
Mercedes
Perkins, Matthew B.
Peroski, Michael S.
Perrin, Andrew
Pesa, Jacqueline
Peseschkian, Hamid
Pestana Knight, Elia M.
Peteet, John
Petersen, Christopher A.
Petersen, Daena L.
Petitjean, Francois
Petitgrew, Roderic
Pflanz, Steven E.
Phillips, Steven R.
Piddoubny, Walter
Pier, Katherine
Pierce, Andrew
Pilla, Malathi
Pinals, Debra
Pine, Daniel S.
Pinninti, Narasimha
Plakun, Eric M.
Plek, Richard R.
Pollack, Mark H.
Poon, Amy
Porche, Michelle V.
Porter- O’Grady, Tim
Portilla, GarcA-a
Potter, Nancy
Pourezzaei Kimia
Powsner, Seth
Prabhat, Deepak
Preti, Emanuel
Price, Marilyn
Puchakayala, Nandita
Pula, Jack
Purcell, David W.
Puri, M. Rehan
Quang- Dang, Uyen-Khanh
Quintanilla, Maria Beatriz
Qureshi, Naema
Raad, Raymond
Rachakonda, Saumya
RadhaKrishnan, Rajiv
Radonic, Vanja
Raheja, Uttam
Rahmani, Rumana
Rai, Abhishek
Rajewska- Rager, Aleksandra
Raksh, Gopal Kumar
Rally, Sanjeev K.
Ramaswamy, Srim
Ramsey, Drew
Raney, Lori
Ranganathan, Mohini
Rao, Nyapati R.
Rao, Vani
Rapaport, Mark H.
Rathod, Shanaya
Ratnakaran, Badr
Ratzliff, Anna
Rauch, Sheila A. M.
Razafsha, Mahdi
Razdan, Anupriya
Reddy, Abhishek
Reese, LeRoy
Reeggenbogen, Alexandra
Reginos, Rosa
Rehim, Aimi
Reich, James H.
Reid, Czerne M.
Rodin, Rebecca
Rogers, Robert
Rosenheck, Robert
Rosenquist, Peter B.
Robes, Erik
Rothe, Eugenio M.
Rothenberg, Kasia G.
Rotter, Merrill
Roy, Arunima
Roy, Kamalika
Rozel, John S.
Ruedrich, Stephen
Rui, Amanda
Rui, Pedro
Rumbaugh, William D.
Runels, Diane
Rus, Mark
Ryan, Deirdre M.
Sabetello, Maya
Sachdeva, Shilpa
Sadat Azizi, Nargis
Saeed, Sy A.
Safar, Laura
Safin, Daniel
Sahu, Geetanjali
Salerno, Karen E.
Disclosure Index

Shah, Pooja
Severe, Jennifer
Setlow, Barry
Severe, Jennifer
Sarhany, Walid
Sarkari, Varlika directives
Sarver, Bart
Satcher, David
Sarvet, Barry D.
Savu, Vasile
Sato, Masao
Schwartz, Victor
Schwartz, Thomas L.
Schwartz, Patricia
Schwartz, Thomas L.
Schwartz, Victor
Schrogin, Steven
Schott, Charles
Scully, Stephenie A.
Secareanu, Cristiana
Seder, L奥运会
Sege, Alexis A.
Segal, Andra G.
Seibell, Philip J.
Serhal, Eva
Serrano, Patricia
Serrano-Villar, Maria
Setlow, Barry
Shah, Apeksha
Shah, Pooja

Shah, Ravi N.
Shah, Saloni
Shahzadi, Ulfat
Shakeri, Jalal
Shao, Wanda
Shapiro, Anna P.
Shapiro, Edward R.
Shapiro, Gabrielle L.
Sharfstein, Steven S.
Sharma, Ashish
Sharma, Shriddhar
Sharon, Haggai
Sharp, Carla
Shayanpur, Mahrokh
Shear, Matthew
Sheehan, Kathleen
Sheehan, Matthew M.
Sheikh, Sarah
Sheine, Yvette
Shenava, Manisha
Sher, Leo
Sher, Yelizaveta
Shim, Ruth
Shim, Se-Hoon
Shindler, Maria L.
Shivanekar, Sharvari P.
Short, Jessica M.
Shrivastava, Amresh
Shtasel, Derri
Shuara, Saod
Shulman, Barbara
Sidaros, Rafik
Siegele, Harry
Sierzchula, Jessica J.
Silk, Kenneth R.
Simkin, Deborah R.
Simon, Kevin M.
Simpson, Annabelle K.
Singh, Balwinder
Singh, Gurjot
Singh, Harvinder
Singh, Jasbir
Sinha, Preti
Sinkhevicute, Igne
Sironga, Joseph
Sisti, Dominic
Sjöstrand, Hanna
Skolnick, Phil
Smith, Mary Kay
Smith, Paula Marie
Snyder, Elise
Sockalingam, Sanjeev
Sohn, Sungyun
Sola, Christopher
Soldinger, Steve
Soloway, Scott
Song, Jaemin
Sonny, Ramanya
Sood, Shabnam
Sorel, Eliot
Sorrentino, Renee
Sosounmoli, Shoyinka O.
Spencer, Andrea E.
Sperber, Jacob
Sperry, Len
Spiegel, David
Spokes, Laima
Spollen, John
Spoth, Richard
Sreekathi, Ananya R.
Reshta, Nina E.
Srinivasan, Shilpa
Srinivasaraghavan, Jagannathan
St. Victor, Guadel
Starn, Meghan N.
Stein, Aliza T.
Steinberg, Leah R.
Steinberg, Louise J.
Steff, Stephanie
Sterling, Stacy
Stern, Barry L.
Stern, Stephen L.
Stewart, Altha J.
Stokes, Wesley
Stone, Alan
Stone, Alice E.
Stotland, Nada L.
Strain, James J.
Stratton, Tyler E.
Stubbeblman, William F.
Stupinski, John
Subedi, Jagannath
Subhash, Ajith
Subramaniham, Geetha A.
Sugumar, Archana
Suh, Ho-Suk
Suh, HwaGyu
Sultan, Ryan S.
Summergrad, Paul
Sung II, Jung
Sung, Dawn
Sung, Hyung-Mo
Suo, Shannon
Suryadevara, Uma
Sussmanickam, Bibiana
M.
Susser, Leah
Suzuki, Amanda
Swartz, Marvin S.
Swiggart, William H.
Syed, Sharif
Szerman, Nestor
Tafet, Gustavo E.
Takada, Ryosh
Takahashi, Hidetoshi
Takayasu, Alexandra
Talbott, John A.
Tamburello, Anthony
Tampi, Rajesh R.
Tandon, Rajiv
Tapias, Rafael E.
Tardelli, Vitor S.
Tarman, Daniel D.
Tarshis, Thomas P.
Taube-Schiff, Marlene
Taylor, Doug
Taylor, Geoffrey P.
Taylor, Jared K.
Taylor, Jerome H.
Taylor-Desir, Monica
Tegn, Cuneby
Teo, Alan R.
Thakrar, Tina S.
Thangaj, Swaminathan
Thelen, Mindi
Thelen, Tim
Thiand, Melinda A.
Thiand, Gunneet S.
Thielman, Samuel
Thomas, Anil A.
Thomas, Christopher
Thomas, Connie
Thomas, Jean M.
Thompson, Kenneth
Thompson, Sonda
Thompson, William W.
Tillman, Jane G.
Timmons-Mitchell, Jane C.
Titchcombe-Parekh, Roseann F.
Tobres, Taylor
Toldeo, Theresa
Toll, Alba
Torbev, Souraya
Torous, John
Trager, Evan J.
Tran, David
Tran, Shelly T.
Trestman, Robert L.
Trevisan, Louis
Trimble, Michael
Trivedi, Madhukar
Truong, Anh L.
Tseng, Mei-Chih M.
Tsuang, John W.
Tucci, Veronica
Tuck, Andrew N.
Tucker, Phebe M.
Turner, Ana
Turner, Andia H.
Uck, Alp
Ujim, Jusuf S.
Ummrani, Hiren
Unützer, Jürgen
Uzal Fernandez, Cristina
Vaaler, Arne E.
Vahia, Ispit
Vanderlip, Erik
Vannucci, Adriana
Vargas Cruz, Cindy
Varghese, Celia
Varliki, Cen
Vasan, Nina
Vaughn, Rubaiha
Vela, Ricardo M.
Velliz, Philip
Vemuri, Divya
Venigalla, Hema
Verduin, Marcia L.
Vergare, Michael
Verma, Chitrannan B.
Vermetten, Eric
Vevera, Jan
Vijapura, Sagar
Vinacour, Carlos
Vinson, Sarah Y.
Vito, Jose
Vo, Lan Chi Krysti L.
Volkow, Nora
Voiman, Susan F.
von Hafften, Alexander
Vora, Ankita
Wager, Tor
Waggoner, Thuy Hong
N.
Wainberg, Milton
Waits, Wendi
Disclosure Index

Walaszek, Art
Waldman, Randee
Walker, Anitra
Walker, Melissa
Walker, Sandra C.
Wallack, Joel J.
Walsh, B. Timothy
Wang, Dana
Wang, Dora
Wang, Jack
Wang, Paul
Wang, Philip
Wang, Po
Wang, Shao-Cheng
Ward, Herbert
Ward, Martha C.
Warner, Christopher H.
Warnick, Stephen J.
Wasser, Tobias
Watson, Clarence
Watson, Hunna J.
Webb, Allison
Weber, Jenine
Wei, Mike
Weinberg, Igor
Weine, Stevan M.
Weinstock, Robert
Weisensel, Nicolette
Weiss, Kenneth J.
Weiss, Roger D.
Weiss, Susan R. B.
Weisser, Lydia E.
Weissman, Anna
Weissman, Sidney
Welch, Stephen
Wendt, Burdette
Wertheimer, Moira
West, James C.
Westermeyer, Joseph J.
White, Christopher
White, Leigh
Wick, Paul H.
Wiechers, Ilse
Wiegand, Hauke F.
Wiles, Preston
Wilkins, Kirsten
Wilkins, Victoria
Wilkinson, Samuel
Williamson, Johnny
Wills, Cheryl
Winfrey, Chris
Wininger, Bryce
Winter, Christine A.
Wiste, Anna K.
Witter, Daniel
Wnuk, Susan
Wolf, Jonathan P.
Wolf, Kari M.
Wonodi, Ikwunga
Woo, Benjamin
Woo, Jong Min
Wood, Keith
Woolley, Stephen
Works, Lindsay
Worley, Linda L. M.
Wrenn, Glenda
Wu, Hanjing E.
Wynn, Gary H.
Xiang, Shuo
Yager, Joel
Yakov, Svetlana
Yam, Philip M.
Yamamura, Kazuhiko
Yancovitch, Alan C.
Yang, Fang
Yang, Jong-Chul
Yao, Lihua
Yap, Yen Ling
Yaseen, Zimri S.
Ye, Chuanzhong
Yeaw, Jennifer
Yehia, Baligh R.
Yehuda, Rachel
Yelloweex, Peter
Yeomans, Frank E.
Yin, Yingying
Yohanan, Monique
Yohanna, Daniel
Young, Allan H.
Young, John Q.
Yousuf, Mohammad
Yue, Yingying
Yuen, Laura D.
Yur’yev, Andriy
Yurgelen-Todd, Deborah
Zafar, Jawad
Zafer, Maryam
Zakers, Aleema
Zalpuri, Isheeta
Zanarini, Mary C.
Zarra, Julio C.
Zeid, Dana
Zeng, Mary C.
Zerrate, Maria C.
Zeshan, Muhammad
Zhan, Chang-Guo
Zhang, Layan
Zhang, Tingting
Zheng, Yuqun
Zhong, Jun
Zimmerman, Mark
Zinns, Rachel
Zisook, Sidney
Zonana, Howard
Zonana, Jess
Zun, Leslie
Zuschlag, Zachary
Zembrzuska, Hanna
Zerbo, Erin
Zhand, Naista
Zhang, Layan
Zhang, Melvyn
Ziedonis, Douglas
Zielinska, Anna
Zilber, Claire
Zimmerman, Mark
Zisook, Sidney
Zobel, Craig
Zonana, Howard
Zubera, Atika
Zurowski, Mateusz
Zuschlag, Zachary
To receive your certificate online:
Complete the online evaluation at psychiatry.org/AnnualMeetingCME
*Retain badge number to access evaluation online

The website will remain active until:
August 18, 2016
CME credit for APA members will be recorded at apaeducation.org and transferred to your ABPN Physician Folio in October 2016.

To receive your certificate in person:
Complete the general evaluation form at the CME Certificate of Attendance Booth
Located in the Escalator to B3-B4, Level 2

Types of Certificates
• Certificate of Credit for physicians
• Certificate of Attendance for non-physicians

Accreditation & Designation
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Psychiatric Association designates this live activity for a maximum of 40 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For questions, contact the American Psychiatric Association Department of CME:
educme@psych.org
Can’t Attend Every Session?

Order APA Annual Meeting On Demand and Save $1,000!

With many sessions occurring simultaneously, your On Demand program gives you the opportunity to participate in all key presentations, helping you maximize the investment you’ve made in attending the live meeting.

Features of APA Annual Meeting on Demand:

- Online access to 400 hours* of presentations from any computer or mobile device (available within 24 hours of the live session)
- CME credit available via integrated online tests
- Downloadable MP3 audio files for enhanced mobility
- Complimentary portable USB drive** for offline viewing

<table>
<thead>
<tr>
<th>LIST PRICE</th>
<th>YOUR PRICE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Attendee: MD’s</td>
<td>$1,399</td>
</tr>
<tr>
<td>Attendee: Residents</td>
<td>$1,399</td>
</tr>
</tbody>
</table>

Order Today!
Special offer ends May 18, 2016.

Visit One of Our Sales Booths  Education Center – Level 2 or Registration Area – Level 1
Order Online Orders.OnDemand.org/ APA/Atlanta
Order by Phone 800-501-2303 (U.S Only) or 818-844-3299
Monday – Friday 6 a.m. – 5 p.m. PST

* Specific presentations within a session may not be available or may be audio only if the presenter has confidential patient information or otherwise declines to be recorded.
** USB drive does not include all the functionality available online, such as Advanced Search, Recently Viewed, MP3 Downloads, Bookmarks and CME testing.
LEARN HOW ACADIA PHARMACEUTICALS IS CHANGING THE CONVERSATION IN PARKINSON’S DISEASE PSYCHOSIS.

BOOTH #1437

THE AMERICAN PSYCHIATRIC ASSOCIATION ANNUAL MEETING
57,000+

PSYCHIATRY-SPECIFIC RISK MANAGEMENT ISSUES ADDRESSED

WE SUPPORT YOU

Having addressed over 57,000 psychiatry-specific risk management issues on the Risk Management Consultation Service helpline since 1997, our knowledgeable team of in-house risk managers is committed to providing assistance when you need it most. With a library of 360 risk management articles and tips, our clients have access to informative and timely resources free of charge.

Unparalleled risk management services are just one component of our comprehensive professional liability insurance program. When selecting a partner to protect you and your practice, consider the program that puts psychiatrists first. Contact us today.

More than an insurance policy

800 245 3333  |  PsychProgram.com/Dedicated  |  TheProgram@prms.com

In California, dba’s Transcendental Professional Risk Management and Insurance Services.

CHARLES D. CASH, JD, LLM, ARM
ASSISTANT VICE PRESIDENT, RISK MANAGEMENT

PARCO is an authorized carrier in California, ID number 3176-7. www.parco.com

Actual terms, coverages, conditions and exclusions may vary by state. Unlimited consent to settle does not extend to sexual misconduct.
Program

Format Descriptions .................................. 56
Daily Attendance Log ................................. 58
Saturday’s Program ................................. 59
Sunday’s Program ................................. 73
Monday’s Program ................................. 97
Tuesday’s Program ................................. 123
Wednesday’s Program ......................... 141
Format Descriptions

Advances in Series
These sessions highlight important new advances occurring in the field of psychiatry involving selected disorders or treatments. Some of these sessions are chaired by editors of recent textbooks published by American Psychiatric Association Publishing and feature selected chapter authors from these texts. The books discussed at these sessions may be purchased onsite and online at the APA Bookstore.

Advances in Research
In these sessions, leading clinical researchers will present the latest developments in research.

Advances in Medicine
This format includes sessions designed to provide psychiatrists with the latest in clinical developments in other areas of medicine. The intent is to give participants an update from a physician in a particular specialty. These sessions will help participants keep pace with the rapidly expanding knowledge base and technology in various branches of medicine.

Case Conferences
These 90-minute sessions begin with clinical material presented by videotape or the treating therapist. One or more experts then discuss the case. These sessions are open to APA members only.

Courses
Courses are designed to emphasize learning experiences that actively involve participants and include the opportunity for informal exchange with the faculty. Offered in four-hour (half-day), six-hour (full-day) and eight-hour (full-day) sessions, courses either review basic concepts in a special subject area or present advanced material on a circumscribed topic. Participants must purchase tickets to attend.

FOCUS Live!
These 90-minute sessions allow participants to test their knowledge using an interactive Audience Response System (ARS), offering a new and entertaining way to learn. ARS sessions can make a group of 300 feel like they are having a small-group consultation with an expert clinician. Experts, who served as guest editors of FOCUS, will lead lively multiple-choice question-based discussions, and the audience will enter their answers with hand-held devices. Results are instantly tallied and projected on the screen. Participants should plan to bring their own mobile device to FOCUS Live! sessions.

Forums
Forums are flexible 90-minute to two-hour presentations that afford an opportunity to highlight and select timely topics that are of interest to psychiatrists. Speakers and panel members are chosen for their expertise and leadership in the field.

Interactive Sessions
This 90-minute format allows small groups to meet informally with selected experts in psychiatry to discuss topics chosen by the expert, to obtain consultations around problems in research from senior researchers or to use clinical material offered by the participants and hear clinically based seminars presented by outstanding educators. Some interactive sessions are reserved for residents only. These sessions are limited to a set number of attendees on a first-come, first-served basis.

Lectures
Lectures feature a small number of distinguished speakers discussing scientific and cultural topics, many of which will extend our understanding beyond the usual limits of clinical psychiatry. The Scientific Program Committee invites the lecturers. Award lectures are selected by the various APA Award Boards.
Format Descriptions

Media Workshops
Media Workshops are three-hour sessions in which a panel of presenters shows and then discusses a feature-length film. This discussion is usually open to audience participation.

Poster Sessions
This format highlights presentations of very recent findings. Posters are visual, self-explanatory presentations offered in four categories: International, Medical Student and Resident Competition, New Research and Young Investigators’ New Research. See the New Research section of this book for a complete schedule of poster presentations.

Scientific and Clinical Reports
Scientific and Clinical Reports are oral presentations of papers prepared for submission before publication. In this 90-minute format, reports are grouped by topic, with discussion from the audience following the presentation of each paper. There is no formal discussant.

Seminars
This is a format allowing for in-depth teaching and learning related to “niche” topics or covering issues that represent a service to the profession (e.g., impaired physician programs, patient suicide, etc.). It is also a venue for testing the feasibility of new courses by offering the content free for the first year.

Symposia
Symposia are three-hour sessions consisting of four to six presentations that are thematically linked and focus on a specific topic relevant to clinical psychiatry. They are designed to provide comprehensive treatment of a topic or discussion of the topic from several points of view and stimulate discussion with the audience.

Workshops
Workshops are 90-minute sessions that typically involve brief presentations from individual panel members, followed by the opportunity for lively and informative discussion. This format provides for substantial audience participation and is highly interactive.
This form is for your records and not for submission. Use this page to keep track of your attendance. Reporting is on an honor basis, claim one credit for each hour of participation.

All scientific sessions listed in the Annual Meeting Program Book are designated for AMA PRA Category 1 Credits™, except for Poster Sessions and where otherwise specified.

<table>
<thead>
<tr>
<th>Date/Time</th>
<th>Title of Session</th>
<th># of Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Total
Saturday
May 14, 2016
8:00 a.m. Sessions

Courses

Conversion Disorder: Update on Evaluation and Management
8:00 a.m. – Noon
International 4, International Level Marriott Marquis
Directors: Gaston Baslet, M.D. John Barry, M.D.
Faculty: James Brooks
W. Curt LaFrance Jr., M.D., M.P.H.
Adriana Bermeo-Ovalle, M.D.

Cognitive Behavior Therapy for Severe Mental Disorders: Building Treatment Skills That Work
8:00 a.m. – Noon
International 5, International Level Marriott Marquis
Directors: James Brooks
W. Curt LaFrance Jr., M.D., M.P.H.
Adriana Bermeo-Ovalle, M.D.

Management of Psychiatric Disorders in Pregnant and Postpartum Women
8:00 a.m. – Noon
International 6, International Level Marriott Marquis
Directors: James M. Ellison, M.D., M.P.H.
 Yusuf Sivrioglu, M.D.
Faculty: Donald A. Davidoff, Ph.D.
Brent Forester, M.D., M.Sc.
Grace C. Niu, Ph.D.

Weight Issues and Bariatric Surgery
5
9:00 a.m. – 10:30 a.m.
Room B405, Level 4
Georgia World Congress Center
1. Toronto Bariatric Interprofessional Psychosocial Assessment Suitability Scale (BIPASS): A Retrospective Pilot Study Evaluating a New Clinical Tool
Gurneet S. Thiara, M.D.
2. Evidence for Neurocognitive Improvement After Bariatric Surgery: A Systematic Review
Gurneet S. Thiara, M.D.
3. Childhood Abuse Associated With an Increase in Body Mass Index (BMI), Sleep Disturbances, and Psychological and Physical Symptoms Among Midlife Women
Wilma Ines Castilla-Puentes, M.D.

Mood Disorders in Later Life: Achieving Accurate Diagnosis and Effective Treatment
4
8:00 a.m. – Noon
International 4, International Level Marriott Marquis
Directors: James M. Ellison, M.D., M.P.H.
 Yusuf Sivrioglu, M.D.
Faculty: Donald A. Davidoff, Ph.D.
Brent Forester, M.D., M.Sc.
Grace C. Niu, Ph.D.

Buprenorphine and Office-Based Treatment of Opioid Use Disorder
1
8:00 a.m. – 5:00 p.m.
Marquis Ballroom A, Marquis Level Marriott Marquis
Chair: James Brooks
Director: Petros Levounis, M.D.

9:00 a.m. Sessions

Scientific and Clinical Reports

Why Sex Is Important: A Seminar on the Impediments to Adult Love
8:00 a.m. – Noon
International 7, International Level Marriott Marquis
Director: Stephen B. Levine, M.D.

Program changes are printed each day in the APA Daily, which is available at locations throughout the Georgia World Congress Center. Up to date program listings are also available and searchable in the APA Meetings app.
Workshops

**The What, When and Why of EKGs in Psychiatric Practice**
9:00 a.m. – 10:30 a.m.
Room A303, Level 3
Georgia World Congress Center

*Chairs:*
Rohul Amin, M.D.
Adam Hunzeker, M.D.

*Speakers:*
Jed P. Mangal, M.D.
Aniceto Navarro, M.D.

**Making Your Presentation More Interactive: The Better Way!**
9:00 a.m. – 10:30 a.m.
Room A304, Level 3
Georgia World Congress Center

*Chair:*
Jon S. Davine, M.D.

**Leading System Change Toward Integrated Care: Unfunded, Not Ready, Unsure? Start Here**
9:00 a.m. – 10:30 a.m.
Room A313, Level 3
Georgia World Congress Center

*Chair:*
Glenda Wrenn, M.D.

*Speakers:*
Christopher Hoffman, M.D.
Courtney L. McMickens, M.D., M.P.H.
Kevin M. Simon, M.D.
Elizabeth A. Frye, M.D., M.P.H.

---

**Fort Hood Tragedy: An Inside Perspective**
9:00 a.m. – 10:30 a.m.
Room B310, Level 3
Georgia World Congress Center

*Chair:*
Kaustubh G. Joshi, M.D.

**Dimensional Conceptualization and Diagnosis of Narcissistic Personality Disorder**
9:00 a.m. – 10:30 a.m.
Room B311, Level 3
Georgia World Congress Center

*Chairs:*
Elsa F. Ronningstam, Ph.D.
Igor Weinberg

**East and West: Integrating Concepts of Mental Health Through Storytelling in the Refugee Population**
9:00 a.m. – 10:30 a.m.
Room B315, Level 3
Georgia World Congress Center

*Chairs:*
Shirali S. Patel, M.D.
Sophia Banu, M.D.

*Speakers:*
Ye B. Du, M.D., M.P.H.
Elisabeth Netherton, M.D.
Asim Shah, M.D.

**When You Hear Hoof Beats, Think Horses and Zebras: The Importance of a Wide Differential in Delirium/Dementia Cases**
9:00 a.m. – 10:30 a.m.
Room B316, Level 3
Georgia World Congress Center

*Chair:*
Ana Turner, M.D.

*Speakers:*
Sai Hu, D.O.
Bruce Bassi, M.D., M.S.
Uma Suryadevara, M.D.
Stephen Welch, M.D.

**Cognitive Behavior Therapy for Personality Disorders**
9:00 a.m. – 10:30 a.m.
Room B403, Level 4
Georgia World Congress Center

*Chair:*
Judith S. Beck, Ph.D.

**Online Education: Opportunities for Teaching, Collaboration, Funding and Advancement**
9:00 a.m. – 10:30 a.m.
Room B404, Level 4
Georgia World Congress Center

*Chairs:*
Czerne M. Reid, Ph.D.
Regina Bussing, M.D.

*Speakers:*
Czerne M. Reid, Ph.D.
Jacqueline A. Hobbs, M.D., Ph.D.
Barry Setiow, Ph.D.
Regina Bussing, M.D.

**Media Workshop**
120 Years of Inpatient Psychiatry: “Stonehearth Asylum” and Discussion of the Evolution of Psychiatric Hospitalization into the 21st Century
9:00 a.m. – Noon
Room B308, Level 3
Georgia World Congress Center

*Chair:*
Mark Komrad, M.D.

*Speakers:*
Mimi Baird
Steven S. Sharfstein, M.D., M.P.A.
Mark Komrad, M.D.

**Symposia**
Improving the Effectiveness of CBT Across Cultures
9:00 a.m. – Noon
Room B309, Level 3
Georgia World Congress Center

*Chair:*
Muhammad Irfan, M.B.B.S., M.S.
Discussant: Farooq Naeem, Ph.D., M.Sc.

1. Developing a Model for Cultural Adaptation of CBT for an English-Speaking Caribbean Origin Group
   Kwame McKenzie, M.D.

2. Cultural Issues on the Use of CBT and ACT
   Kenneth P. Fung, M.D.

3. Cultural Adaptation of CBT: Process, Methods and Findings
   Farooq Naeem, Ph.D., M.Sc.

4. Cultural Adaptation of CBT for Psychotic Disorders
   Shanaya Rathod, M.D.

5. A Depressed British South Asian Mother’s “Voices Within the Four Walls”: A Mixed Methods Study
   Nusrat Husain, M.D.

6. Evaluation of Culturally Adapted CBT (CaCBT) Through Randomized Controlled Trials (RCTs) in Low- and Middle-Income (LAMI) Countries: Developing the Evidence Base
   Muhammad Irfan, M.B.B.S., M.S.

Comorbid Psychiatric and Substance Use Disorders: Recent Research to Improve Diagnosis and Treatment

National Institute on Drug Abuse

9:00 a.m. – Noon
Room B312, Level 3
Georgia World Congress Center

Chairs:
Susan F. Volman, Ph.D.
Carlos Blanco, M.D.

Discussant:
Carlos Blanco, M.D.

1. Diagnostic Dilemmas in Co-Occurring Mental and Substance Use Disorders
   Edward V. Nunes, M.D.

2. Neuroimaging Correlates of Psychopathology and Substance Abuse
   Deborah Yurgelen-Todd, Ph.D.

3. Comorbidity in Substance Abuse and Depression: Common Substrates Linked Through Amygdala-Dependent Dopamine System Down-Regulation
   Anthony A. Grace, Ph.D.

4. Treatment of Co-Occurring Mental and Substance Use Disorders: Focus on Depression
   Kathleen Brady, M.D., Ph.D.

Established Curricula on Religion, Spirituality and Psychiatry in Psychiatric Residency Programs: A Longitudinal Perspective

APA Caucus on Religion, Spirituality and Psychiatry

9:00 a.m. – Noon
Room B401, Level 4
Georgia World Congress Center

Chairs:
Francis Lu, M.D.
John Peteet, M.D.

Discussant:
Steven Scoggin, Psy.D.

1. Religion, Spirituality and Psychiatry: The Harvard Longwood Course 20 Years Later
   John Peteet, M.D.

2. Personal and Institutional Consequences of Educational Efforts to Integrate Religious and Spiritual Resources Into the Care of Psychiatric Patients: A 17-Year “Perspective”
   James W. Lomax, M.D.

3. A 25-Year Evolution From Teaching Cultural Sensitivity to Teaching the Social Neuroscience of Spirituality in Psychiatric Care
   James Griffith, M.D.

4. Religion and Spirituality in Child and Adolescent Psychiatry Training
   Mary Lynn Dell, D.Min., M.D.

5. Residency Education on Spirituality/Religion and Psychiatry: A Canadian Perspective
   Wai Lun Alan Fung, M.D., Sc.D.

Smoking Cessation: What Psychiatrists Need to Know to Help Bring About Change

9:00 a.m. – Noon
Room B314, Level 3
Georgia World Congress Center

Chairs:
Stephan M. Carlson, M.D.
Jose Vito, M.D.

Discussant:
Aniyizhai Annamalai, M.D.

1. The History of Smoking Cessation in Psychiatry and the Current Epidemiology in Patients With Mental Illness
   Hugh Cummings, M.D.

2. Smoking Cessation Through Quality Improvement and System Change in Inpatient Psychiatry
   Anil A. Thomas, M.D.
Marijuana: A Clinical Update on the Therapeutic and Recreational Uses of Cannabis for General Psychiatrists and Researchers

9:00 a.m. – Noon
Room B407, Level 4
Georgia World Congress Center

Chair:
Godfrey D. Pearlson, M.D.

Discussant:
Deepak Cyril D’Souza, M.D., M.B.B.S.

1. Therapeutic Potential of Cannabinoids
   Donald C. Goff, M.D.

2. Predictors and Consequences of Adolescent Cannabis Abuse
   Hugh Garavan, Ph.D.

3. Driving While Stoned: How Dangerous?
   Godfrey D. Pearlson, M.D.

4. Medical Cannabis: For Which Conditions and Under What Circumstances?
   Deepak Cyril D’Souza, M.D., M.B.B.S.

5. Neurocognitive Implications of Heavy Marijuana Use in Adolescence: Insights From Neuroimaging
   Alecia D. Dager, Ph.D.

Transgender and Intersex for the Practicing Psychiatrist

APA Council on Quality Care

9:00 a.m. – 4:00 p.m.
International 8, International Level
Marriott Marquis

Update on Pediatric Psychopharmacology

9:00 a.m. – 4:00 p.m.
Imperial Ballroom B, Marquis Level
Marriott Marquis

Director:
Christopher Kratochvil, M.D.

Sleep Medicine: A Review and Update for Psychiatrists

9:00 a.m. – 4:00 p.m.
M301 – 302, Marquis Level
Marriott Marquis

Directors:
Thomas D. Hurwitz, M.D.
Imran S. Khawaja, M.B.B.S.

Faculty:
Elliott K. Lee, M.D.
R. Robert Auger, M.D.
11:00 a.m. Sessions
Scientific and Clinical Reports

Perioperative and Peripartum Situations
11:00 a.m. – 12:30 p.m.
Room B405, Level 4
Georgia World Congress Center

1. Serotonergic Antidepressants and Perioperative Bleeding Risk: A Systematic Review
   Artin Mahdanian, M.D.

2. The Cornell Peripartum Psychosis Management Tool: A Case Series and Template
   Benjamin Brody, M.D.

Workshops

Prodromal Psychosis: Ethical Challenges in Classification, Diagnosis and Treatment
APA Ethics Committee and Penn-Scattergood Ethics Program
11:00 a.m. – 12:30 p.m.
Room B218, Level 2
Georgia World Congress Center

Chairs:
Raquel Gur, M.D.
Dominic Sisti, Ph.D.

Speakers:
Dominic Sisti, Ph.D.
Monica E. Calkins, Ph.D.
Erich M. Dress, B.S.
Andrea G. Segal, M.S.

Teaching Diagnostic Reasoning Skills and the Mitigation of Cognitive Bias
11:00 a.m. – 12:30 p.m.
Room A303, Level 3
Georgia World Congress Center

Chairs:
Adam Hunzeker, M.D.
Rohul Amin, M.D.

Speakers:
Jarred Hagan, D.O.
Allison Webb, M.D.
Adam Hunzeker, M.D.
Rohul Amin, M.D.

Trauma, Conduct Disorder and Violence Prevention in the Community
11:00 a.m. – 12:30 p.m.
Room A304, Level 3
Georgia World Congress Center

Chair:
Lara J. Cox, M.D., M.S.

Speakers:
Matthew L. Dominguez, M.D., M.P.H.
Anish R. Dube, M.D., M.P.H.

Diagnosing Dementia: A Guide to Biomarker Testing in the Clinic
11:00 a.m. – 12:30 p.m.
Room A307, Level 3
Georgia World Congress Center

Chair:
Vimal M. Aga, M.D.

Sports Psychiatry: Providing Behavioral Health and Performance Services to Sports Organizations/Teams at High School/Club, College and Professional Levels
11:00 a.m. – 12:30 p.m.
Room B310, Level 3
Georgia World Congress Center

Chair:
David R. McDuff, M.D.

How to Use Alcoholics Anonymous in Clinical Practice
11:00 a.m. – 12:30 p.m.
Room B315, Level 3
Georgia World Congress Center

Chair:
Marc Galanter, M.D.

Speakers:
Joseph J. Westermeyer, M.D., Ph.D.
John A. Fromson, M.D.
Alphonse Kenison Roy III, M.D.

Effective Management of Reassurance-Seeking Behavior in OCD: Strategies for Clinicians and Family Members
11:00 a.m. – 12:30 p.m.
Room B316, Level 3
Georgia World Congress Center

Chairs:
Phillip J. Seibell, M.D.
Megan Hughes-Feltenberger, Ph.D.

Speakers:
Phillip J. Seibell, M.D.
Megan Hughes-Feltenberger, Ph.D.

Practicing Cognitive Behavior Therapy: An Experiential Workshop
11:00 a.m. – 12:30 p.m.
Room B403, Level 4
Georgia World Congress Center

Chair:
Judith S. Beck, Ph.D.
1:00 p.m. Sessions

Courses

What Every Psychiatrist Needs to Know About Epilepsy

1:00 p.m. – 5:00 p.m.
International 4, International Level Marriott Marquis

Director: Rochelle Caplan, M.D.
Faculty: Tatiana Falcone, M.D., Jana Jones, Ph.D., Elia M. Pestana Knight, M.D., Gaston Baslet, M.D.

A Psychiatrist’s Guide to Patients With Severe Obesity: Assessment and Beyond

1:00 p.m. – 5:00 p.m.
International 5, International Level Marriott Marquis

Directors: Raed Hawa, M.D., Sanjeev Sockalingam, M.D.
Faculty: Stephanie Cassin, Ph.D., Timothy Jackson, Marlene Taube-Schiff, Ph.D., Susan Wnuk, Ph.D.

Identifying and Helping Older Adults With Mild Neurocognitive Disorders

1:00 p.m. – 5:00 p.m.
International 6, International Level Marriott Marquis

Director: James M. Ellison, M.D., M.P.H.
Faculty: Jennifer Gatchel, M.D., Ph.D., David P. Olson, M.D., Ph.D., Donald A. Davidoff, Ph.D.

Melatonin and Light Treatment of SAD, Sleep and Other Body Clock Disorders

1:00 p.m. – 5:00 p.m.
International 7, International Level Marriott Marquis

Director: Alfred J. Lewy, M.D.

1:30 p.m. Sessions

Scientific and Clinical Reports

Forensic and Medical-Legal Issues

1:30 p.m. – 3:00 p.m.
Room B405, Level 4
Georgia World Congress Center

1. Empirical Findings on Legal Difficulties Among Practicing Psychiatrists
   James H. Reich, M.D., M.P.H.

2. Traumatophobia: Paradoxical Amplification of Post-Traumatic Symptoms and the Role of Third Parties
   John O. Beahrs, M.D.

Identifying and Helping Older Adults With Mild Neurocognitive Disorders

1:30 p.m. – 3:00 p.m.
Room B218, Level 2
Georgia World Congress Center

Chair: Susan Samuels, M.D.
Speakers: Matthew Shear, M.D., Jonathan Avery, M.D., Susan Samuels, M.D.

At What Cost? Psychiatry, the Finances Involved and the Future of the Field

1:30 p.m. – 3:00 p.m.
Room A303, Level 3
Georgia World Congress Center

Chairs: Matthew D. Erlich, M.D., Sharat P. Iyer, M.D., M.S.
Speakers: Matthew D. Erlich, M.D., Sharat P. Iyer, M.D., M.S., Andres Barkil-Oteo, M.D., M.Sc., Leslie Marino, M.D., M.P.H.
Mindfulness and Qigong for Stress Reduction
1:30 p.m. – 3:00 p.m.
Room A304, Level 3
Georgia World Congress Center
Chair: Colleen Loehr, M.D.

Mental Health and the Case for Single Payer Post-ACA
1:30 p.m. – 3:00 p.m.
Room A307, Level 3
Georgia World Congress Center
Chairs: Leslie H. Gise, M.D.
Steven S. Sharfstein, M.D., M.P.A.
Speakers: J. Wesley Boyd, M.D., Ph.D.
Stephen B. Kemble, M.D.

The Ultimate Balancing Act: Medicine, Marriage, Motherhood and Me
1:30 p.m. – 3:00 p.m.
Room A309, Level 3
Georgia World Congress Center
Chairs: Sarah M. Fayad, M.D.
Almari Ginory, D.O.
Speakers: Jacqueline A. Hobbs, M.D., Ph.D.
Sarah Johnson, M.D.
Misty Richards, M.D., M.S.
Kimberly Gordon, M.D.
Molly McVoy, M.D.

Nonverbal Learning Disability (NVLD): Myth and Reality
APA Council on Children, Adolescents and Their Families
1:30 p.m. – 3:00 p.m.
Room B310, Level 3
Georgia World Congress Center
Chairs: Cindy Vargas Cruz, M.D., M.B.A.
Auralyd Padilla Candelario, M.D.
Speakers: Sheldon Benjamin, M.D.
Ellen Braaten, Ph.D.
Stephen Nowicki, Ph.D.
Steven Schlozman, M.D.

A Cognitive Behavioral Approach to Weight Loss and Maintenance
1:30 p.m. – 3:00 p.m.
Room B403, Level 4
Georgia World Congress Center
Chairs: Judith S. Beck, Ph.D.
Deborah Beck Busis, L.C.S.W.

2:00 p.m. Sessions
Poster Session
Medical Student-Resident Competition Poster 2
2:00 p.m. – 4:00 p.m.
Exhibit Hall B3-B4, Level 1
Georgia World Congress Center
Chairs: Sarah M. Fayad, M.D.
Almari Ginory, D.O.
Speakers: Jacqueline A. Hobbs, M.D., Ph.D.
Sarah Johnson, M.D.
Misty Richards, M.D., M.S.
Kimberly Gordon, M.D.
Molly McVoy, M.D.

Advances in Medicine
Medical Mysteries and Practical Medical Psychiatry Updates: Is It “Medical,” “Psychiatric” or a Little of Both?
2:00 p.m. – 5:00 p.m.
Rooms B207-208, Level 2
Georgia World Congress Center
Chair: Robert M. McCarron, D.O.
Speakers: Pritham Raj, M.D.
Sarah Rivelli, M.D.
Shannon Suo, M.D.

Advances in Psychodynamic Psychiatry
American Psychiatric Association Publishing Editorial Board
2:00 p.m. – 5:00 p.m.
Room A305, Level 3
Georgia World Congress Center
Chair: Elizabeth L. Auchincloss, M.D.
1. The Role of Psychoeducation in Psychodynamic Psychiatry
Fredric N. Busch, M.D.
2. Advances in the Understanding and Treatment of Narcissistic Personality Disorder
Eve Caligor, M.D.
3. Advances in Understanding and Treating Borderline Personality Disorder
Otto F. Kernberg, M.D.
4. The Role of Separation Anxiety in Psychodynamic Psychiatry
Barbara Milrod, M.D.

Media Workshop
“Astu—So Be It”: The Strength of Digital Media in the Training of Health Professionals and in Public Awareness
2:00 p.m. – 5:00 p.m.
Room A314, Level 3
Georgia World Congress Center
Chair: Mohan Agashe

Symposia
Interventions for Early Psychosis in Children and Adolescents: New Advances in Community and Policy Approaches
APA Child and Adolescent Psychiatry Fellowship
2:00 p.m. – 5:00 p.m.
Rooms B216-217, Level 2
Georgia World Congress Center
Psychiatry in the Arab World: A Decade of Progress and a Future of Expectations
Arab American Psychiatric Association

2:00 p.m. – 5:00 p.m.
Room B308, Level 3
Georgia World Congress Center

Chairs:
Ossama Tawakol Osman, M.D.
Abdel F. Amin, M.D., M.P.H.

Discussant:
David V. Sheehan, M.D.

1. Highlights of Arab Psychiatry Over the Past Decade: Elements of Progress and Demands for the Future
Ossama Tawakol Osman, M.D.

2. Mental Health and Psychiatry in Egypt: A Decade of Progress
Afaf Hamed Khalil, M.D., Ph.D.

3. A Decisive Decade for Psychiatry and Mental Health in Morocco: 2006 – 2015
Driss Moussaoui, M.D.

4. Psychiatry in the United Arab Emirates: A Decade of Transformative Progress
Ghanem Al-Hassani, M.D.

Marijuana: Assessing Its Risks in a Changing Environment
National Institute on Drug Abuse

2:00 p.m. – 5:00 p.m.
Room B312, Level 3
Georgia World Congress Center

Chairs:
Nora Volkow, M.D.
Susan R. B. Weiss, Ph.D.

Discussant:
Mark Kleiman, Ph.D., M.P.P.

1. Effects of Marijuana on the Brain and Cognition
Deborah Yurgelen-Todd, Ph.D.

2. Traditional Marijuana, High-Potency Cannabis and Synthetic Cannabinoids: Increasing Risk of Psychosis?
Robin M. Murray, M.D.

3. Cannabis Use Disorder: Diagnosis and Treatment
Frances R. Levin, M.D.

4. Cannabis: Patterns of Use and Risk
James C. Anthony, M.Sc., Ph.D.

Emergency Psychiatry: Changing Issues for Training and Supervision in Psychiatric Emergency Services (PES)
American Psychiatric Association
Publishing Editorial Board

2:00 p.m. – 5:00 p.m.
Room B314, Level 3
Georgia World Congress Center

Chairs:
Michelle B. Riba, M.D.

1. Legal Issues in the Emergency Room
Debra Pinals, M.D.

2. Evaluating and Managing Agitated Patients
Rachel Glick, M.D.

3. Suicide Risk Assessment and Management
Jose R. Maldonado, M.D.

4. Substance-Related Psychiatric Emergencies
Adam Miller, M.D.

Katherine Malay, M.D.

6. Depression, Euphoria and Anger in the Emergency Department
Philippe-Edouard Boursiquot, M.D., B.Sc.

7. The Psychotic Patient
Patricia Schwartz, M.D.
Advancing Biological Markers for PTSD

2:00 p.m. – 5:00 p.m.
Room B401, Level 4
Georgia World Congress Center

Chairs:
Marti Jett, Ph.D.
Charles R. Marmar, M.D.

Discussant:
Eric Vermetten, M.D., Ph.D.

1. GWAS Approaches to Understanding the Genomic Architecture of PTSD
   Kerry Ressler, M.D., Ph.D.

2. Panomic Markers of PTSD
   Rasha Hammamieh, Ph.D., Pharm.D.

3. Metabolism, Inflammation and Cell Aging Markers for PTSD
   Synthia H. Mellon, Ph.D.

4. Neuroendocrine and Molecular Markers and PTSD
   Rachel Yehuda, Ph.D.

5. PTSD and White Matter Abnormalities
   Kirstin Aschbacher, Ph.D.

Impact of Mental Illness in an Army Basic Training Environment: From the Recruits Who Join the Military to the Individuals Who Recruit and Train Them

2:00 p.m. – 5:00 p.m.
Room B402, Level 4
Georgia World Congress Center

Chairs:
Melinda A. Thiam, M.D.
Keith Penska, M.D.

Discussant:
Sonda Thompson, M.S.N.

1. “Ghosts” That Join the Military: Psychological Challenges of Recruits Who Seek to Join the Military
   Melinda A. Thiam, M.D.

2. For Those Who Sneak Through: Challenges of Separating Individuals Who Are Mentally Unfit for Duty
   Keith Penska, M.D.

3. “How Did This Person Get Into the Military?” The Challenges of Severe Mental Illness in Army Recruits and the Impact on Basic Training Missions
   David S. Hudson, Ed.D., Sonda Thompson, M.S.N.

4. Army Ambassador to the Public: The Psychological Requirements as Well as Challenges of Becoming an Army Recruiter
   Chaska Gomez, Psy.D.

5. The Challenge of Wearing the Hat: Stressors and Mental Health Challenges of Drill Sergeant Duty
   Wesley N. Stokes, Psy.D., Kimberly D. Goode, A.A.S.

Defining the Syndrome of the Acute Suicidal Crisis

2:00 p.m. – 5:00 p.m.
Room B407, Level 4
Georgia World Congress Center

Chairs:
Igor Galynker, M.D., Ph.D.
Thomas Joiner, Ph.D.

1. The Existence, Necessity, Validity and Clinical Utility of a New Diagnostic Entity: Acute Suicidal Affective Disturbance (ASAD)
   Thomas Joiner, Ph.D.

2. Agitation at Psychiatric Inpatient Admission: Sign of Acute Suicidal Crisis and Predictor of Suicide After Discharge?
   Arne E. Vaaler, M.D., Ph.D.

3. Understanding Suicide Risk Through the Patient’s Eyes
   Keith W. Jennings, Ph.D.

4. Development of an Implicit Measure of Suicidal Risk
   Lisa J. Cohen, Ph.D.

5. Understanding the Acute Suicidal Crisis
   Igor Galynker, M.D., Ph.D.
2. PTSD and Risk of Alzheimer’s Disease in Vietnam Veterans: Preliminary Amyloid PET Findings From AIBL-VETS
   Alby Elias, M.B.B.S., M.D.

3. Five Enduring Psychiatric Responses to War: Freud, Gonda, Salmon, Rivers and Ferenczi
   Thomas B. Horvath, M.D.

Workshops

Not Your Grandfather’s VA: Innovative Health Care Offering Exceptional Psychiatric Careers
3:30 p.m. – 5:00 p.m.
Room B215, Level 2
Georgia World Congress Center
Chair: R. Jill Pate, M.D.
Speakers: Shahla Ali, M.D.
Erin L. Patel, Psy.D.
Shagufta Jabeen, M.D.
Jennifer Bean, Pharm.D.

Challenges and Successes in Conducting Practice-Based Research in Psychiatry
3:30 p.m. – 5:00 p.m.
Room B218, Level 2
Georgia World Congress Center
Chairs: Farifteh F. Duffy, Ph.D.
Diana E. Clarke, Ph.D., M.Sc.
Speakers: Joyce C. West, Ph.D., M.P.P.
Eve Moscicki, Sc.D., M.P.H.
Farifteh F. Duffy, Ph.D.
Keila D. Barber, M.H.S.
Diana E. Clarke, Ph.D., M.Sc.
Bernadette Cullen, M.B.

Focusing on Improvement Every Day: The Context and Application of a Lean Daily Management System at a Behavioral Health Care System
3:30 p.m. – 5:00 p.m.
Room A303, Level 3
Georgia World Congress Center
Chair: Sunil Khushalani, M.D.
Speakers: Steven S. Sharfstein, M.D., M.P.A.
Robert Roca, M.D., M.P.H.
Antonio DePaolo, Ph.D.

Enhancing Resilience in College Students: Developmental Perspectives in the Practice of College Psychiatry
APA College Mental Health Caucus
3:30 p.m. – 5:00 p.m.
Room A307, Level 3
Georgia World Congress Center
Chair: Doris Iarocici, M.D.
Speakers: Doris Iarocici, M.D.
Preston Wiles, M.D.
Daniel Kirsch, M.D.

Physician Burnout, Depression, Suicide: Identification, Assessment, Treatment and Prevention
3:30 p.m. – 5:00 p.m.
Room A309, Level 3
Georgia World Congress Center
Chairs: Almari Ginory, D.O.
Michelle Chaney, M.D., M.Sc.
Speakers: Anu Mathur, M.D.
Jacqueline A. Hobbs, M.D., Ph.D.
Lisa J. Merlo, Ph.D.

Diversity Experiences in Residency Training
American Association for Social Psychiatry
3:30 p.m. – 5:00 p.m.
Room B310, Level 3
Georgia World Congress Center
Chair: Beverly Fauman, M.D.
Speakers: Aida Spahic Mihajlovic, M.D., M.S.
Jacob Sperber, M.D.

The Exploration of Faith and Spirituality in the Psychiatric Assessment and Treatment of Minority Patients
APA/SAMHSA Minority Fellows
3:30 p.m. – 5:00 p.m.
Room B311, Level 3
Georgia World Congress Center
Chair: Danielle Hairston, M.D.
Speakers: Lynneice Bowen, M.D., M.Ed.
Matthew L. Dominguez, M.D., M.P.H.
Josepha Immanuel, M.D.
Ayana Jordan, M.D., Ph.D.
Jennifer Severe, M.D.
Annabelle K. Simpson, M.D.

5:30 p.m. Session

Forum

Ragtime: The Mind and Music of Scott Joplin
5:30 p.m. – 7:00 p.m.
Sidney Marcus Auditorium, Level 4
Georgia World Congress Center
Speaker: Richard Kogan, M.D.
Understanding Mental Disorders: Your Guide to DSM-5® is a vital resource for anyone who has been touched by mental illness.

Most of us know someone who suffers from a mental illness. This book helps those who may be struggling with mental health problems, as well as those who want to help others achieve mental health and well-being.

Based on the latest, fifth edition of the Diagnostic and Statistical Manual of Mental Disorders—known as DSM-5®—Understanding Mental Disorders provides valuable insight on what to expect from an illness and its treatment—and will help readers recognize symptoms, know when to seek help, and get the right care. Featured disorders include depression, schizophrenia, ADHD, autism spectrum disorder, posttraumatic stress disorder, and bipolar disorder, among others.

The common language for diagnosing mental illness used in DSM-5® for mental health professionals has been adapted into clear, concise descriptions of disorders for nonexperts. In addition to specific symptoms for each disorder, readers will find:

- Risk factors and warning signs
- Related disorders
- Ways to cope
- Tips to promote mental health
- Personal stories
- Key points about the disorders and treatment options
- A special chapter dedicated to treatment essentials and ways to get help
- Helpful resources that include a glossary, list of medications and support groups

For more resources and information, go to www.psychiatry.org/UnderstandingMentalDisorders

2015 • 370 pages • ISBN 978-1-58562-491-1 • Paperback • $24.95 • Item #62491
Sunday
May 15, 2016
Fred H. Gage, Ph.D., a Professor with the Laboratory of Genetics, joined The Salk Institute in 1995. He received his Ph.D. in 1976 from The Johns Hopkins University. Dr. Gage’s work concentrates on the adult central nervous system and unexpected plasticity and adaptability to environmental stimulation that remains throughout the life of all mammals. In addition, he models human neurological and psychiatric diseases in vitro using human stem cells. His lab studies the genomic mosaicism that exists in the brain as a result of mobile elements that are active during neurogenesis.

Matthew State, M.D., received his medical degree from Stanford University, completed a residency in psychiatry and a fellowship in child psychiatry at UCLA and earned a PhD in genetics from Yale University, where he joined the faculty in 2001. In 2013, he moved to UCSF as the Oberndorf Family Distinguished Professor and Chair of the Department of Psychiatry. Dr. State’s lab studies the genetics and genomics of childhood neuropsychiatric disorders. He co-leads several international genomics collaborations, including the NIH-funded Autism Sequencing Consortium, and has been the recipient of multiple awards, including recent induction into the Institute of Medicine and the AACAP George Tarjan Award for Contributions in Developmental Disabilities.

Michael R. Trimble, M.D., is Emeritus Professor of Behavioral Neurology at the Institute of Neurology, Queen Square, London. His initial degree was in neuroanatomy, a discipline he has followed throughout his career. His interests include neuropsychopharmacology with special reference to neuropsychiatric disorders: epilepsy, its treatment and relationship to disturbances of behavior, and the effects of antiepileptic drugs and other treatment for epilepsy on the brain and behavior. Other research and clinical interests include movement disorders and their treatment, especially the development of psychiatric disorders in Parkinson’s disease and Gilles de la Tourette syndrome; head injuries; dementia; and the spectrum of presentations in the neurology and psychiatry of patients with medically unexplained neurological symptoms.
8:00 a.m. Sessions

**Forum**

LGBT Psychiatry: Update for 2016
8:00 a.m. – 9:30 a.m.
Room B206, Level 2
Georgia World Congress Center
Chair: Ellen Haller, M.D.
Speakers: Amir Ahuja, M.D.
Laura Erickson-Schroth
Ellen Haller, M.D.

**Interactive Session**

Psychiatry at the Forefront of Leadership: Why You? Why Now?
8:00 a.m. – 9:30 a.m.
Room A301, Level 3
Georgia World Congress Center
Chair: Patrice Harris, M.D.

**Lectures**

Why Humans Like to Cry: Tragedy, Evolution and the Brain
APA International Psychiatrist Lecture Series
8:00 a.m. – 9:30 a.m.
Sidney Marcus Auditorium, Level 4
Georgia World Congress Center
Lecture Chair: Renée Binder, M.D.
Lecturer: Michael Trimble, M.D.

The Person in Personalized Medicine: Lessons from the IMAGES Study
Simon Bolivar Award
8:00 a.m. – 9:30 a.m.
Room B406, Level 4
Georgia World Congress Center
Lecturer: Gabriel De Erausquín, M.D., Ph.D.

**Scientific and Clinical Reports**

Terror and Community Violence
8:00 a.m. – 9:30 a.m.
Room B405, Level 4
Georgia World Congress Center
1. Homicides of Mental Health Workers by Patients
   Michael B. Knable, D.O.
2. Exposure to Community Violence, Use of Mental Health Services and Depressive Symptoms Among Adolescents and Young Adults
   Wan-Yi Chen, Ph.D., M.S.W.
   Phebe M. Tucker, M.D.

**Workshops**

The Clinical Evaluation and Management of Substance Use Disorders in Transgender Patient Populations
APA Council on Addiction Psychiatry
8:00 a.m. – 9:30 a.m.
Room B215, Level 2
Georgia World Congress Center
Chairs: Hector Colon-Rivera, M.D.
Elie Aoun, M.D.

**SESSiON TRACkS**

1. Addiction Psychiatry
2. Child and Adolescent Psychiatry
3. Forensic Psychiatry
4. Geriatric Psychiatry
5. Psychosomatic Psychiatry
6. NIDA
7. Residents, Fellows and Medical Students
8. APA Annual Meeting On Demand
9. Bring Your Own Device
Learning From Each Other: Facilitators and Barriers in Health Care Organizations for Improving Quality of Care—Insights From the U.S., U.K. and Zambia
8:00 a.m. – 9:30 a.m.
Room B404, Level 4
Georgia World Congress Center
Chair: Sunil Khushalani, M.D.
Speakers: Steven S. Sharfstein, M.D., M.P.A., Ananta Dave, M.D., Subodh Dave, M.D.

Best Practice in International Medical Graduates—Training and Assessment
7
8:00 a.m. – 9:30 a.m.
Room B310, Level 3
Georgia World Congress Center
Chair: Subodh Dave, M.D.
Speaker: Nyapati R. Rao, M.D.

The Use of Buprenorphine in Abstinence-Based Treatment for Addiction
1
8:00 a.m. – 9:30 a.m.
Room B315, Level 3
Georgia World Congress Center
Chair: Alphonse Kenison Roy III, M.D.

The Academic Hospital Clinic: Adapting to Changing Needs in Patient Care, Residency Training, Regulations and Reimbursement
8:00 a.m. – 9:30 a.m.
Room A408, Level 4
Georgia World Congress Center
Chair: Jess Zonana, M.D.
Speakers: Breck Borcherding, M.D., John Q. Young, M.D., M.P.H., Mark Zimmerman, M.D.

Physicians for Criminal Justice Reform: How Do I Fit In?
3
8:00 a.m. – 9:30 a.m.
Room B403, Level 4
Georgia World Congress Center
Chairs: Nzinga Harrison, M.D., Osvaldo Gaytan Jr., M.D., Ph.D.
Chair:
Michael J. Vergare, M.D.

Discussant:
Thomas J. Craig, M.D.

1. Developing Practice Guidelines: Why and How
   Michael J. Vergare, M.D.

2. Physical Health Assessment as Part of the Psychiatric Evaluation
   Joel J. Silverman, M.D.

3. Aligning Practice Guidelines With Evidence: When and How Should Antipsychotics Be Used in Individuals With Dementia
   Victor I. Reus, M.D.

4. Quantitative Measurement in Psychiatry: Positives and Pitfalls
   Laura J. Fochtmann, M.D.

Media Workshop

“Inside Out”: Emotions, Imagination and Growing Up

8:00 a.m. – 11:00 a.m.
Room A314, Level 3
Georgia World Congress Center

Chairs:
Martin K. Huynh, B.S.
Harry Siegele, B.S.

Speaker:
Alice R. Mao, M.D.

Presidential Symposia

Issues for Child and Adolescent Psychiatry in the 21st Century
American Academy of Child and Adolescent Psychiatry
The Agnes Purcell McGavin Awards will be presented during this session.

8:00 a.m. – 11:00 a.m.
Rooms B213-214, Level 2
Georgia World Congress Center

Chairs:
Amresh Shrivastava, M.D.
Charles B. Nemeroff, M.D., Ph.D.
James Brooks

1. Central and Peripheral Immune Markers in Depression and Suicide
   Ghanshyam N. Pandey, Ph.D.

2. Inflammation in Mood/Cognitive Disorders: Conceptual and Practical Considerations
   Roger S. McIntyre, M.D.

3. Personalized Medicine: Depression
   Charles B. Nemeroff, M.D., Ph.D.

4. Psychoneurobiology of Resilience
   Gustavo E. Tafet, M.D., Ph.D.

5. Resilience: A Psychobiological Construct for Suicidality
   Amresh Shrivastava, M.D.

6. HPA Axis Genetic Variation, Psychosis and Cognition in Depression
   Alan F. Schatzberg, M.D.

Symposia

Deconstructing the Neurobiology of Depression

8:00 a.m. – 11:00 a.m.
Rooms B216-217, Level 2
Georgia World Congress Center

Chair:
Gregory K. Fritz, M.D.

1. Pediatric Integrated Care: Children Are Not Short Adults
   Gregory K. Fritz, M.D.

2. Global Mental Health: Why Partnerships Are Important
   Paramjit Joshi, M.D.

3. Management of Depression in Children and Adolescents
   Karen Dineen Wagner, M.D., Ph.D.

4. “Acting Out” Youth: Timely Forensic and Correctional Approaches
   Joseph V. Penn, M.D.

Translating the Evidence for the Next Generation: Addressing the Mental Health of Youth and Emerging Adults of Color

8:00 a.m. – 11:00 a.m.
Room B313, Level 3
Georgia World Congress Center

Chair:
Lisa R. Fortuna, M.D., M.P.H.

1. Between Two Worlds: Culture, Environment, Race and Mental Health for First- and Second-Generation Immigrant Emerging Adults
   Kiara Alvarez, Ph.D.

2. Can We Train Providers and Patients to Do Shared Decision Making in Behavioral Health Encounters?
   Margarita Alegria, Ph.D.

3. Why Capable Young People Struggle: Educational Attainment and Mental Health in Communities of Color
   Michelle V. Porche, Ed.D.

4. Psychiatry Serving the Needs of a Diverse Next Generation: Where We Hit It and Where We Miss It
   Lisa R. Fortuna, M.D., M.P.H.

All scientific sessions listed in the Program are designated for AMA PRA Category 1 Credits™, except for Poster Sessions.
Autism Spectrum Disorders (ASD): Epidemiology, Genetics, Revisiting Risperidone, Parent Training and Early Detection
APA Council on Children, Adolescents and Their Families

8:00 a.m. – 11:00 a.m.
Room B309, Level 3
Georgia World Congress Center

Chairs:
Lan Chi Krysti L. Vo, M.D.
Lawrence Scahill, Ph.D., M.S.N.

Discussant:
Paul Wang, M.D.

1. Epidemiology of Autism Spectrum Disorders (ASD): To Know What We See Rather Than to See What We Know
Young Shin Kim, M.D., Ph.D.

2. Advances in Molecular Genetics of Autism Spectrum Disorders (ASD): Applications in the Clinic, New Perspectives in Clinical Neuroscience
Joseph F. Cubells, M.D., Ph.D.

3. Revisiting Risperidone
Lan Chi Krysti L. Vo, M.D.

4. Parent Training in Children With Autism Spectrum Disorders (ASD): Results of a Randomized Clinical Trial
Lawrence Scahill, Ph.D., M.S.N.

5. Toward Universal Screening and Improved Access to Early Intervention in Autism Spectrum Disorders (ASD)
Ami Klin, Ph.D.

Mood, Art and Politics: Abraham Lincoln, Vincent Van Gogh, Sylvia Plath and Robin Williams—Resilience and Creativity in the Face of Great Odds

8:00 a.m. – 11:00 a.m.
Room B312, Level 3
Georgia World Congress Center
Chair:
John P. O’Reardon, M.D.

Discussant:
John P. O’Reardon, M.D.

Thomas Newmark, M.D.

2. Sylvia Plath and Robin Williams
Michelle Nagurney, M.D.

3. Abraham Lincoln and Vincent Van Gogh
John P. O’Reardon, M.D.

Forgiveness, Trauma and Psychiatry: The Clinical Relevance From Diverse Faith Perspectives in the Wake of the Charleston Church Tragedy

APA Caucus on Religion, Spirituality and Psychiatry

8:00 a.m. – 11:00 a.m.
Room B401, Level 4
Georgia World Congress Center
Chair:
Chris Winfrey, M.D.

Discussant:
Rama Rao Gogineni, M.D.

1. Emmanuel AME Massacre: Baha’i Faith Perspective on Forgiveness
Deborah Deas, M.D., M.P.H.

2. Forgiveness and Trauma: Clinical Perspectives From the Christian Faith
Kevin Brown

3. Jewish Perspectives on Forgiveness Related to Psychiatry
H. Steven Moffic, M.D.

4. Forgiveness, Islamic Religion/Culture and Psychiatry
Driss Moussaoui, M.D.

5. Forgiveness: Hindu and Buddhist Perspectives
Shridhar Sharma, M.D., D.P.M.

Integrating Sociocultural Perspectives of Postpartum Depression (PPD) Among Diverse Women Improves Care
APA Council on Minority Mental Health and Health Disparities

8:00 a.m. – 11:00 a.m.
Room B402, Level 4
Georgia World Congress Center

Chairs:
Pamela C. Montano Arteaga, M.D.
Maria Jose Lisotto, M.D.

Discussants:
Roberto Lewis-Fernandez, M.D.
Elizabeth Fitelson, M.D.

1. Sociocultural Risk Factors for Postpartum Depression Among Immigrant and Minority Women
Pamela C. Montano Arteaga, M.D.

2. Overview of the Assessment and Treatment of Postpartum Depression
Elizabeth Fitelson, M.D.

3. Postpartum Rituals and Other Cultural Considerations in the Management of Postpartum Depression (PPD)
Kenneth P. Fung, M.D.

4. Intimate Partner Violence and Postpartum Depression
Ludmila De Faria, M.D.

5. An End to Painting by Numbers: A Culturally Informed Assessment and Treatment Model for Postpartum Depression
Matthew L. Dominguez, M.D., M.P.H.

Bipolar Disorder in Children and Adults in France and North America: Vive La Difference!

8:00 a.m. – 11:00 a.m.
Room B407, Level 4
Georgia World Congress Center

Chairs:
John A. Talbott, M.D.
Francois Petitjean, M.Psy.

Discussant:
John P. O’Reardon, M.D.

1. French Guidelines for the Treatment of Bipolar Disorder: Interests and Limits
Ludovic Samalin, M.D.
2. Antidepressant-Emergent Manic Switch: Identifying At-Risk Bipolar I and II Patients
   Clara Brichant-Petitjean, M.D.

3. An American Approach to Bipolar Disorder: Patient and Family Education
   J. Raymond DePaulo Jr., M.D.

4. The North American Approach to Bipolar Disorder During Pregnancy
   Gail Erlick Robinson, M.D.

5. Bipolar Disorder During the Peripartum Period: A French Integrative Model
   Gisele Apter, M.D., Ph.D.

Street Drugs and Mental Disorders: Overview and Treatment of Dual Diagnosis Patients

8:00 a.m. – Noon
Marriott Ballroom D, Marquis Level
Marriott Marquis

Director:
John W. Tsuang, M.D.

Faculty:
Tim Fong, M.D.
Reef Karim, D.O.
Larissa Mooney

Understanding and Treating Narcissistic Personality Disorder

8:00 a.m. – Noon
M103-105, Marquis Level
Marriott Marquis

Directors:
Frank E. Yeomans, M.D.
Otto F. Kernberg, M.D.

Faculty:
Eve Caligor, M.D.
Diana Diamond, Ph.D.

Training Practitioners to Use a Psychopathology Clinical Rating Scale

8:00 a.m. – Noon
International 7, International Level
Marriott Marquis

Director:
Ahmed Aboraya, M.D., D.P.H.

Faculty:
Daniel Elswick, M.D.
Henry A. Nasrallah, M.D.

Interpersonal Psychotherapy

8:00 a.m. – Noon
International 4, International Level
Marriott Marquis

Director:
John C. Markowitz, M.D.

Good Psychiatric Management for Borderline Personality Disorder: What Every Psychiatrist Should Know

8:00 a.m. – Noon
International 6, International Level
Marriott Marquis

Directors:
John Gunderson, M.D.
Paul Links

Faculty:
Brian Palmer, M.D., M.P.H.

Practical Assessment and Management of Behavior Disturbance in Patients With Moderate to Severe Dementia
American Association for Geriatric Psychiatry

9:00 a.m. – 4:00 p.m.
International 8, International Level
Marriott Marquis

Director:
Maureen C. Nash, M.D., M.S.

Faculty:
Sarah Foidel, O.T.R./L.
Maria L. Shindler, M.S.N.

Integrating Behavioral Health and Primary Care: Practical Skills for the Consulting Psychiatrist

9:00 a.m. – 4:00 p.m.
Marriott Ballroom A, Marquis Level
Marriott Marquis

Directors:
Anna Ratziuff, M.D., Ph.D.
Lori Raney, M.D.

Faculty:
John Kern, M.D.

Psychodynamic Psychopharmacology: Applying Practical Psychodynamics to Improve Pharmacological Outcomes With Treatment-Resistant Patients

9:00 a.m. – 4:00 p.m.
M301-302, Marquis Level
Marriott Marquis
Master Courses

Course descriptions are available in the APA Meetings app. Admission to all courses, including master courses, is by ticket only. Course tickets can be purchased at Registration at the Marquis Fountain, Marquis Level in the Marriott Marquis, or at Registration in Exhibit Hall B3-B4, Level 1 in the Georgia World Congress Center.

Advances in the Treatment of Bipolar Disorder

9:00 a.m. – 4:00 p.m.
Marquis Ballroom C, Marquis Level Marriott Marquis
Director: Terence A. Ketter, M.D.
Faculty: Po Wang, M.D.
Shefali Miller, M.D.
Kiki Chang, M.D.
Natalie Rasgon
John Brooks

Assessment and Treatment of Eating Disorders

9:00 a.m. – 4:00 p.m.
Imperial Ballroom B, Marquis Level Marriott Marquis
Director: B. Timothy Walsh, M.D.
Faculty: Evelyn Attia, M.D.
Eve Khlyavin-Freidi, M.D.
Michael Devlin, M.D.
Tom Hildebrandt, Psy.D.
Anne Becker, M.D., Ph.D.

10:00 a.m. Sessions

Case Conference

These sessions are open to APA members only. A blue registration badge or an APA membership card are required for admittance.

Forum

AASP Abraham L. Halpern Humanitarian Award Forum—Abortion: What’s Happening and Why It Matters to Women, Society and Psychiatry
American Association for Social Psychiatry
10:00 a.m. – 11:30 a.m.
Rooms A315-316, Level 3
Georgia World Congress Center
Chair: Sahil Munjal, M.D.

Scientific and Clinical Reports

Psychiatric Considerations in Pre-Op and Transplant

10:00 a.m. – 11:30 a.m.
Room B405, Level 4
Georgia World Congress Center
1. The Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT): A Prospective Study of Medical and Psychosocial Outcomes
Jose R. Maldonado, M.D.
2. Preoperative Opioid Reduction Program: A Pilot Study
   Sameer Hassamal, M.D.

3. Delirium in Lung Transplant Recipients and Its Effects on Post-Transplant Outcomes
   Yelizaveta Sher, M.D.

**Workshops**

**CBT for Suicide Risk**

10:00 a.m. – 11:30 a.m.
Room B215, Level 2
Georgia World Congress Center

Chair: Donna M. Sudak, M.D.

Speakers:
   Jesse H. Wright, M.D., Ph.D.
   Judith S. Beck, Ph.D.

**Placebo: Parsing and Using Its Therapeutic Action**

10:00 a.m. – 11:30 a.m.
Room B218, Level 2
Georgia World Congress Center

Chair: Donald J. Meyer, M.D.

Speakers:
   Robert C. Joseph, M.D., M.S.
   Don Lipsitt, M.D., M.A.
   Philip R. Muskin, M.D., M.A.
   Malkah T. Notman, M.D.

**The “F-Word” Feedback: If It’s So Important, Why Is It So Difficult to Do?**

10:00 a.m. – 11:30 a.m.
Room A303, Level 3
Georgia World Congress Center

Chairs:
   Josepha A. Cheong, M.D.
   Marcia L. Verduin, M.D.

Speakers:
   John Luo, M.D.
   Robert J. Boland, M.D.

**Military Behavioral Health Through the Lens of the 4077th: The Realities and Myths of Military Behavioral Health Shown on M.A.S.H.**

10:00 a.m. – 11:30 a.m.
Room A304, Level 3
Georgia World Congress Center

Chairs:
   Sebastian Schnellbacher, D.O.
   Wendi Waits, M.D.

**Psychiatry in the Courts: APA Confronts Legal Issues of Concern to the Field**

APA Committee on Judicial Action

10:00 a.m. – 11:30 a.m.
Room A307, Level 3
Georgia World Congress Center

Chair: Marvin S. Swartz, M.D.

Speakers:
   Paul S. Appelbaum, M.D.
   Howard Zonana, M.D.

**The Impact of Social Media and Societal Change on Young Gay Men’s Development: Implications for Intimacy, Sexuality and Psychotherapy**

Association of Gay and Lesbian Psychiatrists

10:00 a.m. – 11:30 a.m.
Room A309, Level 3
Georgia World Congress Center

Chair: Marshall Forstein, M.D.

Speaker: Lawrence McGlynn, M.D., M.S.

**The DSM-5 Anxious Distress Specifier: Convergent Validity and Clinical Implications**

10:00 a.m. – 11:30 a.m.
Room A313, Level 3
Georgia World Congress Center

Chairs:
   Gayle M. Wittenberg, Ph.D.
   Jan Fawcett, M.D.

Speakers:
   Jan Fawcett, M.D.
   Brenda W. Penninx, Ph.D.
   Marsha Ann Wilcox, Ed.D., Sc.D.
   Justine M. Kent, M.D.

**Treatment of People With First-Episode Psychosis in Forensic Psychiatric Hospitals: Challenges and Outpatient Follow-Up**

American Association of Community Psychiatrists

10:00 a.m. – 11:30 a.m.
Room B311, Level 3
Georgia World Congress Center

Chair: Ann Hackman, M.D.

Speakers:
   Keith Gallagher, M.D.
   Elizabeth Jane Richardson, M.D.

**She for All: Engaging Community Leaders to Advance Global Mental Health**

Association of Women Psychiatrists

10:00 a.m. – 11:30 a.m.
Room B310, Level 3
Georgia World Congress Center

Chair: Christina Tara Khan, M.D., Ph.D.

Speakers:
   Mary Kay Smith, M.D.
   P. Lynn Ouellette, M.D.
   Geetha Jayaram, M.D.

**Children of Psychiatrists**

10:00 a.m. – 11:30 a.m.
Room B315, Level 3
Georgia World Congress Center

Chairs:
   Michelle B. Riba, M.D.
   Leah Dickstein, M.D.
Interactive Session
Using the DSM-5 Cultural Formulation Interview in Daily Practice
American Psychiatric Association Publishing Editorial Board
12:30 p.m. – 2:00 p.m.
Room A301, Level 3
Georgia World Congress Center
Chair:
Roberto Lewis-Fernandez, M.D.

Psychiatric Communication Strategies: Intervention Models for Inpatient Medical/Surgical Settings

12:30 p.m. – 2:00 p.m.
Rooms B207-208, Level 2
Georgia World Congress Center
Chair:
Erika L. Nurmi, M.D., Ph.D.
Speakers:
John Krystal, M.D.
J. Michael Bostwick, M.D.
Stephen R. Marder, M.D.
James T. McCracken, M.D.
Kristin Cadenhead, M.D.
Charles Grob, M.D.

Addressing the Demand for Mental Health Care Needs of Hispanics in the United States
APA Caucus of Hispanic Psychiatrists
10:00 a.m. – 11:30 a.m.
Room B408, Level 4
Georgia World Congress Center
Chairs:
Esperanza Diaz, M.D.
Jose E. de la Gandara, M.D.
Speakers:
Julio Ballestas, M.D.
Andres Barkil-Oteo, M.D., M.Sc.
Daniel Castellanos, M.D.

Poster Session
International Poster Session 1
10:00 a.m. – Noon
Exhibit Hall B3-B4, Level 1
Georgia World Congress Center

12:30 p.m. Sessions
Session
APA Business Meeting
APA Members only
12:30 p.m. – 1:30 p.m.
Rooms A411-412, Level 4
Georgia World Congress Center

Case Conference
These sessions are open to APA members only. A blue registration badge or an APA membership card are required for admittance.

I Just Want to Be Clean
12:30 p.m. – 2:00 p.m.
Rooms A315-316, Level 3
Georgia World Congress Center
Chairs:
Philip R. Muskin, M.D., M.A.
Geoffrey P. Taylor, M.D.
Speakers:
Donna Chen, M.D., M.P.H.
David Lowenthal, M.D., J.D.

Our Toughest Addiction Challenge: Treating Tobacco Use Disorders in Patients With Mental Illness and Addictions and Informing Them About E-Cigarettes
10:00 a.m. – 11:30 a.m.
Room B404, Level 4
Georgia World Congress Center
Chairs:
Sunil Khushalani, M.D.
George Kolodner, M.D.

Seeking Refuge: Effects of Psychological Evaluations in Asylum Cases

12:30 p.m. Sessions
Session
Controversial Treatment Debate: Should I Prescribe Ketamine and Marijuana? (Part 1)
12:30 p.m. – 2:00 p.m.
Rooms B207-208, Level 2
Georgia World Congress Center
Chair:
Erika L. Nurmi, M.D., Ph.D.
Speakers:
John Krystal, M.D.
J. Michael Bostwick, M.D.
Stephen R. Marder, M.D.
James T. McCracken, M.D.
Kristin Cadenhead, M.D.
Charles Grob, M.D.

Evidence-Based Mindfulness Meditation Interventions for Mental Health Conditions
10:00 a.m. – 11:30 a.m.
Room B316, Level 3
Georgia World Congress Center
Chair:
Marina Khusid, M.D.
Speakers:
Marina Khusid, M.D.

Psychiatric Communication Strategies: Intervention Models for Inpatient Medical/Surgical Settings

10:00 a.m. – 11:30 a.m.
Room A403, Level 4
Georgia World Congress Center
Speakers:
Joel J. Wallack, M.D.
Nancy Maruyama, M.D.
Stephanie Cheung, M.D.
Simona Goschin

Addressing the Demand for Mental Health Care Needs of Hispanics in the United States
APA Caucus of Hispanic Psychiatrists
10:00 a.m. – 11:30 a.m.
Room B408, Level 4
Georgia World Congress Center
Chairs:
Esperanza Diaz, M.D.
Jose E. de la Gandara, M.D.
Speakers:
Julio Ballestas, M.D.
Andres Barkil-Oteo, M.D., M.Sc.
Daniel Castellanos, M.D.

Poster Session
International Poster Session 1
10:00 a.m. – Noon
Exhibit Hall B3-B4, Level 1
Georgia World Congress Center

12:30 p.m. Sessions
Session
APA Business Meeting
APA Members only
12:30 p.m. – 1:30 p.m.
Rooms A411-412, Level 4
Georgia World Congress Center

Case Conference
These sessions are open to APA members only. A blue registration badge or an APA membership card are required for admittance.

I Just Want to Be Clean
12:30 p.m. – 2:00 p.m.
Rooms A315-316, Level 3
Georgia World Congress Center
Chairs:
Philip R. Muskin, M.D., M.A.
Geoffrey P. Taylor, M.D.
Speakers:
Donna Chen, M.D., M.P.H.
David Lowenthal, M.D., J.D.

Our Toughest Addiction Challenge: Treating Tobacco Use Disorders in Patients With Mental Illness and Addictions and Informing Them About E-Cigarettes
10:00 a.m. – 11:30 a.m.
Room B404, Level 4
Georgia World Congress Center
Chairs:
Sunil Khushalani, M.D.
George Kolodner, M.D.

Seeking Refuge: Effects of Psychological Evaluations in Asylum Cases

12:30 p.m. Sessions
Session
Controversial Treatment Debate: Should I Prescribe Ketamine and Marijuana? (Part 1)
12:30 p.m. – 2:00 p.m.
Rooms B207-208, Level 2
Georgia World Congress Center
Chair:
Erika L. Nurmi, M.D., Ph.D.
Speakers:
John Krystal, M.D.
J. Michael Bostwick, M.D.
Stephen R. Marder, M.D.
James T. McCracken, M.D.
Kristin Cadenhead, M.D.
Charles Grob, M.D.

Evidence-Based Mindfulness Meditation Interventions for Mental Health Conditions
10:00 a.m. – 11:30 a.m.
Room B316, Level 3
Georgia World Congress Center
Chair:
Marina Khusid, M.D.
Speakers:
Marina Khusid, M.D.

Psychiatric Communication Strategies: Intervention Models for Inpatient Medical/Surgical Settings

10:00 a.m. – 11:30 a.m.
Room A403, Level 4
Georgia World Congress Center
Speakers:
Joel J. Wallack, M.D.
Nancy Maruyama, M.D.
Stephanie Cheung, M.D.
Simona Goschin

Addressing the Demand for Mental Health Care Needs of Hispanics in the United States
APA Caucus of Hispanic Psychiatrists
10:00 a.m. – 11:30 a.m.
Room B408, Level 4
Georgia World Congress Center
Chairs:
Esperanza Diaz, M.D.
Jose E. de la Gandara, M.D.
Speakers:
Julio Ballestas, M.D.
Andres Barkil-Oteo, M.D., M.Sc.
Daniel Castellanos, M.D.

Poster Session
International Poster Session 1
10:00 a.m. – Noon
Exhibit Hall B3-B4, Level 1
Georgia World Congress Center

12:30 p.m. Sessions
Session
APA Business Meeting
APA Members only
12:30 p.m. – 1:30 p.m.
Rooms A411-412, Level 4
Georgia World Congress Center

Case Conference
These sessions are open to APA members only. A blue registration badge or an APA membership card are required for admittance.

I Just Want to Be Clean
12:30 p.m. – 2:00 p.m.
Rooms A315-316, Level 3
Georgia World Congress Center
Chairs:
Philip R. Muskin, M.D., M.A.
Geoffrey P. Taylor, M.D.
Speakers:
Donna Chen, M.D., M.P.H.
David Lowenthal, M.D., J.D.

Our Toughest Addiction Challenge: Treating Tobacco Use Disorders in Patients With Mental Illness and Addictions and Informing Them About E-Cigarettes
10:00 a.m. – 11:30 a.m.
Room B404, Level 4
Georgia World Congress Center
Chairs:
Sunil Khushalani, M.D.
George Kolodner, M.D.

Seeking Refuge: Effects of Psychological Evaluations in Asylum Cases

12:30 p.m. Sessions
Session
Controversial Treatment Debate: Should I Prescribe Ketamine and Marijuana? (Part 1)
12:30 p.m. – 2:00 p.m.
Rooms B207-208, Level 2
Georgia World Congress Center
Chair:
Erika L. Nurmi, M.D., Ph.D.
Speakers:
John Krystal, M.D.
J. Michael Bostwick, M.D.
Stephen R. Marder, M.D.
James T. McCracken, M.D.
Kristin Cadenhead, M.D.
Charles Grob, M.D.

Evidence-Based Mindfulness Meditation Interventions for Mental Health Conditions
10:00 a.m. – 11:30 a.m.
Room B316, Level 3
Georgia World Congress Center
Chair:
Marina Khusid, M.D.
Speakers:
Marina Khusid, M.D.

Psychiatric Communication Strategies: Intervention Models for Inpatient Medical/Surgical Settings

10:00 a.m. – 11:30 a.m.
Room A403, Level 4
Georgia World Congress Center
Speakers:
Joel J. Wallack, M.D.
Nancy Maruyama, M.D.
Stephanie Cheung, M.D.
Simona Goschin

Addressing the Demand for Mental Health Care Needs of Hispanics in the United States
APA Caucus of Hispanic Psychiatrists
10:00 a.m. – 11:30 a.m.
Room B408, Level 4
Georgia World Congress Center
Chairs:
Esperanza Diaz, M.D.
Jose E. de la Gandara, M.D.
Speakers:
Julio Ballestas, M.D.
Andres Barkil-Oteo, M.D., M.Sc.
Daniel Castellanos, M.D.

Poster Session
International Poster Session 1
10:00 a.m. – Noon
Exhibit Hall B3-B4, Level 1
Georgia World Congress Center

12:30 p.m. Sessions
Session
APA Business Meeting
APA Members only
12:30 p.m. – 1:30 p.m.
Rooms A411-412, Level 4
Georgia World Congress Center

Case Conference
These sessions are open to APA members only. A blue registration badge or an APA membership card are required for admittance.

I Just Want to Be Clean
12:30 p.m. – 2:00 p.m.
Rooms A315-316, Level 3
Georgia World Congress Center
Chairs:
Philip R. Muskin, M.D., M.A.
Geoffrey P. Taylor, M.D.
Speakers:
Donna Chen, M.D., M.P.H.
David Lowenthal, M.D., J.D.

Our Toughest Addiction Challenge: Treating Tobacco Use Disorders in Patients With Mental Illness and Addictions and Informing Them About E-Cigarettes
10:00 a.m. – 11:30 a.m.
Room B404, Level 4
Georgia World Congress Center
Chairs:
Sunil Khushalani, M.D.
George Kolodner, M.D.
Lecture

From Genes to Neurobiology in Autism Spectrum Disorders
APA Distinguished Psychiatrist Lecture Series

12:30 p.m. – 2:00 p.m.
Sidney Marcus Auditorium, Level 4
Georgia World Congress Center

Lecture Chair:
Steve H. Koh, M.D., M.P.H.

Lecturer:
Matthew State, M.D.

Scientific and Clinical Reports

Childhood Experiences and Adolescent Suicide Risk

1. Physically Bullied and Cyberbullied Adolescents: Associations With Suicide Feelings and Behaviors in Private School Students
   Stephen Woolley, D.Sc.

2. Bullying Increases Risk of Suicidal Behavior
   Nazanin Alavi, M.D.

Workshops

Marijuana: What Clinicians Need to Know

12:30 p.m. – 2:00 p.m.
Room B215, Level 2
Georgia World Congress Center

Chair:
John Douglas, M.D.

Speakers:
Kevin Hill, M.D., M.H.S.
Brian Hurley, M.D., M.B.A.
Petros Levounis, M.D.

A Penny for Your Thoughts: Paying Cash to Foster Medication Compliance in Patients With Serious and Persistent Mental Illness

APA Ethics Committee and Penn-Scattergood Ethics Program

12:30 p.m. – 2:00 p.m.
Room B218, Level 2
Georgia World Congress Center

Chair:
John Maher, M.D.

Whose Information Is It Anyway? Ethical Issues in the Age of Electronic Health Records

12:30 p.m. – 2:00 p.m.
Room A303, Level 3
Georgia World Congress Center

Chair:
Mark Komrad, M.D.

Advanced Ethical Analysis and Practical, Clinical Guidelines for Psychiatrists, Especially Those Who Are Ethics Consultants or on Ethics Committees

12:30 p.m. – 2:00 p.m.
Room A313, Level 3
Georgia World Congress Center

Chair:
Edmund G. Howe III, M.D.

A Resident’s Guide to Borderline Personality Disorder: From the Experts (Part 1 of 2)

12:30 p.m. – 2:00 p.m.
Room B306, Level 3
Georgia World Congress Center

Chair:
Brian Palmer, M.D., M.P.H.

Speakers:
Brian Palmer, M.D., M.P.H.
John Gunderson, M.D.
Marianne Goodman, M.D.
Kenneth R. Silk, M.D.
Perry Hoffman, Ph.D.

Infectious Disease/Psychiatry HIV Collaborative Care: An Innovative Model for Person-Centered Care for the Southern Underserved

APA Council on Minority Mental Health and Health Disparities

12:30 p.m. – 2:00 p.m.
Room B310, Level 3
Georgia World Congress Center

Chair:
Daena L. Petersen, M.D., M.P.H.
APA Annual Business Meeting

Sunday, May 16
12:30 p.m. – 1:30 p.m.
Voting Members Only
Room A411-412, Level 4
Georgia World Congress Center

Call to Order
Renée L. Binder, M.D., President

Memorial to Deceased Members

Announcement of Election Results
Catharine S. May, M.D.
Chairperson, Committee of Tellers

Reports to the Membership
Saul Levin, M.D., M.P.A.
CEO and Medical Director
Frank W. Brown, M.D.
Treasurer
Altha J. Stewart, M.D.
Secretary
Glenn Martin, M.D.
Speaker

Chair:
Joan Anzia, M.D.

Speakers:
Edward Kantor, M.D.
Cassandra Salgado, M.D., M.S.

“Closed” Resident Tales From the Front Line—and What We Can Learn—When a Psychiatric Emergency Department Shuts Its Doors
APA Child and Adolescent Psychiatry Fellowship
12:30 p.m. – 2:00 p.m.
Room B311, Level 3
Georgia World Congress Center

Chairs:
Sol Adelsky, M.D., M.P.P.
Jon Berlin, M.D.

Speakers:
Rachel Glick, M.D.
Steve Miccio, B.A.
Leslie Zun, M.D.

Close Encounters of Three Kinds: Challenges in the Residents’ Clinic
7
12:30 p.m. – 2:00 p.m.
Room B315, Level 3
Georgia World Congress Center

Chair:
Tim Fong, M.D.

Speakers:
Edward Kantor, M.D.
Cassandra Salgado, M.D., M.S.

Challenges in Cognitive Behavior Therapy: Overcoming Barriers to Effective Treatment
12:30 p.m. – 2:00 p.m.
Room B404, Level 4
Georgia World Congress Center

Chairs:
Jesse H. Wright, M.D., Ph.D.
Judith S. Beck, Ph.D.

GRADEing “Evidence” in Psychiatry: The Case of Medical Marijuana for Psychiatric Indications
12:30 p.m. – 2:00 p.m.
Room B403, Level 4
Georgia World Congress Center

Chairs:
Deepak Cyril D’Souza, M.D., M.B.B.S.
Rajiv Radhakrishnan, M.D., M.B.B.S.

1:00 p.m. Sessions

Learning Lab


APA Council on Quality Care

12:30 p.m. – 2:00 p.m.
Rooms B211-212, Level 2
Georgia World Congress Center
1. Cancer and Psychiatric Medications
Virginia O’Brien, M.D.

2. Beyond Metformin: New Medications for Diabetes Mellitus and Review of Novel Anticoagulants
Sarah Rivelli, M.D.

3. New Medications for Hepatitis C
Jeffrey T. Rado, M.D., M.P.H.

Readjustment of Combat Veterans in Vet Centers and Psychiatric Clinics: Competition or Collaboration
1:00 p.m. – 4:00 p.m.
Room B309, Level 3
Georgia World Congress Center
Chair:
Thomas B. Horvath, M.D.
Discussant:
Charles Hoge, M.D.

1. Origins of VA Readjustment Counseling: The Rise and Fall and Rise of Understanding the Psychological Effects of War
Arthur S. Blank Jr., M.D.

2. Perspectives on the Vet Center Service Mission
Charles M. Flora, L.C.S.W.

3. Good Fences and Better Neighbors: A Veteran-Centered Community Approach
Harold Kudler, M.D.

4. The Combat Veterans’ Perspective: Reducing Barriers to Accessing Care and Establishing a Therapeutic Alliance
Cathleen A. Lewandowski, Ph.D., M.S.W.

Opioids: Crisis and Solutions
National Institute on Drug Abuse
1:00 p.m. – 4:00 p.m.
Room B312, Level 3
Georgia World Congress Center
Chairs:
Phil Skolnick, Ph.D.
Ivan D. Montoya, M.D., M.P.H.
Discussant:
Ivan D. Montoya, M.D., M.P.H.
1. Abuse-Deterrent Opioids: Advancing Beyond Tamper Resistance
   Thomas Jenkins, Ph.D.

2. Lay Naloxone for Opioid Safety
   Phillip O. Coffin, M.D., M.A.

3. Opiate Analgesics: Separating the Good, the Bad and the Ugly
   Gavril Pasternak, M.D., Ph.D.

4. Vaccination as a Means to Mitigate Opioid Addiction
   Kim D. Janda, Ph.D.

"Fresh off the Boat" Learning From a TV Sitcom About Acculturation, Family Dynamics and Mental Health in Asian-American Immigrant Families
APA Caucus of Asian-American Psychiatrists

1:00 p.m. – 4:00 p.m.
Rooms A406-407, Level 4
Georgia World Congress Center

Chairs:
Dana Wang, M.D.
Justin Chen, M.D., M.P.H.

Discussant:
Edmond H. T. Pi, M.D.

1. Struggles of an ABC (American-Born Chinese)
   Justin Chen, M.D., M.P.H.

2. The Double-Edged Sword of Parental Expectations
   Lusha Liu, M.D.

3. “I Love You, I'm Sorry”: Communication Challenges in Immigrant Families
   Dana Wang, M.D.

Top 10 Genetic Syndromes That Psychiatrists Need to Know

1:00 p.m. – 4:00 p.m.
Room B409, Level 4
Georgia World Congress Center

Chairs:
Robert J. Pary, M.D.
Janice Forster, M.D.

1. Overview of DiGeorge, Phelan-McDermid and Klinefelter Syndromes
   Jeffrey I. Bennett, M.D.
Scientific and Clinical Reports

Suicide

2:30 p.m. – 4:00 p.m.
Room B405, Level 4
Georgia World Congress Center

1. Driving Suicide to Zero: Redesigning the Clinical System of Care to Systematically Address Suicide Prevention
   Shareh O. Ghani, M.D.

2. Depressed Multiple Suicide Attempters: A High-Risk Phenotype
   Leo Sher, M.D.

   Shareh O. Ghani, M.D.

Workshops

Teaching the DSM-5 Cultural Formulation Interview: Innovative Web-Based Approaches and Videos to Demonstrate Culturally Appropriate Assessment Skills

2:30 p.m. – 4:00 p.m.
Room B215, Level 2
Georgia World Congress Center

Chairs:
Russell F. Lim, M.D., M.Ed.
Roberto Lewis-Fernandez, M.D.

Speakers:
Roberto Lewis-Fernandez, M.D.
Francis Lu, M.D.
Russell F. Lim, M.D., M.Ed.

Recovering Inside: Is Correctional Psychiatry an Oxymoron?

APA Ethics Committee and Penn-Scattergood Ethics Program

2:30 p.m. – 4:00 p.m.
Room B218, Level 2
Georgia World Congress Center

Chair:
Dominic Sisti, Ph.D.

Speakers:
Philip Candilis, M.D.
Jeffrey L. Metzner, M.D.

Intimacy After Injury: Combat Trauma and Sexual Health

2:30 p.m. – 4:00 p.m.
Room A303, Level 3
Georgia World Congress Center

Chairs:
Elsbeth C. Ritchie, M.D., M.P.H.
Christopher Nelson, M.D.

Speakers:
Elsbeth C. Ritchie, M.D., M.P.H.
Christopher Nelson, M.D.

Resident Well-Being: Strategies to Prevent Burnout

2:30 p.m. – 4:00 p.m.
Room A304, Level 3
Georgia World Congress Center

Chair:
Ijeoma Chukwu, M.D., M.P.H.

Speakers:
Ijeoma Chukwu, M.D., M.P.H.
Stella Cai, M.D.

Interactive Training and Dissemination of Tobacco Cessation in Psychiatry: An Rx for Change

Council on Addiction Psychiatry

1

2:30 p.m. – 4:00 p.m.
Room A307, Level 3
Georgia World Congress Center

Chair:
Smita Das, M.D., Ph.D.

Speakers:
Smita Das, M.D., Ph.D.
Andrew J. Saxon, M.D.
Jill M. Williams, M.D.

Breaking Bad: Communicating “Bad News” to Patients and Families

5

2:30 p.m. – 4:00 p.m.
Room A309, Level 3
Georgia World Congress Center

Chair:
Jeanne Lackamp, M.D.

Speakers:
Jennifer M. Brandstetter, M.D.
Christine Koniaris, M.D.

WARNING: This document contains sensitive and potentially triggering content. Please exercise caution when accessing or discussing its topics.
Treating Adolescents With Eating Disorders: Special Issues
2
2:30 p.m. – 4:00 p.m.
Room A313, Level 3
Georgia World Congress Center
Chair:
Matthew Shear, M.D.
Speakers:
Tom Hildebrandt, Psy.D.
Evelyn Attia, M.D.

Advocating for Our Patients by Fighting Stigma: Overview of Stigma, How to Advocate, and Using Media and TED Talks to Combat Stigma
2:30 p.m. – 4:00 p.m.
Rooms A315-316, Level 3
Georgia World Congress Center
Chairs:
Amy Poon, M.D.
Helen Farrell, M.D.
Speaker:
Laura Roberts, M.D., M.A.

A Resident’s Guide to Borderline Personality Disorder: From the Experts (Part 2 of 2)
2:30 p.m. – 4:00 p.m.
Room B306, Level 3
Georgia World Congress Center
Chair:
Brian Palmer, M.D., M.P.H.
Speakers:
Brian Palmer, M.D., M.P.H.
John Gunderson, M.D.
Marianne Goodman, M.D.
Kenneth R. Silk, M.D.
Perry Hoffman, Ph.D.

Addressing Diversity in Psychiatric Training: Our Past, Present and Future With Diversity Systemic/Academic Strategic Initiatives
APA/SAMHSA Minority Fellows
7
2:30 p.m. – 4:00 p.m.
Room B310, Level 3
Georgia World Congress Center
Chairs:
Roberto E. Montenegro, M.D., Ph.D.
Auralyd Padilla Candelario, M.D.
Speakers:
Roberto E. Montenegro, M.D., Ph.D.
Paula Marie Smith, M.D.
Daena L. Petersen, M.D., M.P.H.
Ed Childs
Ranna Parekh, M.D., M.P.H.
Lisette Rodriguez-Cabezas, M.D.

Optimizing Psychopharmacology Training During Residency
2:30 p.m. – 4:00 p.m.
Room B315, Level 3
Georgia World Congress Center
Chair:
Jeffrey J. Rakofsky, M.D.
Speakers:
Jeffrey J. Rakofsky, M.D.
Sidney Zisook, M.D.
John Q. Young, M.D., M.P.H.
Ira Glick, M.D.

Addressing Stigma Using Acceptance and Commitment Therapy
2:30 p.m. – 4:00 p.m.
Room B316, Level 3
Georgia World Congress Center
Chair:
Kenneth P. Fung, M.D.
Speaker:
Kenneth P. Fung, M.D.

Online Dating, Cyberbullying and Harassment in the 21st Century: Prevalence, Psychiatric Consequences and Strategies for Prevention
2
2:30 p.m. – 4:00 p.m.
Room B404, Level 4
Georgia World Congress Center
Chairs:
Christopher F. Ong, M.D.
Almari Ginory, D.O.
Speakers:
Laura Ginory, M.D.
Yuliet Sanchez-Rivero, M.D.

What Can Mental Health Providers Learn From Pediatric Practices Regarding Prevention and Management of Cannabis Use by Youth?
National Institute on Drug Abuse
2 6
2:30 p.m. – 4:00 p.m.
Room B406, Level 4
Georgia World Congress Center
Chair:
Geetha A. Subramaniam, M.D.
Speakers:
Sharon Levy, M.D., M.P.H.
Stacy Sterling, M.P.H., M.S.W.

Crisis in Transit: Perspectives on Global Refugee and Migrant Mental Health
2:30 p.m. – 4:00 p.m.
Room B403, Level 4
Georgia World Congress Center
Chairs:
Damir Huremovic, M.D., M.P.P.
Nyapati R. Rao, M.D.

Opening Session
4:30 p.m. – 6:45 p.m.
Hall B2, Level 1
Georgia World Congress Center
Opening Session

May 15, 2016
4:30 p.m.
Hall B2, Building B, Level 1
Georgia World Congress Center

Call to Order by APA President
Renée L. Binder, M.D.

Presentation of APA Gives Back Check to Skyline Trails
Renée L. Binder, M.D.

Introduction of Stage Guests
Renée L. Binder, M.D.

Introduction of Dr. Steve H. Koh
Renée L. Binder, M.D.

Report from the Chairperson of the Scientific Program Committee
Steve H. Koh, M.D.

Introduction of Presidents and Representatives of United States and International Allied Organizations
Renée L. Binder, M.D.

Introduction of the President for the Presidential Address
Paul Summergrad, M.D.

Presidential Address
Renée L. Binder, M.D.

Introduction of the President-Elect for the Response to the Presidential Address
Robert Freedman, M.D.

Response of the President-Elect
Maria A. Oquendo, M.D.

Brief break before Special Lecture.

Special Lecture by Atul Gawande, M.D., M.P.H.

Atul Gawande’s bold visions for improving performance and safety in healthcare have made him one of the most sought-after speakers in medicine. His three books, Complications, Better and The Checklist Manifesto, have all been highly praised inside and outside the medical community. His new book is Being Mortal: Medicine and What Matters in the End. TIME placed him among the world’s 100 most influential thinkers.

Atul Gawande is a MacArthur “Genius” Fellowship winner, a New Yorker columnist, an author — but, most of all, a physician, with a practitioner’s grasp of the everyday challenges of healthcare delivery. Atul explains that medical practice and philosophy has not kept pace with the changes in healthcare over the last hundred years. We need reform — and Atul is on a lifelong search to discover what shape that reform should take. What does an effective healthcare system look like in the 21st century? How can we improve quality, manage risk and measure performance more effectively? Atul brings an eloquence and an intellect to these questions that allow him to offer deeply considered and beautifully expressed solutions with implications for healthcare and beyond.

Dr. Gawande is broadly known for his influential articles, two of which won him the National Magazine Award. He has written about the shift from lone-ranger physicians to teams of co-operating specialists, and the new values this shift requires. He popularized the checklist as a means of co-ordinating complex work in hospitals. His ideas about how to rein in healthcare costs while increasing efficiency and quality have transformed the national discussion of these issues. His writing sets itself apart by its depth of thought and research, but also by its willingness to look outside of healthcare and see how other fields have delivered high-quality service in complex industries.

Atul is a general and endocrine surgeon at Brigham and Women’s Hospital in Boston, and a professor in both the Department of Health Policy and Management at Harvard School of Public Health and the Department of Surgery at Harvard Medical School. He is the Executive Director of Ariadne Labs, a joint center for health systems innovation, and chairman of Lifebox, a nonprofit making surgery safer globally. He has won Academy Health’s Impact Award for highest research impact on health care, and the Lewis Thomas Award for Writing about Science.
Visit the APA Bookstore in the Exhibit Hall
May 14–17, 2016

The APA Bookstore has over 400 titles that can help you grow professionally and expand your knowledge!

<table>
<thead>
<tr>
<th>Bookstore Hours</th>
<th>Special Discounts!</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday 9:00am – 4:00pm</td>
<td>20% for APA Members</td>
</tr>
<tr>
<td>Sunday 10:00am – 4:00pm</td>
<td>25% for APA Resident-Fellow Members</td>
</tr>
<tr>
<td>Monday 10:00am – 4:00pm</td>
<td>15% for Non-Members</td>
</tr>
<tr>
<td>Tuesday 10:00am – 4:00pm</td>
<td></td>
</tr>
</tbody>
</table>

Don’t miss the Author Book Signings at the APA Bookstore!

**Saturday, May 14**
Noon – 1:00pm
Otto F. Kernberg, M.D.

**Sunday, May 15**
11:00am – Noon
Mina K. Dulcan, M.D.
Glen O. Gabbard, M.D.

Noon – 1:00pm
Petros Levounis, M.D., M.A.

**Tuesday, May 17**
Noon – 1:00pm
Patricia R. Casey, M.D., F.R.C.Psych
Liza H. Gold, M.D.
David Read Johnson, Ph.D.
Hadar Lubin, M.D.
James J. Strain, M.D.
# Presidents/Representatives of U.S. Allied Organizations

<table>
<thead>
<tr>
<th>Organization</th>
<th>President/Representative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Academy of Organizational and Occupational Psychiatry</td>
<td>Andrew O. Brown, M.D.</td>
</tr>
<tr>
<td>Academy of Cognitive Therapy</td>
<td>John P. Williams, M.D.</td>
</tr>
<tr>
<td>American Academy of Addiction Psychiatry</td>
<td>John A. Renner, M.D.</td>
</tr>
<tr>
<td>American Academy of Child and Adolescent Psychiatry</td>
<td>Gregory K. Fritz, M.D.</td>
</tr>
<tr>
<td>American Academy of Family Physicians</td>
<td>Wanda Filer, M.D.</td>
</tr>
<tr>
<td>American Academy of Neurology</td>
<td>Terrence L. Cascino, M.D.</td>
</tr>
<tr>
<td>American Academy of Psychiatry and the Law</td>
<td>Emily A.H. Keram, M.D.</td>
</tr>
<tr>
<td>American Academy of Psychoanalysis and Dynamic Psychiatry</td>
<td>Jennifer I. Downey, M.D.</td>
</tr>
<tr>
<td>American Association for Emergency Psychiatry</td>
<td>Leslie S. Zun, M.D.</td>
</tr>
<tr>
<td>American Association for Social Psychiatry</td>
<td>Kenneth S. Thompson, M.D.</td>
</tr>
<tr>
<td>American Association for the Advancement of Science</td>
<td>Barbara A. Schaal, M.D.</td>
</tr>
<tr>
<td>American Association of Chairs of Departments of Psychiatry</td>
<td>Gregory W. Dalack, M.D.</td>
</tr>
<tr>
<td>American Association of Community Psychiatrists</td>
<td>Anita S. Everett, M.D.</td>
</tr>
<tr>
<td>American Association of Directors of Psychiatric Residency Training</td>
<td>Art C. Walaszek, M.D.</td>
</tr>
<tr>
<td>American Association of Practicing Psychiatrists</td>
<td>Janis G. Chester, M.D.</td>
</tr>
<tr>
<td>American Association of Psychiatric Administrators</td>
<td>Geetha Jayaram, M.D.</td>
</tr>
<tr>
<td>American Board of Psychiatry and Neurology, Inc</td>
<td>Larry R. Faulkner, M.D.</td>
</tr>
<tr>
<td>American College of Emergency Physicians</td>
<td>Jay A. Kaplan, M.D.</td>
</tr>
<tr>
<td>American College of Obstetricians and Gynecologists</td>
<td>Mark S. DeFrancesco, M.D.</td>
</tr>
<tr>
<td>American College of Physicians</td>
<td>Nitin S. Damle, M.D.</td>
</tr>
<tr>
<td>American College of Psychiatrists</td>
<td>Frank W. Brown, M.D.</td>
</tr>
<tr>
<td>American College of Psychoanalysts</td>
<td>Norman A. Clemens, M.D.</td>
</tr>
<tr>
<td>American College of Surgeons</td>
<td>J. David Richardson, M.D.</td>
</tr>
<tr>
<td>American Group Psychotherapy Association</td>
<td>Eleanor F. Counselman, M.D.</td>
</tr>
<tr>
<td>American Medical Association</td>
<td>Stephen R. Permut, M.D., J.D.</td>
</tr>
<tr>
<td>American Medical Women's Association</td>
<td>Kimberly Templeton, M.D.</td>
</tr>
<tr>
<td>American Neurological Association</td>
<td>Barbara Vickrey, M.D.</td>
</tr>
<tr>
<td>American Neuropsychiatric Association</td>
<td>Jeremy Schmahmann, M.D.</td>
</tr>
<tr>
<td>American Nurses Association</td>
<td>Pamela Cipriano, M.D.</td>
</tr>
<tr>
<td>American Orthopsychiatric Association</td>
<td>Deborah Klein Walker, M.D.</td>
</tr>
<tr>
<td>American Psychoanalytic Association</td>
<td>Mark Smaller, M.D.</td>
</tr>
<tr>
<td>American Psychological Association</td>
<td>Susan H. McDaniel, M.D.</td>
</tr>
<tr>
<td>American Psychosomatic Society</td>
<td>Christoph Herrmann-Lingen, M.D.</td>
</tr>
<tr>
<td>American Society for Adolescent Psychiatry</td>
<td>Manuel Lopez, M.D.</td>
</tr>
<tr>
<td>American Society of Addiction Medicine</td>
<td>R. Jeffrey Goldsmith, M.D.</td>
</tr>
<tr>
<td>American Society of Clinical Psychopharmacology, Inc.</td>
<td>Mark H. Rapaport, M.D.</td>
</tr>
<tr>
<td>American Society of Hispanic Psychiatry</td>
<td>Mauricio Tohen, M.D.</td>
</tr>
<tr>
<td>Arab American Psychiatric Association</td>
<td>Abdel F. Amin, M.D., M.P.H.</td>
</tr>
<tr>
<td>Association for Academic Psychiatry</td>
<td>Jason P. Caplan, M.D.</td>
</tr>
<tr>
<td>Association for Behavioral and Cognitive Therapies</td>
<td>Michelle Craske, M.D.</td>
</tr>
<tr>
<td>Association of American Medical Colleges</td>
<td>Darrell G. Kirch, M.D.</td>
</tr>
<tr>
<td>Association of Chinese American Psychiatrists</td>
<td>Edmond H. Pi, M.D.</td>
</tr>
<tr>
<td>Association of Directors of Medical Student Education in Psychiatry</td>
<td>Brenda Roman, M.D.</td>
</tr>
<tr>
<td>Association of Gay and Lesbian Psychiatrists</td>
<td>Eric Yarbrough, M.D.</td>
</tr>
<tr>
<td>Association of Korean American Psychiatrists</td>
<td>Jaesu Han, M.D.</td>
</tr>
<tr>
<td>Association of Women Psychiatrists</td>
<td>Mary Barber, M.D.</td>
</tr>
<tr>
<td>College for Behavioral Health Leadership</td>
<td>Leigh Steiner, M.D.</td>
</tr>
<tr>
<td>Council of Medical Specialty Societies</td>
<td>Norman Kahn, M.D.</td>
</tr>
<tr>
<td>Depression and Bipolar Support Alliance</td>
<td>Allen Doederlein, M.D.</td>
</tr>
<tr>
<td>Group for the Advancement of Psychiatry</td>
<td>Steven S. Sharfstein, M.D.</td>
</tr>
<tr>
<td>Haitian American Psychiatric Association</td>
<td>Frantz H. Lubin, M.D.</td>
</tr>
<tr>
<td>Hellenic American Psychiatric Association</td>
<td>Philip Candilis, M.D.</td>
</tr>
<tr>
<td>Indo-American Psychiatric Association</td>
<td>Ashwin A. Patkar, M.D.</td>
</tr>
<tr>
<td>Mental Health America</td>
<td>Paul Gionfriddo, M.D.</td>
</tr>
<tr>
<td>National Alliance on Mental Illness (NAMI)</td>
<td>Marilyn Ricci, M.D.</td>
</tr>
<tr>
<td>National Association of County Behavioral Health and Developmental Disability Directors</td>
<td>Cheryl May Ramirez, M.D.</td>
</tr>
</tbody>
</table>
Presidents/Representatives of U.S. Allied Organizations

National Association of Psychiatric Health Systems
John Stupak, M.D.
National Association of Social Workers, Inc
Darrell P. Wheeler, M.D.
National Council for Community Behavioral Healthcare
Linda Rosenberg, M.D.
National Institute of Mental Health (NIMH)
Bruce Cuthbert, M.D.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
George Koob, M.D.
National Institute on Drug Abuse (NIDA)
Nora D. Volkow, M.D.

Nigerian American Psychiatric Association
Charles C. Dike, M.D.
Philippine Psychiatric Association
Maria I. Lapid, M.D.
Substance Abuse and Mental Health Services Administration (SAMHSA)
Kana Enomoto, M.A.
Turkish American Neuropsychiatric Association
Erol Ucer, M.D.

Presidents of International Allied Organizations

Albanian Psychiatric Association
Dr. Fatime Elezi
Algerian Psychiatric Association
Dr. Farid Kacha
Arab Gulf Psychiatric Association
Dr. Mohamed Al-Haddad
Argentinean Association of Psychiatrists
Dr. Nestor Marchant
Argentinean Psychiatrists Association
Dr. Anaia Elena Ravenna
Armenian Psychiatric Association
Dr. Armen Soghoyan
Association of Free Psychiatrists of Romania
Dr. Aurel Romila
Association of Psychiatric Institutions of Serbia
Dr. Milutin Nenadović
Association of Psychiatrists in Nigeria
Dr. Joseph D. Adeyemi
Association of Psychiatrists of Uzbekistan
Dr. Ulugbek Alimov
Austrian Association of Psychiatry and Psychotherapy
Dr. Georg Psota
Azerbaijan Psychiatric Association
Dr. Nadir Ismayilov
Bangladesh Association of Psychiatrists
Dr. Md. Golam Rabbani
Barbados Association of Psychiatrists
Dr. Sharon Harvey
Belarusian Psychiatric Association
Dr. Oleg Skugarevsky
Bolivian Society of Psychiatry
Dr. Lupe Isnelda Gomez Montalvo
Brazilian Association of Psychiatry
Dr. Antonio Geraldo da Silva
Bulgarian Psychiatric Association
Dr. Hristo Kozhuharov
Canadian Psychiatric Association
Dr. Sonu Gaind
Chinese Society of Psychiatry
Dr. Xin Yu

College of Psychiatry of Ireland
Dr. Anthony McCarthy
Colombian Association of Psychiatry
Dr. Iván A. Jiménez R.
Costa Rican Psychiatric Association
Dr. Francisco Gólcher Valverde
Croatian Psychiatric Association
Dr. Vlado Jukic
Cuban Society of Psychiatry
Dr. Miguel Valdes Mier
Cyprus Psychiatric Association
Dr. Giannis Kalakoutsas
Czech Psychiatric Association
Dr. Tomas Kasparek
Danish Psychiatric Society
Dr. Thomas Middelboe
Dominican Society of Psychiatry
Dr. Fior Solis de Mendez
Ecuadorian Psychiatric Association
Dr. José Mosquera A.
Egyptian Psychiatric Association
Dr. Ahmed Okasha
Emirates Psychiatric Society
Dr. Adel Karrani
Estonian Psychiatric Association
Dr. Andres Lehtimets
Ethiopian Psychiatric Association
Dr. Solomon Teferra
Finnish Psychiatric Association
Dr. Minna Valkonen-Korhonen
Flemish Psychiatric Association
Dr. Jürgen De Fruyt
Foundation for Interdisciplinary Investigation of Communication (Argentina)
Dr. Miguel Angel Materazzi
French Association of Psychiatrists in Private Practice
Dr. Patrice Charbit
French Association of Psychiatry
Dr. Jean-Yves Cozic
French Psychiatric Information Society
Dr. Gisèle Apter
<table>
<thead>
<tr>
<th>Organization</th>
<th>President</th>
</tr>
</thead>
<tbody>
<tr>
<td>German Association for Psychiatry, Psychotherapy and Psychosomatics</td>
<td>Dr. Iris Hauth</td>
</tr>
<tr>
<td>Ghana Psychiatric Association</td>
<td>Dr. Sammy Ohene</td>
</tr>
<tr>
<td>Guatemalan Psychiatric Association</td>
<td>Dr. Nery Adolfo Ortiz Alvarez</td>
</tr>
<tr>
<td>Hellenic Psychiatric Association (Greece)</td>
<td>Dr. Dimitrios Ploumpidis</td>
</tr>
<tr>
<td>Hellenic Society of Neurology and Psychiatry (Greece)</td>
<td>Dr. Costas Stefanis</td>
</tr>
<tr>
<td>Honduran Society of Psychiatry</td>
<td>Dr. Alejandra María Munguia Matamoros</td>
</tr>
<tr>
<td>Hong Kong College of Psychiatrists</td>
<td>Dr. Eric Chen Yu Hai</td>
</tr>
<tr>
<td>Hungarian Psychiatric Association</td>
<td>Dr. Károly Molnár</td>
</tr>
<tr>
<td>Icelandic Psychiatric Association</td>
<td>Dr. Thorgunnur Ársaelsdottir</td>
</tr>
<tr>
<td>Independent Psychiatric Association of Russia</td>
<td>Dr. Yury Savenko</td>
</tr>
<tr>
<td>Indian Association for Social Psychiatry</td>
<td>Dr. Sudhir Khandelwal</td>
</tr>
<tr>
<td>Indian Psychiatric Society</td>
<td>Dr. Vidyadhar Wavle</td>
</tr>
<tr>
<td>Indonesian Psychiatric Association</td>
<td>Dr. Danardi Sosrosumihardjo</td>
</tr>
<tr>
<td>International Society of Psychopathology of Expression (France)</td>
<td>Dr. Laurent Schmitt</td>
</tr>
<tr>
<td>Iranian Psychiatric Association</td>
<td>Dr. Ahmad Jalili</td>
</tr>
<tr>
<td>Iraqi Society of Psychiatrists</td>
<td>Dr. Qassim Hadi Al-Awadi</td>
</tr>
<tr>
<td>Israeli Psychiatric Association</td>
<td>Dr. Haim Belmaker</td>
</tr>
<tr>
<td>Italian Association for Research in Schizophrenia</td>
<td>Dr. Massimo Clerici</td>
</tr>
<tr>
<td>Italian Psychiatric Association</td>
<td>Dr. Claudio Mencacci</td>
</tr>
<tr>
<td>Jamaica Psychiatric Association</td>
<td>Dr. Geoffrey Omar Walcott</td>
</tr>
<tr>
<td>Japanese Society of Psychiatry and Neurology</td>
<td>Dr. Masatoshi Takeda</td>
</tr>
<tr>
<td>Jordanian Association of Psychiatrists</td>
<td>Dr. Walid Moh’d Shnaigat</td>
</tr>
<tr>
<td>Kazakh Association of Psychiatrists and Narcologists</td>
<td>Dr. Saltanat Nurmagambetova</td>
</tr>
<tr>
<td>Kenya Psychiatric Association</td>
<td>Dr. Simon Nyuguna Kahonge Mutiso</td>
</tr>
<tr>
<td>Korean Neuropsychiatric Association</td>
<td>Dr. Young-Hoo Kim</td>
</tr>
<tr>
<td>Kuwait Psychiatric Association</td>
<td>Dr. Sulaiman Al-Khadhari</td>
</tr>
<tr>
<td>Kyrgyz Psychiatric Association</td>
<td>Dr. T. I. Galako</td>
</tr>
<tr>
<td>Latvian Psychiatric Association</td>
<td>Dr. Elmars Terauds</td>
</tr>
<tr>
<td>League for Mental Health from Republic of Moldova</td>
<td>Dr. Mihail Hotineanu</td>
</tr>
<tr>
<td>Lebanese Psychiatric Society</td>
<td>Dr. Charles Badoura</td>
</tr>
<tr>
<td>Lithuanian Psychiatric Association</td>
<td>Dr. Alvydas Navickas</td>
</tr>
<tr>
<td>Luxembourg Society of Psychiatry, Neurology and Psychotherapy</td>
<td>Dr. Chretien Jacoby</td>
</tr>
<tr>
<td>Malaysian Psychiatric Association</td>
<td>Dr. Teck Hoe Yen</td>
</tr>
<tr>
<td>Mauritius Psychiatric Association</td>
<td>Dr. Jagessur Ariyee Kumar</td>
</tr>
<tr>
<td>Medical Psychologic Society (France)</td>
<td>Dr. Aimé Charles-Nicolas</td>
</tr>
<tr>
<td>Mental Health Association of Cambodia</td>
<td>Dr. Kim Savuon</td>
</tr>
<tr>
<td>Mexican Psychiatric Association</td>
<td>Dr. Enrique Chavez-Leon</td>
</tr>
<tr>
<td>Mexican Society of Neurology and Psychiatry</td>
<td>Dr. Juan Ignacio Rosas</td>
</tr>
<tr>
<td>Mongolian Mental Health Association</td>
<td>Dr. Ayushjav Bayankhhuu</td>
</tr>
<tr>
<td>Montenegrin Psychiatric Association</td>
<td>Dr. Lidija Injac-Stevovic</td>
</tr>
<tr>
<td>Moroccan Society of Psychiatry</td>
<td>Dr. Fatima-Zahra Sekkat</td>
</tr>
<tr>
<td>Mozambican Association of Psychiatry and Mental Health</td>
<td>Dr. Maria Lidia Chauque Gouveia</td>
</tr>
<tr>
<td>Myanmar Medico-Psychological Society</td>
<td>Dr. Win Aung Myint</td>
</tr>
<tr>
<td>Netherlands Psychiatric Association</td>
<td>Dr. Aartjan Beekman</td>
</tr>
<tr>
<td>Nicaraguan Psychiatric Association</td>
<td>Dr. Elda Yessenia Jiron Gonzalez</td>
</tr>
<tr>
<td>Norwegian Psychiatric Association</td>
<td>Dr. Ketil Joachim Ødegård</td>
</tr>
<tr>
<td>Pakistan Psychiatric Society</td>
<td>Dr. Syed Muhammad Sultan</td>
</tr>
<tr>
<td>Palestinian Psychiatric Association</td>
<td>Dr. Ziad Naji Arandi</td>
</tr>
<tr>
<td>Panamanian Society of Psychiatry</td>
<td>Dr. Lixma Magalís Ruiz Martez</td>
</tr>
<tr>
<td>Papua New Guinea Psychiatric Association</td>
<td>Dr. Urmadevi Ambhaipahar</td>
</tr>
<tr>
<td>Paraguayan Society of Psychiatry</td>
<td>Dr. Martin Moreno</td>
</tr>
<tr>
<td>Peruvian Psychiatric Association</td>
<td>Dr. Juan Manue Yori</td>
</tr>
<tr>
<td>Philippine Psychiatric Association</td>
<td>Dr. Edgardo Juan Tolentino Jr.</td>
</tr>
<tr>
<td>Polish Psychiatric Association</td>
<td>Dr. Andrzej Rajewski</td>
</tr>
<tr>
<td>Portuguese Association of Psychiatry</td>
<td>Dr. João Marques Teixeira</td>
</tr>
<tr>
<td>Portuguese Society of Psychiatry and Mental Health</td>
<td>Dr. Maria Luisa Figueira</td>
</tr>
</tbody>
</table>
Presidents of International Allied Organizations

Psychiatric Association of Bosnia-Herzegovina
Dr. Abdulah Kučukalić

Psychiatric Association of Macedonia
Dr. Dimitar Bonevski

Psychiatric Association of Rio de Janeiro State (Brazil)
Dr. Carlos Alberto Iglesias Salgado

Psychiatric Association of Slovenia
Dr. Peter Pregelj

Psychiatric Association of Thailand
Dr. Nawaporn Hirunwattkul

Psychiatric Association of Turkey
Dr. Simavi Yahio

Psychiatrists’ Association of Nepal
Dr. Saroj Prasad Ojha

Puerto Rican Society of Psychiatry
Dr. Edgardo Prieto-Agostini

Romanian Association of Psychiatry and Psychotherapy
Dr. Aurel Niresteam

Royal Society of Mental Medicine of Belgium
Dr. William Pitchot

Russian Society of Psychiatrists
Dr. Nikolay Neznanov

Salvadorean Association of Psychiatry
Dr. Tirza Merino Gomez

Saudian Psychiatric Association
Dr. Mahdi Saed Abumadini

Scientific Society of Neurologists, Psychiatrists and Narcologists of Ukraine
Dr. Petro V. Voloshyn

Serbian Psychiatric Association
Dr. Dusica Lecic-Tosevska

Singapore Psychiatric Association
Dr. Lee Cheng

Slovak Psychiatric Association
Dr. Lubomira Izakova

Society of Georgian Psychiatrists
Dr. Eka Chkonia

Society of Neurology, Psychiatry and Neurosurgery (Chile)
Dr. Rodrigo Chamorro Oschilewsky

Society of Psychiatry of Uruguay
Dr. Rafael Sibils

South African Society of Psychiatrists
Dr. Mvuyiso Talatala

Spanish Association of Neuropsychiatry
Dr. Eudoxia Gay Pamos

Spanish Society of Psychiatry
Dr. Miguel Gutierrez

Sri Lanka College of Psychiatrists
Dr. Samudra Katheriarachchi

Sudanese Association of Psychiatrists
Dr. Abdalla Abdelrahman

Swedish Psychiatric Association
Dr. Lena Flyckt

Swiss Society of Psychiatry
Dr. Pierre Vallon

Syrian Arab Association of Psychiatrists
Dr. Mazen Hedar

Taiwanese Society of Psychiatry
Dr. Te-Jen Lai

The Psychiatric Evolution (France)
Dr. Eric Marcel

The Royal Australian and New Zealand College of Psychiatrists
Dr. Malcolm Hopwood

The Royal College of Psychiatrists (United Kingdom)
Dr. Simon Wessely

Tunisian Society of Psychiatry
Dr. Rym Ghachem Attia

Turkish Neuropsychiatric Society
Dr. Mustafa Sercan

Uganda Psychiatric Association
Dr. David Kyemba Basangwa

Ukrainian Psychiatric Association
Dr. Viktor Shumlyansky

Venezuelan Society of Psychiatry
Dr. Yolanda R. Alvarado

World Federation for Mental Health
Dr. Gabriel Ivbijoro

World Psychiatric Association
Dr. Dinesh Bhugra

Yemen Psychiatrists and Neurologists Association
Dr. Abdelmagid S. Al-Khulaidi

Officers reported to the American Psychiatric Association as of January 1, 2016
Monday

May 16, 2016
Richard J. Bonnie, J.D., is Harrison Foundation Professor of Law and Medicine; Professor of Public Policy; Professor of Psychiatry and Neurobehavioral Science; and Director of the Institute of Law, Psychiatry and Public Policy at the University of Virginia. He specializes in health law and policy, bioethics, criminal law and public policies relating to mental health, substance abuse and public health. Professor Bonnie has participated in public service throughout his career. He was Associate Director of the National Commission on Marijuana and Drug Abuse (1971–1973), Secretary of the first National Advisory Council on Drug Abuse (1975–1980), Chair of Virginia’s State Human Rights Committee responsible for protecting the rights of persons with mental disabilities (1979–1985) and Chief Advisor for the ABA Criminal Justice Mental Health Standards Project (1981–1988). He recently chaired the Commission on Mental Health Law Reform at the request of the Chief Justice of Virginia (2006–2011).

Jeffrey L. Metzner, M.D., received his medical degree from the University of Maryland Medical School in 1975 and completed his psychiatric residency at the University of Colorado’s Department of Psychiatry in 1979. He is Clinical Professor of Psychiatry at the University of Colorado School of Medicine in Denver, Colo. Dr. Metzner has written extensively on the psychiatric care of prison populations. He has provided consultation to judges, special masters, monitors, state departments of corrections, city and county jails, the U.S. Department of Justice, the National Prison Project and others involved in the field of correctional psychiatry in 35 states. Dr. Metzner was a member (2006) of the Institute of Medicine Committee on Ethical Considerations for Revisions to DHHS Regulations for Protection of Prisoners Involved in Research. He was part of the APA workgroups that produced the first and third editions of the guidelines for psychiatric services in correctional facilities.

John Monahan, Ph.D., is the John S. Shannon Distinguished Professor of Law at the University of Virginia, where he is also Professor of Psychology and Professor of Psychiatry and Neurobehavioral Sciences. He is a member of the National Academy of Medicine and serves on the National Research Council. Monahan was the founding President of the American Psychological Association’s Division of Psychology and Law and has been a fellow of the John Simon Guggenheim Foundation and the Center for Advanced Study in the Behavioral Sciences. He twice directed research networks on mental health law for the John D. and Catherine T. MacArthur Foundation. He has received an honorary law degree from the City University of New York and the Isaac Ray Award of the American Psychiatric Association.

Roy O’Shaughnessy, M.D., completed his medical school education at the University of Ottawa in 1974. Afterward, he completed one year of internal medicine and two years of postgraduate training in psychiatry at the University of British Columbia and two years at Yale University. In 1980, he completed his fellowship in forensic psychiatry at Yale University. From 1981 through 2005, Dr. O’Shaughnessy was the Clinical Director of the Youth Forensic Psychiatric Services of the Province of British Columbia, responsible for the assessment and treatment of juvenile offenders. He is Clinical Professor in the Department of Psychiatry, UBC. From 1985 through 2012, he was Head of the Division of Forensic Psychiatry at UBC. After stepping down as Head in 2012, he remained as the Site Director for Civil Forensic Psychiatry at St. Paul’s Hospital.

Dr. Stephen M. Stahl, M.D., Ph.D., received his undergraduate and medical degrees from Northwestern University in Chicago and his Ph.D. degree in pharmacology and physiology from the University of Chicago. He has trained in three specialties: internal medicine at the University of Chicago, neurology at the University of California, San Francisco, and psychiatry at Stanford University. He is board certified in psychiatry. Dr. Stahl has held faculty positions at Stanford University, the University of California, Los Angeles, the Institute of Psychiatry, London, the Institute of Neurology, London, and, currently, the University of California, San Diego. Dr. Stahl’s major interests are dedicated to producing and disseminating educational information about diseases and their treatments in psychiatry and neurology, with a special emphasis on multimedia, the Internet and teaching how to teach.
8:00 a.m. Sessions

Courses

Course descriptions are available in the APA Meetings app. Admission to all courses, including master courses, is by ticket only. Course tickets can be purchased at Registration at the Marquis Fountain, Marquis Level in the Marriott Marquis, or at Registration in Exhibit Hall B3-B4, Level 1 in the Georgia World Congress Center.

Exploring Technologies in Psychiatry
American Association for Technology in Psychiatry

8:00 a.m. – Noon
International 5, International Level Marriott Marquis

Directors:
Robert Kennedy, M.D.
John Luo, M.D.

Faculty:
Carlyle Chan
Steven Chan
John Torous, M.D.

Emergency Psychiatry: The Basics and Beyond
American Association for Emergency Psychiatry

8:00 a.m. – Noon
International 6, International Level Marriott Marquis

Director:
Kimberly D. Nordstrom, M.D., J.D.

Faculty:
Scott Zeiler, M.D.
Leslie Zun, M.D.
Jon Berlin, M.D.
Seth Powsner, M.D.

The Clinical Assessment of Malingered Mental Illness

8:00 a.m. – Noon
M103-105, Marquis Level Marriott Marquis

Director:
Phillip J. Resnick, M.D.

Seminars

CPT Coding

8:00 a.m. – Noon
International 7, International Level Marriott Marquis

Director:
Gregory G. Harris, M.D., M.P.H.

9:00 a.m. Sessions

Advances in Medicine

When Inflammation Weeps: The Emerging Role of the Immune System in Depression

9:00 a.m. – 10:30 a.m.
Rooms A315-316, Level 3
Georgia World Congress Center

Chair:
Andrew Miller, M.D.

Forum

Re-Examining ECT: From Patient Perspectives on Stigma to Benefit for Veteran Mental Health

9:00 a.m. – Noon
Room B407, Level 4
Georgia World Congress Center

Chairs:
Peter Hauser, M.D.
Richard Weiner

Speakers:
Kitty Dukakis
Richard Weiner
Georgios Petrides
Mark George

Interactive Session

Comorbid Medical Illness in Serious Psychiatric Disorders

9:00 a.m. – 10:30 a.m.
Room A301, Level 3
Georgia World Congress Center

Chair:
Henry A. Nasrallah, M.D.

This session will be captured as part of APA Annual Meeting On Demand, subject to speaker permission. Visit the On Demand sales booth in the Education Center to learn more and purchase.
Neuromodulation Primer for Residents: An Introduction to ECT, TMS and DBS
9:00 a.m. – 10:30 a.m.
Room A303, Level 3
Georgia World Congress Center
Chair: Almari Ginory, D.O.
Speakers: Richard Holbert, M.D., Herbert Ward, M.D., Jacqueline A. Hobbs, M.D., Ph.D.

Training American Psychiatrists as Global Mental Health Investigators, Implementers and Partners: What Have We Learned That Can Inform Best Practices?
APA Council on International Psychiatry
9:00 a.m. – 10:30 a.m.
Room A304, Level 3
Georgia World Congress Center
Chairs: Michael D. Morse, M.D., M.P.A. Anne Becker, M.D., Ph.D.

The Behavioral Addictions and the Brave New World of the DSM-6 (Yes, Six)
APA Council on Addiction Psychiatry
9:00 a.m. – 10:30 a.m.
Room B306, Level 3
Georgia World Congress Center

Workshops
Involuntary Inpatient Psychiatric Treatment: Past, Present and Future
9:00 a.m. – 10:30 a.m.
Room B215, Level 2
Georgia World Congress Center
Chairs: David A. Nissan, M.D. Julie B. Penzner, M.D.
Speakers: Raymond Raad, M.D., M.P.H. David A. Nissan, M.D. Paul S. Appelbaum, M.D. Julie B. Penzner, M.D. Mark J. Russ, M.D.

Structured Clinical Interview for DSM-5 — Clinician Version (SCID-5-CV)
American Psychiatric Association
9:00 a.m. – 10:30 a.m.
Room B218, Level 2
Georgia World Congress Center
Chair: Michael B. First, M.D.
<table>
<thead>
<tr>
<th>Event Title</th>
<th>Time</th>
<th>Room</th>
<th>Location</th>
<th>Chairs</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>How Should We Determine What Is Most Ethical? A Framework for Analyzing Ethics Dilemmas in Psychiatric Practice</td>
<td>9:00 a.m. – 10:30 a.m.</td>
<td>Room B408, Level 4</td>
<td>Georgia World Congress Center</td>
<td>Robert Weinstock, M.D.</td>
<td>William C. Darby, M.D. and Robert Weinstock, M.D.</td>
</tr>
<tr>
<td>Pre-Exposure Prophylaxis (PrEP) for HIV: The Science, Psychology and Implications for Clinical Practice</td>
<td>9:00 a.m. – 10:30 a.m.</td>
<td>Room B311, Level 3</td>
<td>Georgia World Congress Center</td>
<td>Kenneth Ashley, M.D.</td>
<td>Marshall Forstein, M.D. and David W. Purcell, J.D., Ph.D.</td>
</tr>
<tr>
<td>The AshleyMadison.com Hack: Understanding and Treatment of Infidelity From Discovery to Recovery</td>
<td>9:00 a.m. – 10:30 a.m.</td>
<td>Room A303, Level 3</td>
<td>Georgia World Congress Center</td>
<td>Scott Haltzman, M.D.</td>
<td>R. Kaan Ozbayrak, M.D. and Cynthia Grant, Ph.D., L.C.S.W.</td>
</tr>
<tr>
<td>The Kids Are Not All Right: Mental Health Impact of Parental Incarceration APA Council on Children, Adolescents and Their Families</td>
<td>9:00 a.m. – 10:30 a.m.</td>
<td>Room A313, Level 3</td>
<td>Georgia World Congress Center</td>
<td>Jerome H. Taylor, M.D. and Jennifer Severe, M.D.</td>
<td>Hector Colon-Rivera, M.D. and Tanuja Gandhi, M.D.</td>
</tr>
<tr>
<td>The Context of Psychosis: Cultural Curiosity and Enhanced Clinical Care APA Council on Minority Mental Health and Health Disparities</td>
<td>9:00 a.m. – 10:30 a.m.</td>
<td>Room B315, Level 3</td>
<td>Georgia World Congress Center</td>
<td>Nicole Guanci and Cristina Montalvo, M.D.</td>
<td>Mohini Ranganathan, M.B.B.S. and Caroline D. Brozyna, M.D.</td>
</tr>
<tr>
<td>Does Open Access Beat Traditional Scheduling?</td>
<td>9:00 a.m. – 10:30 a.m.</td>
<td>Room B316, Level 3</td>
<td>Georgia World Congress Center</td>
<td>Rachel Zinns, M.D., Ed.M.</td>
<td>Anish R. Dube, M.D., M.P.H. and Courtney L. McMickens, M.D., M.P.H.</td>
</tr>
<tr>
<td>Telepsychiatry and Its Myriad Applications for Treating People With Serious Mental Illness in the Public Sector (and for Residency Training)</td>
<td>9:00 a.m. – 10:30 a.m.</td>
<td>Room B310, Level 3</td>
<td>Georgia World Congress Center</td>
<td>Scott Haltzman, M.D.</td>
<td>Rachel Zinns, M.D., Ed.M. and Jennifer Severe, M.D.</td>
</tr>
<tr>
<td>EEG in Psychiatric Practice World Psychiatric Association</td>
<td>9:00 a.m. – 10:30 a.m.</td>
<td>Room B404, Level 4</td>
<td>Georgia World Congress Center</td>
<td>Rasha Aggarwal, M.D.</td>
<td>Oliver Pogarell, M.D. and Nashaat Boutros, M.D.</td>
</tr>
<tr>
<td>Residents Teaching About Racism: A Novel Educational Approach to Combating Racial Discrimination in Mental Health Care APA Council on Medical Education and Lifelong Learning</td>
<td>9:00 a.m. – 10:30 a.m.</td>
<td>Room B409, Level 4</td>
<td>Georgia World Congress Center</td>
<td>Andrew D. Carlo, M.D. and Jerrold F. Rosenbaum, M.D.</td>
<td>Matthew B. Perkins, M.D., M.P.H. and Matthew D. Erlich, M.D. and Rachel Zinns, M.D., M.D.</td>
</tr>
</tbody>
</table>
Media Workshops

Remaking the Bad Seed in Blood Red

9:00 a.m. – Noon
Room A314, Level 3
Georgia World Congress Center
Chair: Lynn Maskel, M.D.
Speakers: Elissa P. Benedek, M.D.
Kevin D. Moore, M.D.

Presidential Symposia

Critical Issues in the Delivery of Psychiatric Care Through Videoconferencing

9:00 a.m. – Noon
Rooms B213-214, Level 2
Georgia World Congress Center
Chair: Jay Shore, M.D., M.P.H.

1. APA Telepsychiatry Resources for Advancing Telepsychiatric Care and Training: Website Toolkit and Work Group
Jay Shore, M.D., M.P.H.

2. Training Yourself and Others in Telepsychiatry
Jeffrey I. Bennett, M.D.

Jay Shore, M.D., M.P.H., Alexander H. von Hafften, M.D., Steven Roy Davis, M.D., Robert Caudill, M.D., Donald M. Hilty, M.D., Peter Yellowlees, M.D.

4. Direct In-Home Telepsychiatry
Meera Narasimhan, M.D., Jay Shore, M.D., M.P.H.

--

Advances in Research

New Developments in Clinical Psychiatry
9:00 a.m. – Noon
Rooms A411-412, Level 4
Georgia World Congress Center
Chair: Herbert Pardes, M.D.

1. Treatment of Minority Young Adults With Anxiety Disorders: Closing the Disparity Gap
Maria Carolina Zerrate, M.D., M.H.S.

2. Depression: An Update on Research and New Treatment Options
Fritz A. Henn, M.D., Ph.D.

3. Advances in the Care of Late-Life Depression
George S. Alexopoulos, M.D.

4. Introduction of a Precision Medicine-Based Approach in Psychiatry
Sander Markx, M.D.

5. Eating Disorders
Evelyn Attia, M.D.

Learning Labs


9:00 a.m. – Noon
Rooms B207-208, Level 2
Georgia World Congress Center
Chair: Laura Roberts, M.D., M.A.

Mock Trial: Lessons for Psychiatrists From the Bar and Risk Management

9:00 a.m. – Noon
Rooms B211-212, Level 2
Georgia World Congress Center
Chair: Kristen M. Lambert, J.D., M.S.W.

--

Advances in Series

Managing the Side Effects of Psychotropic Medications
American Psychiatric Association Publishing Editorial Board

9:00 a.m. – Noon
Room A305, Level 3
Georgia World Congress Center
Chairs: Joseph F. Goldberg, M.D.
Carrie L. Ernst, M.D.

1. Clinical and Pharmacologic Considerations in Assessing Adverse Effects of Psychotropic Drugs
Joseph F. Goldberg, M.D.

2. State-of-the-Art Assessment and Management of Latrogenic Weight Gain and Metabolic Dysregulation
Roger S. McIntyre, M.D.

--

SESSION TRACKS

1. Addiction Psychiatry
2. Child and Adolescent Psychiatry
3. Forensic Psychiatry
4. Geriatric Psychiatry
5. Psychosomatic Psychiatry
6. NIDA
7. Residents, Fellows and Medical Students

This session will be captured as part of APA Annual Meeting On Demand, subject to speaker permission. Visit the On Demand sales booth in the Education Center to learn more and purchase.

--

Speakers:
Morgan Medlock, M.D.
Anna Weissman, M.D.
Andrew D. Carlo, M.D.
Mary C. Zeng, M.D.
Derri Shtasel, M.D., M.P.H.
Jerrold F. Rosenbaum, M.D.

Evaluating and Managing Sexual Dysfunction From Psychotropic Medications
Anita Clayton

An Update on Cardiovascular and Arrhythmogenic Risks of Psychotropic Drugs
Carrie L. Ernst, M.D.

--
1. Care Integration on the Streets: Primary Care and Wound Care as Methods of Engaging Mentally Ill Homeless People
   Sapna B. Morris, M.D., M.B.A., Tim Porter-O’Grady, Ed.D., R.N.

2. Technology on the Streets: Telemedicine as a Tool to Expand Psychiatric Care for Rough Sleepers
   Kathy Schaaf, B.Sc., R.N.

3. Peer Specialists and Their Unique Role in Street Medicine Teams
   Ricky Alexander

4. Student Perspectives and Education With Homeless Populations/ Patient Satisfaction and Quality Improvement on the Streets
   Aleta Christensen, M.P.H.

---

**Critical Issues in Addiction Psychiatry**

*American Academy of Addiction Psychiatry*

1. Choice vs. Compulsion in Addiction Psychiatry
   Richard N. Rosenthal, M.D., M.A.

---

**Symposia**

**Senior Psychiatrists and Positive Aging**

*4*

9:00 a.m. – Noon
Rooms B216-217, Level 2
Georgia World Congress Center

Chairs:
Dilip V. Jeste, M.D.
Glen O. Gabbard, M.D.

Discussant:
Michelle Conroy

1. Successful Aging of Psychiatrists
   Dilip V. Jeste, M.D.

2. Identity Issues in the Senior Psychiatrist
   Glen O. Gabbard, M.D.

3. Positive Aging: The Role of Meaning
   Michelle B. Riba, M.D.

4. Lifers and Senior Psychiatrists: Identifying Problems and Solutions
   Stephen C. Scheiber, M.D.

5. Sociocultural Issues in the Aging of Ethnically Diverse Senior Psychiatrists
   Renato D. Alarcón, M.D., M.P.H.

---

**Street Psychiatry: Integrated Care for Atlanta’s Unsheltered Homeless**

*3*

9:00 a.m. – Noon
Room B308, Level 3
Georgia World Congress Center

Chair:
Elizabeth A. Frye, M.D., M.P.H.

Discussant:
Anitra Walker, L.C.S.W.

---

**Correctional Psychiatry, Criminalization of the Mentally Ill and Avoiding the Criminal Justice System**

9:00 a.m. – Noon
Rooms A311-312, Level 3
Georgia World Congress Center

Chair:
Rebecca Weintraub Brendel, M.D., J.D.

1. Engaging Ethical Challenges in Psychiatry: Past and Present
   Laura Roberts, M.D., M.A.

   Rebecca Weintraub Brendel, M.D., J.D.

3. Universal, Unifying Ethics: The New Hope
   Philip Candilis, M.D.

4. Psychiatric Ethics: A Peek at the Future
   Paul S. Appelbaum, M.D.

---

**Contemporary Issues in Juvenile Justice**

*2*

9:00 a.m. – Noon
Room B309, Level 3
Georgia World Congress Center

Chairs:
William Arroyo, M.D.
Jorien Gemma Breur, M.D.

Discussant:
Louis Kraus, M.D.

1. The Impact of Changing Views of Adolescent Culpability
   Peter Ash, M.D.

2. Current Issues and Future Directions in the Assessment of Juvenile Competency to Stand Trial
   Caitlin Costello, M.D.

3. Adolescent Parricide: Personality, Crime Characteristics and Sentencing
   Wade C. Myers, M.D.

4. Education of Youth in Juvenile Justice Systems
   William Arroyo, M.D.

---

**Brief Therapy With “Difficult” Patients**

*American Psychiatric Association Publishing Editorial Board*

9:00 a.m. – Noon
Room B314, Level 3
Georgia World Congress Center
Current Challenges and Opportunities in Psychiatric Administration and Leadership  
*American Association of Psychiatric Administrators*

9:00 a.m. – Noon  
Rooms A404-405, Level 4  
Georgia World Congress Center

**Chairs:**  
Victor J. A. Buwalda, M.D., Ph.D.  
Sy A. Saeed, M.D., M.S.

**Discussants:**  
Steven S. Sharfstein, M.D., M.P.A.  
Saul Levin, M.D., M.P.A.

1. Lean Management in Mental Health Care  
Lydia E. Weisser, D.O., M.B.A.

2. Role of Leadership in Narrowing the Gap Between Science and Practice: Improving Treatment Outcomes at the Systems Level  
Sy A. Saeed, M.D., M.S.

3. Training Future Leaders: Challenges and Opportunities  
Faroq Mahyuddin, M.D., M.B.B.S.

4. Cultural Issues in Psychiatric Administration  
Neil K. Aggarwal, M.D., M.B.A.

5. Ethical Leadership in Psychiatry  
H. Steven Moffic, M.D.

**The Surgeon General’s Report on Mental Health, Parity and Integrated Care**  
*APA Council on International Psychiatry*

The Human Rights Award will be presented during this session.

9:00 a.m. – Noon  
Room B402, Level 4  
Georgia World Congress Center

**Chairs:**  
Eliot Sorel, M.D.  
Constance E. Dunlap, M.D.

**Discussants:**  
Erin Hazlett, Ph.D.  
Alan F. Schatzberg, M.D.

1. Social Cognition as a New Therapeutic Target in Personality Disorders  
M. Mercedes Perez-Rodriguez, M.D., Ph.D.

2. Neurobiology and Treatment of Impulsive Aggression in Human Subjects  
Emil Coccaro, M.D.

3. Therapeutic Implications of Recent Neuroimaging Findings on Emotion Dysregulation in Personality Disorders  
Harold W. Koenigsberg, M.D.

4. Neurobiological Evidence for Impaired Mentalization in Borderline Personality Disorder  
Antonia S. New, M.D.

5. Moving From Treatment as Usual to Good Clinical Care for Personality Disorder: Traits for the Office-Based Clinician  
James H. Reich, M.D., M.P.H.
Course descriptions are available in the APA Meetings app. Admission to all courses, including master courses, is by ticket only. Course tickets can be purchased at Registration at the Marquis Fountain, Marquis Level in the Marriott Marquis, or at Registration in Exhibit Hall B3-B4, Level 1 in the Georgia World Congress Center.

Psychodynamic Principles With Treatment-Resistant Mood Disorders: Breaking Through Treatment Resistance by Focusing on Comorbidity

9:00 a.m. – 4:00 p.m.
International 8, International Level
Marriott Marquis

Director:
Eric M. Plakun, M.D.

Faculty:
Edward R. Shapiro, M.D., M.A.
David L. Mintz, M.D.

Integrating Behavioral Health and Primary Care: Practical Skills for the Consulting Psychiatrist

9:00 a.m. – 4:00 p.m.
Marquis Ballroom A, Marquis Level
Marriott Marquis

Directors:
Anna Ratzliff, M.D., Ph.D.
Lori Raney, M.D.

Faculty:
John Kern, M.D.

Mind-Body Programs: Stress, Anxiety, Depression, PTSD, Military Trauma and Mass Disasters: Lecture and Experiential (Replaces Yoga of the East and West)

APA Caucus on Complementary and Alternative Medicine

9:00 a.m. – 4:00 p.m.
Marquis Ballroom D, Marquis Level
Marriott Marquis

SESSION TRACKS

1. Addiction Psychiatry
2. Child and Adolescent Psychiatry
3. Forensic Psychiatry
4. Geriatric Psychiatry
5. Psychosomatic Psychiatry
6. NIDA
7. Residents, Fellows and Medical Students

APA Annual Meeting On Demand
Bring Your Own Device
Medical Conditions Mimicking Psychiatric Disorders Versus Psychiatric Disorders Mimicking Medical Conditions: Diagnostic and Treatment Challenges
11:00 a.m. – 12:30 p.m.
Room B218, Level 2
Georgia World Congress Center
Chair: Catherine Crone, M.D.

The History, Ethics and Promise of Psychedelic Therapies
APA Ethics Committee and Penn-Scattergood Ethics Program
11:00 a.m. – 12:30 p.m.
Room A303, Level 3
Georgia World Congress Center
Chair: Dominic Sisti, Ph.D.
Speakers: Paul Summergrad, M.D.
Rick Doblin, Ph.D.
Matthew J. Baggott, Ph.D.

Exploring Barriers to Treatment for Child Transgender Patients in the Institutional and Inpatient Psychiatric Settings
2
11:00 a.m. – 12:30 p.m.
Room A304, Level 3
Georgia World Congress Center
Chairs: Rabiya Hasan, M.D.
Speaker: Chioma Linda Iheagwara, D.O.

Criminalization of Black Males: The Effects of Untreated Bipolar, ADHD and Substance Abuse Disorders
APA Caucus of Black Psychiatrists
3
11:00 a.m. – 12:30 p.m.
Room A313, Level 3
Georgia World Congress Center
Chair: Napoleon B. Higgins Jr., M.D.
Speakers: Otis Anderson, M.D.
Timothy Benson, M.D.
Ericka Goodwin, M.D.
Johnny Williamson, M.D.
Rahn Bailey, M.D.

Future of the DSM: An Update From the DSM Steering Committee
11:00 a.m. – 12:30 p.m.
Room B306, Level 3
Georgia World Congress Center
Chair: Paul S. Appelbaum, M.D.
Speakers: Michael B. First, M.D.
Kenneth Kendler, M.D.

Top 10 Geriatric Psychiatry Issues for the General Psychiatrist: An Update
4
11:00 a.m. – 12:30 p.m.
Room B310, Level 3
Georgia World Congress Center
Chairs: Joseph A. Cheong, M.D.
Iqbal Ahmed, M.D.
Speaker: Shilpa Srinivasan, M.D.

Disruptive Behavior in Preschool Children: What Does It Mean? Differential Diagnosis and Pharmacologic Approaches
APA Council on Children, Adolescents and Their Families
2
11:00 a.m. – 12:30 p.m.
Room B311, Level 3
Georgia World Congress Center
Chair: Jean M. Thomas, M.D.
Speakers: Jean M. Thomas, M.D.
Swathi Krishna, M.D.
Caroline D. Brozyna, M.D.

Acknowledging and Accommodating Age and Ability Senior Psychiatrists
4
11:00 a.m. – 12:30 p.m.
Room B403, Level 4
Georgia World Congress Center
Chairs: Paul H. Wick, M.D.
Nada L. Stotland, M.D., M.P.H.
Speakers: Paul H. Wick, M.D.
James W. Lomax, M.D.
Sheila Hafter Gray, M.D.

This session will be captured as part of APA Annual Meeting On Demand, subject to speaker permission. Visit the On Demand sales booth in the Education Center to learn more and purchase.
1:00 p.m. Sessions

Courses

Evaluation and Treatment of Sexual Dysfunctions

1:00 p.m. – 5:00 p.m.
International 4, International Level Marriott Marquis

Director:
Waguih William IsHak, M.D.

Risk Assessment for Violence

1:00 p.m. – 5:00 p.m.
International 5, International Level Marriott Marquis

Director:
Phillip J. Resnick, M.D.

Acute Brain Failure: Neurobiology, Prevention and Treatment of Delirium

Academy of Psychosomatic Medicine

1:00 p.m. – 5:00 p.m.
International 6, International Level Marriott Marquis

Director:
Jose R. Maldonado, M.D.

Neuroanatomy of Emotions

1:00 p.m. – 5:00 p.m.
MI03-105, Marquis Level Marriott Marquis

Chair:
Ricardo M. Vela, M.D.

Director:
Ricardo M. Vela, M.D.

Learning Lab

Participant Debates: Ethical Issues in Psychiatry

1:00 p.m. – 4:00 p.m.
Rooms B211-212, Level 2
Georgia World Congress Center

Chair:
Rebecca Weintraub Brendel, M.D., J.D.

Seminars

Women in Psychiatry: Career Advancement, Academics, Advocacy and Balance: The Real World

1:00 p.m. – 5:00 p.m.
International 7, International Level Marriott Marquis

Directors:
Isabel Schuermeyer, M.D., M.S.
Margo Funk, M.D., M.A.

Faculty:
Kathleen Franco
Karen Jacobs, D.O.
Tatiana Falcone, M.D.

Program changes are printed each day in the APA Daily, which is available at locations throughout the Georgia World Congress Center. Up to date program listings are also available and searchable in the APA Meetings app.
1:30 p.m. Sessions
 Advances in Medicine

Top 10 Medical Stories 2015: A Comprehensive and Practical Review of What Psychiatrists Need to Know
1:30 p.m. – 3:00 p.m.
Rooms A315-316, Level 3
Georgia World Congress Center
Chair:
Monique Yohanan, M.D., M.P.H.

Conversations

Diversity 3.0: From Fairness to Excellence
1:30 p.m. – 3:00 p.m.
Room B409, Level 4
Georgia World Congress Center
Speaker:
Marc Nivet

Focus Live

Focus Live! OCD and Related Disorders (OCDR): Diagnosis to Treatment
1:30 p.m. – 3:00 p.m.
Rooms B207-208, Level 2
Georgia World Congress Center
Moderators:
Mark H. Rapaport, M.D.
Tristan Gorrindo, M.D.
Speakers:
Michele T. Pato, M.D.
Katharine A. Phillips, M.D.

Forum

The Financing of Psychiatric Care: Past, Present and Future
1:30 p.m. – 3:00 p.m.
Room B206, Level 2
Georgia World Congress Center
Chair:
Steven S. Sharfstein, M.D., M.P.A.
Speakers:
Steven S. Sharfstein, M.D., M.P.A.
Frank W. Brown, M.D.
Anita Everett, M.D.

Interactive Sessions

Women’s Mental Health: What Is It? How to Do It? Why Do It?
1:30 p.m. – 3:00 p.m.
Room A301, Level 3
Georgia World Congress Center
Chair:
Gail Erlick Robinson, M.D.

Lectures

Thinking Differently About Mental Illness and Gun Violence: Balancing Risk and Rights for Effective Policy
APA Frontiers of Science Lecture Series
1:30 p.m. – 3:00 p.m.
Rooms A411-412, Level 4
Georgia World Congress Center
Lecturer:
Jeff O. Swanson, M.D.

The Sweet Enchantment of “Post-Racial” Racism in America
Solomon Carter Fuller Award
1:30 p.m. – 3:00 p.m.
Sidney Marcus Auditorium, Level 4
Georgia World Congress Center
Lecturer:
Eduardo Bonilla-Silva, Ph.D.

Beyond MacArthur: The Past, Present and Probable Future of Violence Risk Assessment
APA Frontiers of Science Lecture Series
1:30 p.m. – 3:00 p.m.
Sidney Marcus Auditorium, Level 4
Georgia World Congress Center
Lecturer:
Lara J. Cox, M.D., M.S.

Beyond MacArthur: The Past, Present and Probable Future of Violence Risk Assessment

1. Caregiving for Individuals With Schizophrenia and Its Impact on Caregiver Employment and Work Productivity
Debra Lerner, Ph.D., M.Sc.

2. Caregiver-Directed Psychosocial Interventions in Schizophrenia: Systematic Review and Meta-Analysis
Branislav Mancevski, M.D.

3. Post-Discharge Physician Visits and Readmission Rates in a Population-Based Sample of Patients With Schizophrenia
Paul Kurdyak, M.D., Ph.D.

Scientific and Clinical Reports

Schizophrenia: Caregiver Techniques and Post-Discharge Strategies
1:30 p.m. – 3:00 p.m.
Room B405, Level 4
Georgia World Congress Center

1. Caregiving for Individuals With Schizophrenia and Its Impact on Caregiver Employment and Work Productivity
Debra Lerner, Ph.D., M.Sc.

2. Caregiver-Directed Psychosocial Interventions in Schizophrenia: Systematic Review and Meta-Analysis
Branislav Mancevski, M.D.

3. Post-Discharge Physician Visits and Readmission Rates in a Population-Based Sample of Patients With Schizophrenia
Paul Kurdyak, M.D., Ph.D.

Biological Psychiatry

Inflammatory Markers in PTSD: A Meta-Analysis and Meta-Regression Study
Fang Yang, M.D., Ph.D.

Analysis of Baseline Mental Health Data From the Sonya Slifka Longitudinal Multiple Sclerosis Study
Laura Safar, M.D.

Brain-Derived Neurotrophic Factor (BDNF) as a Predictive Biomarker of the Occurrence of PTSD: Pilot Prospective Study
Hafid Belhadj-Tahar, M.D., Ph.D.

CACNA1C Gene and Schizophrenia: A Case-Control and Pharmacogenetic Study
Tae-Youn Jun, M.D., Ph.D.
Workshops

Addressing the Social Determinants of Mental Health Through Integrated Behavioral Health

1:30 p.m. – 3:00 p.m.
Room B215, Level 2
Georgia World Congress Center
Chair:
Monica Taylor-Desir, M.D., M.P.H.
Speakers:
Ruth Shim, M.D., M.P.H.
Lori Raney, M.D.
Dyanna Leolani Ah Quin, M.S.W.
LeRoy C. Eswonia, B.S.

A Collaboratory for Psychiatric App Development
American Association for Technology in Psychiatry
1:30 p.m. – 3:00 p.m.
Room B218, Level 2
Georgia World Congress Center
Chairs:
Seth Powsner, M.D.
Victor J. A. Buwalda, M.D., Ph.D.
Speakers:
Robert Kennedy, M.D.
John Torous, M.D.
Victor J. A. Buwalda, M.D., Ph.D.
Seth Powsner, M.D.
John Luo, M.D.

My Patient Just Got Pharmacogenetic Testing; What Do I Do Now?
1:30 p.m. – 3:00 p.m.
Room A303, Level 3
Georgia World Congress Center
Chairs:
Simon Kung, M.D.
Scott Schmidt, D.O.

From Dementia to Neurocognitive Disorder: Understanding the Changes Made in the DSM-5
1:30 p.m. – 3:00 p.m.
Room A304, Level 3
Georgia World Congress Center
Chair:
Mehrun Hasnain, M.D.

Sexuality During Pregnancy and the Postpartum Period
1:30 p.m. – 3:00 p.m.
Room B306, Level 3
Georgia World Congress Center
Chairs:
Damir Huremovic, M.D., M.P.P.
Guitelle St. Victor, M.D.
Speakers:
Madhavi Nagalia, M.D.
Nyapati R. Rao, M.D.
Ateaya Lima, M.D.

“Oh, the Places You’ll Go”: Opportunities to Teach Child Psychiatry in Low- and Middle-Income Countries through IACAPAP Volunteer Programs
1:30 p.m. – 3:00 p.m.
Room B310, Level 3
Georgia World Congress Center
Chair:
Julie A. Chilton, M.D.

Joining Forces: The Neurology-Psychiatry Connection: Bridging Education and Patient Care Across Disciplines
1:30 p.m. – 3:00 p.m.
Room B315, Level 3
Georgia World Congress Center
Chairs:
Ann Schwartz, M.D.
Wendy Baer, M.D.
Speakers:
Jaffar Khan, M.D.
Adriana Hermida, M.D.
Martha C. Ward, M.D.
Joash T. Lazarus, M.D.

Evidence-Based Management of Patients at Risk for Suicide: VA/DoD Clinical Practice Guidelines for the Prevention of Suicide
1:30 p.m. – 3:00 p.m.
Room B316, Level 3
Georgia World Congress Center
Chairs:
John Bradley, M.D.
Brett Schneider, M.D.

Active Shooter Hospital Lockdown: To Treat or Not to Treat
1:30 p.m. – 3:00 p.m.
Room A408, Level 4
Georgia World Congress Center
Chair:
Edmund G. Howe III, M.D.
Speakers:
Kyle J. Gray, M.D., M.A.
James C. West Jr., M.D.
Gary H. Wynn, M.D.

Comorbid Post-Traumatic Stress Disorder, Pain and Opiate Addiction
1:30 p.m. – 3:00 p.m.
Room B404, Level 4
Georgia World Congress Center
Chair:
Ayman Fareed
Speakers:
Pamela Eilender, Psy.D.
Bethany Ketchen, Ph.D.

Psychiatry and Health Care Reform: Where Are We? What’s Ahead?
1:30 p.m. – 3:00 p.m.
Room A408, Level 4
Georgia World Congress Center
Chairs:
Joyce C. West, Ph.D., M.P.P.
Kristin Kroeger Ptakowski
Speakers:
Philip Wang, M.D., Dr.P.H.
Anita Everett, M.D.
Irvin L. Muszynski, J.D.
2:00 p.m. Sessions

Poster Session

New Research Poster 1
2:00 p.m. – 4:00 p.m.
Exhibit Hall B3-B4, Level 1
Georgia World Congress Center

Lectures

Psychiatric Faculty Development: Challenges for the 21st Century
Vestermark Psychiatry Educator Award

2:00 p.m. – 5:00 p.m.
Rooms A406-407, Level 4
Georgia World Congress Center
Lecture Chairs:
Christopher R. Thomas, M.D.
Richard Summers, M.D.
Lecturers:
Robert E. Hales, M.D.
John H. Coverdale, M.D.

Media Workshops

The Resilience of the Family in Film: “Aparajito” (Part 2 of “The Apu Trilogy”)
APA Caucus of Asian-American Psychiatrists
2:00 p.m. – 5:00 p.m.
Room A314, Level 3
Georgia World Congress Center
Chairs:
Francis Lu, M.D.
Edmond H. T. Pi, M.D.
Speakers:
Ramaswamy Viswanathan, M.D.
Russell F. Lim, M.D., M.Ed.
Jagannathan Srinivasaraghavan, M.D.

“The Resilience of the Family in Film: “Aparajito” (Part 2 of “The Apu Trilogy”)
APA Caucus of Asian-American Psychiatrists
2:00 p.m. – 5:00 p.m.
Room B313, Level 3
Georgia World Congress Center
Chairs:
Lloyd I. Sederer, M.D.
Alan Stone, M.D.
Speakers:
Mayada Akil, M.D.
Lloyd I. Sederer, M.D.
Alan Stone, M.D.

Symposia

New Perspectives on Treatment of Borderline Personality Disorder (BPD)

1. Pros and Cons of Inter-Session Contact With Borderline Personality Disorder (BPD) Patients
   Karen L. Jacob, Ph.D.
2. Rejection Sensitivity as a Paradigm for Understanding Borderline Personality Disorder (BPD) and Its Comorbidities
   Lois W. Choi-Kain, M.D., M.Ed.

3. A Generalist Model Is “Good Enough” for Treating Most Borderline Personality Disorder (BPD) Patients
   John Gunderson, M.D.
4. Guidelines for Emergency Room Management of Borderline Personality Disorder (BPD) Patients
   Victor Hong, M.D.
5. A 40-Year Retrospective on Borderline Personality Disorder (BPD) and Countertransference
   Glen O. Gabbard, M.D.
Biologics (Vaccines, Monoclonal Antibodies and Enzymes) to Treat Substance Use Disorders

National Institute on Drug Abuse

2:00 p.m. – 5:00 p.m.
Room B312, Level 3
Georgia World Congress Center

Chairs:
Ivan D. Montoya, M.D., M.P.H.
Phil Skolnick, Ph.D.

Discussant:
Phil Skolnick, Ph.D.

1. Enzyme Therapies for Cocaine Addiction and Overdose
Chang-Guo Zhan, Ph.D., M.Sc.

2. Monoclonal Antibodies to Treat Substance Use Disorders and Overdose
Samuel M. Owens, Ph.D.

3. Pharmacokinetic Strategies to Mitigate Nicotine’s Psychoactive Effects
Matthew W. Kalnik, Ph.D.

4. Vaccines for Cocaine and Methamphetamine Addictions
Thomas Kosten, M.D.

Effective Responses to Justice-Involved Persons With Mental Illnesses

American Psychiatric Association Publishing Editorial Board

2:00 p.m. – 5:00 p.m.
Room B314, Level 3
Georgia World Congress Center

Chairs:
Robert L. Trestman, M.D., Ph.D.
Fred C. Osher, M.D.

Discussant:
Debra Pinals, M.D.

1. Effective Responses to Justice-Involved Persons With Mental Illnesses
Robert L. Trestman, M.D., Ph.D.
Fred C. Osher, M.D.

2. What Can We Do to Prevent Incarceration?
Fred C. Osher, M.D.

3. Treatment Options for Incarceration
Merrill Rotter, M.D.

Are Involuntary Outpatient Commitment Laws a Good Thing? Ethics Considerations and Analysis

APA Ethics Committee

2:00 p.m. – 5:00 p.m.
Room B308, Level 3
Georgia World Congress Center

Chair:
Robert Weinstock, M.D.

Discussant:
Steven Hoge, M.D., M.B.A.

1. For Whom and Under What Conditions Can Involuntary Outpatient Commitment Be Effective?
Marvin S. Swartz, M.D.

2. An Ethics-Based View of Involuntary Outpatient Commitment
Ezra Griffith, M.D.

3. Dialectical Principlism: An Approach to Analyzing and Resolving Ethical Dilemmas
Robert Weinstock, M.D.

4. Balancing Conflicting Ethical Considerations in Involuntary Outpatient Commitment
William C. Darby, M.D.

The Face of Resilience: Working With Survivors of Intimate Partner Violence (IPV)—A Holistic Model to Care

2:00 p.m. – 5:00 p.m.
Room B309, Level 3
Georgia World Congress Center

Chair:
Joel E. Dimsdale, M.D.

Discussant:
Paul Summergrad, M.D.

1. Anatomy of Malice: Using Research Archives to Study Psychopathology in Nazi War Criminals
Joel E. Dimsdale, M.D.

2. How Could It Happen? From Social Darwinism to the Nazi Euthanasia Program
Hans-Jurgen Moller, M.D.

3. Using Fiction to Tell the Story of Aktion T4
Stephen M. Stahl, M.D., Ph.D.
An Update on Diagnostic and Assessment Considerations for the Treatment of Comorbid Opioid Addiction and Chronic Pain

*National Institute on Drug Abuse*

2:00 p.m. – 5:00 p.m.
Rooms A404-405, Level 4
Georgia World Congress Center

**Chair:**
Will M. Aklin, Ph.D.

**Discussant:**
Wilson M. Compton, M.D.

1. Neuroimaging of Pain and Distress: From Biomarkers to Brain Representation
   *Tor Wager, Ph.D.*

2. Prescription Opioid Use and the Transition of Acute to Chronic Pain: Preventing Problematic Opioid Use and Persistent Pain After Surgery
   *Jennifer Hah, M.D., M.S.*

3. Treatment of Co-Occurring Chronic Pain and Opioid Use Disorder
   *Declan Barry, Ph.D.*

4. Update on the Treatment of Acute and Chronic Pain in the Patient With a History of Substance Abuse
   *Sean Mackey, M.D., Ph.D.*

5. Long-Term Outcomes From the Prescription Opioid Addiction Treatment Study
   *Roger D. Weiss, M.D.*

**Treatment of Cognitive Impairment and Functional Disability Across Psychiatric Conditions: What Has Been Achieved**

2:00 p.m. – 5:00 p.m.
Room A410, Level 4
Georgia World Congress Center

**Chairs:**
*Herbert Y. Meltzer, M.D.*
*Philip D. Harvey, Ph.D.*

1. Treatment of Cognition and Disability: Rationale and Strategies
   *Philip D. Harvey, Ph.D.*

2. Atypical Antipsychotic Drugs Partially Correct Cognitive Dysfunction in Some Schizophrenia Patients: Understanding the Effect of Antipsychotic Drugs on Neuroplasticity Critical for Learning and Memory
   *Herbert Y. Meltzer, M.D.*

3. Treatment of Cognitive Deficits in Patients With Schizophrenia and Major Depression
   *Richard Keefe, Ph.D.*

4. fMRI and MEG Studies of Cortical Plasticity Induced by Cognitive Training in Schizophrenia
   *Sophia Vinogradov, M.D.*

**Countering Violent Extremism**

2:00 p.m. – 5:00 p.m.
Room B402, Level 4
Georgia World Congress Center

**Chairs:**
*Stevan M. Weine, M.D.*
*Aliya Saeed, M.D.*

**Discussant:**
*Neil K. Aggarwal, M.D., M.B.A.*

1. A Comparative Analysis of Terrorist Propaganda Magazines: Understanding the Motivational Dimensions
   *Anthony Lemieux, Ph.D., M.A.*

All scientific sessions listed in the Program are designated for AMA PRA Category 1 Credits™, except for Poster Sessions.
2. Violent Extremism: Challenges Faced by Muslim Communities
   Aliya Saeed, M.D.

3. Suffer the Little Children: Child Recruitment Into Violent Extremist Groups
   Mia M. Bloom, Ph.D.

4. Moving Beyond Motive-Based Categories of Targeted Violence Interventions
   Stevan M. Weine, M.D.

5. Evaluating CVE Programs: Lessons Learned and Future Directions for Research
   John Horgan, Ph.D.

Changing Behavioral Health Systems to Treat Tobacco Through Training and Policy Initiatives
American Academy of Addiction Psychiatry

1. Training Psychiatrists and Behavioral Health Providers in Treating Tobacco Through Continuing Education
   Jill M. Williams, M.D.

2. Dissemination of an Evidence-Based Tobacco Treatment Curriculum to Psychiatric Residency Programs
   Smita Das, M.D., Ph.D.

3. Lessons Learned From Creating a Tobacco-Free Health System
   Tim Fong, M.D.

4. Implementation of Integrated Tobacco Treatment Into Mental Health Care for Veterans With PTSD
   Andrew J. Saxon, M.D.

3:30 p.m. Sessions
Case Conference

These sessions are open to APA members only. A blue registration badge or an APA membership card are required for admittance.

Catatonia and Serotonin Syndrome Following Abrupt Cessation of Clozapine: Considerations for a Consultation-Liaison Psychiatrist
3:30 p.m. - 5:00 p.m.
Rooms A315-316, Level 3
Georgia World Congress Center
Chair: Ewald Horwath, M.D.
Speaker: Mohsina Ahmed, M.D.

Focus Live

Focus Live! Understanding the Evidence for Off-Label Use of Atypical Antipsychotics

3:30 p.m. - 5:00 p.m.
Moderators:
Mark H Rapaport, M.D.
Tristan Gorrindo, M.D.
Speakers:
David L. Fogelson M.D.
Joel Yager, M.D.

Interactive Session

The Difficult Patient
3:30 p.m. - 5:00 p.m.
Room A301, Level 3
Georgia World Congress Center
Chair: Philip R. Muskin, M.D., M.A.

Lectures

Unfreezing the Gun Debate: How New Research at the Intersection of Guns, Violence and Mental Illness Creates Opportunities for Policy Change
APA Frontiers of Science Lecture Series

3:30 p.m. - 5:00 p.m.
Rooms A411-412, Level 4
Georgia World Congress Center
Lecturer: Josh Horwitz, M.D.
Role Conflicts in the Management of Sexual Offenders  
*APA International Psychiatrist Lecture Series*  
3:30 p.m. – 5:00 p.m.  
Sidney Marcus Auditorium, Level 4  
Georgia World Congress Center  
Lecturer:  
Roy O'Shaughnessy, M.D.

### Scientific and Clinical Reports

#### Addiction: Tobacco

3:30 p.m. – 5:00 p.m.  
Room B405, Level 4  
Georgia World Congress Center  
1. Tobacco Treatment in Hospitalized Patients With Acute Psychiatric and Addictive Disorders  
_Smita Das, M.D., Ph.D._  

#### Management of Schizophrenia and Psychosis

3:30 p.m. – 5:00 p.m.  
Room B406, Level 4  
Georgia World Congress Center  
1. Treatment of Negative Symptoms of Schizophrenia With Dextromethorphan/Quinidine Augmentation of Antipsychotics: An Open Trial in 42 Patients  
_Paul J. Markovitz, M.D., Ph.D._  
2. Case Challenge to Manage Psychosis in Patients With Trisomy X  
_Sheema Imran, M.D._  

---

### Workshops

**The Evolution of Integrated Care for HIV and Mental Illness**  
3:30 p.m. – 5:00 p.m.  
Room B215, Level 2  
Georgia World Congress Center  
Chair:  
_Francine Cournos, M.D._  
Speakers:  
_Marshall Forstein, M.D._  
_William W. Thompson, Ph.D._

**Brief Cognitive Behavioral Interventions to Augment Psychopharmacology in Mood and Psychotic Disorders**  
3:30 p.m. – 5:00 p.m.  
Room B218, Level 2  
Georgia World Congress Center  
Chairs:  
_Mohammed A. Khan, M.D._  
_Mark Farnamor, M.D._  
Speakers:  
_Dana Foglesong, B.S._  
_Narsimha Pinninti, M.D., D.P.M._  
_Donna M. Sudak, M.D._

**Update on Body Dysmorphic Disorder: Clinical Features, Neurobiology and Treatment**  
3:30 p.m. – 5:00 p.m.  
Room A303, Level 3  
Georgia World Congress Center  
Chairs:  
_Katharine A. Phillips, M.D._  
_Jamie Feusner, M.D._  

---

### Scientific and Clinical Reports

**Addiction: Tobacco**  
1. Tobacco Treatment in Hospitalized Patients With Acute Psychiatric and Addictive Disorders  
_Smita Das, M.D., Ph.D._

**Management of Schizophrenia and Psychosis**  
1. Treatment of Negative Symptoms of Schizophrenia With Dextromethorphan/Quinidine Augmentation of Antipsychotics: An Open Trial in 42 Patients  
_Paul J. Markovitz, M.D., Ph.D._  
2. Case Challenge to Manage Psychosis in Patients With Trisomy X  
_Sheema Imran, M.D._

---

**Not Just National News: Can Multiple Isolated Incidents of Racially or Ethnically Motivated Violence Traumatize the Larger Minority Group?**  
*APA Council on Minority Mental Health and Health Disparities*  
3:30 p.m. – 5:00 p.m.  
Room A307, Level 3  
Georgia World Congress Center  
Chair:  
_Mawuena Agbonyitor, M.D., M.Sc._  
Speakers:  
_Meredith Harewood, M.D._  
_Racquel E. Reid, M.D._  
_Rubiañana Vaughn, M.D., M.P.H._  
_Aleema Zakers, M.D., M.P.H._  
_Danielle Hairston, M.D._

---

**Planes, Trains, Automobiles and Boats: Psychiatrists as Emergency First Responders**  
3:30 p.m. – 5:00 p.m.  
Room B306, Level 3  
Georgia World Congress Center  
Chairs:  
_Jean E. Aycock, M.D._  
_Lee S. Hyde, M.D._

---

**From the Geriatric Hospital Bed to the Witness Stand: Delirium in the Courtroom**  
3:30 p.m. – 5:00 p.m.  
Room A303, Level 3  
Georgia World Congress Center  
Chair:  
_Alberto M. Goldwaser, M.D._

---

**Sexual Offenders: A Psychiatric Perspective**  
3:30 p.m. – 5:00 p.m.  
Room A304, Level 3  
Georgia World Congress Center  
Chair:  
_Renee Sorrentino, M.D._

---

All scientific sessions listed in the Program are designated for AMA PRA Category 1 Credits™, except for Poster Sessions.
### How Does Countertransference Fit in Modern Health Care: Impact of Provider Feelings on Diagnosis and Medical Decision Making

**5**

3:30 p.m. – 5:00 p.m.
Room B311, Level 3
Georgia World Congress Center

**Chair:**
Nidal Moukaddam, M.D., Ph.D.

**Speakers:**
Asim Shah, M.D.
Veronica Tucci, M.D., J.D.
Nidal Moukaddam, M.D., Ph.D.

### Access to Physician-Assisted Suicide for Intractable Suffering and Chronic Mental Illness: An Approaching Ethics Crisis

**3**

3:30 p.m. – 5:00 p.m.
Room A313, Level 3
Georgia World Congress Center

**Chair:**
Mark Komrad, M.D.

**Speakers:**
Mark Komrad, M.D.
Robert Roca, M.D., M.P.H.
Samuel J. Leistedt, M.D., Ph.D.

### Clinical Issues in Schizophrenia With Comorbid Disorders: Update

**7**

3:30 p.m. – 5:00 p.m.
Room B315, Level 3
Georgia World Congress Center

**Chair:**
Jean-Pierre Lindenmayer, M.D.

### PTSD in Psychiatrists: A Hidden Epidemic

3:30 p.m. – 5:00 p.m.
Room B316, Level 3
Georgia World Congress Center

**Chair:**
Arthur Lazarus, M.D., M.B.A.

**Speakers:**
Michael F. Myers, M.D.
H. Steven Moffic, M.D.

### Managing Violence Risk and Interview Safety: A Primer for Residents

**7**

3:30 p.m. – 5:00 p.m.
Room A408, Level 4
Georgia World Congress Center

**Chair:**
Tobias Wasser, M.D.

### Cultural Family Therapy: Integrating Family Therapy With Cultural Psychiatry

**2**

3:30 p.m. – 5:00 p.m.
Room B403, Level 4
Georgia World Congress Center

**Chairs:**
Vincenzo Di Nicola, M.D., Ph.D.
Ellen Berman, M.D.

**Speakers:**
Vincenzo Di Nicola, M.D., Ph.D.
Ellen Berman, M.D.

### The General Psychiatrist’s Approach to Personality Disorders: Practical Applications of Transference-Focused Psychotherapy (TFP) Principles

3:30 p.m. – 5:00 p.m.
Room B404, Level 4
Georgia World Congress Center

**Chair:**
Richard Hersh, M.D.

**Speakers:**
Frank E. Yeomans, M.D.
Eve Caligor, M.D.

### The Extension for Community Health Outcomes (ECHO) Model: Creating a Community of Mental Health and Addictions Practice

3:30 p.m. – 5:00 p.m.
Room B408, Level 4
Georgia World Congress Center

**Chairs:**
Allison Crawford, M.D., M.A.
Sanjeev Sockalingam, M.D.

**Speakers:**
Allison Crawford, M.D., M.A.
Sanjeev Sockalingam, M.D.
Paul Kurdyak, M.D., Ph.D.
Eva Serhal, M.B.A.

### Convocation of Distinguished Fellows

5:30 p.m. – 6:30 p.m.
Hall B2, Level 1
Georgia World Congress Center

**Speaker:**
Tom Frieden, M.D., M.P.H.
60th Convocation of Distinguished Fellows

5:30 p.m. – 6:30 p.m.
Hall B2, Level 1,
Georgia World Congress Center

Call to Order
Renée L. Binder, M.D.
APA President

Introduction of Distinguished Life Fellows,
Induction of Distinguished Fellows and
the Pledge of Distinguished Fellowship
Maria A. Oquendo, M.D.
APA President-Elect

Introduction of Fellows and Life
Fellows; Introduction of the 50-Year
Distinguished Life Fellows, Life Fellows
and Life Members; Introduction of the
International Distinguished Fellows and
Introduction of International Fellows
Renée L. Binder, M.D.

Awards for 2016
All awards will be presented by
Renée L. Binder, M.D.

Special Presidential Commendations
Richard J. Bonnie, J.D.
Larry R. Faulkner, M.D.
Robert L. Hendren, D.O.
Francis G. Lu, M.D.
Jeffrey L. Metzner, M.D.

Distinguished Service Awards
Donna M. Norris, M.D.
Steven S. Sharfstein, M.D.
Daniel K. Winstead, M.D.

Organizational Distinguished
Service Award
American Academy of Psychiatry and the Law

Introduction of the Membership
Committee and Its Chairperson
Renée L. Binder, M.D.

All Distinguished Life Fellows, Distinguished Fellows, Life Fellows, International Fellows, APA Members
and Registered Guests are invited to attend.

The William C. Menninger
Memorial Convocation Lecture

Established in 1972, this lecture honors the late William C. Menninger, M.D.,
President of APA 1948–49, who brought to the association a formalized
Convocation of Fellows, first held in 1956.

Tom Frieden, M.D., M.P.H.
Director, Centers for Disease Control and Prevention

Tom Frieden, M.D., M.P.H., is Director of the Centers for Disease Control and Prevention (CDC). Since
2009, Dr. Frieden has intensified CDC’s constant work to protect the health, safety and security of the
American people, including leading the agency’s response to the recent Ebola epidemic and other
health emergencies. Under his direction, new CDC programs have focused on combating antibiotic
resistance, preventing foodborne and health care-associated infections, helping people quit smoking,
addressing the prescription drug overdose epidemic, and advancing global health security world-
wide. He previously led New York City’s program that cut multidrug-resistant tuberculosis by 90%
and helped India prevent more than 3 million tuberculosis deaths. As New York City’s health commis-
sioner from 2002 to 2009, he helped reduce teen smoking by half and adult smoking by one-third.
Dr. Frieden received his medical and master of public health degrees from Columbia University. He
completed infectious disease training at Yale University.
Focus LIVE!

Test Your Knowledge!
May 16, 2016

Georgia World Congress Center
Learning Lab, Rooms B207-208, Level 2

Sessions will be moderated by Mark H. Rapaport, M.D., Editor of FOCUS and Tristan Gorrindo, M.D., Director of Education, American Psychiatric Association

Focus Live! 1  Obsessive-Compulsive and Related Disorders
Monday, May 16, 1:30pm - 3:00pm

Michele T. Pato M.D., Director, Institute for Genomic Health, Professor and Vice Chair for Research- Department of Psychiatry/College of Medicine, SUNY Downstate- Brooklyn, N.Y.

Katharine A. Phillips, M.D., Senior Research Scientist and Director of the Body Dysmorphic Disorder Program, Rhode Island Hospital, and Professor of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, R.I.

Focus Live! 2  Understanding the Evidence for Off-label Use of Atypical Antipsychotics
Monday, May 16, 3:30pm - 5:00pm

David L. Fogelson, M.D., Clinical Professor of Psychiatry, David Geffen School of Medicine at UCLA, and The Semel Institute for Neuroscience and Human Behavior at UCLA

Joel Yager, M.D., Professor of Psychiatry, University of Colorado School of Medicine

Each FOCUS LIVE session is approved by ABPN for 2 MOC part 2 self-assessment credits.

The American Board Of Psychiatry And Neurology Has Reviewed Focus Live: Understanding The Evidence For Off-Label Use Of Atypical Antipsychotics And Focus Live: Obsessive-Compulsive And Related Disorders And Has Approved This Program As Part Of A Comprehensive Self-Assessment Program, Which Is Mandated By The ABMS As A Necessary Component Of Maintenance Of Certification.

Special Interactive Multiple choice Q & A Session using FXP technology.
Participants answer multiple choice questions using personal computer/smart phone technology in OCD and Related Disorders topic areas and compare results anonymously to peers for self-assessment credit.
APA JobCentral is FREE to job-seekers.

As a job-seeker you will be able to:

- Browse over 1,800 active job listings.
- **New! 2016 APA JobCentral Recruitment Guide!**
- Sign up for a free account and upload your resume for employers to view.
- Register for job alerts and receive immediate information when jobs are posted in a preferred location and/or specialty.
- Post your Annual Meeting contact information along with your resume and be contacted by interested employers attending the meeting.

Please visit jobs.psychiatry.org to begin your search. An APA JobCentral representative will be available during exhibit hours to answer any questions you may have!
Subscribe today to the highest-ranking mental health journal in the Health Policy & Services category!*

Don’t miss the May issue:
- Supply-side solutions to increasing the number of psychiatric beds
- Use of evidence-based treatments in state systems, 2001–2012
- Interventions to increase treatment retention: a systematic review
- Growth in behavioral health service use after the Great Recession

Coming in the June issue:
- Recovery-oriented practice in inpatient settings: a literature review
- Effects of Housing First on participants’ employment and income
- Marketing residential eating disorder programs: a call for transparency
- Use of services by firefighters with suicidal thoughts and behaviors

Don’t miss another issue of Psychiatric Services.
Visit the APA Bookstore to subscribe.

ps.psychiatryonline.org

*A total of 71 peer-reviewed journals are rated in this JCR category. Psychiatric Services is ranked 15th, making it the highest-ranking mental health journal in the category.
Tuesday

May 17, 2016
Emmanuel G. Cassimatis, M.D., is President and CEO of the Educational Commission for Foreign Medical Graduates and Chair of the Foundation for Advancement of International Medical Education and Research. He was formerly Vice President for Affiliations and International Affairs at the Uniformed Services University of the Health Sciences, Associate Dean for Clinical Affairs and Professor of Psychiatry at the university’s F. Edward Hébert School of Medicine. Dr. Cassimatis received his B.A. from the University of Chicago, his M.D. from Harvard Medical School and his psychoanalytic training at the Washington Psychoanalytic Institute. Dr. Cassimatis continues to serve as Professor of Psychiatry at USUHS and is a member of the Executive Council of the World Federation for Medical Education and the Composite Committee of the U.S. Medical Licensing Examination. He is a past Chair of the ACGME and the AMA Council on Medical Education.

Larry R. Faulkner, M.D., is currently the President and CEO of the American Board of Psychiatry and Neurology (ABPN) and Clinical Professor of Neuropsychiatry and Behavioral Science at the University of South Carolina School of Medicine (USCSM). From 1994 until he assumed his current position at the ABPN in 2006, Dr. Faulkner served as Vice President for Medical Affairs and Dean of the School of Medicine at USC. From 1990 to 1996, he was Chair of the Department of Neuropsychiatry and Behavioral Science and Director of the William S. Hall Psychiatric Institute at USCSM, and from 1980 to 1990, he was Director of Psychiatric Education at the Oregon Health Sciences University. Dr. Faulkner is a past Director of the ABPN, a past member and current ex-officio member of the Psychiatry RRC, a current ex-officio member of the Neurology RRC and a past President of the American Academy of Psychiatry and the Law.

Mardi Horowitz, M.D., is a Distinguished Professor of Psychiatry at the University of California, San Francisco. He has been president of the San Francisco Center for Psychoanalysis and the International Society for Psychotherapy Research. He has directed the NIMH Center for the Study of Neuroses and the John D. and Catherine T. MacArthur Foundation’s Program on Conscious and Unconscious Mental Processes. He is a founding member of the International Society for Traumatic Stress Studies and the Society to Explore Psychotherapy Integration. Dr. Horowitz is the recipient of multiple awards, including the Pioneer Award of the International Society for Traumatic Stress Studies for his achievements in developing the diagnoses of post-traumatic stress disorder and disorders of complicated grief. He also received the Foundation’s Fund Prize for psychiatric research “for his distinguished contribution to an understanding of the psychological processes following serious life events, and of the adaptive changes facilitated by psychotherapy.”

Francis G. Lu, M.D., is the Luke and Grace Kim Professor in Cultural Psychiatry, Emeritus, and Assistant Dean for Faculty Diversity, Emeritus, at the University of California, Davis, School of Medicine. From 1977 to 2009, he was a UCSF faculty member at the UCSF/San Francisco General Hospital inpatient psychiatric services. As a Distinguished Life Fellow of the American Psychiatric Association, Dr. Lu has contributed to the areas of cultural psychiatry; psychiatric education; film and psychiatry; and the interface of psychiatry, religion and spirituality. Since 2003, he has served on the APA Council on Minority Mental Health and Health Disparities. He is currently Secretary of the Society for the Study of Psychiatry and Culture, a member of the Group for the Advancement of Psychiatry Cultural Psychiatry Committee and a board member of the World Association of Cultural Psychiatry.
8:00 a.m. Sessions

Courses

Course descriptions are available in the APA Meetings app. Admission to all courses, including master courses, is by ticket only. Course tickets can be purchased at Registration at the Marquis Fountain, Marquis Level in the Marriott Marquis, or at Registration in Exhibit Hall B3-B4, Level 1 in the Georgia World Congress Center.

Evidence-Based Psychodynamic Therapy: A Pragmatic Clinician’s Workshop

8:00 a.m. – Noon
International 4, International Level Marriott Marquis
Director: Richard F. Summers, M.D.

ECT Practice Update for the General Psychiatrist

8:00 a.m. – Noon
M103-105, Marquis Level Marriott Marquis
Director: Peter B. Rosenquist, M.D.

Seminar

The Psychiatrist as Expert Witness

8:00 a.m. – Noon
International 7, International Level Marriott Marquis
Director: Phillip J. Resnick, M.D.

Master Course

Course descriptions are available in the APA Meetings app. Admission to all courses, including master courses, is by ticket only. Course tickets can be purchased at Registration at the Marquis Fountain, Marquis Level in the Marriott Marquis, or at Registration in Exhibit Hall B3-B4, Level 1 in the Georgia World Congress Center.

Essential Psychopharmacology

8:00 a.m. – 5:00 p.m.
Imperial Ballroom B, Marquis Level Marriott Marquis
Director: Alan F. Schatzberg, M.D.

9:00 a.m. Sessions

Advances in Medicine

Critical Advances in Sleep Medicine for the Psychiatrist

9:00 a.m. – 10:30 a.m.
Rooms A315-316, Level 3
Georgia World Congress Center
Chair: Karl Doghramji, M.D.

Interactive Session

Meet the Authors: Clinical Manual of Palliative Care Psychiatry
American Psychiatric Association
Publishing Editorial Board

5

9:00 a.m. – 10:30 a.m.
Room A301, Level 3
Georgia World Congress Center
Chair: Nathan Fairman, M.D., M.P.H.
Scott A. Irwin, M.D., Ph.D.

Lectures

Regulating the Entry of International Medical Graduates into U.S. Medicine and Psychiatry and endeavoring to contribute to their professional development: The Role of the ECFMG
George Tarjan Award

9:00 a.m. – 10:30 a.m.
Room A302, Level 3
Georgia World Congress Center
Lecturer: Emmanuel Cassimatis, M.D.

Perspectives on Physician Competence and Lifelong Learning
APA Distinguished Psychiatrist Lecture Series

9:00 a.m. – 10:30 a.m.
Rooms A411-412, Level 4
Georgia World Congress Center
Lecture Chair: Steve H. Koh, M.D., M.P.H.
Lecturer: Larry R. Faulkner, M.D.

SESSION TRACKS

1. Addiction Psychiatry
2. Child and Adolescent Psychiatry
3. Forensic Psychiatry
4. Geriatric Psychiatry
5. Psychosomatic Psychiatry
6. NIDA
7. Residents, Fellows and Medical Students

This session will be captured as part of APA Annual Meeting On Demand, subject to speaker permission. Visit the On Demand sales booth in the Education Center to learn more and purchase.
Scientific and Clinical Reports

Further Topics in Biological Psychiatry

1. Vagal Activity Predicts Survival in Women With Advanced Breast Cancer
   - David Spiegel, M.D.

2. Serum Levels and mRNA Expression of Neurotrophic Factors and Related Receptors Are Crucial in Different Subtypes of Depression
   - Yingying Yue, M.Med.

3. Hypothalamic Gastrin-Releasing Peptide Receptor Mediates an Antidepressant-Like Effect in a Mouse Model of Stress
   - Lihua Yao, M.Psy.

4. Prospective Validation Study of the Prediction of Alcohol Withdrawal Severity Scale (PAWSS): A New Tool for the Prediction of Patients at Risk for AWS
   - Jose R. Maldonado, M.D.

Workshops

Adaptation and Dissemination of Evidence-Based Psychotherapies for Use in Acute Psychiatric Care

- 9:00 a.m. – 10:30 a.m.
- Room B215, Level 2
- Georgia World Congress Center

Chairs:
- Aliza T. Stein, B.A.
- Patricia Marino, Ph.D.

Speakers:
- Kean J. Hsu, Ph.D.
- Patricia Marino, Ph.D.
- Amanda McGovern, Ph.D.
- Theresa A. Morgan, Ph.D.
- Victoria Wilkins, Ph.D.

What Is New in Suicide Prevention? From Primary to Tertiary Prevention in Physicians, Youth and Medically Ill Patients

- 9:00 a.m. – 10:30 a.m.
- Room B218, Level 2
- Georgia World Congress Center

Chairs:
- Tatiana Falcone, M.D.
- Jane C. Timmons-Mitchell, Ph.D.

Speakers:
- Ruby C. Castilla-Puentes, M.D., Dr.P.H.
- Fernando Espi Forcen, M.D.
- Tatiana Falcone, M.D.
- Jane C. Timmons-Mitchell, Ph.D.
- Margo Funk, M.D., M.A.

Adolescents’ Decision Making Capacity in the Consultation-Liaison Setting: From Juvenile Rights to Case Law

- 9:00 a.m. – 10:30 a.m.
- Room A303, Level 3
- Georgia World Congress Center

Chairs:
- Anish R. Dube, M.D., M.P.H.
- Barbara Robles-Ramamurthy, M.D.

Speakers:
- Megan E. Baker, M.D.
- Hassan M. Minhas, M.D., M.B.B.S.
- Lara J. Cox, M.D., M.S.

“Tuesdays in May”:

Determining Who Needs Psychiatric Hospitalization

- 9:00 a.m. – 10:30 a.m.
- Room B306, Level 3
- Georgia World Congress Center

Chairs:
- Kenneth M. Certa, M.D.
- Jessica Mosier, M.D.

Speaker:
- Daniel Neff, M.D.
Tuesday, May 17

Rahel C. Bachem, D.Phil.

Opioids and Cannabis: Myths and Misperceptions
Nora Volkow, M.D.

What Happened, Miss Simone?
Ruth Shim, M.D., M.P.H.
Annelle Primm, M.D., M.P.H.

New Nomenclature for Medications (Neuroscience-Based Nomenclature—NbN)
Maria A. Oquendo, M.D.

Stigma of Psychiatry Among Ethnic Minorities and the Use of Social Media and the Internet to Reach Underserved Populations
Wilsa M. S. Charles Malveaux, M.D., M.A.
Borderline Personality Disorder (BPD) Across the Lifespan: Developmental Precursors in Infancy Through Old Age
North American Association for the Study of Personality Disorders

9:00 a.m. – Noon
Rooms B216-217, Level 2
Georgia World Congress Center

Chairs:
Marianne Goodman, M.D.
Mary C. Zanarini, Ed.D.

Discussant:
John Gunderson, M.D.

1. Infancy, Childhood and Adolescent Precursors to the Development of Borderline Personality in Male and Female Offspring
Marianne Goodman, M.D.

2. The Course of Borderline Symptoms in Adolescents With and Without DSM-IV Criteria-Defined Borderline Personality Disorder (BPD)
Carla Sharp, Ph.D.

3. The Course of Borderline Personality Disorder (BPD) From Adolescence to Young Adulthood
Stephanie Stepp, Ph.D.

4. Levels of Acceptance and Forgiveness Reported by Borderline Patients and Axis II Comparison Subjects Over 16 Years of Prospective Follow-Up
Mary C. Zanarini, Ed.D.

5. Borderline Personality Disorder (BPD) in an Aging Population
Robert Biskin, M.D., M.Sc.

Sexuality and Psychiatry: Ethical and Policy Dilemmas
APA Ethics Committee and Penn-Scattergood Ethics Program

9:00 a.m. – Noon
Room B308, Level 3
Georgia World Congress Center

Chair:
Kenneth J. Weiss, M.D.

Discussant:
Mario Maj, M.D., Ph.D.

1. Sexual Self-Determination in Persons With Dementia
Kenneth J. Weiss, M.D.

2. Beyond a Question of Competency:

The Rights of Individuals With Mental Illness to Engage in Voluntary Sexual Acts
Alison J. Lynch, Esq.

3. Reporting Child Pornography Use: Psychiatrists as Police
Michelle Joy, M.D.

4. Sexual Victimization in Correctional Settings
Clarence Watson

Food and the Brain

9:00 a.m. – Noon
Room B309, Level 3
Georgia World Congress Center

Chairs:
Emily C. Deans, M.D.
Laura R. LaChance, M.D.

1. Food as a Vital Sign: The Simple Food Assessment
Drew Ramsey, M.D.

Laura R. LaChance, M.D.

3. You Are What You Eat: Special Diets and Their Implications in Mental Health and Guest or Host—The Microbiome and Behavior
Emily C. Deans, M.D.

DSM-5 and RDoC: Moving Toward a Common Agenda for Understanding Mental Disorders

9:00 a.m. – Noon
Room B314, Level 3
Georgia World Congress Center

Chairs:
Philip Wang, M.D., Dr.P.H.
Diana E. Clarke, Ph.D., M.Sc.

Discussant:
Mario Maj, M.D., Ph.D.

1. Using the NIMH RDoC to Help Clarify Psychiatric Disorders
Charles A. Sanislow, Ph.D.

2. The Conceptual Bridging of DSM-5 and RDoC: Moving the Field of Psychiatry Forward?
Philip Wang, M.D., Dr.P.H.
Choosing the Right Treatment for Substance Use Disorders
**APA Council on Addiction Psychiatry**

9:00 a.m. – Noon
Rooms A404-405, Level 4
Georgia World Congress Center

Chairs:
Herbert D. Kleber, M.D.
Edward V. Nunes, M.D.

1. Detecting and Managing Misuse of Prescription Stimulants and Sedative Hypnotics
   John J. Mariani, M.D.

2. Managing Opioid Use Disorder Using Medications: Role for Opioid Agonists and Antagonists
   Adam Bisaga, M.D.

3. Choosing Treatment for Problematic Non-Prescription Stimulant Use
   Elias Dakwar, M.D.

4. Choosing Treatment for Cannabis Use Disorders
   Frances R. Levin, M.D.

5. Combining Medication and Psychosocial Interventions in the Treatment of Substance Use Disorders
   Edward V. Nunes, M.D.

Biomarkers of Treatment Response and Tolerability in Psychotic and Mood Disorders
**Royal College of Psychiatrists**

9:00 a.m. – Noon
Rooms A406-407, Level 4
Georgia World Congress Center

Chairs:
Sophia Frangou, M.D., Ph.D.
Peter Buckley, M.B.B.S.

Discussant:
Godfrey D. Pearson, M.D.

   Peter Buckley, M.B.B.S.
2. Impact of Patient Suicide on Trainees: The Role of Educational Curricula
   Deepak Prabhakar, M.D., M.P.H.

3. Impact of Patient Suicide on Residents and Helping Residents Cope With Suicide
   James W. Lomax, M.D.

4. Emotional and Cognitive Responses of Clinicians to Patient Suicide
   Joan Anzia, M.D.

Dual Disorders: Two Different Disorders or One?

9:00 a.m. – Noon
Room B407, Level 4
Georgia World Congress Center

Chair:
Alan I. Green, M.D.

Discussant:
Roger D. Weiss, M.D.

1. Epidemiology of Dual Disorders: The Current State of Research and Methodological Challenges
   Shaul Lev-Ran, M.D.

2. Dual Disorders: Two Different Mental Disorders?
   Nestor Szerman, M.D.

3. Is Criticality Critical to Understand Dual Disorders?
   Ruben Baier, Ph.D.

4. Suicidal Behavior in Patients With Dual Disorders
   Leo Shear, M.D.

5. Schizophrenia and Substance Use Disorder: Is It All About Reward?
   Alan I. Green, M.D.

Integrating Behavioral Health and Primary Care: Practical Skills for the Consulting Psychiatrist

9:00 a.m. – 4:00 p.m.
Marquis Ballroom A, Marquis Level
Marriott Marquis

Directors:
Anna Ratzliff, M.D., Ph.D.
Lori Raney, M.D.

Faculty:
John Kern, M.D.

DSM-5 Changes: Overview and Practical Applications (Including the Transition to ICD-10-CM)

9:00 a.m. – 4:00 p.m.
M301-302, Marquis Level
Marriott Marquis

Director:
Michael B. First, M.D.

10:00 a.m. Session
Poster Session

Young Investigators’ New Research 2
10:00 a.m. – Noon
 Exhibit Hall B3-B4, Level 1
Georgia World Congress Center

10:30 a.m. Session
Lecture

The Marine Corps and Mental Health Issues
10:30 a.m. - Noon
Room B406, Level 4
Georgia World Congress Center

Lecturer:
Gen. Robert B. Neller

11:00 a.m. Sessions
Advances in Medicine

The Evolving Role of Imaging in Optimizing Treatment for Depression: From CBT to DBS
11:00 a.m. – 12:30 p.m.
Rooms A315-316, Level 3
Georgia World Congress Center

Chair:
Helen Mayberg, M.D.

Lecture

How the Mind Works: Using Trauma and Grief as Models
APA Distinguished Psychiatrist Lecture Series
11:00 a.m. – 12:30 p.m.
Rooms A411-412, Level 4
Georgia World Congress Center

Lecture Chair:
Renée Binder, M.D.

Lecturer:
Mardi Horowicz, M.D.

Media Workshops

Mad Men (and Women): Is Character Immutable? Case Studies From the TV Series
11:00 a.m. – 12:30 p.m.
Room B306, Level 3
Georgia World Congress Center

Chairs:
Joseph A. Cheong, M.D.
Kenneth R. Silk, M.D.

Speaker:
Steven E. Hyler, M.D.
General Robert B. Neller

General Robert B. Neller is the 37th Commandant of the United States Marine Corps. Prior to his current assignment, he served as the Commander, Marine Forces Command, from July 2014 to September 2015 and Commander, Marine Forces Central Command, from September 2012 to June 2014.

A native of East Lansing, Mich., General Neller graduated from the University of Virginia and was commissioned in 1975. He has served as an infantry officer at all levels, including command of Marine Security Force Company Panama during Operations JUST CAUSE and PROMOTE LIBERTY, 3rd Light Armored Infantry Battalion during Operation RESTORE HOPE, 6th Marine Regiment, and 3rd Marine Division.

General Neller also served as Deputy Commanding General, I Marine Expeditionary Force (Forward) during Operation IRAQI FREEDOM (05-07), Assistant Division Commander for 1st and 2nd Marine Divisions and President of Marine Corps University.

His joint assignments include service in the Policy Division of Supreme Headquarters Allied Powers Europe (SHAPE) in Casteau, Belgium, and as the Director of Operations (J-3) of the Joint Staff in Washington, D.C.

General Neller is a graduate of the Armor Officer Advanced Course, Marine Corps Command and Staff College, NATO Defense College, and the Armed Forces Staff College. He holds a master’s degree in human resource management from Pepperdine University.

### Scientific and Clinical Reports

#### Measurements and Scales

1. **A Scale of Partner Addiction: Underlying Mechanisms in Reward Deficits and Insecure Attachments and Manifestations in Clinical Issues**
   - Jacob Mills, B.S.
   - 1

2. **Self-Monitoring and Psychoeducation in Bipolar Patients With a Smartphone Application (SIMPLe) Project: Preliminary Results From a Feasibility Study**
   - Eduard Vieta, M.D., Ph.D.
   - 2

3. **The Proxy Test for Delirium (PTD): A New Tool for the Screening of Delirium Based on DSM-5 and ICD-10 Criteria**
   - Jose R. Maldonado, M.D.
   - 5

#### Workshops

**Are You a Sitting Duck Online? What You Can (and Can’t, or Shouldn’t) Do to Avoid, and to Respond to, Negative Reviews by Patients**

- 11:00 a.m. – 12:30 p.m.
- Room B215, Level 2
- Georgia World Congress Center

**The Biopsychosocial Revolution: Assessing Patients in Psychiatry Using the DSM-5 Cultural Formulation Interview**

**American Psychiatric Leadership Fellowship**

- 11:00 a.m. – 12:30 p.m.
- Room B215, Level 2
- Georgia World Congress Center

**Psychiatrists Who Have Survived the Suicide Death of a Loved One: Their Insights**

- 11:00 a.m. – 12:30 p.m.
- Room B215, Level 2
- Georgia World Congress Center

**Speakers:**

- Anna Halperin Rosen, M.D.
- Akshay Lohitsa, M.D.
- Michael Hann, M.D., M.S.
- Misty Richards, M.D., M.S.
- Nina Vasan, M.D.
- Jeremy D. Kidd, M.D., M.P.H.
- Robert Hsiung, M.D.
- Paul S. Appelbaum, M.D.
- Laura Roberts, M.D., M.A.

---

This session will be captured as part of APA Annual Meeting On Demand, subject to speaker permission. Visit the On Demand sales booth in the Education Center to learn more and purchase.
Standing Up to Violence in Police Encounters: The Players, the Victims, the Trauma and the Solutions
APA Council on Minority Mental Health and Health Disparities
4
11:00 a.m. – 12:30 p.m.
Room A304, Level 3
Georgia World Congress Center
Chairs:
Elie Aoun, M.D.
Racquel E. Reid, M.D.
Speakers:
Sandra C. Walker, M.D.
Amanda Ruiz, M.D.
Moore Jessica, M.D.
Matthew L. Dominguez, M.D., M.P.H.
Jared K. Taylor, M.D.
Lama Bazzi, M.D.

Developing and Running a Successful Research Track for Psychiatry Residents
11:00 a.m. – 12:30 p.m.
Room B310, Level 3
Georgia World Congress Center
Chair:
Katharine A. Phillips, M.D.
Speakers:
Erik Vanderlip, M.D., M.P.H.
Anna Ratzliff, M.D., Ph.D.
John Kern, M.D.

Risk Management Considerations When Prescribing Controlled Substances
3
11:00 a.m. – 12:30 p.m.
Room B311, Level 3
Georgia World Congress Center
Chair:
Kristen M. Lambert, J.D., M.S.W.
Speaker:
Moira Wertheimer, J.D., B.S.N.

Treatment in the Immediate Aftermath of Trauma: From the Hospital to the Battlefield
11:00 a.m. – 12:30 p.m.
Room B315, Level 3
Georgia World Congress Center
Chair:
Judith Cukor, Ph.D.
Speakers:
John W. Barnhill, M.D.
Judith Cukor, Ph.D.
David A. Nissan, M.D.
Amy B. Adler, Ph.D.

Feeling Burned Out? Using Science and Wisdom of Contemplative Practices to Manage Your Stress and Reduce Burnout
5
11:00 a.m. – 12:30 p.m.
Room B316, Level 3
Georgia World Congress Center
Chair:
Sermsak Lolak, M.D.
Speaker:
Sermsak Lolak, M.D.

A Year After Winning Marriage: The Impact of Obergefell v. Hodges on LGBT Mental Health
11:00 a.m. – 12:30 p.m.
Room A307, Level 3
Georgia World Congress Center
Chair:
Robert M. Kertzner, M.D.
Speakers:
Stewart L. Adelson, M.D.
Mary Barber, M.D.
Marshall Forstein, M.D.

Dynamic Therapy With Self-Destructive Borderline Patients: An Alliance-Based Intervention for Suicide
11:00 a.m. – 12:30 p.m.
Room B404, Level 4
Georgia World Congress Center
Chairs:
Eric M. Plakun, M.D.
Samar Habl, M.D.

What a Pain! How Pills, Talking and Marijuana May Help Your Patients With Chronic Pain
Academy of Psychosomatic Medicine
5
11:00 a.m. – 12:30 p.m.
Room B403, Level 4
Georgia World Congress Center
Chair:
Wendy Baer, M.D.
Speakers:
Kim Curseen, M.D.
Shweta Kapoor, Ph.D., M.B.B.S.
Ann Schwartz, M.D.
Martha C. Ward, M.D.

APA Council on Psychiatry and the Law: Update
APA Council on Psychiatry and Law
3
11:00 a.m. – 12:30 p.m.
Rooms A311-312, Level 3
Georgia World Congress Center
Chair:
Steven Hoge, M.D., M.B.A.
Speakers:
Richard J. Bonnie, J.D.
Marvin S. Swartz, M.D.

The Art of the Curbside Consultation: Nicely Done
11:00 a.m. – 12:30 p.m.
Room A313, Level 3
Georgia World Congress Center
Chair:
Lori Raney, M.D.

APA Council on Psychiatry and Law
3
11:00 a.m. – 12:30 p.m.
Rooms A311-312, Level 3
Georgia World Congress Center
Chair:
Steven Hoge, M.D., M.B.A.
Speakers:
Richard J. Bonnie, J.D.
Marvin S. Swartz, M.D.

The Court and the World
1:00 p.m. Sessions
Lecture
The Court and the World
1:00 p.m. – 2:30 p.m.
Sidney Marcus Auditorium, Level 4
Georgia World Congress Center
Lecture Chair:
Renée Binder, M.D.
Lecturer:
Stephen Breyer

This session will be captured as part of APA Annual Meeting On Demand, subject to speaker permission. Visit the On Demand sales booth in the Education Center to learn more and purchase.
Justice Stephen Breyer

Stephen Breyer, born in San Francisco in 1938, is a Justice on the Supreme Court of the United States. He is a graduate of Stanford University, Oxford University and Harvard Law School. He taught law for many years as a professor at Harvard Law School and at the Kennedy School of Government. He has also worked as a Supreme Court law clerk (for Justice Arthur Goldberg), a Justice Department lawyer (antitrust division), an Assistant Watergate Special Prosecutor, and Chief Counsel of the Senate Judiciary Committee (working closely with Senator Edward M. Kennedy to pass the Airline Deregulation Act). In 1980, he was appointed to the United States Court of Appeals for the First Circuit by President Carter, becoming Chief Judge in 1990. In 1994, he was appointed Supreme Court Justice by President Clinton. He has written books and articles about administrative law, economic regulation and constitutional law, including Regulation and Its Reform, Breaking the Vicious Circle: Toward Effective Risk Regulation, Active Liberty, Making Our Democracy Work: A Judge’s View and The Court and the World, published in 2015. His wife, Joanna, was born in Great Britain and is a retired clinical psychologist. They have three children (Chloe, Nell and Michael) and five grandchildren.

Courses

Course descriptions are available in the APA Meetings app. Admission to all courses, including master courses, is by ticket only. Course tickets can be purchased at Registration at the Marquis Fountain, Marquis Level in the Marriott Marquis, or at Registration in Exhibit Hall B3-B4, Level 1 in the Georgia World Congress Center.

Talking With Your Patients About Marijuana Use: What Every Psychiatrist Should Know

1:00 p.m. – 5:00 p.m.
International 4, International Level Marriott Marquis

Director:
Henry S. Levine, M.D.

Advanced Assessment and Treatment of ADHD

1:00 p.m. – 5:00 p.m.
International 5, International Level Marriott Marquis

Director:
Thomas Brown, Ph.D.

Faculty:
Anthony Rostain, M.D.

Motivational Interviewing for the Routine Practice of Psychiatry

1:00 p.m. – 5:00 p.m.
M103-105, Marquis Level Marriott Marquis

Director:
Steven Cole, M.D., M.A.

How to Give More Effective Lectures: Punch, Passion and Polish

1:00 p.m. – 5:00 p.m.
International 7, International Level Marriott Marquis

Director:
Phillip J. Resnick, M.D.

1:30 p.m. Sessions

Scientific and Clinical Reports

Marijuana and Opiates

1:30 p.m. – 3:00 p.m.
Room B405, Level 4
Georgia World Congress Center

1. Reasons for Relapse and Natural Quitting in Adult Recreational Cannabis Smokers

David Gorelick, M.D., Ph.D.

SESSION TRACKS

1. Addiction Psychiatry
2. Child and Adolescent Psychiatry
3. Forensic Psychiatry
4. Geriatric Psychiatry
5. Psychosomatic Psychiatry
6. NIDA
7. Residents, Fellows and Medical Students

APA Annual Meeting on Demand
Bring Your Own Device

All scientific sessions listed in the Program are designated for AMA PRA Category 1 Credits™, except for Poster Sessions.
Workshops

Assisted Outpatient Treatment for Individuals With Mental Illness Referred by Correctional Services: Synergy or Redundancy?
1:30 p.m. – 3:00 p.m.
Room B404, Level 4
Georgia World Congress Center
Chair:
Scott Soloway, M.D.
Speakers:
Jennifer Correale, J.D., Esq.
Carolyn D’Aquila, L.C.S.W., M.P.H.
Patricia Schwartz, M.D.

Social Withdrawal in Modern Society: An Emerging Cultural Concept of Distress in East Asia
1:30 p.m. – 3:00 p.m.
Room B215, Level 2
Georgia World Congress Center
Chairs:
Takahiro A. Kato, M.D., Ph.D.
Alan R. Teo, M.D., M.S.
Speakers:
Takahiro A. Kato, M.D., Ph.D.
Alan R. Teo, M.D., M.S.
Francis Lu, M.D.
Shigenobu Kanba, M.D., Ph.D.

The Management of Acute Agitation on Medical Units and in the Intensive Care Unit
1:30 p.m. – 3:00 p.m.
Room A303, Level 3
Georgia World Congress Center
Chair:
Michael S. Peroski, D.O.
Speakers:
Eileen K. R. Breen, M.D.
Anique Forrester, M.D.
Bhinnia Pearl Park, M.D.

The APA: An NGO of The United Nations
APA Council on International Psychiatry
1:30 p.m. – 3:00 p.m.
Room A304, Level 3
Georgia World Congress Center
Chair:
Vivian Pender, M.D.
Speaker:
Andriy Yur’yev, M.D., Ph.D.

Promoting Overall Wellness and Eliminating Risk of Burnout in Trainees (POWER BIT)
1:30 p.m. – 3:00 p.m.
Room B306, Level 3
Georgia World Congress Center
Chairs:
Deepak Prabhakar, M.D., M.P.H.
Cindy Devassy, M.D.
Speaker:
Theresa Toledo

Writing a Scholarly Article: The American Journal of Psychiatry Residents’ Journal Workshop
1:30 p.m. – 3:00 p.m.
Room B310, Level 3
Georgia World Congress Center
Chairs:
Rajiv Radhakrishnan, M.D., M.B.B.S.
Robert Freedman, M.D.
Speakers:
Hun Millard, M.D.
Katherine Pier, M.D.

New Directions in CBT for Psychosis (CBTp): CBTp in Busy Clinics Using a Guided Self-Help Approach
1:30 p.m. – 3:00 p.m.
Room B311, Level 3
Georgia World Congress Center
Chair:
Farooq Naeem, Ph.D., M.Sc.

Transformation in New York State: Will Town and Gown Really Partner?
The DSRIP Experience of the Behavioral Health Team at NYPH
1:30 p.m. – 3:00 p.m.
Room B315, Level 3
Georgia World Congress Center
Chair:
Dianna Dragatsi, M.D.
Speakers:
Mary Hanrahan, L.C.S.W.
Daniel L. Lowy, L.C.S.W.

The Civilian Soldiers: Expanding Our Approach to Mental Health for Our One Million Military Reservists and Guardsmen
1:30 p.m. – 3:00 p.m.
Room B403, Level 4
Georgia World Congress Center
Chair:
Philip Michael Yam, M.D.
Speakers:
Hoa Le, D.O.
Rita R. Richardson, M.D.
Christine A. Winter, D.O., M.B.A.
Vincent F. Capaldi II, M.D., M.Sc.

Twists in the Double Helix: Ethical Challenges in Genetic Testing in Psychiatry
APA Ethics Committee and Pennsylvania Scattergood Ethics Program
1:30 p.m. – 3:00 p.m.
Room B404, Level 4
Georgia World Congress Center
Chair:
Michael S. Peroski, D.O.
Speakers:
Ellen K. R. Breen, M.D.
Anique Forrester, M.D.
Bhinna Pearl Park, M.D.

Generating Medical Marijuana Guidelines at Your Institution
Ilana M. Braun, M.D.
5

Long-Term Outcomes From the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study
Roger D. Weiss, M.D.
5

Social Withdrawal in Modern Society: An Emerging Cultural Concept of Distress in East Asia
2

Addiction Psychiatry

Child and Adolescent Psychiatry

Forensic Psychiatry

Geriatric Psychiatry

Psychosomatic Psychiatry

NIDA

Residents, Fellows and Medical Students

APA Annual Meeting on Demand

Bring Your Own Device
Chair: Paul S. Appelbaum, M.D.
Speaker: Maya Sabatello, Ph.D., LL.B.

2:00 p.m. Sessions
Poster Session

New Research Poster 2
2:00 p.m. – 4:00 p.m.
Exhibit Hall B3-B4, Level 1
Georgia World Congress Center

Advances in Series

Gun Violence and Mental Health
American Psychiatric Association
Publishing Editorial Board

2:00 p.m. – 5:00 p.m.
Room A305, Level 3
Georgia World Congress Center
Chair: Liza H. Gold, M.D.
1. Suicide and Firearms
   Liza H. Gold, M.D.
2. NICS, Mental Illness and Firearms Legislation: What You Should Know
   Marilyn Price, M.D.
3. When Firearms Affect Children: Clinical and Forensic Evaluation
   Cheryl Wills, M.D.
4. Mass Shootings: Mass Distractions and Sociocultural Factors
   James L. Knoll IV, M.D.
5. Firearm Risk Prevention: Considering Legal and Clinical Reforms
   Debra Pinals, M.D.

Presidential Symposia

Psychosomatic Medicine: Offering a Multifaceted Approach to Clinical, Educational and Research Challenges Impacting Patient Care
Academy of Psychosomatic Medicine

2:00 p.m. – 5:00 p.m.
Rooms B216-217, Level 2
Georgia World Congress Center

Chair: Catherine Crone, M.D.
1. An Update on Conversion Disorder
   Steve E. Epstein, M.D.
2. ASQ: Pediatric Suicide Risk Screening in Medical Settings
   Maryland Pao, M.D.
3. Proactive Consultation-Liaison Psychiatric Services: A New Model for Delivery of Psychiatric Service for Hospitalized Medico-Surgical Patients
   Hochang B. Lee, M.D.
4. Training for Complexity: Psychosomatic Medicine as the Model for the 21st Century
   Sanjeev Sockalingam, M.D.
5. Collaborative Care: Evolving Models of Care
   Thomas N. Wise, M.D.

Back to the Future: Integrating Primary Care and Behavioral Health 2020

2:00 p.m. – 5:00 p.m.
Room B313, Level 3
Georgia World Congress Center
Chair: Lori Raney, M.D.
Discussant: Paul Summergrad, M.D.
1. Collaborative Care in the Year 2020
   Jürgen Unützer, M.D., M.P.H.
2. Financial and Administrative Models of Care Integration: Transitioning to Successful and Sustainable Care Delivery Support
   Roger Kathol, M.D.
3. Improving Health and Health Care for Patients With Serious Mental Illnesses in a Postintegration Era
   Benjamin G. Druss, M.D.
4. Integration at the State Level: A Payer Perspective
   Joseph Parks, M.D.

Symposia

Understanding Borderline Personality Disorder: 35 Years of Progress Through Empirical Research: Part 2

2:00 p.m. – 5:00 p.m.
Room B309, Level 3
Georgia World Congress Center
Chairs: Kenneth R. Silk, M.D.
Perry Hoffman, Ph.D.
Discussant: Mary C. Zanarini, Ed.D.
1. Family Interventions for Borderline Personality Disorder (BPD) in the Age of EBTs
   Lois W. Choi-Kain, M.D., M.Ed.
2. How Neurobiology Can Help to Improve Psychotherapy for Borderline Personality Disorder (BPD)
   Christian Schmahl, M.D.
3. Pharmacologic Treatment in Borderline Personality Disorder (BPD)
   Kenneth R. Silk, M.D.
4. Dimensional Versus Categorical Diagnosis of Borderline Personality Disorder (BPD)
   Christian Schmahl, M.D.
5. Future Direction of Research and Clinical Approaches to Borderline Personality Disorder (BPD)
   Otto F. Kernberg, M.D.

Program changes are printed each day in the APA Daily, which is available at locations throughout the Georgia World Congress Center. Up to date program listings are also available and searchable in the APA Meetings app.
Teen and Young Adult Misuse and Abuse of Prescription Drugs: Pathways to Drug Addiction?
National Institute on Drug Abuse

2:00 p.m. – 5:00 p.m.
Room B312, Level 3
Georgia World Congress Center

Chairs:
Cheryl A. Boyce, Ph.D.
Timothy Wilens, M.D.

Discussant:
Carol J. Boyd, Ph.D., R.N.

1. Adolescent Athletes: Exercise, Performance and Prescription Drug Abuse of Opioids
   Philip Velliz, Ph.D.

2. Trends and Trajectories of Prescription Drug Misuse Among U.S. Adolescents
   Sean Esteban McCabe, Ph.D.

3. Characteristics of College Students Who Misuse Stimulant Medications
   Timothy Wilens, M.D.

4. Three RCTs Evaluating Universal Preventive Interventions: Longitudinal Effects on Prescription Drug Misuse and Cost-Effectiveness
   Richard Spoth, Ph.D.

Physician Suicide: Toward Prevention

2:00 p.m. – 5:00 p.m.
Rooms A402-403, Level 4
Georgia World Congress Center

Chair:
Michael F. Myers, M.D.

1. Why Do Physicians Kill Themselves?
   Michael F. Myers, M.D.

2. Suicide in Medical Students: Interventions and Culture Change
   Christine Moutier, M.D.

3. Suicide in Residents and Fellows: ACGME Initiatives and Recommendations
   Matthew L. Goldman, M.D., M.S.,
   Ravi N. Shah, M.D., M.B.A.,
   Carol A. Bernstein, M.D.

4. Critical Issues in the Treatment of Suicidal Physicians
   Glen O. Gabbard, M.D.

5. Saving Lives: One Medical Center’s Response to a Faculty Member’s Suicide
   Sidney Zisook, M.D.

Innovative Practices in College Mental Health

2:00 p.m. – 5:00 p.m.
Rooms A404-405, Level 4
Georgia World Congress Center

Chair:
Michelle B. Riba, M.D.
Daniel Kirsch, M.D.

Discussant:
Victor Schwartz, M.D.

1. Clinical Illustrations of Management Issues in College Mental Health
   Richard Balon, M.D.

2. Developing and Implementing Wellness Programs for Medical Students
   Preston Wiles, M.D.

3. Improving Collaborative Depression Care in College Health: The National College Depression Partnership
   Carlo Ciotoli, M.D.

4. Innovations in Service Provision for International Students
   Leigh White, M.D.

5. A Curriculum for College Mental Health and Young Adult Psychiatry
   Daniel Kirsch, M.D.

Queerly Invisible: LGBTQ People of Color as Psychiatrists and Patients
APA/SAMHSA Minority Fellows

2:00 p.m. – 5:00 p.m.
Rooms A406-407, Level 4
Georgia World Congress Center

Chairs:
Vivek Datta, M.D., M.P.H.
Dinesh Bhugra

Discussants:
Debbie R. Carter, M.D.
Dinesh Bhugra

1. Multiple Minorities as Multiply Marginalized: Applying the Minority Stress Theory to LGBTQ People of Color
   Kali Cyrus, M.D., M.P.H.

2. Traumatic Identities: A Trauma-Based Approach to the Mental Health Treatment of LGBTQ People of Color
   Rashad Hardaway, M.D., James Murphy, M.D.

3. Understand the Challenge of LGBTQ Adolescents of Color
   Matthew L. Dominguez, M.D., M.P.H.

4. Gray, Gay, Black and Blue: Depression in Older LGBTQ People of Color
   Seon Kum, M.D.

Psychiatrists as Leaders: The Importance of Leadership Development in a New Era of Health Care

2:00 p.m. – 5:00 p.m.
Room B314, Level 3
Georgia World Congress Center

Chair:
William D. Rumbaugh Jr., M.D.

1. Leadership as a Behavioral Science and Clinical Competency: From Odysseus to the Present
   Matthew Mooney, M.S.

2. Managing Behavioral Health Providers: The Nuances of Leading This Unique Population
   Wendi Waits, M.D.

3. Building Teams and Morale by Bringing Fun Into the Workplace
   Ashley H. Chatigny, D.O.

1. SESSION TRACKS

   1. Addiction Psychiatry
   2. Child and Adolescent Psychiatry
   3. Forensic Psychiatry
   4. Geriatric Psychiatry
   5. Psychosomatic Psychiatry
   6. NIDA
   7. Residents, Fellows and Medical Students
   8. APA Annual Meeting on Demand

   Bring Your Own Device
3:30 p.m. Sessions

Lecture

Personal Transformations Through an Encounter With Death: A Study of Akira Kurosawa’s “Ikiru”

APA Distinguished Psychiatrist Lecture Series

3:30 p.m. – 5:00 p.m.
Rooms A411-412, Level 4
Georgia World Congress Center

Lecture Chair:
Robert M. McCarron, D.O.

Lecturer:
Francis Lu, M.D.

Scientific and Clinical Reports

Further Topics in Schizophrenia

3:30 p.m. – 5:00 p.m.
Room B405, Level 4
Georgia World Congress Center

1. Fluctuation in Cognitive Functioning in Community-Dwelling Older Adults With Schizophrenia: Implications for Treatment
   Carl I. Cohen, M.D.

2. Multiple Retinal Pathologies in Schizophrenia
   Selin Acar, B.S.

3. The Missing Link: Role of Human Endogenous Retroviruses in Schizophrenia
   Awais Aftab, M.B.B.S.

Workshops

Burnout in Resident Physicians: What Can We Do?

7

3:30 p.m. – 5:00 p.m.
Room B215, Level 2
Georgia World Congress Center

Chair:
Mahgul Malik, M.D.

Speaker:
Michal Sapieha, M.D.

Sex Ed: A Psychiatric Primer on Managing Patients’ Sexual Behaviors

3

3:30 p.m. – 5:00 p.m.
Room A303, Level 3
Georgia World Congress Center

Chair:
Abhishek Jain, M.D.

Speakers:
Renee Sorrentino, M.D.
Ryan Hall, M.D.
Susan Joy Hatters-Friedman, M.D.

In Harm’s Way: Job Stress and Mental Health in the Military

3:30 p.m. – 5:00 p.m.
Room A304, Level 3
Georgia World Congress Center

Chair:
Steven E. Pflanz, M.D.

Speaker:
Steven E. Pflanz, M.D.

Getting Back to Work: Guidance for Clinicians From an Employer Perspective

APAF Partnership Advisory Council

3:30 p.m. – 5:00 p.m.
Room B310, Level 3
Georgia World Congress Center

Chairs:
Paul Pendler, Psy.D.
R. Scott Benson, M.D.

Updates in HIV Psychiatry 2016

2:00 p.m. – 5:00 p.m.
Room B407, Level 4
Georgia World Congress Center

Chair:
Lawrence McGlynn, M.D., M.S.

Discussant:
Marshall Forstein, M.D.

1. Depression in Persons With HIV
   Jordi Blanch

2. Prescribed Stimulants in HIV: Indications, Safety and Controversies
   Lawrence McGlynn, M.D., M.S.

3. Tobacco and HIV: An Urgent Need to Take Action
   Antoine Douaihy, M.D.

4. Compassionate Care of Transgender People Living With HIV
   Yavar Moghimi, M.D.

This session will be captured as part of APA Annual Meeting On Demand, subject to speaker permission. Visit the On Demand sales booth in the Education Center to learn more and purchase.
Designer Drugs, Legal Highs: Is It Really Plant Food and Bathing Salts?
1
3:30 p.m. – 5:00 p.m.
Room B311, Level 3
Georgia World Congress Center
Chair:
Roger Duda, M.D.
Speaker:
Tyler E. Stratton, M.D.

Smartphones, Sensors and Mobile Mental Health: Regulations, Research and Real Life
3:30 p.m. – 5:00 p.m.
Room B315, Level 3
Georgia World Congress Center
Chair:
John Torous, M.D.
Speakers:
Gregory G. Harris, M.D., M.P.H.
John Torous, M.D.
Jung W. Kim, M.D.
Shih Yee-Marie Tan Gipson, M.D.

Women at War: Medical and Psychological Challenges for U.S. Female Service Members
3:30 p.m. – 5:00 p.m.
Room B316, Level 3
Georgia World Congress Center
Chair:
Elspeth C. Ritchie, M.D., M.P.H.
Paulette Cazares, M.D., M.P.H.
Speaker:
Tyler E. Stratton, M.D.

Responding to the Impact of Suicide on Clinicians
3:30 p.m. – 5:00 p.m.
Room B404, Level 4
Georgia World Congress Center
Chair:
Eric M. Plakun, M.D.
Speaker:
Jane G. Tillman, Ph.D.

Ethical Dilemmas in Psychiatric Practice
3:30 p.m. – 5:00 p.m.
Room A313, Level 3
Georgia World Congress Center
 Chairs:
Ezra Griffith, M.D.
Richard K. Harding, M.D.

5:15 p.m. Session
MindGames
5:15 p.m. – 6:15 p.m.
Room B206, Level 2
Georgia World Congress Center
American Psychiatric Association Publishing

Visit the APA Bookstore in the Exhibit Hall
May 14–17, 2016

Bookstore Hours
Saturday 9:00 am – 4:00 pm
Sunday 10:00 am – 4:00 pm
Monday 10:00 am – 4:00 pm
Tuesday 10:00 am – 4:00 pm

Special Discounts!
20% for APA Members
25% for APA Resident-Fellow Members
15% for Non-Members

Order Online: www.appi.org
Phone: 703-907-7322  •  Toll Free: 1-800-368-5777
Email: appi@psych.org
Your one-stop resource for information on diagnosis, treatment, guidelines, the latest research, and breaking news from the field.

Visit the APA Bookstore for a demo!

Subscribe to products individually or to the DSM Select package that includes the DSM-5® library, books and select journals.

Go to www.appi.org to subscribe, or visit the APA Bookstore in the Exhibit Hall.
### 9:00 a.m. Sessions

#### Interactive Session

**The Making of a Forensic Psychiatrist: Personal Reflections**
9:00 a.m. – 10:30 a.m.
Room B408, Level 4
Georgia World Congress Center

Chair: Phillip J. Resnick, M.D.

---

**Lecture**

**VHA’s Plan to Transform Veterans’ Access to Community Care**
9:00 a.m. – 10:30 a.m.
Rooms B216-217, Level 2
Georgia World Congress Center

Lecturer: Baligh R. Yehia

---

**Scientific and Clinical Reports**

**PTSD and Stress**

9:00 a.m. – 10:30 a.m.
Room B405, Level 4
Georgia World Congress Center

1. Neural Alterations in Recalling the Past and Imagining the Future in PTSD
   Adam Brown, Ph.D.

2. Pharmacological Treatment of Combat Nightmares: A Veteran's Hospital Experience
   Mark Budd Detweiler, M.D., M.S.

3. Stress Across the Life Course and Depression in a Rapidly Developing Population: The Guangzhou Biobank Cohort Study
   Michael Ni, M.B. B.S., M.P.H.

4. Pharmacological Treatment of Combat Nightmares: A Veteran's Hospital Experience
   Mark Budd Detweiler, M.D., M.S.

---

**Workshops**

**The Interface of Ethics and Psychiatry: A Collaborative Consultation Approach**
APA Ethics Committee and Penn-Scattergood Ethics Program
9:00 a.m. – 10:30 a.m.
Room B218, Level 2
Georgia World Congress Center

Chair: Nancy N. Potter, Ph.D.
Speaker: Rif S. El-Mallakh, M.D.

**Slidecraft: How to Fashion Your Slide Presentation, Captivate and Resonate With Your Audience**
9:00 a.m. – 10:30 a.m.
Room B306, Level 3
Georgia World Congress Center

Chairs: Sunil Khushalani, M.D.
Mark Komrad, M.D.

**Speaking for One’s Self: Psychiatric Advanced Directives**
9:00 a.m. – 10:30 a.m.
Room B310, Level 3
Georgia World Congress Center

Chairs: Nubia G. Lluberes Rincon, M.D.
Abhishek Jain, M.D.

Speaker: John S. Rozel, M.D.

---

**Combat-Related PTSD, Homicide and Attempted Suicide-by-Cop**

9:00 a.m. – 10:30 a.m.
Room B311, Level 3
Georgia World Congress Center

Chairs: Elspeth C. Ritchie, M.D., M.P.H.
Keith A. Caruso, M.D.

Speakers: Elspeth C. Ritchie, M.D., M.P.H.
Keith A. Caruso, M.D.
Kevin D. Moore, M.D.

---

**College Mental Health Practice: Adjusting for Seasonality, Setting and Scope of Services**
APA College Mental Health Caucus
9:00 a.m. – 10:30 a.m.
Room B315, Level 3
Georgia World Congress Center

Chair: Marshall L. Garrick, M.D.
Speaker: Amy Poon, M.D.

**Build a Skill: Interactive Screening, Brief Intervention and Referral to Treatment (SBIRT) Training to Enhance Clinical Practice**
9:00 a.m. – 10:30 a.m.
Room B316, Level 3
Georgia World Congress Center

Chair: Shilpa Srinivasan, M.D.

Speakers: Suzanne M. Hardeman, N.P.
Matt Orr, Ph.D.
Shilpa Srinivasan, M.D.

---

**SESSION TRACKS**

1. Addiction Psychiatry
2. Child and Adolescent Psychiatry
3. Forensic Psychiatry
4. Geriatric Psychiatry
5. Psychosomatic Psychiatry
6. NIDA
7. Residents, Fellows and Medical Students
   - APA Annual Meeting on Demand
   - Bring Your Own Device

---

Program changes are printed each day in the APA Daily, which is available at locations throughout the Georgia World Congress Center. Up to date program listings are also available and searchable in the APA Meetings app.
Explorations of Medical Students’ Choice of Psychiatry as a Career
9:00 a.m. – 10:30 a.m.
Room B403, Level 4
Georgia World Congress Center
Chair:
Leonard M. Gralnik, M.D., Ph.D.
Mitchell J. Cohen, M.D.
Speakers:
Matthew N. Goldenberg, M.D., M.Sc.
Sergio Hernandez, M.D.
Peter J. Holland, M.D.
John Spollen, M.D.
Thomas L. Schwartz, M.D.

Media Workshop

The Art of Storytelling
9:00 a.m. – Noon
Room B402, Level 4
Georgia World Congress Center
Chair:
Michelle Furuta, M.D.
Speakers:
Linda Do, D.O.
Arsalan Malik, M.D.
Steve Soldinger, M.D.
Mindi Thelen
Tim Thelen

Symposia

Consequences of Polypharmacy in Patients With Traumatic Brain Injury and Comorbid Psychological Health Conditions
9:00 a.m. – Noon
Room B308, Level 3
Georgia World Congress Center
Chair:
Geoffrey Grammer, M.D.
Discussant:
Linda Fuller, D.O.
1. Case Report of a Service Member With Severe Postconcussive Syndrome and Polypharmacy and Their Recovery Facilitated by Creative Art Therapy
   Melissa Walker, M.A.
2. Polypharmacy Patterns in Active Duty Service Members With Traumatic Brain Injury and Comorbid Psychological Health Conditions
   Thomas J. DeGraba, M.D.
   Jonathan P. Wolf, M.D.
4. Severe Medication Interactions Associated With Increased Morbidity in Service Members With Mild Traumatic Brain Injury and Comorbid Psychological Health Conditions
   Christopher Flinton, M.D.

“High Tech” Solutions to Improving Interprofessional Communication and Patient Care in Integrated Psychosomatic Medicine Programs
9:00 a.m. – Noon
Room B309, Level 3
Georgia World Congress Center
Chair:
Sanjeev Sockalingam, M.D.
Discussant:
Susan Abbey, M.D.
1. Supporting HIV-Positive Women in Ways That Work
   Adriana Carvalhal, M.D., Ph.D.
2. Experiencing the Unexpected: A Mixed Methods Study of Clinician Experiences Using a Novel Advanced Clinical Documentation iPad Tool in a Consultation-Liaison Psychiatry Setting
   Kathleen Sheehan, M.D., Ph.D.
3. “There’s an App for That”: Using Mental Health Smartphone Applications in Integrated Care Settings
   Raed Hawa, M.D.
4. An Integrated Telephone-Based CBT Intervention After Bariatric Surgery: A Model for Increasing Access
   Sanjeev Sockalingam, M.D.

Learning Lab

Collaborative Care Lab: Experience the Newest Way to Practice
APA Council on Psychosomatic Medicine
9:00 a.m. – Noon
Rooms B211-212, Level 2
Georgia World Congress Center
Chairs:
Erik Vanderlip, M.D., M.P.H.
Lori Raney, M.D.
Speakers:
Anna Ratzliff, M.D., Ph.D.
Lydia Chwastiak, M.D., M.P.H.

Addressing the Commercial Sexual Exploitation of Children
APA Council on Children, Adolescents and Their Families
9:00 a.m. – 10:30 a.m.
Room B404, Level 4
Georgia World Congress Center
Chair:
Shama Patel, M.D.
Speakers:
Eraka Bath, M.D., LL.B.
Yolanda P. Graham, M.D.
Jordan Greenbaum, M.D.

The Evolving Picture of ADHD
9:00 a.m. – Noon
Room B312, Level 3
Georgia World Congress Center
Chair:
Niall Boyce, Ph.D., M.B.
1. Clinical Care Pathways for ADHD
   David Coghill, M.D.
2. The Genetic and Neural Basis of ADHD
   Jonathan Posner, M.D.
3. ADHD as a Lifespan Disorder
   Philip Asherson, Ph.D., M.B.B.S.
Building Capacity for Psychiatric Care and Research in Nigeria: Challenges and Opportunities for International Collaboration

9:00 a.m. – Noon
Room B314, Level 3
Georgia World Congress Center

Chairs:
Theodore Iheanacho, M.D.
Charles C. Dike, M.D.

Discussant:
Shoyinka O. Sosunmolu, M.D.

1. Building Capacity for and Conducting Biomedical Research in Nigeria: Lessons Learned and Prospects
   Ikwunogu Wonodi, M.B.B.S.

2. Child Mental Health Care and Training in Child and Adolescent Psychiatry in Nigeria: Opportunities and Prospects
   Patricia Ibeziako, M.D.

3. The Role of Health Services Research in Improving Access to Mental Health Care in Nigeria
   Robert Rosenheck, M.D.

4. Mental Health in Nigeria: Suffering in the Midst of Plenty
   Theodore Iheanacho, M.D.

5. Psychiatry and the Law in Nigeria: Challenges and Prospects
   Charles C. Dike, M.D.

Ethical Challenges at the Interface Between Psychiatry and Religion/ Spirituality

APA Caucus on Religion, Spirituality and Psychiatry

9:00 a.m. – Noon
Room B401, Level 4
Georgia World Congress Center

Chair:
John Peteet, M.D.

1. Addressing Ethical Issues of Psychiatrists Who Respond to Emergencies and Disasters
   Samuel Thielman, M.D., Ph.D.

2. Ethical Challenges at the Interface Between Psychiatry and Religion/Spirituality: Diagnostic Considerations
   Allan Josephson, M.D.

3. Ethical Challenges of the Interface Between Psychiatry and Religion/Spirituality: Community and International Psychiatry
   Walid Sarhan, M.D.

4. Ethical Considerations Regarding Religion/Spirituality in Psychiatric Research
   Alexander Moreira-Almeida, M.D., Ph.D.

5. Religious/Spiritual Needs in Treatment
   Len Sperry, M.D.

What Is the Emotional Pain of Suicide?

9:00 a.m. – Noon
Room B406, Level 4
Georgia World Congress Center

Chair:
Igor Galynker, M.D., Ph.D.

1. The Measurement of Psychological Pain and Suicide Risk
   Gregory K. Brown, Ph.D.

2. Anxiety Severity as an Acute Risk Factor for Suicide
   Jan Fawcett, M.D.

3. Reward- and Threat-Processing Contributions to Suicidality
   Zimri S. Yaseen, M.D.

4. Negative Emotions Predictive of Near-Term Suicidal Behavior
   Igor Galynker, M.D., Ph.D.

Cross-Cultural Psychiatry

11:00 a.m. – 12:30 p.m.
Room B405, Level 4
Georgia World Congress Center

1. Evidence-Based Psychiatric Rehabilitation Practices: Illness Management and Recovery, Psychoeducation, and Case Management in Karachi, Pakistan
   Ajmal Kazmi, M.D., D.P.M.

2. A Comparison of Stigma in Dementia and Diabetes Among Chinese Americans
   Benjamin Woo, M.D.

Workshops

Creating a Leadership Development Program to Prepare Your Department/Organization to Successfully Navigate Turnover of Key Leadership Positions

11:00 a.m. – 12:30 p.m.
Room B310, Level 3
Georgia World Congress Center

Chair:
Kari M. Wolf, M.D.

Speaker:
Jane Ripperger-Suhler, M.D., M.A.

VitalSign6: Partnering With Primary Care Providers in Using Innovative Software to Implement Universal Depression Screening and Measurement-Based Care

11:00 a.m. – 12:30 p.m.
Room B315, Level 3
Georgia World Congress Center

Chairs:
Manish K. Jha, M.B.B.S.
Madhukar Trivedi, M.D.

Speakers:
Madhukar Trivedi, M.D.
Manish K. Jha, M.B.B.S.
Katherine Sanchez, Ph.D., L.C.S.W.
Tracy Greer, Ph.D.
The Transcultural Competent Psychiatrist: Characteristics, Challenges and Abilities
11:00 a.m. – 12:30 p.m.
Room B316, Level 3
Georgia World Congress Center
Chair:
Hamid Peseschkian, M.D., D.M.Sc.
Speakers:
Hamid Peseschkian, M.D., D.M.Sc.
Afrim A. Blyta, M.D.
Jusuf S. Ulaj, M.D.

LGBT in the Military
11:00 a.m. – 12:30 p.m.
Room B403, Level 4
Georgia World Congress Center
Chairs:
Christopher H. Warner, M.D.
Cari Castro, Ph.D.
Speakers:
Jeremy Goldbach, Ph.D.
Ian W. Holloway, Ph.D., M.P.H.

Psychology Prescription Privileges: The Illinois Experience
11:00 a.m. – 12:30 p.m.
Room B404, Level 4
Georgia World Congress Center
Chair:
Daniel Yohanna, M.D.
Speakers:
Peter Fore, M.D.
Linda F. Gruenberg, D.O.
Sidney Weissman, M.D.
James G. MacKenzie, D.O.

1:30 p.m. Sessions
Scientific and Clinical Reports

Mental State Disorders
1:30 p.m. – 3:00 p.m.
Room B405, Level 4
Georgia World Congress Center
1. Anxiety Disorders Co-Occurring With Binge Eating Disorder: Sequence and Associations With Other Comorbidities and With Eating Disorder Psychopathology
   Daniel F. Becker, M.D.
2. Does Negative Emotional Temperament Link Both PUFA Concentrations and Childhood Adversity to Persistent Depressive Symptoms?
   William Coryell, M.D.
3. Postpartum Depression, Maternal Acceptance-Rejection and Child Behavioral Problems in Early Childhood
   Miriam Schiff, Ph.D.

Workshops

Working With African Immigrant Adolescents and Young Adults: From the Experts
1:30 p.m. – 3:00 p.m.
Room B306, Level 3
Georgia World Congress Center
Chairs:
Tolu Olupona, M.D.
Evaristo Akerele, M.D.

What We’ve Learned From Genetic Obesity Syndromes: Are Overweight/Obesity, Anorexia Nervosa, Bulimia Nervosa and Binge Eating Disorder So Dissimilar?
1:30 p.m. – 3:00 p.m.
Room B310, Level 3
Georgia World Congress Center
Chair:
Elias Khawam, M.D.
Speakers:
Syma Dar, M.D.
Margo Funk, M.D., M.A.
Karen E. Salerno, M.S.W.
Lara W. Feldman, D.O.
Christopher Sola, D.O.

Serving the Household and the Homeless: Behavioral Health-Primary Care Integration in Two Health Care Models Focused on Social Determinants of Health
1:30 p.m. – 3:00 p.m.
Room B311, Level 3
Georgia World Congress Center
Chair:
Eduardo Camps-Romero, M.D.
Speakers:
Frederick Anderson, M.D.
Mohammad Asim Nisar, M.D.
Carissa Caban-Aleman, M.D.

Transformation of Mental Health Care for U.S. Soldiers and Families During the Iraq and Afghanistan Wars: Where Science and Politics Intersect
1:30 p.m. – 3:00 p.m.
Room B315, Level 3
Georgia World Congress Center
Chair:
Christopher H. Warner, M.D.
Speakers:
Millard Brown, M.D.
Christopher Ivany, M.D.
Charles Hoge, M.D.

Foreign Body Ingestors: Management Challenges for Consultation Liaison Psychiatrists
1:30 p.m. – 3:00 p.m.
Room B403, Level 4
Georgia World Congress Center
Chair:
Elias Khawam, M.D.
Speakers:
Syma Dar, M.D.
Margo Funk, M.D., M.A.
Karen E. Salerno, M.S.W.
Lara W. Feldman, D.O.
Christopher Sola, D.O.

This session will be captured as part of APA Annual Meeting On Demand, subject to speaker permission. Visit the On Demand sales booth in the Education Center to learn more and purchase.
2:00 p.m. Sessions

Symposia

Health Policy and Social Justice: The Role of Psychiatry in Promoting Integrated Health Care

1. Innovative Academic-Community Partnerships to Address Special-Population Mental Health Needs
   Laura Roberts, M.D., M.A.

2. The Critical Role of Public Education in Patient-Centered Collaborative Care
   Eugene V. Beresin, M.D., M.A.

3. The Role of Psychiatry in Advancing Integrated Care for Underserved and Rural Populations
   Howard J. Osofsky, M.D., Ph.D.

Your Patient at Work: Privacy, Peril and Public Safety

1. Persons With Mental Illness at Work: Are They More Violent?
   Jessica Ferranti, M.D.

2. Fundamental Foundation of Risk Assessment
   Jason Roof, M.D.

3. How to Handle At-Risk Scenarios
   Charles Scott, M.D.

Online Psychotherapy: A New Method of Delivering Therapy

1. CBT by Email for Children and Adolescents With Anxiety/Depression
   Sarosh Khalid-Khan, M.D.

2. CBT by Email in Patients With Depression and/or Anxiety
   Nazanin Alavi, M.D.

3. Dialectical Behavior Therapy (DBT)? There Is an App for That!
   Margo Rivera

Scientific and Clinical Reports

The Broad Interest of Psychiatry

1. Undocumented Immigrants in Psychiatric Wards: A Case Report and Concise Review
   Mike Wei, B.S.

2. Normalization of Increased Background Noise After Treatment in ADHD: A Neuronal Correlate
   Emanuel Bubl, M.D.

3. Motivational Interviewing Education and Psychiatry Residents’ Attitude Toward Addiction Training and Treatment
   Manish K. Jha, M.B.B.S.

Workshops

Don’t Tell Me to Calm Down! Identifying Triggers and Nonpharmacological Management of Child and Adolescent Patients at Risk for Agitation

1. Persons With Mental Illness at Work: Are They More Violent?
   Jessica Ferranti, M.D.

2. Fundamental Foundation of Risk Assessment
   Jason Roof, M.D.

3. How to Handle At-Risk Scenarios
   Charles Scott, M.D.

Accelerated Resolution Therapy: A “Magic Bullet” for PTSD?

1. CBT by Email for Children and Adolescents With Anxiety/Depression
   Sarosh Khalid-Khan, M.D.

2. CBT by Email in Patients With Depression and/or Anxiety
   Nazanin Alavi, M.D.

3. Dialectical Behavior Therapy (DBT)? There Is an App for That!
   Margo Rivera

Research Literacy in Psychiatry: How to Critically Appraise the Scientific Literature

1. Undocumented Immigrants in Psychiatric Wards: A Case Report and Concise Review
   Mike Wei, B.S.

2. Normalization of Increased Background Noise After Treatment in ADHD: A Neuronal Correlate
   Emanuel Bubl, M.D.

3. Motivational Interviewing Education and Psychiatry Residents’ Attitude Toward Addiction Training and Treatment
   Manish K. Jha, M.B.B.S.
This new edition of *Diagnostic and Statistical Manual of Mental Disorders* (DSM-5®), used by clinicians and researchers to diagnose and classify mental disorders, is the product of more than 10 years of effort by hundreds of international experts in all aspects of mental health. Their dedication and hard work have yielded an authoritative volume that defines and classifies mental disorders in order to improve diagnosis, treatment, and research.

The criteria are concise and explicit, intended to facilitate an objective assessment of symptom presentations in a variety of clinical settings—inpatient, outpatient, partial hospital, consultation-liaison, clinical, private practice, and primary care.

- The latest findings in neuroimaging and genetics have been integrated into each disorder along with gender and cultural considerations.
- The revised organizational structure recognizes symptoms that span multiple diagnostic categories, providing new clinical insights in diagnosis.

Both ICD-9-CM and ICD-10-CM codes are included for each disorder.

The *Diagnostic and Statistical Manual of Mental Disorders*, Fifth Edition, is the most comprehensive, current, and critical resource for clinical practice available to today’s mental health professionals.
Focus
The Journal of Lifelong Learning in Psychiatry

Visit Focus Booth #1528 or the APA Bookstore to subscribe!

The Best Resource for
Guidance for Clinical Practice • Lifelong Learning
Maintenance of Certification • Self-Assessment

In four issues, a quarterly subscription to Focus provides a review of current clinical practice based on the content outlined by the ABPN recertification exam.

A subscription offers:
• New articles that brief you on new developments and review the current state of practice.
• Features designed to improve your ability to evaluate, diagnose, and manage clinical problems; communicate with your patients; and handle ethical dilemmas.
• Curation of the publications that have shaped the thinking in the field, with some reprinted in the issue itself.
• Quizzes that allow you to earn up to five AMA PRA Category 1 Credits™ by completing CME credits for each issue—for a total of up to 20 credits per year.
• An annual 120-question self-assessment exam for 24 self-assessment CME credits—with the opportunity to anonymously compare your results against those of your peers.
• Online access to current and back issues with CME credits available only for your subscription year.

Focus covers core clinical areas:
• Volume XI (2013): Geriatric Psychiatry; Personality Disorders; Posttraumatic Stress Disorder and Traumatic Brain Injury; Integrated Care and Psychosomatic Medicine
• Volume XII (2014): Sleep: New Biologies and New Therapies; Psychopharmacology; Psychotherapies; Eating Disorders
• Volume XIII (2015): Bipolar Disorders; Obsessive Compulsive Disorders; Substance-Related and Addictive Disorders; Psychiatry and Society
• Volume XIV (2016): Child and Adolescent Psychiatry; Depression; Schizophrenia; Neuropsychiatry

With your paid subscription, you’ll also get unlimited online access to all past volumes at no extra charge. (CME for past volumes not included.) Focus gives you the opportunity to earn 44 or more AMA PRA Category 1 Credits™ per year.

One-Year Prices:
• U.S. APA Members: $394
• APA International Member: $495
• APA Resident-Fellow Member (Online Only): $128
• Non-Member price: $566
• International Non-Members: $775
• International Non-Members: $683

The American Board of Psychiatry and Neurology (ABPN) has reviewed Focus: The Journal of Lifelong Learning in Psychiatry and the Focus Self-Assessment Examination and has approved this program as part of a comprehensive lifelong learning and self-assessment program, which is mandated by the ABMS as a necessary component of maintenance of certification. ABPN has reviewed and approved each of the following Focus Performance in Practice clinical chart review tools for ABPN MOC Part 4 (clinical module) requirements for improvement in Medical Practice:
• Screening for Adults with Substance Use Disorder
• Assessment and Treatment of Adults with Substance Use Disorder
• Assessment and Treatment of Adults at Risk for Suicide and Suicide-Related Behaviors
• Physician Practice Assessment Tool for the Care of Adults with Schizophrenia

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Self-Assessment CME programs listed below have been reviewed and approved for a maximum of 24 AAPA Category 1 Self-Assessment CME credits by the Physician Assistant Review Panel. Approval is valid until the expiration date listed below. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity. These programs were planned in accordance with AAPA’s CME Standards. FOCUS Self-Assessment Exam Volume XI (2013) — Expires 10/31/2016
FOCUS Self-Assessment Exam Volume XII (2014) — Expires 10/31/2017
New Research

Poster Session 1, Saturday, May 14 ............. 152
Poster Session 2, Saturday, May 14 ............. 157
Poster Session 3, Sunday, May 15 ............... 161
Poster Session 4, Sunday, May 15 ............... 162
Poster Session 5, Monday, May 16 ............... 163
Poster Session 6, Monday, May 16 ............... 166
Poster Session 7, Tuesday, May 17 ............... 171
Poster Session 8, Tuesday, May 17 ............... 174
New Research Topic Index ....................... 180
**Poster Session 1**  
Saturday, May 14

---

**P1-001**  
Clinical Characteristic of Synthetic Cannabinoid Users Admitted to the Inpatient Psychiatric Service  
Sabina Fink, M.D.

**P1-002**  
A Unique Case of Post-Electroconvulsive Therapy Status Epilepticus  
Sameera Guttikonda, M.D.

**P1-003**  
Combined Loxapine and Cyproheptadine Limits Clozapine Rebound Psychosis and May Also Predict Clozapine Response  
Lila Aboueid, D.O.

**P1-004**  
Body Snatchers: The Neuropsychiatry of the Capgras Delusion  
Caitlin Adams, M.D.

**P1-005**  
Demoralization: Two Cases From a Cancer Center Setting and Literature Review  
Crispa Aeschbach Jachmann, M.D.

**P1-006**  
Geriatric Olfactory Reference Syndrome Responding to Duloxetine: Case Report and Literature Review  
Awais Aftab, M.B.B.S.

**P1-007**  
Rare Clinical Manifestation of Neurosyphilis: Role of Psychiatrists and Importance of a Routine Screening Test  
Saba Afzal, M.D.

**P1-008**  
Case Report on Munchausen Syndrome  
Fariha Afzal, M.B.B.S.

**P1-009**  
The Presentation of Somatic Delusions in the Setting of Lyme Disease: A Case Report and Literature Review  
Ammar Y. Ahmad, M.D.

**P1-010**  
Cyber-Mania in Bipolar Disorder  
Saeed Ahmed, M.D.

**P1-011**  
Can Bullying Lead to Development of Dissociation Identity Disorder?  
Sameerah Akhtar, M.D.

**P1-012**  
Somatic Delusions in Psychosis  
Sameerah Akhtar, M.D.

**P1-013**  
Medication-Induced Myoclonus: A Case Report  
Ahmed Albassam, M.D.

**P1-014**  
Dissociative Rage: Fact or Myth?  
Arshand Ali, M.D.

**P1-015**  
Treatment of Pseudobulbar Affect With Bupropion: Case Report  
Saifa Al-Rubaye, M.D.

**P1-016**  
Does Time Heal All Wounds? A Case of First-Time Manic Episode and Bereavement  
Tarek Aly, M.D.

**P1-017**  
Alprazolam-Induced Rhabdomyolysis Associated With Buprenorphine-Naloxone Maintenance Therapy  
Tarek Aly, M.D.

**P1-018**  
Erotic Hypoglycemia? A Patient With Multiple Episodes of Insulin Overdose for Euphoric Experience  
Ritesh Amin, M.D.

**P1-019**  
Aripiprazole Treatment for Hallucinations in a Patient With PTSD  
Aaron K. Andersen, D.O.

**P1-020**  
Treatment of Mania Secondary to HIV  
Yohannis L. Anglero Diaz, M.D.

**P1-021**  
Interesting Case Highlighting Typical Antipsychotic-Induced Depression and Olanzapine-Fluoxetine-Induced Mania  
Darinka Aragon, M.D.

**P1-022**  
Influenza-Induced Mania  
Shehzad Ayub, D.O.

**P1-023**  
Lithium Toxicity in a Bariatric Surgery Patient: A Case Report  
Shahana Ayub, M.D.

**P1-024**  
Takotsubo Cardiomyopathy: Rare Cardiac Syndrome Linked to Neuropsychiatric Illness  
Shahana Ayub, M.D.

**P1-025**  
Synthetic Cannabinoid Use in Pregnancy: A Case Report and Literature Review  
Malikarijuna Bagewadi Ellur, M.D.

**P1-026**  
Trazodone-Induced Nightmares  
Nicholas P. Basalay, M.D.

**P1-027**  
Schizoaffective Disorder and Comorbid Bartter Syndrome: A Case Report  
Jessica S. Bayner, M.D.

**P1-028**  
Case Report: Five Supplements and Multiple Psychotic Symptoms  
Robert G. Bota, M.D.

**P1-029**  
Late-Onset Bipolar Disorder: A Case Report and Literature Review  
Matthew Boyer, B.A.

**P1-030**  
Synthetic Cannabis: Diverse Case Presentations, Literature Review, and Treatment Modalities and Recommendations in the Adolescent Population  
Dakota Carter, M.D.

**P1-031**  
Childhood Functional Abdominal Pain Syndrome  
Amarsha Chakraburty, M.D.

**P1-032**  
Case Report: Renal Transplantation in a Patient With Schizoaffective Disorder, Bipolar Type  
Monika Chaudhry, M.D.
P1-033 Challenges in Diagnosing Factitious Disorder: A Case Report
Raminder Pal Cheema, M.D.

P1-034 Clozapine-Induced Tachycardia: Clinical Considerations
Yon J. Chong, M.D., M.P.H.

P1-035 Self-Induced DKA in a Patient With Diabetes Type 1 and Anorexia Nervosa With Comorbid Depression and Anxiety: A Case Report
Mehak Chopra, D.O.

P1-036 Marchiafava-Bignami Disease (MBD) and Diffusion Tensor Image (DTI) Tractography
Priscilla N. Chukwueke, M.D., M.P.H.

P1-037 Olfactory Reference Syndrome: A Case Series Demonstrating Different Underlying Pathologies Manifesting With Similar Signs and Symptoms
Frank Breckenridge Chumley, M.D.

P1-038 Leptomeningeal Carcinomatosis Presenting Primarily as Psychosis
Wilson Chung, D.O.

P1-039 A Case Report of Namenda (Memantine) Use in ADHD
Omar A. Colon, M.D.

P1-040 “Scary Thoughts” and Pregnancy: A Case Series and Literature Review
Shalini D. Dave, D.O.

P1-041 Observed Difference Between Intramuscular and Oral Lorazepam for Treatment of Catatonia: A Case Report and Literature Review
Andrew Davidowitz, M.S.

P1-042 Reemergence of Adult Onset PICA: A New Presentation of an Old Problem
Deepak M. Davidson, M.D.

P1-043 Visualizing Pharmacodynamic Interactions: PRN Medications Can Be a Window to Drug Interactions
Arashinder Dhaliwal, M.D.

P1-044 Anti-N-Methyl-D-Asparate Receptor Encephalitis Presenting as an Emerging Culprit for Conversion Disorder: An Adolescent Case Report
Swati Divakaria, M.D.

P1-045 A Rare Case of Wrist Fracture Resulting From Electroconvulsive Therapy: A Case Report
Erin Dooley, M.D.

P1-046 Visualization of Medication Response in the Long-Term Institutionalized Mentally Ill Utilizing PSYCKES Data
Ammar El Sara, M.D.

P1-047 Psychiatric Comorbidities With CHARGE Syndrome: A Case Report
Rasha Elkady, M.D.

P1-048 Refractory Psychosis in a Patient With Mega Cisterna Magna
Narissa R. Etwaroo

P1-049 The Case of a “Queer Heterosexual”: Exploring the Concept of ‘Mostly Heterosexuals’ and Their Unique Experiences of Mental Illness
Alec Faggen

P1-050 Absent Septum Pellucidum and Gray Matter Heteropia in a Patient With MDD With Psychotic Features and Intractable Epileptic Seizures: A Case Report
Mobeen Farooq

P1-051 Improvement of Catatonia After Cardiac Arrest
Michael Peroski, D.O.

P1-052 Intentional Ingestion: A Case Series Regarding Swallowing of Foreign Objects: Treatment Alternatives
Suhey G. Franco Cadet, M.D.

P1-053 Sleep State Misperception or Subjective Insomnia in Patients With Depression and Anxiety: A Case Report
Suhey G. Franco Cadet, M.D.

P1-054 The Role of Amantadine Withdrawal in Treatment-Refractory Altered Mental Status
Leah D. Fryml, M.D.

P1-055 Recurrent Priapism Associated With Olanzapine Treatment: Case Report
Emily Fu, M.D.

P1-056 Electroconvulsive Therapy in a Patient With Moyamoya Syndrome
Erica Ghignone, M.D., M.A.

P1-057 “Do No Harm”: Ethical Implications of Treating Psychosis in Two Patients With Delusional Denial of Insulin-Dependent Diabetes Mellitus (IDDM)
Deepthi Ghiya, M.D.

P1-058 Anxiety Treatment Improves Lichen Simplex Chronicus
Amy C. Gomez Fuentes, M.D.

P1-059 Let’s Build Bridges and Not Walls: For Bridge-to-Transplantation: The Power of Effective Doctor-Patient Communication in Patients With LVAD Implant
Arpita Goswami Banerjee, M.D.

P1-060 Acute Psychosis Associated With Septo-Optic Dysplasia (de Morsier Syndrome)
Dharmendra K. Goyal, M.B.B.S.

P1-061 The Contribution of Childhood Attachment Failure to Development of Borderline Personality Disorder in Adulthood: A Case Report and Literature Review
Neha Gupta, M.D.

P1-062 Substance-Induced Psychosis Versus Substance Withdrawal: A Case Report and Discussion of Treatment Approach and Diagnostic Framework
Pramathri Murthyunjaya, M.D.

P1-063 SLE-Induced Mania and Psychosis: A Case Report
Pramathri Murthyunjaya, M.D.

P1-064 The Thyroid Connection: A Case of New Onset Psychosis
Najma F. Hamdani, M.D., M.H.A.
P1-065
Safety Precautions for a Psychotic Patient With PICA on the Inpatient Service
Amina Hanif, M.D.

P1-066
A Case of Laryngeal Dystonia in a Young Male Receiving Paliperidone Palmitate
Sharif Haque, M.D.

P1-067
A Case Report of Adderall-Induced Bizarre Delusions
Michael R. Harrigan, M.D., M.B.A.

P1-068
A Case of Mistaken Identity: When Organic Pathology Is Thought to Be Psychological in Origin
Christopher Harris, D.O.

P1-069
Psychiatric Manifestations Co-Occurring in a Father-Son Pair With Waardenburg Syndrome
Joseph Hart, B.A.

P1-070
Exploring Staff Issues for Child Transgender Patients in the Child Psychiatric Inpatient Unit: A Case Report
Rabiya Hasan, M.D.

P1-071
Fatal Multi-Organ Failure From Diphenhydramine Overdose
Vineka Heeramun, M.D.

P1-072
Seizures Dismissed as Pseudoseizures
Vineka Heeramun, M.D.

P1-073
Use of Clozapine in a Chronic Schizophrenic During Induction Chemotherapy and Stem Cell Transplant: Anticipatory Measure to Consider
Umair M. Hemani, D.O., M.S.

P1-074
Case Report of Aripiprazole Use in the Treatment of Adolescent Stuttering
Julia L. Hoang, M.D.

P1-075
Brown Sugar: A Case of Opiate-Induced Paralytic Ileus
M. Daniel Holsey, D.O.

P1-076
“This Is Serious”: Delay in Cancer Treatment in a 70-Year-Old Female With Delusional Parasitosis: A Case Report
Avjola Hoxha, M.D.

P1-077
Challenges in the Management of Psychosis in Teenage Pregnancy: A Case Report and Review of Literature
Geeta S. Ilipilla, M.D.

P1-078
Rapid Development of Pulmonary Emboli Two Days After Onset of Catatonic Symptoms: A Case Report and Literature Review
Danielle Ivanova, D.O.

P1-079
Elopement in Autism Spectrum Disorders (ASD) and Evolving Case Presentations: A Case Report and Review
Veerarghavan J. Iyer, M.D., M.B.B.S.

P1-080
The “Caitlyn Jenner” Effect
Robert J. H. Johnston, M.D.

P1-081
Use of Ketamine Infusion in Chronic Refractory Depression and Pain: A Case Report
Travis W. Jones, M.D.

P1-082
Anti-NMDA Receptor Encephalitis: From Love to Madness
Courtney Joseph, D.O.

P1-083
Clozapine-Induced Sialorrhea and Incontinence of Bowel and Bladder
Astito Joshi, M.D.

P1-084
Novel Psychiatric Disorders (NPD): Pediatric Bipolar and Obsessive Compulsive Disorder (OCD) After Traumatic Head Injury
Rajasekhar Kannali, M.D.

P1-085
A Case of Psychosis in a Patient With Grave’s Disease and Hashimoto’s Disease
Vandana Kethini, M.D.

P1-086
Broken Heart Syndrome: A Case of Takotsubo Cardiomyopathy in a Female Presenting With Bereavement
Mohsin Khan, M.D.

P1-087
To Feed or Not to Feed? The Moral Dilemma of Feeding a Patient With Treatment Refractory Depression Who Refuses to Eat
Surbhi Khanna, M.B.B.S.

P1-088
Levofoxacin-Induced Delirium and Acute Psychosis: A Clinical Case Report
Jyotsna Kilani, M.D.

P1-089
Delirious Mania in Bipolar Disorder: A Case Report
Tyler Kimm, M.D.

P1-090
Borderline Personality Disorder in the Geriatric Patient: Remission and Relapse
Benjamin O. Klass, M.D.

P1-091
Educating a Geriatric Patient About Somatic Symptom Disorder: A Resident’s Challenge
Kavita Kothari, M.B.B.S.

P1-092
Minimal Hepatic Encephalopathy Presenting as Psychosis
Kristina E. Kurtz, D.O.

P1-093
Coprolalia as a Presentation of Severe Aphasia Status Post-CVA: A Case Report
Audrey La Noce, D.O.

P1-094
Double Trouble: A Case of Kleine-Levin Syndrome in an Adolescent Female After a Road Traffic Accident
Jasmin G. Lagman, M.D.

P1-095
Malignant Catatonia in a Patient With Hydrocephalus Responsive to Electroconvulsive Therapy (ECT)
Hank Lai, M.D.

P1-096
WITHDRAWN

P1-097
Testimonial Therapy in Latin American Survivors of Intimate Partner Violence: Implications for the Application of a Transcultural Therapeutic Ritual
Pooja Lakshmin, M.D.

P1-098
Topiramate-Induced Psychosis
Camilo Leal, M.D.
Making the Covert Overt: Fine Grain Analysis of Medication History Can Reveal Effective Treatments, Recognize Problems and Improve Care
Jacob Leivent, M.D.

The Impact of High Expressed Emotion and the Environment on Twins With the Development of Psychosis in One
William Levitt, M.D.

A Tale of Two Brothers: Psychosis, Suicidality, Homicidality and Substance Abuse
William Levitt, M.D.

A Curious Case of Capgras: The Psychodynamic and Neurocognitive Approaches to Capgras Syndrome
William Levitt, M.D.

A Case of Sertraline-Induced Vaginal Hemorrhagia
William Levitt, M.D.

Early Recognition of Tricyclic Antidepressant Overdose: A Case Report
Kevin J. Li

Decoding Detox: Troubling Interactions Between Aripiprazole and Over-The-Counter Dietary Supplements
Max A. Lichtenstein, M.D.

Citalopram and Escitalopram: Adverse Cardiac Outcomes in Medically Ill Inpatients
Artin Mahdianian, M.D.

Pulmonary Embolism in Catatonia: Assessing Risk in Specific Populations in the Inpatient Setting: A Case Report
Mario Mangiardi, M.D.

A Case Report of Mania in a Patient During Aripiprazole Treatment
Adeyemi Marcus, M.D.

A Bad Trip From “The Bomb”: A Case Report
Gloria Martz, D.O.

Case Report: Irregular Menses and PMS Alleviated With the Use of Buspiron
Syed E. Maududi, M.D.

The Potential Therapeutic Role of Oxytocin in Autism Spectrum Disorder Patients
Syed E. Maududi, M.D.

Decreasing Morbidity Through Early Detection of Clozapine-Induced Cardiotoxicity: A Case Report
Shawn E. McNeil, M.D.

Differential Diagnosis in Patients With Psychosis: A Case of Hypothyroidism-Induced Mental Disorder
Tomas Melicher, M.D.

Snakes in the Hospital
Amit Mistry, M.D.

Postictal Psychosis: Recognition and Impact on Long-Term Psychological Care
Paroma Mitra, M.D., M.P.H.

SSRI-Induced Sleep Paralysis
Raja Mogalla, M.D.

Hyperosmolar Hyperglycemic State With Olanzapine: A Case Report and Review of Literature
Lauren E. Moore, M.D.

Lisdexamfetamine for the Treatment of Binge Eating Disorder: A Case Report and Literature Review
Maria E. Moreno, M.D.

Assessment of Decision Making Capacity in a Psychiatric Patient: A Common Myth
Sahil Munjal, M.D.

Bupropion-Induced Hyponatremia: A Case Report and Literature Review
Sahil Munjal, M.D.

Psychiatric Sequelae of Urea Cycle Disorders: A Case Report and Literature Review
Dewey S. Murphy, M.D.

Diabulimia: A Case Report and Literature Review on a Rare and Unusual Eating Disorder
Trenton Myers, M.D.

Undiagnosed Trauma in Severe Mentally Ill Patients
Vahid Nikzad, M.D.

PTSD After a BERT Alert in a Patient With Acute MI and a Past History of Depression
Abhishek R. Nitturkar, M.B.B.S.

Recall of Delusions During Delirium Related to Development of PTSD After Delirium in the ICU: A Case Report
Abhishek R. Nitturkar, M.B.B.S.

Multi-Modal Approach to Management of Reflex Sympathetic Dystrophy: A Case Report
Vincent N. Nwankwo, M.B.B.S.

Mental Health Considerations in the GI Patient: Reclassifying Diagnosis of Functional GI Complaints
Andrew Owen, M.S.

Educating a Schizophrenic Patient About MET: Challenges of Starting on the Inpatient Unit
Ronak Patel, M.D.

Treatment of Catatonic Syndrome in Bipolar Disorder With Aripiprazole
Mitesh Patel, M.D.

Usher’s Syndrome and Psychopathology: A Case Report
Irina Chikvashvili, D.O.

Very Late Onset Schizophrenia-Like Psychosis: A Case Study
Markian Pazuniak, M.D.

Case Report: Tactile Hallucinations: An Atypical Presentation of Creutzfeldt-Jakob Disease
Luis Pereira, M.D.
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1-133</td>
<td>The Psychedelic Renaissance in Psychiatry: An Evidence-Based Review</td>
<td>Kimia Pourrezaei, D.O.</td>
</tr>
<tr>
<td>P1-134</td>
<td>Role of Inflammatory Cytokines and a New Outlook on Pathophysiology and Treatment Modalities in Bipolar Disorder</td>
<td>Rumana Rahmani, M.D.</td>
</tr>
<tr>
<td>P1-135</td>
<td>Antisocial Personality Disorder: Where and How Should We Manage These Patients?</td>
<td>Rumana Rahmani, M.D.</td>
</tr>
<tr>
<td>P1-137</td>
<td>Foreign Accent Syndrome (FAS) Presenting as Conversion Disorder: A Rare Presentation</td>
<td>Abhishek Reddy, M.D.</td>
</tr>
<tr>
<td>P1-138</td>
<td>The Stalker Who Became Her Own Victim: A Case and Literature Review on Stalking Phenomenology</td>
<td>Sonia Riyaz, M.D.</td>
</tr>
<tr>
<td>P1-139</td>
<td>Six Ways to Die: A Case Report of a High-Lethality Multi-Method Suicide Attempt</td>
<td>Diana Mungall Robinson, M.D.</td>
</tr>
<tr>
<td>P1-140</td>
<td>Atypical Mania Presentation: Was It Caused by Corticosteroids, a Mycoplasma Infection or Just Late Onset Bipolar Disorder?</td>
<td>Laura Rodriguez-Roman, M.D.</td>
</tr>
<tr>
<td>P1-141</td>
<td>Ritualistic Behavior Leading to Long-Term Hospitalization in Patients With Schizoaffective Disorder</td>
<td>Daniel O. Roman, M.D.</td>
</tr>
<tr>
<td>P1-142</td>
<td>Refractory Catatonia: Role of N-Methyl-D-Aspartic Acid Antagonist</td>
<td>Kamalika Roy, M.D.</td>
</tr>
<tr>
<td>P1-143</td>
<td>Negative Countertransference in Borderline Personality Disorder: Case Report, Literature Review and Treatment Recommendations</td>
<td>Kruthika Sampathgiri, M.D.</td>
</tr>
<tr>
<td>P1-144</td>
<td>A Case of a Patient With K2 Use Presenting With Prolonged Delirium</td>
<td>Eric Santos, M.D.</td>
</tr>
<tr>
<td>P1-145</td>
<td>Case Report of Neutropenia in a Patient Diagnosed With Schizophrenia and Treated With Lurasidone</td>
<td>Ayesha Sattar, M.D., M.B.B.S.</td>
</tr>
<tr>
<td>P1-146</td>
<td>Case Report of “Folie a Deux” Between Two Sisters</td>
<td>Adam H. Schindzielo, M.D.</td>
</tr>
<tr>
<td>P1-147</td>
<td>Foreign Accent Syndrome as an Under-Recognized Manifestation of Chronic Psychological Trauma</td>
<td>Alexis A. Seegan, M.D.</td>
</tr>
<tr>
<td>P1-148</td>
<td>The Case of the Bright Splenium</td>
<td>Patricia Serrano, M.D.</td>
</tr>
<tr>
<td>P1-149</td>
<td>Psychosis Resulting From Fahn’s Syndrome: Case Report and Review of Literature</td>
<td>Apkasha Shah, M.B.B.S.</td>
</tr>
<tr>
<td>P1-150</td>
<td>Low Dose Testosterone Replacement Therapy-Induced Psychotic Mania</td>
<td>Wanda Shao, D.O.</td>
</tr>
<tr>
<td>P1-151</td>
<td>The Importance of Considering Delirium Due to Polypharmacy in Psychiatric Patients With Neurologic Disorders: A Case Report and Review of Literature</td>
<td>Anna P. Shapiro, B.A.</td>
</tr>
<tr>
<td>P1-152</td>
<td>Lithium-Induced Dental Complications</td>
<td>Ashish Sharma, M.D.</td>
</tr>
<tr>
<td>P1-153</td>
<td>Pharmacogenomic Testing Predicts a More Favorable Clinical Outcome in a Patient With Treatment-Resistant Depression and “Borderline Personality”</td>
<td>Matthew M. Sheehan, B.A.</td>
</tr>
<tr>
<td>P1-154</td>
<td>Neuropsychiatric Manifestations of Wilson’s Disease in the Inpatient Hospital Setting</td>
<td>Sarah Sheikh, M.D.</td>
</tr>
<tr>
<td>P1-155</td>
<td>Differentiating Between Psychiatric Disorders and Wernicke-Korsakoff Syndrome: A Case Report</td>
<td>Manisha Shenav, M.D.</td>
</tr>
<tr>
<td>P1-156</td>
<td>Valproic Acid-Induced Delirium: A Case Study</td>
<td>Saoda Shara, M.D.</td>
</tr>
<tr>
<td>P1-157</td>
<td>Clozapine Refractory Schizophrenia: Augmentation Therapy With Fluphenazine</td>
<td>Gurjot Singh, M.D.</td>
</tr>
<tr>
<td>P1-158</td>
<td>K2/Spice-Induced Seizures: Tip of an Iceberg</td>
<td>Jasbir Singh, M.D.</td>
</tr>
<tr>
<td>P1-159</td>
<td>The Need for Maintenance ECT in Preventing Relapse in Elderly Populations With Major Depression: A Case Report</td>
<td>Laima Spokas, M.D.</td>
</tr>
<tr>
<td>P1-160</td>
<td>The Therapeutic Interventions for Pediatric Bipolar Disorder</td>
<td>Laima Spokas, M.D.</td>
</tr>
<tr>
<td>P1-161</td>
<td>Use of THC Analogs in Cannabis Use Disorder</td>
<td>Ananya R. Sreepathi, M.D.</td>
</tr>
<tr>
<td>P1-162</td>
<td>Impulse-Control, Conduct Disorders and Intellectual Disability: A Concerning Combination</td>
<td>Ananya R. Sreepathi, M.D.</td>
</tr>
<tr>
<td>P1-163</td>
<td>WITHDRAWN</td>
<td></td>
</tr>
<tr>
<td>P1-164</td>
<td>Erotomania and the Frontal Lobe: A Case Report of Delusional Disorder Arising From a CNS Neoplasm</td>
<td>John Stupinski, B.A.</td>
</tr>
<tr>
<td>P1-165</td>
<td>Menstrual Psychosis: A Case of Estrogen Withdrawal Psychosis</td>
<td>Leah Susser, M.D.</td>
</tr>
<tr>
<td>P1-166</td>
<td>Electroconvulsive Therapy in the Treatment of Delirious Catatonic Mania: A Case Presentation</td>
<td>Cuneyt Tegin, M.D.</td>
</tr>
<tr>
<td>P1-167</td>
<td>K2-Induced Psychosis: Recurrent Relapse and Treatment Challenges</td>
<td>Swaminathan Thangaraj, D.O.</td>
</tr>
</tbody>
</table>
P1-168
Serotonin Syndrome in the Burn ICU
Taylor Tobkes, M.D.

P1-169
Metabolic Side Effects of the Rise: The Use of Metformin to Counteract Clozapine-Induced Adverse Reactions: A Case Report
Celia Varghese, M.D.

P1-170
12-Year-Old With Landau-Kleffner Syndrome and Nonepileptic Seizures: A Complex Case Presentation With Literature Review
Divya Vemuri, M.D.

P1-171
Rage Against Self and Object: A Case Report of Treatment-Resistant Schizophrenia With Literature Review
Chittranjan B. Verma, M.D.

P1-172
Microvascular CNS Lesions, Hypomania, Seizure Activity and Pseudobulbar Affect in the Elderly: A Case Report
Ankita Vora, M.D., M.P.H.

P1-173
WITHDRAWN

P1-174
Undocumented Immigrants in Psychiatric Wards: A Case Report and Concise Review
Mike Wei, B.S.

P1-175
Depersonalization/Derealization: Neurobiology, Psychodynamics and a Case in Schizophrenia
Bryce Wininger, M.D.

P1-176
The Impact of Medication on Teeth Pulling and Skin Picking
Mohammad Yousuf, M.D.

P1-177
Prediction Challenges of Readmission in the Psychiatric Inpatient Setting: A Resident-Run Performance Improvement Initiative
Muhammad Zeshan, M.D.

P1-168

P2-001
Dissemination and Implementation of CBT for Depression: Examining Attitudes, Therapy Patterns and Level of Competency Among Third-Year Clinic Residents
Earl Andrew B. De Guzman, M.D.

P2-002
Prevalence of Metabolic Syndrome in a Population Being Served by an Assertive Community Treatment Team
Jonathan Fairbairn, M.D.

P2-003
Integrating and Redesigning Mental Health at Primary Care Level: TRipleaim Universal MPsychiatry (TRIUMPH) Model
Abhishek Rai, M.D.

P2-004
Program Development of a Buprenorphine/Naloxone (Bup/Nx) Outpatient Program in a Safety Net Hospital
William Levitt, M.D.

P2-005
The University of Virginia-Guatemala Initiative: Mental Health Care Delivery in Low-Resource Settings
Souraya Torbey, M.D.

P2-006
Clinical Implications of Companion Animals in Patients With Serious Mental Illness
Sa Eun Park, M.D.
P2-016
Seeking a Better Outcome: A Survey About LGBTQQI2S Knowledge
Juan A. Rivolta, M.D.

P2-017
Standardization of the Handoffs in Psychiatry Residency Training
Amanpreet K. Mashiana, B.S.

P2-018
Is My Evaluation Truly Anonymous? A Survey of Residents About Their Evaluation of Faculty Physicians in a Community Hospital
Varma Penumetcha, M.D.

P2-019
Coping With Patient Suicide: A Cross-Sectional Study on the Effects of Patient Suicide on Psychiatry Residents and Faculty
Archna Sugumar, M.B.B.S.

P2-020
Improving Resident Handoffs Using Quality Improvement Matrix
Katherine Robertson, M.D.

P2-021
An Assessment of Attitudes Towards Homeless Individuals With Mental Illness Among Medical Students and Physicians
Pallavi Joshi, M.A.

P2-022
The Compassion Crisis in Medical Education
Rachel Conrad, M.D.

P2-023
Effective Mentorship During Residency Training: Needs Assessment and Perspectives of Residents
Hermioni Lokko, M.D., M.P.P.

P2-024
Feasibility and Acceptability of Performing Screening, Brief Intervention and Referral to Treatment (SBIRT) on an Inpatient Unit at UVA
Andrew R. Alkis, M.D.

P2-025
Special-“T” Training: Pre-, Post- and 90-Day Outcomes From a Residency-Wide Professionalism Workshop on Transgender Health
Jeremy D. Kidd, M.D., M.P.H.

P2-026
Dissemination of an Evidence-Based Tobacco Treatment Curriculum to Psychiatry Residency Programs
Smita Das, M.D., Ph.D.

P2-027
Guidelines for Discontinuing Benzodiazepines in Patients Who Are Chronic Users
Joseph Siragusa, M.D.

P2-028
Understanding the Role of Morbidity and Mortality Rounds in Psychiatry: A Systematic Review of Implementation and Educational Outcomes
Paul V. Benassi, M.D.

P2-029
Are Medical Doctors Educated Research Consumers?
Priscilla N. Chukwueme, M.D., M.P.H.

P2-030
A Call for the Increase in Clozapine Clinics to Improve the Treatment of Schizophrenia
Balwinder Singh, M.D., M.S.

P2-031
Assisted Death From a Psychiatric Perspective: An Overview and Review of Literature
Tanuja Gandhi, M.D.

P2-032
Difficult Interactions: A Reason for Inpatient Psychiatric Consultation?
Meena Kumari, M.D.

P2-033
Self-Injurious Behavior in Patients With Eating Disorders: A Literature Review
M. Rehan Puri, M.D., M.P.H.

P2-034
Training and Assessment of Psychiatry Residents’ De-escalation Competency in Standardized Patients
Jenine Weber, D.O.

P2-035
Patient-Targeted Googling and Psychiatric Professionals
Liliya Gershengoren, M.D., M.P.H.

P2-036
The Efficacy of Complementary and Alternative Therapies to Treat Depression During Pregnancy: A Meta-Analysis
Alexandra K. Rice, M.D., M.A.

P2-037
Sexual Offenders With Substance Usage: Do Psychiatric Comorbidities Differ in This Population?
Edward Thomas Lewis, M.D.

P2-038
Correlates of 1-Year Prospective Depression Severity in Bipolar Disorder: Results From the Systemic Treatment Enhancement Program for Bipolar Disorder
Sharif Syed

P2-039
Prevalence and Correlates of Pseudobulbar Affect Symptoms in Urban Setting Nursing Home Residents With Dementia
Milania Dela Cruz, M.D., M.P.H.

P2-040
Inpatient Burden of Alcohol Withdrawal (Delirium Tremens) in the United States: An Analysis of National Trends
Raghu Gandhi, M.D., M.B.B.S.

P2-041
The Right to Keep and Bear Arms When Mentally Ill
Furqan Nusair, M.B.B.S.

P2-042
Gender Differences in the Experience of Depression in Parkinson’s Disease
Andrew Perrin, M.D., Ph.D.

P2-043
Sex Differences in Psychiatry Comorbidity Profiles Among Adults With ADHD and Alcoholism
Maria M. Reyes, M.D.

P2-044
Internal State Scale (ISS): A Promising Patient-Rated Screen for Identifying Bipolar NOS?
Travis Hendryx, M.D.

P2-045
PRN Hospitalization for Borderline Personality Disorder: Our Experience and Literature Review
Lakshit Jain, M.D.

P2-046
Does Presenting Mood State Predict Length of Inpatient Stay in Bipolar Disorder?
Jigar K. Chotalia, M.B.B.S., M.P.H.

P2-047
“She’s Not My Sister!” A Case Report of Capgras Syndrome in a Patient With Schizophrenia and Vascular Dementia
Lauren Pengrin, D.O.
P2-048  National Trends, Rates of Cardiac Catheterizations, Revascularization After Myocardial Infarction in Patients With Dementia
Malathi Pilla, M.D.

P2-049  Whoonga or Nyaope: Antiretroviral Medication Abuse: An Emerging Problem or Media Hype?
Subani Maheshwari, M.D.

P2-050  Prevalence of Comorbid Anxiety-Disorder Among Adult Outpatients in an Academic Psychiatric Setting
Jessica M. Short, D.O.

P2-051  Substance Use Disorders in Psychiatric Inpatients With Primary Mood or Chronic Psychotic Disorders: Prevalence and Relationship to Comorbid PTSD
Pratikumar Desai, M.D., M.P.H.

P2-052  Comparing the Efficacy, Safety and Tolerability of ATX vs Stimulants for ADHD Treatment in Children and Adolescents: A Systematic Review and Meta-Analysis
M. M. Naveen, M.D.

P2-053  Interrater Variability Among Intraining Psychiatric Residents in Identifying Diagnoses of Schizophrenic Disorder and Treatment-Resistant Schizophrenia
Balwinder Singh, M.D., M.S.

P2-054  Examining Racial Differences in Diabetes Among People With Serious Mental Illness
Walker Daniel Keenan, B.S.

P2-055  Patient Feedback of Electronic Medical Records in an Outpatient Psychiatric Setting
Walter Piddoubny, M.D.

P2-056  PTSD Symptoms in Acute Psychiatric Inpatients: Prevalence and Impact on Comorbid Diagnoses, Demographics and Length of Stay (LOS)
Christopher James

P2-057  Borderline Personality Traits in Psychiatric Inpatients: A Positive Predictor?
Sheily T. Tran, M.D.

P2-058  Delirium: Could Be a Nightmare on Call at an Inpatient Psychiatric Facility
Reena Kumar, M.D.

P2-059  Religiosity in Acute Psychiatric Inpatients: Relationship With Demographics, Clinical Features and Length of Stay
Noha Abdel Gawad, M.D.

P2-060  Conversion Disorder: Modalities of Treatment
Muhammad A. Anees, M.D.

P2-061  Weight Effects of Aripiprazole Monotherapy Versus Aripiprazole Antidepressant Polypharmacy in an Outpatient Sample: A Retrospective Chart Review
Amanda Suzuki, M.D.

P2-062  Associations of Alcohol Consumption and Marijuana Use With Major Depressive Episode: Results From the 2011 National Survey on Drug Use and Health Data
Joseph C. Ikekwere, M.D., M.P.H.

P2-063  Suicide Crisis on Campus: Suicide Attempts and Ideation in the Collegiate Population Evaluated in the Emergency Department
Souraya Torbey, M.D.

P2-064  GGT as a Marker of Alcohol Abuse: Is It a Must?
Narissa R. Etwaroo

P2-065  Where Do We Stand in Therapeutic Drug Monitoring for Mood Stabilizers in Patients With Bipolar Disorder?
Zahid Islam, M.D.

P2-066  Homicidal Ideation in Psychiatric Emergency Room
Jack Wang, D.O.

P2-067  Schizoaffective Disorder Depressive Type and Psychosis
Qaiser S. Khan, M.D.

P2-068  SensoryReduction of Internal Milieu as a Means of Reducing Physical Restraints in a High-Acuity Inpatient Psychiatric Unit: A QI Project
Svetlana Yakov, M.D., Ph.D.

P2-069  Relevance of Obtaining Magnesium Levels in Patients With Alcohol Abuse
Astik Joshi, M.D.

P2-070  Relationship of Physical Activity to Depression in Adolescents With and Without History of Psychological Trauma
Andriy Yur’yev, M.D., Ph.D.

P2-071  Tobacco Use and Associated Factors Among Patients Presenting to a Psychiatric ER
Ashley D. Collins, D.O.

P2-072  Determinants for Follow-Up in Treatment-Resistant Schizophrenia Patients Started on Clozapine: Retrospective Analysis From Atlanta Public Hospital
Rafael E. Tapias, M.D.

P2-073  Increasing Cardiometabolic Risk Screening and Reduction of the Risk Among the Patients on Antipsychotics in the Adult Outpatient Psychiatry Clinic
Sasidhar Gunturu, M.D., M.B.B.S.

P2-074  Psychiatric and Legal Challenges in the Care of Transgender Inmates
Rafik Sidaros, M.D.

P2-075  Chronic Phencyclidine (PCP) Use as a Dissociative Respite in Stress Exposure and Mode of Self-Medication in Post-Traumatic Stress Disorder (PTSD)
Megan L. Gilman, M.D.

P2-076  Hyperprolactinemia During Antipsychotic Use in the Pediatric Population: Early Identification and Management
Chidinma Isinguzo, M.D.

P2-077  Trazodone-Induced Acute Urinary Retention: A Case Report
Vasile Savu, M.D.
<table>
<thead>
<tr>
<th>Presentation Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2-078</td>
<td>Mastering the Interpreter Phone: An Integrated Literature Review</td>
<td>Darrow Khosh-Chashm, M.D.</td>
</tr>
<tr>
<td>P2-079</td>
<td>Impact of Substance Abuse Discharge Recommendation Compliance on ED Readmission Rate in a College Population</td>
<td>Derek Blevins, M.D.</td>
</tr>
<tr>
<td>P2-080</td>
<td>Impact of the Affordable Care Act on Psychiatric Patients’ Access to Care at a California University Hospital Emergency Room</td>
<td>Andia H. Turner, B.Sc.</td>
</tr>
<tr>
<td>P2-081</td>
<td>Long-Term Injectable Use and Psychiatric Readmission Rates at a State Safety Net Hospital</td>
<td>William Levitt, M.D.</td>
</tr>
<tr>
<td>P2-082</td>
<td>Comfort Level and Barriers to the Appropriate Use of Clozapine for Patients With Schizophrenic Disorders Among U.S. Psychiatric Residents: A Proposal</td>
<td>Balwinder Singh, M.D., M.S.</td>
</tr>
<tr>
<td>P2-083</td>
<td>Literature Review of Effects of Atypical Antipsychotics on Infants of Breastfeeding Mothers</td>
<td>Tapan Parikh, M.D., M.P.H.</td>
</tr>
<tr>
<td>P2-084</td>
<td>Mindfulness-Based Cognitive Therapy for Major Depressive Disorder</td>
<td>Jeannie Lochhead, M.D.</td>
</tr>
<tr>
<td>P2-085</td>
<td>Relationship Between ASD and FXS Regional Expression of Fmr1 MRNAs in the Brains of Wild Type and Fmr1 Null Mice</td>
<td>Jun Zhong, M.D.</td>
</tr>
<tr>
<td>P2-086</td>
<td>Effects of Childhood Adversity and Adulthood Trauma on C-Reactive Protein in the Health and Retirement Study</td>
<td>Joy E. Lin, B.S.</td>
</tr>
<tr>
<td>P2-087</td>
<td>The DSM-5-Defined Attenuated Psychosis Syndrome and Conversion to Schizophrenia Spectrum Disorders: An Institution-Wide Retrospective Review</td>
<td>Zachary D. Zuschlag, D.O.</td>
</tr>
<tr>
<td>P2-088</td>
<td>Serum BDNF, TNFÎ±, IL-2, IL-6 and IL-8 Changes and Correlation in Schizophrenia Patients</td>
<td>Hanjing E. Wu, M.D., Ph.D.</td>
</tr>
<tr>
<td>P2-089</td>
<td>Trans-Cranial Magnetic Stimulation (TMS) in Psychiatry: Review of Current Updates and Future Directions</td>
<td>Ramkrishna D. Makani, M.D., M.P.H.</td>
</tr>
<tr>
<td>P2-090</td>
<td>A Study on the Awareness, Utility and Barriers to the Utilization of Psychiatric Advanced Directives</td>
<td>Tanuja Gandhi, M.D.</td>
</tr>
<tr>
<td>P2-091</td>
<td>Evidence for Using Acetylcholinesterase Inhibitors and Memantine in Individuals With Traumatic Brain Injury (TBI): A Systematic Review</td>
<td>Rajesh R. Tampi, M.D., M.S.</td>
</tr>
<tr>
<td>P2-092</td>
<td>The Effect of Social Networking Sites on the Relationship Between Perceived Social Support and Depression</td>
<td>Matthew A. McDougall, M.D.</td>
</tr>
<tr>
<td>P2-093</td>
<td>Evidence for Using Electroconvulsive Therapy in Individuals With Dementia: A Systematic Review</td>
<td>Rajesh R. Tampi, M.D., M.S.</td>
</tr>
<tr>
<td>P2-094</td>
<td>Efficacy of Prazosin in Post-Traumatic Stress Disorder: A Systematic Review and Meta-Analysis</td>
<td>Balwinder Singh, M.D., M.S.</td>
</tr>
<tr>
<td>P2-095</td>
<td>Comparison Between GAF and World Health Organization Disability Assessment Schedule (WHODAS-2) in Patients With Schizophrenia-Spectrum Illness</td>
<td>Scott Gspandl, M.D.</td>
</tr>
<tr>
<td>P2-096</td>
<td>Early Life Trauma in Hospitalized Mood Disorder Patients and Its Association With Clinical Outcomes</td>
<td>Ajay Parsaik, M.D., M.S.</td>
</tr>
<tr>
<td>P2-097</td>
<td>Use of Nicotine Replacement Among Psychiatric Inpatients Treated With Clozapine Versus Other Antipsychotic Drugs</td>
<td>Maryam Jahdi, M.D., M.P.H.</td>
</tr>
<tr>
<td>P2-098</td>
<td>Reel Comfort: A Pilot Study of the Therapeutic Effect of Facilitated Film Screenings and Discussions on General Psychiatric Inpatients</td>
<td>Phillion Gregoire, M.Sc.</td>
</tr>
<tr>
<td>P2-099</td>
<td>5-HTTLPR Association With Childhood Characteristics in Mood Disorder</td>
<td>Tae Kyung Eun, M.D.</td>
</tr>
<tr>
<td>P2-100</td>
<td>The Psychiatric Perspective: Factors Affecting Medical Students’ View of Psychiatry</td>
<td>William Levitt, M.D.</td>
</tr>
<tr>
<td>P2-101</td>
<td>Climate Change and Mental Health: A Need for Increased Research</td>
<td>Ekatherina Osman, D.O.</td>
</tr>
<tr>
<td>P2-102</td>
<td>A Randomized Double-Blind Clinical Trial Comparing Qsymia (Phentermine-Topiramate) Versus Placebo in Patients With Bulimia and Binge Eating Disorder</td>
<td>Shebani Sethi Dalai, M.D., M.S.</td>
</tr>
<tr>
<td>P2-103</td>
<td>Good Cop, Bad Cop, Killer Cop? A Study of Antisocial Personality Disorder in Police Officers</td>
<td>William Levitt, M.D.</td>
</tr>
<tr>
<td>P2-104</td>
<td>Medical Complications Associated With Delays in Public Guardianship Assignment</td>
<td>Rebecca E. Goedken, M.D.</td>
</tr>
<tr>
<td>P2-105</td>
<td>Coffee and Tea to Prevent Depression?</td>
<td>Hanan Khairalla, M.D.</td>
</tr>
<tr>
<td>P2-106</td>
<td>From Snow White to Elsa: A Transformation of the Disney Princess! How Gender Role Portrayals Present in Disney Films May Influence Children Over Time</td>
<td>Kalliopi S. Nissirios, M.D.</td>
</tr>
<tr>
<td>P2-107</td>
<td>Characteristics of Pain Expression in Children Across Developmental Stages</td>
<td>Jawad Zafar, D.O.</td>
</tr>
</tbody>
</table>
A Case Report: Schizophrenic Patient Using “Sour Diesel” to Treat His Depression
Rahulkumar Patel, M.D., M.P.H.

Prevalence of Eating Disorders Among Individuals With Type 1 Diabetes Mellitus (T1DM) and Diabetes-Specific Emotional Distress
Ahmad Alhadi, M.D., M.B.B.S.

Smartphone Use Addictive Phenomenon Among University Students in King Saud University in Riyadh, Saudi Arabia
Fahad D. Alosaimi, M.D.

The Psychosocial Correlates of Infertility in Saudi Arabia
Fahad D. Alosaimi, M.D.

The Effect of Thought Disorder on Remission of Symptoms in Schizophrenia
Koksal Alptekin, M.D.

Treatment Options for Spitting Behavior in an Adult Patient With History of Chronic Schizophrenia and Pervasive Developmental Disorder
Muhammad Asif, M.D.

Recurring Catatonia in Schizophrenia Following Acute ECT: A Case Report and Review
Muhammad Asif, M.D.

Synthetic Marijuana: Potential Pitfalls!
Sumayya B. Ayaz, M.D.

Pre- and Perinatal Exposures and Risk of Autism Spectrum Disorders
Yael Barnea, M.D., L.L.B.

Case Report of an Acute Psychosis Episode Induced by Emerging Cathinone-Like Designer Drug Available on Internet
Hafid Belhady-Tahar, M.D., Ph.D.

Associations of Ethnic Discrimination With Symptoms of Depression and Anxiety Among Hispanic Emerging Adults: A Moderated Mediation Model
Miguel Angel Cano, Ph.D., M.P.H.

The HARM: The Development of a Nimble Violence Risk Assessment Tool
Gary Chaimowitz, M.D., M.B.

Lifet ime Obesity and Diabetes Associated With Cardiovascular Diseases in Old-Age Bipolar Disorder: A 30-Year Retrospective Case-Control Study in Taiwan
Pao-Huan Chen, M.D.

Increased Risk of Hyperlipidemia in Patients With Anxiety Disorders: A Population-Based Study
I-Chia Chien, M.D., Ph.D.

Are Medical Doctors Educated Research Consumers?
Priscilla N. Chukwuke, M.D., M.P.H.

Marchiafava-Bignami Disease (MBD) and Diffusion Tensor Image (DTI) Tractography
Priscilla N. Chukwuke, M.D., M.P.H.

Cognitive and Emotional Empathy in Autism Spectrum Disorder: An FMRI Study
Seungwon Chung, M.D.

Temperament and Character Traits in Mood Disorders
Sabrina Correa da Costa, M.D.

Intergenerational Transmission of Antisocial Personality Disorder: Maternal Role and Its Declination
Ester di Giacomo, M.D.

New Onset Psychosis in Patient With Cerebral Palsy
Asha Dusad, M.D.

Overconsumption of Benzodiazepines: Is VAS the Solution?
Gael Fournis, M.D.

Opportunity and Challenges in Mental Health and Psychosocial Support Sector After Mega Earthquake in Nepal
Shree Ram Ghimire, M.D.

Factors Associated With Noncompliance in Schizophrenia
Shree Ram Ghimire, M.D.

Duloxetine Induced Urinary Retention
Shree Ram Ghimire, M.D.

DMDD: A Diagnostic Dilemma in Pediatric and Adolescent Mood Disorders
Pooja Shah, M.D.

Psychotic Episode as First Manifestation of Anti-NMDA Encephalitis: Case Report
Jesus Gomez-Trigo Baldominos, M.D.

Sociodemographic Characteristics of Children and Adolescents Referred by The School for Mental Health Treatment in a Brazilian University Clinic
Valeria Soares Gularte

Frontal Lobe Aboulia Masquerading as MDD: A Case Report and Literature Review
John Gurski, D.O.

Canadian Psychiatry Residents’ Attitudes to Becoming Mentally Ill
Tariq Hassan
P3-029
The Effect of Exposure to Forest Environment on Cytokines and Anti-Oxidants in Comparison to Urban Among Young Adults With Moderate Level of Stress
Won Kim

P3-030
Associations of Late Onset Bipolar Disorder and Brain Hyperintensities in Patients With High Intelligence: A Case Report
Muhammad Navaid Iqbal, M.D., M.B.B.S.

P3-031
Therapeutic Modalities for Psychological and Behavioral Manifestations in Patients With Lewy Body Dementia
Muhammad Navaid Iqbal, M.D., M.B.B.S.

P3-032
Late-Onset Lyme Disease-Induced Psychosis: Is it Treatable?
Muhammad Navaid Iqbal, M.D., M.B.B.S.

P3-033
Age-Related Differences in Suicidality Between Younger People and Older Adults With Depression
Tae-Youn Jun, M.D., Ph.D.

P3-034
Does Admission to Hospital Improve Short-Term Outcomes in Young People With Severe Somatic Symptom Disorders and Functional Neurological Disorders?
Sara Kakhi, M.D.

P3-035
Heart Rate Variability of Posttraumatic Stress Disorder in Korean Veterans
Suk-Hoon Kang, M.D.

P3-036
Comparison of Neurocognition Between Positional OSA Patients and Nonpositional OSA Patients in the Korean Elderly
Moon Yong Chung, M.D., Ph.D.

P3-037
Bipolar Disorder Severity Robustly Related to Illness Duration and Episode Accumulation
Saloni Shah, B.S.
Assessment of the Acute Effects of Oxytocin on Music Performance Anxiety: Preliminary Results Involving a Situation of Simulated Performance
Flávia L. Osório

Cerebral Calcification as a Differential Diagnosis for Psychiatric Disorders: A Review of the Literature
Ossama Tawakol Osman, M.D.

Alcohol Dependence and Psychiatric Comorbidity
Jerome Palazzolo, M.D., Ph.D.

Contribution of New Technologies in Therapeutic Mediation With Elderly People
Jerome Palazzolo, M.D., Ph.D.

Drug-Free Approach in Alzheimer’s Disease: A Musical Support of Behavioral Disorder During Daily Care
Jerome Palazzolo, M.D., Ph.D.

Animal Mediation With the Help of Dogs and Alzheimer-Type Dementia With Apathetic Behavior Placed in Institutions
Jerome Palazzolo, M.D., Ph.D.

The Interpretation of the Evolution of the Grasping Reflex in Dementia: Communication or Symptom?
Jerome Palazzolo, M.D., Ph.D.

Factors Affecting the Cosmetic Plastic Surgery Intention of Korean University Students
Hyemi Park, M.D.

Brain Neurochemistry as Assessed by 1H-MRS in Unmedicated Obsessive Compulsive Disorder Patients and Changes After 12 Weeks of Escitalopram Treatment
Arpit Parmar, M.D., M.B.B.S.

The Use of Anticholinergics in People With Intellectual Developmental Disability and Its Impact on the Management of Dementia
Rupal Patel, M.B.B.S.

Burnout and Academic Performance in Medical Students
Maria Beatriz Quintanilla, M.D., Ph.D.

Dementia in Indian Cinema: A Narrative Review
Badr Ratnakaran, D.P.M., M.B.B.S.

Interaction Between CRP and Cognitive Functions in Relation to APOE Gene Polymorphism in Postmenopausal Women
Kasia Gustaw Rothenberg, M.D., Ph.D.

Hepatitis C Virus and Cognitive Impairment: A Longitudinal Study
Pedro M. Sánchez-Gómez, M.D.

The Toronto Bariatric Interprofessional Psychosocial Assessment Suitability Scale (BIPASS™): A Delphi Study to Inform Assessment Tool Development
Vincent A. Santiago, B.Sc.

Status Post-Cardiac Arrest and Non-ST-Elevation Myocardial Infarction Secondary to Cocaine Abuse: A Case Report
Ulfat Shahzadi, M.D., M.B.B.S.

Chronic Pain as a Potential Risk Factor of Suicide: A Case Report
Ulfat Shahzadi, M.D., M.B.B.S.

Case Report: Psychiatric Adverse Effects of Tizanidine
Harvinder Singh, M.D.

Acetylcholinesterase Inhibitors for Delirium in Older Adults
Rajesh R. Tampi, M.D., M.S.

Are Stimulants Beneficial in Individuals With Traumatic Brain Injury?
Rajesh R. Tampi, M.D., M.S.

Substance Abuse in Consultation-Liaison Psychiatry Unit
Cristina Uzal Fernandez, M.D.

Introducing EGuru
Shuo Xiang, M.D.

Intravenous Midazolam-Droperidol (Combination), Droperidol or Olanzapine for Methamphetamine-Related Agitation in the Emergency Department
Yen Ling Yap, M.Sc.

POSTER SESSION 5 MONDAY, MAY 16

NEW RESEARCH

Mental Health During Residency and Fellowship Training: Assessing the Barriers to Seeking Care
Alexandra L. Aaronson, M.D.

Association of Platelet Hyperaggregability With Dementia: A Report of a Colombian Kindred
Juliana Acosta-Uribe

Mental Health Screening for the Baby Boomer Generation in South Korea: The Results of a Demonstration Project
Seung-Min An, M.D.

Meclofenamic Acid-Reduced Plasma CRP and Improved Scores on the NIH Toolbox Cognitive Test Battery in a Patient With Schizoaffective Disorder
Taiwo Babatope, M.D., M.B.A., M.P.H.
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P5-007</td>
<td>Developing a Quality Dashboard for Consultation-Liaison Psychiatry Services in Canada: a Pilot of Two Quality Indicators</td>
<td>Janooshsheya Balasundaram, M.D.</td>
</tr>
<tr>
<td>P5-008</td>
<td>Vortioxetine-Induced Distal Interphalangeal Joint Inflammation of the Great Toe</td>
<td>Priya Batta</td>
</tr>
<tr>
<td>P5-009</td>
<td>Psychiatric Emergency Workflow: A Resident-Driven Quality Improvement Project</td>
<td>Thomas Blair, M.D., M.S.</td>
</tr>
<tr>
<td>P5-010</td>
<td>Systematic Review of Nalmefene in Alcohol Use Disorder</td>
<td>Meelie Bordoloi, M.D.</td>
</tr>
<tr>
<td>P5-011</td>
<td>Substance Use Disorder Training in Child and Adolescent Psychiatry Fellowship: The Effect on Fellows’ Fund of Knowledge and Confidence to Treat</td>
<td>Ali Canton, M.D.</td>
</tr>
<tr>
<td>P5-012</td>
<td>Assessing Newly Developed Educational Tools Targeting Prenatal Care Providers’ Knowledge of Perinatal Mental Illnesses</td>
<td>Stephanie H. Chan, M.D.</td>
</tr>
<tr>
<td>P5-013</td>
<td>WITHDRAWN</td>
<td></td>
</tr>
<tr>
<td>P5-014</td>
<td>Discussing the Bleeding Risk of Co-Administered Paroxetine and Warfarin</td>
<td>Beatriz Cruz Alvarez, M.D.</td>
</tr>
<tr>
<td>P5-015</td>
<td>WITHDRAWN</td>
<td></td>
</tr>
<tr>
<td>P5-017</td>
<td>The Relationship Between Childhood Trauma, Impulsivity and Suicidality in an Inpatient Sample</td>
<td>Laura DeRubeis, B.A.</td>
</tr>
<tr>
<td>P5-018</td>
<td>Strep, Tics and PANDAS, Oh My!</td>
<td>Kanwaldeep Dhillon, M.D.</td>
</tr>
<tr>
<td>P5-019</td>
<td>Management of Psychosis in an AIDS Patient During Febrile Neutropenia: A Case Report</td>
<td>Jennifer M. Erickson, D.O.</td>
</tr>
<tr>
<td>P5-020</td>
<td>Premature Deaths of Consumers in a County Mental Health System in Southern California</td>
<td>Carlos Fernandez, M.D.</td>
</tr>
<tr>
<td>P5-021</td>
<td>Metabolic Abnormalities Related to Treatment With Selective Serotonin Reuptake Inhibitors in Patients With Schizophrenia or Bipolar Disorder</td>
<td>Katrine Kveli Fjukstad, M.D.</td>
</tr>
<tr>
<td>P5-022</td>
<td>Mental Health Screening in National Collegiate Athletic Association Division I Athletes: Is the Preparticipation Evaluation Form Effective?</td>
<td>Elyse Galles, B.A.</td>
</tr>
<tr>
<td>P5-023</td>
<td>Exacerbation of Psychosis During Titration From Fluphenazine to Aripiprazole: A Case Report and Literature Review</td>
<td>Nicholas J. Genova, M.D.</td>
</tr>
<tr>
<td>P5-024</td>
<td>Mental Illness Among Bhutanese Refugees Settled in the United States: A Review of Current Evidence</td>
<td>Aditi Giri, M.B.B.S.</td>
</tr>
<tr>
<td>P5-025</td>
<td>Health Care Utilization and Costs Associated With a Cluster of Factitious Disorder: A Case Series</td>
<td>Juliet A. Glover, M.D.</td>
</tr>
<tr>
<td>P5-026</td>
<td>Self-Inflicted Injury in Children and Adolescents: A Study From Psychiatric Services of a Latin American Hospital</td>
<td>Paloma Andrea Guerra, M.D.</td>
</tr>
<tr>
<td>P5-027</td>
<td>Wise, What and How: A Six-Session DBT Mindfulness Group in a Limited-Resource Clinic</td>
<td>Meredith Harewood, M.D.</td>
</tr>
<tr>
<td>P5-028</td>
<td>A National Dataset Analysis on the Association Between Depression and Stroke</td>
<td>Vineka Heeramun, M.D.</td>
</tr>
<tr>
<td>P5-029</td>
<td>After the First Script: Long-Term Use Trajectory of Opioids Versus NSAIDs for Non-Cancer Pain</td>
<td>Lamis Jabri, M.D.</td>
</tr>
<tr>
<td>P5-030</td>
<td>Depression Is Associated With Vitamin D Deficiency, but Not With C-Reactive Protein: A Large Retrospective Observational Study in Korean Adults</td>
<td>Chan Hyun Jung, M.D.</td>
</tr>
<tr>
<td>P5-031</td>
<td>Comparison of Depressive Symptoms Between Social Anxiety Disorder and Panic Disorder</td>
<td>Chan Hyun Jung, M.D.</td>
</tr>
<tr>
<td>P5-032</td>
<td>The Association of PHQ1 and PHQ9 Screening Results With Readmission Rates of Medically and Surgically Admitted Patients</td>
<td>Dheeraj Kaplish, M.D.</td>
</tr>
<tr>
<td>P5-033</td>
<td>Factors Associated With Insomnia in Thyroid Disorder</td>
<td>Minsu Kim</td>
</tr>
<tr>
<td>P5-034</td>
<td>Associations Between Actigraphy-Assessed Sleep Onset Latency, Inflammatory Markers and Insulin Resistance: Midlife in the United States (MIDUS) Study</td>
<td>Taeho Kim, M.D.</td>
</tr>
<tr>
<td>P5-035</td>
<td>Mental Imagery and Its Relation to Emotion Regulation in Euthymic Patients With Bipolar I Disorder</td>
<td>Keun You Kim, M.D.</td>
</tr>
<tr>
<td>P5-036</td>
<td>Association Between Alu Insertion/Deletion Polymorphism on the TPa Gene and Mirtazapine Response in Koreans With Major Depression</td>
<td>Daseul Kim, M.D.</td>
</tr>
<tr>
<td>P5-037</td>
<td>The Role of Filial Piety in Mediating Risk and Recovery in Chinese Women With a History of Suicidal Behavior: A Cross-Cultural Qualitative Study</td>
<td>June Lam, M.D.</td>
</tr>
<tr>
<td>P5-038</td>
<td>The Treatment Rate of Five-Year Tendency of Postpartum Depression in Korea: A National Health Insurance Database Study</td>
<td>Soyoen Lee, M.D.</td>
</tr>
</tbody>
</table>
P5-039 Sleep Quality of Korean Workers and Its Association With Depression and Anxiety
Woo Hyung Lee, M.D.

P5-040 Altered Resting State Functional Connectivity in Internet Gaming Disorder With Childhood Attention-Deficit/Hyperactivity Disorder Comorbidity
Deokjong Lee, M.D.

P5-041 Key Stakeholder Perceptions of Psychosocial Rehabilitation in Hunan, China: A Qualitative Study of Community Mental Health Implementation
Luming Li, M.D.

P5-042 Differential Stress Reaction Between Anxiety and Depressive Disorder
Eun Jung Li, M.D.

P5-043 Alteration of Olfactory Identification and Cognitive Function After Chemotherapy in Patients With Breast Cancer
Jongseok Lim

P5-044 Knowledge of and Attitudes Toward Alcoholism Among Church Leaders in Saint Vincent and the Grenadines
Shiyuan Liu, B.A.

P5-045 A Tale of Kraepelin and Ketamine: Using Historic Diagnostics and Experimental Therapy to Reach the Most Ill
Kelly MacDonald, M.D.

P5-046 Innovation in the Age of Health Care Reform: Implementing a “Behavioral Vaccine” to Prevent Adolescent Depression
Nicholas Mahoney, D.O.

P5-047 NIH Toolbox Flanker Inhibitory Control and Attention Test Scores Are Negatively Correlated With Plasma Levels of IL-1β in Patients With Schizophrenia
Titilayo Makanjuola, M.D.

P5-048 Putting the PEP in CPEP: A Lecture Series Designed to Orient Residents to the Psychiatric Emergency Room
Megan McLeod, M.D.

P5-049 Impact of Anti-Inflammatory Drugs on Risk of Depression After Intensive Care Requiring Mechanical Ventilation
Clara Reece Medici, B.S.

P5-050 Analysis of 30-Day Readmissions in the Context of an Atypical Psychiatric Presentation
Sahil Munjal, M.D.

P5-051 Current Trends and Attitudes of Residents Toward Personal Psychotherapy During Residency Training
Sahil Munjal, M.D.

P5-052 Utilization of Crisis Helplines as a Coping Tool: A Case Report
Insiya Nasrulla, M.B.B.S.

P5-053 Use of Involuntary Medication, Seclusion and Restraint in a State Psychiatric Hospital
Malini Neramballi, M.D.

P5-054 Evaluation of Risk Factors for Antipsychotic Polypharmacy in Patients Admitted to Psychiatric Units: A Retrospective Analysis
Shreedhar Paudel, M.D., M.P.H.

P5-055 Metrics of Care Received by Catatonic Patients at Duke University Hospital
Gopalkumar Rakesh, M.D.

P5-056 Health Care Utilization in an Elderly Patient With Somatic Symptom Disorder
Matthew Richter, M.D.

P5-057 Alcoholism and Legal Implications
Maria Robles Martinez

P5-058 Emotional Flexibility and Post-Traumatic Stress Disorder Among Combat Veterans
Rebecca Rodin, M.Sc.

P5-059 Patient Characteristics, Attitude and Perceptions of Being Physically Restrained During Hospitalization
Lorena Rodriguez, M.D.

P5-060 A Case Study of Acute Onset of Mania in the Context of Mild Traumatic Brain Injury
Courtney Ann Romba, M.D.

P5-061 Childhood Factors Affecting Persistence and Desistence of ADHD Symptoms in Adulthood: Results From the MTA
Arunima Roy, M.B.B.S.

P5-062 Gene-Environment Interplay in Severity of Cognitive Impairment in Psychotic Patients
Geetanjali Sahu, M.B.B.S.

P5-063 A Case of Clinical Confusion: When Lennox-Gastaut Syndrome Is Mistaken for an Anxiety Disorder
Meghan Schott, D.O.

P5-064 Treating Incompetence to Stand Trial
Cristina M. Secarea, M.D.

P5-065 Excited Delirium With Bath Salts and Designer Drugs: A Clinical, Toxicological, Public Health and Legal Perspective
Pooja Shah, M.D.

P5-066 Aftereffects of Legalization of Marijuana: America on the Giant Chill Pill!
Pooja Shah, M.D.

P5-067 Oral Ketamine for Treatment-Resistant Major Depression: A Double-Blind Randomized Controlled Trial
Haggai Sharon, M.D.

P5-068 Left Ventricular Thrombus as a Complication of Clozapine-Induced Cardiomyopathy: A Case Report
Balwinder Singh, M.D., M.S.

P5-069 Explanatory Models of Addictive Behavior Among Ugandans
Hanna Sjöstrand, M.D.
Neurobiological Evidence of Vulnerability to PTSD in ADHD: A Controlled MRI Study Assessing Fear Circuitry in Non-Traumatized Adults With ADHD
Andrea E. Spencer, M.D.

The King of Spirochetes Goes Wild! Neurosyphilis-Triggered Mania
Leah R. Steinberg, M.D.

Changes in FDA Guidelines for a Clozapine Monitoring System in the Veteran Affairs Medical System
Ryan S. Sultan, M.D.

Examining the Clinical Course of Major Depressive Disorder in Severely Obese Patients: The Toronto Obesity Psychosocial Cohort Study
Gurneet S. Thiara, M.D.

Tobacco Use in First-Episode Psychosis: Clinical Characteristics at Baseline
Alba Toll, M.D.

Neurocognitive Performance in Adult Patients With ADHD, Bipolar Disorder (BPD) and Comorbid ADHD/BPD: Are There Different Neurocognitive Profiles?

The Summer Bridge Program: Recruiting Youth for a New Generation of Mental Health Professionals
David Tran, M.D., M.P.P.

Changes in Patient Beliefs Regarding Treatment Assignment Within a Placebo-Controlled Randomized Controlled Trial of Major Depressive Disorder
Sagar Vijapura, M.D.

Sociocultural Influence on Delusional Content in a Japanese Woman With Erotomania: A Clinical Case Report
Jose Vito, M.D.

How Do We Analyze Long-Term Injection Behavior Among Heroin Abusers?
Shao-Cheng Wang, M.D., Ph.D.

Predicting Hospitalization During Emergency Department Visits by Children and Adolescents for Psychiatric Complaints
Anna K. Wiste, M.D., Ph.D.

Utilizing Measures of Client Motivation as Indicators of Completion in Residential Substance Use Disorder Treatment in the Public Mental Health System
Keith Wood, M.D.

Reminiscence Therapy in a Patient With Depression Following Glioblastoma Multiforme Resection
Lindsay Works, D.O.

Pentosan Polysulfate Sodium Specifically Reduced Plasma Level of Soluble P-Selectin in a Patient With Schizoaffective Disorder
Fang Yang, M.D., Ph.D.

Longitudinal Impact of Current Irritability in Bipolar Disorder
Laura D. Yuen, B.A.

Alcohol and Drug Dependence in Terms of Attachments: Possible Developmental Precursors
Dana Zeid

Development of the Working Memory Test Battery in Chinese Older Adults
Layen Zhang, M.B.B.S., M.S.

Canine-Assisted Group Psychotherapy for Hospitalized Psychiatric Patients With Mood and Psychotic Disorders: A Pilot Study
Brittany B. Albright, M.D., M.P.H.

Polycystic Ovarian Syndrome in Patients Presenting to Mental Health: Incidence, Natural History and Treatment
Eric Meyer, M.D.

Mesial Temporal Lobe Resection and Impulse Control Dysfunction in a 33-Year-Old Female
Matthew Richter, M.D.

General Medical Conditions Occurring Before Suicide: A Case-Control Study
Brian K. Ahmedani, Ph.D., M.S.W.

Use of Lithium in Inpatients With Acute Bipolar Mania
Cana Aksoy Poyraz, M.D.

Association Between Neuroticism and Future Occurrence of Cardiovascular Diseases Among Depressed Persons in a Swedish Population
Aysha Almas, M.B.B.S., M.Sc.

Depression in Saudi Patients With Systemic Lupus Erythematosus: A Multicenter Study
Abdulrahman Alwahibi, M.D.

How Do Anger Expressed Inward and Anger Expressed Outward Differentially Relate to Depression, Impulsivity and Suicide Risk?
Firouz Ardalan, B.A.
<table>
<thead>
<tr>
<th>Paper Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P6-009</td>
<td>Demographic Differences in Disruptive Mood Dysregulation Disorder (DMDD) Symptoms in Psychiatric and General Population Samples</td>
<td>Raman Baweja, M.D., M.S.</td>
</tr>
<tr>
<td>P6-010</td>
<td>Comparing Caregiver Burden in Schizophrenia, Bipolar Disorder and Major Depression</td>
<td>Saagar Seth, B.S.</td>
</tr>
<tr>
<td>P6-011</td>
<td>The Effects of Long-Acting Injectables on Polypharmacy</td>
<td>Niketa Parikh, B.S.</td>
</tr>
<tr>
<td>P6-012</td>
<td>Development of an Educational Resource and Model Curriculum for Psychiatric Trainees on Use of Psychotropic Medications During Pregnancy and Lactation</td>
<td>Sheema Khan, M.D.</td>
</tr>
<tr>
<td>P6-013</td>
<td>The Relationship Between ADHD and Substance Use Disorders Among Adolescents in a Residential Setting</td>
<td>Amy B. Carnall, D.N.P., N.P.</td>
</tr>
<tr>
<td>P6-014</td>
<td>Relationship of Cariprazine Plasma Concentration to Efficacy and Safety in Patients With Schizophrenia or Bipolar Mania</td>
<td>Timothy J. Carrothers, Sc.D.</td>
</tr>
<tr>
<td>P6-015</td>
<td>Medical Comorbidity in Vascular Neurocognitive Disorders: A Matched Case-Control Study</td>
<td>Miguel Habeych, M.D., M.P.H.</td>
</tr>
<tr>
<td>P6-016</td>
<td>WITHDRAWN</td>
<td></td>
</tr>
<tr>
<td>P6-017</td>
<td>Prevalence of Disruptive Mood Dysregulation Disorder (DMDD) and Its Comorbidity With Other Clinical Disorders</td>
<td>Daria Chase, Ed.M.</td>
</tr>
<tr>
<td>P6-018</td>
<td>Efficacy of HLD200 in a Phase III Analog Classroom Study of Children With Attention-Deficit/Hyperactivity Disorder</td>
<td>Ann C. Childress, M.D.</td>
</tr>
<tr>
<td>P6-019</td>
<td>Parental Age as a Risk Factor for Obsessive-Compulsive Disorder (OCD) in a Nationwide Population-Based Sample</td>
<td>Roshan Chudal, Ph.D., M.B.B.S., M.P.H.</td>
</tr>
<tr>
<td>P6-020</td>
<td>Multidimensional Relationship Between Auditory Verbal Hallucinations and PANSS Factors of Psychopathology in Patients With Schizophrenia</td>
<td>In-Won Chung, M.D., Ph.D.</td>
</tr>
<tr>
<td>P6-021</td>
<td>Effectiveness of Electroconvulsive Therapy on Clozapine-Resistant Schizophrenia</td>
<td>In-Won Chung, M.D., Ph.D.</td>
</tr>
<tr>
<td>P6-022</td>
<td>Risk Factors and Population Attributable Fractions of Suicidal Ideation Among Korean Elderly</td>
<td>Sang-Keun Chung</td>
</tr>
<tr>
<td>P6-023</td>
<td>Mental Health Status Among Users of Mobile Mental Health Application “Mindscan” in Korea</td>
<td>Jong-II Park, M.D., Ph.D.</td>
</tr>
<tr>
<td>P6-024</td>
<td>Impact of Dose on Duration of Atomoxetine Treatment in Adults With ADHD</td>
<td>David B. Clemow, Ph.D.</td>
</tr>
<tr>
<td>P6-025</td>
<td>Prehospital Diversion of Patients With Acute Mental Health Crises With ADHD</td>
<td>Jamie O. Creed, B.S.</td>
</tr>
<tr>
<td>P6-026</td>
<td>Age at Onset in Patients With Bipolar I and II Disorders: A Comparison of Large-Sample Studies</td>
<td>Bernardo Dell’Osso, M.D.</td>
</tr>
<tr>
<td>P6-027</td>
<td>Treatment of Unipolar, Nonpsychotic Major Depressive Disorder With Transcranial Magnetic Stimulation: Examining Long-Term Efficacy of TMS</td>
<td>Kim K. Cress, M.D.</td>
</tr>
<tr>
<td>P6-028</td>
<td>A Retrospective Analysis of Transcranial Magnetic Stimulation Right Dorsolateral Prefrontal Cortex Treatments for Generalized Anxiety Disorder</td>
<td>Kim K. Cress, M.D.</td>
</tr>
<tr>
<td>P6-029</td>
<td>Mindfulness-Based Cognitive Therapy Versus Psychoeducation in Bipolar Outpatients With Subthreshold Depressive Symptoms: Preliminary Results</td>
<td>Consuelo De Dios, M.D., Ph.D.</td>
</tr>
<tr>
<td>P6-030</td>
<td>Shorter Time to Depressive Recurrence in Bipolar II Versus Bipolar I Disorders</td>
<td>Bernardo Dell’Osso, M.D.</td>
</tr>
<tr>
<td>P6-031</td>
<td>General and Mental Health Outcomes in Outdoor Behavioral Health Care: An Integrated Care Approach</td>
<td>Steven M. DeMille, Ph.D.</td>
</tr>
<tr>
<td>P6-032</td>
<td>Predictive Validity of the Modular Assessment of Risk for Imminent Suicide (MARIS) Scale: A Novel Approach to Suicide Risk Assessment</td>
<td>Nicole E. Derish, M.D.</td>
</tr>
<tr>
<td>P6-033</td>
<td>When Clozapine Fails: Acute Admissions of Patients With Treatment-Resistant Schizophrenia Who Relapsed Following Clozapine Therapy: Preliminary Data</td>
<td>Luiz Dratcu, M.D., Ph.D.</td>
</tr>
<tr>
<td>P6-034</td>
<td>Thyroid Axis Activity and Dopamine Function in Major Depression</td>
<td>Marie-Claude Mokrani, Ph.D.</td>
</tr>
<tr>
<td>P6-035</td>
<td>Early Changes in Prolactin Secretion During Antidepressant Treatment</td>
<td>Alexis Erb, M.D.</td>
</tr>
<tr>
<td>P6-036</td>
<td>An Interesting Relationship in a Psychodermatology Clinic: A Retrospective Study on the Correlation of Delusions of Infestation and Narcotic Use</td>
<td>Kristin V. Escamilla, M.D.</td>
</tr>
<tr>
<td>P6-037</td>
<td>Severity of PTSD Symptoms and Its Relationship With Severity of Alcohol-Related Problems in a Sample of Inpatients With Alcohol Use Disorder</td>
<td>Cuneyt Evren, M.D.</td>
</tr>
</tbody>
</table>
Severity of Craving Related to Severity of Adult ADHD Symptoms Among Inpatients With Alcohol Use Disorder
Cuneyt Evren, M.D.

Relationship Between Self-Mutilative Behavior and Impulsivity, Suicide Attempt and Early Onset Alcoholism Among Inpatients With Alcohol Use Disorder
Cuneyt Evren, M.D.

Relationship Between ADHD and Dissociative Experiences and PTSD in a Sample of Inpatients With Alcohol Use Disorder
Cuneyt Evren, M.D.

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Measuring the Efficacy and Safety of MLR Methylphenidate in Adults With ADHD
Angelo Fallu, M.D.

Abnormal Resting State Functional Connectivity in the Anterior Cingulate Cortex in Obsessive-Compulsive Disorder Patients
Qing Fan, M.D., Ph.D.

Home Treatment in Germany: Current Implementation Status
Karel J. Frasch, M.D.

Atomoxetine for Hoarding Disorder: A Preclinical and Clinical Investigation
Giacomo Grassi, M.D.

Distribution of Disability Attributable to Mental and Behavioral Disorders Due to Psychoactive Substances in China
Qi Guo, Ph.D.

WITHDRAWN

Adherence and Insight Into the Need for Medication in Schizophrenia: Perspective of Antipsychotic Clinical Trial Participants
Marla Hidalgo, D.O.

Two-Year Mirror Image Evaluation of Paliperidone Palmitate in an English Health Trust

A Cross-Sectional Study of Common Mental Disorders in Community Dwellers in Beijing
Yueqin Huang, M.D., Ph.D., M.P.H.

WITHDRAWN

A Cross-Sectional Study of Disability Prevalence Attributable to Autism Spectrum Disorders and Its Distribution in Children and Adolescents in China
Ning Ji

Expected and Unexpected Findings in a Study of Depot Medication
Per-Axel L. Karlsson, Ph.D.

Soft Signs—a Clinical Reality! Neurological Soft Signs in Patients With Schizophrenia, Schizoaffective Disorder and Bipolar Disorder
Per-Axel L. Karlsson, Ph.D.

ECT Augmentation in Schizophrenia—Clinical Effectiveness and Cognitive Impact: A Large Retrospective Review
Tyler Kaster, M.D.

Faster Recurrence Related to Episode Accumulation in Bipolar Disorder
Terence A. Ketter, M.D.

Difficulties in Managing Alcohol Withdrawal Delirium in a Patient With a History of Schizophrenia
Andrey Khalafian, M.D.

Decreased Task-Positive Network Connectivity in Abstinent Patients With Alcohol Dependence
Siekyeong Kim, M.D., Ph.D.

VEGF May Have a Neuroprotective Role in the Improvement of Schizophrenia or in the Treatment Effects of Antipsychotics
Yong-Ku Kim, M.D., Ph.D.

Mitochondrial Dysfunction and Lipid Peroxidation in Rat Frontal Cortex by Chronic NMDA Administration Can Be Partially Prevented by Lithium Treatment
Helena K. Kim, Ph.D.

Discovery of Serum Protein Biomarkers in Drug-Free Patients With Major Depressive Disorder
Eun Young Kim, M.D., Ph.D.

A Comparison of Clinical and Sociodemographic Characteristics of Elderly and Nonelderly Suicide Attempters
Hyun Kim, M.D., Ph.D.

Early Menarche and Risk-Taking Behavior in Korean Adolescence
Seong Hwan Kim, M.D., Ph.D.

Association Between Cytokine Gene (IFN-r, TNF-a, IL-10) Polymorphisms With Panic Disorder
Han-Joon Kim, M.D.

Combination of Maintenance Electroconvulsive Therapy (ECT) and Clozapine in a Patient With Refractory Schizophrenia: A Case Report
Chul-Eung Kim, M.D., Ph.D.

Epigenetic Regulation of the Glucocorticoid Receptor Promoter 17 in Maternally Deprived and Restrained Adult Rats
Young Hoon Kim, M.D., Ph.D.

Effects of p11 on BDNF-Induced Changes in Dendritic Outgrowth and Spine Formation in Primary Hippocampal Cells
Young Hoon Kim, M.D., Ph.D.
P6-069 Prevalence of Depression and Anxiety in Phase I Clinical Trial Oncology Patients at an Academic Cancer Center: A Pilot Study Natalie Kurkjian, M.D.

P6-070 Pharmacogenetics of Lithium Response in Bipolar Disorder in a Genetically-Isolated Population of Latin America Carlos López-Jaramillo, M.D., Ph.D.

P6-071 Emotion Recognition After the Psychotic State: A Longitudinal Study Guillermo Lahera, M.D., Ph.D.

P6-072 Double-Blind Comparison of Vilazodone and Paroxetine in Geriatric Depression Helen Lavretsky, M.D.

P6-073 High Use of Psychotropics Overdose Among Suicide Attempters in Korea Kyoung-UK Lee, M.D.

P6-074 Validation of the Korean Version of the Clinical Assessment Interview for Negative Symptoms Seung-Hwan Lee, M.D., Ph.D.

P6-075 Transitions in Problematic Internet Use: A One-Year Longitudinal Study of Boys Sang Kyu Lee, M.D., Ph.D.

P6-076 Smartphone Addiction in Korean Adolescents and Related Factors: Focusing on Smartphone Use Patterns and Parent-Child Relationships Hyuk Lee, M.D.

P6-077 Gambling Disorder and Concurrent Alcohol Use Disorder Treated With Naltrexone: A Case Report and Review of the Literature Alexandra Takayesu, M.D., M.P.H.

P6-078 Does Change in Cognition Affect Functioning After Cognitive Remediation Intervention for Patients With Schizophrenia? Jean-Pierre Lindenmayer, M.D.

P6-079 A Five-Year Follow-up Study of Mild Cognitive Impairment Incidence in Two Urban and Rural Communities in Beijing Zhaorui Liu, M.D., Ph.D., M.P.H.

P6-080 Association of SF1t-1 With Progressive Cortical Thickness Reduction: A Preliminary Longitudinal Study of Familial High Risk for Psychosis Paulo L. Lizano, M.D., Ph.D.

P6-081 A Review of the Literature on Long-Acting Injectable Antipsychotics in Children, Adolescents and Transitional-Age Youth Sarah M. Lytle, M.D.

P6-082 Psychotropic Drug Changes Contributing to Readmissions in Medically Hospitalized Psychiatric Patients: A Retrospective Study Subramoniam Madhusoodanan, M.D.

P6-083 Associated Factors on Caregiver Burden and Quality of Life in Patients With Schizophrenia Se-Ri Maeng, M.D.

P6-084 Clinical Response and Symptomatic Remission With Aptensio XR® (Methylphenidate Extended-Release Capsules) in Children and Adolescents With ADHD Greg Mattingly, M.D.

P6-085 Psychiatric and Nonpsychiatric Consultations for Substance-Related Emergency Department Visits in a Canadian University-Affiliated Hospital Setting Mir N. Mazhar, M.D.

P6-086 Atomoxetine Treatment and Sluggish Cognitive Tempo in Children With ADHD and Comorbid Dyslexia or Dyslexia in a Randomized, Placebo-Controlled Trial Keith McBurnett, Ph.D.

P6-087 Reducing Burnout in Military Health Care Professionals Through Mind Body Medicine Jeffrey Millegan, M.D., M.P.H.

P6-088 Advances in Psychodynamic Psychiatry: Separation Anxiety Elizabeth L. Auchincloss, M.D.

P6-089 Multimorbidity, Gender and Schizophrenia: A Quebec Cross-Sectional Study Javad Moamai, M.D., M.Sc.

P6-090 Association of Cardiovascular Risk Factors With Cognitive Impairment in Individuals With Schizophrenia: A Systematic Review Satyajit Mohite, M.D., M.P.H.

P6-091 Impaired Interactions Between Circadian Activity of the HPA and HPT Axes in Depression Marie-Claude Mokrani, Ph.D.

P6-092 Resource Use and Cost in a Randomized, Non-Inferiority Trial of Paliperidone Palmitate 3- Versus 1-Month Formulations in Patients With Schizophrenia Carmela Benson, M.S.

P6-093 Long-Term Treatment of Panic Disorder With Clonazepam or Paroxetine Does Not Prevent Relapse After Drug Withdrawal Antonio E. Nardi, M.D., Ph.D.

P6-094 The Association Between Psychiatric Disorders and Overactive Bladder Nicole Negbenebor, B.S.

P6-095 Impact of Early Psychiatric Consultation on Length of Hospital Stay Ivan Nikiforov, M.D.

P6-096 A Psychosocial Assistance Program for Trauma Survivors and Violence Victims in Colombia: Evaluation and Lessons Learned Jorge Ospina Duque, M.D.

P6-097 Who Eats More Cake? A Comparison of Food Addiction Prevalence in the General Population and a Population With Severe Mental Illness Nagesh Pai, M.D.
P6-098
Health Care Resource Use in Schizophrenia Patients Treated With Long-Acting Injectable Antipsychotics: Risperidone Versus Paliperidone Palmitate
Kruti Joshi, M.P.H.

P6-099
Depressive Symptom Profiles Indicating the Potential for Depression in Elderly Patients With Chronic Physical Diseases
Seon-Cheol Park

P6-100
Factor Structure of the Clinician-Rated Dimensions of Psychosis Symptom Severity in Patients With Schizophrenia
Seon-Cheol Park

P6-101
Predicting Placebo Responders: Shifting Report Frames
Steven Pashko, Ph.D.

P6-102
Clinical Lycanthropy Exacerbated by Comorbid Cannabis Use Disorder: A Case Report
Rachit Patel, M.D.

P6-103
Trends in Depression-Related Hospitalizations in the United States From 2008 to 2012
Ankur Patel, M.D.

P6-104
Outcomes Among Schizophrenia Patients Recently Hospitalized or Nonadherent to Antipsychotic Therapy
Jacqueline Pesa, Ph.D., M.P.H.

P6-105
Motives to Use Drugs in Body Dysmorphic Disorder
Katharine A. Phillips, M.D.

P6-106
Medicaid Spending in Schizophrenia Patients Reaching Versus Not Reaching Stabilized Maintenance With Once-Monthly Paliperidone Palmitate
Erik Muser, Pharm.D., M.P.H.

P6-107
Low Heritability of Neopterin in the Old Order Amish
Uttam Raheja, M.B.B.S.

P6-108
The Serum S100B as a Potential Marker in Bipolar Spectrum Disorder in Adolescents and Young Adults: Preliminary Results
Aleksandra Rajewska-Rager, M.D., Ph.D.

P6-109
Tardive Dyskinesia and Valbenazine (NBI-98854) Response as a Function of Concomitant Antipsychotic Use
Gary Remington, M.D.

P6-110
Correlates and Patient-Reported Outcomes of Reaching Early Maintenance Therapy on Paliperidone Palmitate in Community Behavioral Health Organizations
Jeffrey Anderson, Sc.D.

P6-111
A Randomized Controlled Trial of Targeted Training in Illness Management Versus Treatment as Usual in People With Serious Mental Illness and Diabetes
Martha Sajatovic, M.D.

P6-112
Residual Patient-Reported Cognitive Dysfunction: A Potential Predictor for Relapse in MDD?
Deiphine Saragoussi, M.D., M.P.H.

P6-113
Paliperidone Palmitate Three-Month Versus One-Month Formulation in Patients With Schizophrenia: A Randomized, Double-Blind, Non-Inferiority Study
Srihari Gopal, M.D., M.H.S.

P6-114
Symptomatic Remission Status in Schizophrenia Patients Treated With Paliperidone Palmitate (One-Month and Three-Month Formulations)
Srihari Gopal, M.D., M.H.S.

P6-115
Clinical Anger Scale Among Iranian Admitted Patients With Schizophrenia
Jalal Shakeri, M.D.

P6-116
Psychobiology of Suicidal Behavior in Combat Veterans
Leo Sher, M.D.

P6-117
Positive Psychological Characteristics Among Recently Discharged Patients: Strategy for Prevention of Rehospitalization
Amresh Shrivastava, M.D.

P6-118
Neosensitization to Multiple Drugs Following Valproate-Induced DRESS Syndrome
Jaemin Song, M.D.

P6-119
Clinical Significance of Restless Legs Syndrome in Patients With Late-Life Depression
Jaemin Song, M.D.

P6-120
Trends in Compassionate Use of Investigational Medicines and Implications for Mental Health Professionals
Allitia DiBernardo, M.D.

P6-121
A Study of Dog Adoption in Veterans With PTSD
Stephen L. Stern, M.D.

P6-122
Alcohol Use and Its Relation to Future Time Perspective and Need for Achievement in a Sample of Medical Students
Jagannath Subedi, M.D.

P6-123
Alterations of the Cortisol and Dehydroepiandrosterone in Perinatal Depression
Chan-Hyung Kim, M.D., Ph.D.

P6-124
Relation Between Amyloid PET Data and Clinical Factors Including Cognitive Function in Geriatric Depression: A Pilot Study
Wan-Seok Seo, M.D., Ph.D.

P6-125
Reduced Prefrontal Cortex Hemodynamic Response in Adults With Methamphetamine-Induced Psychosis
Kazuhiko Yamamuro, M.D., Ph.D.

P6-126
Eyes Open/Closed Resting State EEG Source Analysis of Children With Autism Spectrum Disorders and Those With Typical Development: A One-Year Follow-Up
Hidetoshi Takahashi, M.D., Ph.D.
Author- and Study-Funding Sources at the American Academy of Adolescent and Child Psychiatry
New Research Poster Sessions
Thomas P. Tarshis, M.D., M.P.H.

Comparative Evaluation of Vortioxetine as a Switch Therapy in Patients With Major Depressive Disorder
Michael E. Thase, M.D.

Clinical and Social Status of Adults With Possible or Probable Schizophrenia Undergoing Substance Abuse Treatment Evaluation
Megan Jones, Pharm.D., M.P.A.

Psychiatric Inpatient Suicide: A National Register-Based Study
Mei-Chin M. Tseng, M.D., Ph.D.

Hoarding Prevalence in Users of Online Classified Advertisements
Michael Van Ameringen, M.D.

A Pilot Study Evaluating the Gut Microbiome in Obsessive-Compulsive Disorder Versus Healthy Controls
Michael Van Ameringen, M.D.

Multiple-Rater Assessment of Personality Disorders in a Sample of Substance-Abusing Women
Adriana Vannucci, M.D.

Domestic Squalor: A Community Mental Health Issue
Cenk Varlik, M.D.

Inclusion of an Expert Patient as Co-Coordinator in Psychoeducation Workshops for Family Members of Bipolar Patients: An Innovative Model
Carlos Vinacour, M.D.

A Register-Based Case-Control Study of Prescription Medication Utilization in Binge Eating Disorder
Barry K. Herman, M.D.

Randomized, Double-Blind Study of the Time-Course of Effect of MLR Methylphenidate in ADHD Adults in a Simulated Adult Workplace Environment
Sharon B. Wigal, Ph.D.

WITHDRAWN

Differential Patterns of Blood Oxygenation in the Prefrontal Cortex Between Patients With Methamphetamine-induced Psychosis and Schizophrenia
Kazuhiko Yamamuro, M.D., Ph.D.

Hyperpigmentation and Bizarre Delusions: A Case Report
Alan C. Yancovitch, M.D.

Predictors of Fear of Falling Among Community-Living Elderly People in Korea: Mediation Effect of Depression and Subjective Health Status
Jong-Il Park, M.D., Ph.D.

Therapeutic Dose of Venlafaxine ER Induced Seizure: A Case Report
Chuanzhong Ye, M.D., Ph.D.

Descriptive Epidemiology of Disability Attributable to Behavioral Syndromes Associated With Physiological Disturbances and Physical Factors in China
Tingting Zhang

The DSM-5 Anxious DistressSpecifier Interview: Reliability and Validity
Mark Zimmerman, M.D.

A Clinically Useful Screen for Borderline Personality Disorder in Psychiatric Outpatients
Mark Zimmerman, M.D.

ITI-007 for the Treatment of Schizophrenia: Primary and Secondary Efficacy Endpoints and Subgroup Analyses From Two Positive Randomized, Double-Blind, Placebo-Controlled Clinical Trials
Cedric O’Gorman, M.D.

Prescription Drug Monitoring Programs: Does the Arizona CSPMP Provide More Information Than Routinely Collected in an Inpatient Psychiatric Facility?
Shabnam Sood, M.D.

Cannabis and Synthetic Cannabinoids’ (K2) Association With Psychosis Compared to Other Substances
Anahita Bassirnia, M.D.

Metabolic and Inflammatory Parameters of Clinical High Risk (CHR) for Developing Psychosis and Healthy Control Subjects: A Case Control Study
Isabel Ribeiro Caldas Domingues, M.D.
P7-003
Olfactory Processing Ability and Risky Decision Making in HIV Patients
Mohammed W. Ahmed, M.D.

P7-004
NIH Toolbox Fluid Cognition Composite Scores Are Associated With IL-1? and IL-10 in Patients With Schizophrenia
Osarhiemen Ruth Aimienwanu, M.B.B.S.

P7-005
Sociodemographic Variables and Concurrent Substance Use Are Not Predictors of Synthetic Cannabis Use
Mohammed A. Azam, M.D.

P7-006
Telecourt Versus Traditional Court for Involuntary Civil Commitments
Saileja Bysani, M.D.

P7-007
Group Process While Community Building as a Psychiatric Resident
Marc L. Campbell, D.O., Ph.D.

P7-008
New-Onset Psychosis in a Patient on Ketamine Treatment for Depression: A Case Report
Arthur Thomas Carter, M.D.

P7-009
WITHDRAWN

P7-010
Trends in Asian-American Utilizers of County Mental Health Services
Richard J. Lee, M.D.

P7-011
A Meta-Analysis of Placebo-Controlled Trials of NAC Augmentation in Schizophrenia: Possible Oxidative Profile Effects
Alexander Chen, B.A.

P7-012
Frontal Alpha Asymmetry in People With Early Life Trauma: A Resting-State Magnetoencephalography Study
Jooah Cheon

P7-013
Effects of Psychotropic Drugs on Seizure Threshold During Electroconvulsive Therapy
Su Hyuk Chi

P7-014
The Effects of Caregiver Burden, Depression and Emotion Expression on a Patient’s Perceived Criticism in Bipolar Disorder
Jenna Cohen, B.A.

P7-015
Neurocognitive Functions Characteristics of Mild Cognitive Impairment With Depression
Hyunseok Dong, M.D., Psy.D.

P7-016
Efficacy of Azithromycin Treatment for PANDAS in a Pediatric Outpatient Setting
Sarah Elmi, M.D.

P7-017
What Happened to the Fax? Qualitative Evaluation of Specialty Mental Health Referrals to Transition Care to Primary Care
Anna Fiskin, M.D., M.Sc.

P7-018
Patients With Psychotic Disorders Recognize Facial Emotional Expression Better in Emoticons Compared to Images
Mohammad A. Ghairatmal

P7-019
C-Reactive Protein Is Associated With Symptom Severity in Patients With Schizophrenia
Sumana Goddu, M.D., M.P.H.

P7-020
Impulsivity and Anhedonia in Bipolar Patients
Mariah Hawes, B.S.

P7-021
Two Threshold or Four Subthreshold Mood Elevation Symptoms Prolong Time to Recovery From Bipolar Depression
Farnaz Hooshmand, M.D.

P7-022
Trait Aggression and Relationship With Plasma Phenylalanine/Tyrosine Ratio and Toxoplasma Gondii Seropositivity
Ashwin Jacob Mathai, M.D.

P7-023
Exploratory and Confirmatory Factor Analysis of Penn State Worry Questionnaire (PSWQ)
Junwon Jeon, M.D.

P7-024
Work Productivity Improvement in Recurrent MDD Patients: Implications for Future Clinical Improvement
Manish K. Jha, M.B.B.S.

P7-025
Noncompliance to Antipsychotic Medication and Nonpsychiatric Medical Service Utilizations Among Patients With Schizophrenia and Its Related Psychoses
Soohyun Joe

P7-026
WITHDRAWN

P7-027
Hypokinesia, Cognitive Slowing and Emotional Dysregulation in a 17 Year Old: A Diagnostic Conundrum
Amanjot Kaur, M.B.B.S.

P7-028
Self-Esteem, Impulsivity and Suicidal Ideation in Mood Disordered Patients
Kahlen Hong Seon Kim, B.A.

P7-029
The Volumes of Temporal Lobe and Limbic System Are Associated With Treatment Response of Delusional Symptoms to Risperidone in Alzheimer’s Disease
Kyungwon Kim, M.D.

P7-030
Anger Coping Styles in Korean Patients With Mood Disorders
HwaGyu Suh, M.D.

P7-031
Case Series: Deliberate Foreign Body Ingestion and Borderline Personality Disorder
Timothy Kiong, M.D.

P7-032
The Dietary Status of Adults With ADHD
Jesper N. Kjær

P7-033
Evaluating the Risk of Venous Thromboembolism With Atypical Antipsychotic Initiation
Jessica A. Koenig, M.D.

P7-034
Introduction to Psychopharmacology for Psychology Interns: A Pilot Study and Sample Curriculum
Jason V. Lambrese, M.D.
P7-035
Comparison of Wearable Activity Tracker to Actigraphy for Measurement of Sleep-Wake Cycle
Hyun-Ah Lee, M.D.

P7-036
Self-Reported Empathic Responding in Euthymic Patients With Bipolar I Disorder: A Comparison With Schizophrenia Patients and Healthy Controls
Byeonghee Lee, M.D.

P7-037
Rare Occurrence of Covert Dyskinesia After Aripiprazole Discontinuation: A Case Report and Literature Review
Ahmad Hameed, M.D.

P7-038
Mass Shootings and Gun Laws: The Roles of Mental Illness and Psychiatrists on This Debate
Pankaj Manocha, M.D.

P7-039
Illness Insight and Risk for Suicidal Behavior in Bipolar Disorder
Deimante McClure, B.A.

P7-040
The Dilemma of Syrian Refugees
Aida Spahic Mihajlovic, M.D., M.S.

P7-041
Recruitment, Ideology and Strategic Prevention in Radical Extremism: A Literary Review
Aida Spahic Mihajlovic, M.D., M.S.

P7-042
Seasonal Variation in Sleep Duration in the Old Order Amish in Relation to Previously Reported Data in Preindustrial and “Modern” Societies
Hira Mohyuddin

P7-043
Effectiveness of Urgent Outpatient Services in Reducing School-Referred Emergency Room Mental Health Visits
Douna Montazeralghaem, M.D.

P7-044
Magnetic Resonance Spectroscopy Identifies a Treatment-Resistant “Hyperglutamatergic” Obsessive-Compulsive Disorder Subtype
Ross J. Mudgway

P7-045
Association of Vasomotor Symptoms With Depression, Anxiety, Stress and Metabolic Syndrome in Korean Peri- and Postmenopausal Women
Yoonmin Nam

P7-046
Pharmacokinetic Pharmacogenetic Prescribing Guidelines for Antidepressants: A Template for Psychiatric Precision Medicine
Malik Nassan, M.B.B.S.

P7-047
Immediate Mental Health and Psychosocial Problems Among Victims of the Mega Earthquake in Nepal: A Cross-Sectional Study
Hitekshya Nepal, M.D.

P7-048
Importance and Utilization of Family Therapy in Training: Resident Perspectives
Sarah A. Nguyen, M.D.

P7-049
Hospital Staff Burnout and Fatigue at a Military Medical Center During Government Shutdown
Samuel A. Nicolas, M.D.

P7-050
Associations Between Metabolic and Cardiovascular Risk Factors and Nitrite Levels in the Old Order Amish
Gursharon Nijjar, M.D.

P7-051
Personality, Cortisol and Cognition in Nondemented Subjects: A Population-Based Study
Sami Ouanes, M.D.

P7-052
NIH Toolbox Dimensional Change Card Sort Test Is Negatively Correlated With Plasma Cytokines in Patients With Schizophrenia
Ruchirkumar Arvind Patel, M.B.B.S.

P7-053
The Assessment of Hedonic Capacity in Depressed and Healthy Populations: The Snauth-Hamilton Pleasure Scale Modified for Clinician Administration
Roderic Pettigrew, B.S.

P7-054
Recurrent Self-Injurious Behavior With Subcutaneous Foreign Body Insertion in a Teenager: An Interesting Case Study
Diana Mungail Robinson, M.D.

P7-055
Admission Crisis Prevention Plan: A Tool for De-Escalation in an Acute Care Adult Psychiatric Setting
Nandita Puchakayala, M.B.B.S.

P7-056
Evaluation and Management of Functional Neurological Symptoms in Patients With Multiple Sclerosis
Naema Qureshi, M.D.

P7-057
A Case of Gender Dysphoria With Comorbid Psychotic Symptoms
Saumya Rachakonda, M.D.

P7-058
Treating Depression: The Art of Self-Healing With Intermittent Fasting
Sanjeev K. Rally, M.D.

P7-059
A Case of Catatonia and Epstein Barr Virus: Review of the Literature for Catatonia and Viral Infection
Aimy Rehim, M.D., M.P.H.

P7-060
Psychiatric Comorbidities in Eating Disordered Patients
Kathryn K. Ridout, M.D., Ph.D.

P7-061
Sex Differences in Adolescent Patients With Eating Disorders
Samuel J. Ridout, M.D., Ph.D.

P7-062
Health Professional Students as Lay Counselors: An Evidence-Informed Model for the Delivery of Behavioral Health to Uninsured Immigrants
Juan Rodriguez-Guzman, B.S.

P7-063
Data Mining of the Stanley Neuropathology Consortium Integrative Database to Understand the Neurobiology of Major Depressive Disorder: GABA
Shilpa Sachdeva, M.D.

P7-064
A Case of Wilson’s Disease With Normal Copper Levels Presenting as Mania
Shilpa Sachdeva, M.D.

P7-065
Denying Admission to a “Suicidal” Patient
Stuti Bhandari, M.D.
P7-066  
A Comparison of Schizophrenia Patients With or Without Medication Compliance  
Dilek Sarikaya Varlik, M.D.

P7-067  
Inpatient Psychiatry Home Medication Protocol: Reducing Health Care Costs While Improving Safe Patient Care at a Navy Medical Center  
Stephanie A. Scully, M.D.

P7-068  
Evaluation of Relationship Between MBTI Personality Factors and Big Five Personality Traits With Premenstrual Symptoms  
Mahrokh Shayanpour, M.D.

P7-069  
Substance Use in Post-Bariatric Surgery Patients: A Review of the Literature  
Sharvari P. Shivanekar, M.D.

P7-070  
Vaping Special K: A Novel Method of Ketamine Ingestion  
Jessica J. Sierzchula, D.O.

P7-071  
Influence of HTR3 Genetic Variations on Obsessive-Compulsive Disorder: A Single-Marker and Haplotype-Based Association Study  
Sungyun Sohn, M.D.

P7-072  
Is There a Link Between Chronic Infection With Toxoplasma Gondii and Obesity in Schizophrenia?  
Alice E. Stone, M.D.

P7-073  
Genetic Influences on Cardiovascular Side Effects of ADHD Pharmacotherapy  
Ajith Subhash

P7-074  
Can the CANS Be Meaningfully Used to Facilitate Transitions in a County Child Mental Health System?  
Dawn Sung, M.D.

P7-075  
Enhancing Patient Safety in the Context of Patient Falls on Psychiatric Acute Care Units in a Community Hospital  
Bibiana M. Susaimanickam, M.B.B.S.

P7-076  
Vitamin D Level in Patients With Alcohol Use Disorders: A Review of the Current Literature  
Vitor S. Tardelli, M.D.

P7-077  
Public Perceptions of Major Depressive Disorder: A 2015 Disease Awareness Survey  
Doug Taylor, M.B.A.

P7-078  
“Weeding” the Synthetic Weeds: Cutting-Edge Diagnostic Systems to Assess Designer Drug Use  
Tina S. Thakrar, M.D., M.B.A.

P7-079  
The Impact of PTSD and Perceived Self-Efficacy on Resting State Functional Connectivity in Combat Veterans  
Roseann F. Titcombe-Parekh, M.D., Ph.D.

P7-080  
Changes in Child and Adolescent Psychiatric Clients’ Prescriptions Following New Regulatory Requirements in California  
Evan J. Trager, M.D.

P7-081  
Preliminary Findings From the Smartphone and Online Usage-Based Evaluation for Depression (SOLVD) Study: Clinical and Electronic Data Agreement  
Anh L. Truong, M.D.

P7-082  
Scores on NIH Toolbox Pattern Comparison Processing Speed Test Are Negatively Correlated With Plasma Levels of IL-10 in Patients With Schizophrenia  
Hema Venigalla, M.B.B.S.

P7-083  
Feasibility and Acceptability of Implementing Telepsychiatry for Monolingual Spanish Speakers in a Community Behavioral Health System  
Christopher White, M.D.

P7-084  
Personality Disorder Comorbidity in Major Depression Inpatient Treatment: An Analysis of Routine Data From the German VIPP Dataset  
Hauke F. Wiegand, M.D., Ph.D.

P7-085  
Knowledge of and Attitudes Toward Alcohol Use and Alcoholism Among Bar Tenders and Rum Shopkeepers in Saint Vincent and the Grenadines  
Maryam Zafer, M.S.

P7-086  
Brain Regional Homogeneity Underlying Asthma With Health Anxiety  
Yuqun Zhang
P8-005
Subchronic Vortioxetine Treatment—But Not Escitalopram—Enhances Pyramidal Neuron Activity in the Rat Prefrontal Cortex
Francesc Artigas, Ph.D.

P8-006
Mood Stabilizer Therapy for Bipolar Disorder Also Treats Comorbid Chronic Pain
David M. Ash, M.D., M.B.A., M.S.

P8-007
Atypical Neuroleptic Malignant Syndrome: Diagnostic Dilemmas and Treatment Challenges
Hafizullah Azizi, M.D.

P8-008
Effect of Adjunctive Brexpiprazole on Cognitive and Physical Functioning in Five Exploratory, Open-Label Studies on Major Depressive Disorder
Ross A. Baker

P8-009
Antiviral-Induced Depression: A Case Study
Michael Reid Bowes, D.O.

P8-010
Suicide Crisis Syndrome and Near-Term Suicidal Behavior: Validation of the Suicide Crisis Inventory
Jessica Briggs, B.A.

P8-011
Effectiveness of Neurostar Transcranial Magnetic Stimulation (TMS) in Patients With Major Depressive Disorder With Postpartum Onset
David G. Brock, M.D.

P8-012
Evaluation of Paliperidone Palmitate Long-Acting Injectable (LAI) Therapy in Patients With Schizophrenia by Duration of Illness
Brianne Brown, Psy.D.

P8-013
Lurasidone Adjunctive to Lithium or Valproate for Prevention of Recurrence in Patients With Bipolar I Disorder: Results of a 28-Week Study
Joseph Calabrese, M.D.

P8-014
WITHDRAWN

P8-015
Different Attachment Style and Bereavement Response in Parents After Losing a Child Due to Sewol Ferry Accident
Jeong-Ho Chae

P8-016
Unresolved Bereavement and Other Mental Health Problems Among the Bereaved Parents of Sewol Ferry Accident Victims After 18 Months
Jeong-Ho Chae

P8-017
Mental-Physical Comorbidity in Korean Adults: Results From a Nationwide General Population Survey in Korea
Sung Man Chang, M.D., Ph.D.

P8-018
WITHDRAWN

P8-019
Pilot Study of Cardiovascular Risks and Insulin Resistance in Neuroleptic-“Induced Parkinsonism (NIP) in Schizophrenia: A Post-Hoc Analysis of RCT
Simon Chiu, M.D.,Ph.D.

P8-020
Genetic Risk Factors Associated With Commonly Prescribed Psychotropic Medications
Zia Choudhry, M.D., Ph.D., M.Sc.

P8-021
Understanding Differences in Evaluating Insight Into Psychosis Between Clinicians and Individuals With Schizophrenia
In-Won Chung, M.D., Ph.D.

P8-022
Efficacy of Cariprazine in Negative, Cognitive and Social Function Symptoms of Schizophrenia: Post-Hoc Analysis of a Randomized Controlled Trial
Andrew J. Cutler, M.D.

P8-023
WITHDRAWN

P8-024
Smartphone Apps as Therapy Extenders in Anxiety, Mood and Cognitive Disorders: The Consumer’s Perspective
Dale D’Mello, M.D.

P8-025
Spirituality Training in the Medical Curriculum: A Medical Student Perspective
Stacy J. Doumas, M.D.

P8-026
Early Improvement Is a Predictor of Response and Remission in Bipolar I Disorder: A Pooled Analysis of Three Randomized Cariprazine Trials
Suresh Durgam, M.D.

P8-027
Safety and Efficacy of Cariprazine in FDA-Approved Dose Ranges for Schizophrenia and Bipolar I Disorder: A Pooled Post-Hoc Analysis
Willie Earley, M.D.

P8-028
Injection Site Reactions and Pain Associated With Long-Acting Injectable Antipsychotics Paliperidone Palmitate Once-Monthly and Once-Every-3-Months
Erica Elefant, M.S.W., R.N.

P8-029
Effect of Adjunctive Brexpiprazole on Weight and Metabolic Parameters: An Analysis of Short- and Long-Term Trials in Major Depressive Disorder
Hans Eriksson

P8-030
Drug-Related Mortality in Camden, NJ: Demographics and Substance Misuse Trends During the 2010–2013 Period
Kalvin Foo, B.Sc.

P8-031
Dextromethorphan/Quinidine Improved Symptoms of Pseudobulbar Affect Irrespective of Concomitant Antidepressant Use
Andrea Formella, Pharm.D.

P8-032
Schizophrenia Disease Course Trajectory and Early Illness Intervention: A Review of the Literature and the DREaM Study Design
Dong-Jing Fu, M.D., Ph.D.

P8-033
Efficacy of Asenapine in Pediatric Patients With Manic and Mixed Episodes of Bipolar I Disorder
Chris Gache, M.D.

P8-034
Baseline Differences in Two Depressed Populations: Major Depression With Mixed Features Versus Bipolar I Depression
Keming Gao, M.D., Ph.D.
<table>
<thead>
<tr>
<th>Paper ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P8-035</td>
<td>Efficacy and Safety of Adjunctive Bitopertin Versus Placebo in Obsessive-Compulsive Disorder: Results From the Phase II Skylyte Study</td>
<td>Ayana Gibbs, M.D., Ph.D.</td>
</tr>
<tr>
<td>P8-037</td>
<td>Pre- and Intra-Medical School Factors Associated With Psychiatry Specialty Choice: AAMC Data Analysis</td>
<td>Matthew N. Goldenberg, M.D., M.Sc.</td>
</tr>
<tr>
<td>P8-038</td>
<td>Caregiver Burden in Schizophrenia: Pooled Analysis of the Involvement Evaluation Questionnaire Data for Paliperidone Palmitate 3-Month Formulation</td>
<td>Srilhari Gopal, M.D., M.H.S.</td>
</tr>
<tr>
<td>P8-039</td>
<td>Medication Use Among Commercially-Insured Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) in the U.S.</td>
<td>Regina Grebla, Ph.D., M.P.H.</td>
</tr>
<tr>
<td>P8-040</td>
<td>Post-Traumatic Stress in Primary Care</td>
<td>Raz Gross, M.D., M.P.H.</td>
</tr>
<tr>
<td>P8-041</td>
<td>Ocular Biomarker for Diagnosis of Attention-Deficit/Hyperactivity Disorder</td>
<td>Doug Hyun Han, M.D., Ph.D.</td>
</tr>
<tr>
<td>P8-042</td>
<td>Product Features and Support for Optimizing Engagement With Digital Health Tools for Patients With Serious Mental Illness: An Expert Consensus Survey</td>
<td>Ainslie Hatch, Ph.D.</td>
</tr>
<tr>
<td>P8-043</td>
<td>Adrenergic Postprandial Syndrome and Hypotension in Anxiety and Affective Spectrum Disorders—a Diet: A Therapeutic Approach in an Outpatient Sample</td>
<td>Cristian Y. Herrera, M.D., Ph.D.</td>
</tr>
<tr>
<td>P8-044</td>
<td>Lack of Pharmacokinetic or Pharmacodynamic Interaction Between Encenicline and Ethanol</td>
<td>Dana Hilt, M.D.</td>
</tr>
<tr>
<td>P8-045</td>
<td>The Impact of Encenicline on the Cardiometabolic Profile of Patients With Schizophrenia: Results From a Phase 2b Study</td>
<td>Stephen Brannan, M.D.</td>
</tr>
<tr>
<td>P8-046</td>
<td>Maternal Lifestyle Within 24 Hours Before Delivery May Be Linked to the Autism Epidemic</td>
<td>Silvia Haisch-Clapauch, M.D.</td>
</tr>
<tr>
<td>P8-047</td>
<td>New-Onset Anxiety Symptoms Associated With Use of Oxandrolone Bodybuilding Supplement</td>
<td>Mark N. Hreish, M.D.</td>
</tr>
<tr>
<td>P8-048</td>
<td>Lurasidone in Bipolar Depression: Acute Stable Response as a Predictor of Long-Term Treatment Response</td>
<td>Dan V. Iosifescu, M.D., M.Sc.</td>
</tr>
<tr>
<td>P8-049</td>
<td>Improvement in Psychosocial Functioning Predicts Long-Term Symptomatic Remission: Findings From CO-MED Trial</td>
<td>Manish K. Jha, M.B.B.S.</td>
</tr>
<tr>
<td>P8-050</td>
<td>Screening for Depression at a Colocated Behavioral Health Student-Faculty Collaborative Clinic</td>
<td>Meissa M. Jones, M.S.</td>
</tr>
<tr>
<td>P8-051</td>
<td>Undiagnosed Medulloblastoma Presenting With Psychiatric Symptoms: A Case Report</td>
<td>Divya E. Jose, M.D.</td>
</tr>
<tr>
<td>P8-052</td>
<td>Synthetic Marijuana-Induced Rhabdomyolysis: A Case Report</td>
<td>Divya E. Jose, M.D.</td>
</tr>
<tr>
<td>P8-053</td>
<td>Treatment Patterns in Medicaid Patients With Schizophrenia Initiating First- or Second-Generation Long-Acting Injectable Versus Oral Antipsychotics</td>
<td>Kruti Joshi, M.P.H.</td>
</tr>
<tr>
<td>P8-054</td>
<td>Valbenazine (NBI-98854) Is Effective for Treating Tardive Dyskinesia in Individuals With Schizophrenia or Mood Disorder</td>
<td>Richard C. Josiassen, Ph.D.</td>
</tr>
<tr>
<td>P8-055</td>
<td>Long-Term Tolerability of Aripiprazole Once-Monthly in Patients With Schizophrenia Following Treatment of an Acute Exacerbation</td>
<td>Timothy Peters-Strickland, M.D.</td>
</tr>
<tr>
<td>P8-056</td>
<td>Epigenetic Changes of BDNF Promoter Methylation in Post-Traumatic Stress Disorder: Findings From the Korean Combat Veterans of the Vietnam War</td>
<td>Jee In Kang</td>
</tr>
<tr>
<td>P8-058</td>
<td>A Six-Month, Open-Label, Multicenter Study of the Safety and Efficacy of Multi-Layer Release Methylphenidate (MLR) in Adults With ADHD</td>
<td>Sohail Khattak, M.D.</td>
</tr>
<tr>
<td>P8-059</td>
<td>Influence of Depression on Working Memory Measured by Digit Backward Span in Subjects With Mild Cognitive Impairment and Dementia</td>
<td>Chaeri Kim</td>
</tr>
<tr>
<td>P8-060</td>
<td>Sociodemographic Status, Psychological Problems and Quality of Life in Urban-Dwelling Single Mothers in South Korea</td>
<td>Ga Eun Kim</td>
</tr>
<tr>
<td>P8-061</td>
<td>Comparison of Behavioral Problems in Children With Newly Diagnosed, Untreated ADHD and Children With Epilepsy</td>
<td>Hee Yeon Choi, M.D.</td>
</tr>
<tr>
<td>P8-062</td>
<td>Pharmacological Characteristics of Major Human Metabolites of Cariprazine</td>
<td>Béla Kiss, M.Sc.</td>
</tr>
<tr>
<td>P8-063</td>
<td>CSF PK and PD Effects of Multiple Doses of BI 425809, a Novel GlyT1 Inhibitor, in Healthy Volunteers</td>
<td>Oliver Kleiner, Ph.D.</td>
</tr>
</tbody>
</table>
P8-064
Frequency of Urine Drug Monitoring and Illicit Substance Use in Patients With Mental Illness
Mancia Ko, Pharm.D.

P8-065
A Marker of Poor Data Quality: Identical PANSS Ratings During Screening Period Predict Identical PANSS Ratings After Randomization
Alan Kott, M.D.

P8-066
Does Early Improvement With Vilazodone Predict Response and Remission in Patients With MDD?
Kenneth Kramer, Ph.D.

P8-067
A Comparative Study of the Effects of Bupropion and Escitalopram on Internet Gaming Disorder Patients Young Sik Lee, M.D., Ph.D.

P8-068
Medicaid Spending Associated With Paliperidone Palmitate or Oral Atypical Antipsychotic Treatment Among Adults Recently Diagnosed With Schizophrenia
Patrick Lefebvre, M.A.

P8-069
Antidepressant Effect of Wuling Powder in Learned Helplessness Mice Model
Dongmei Li, M.A.

P8-070
Identify the Role of Attachment and Relational Measures in Predicting Postdischarge Imminent Suicidality
Shuang Li, M.D., Ph.D.

P8-071
Psychiatric Stability Maintained in Tardive Dyskinesia Subjects Treated With Valbenazine (NBI-98854)
Jean-Pierre Lindenmayer, M.D.

P8-072
A Profile of Responders to Neurocognitive Remediation in Schizophrenia
Jean-Pierre Lindenmayer, M.D.

P8-073
Encenicline Is Not Associated With Signals of Abuse Potential in Recreational Drug Users
Gordon R. Loewen, Ph.D.

P8-074
The Adherence Challenge in Schizophrenia: Can Medical Education Improve Physicians’ Knowledge of Management Options?
Jovana Lubarda, Ph.D.

P8-075
MDD and GAD: Effect of Continuing Medical Education on Psychiatrists’ Knowledge of the Latest Clinical Data
Jovana Lubarda, Ph.D.

P8-076
Seasonal Affective Disorder and Visual Impairment: Association to Eye Diagnoses
Helie Madsen, M.D.

P8-077
Total PANSS Correlated With Interferon Gamma and Interleukin-1 Beta in Patients With Schizophrenia
Gurtej S. Mann, M.D.

P8-078
Increased Levels of Oxytocin in Adult OCD Patients
Donatella Marazziti, M.D.

P8-079
Efficacy of Cariprazine on Predominant Negative Symptoms of Patients With Schizophrenia: Post-Hoc Analysis of PANSS Data, Marder Factors and Cognition
Stephen R. Marder, M.D.

P8-080
KINECT 3: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Valbenazine (NBI-98854) for Tardive Dyskinesia
Stephen R. Marder, M.D.

P8-081
Risk Factors for New-Onset Major Depressive Disorder and Dysthymia: Results From the Longitudinal Finnish Health 2011 Survey
Niina Markkula, M.D., M.Sc.
P8-094
Psychosis in Machado-Joseph Disease
Antonio L. Nascimento, M.D., M.Sc.

P8-095
Long-Term Cariprazine Treatment for the Prevention of Relapse in Patients With Schizophrenia: Analysis of Additional Efficacy Outcomes
Henry A. Nasrallah, M.D.

P8-096
Clinical Characteristics, Comorbidities and Health Care Utilization Among Patients With Major Depressive Disorder With Mixed Features
Daisy S. Ng-Mak, Ph.D.

P8-097
Cost Savings Associated With Improved Adherence Among Patients With Schizophrenia Using Lurasidone
Daisy S. Ng-Mak, Ph.D.

P8-098
Case Report: Addition of Naltrexone and Bupropion to Lorcaserin to Manage Olanzapine-Induced Weight Gain
Kevin R. Bera, B.S.

P8-099
Symptomatic and Functional Remission as a Therapeutic Objective in Major Depressive Disorder: Vortioxetine Comparative Data in the Working Population
Rebecca Z. Nielsen, M.Sc.

P8-100
Postpartum Patients Admitted to an Inpatient Psychiatric Unit: An 18 Months’ Experience
Armagan Ozdemir

P8-101
Psychometric Properties of the Turkish Version of the Brief Cognitive Assessment Tool
Erguvan T. Ozel-Kizil, M.D.

P8-102
Japanese and Caucasian Pharmacokinetics of Single Doses of BI 425809: A Double-Blind Placebo-Controlled Study in Healthy Volunteers
Jiyeon (Regina) Park

P8-103
Testing Intranasal Oxytocin for Enhancing Social Cognition in Borderline and Schizotypal Personality Disorder
M. Mercedes Perez-Rodriguez, M.D., Ph.D.

P8-104
Characterization of Population Pharmacokinetics of Cariprazine and Its Major Metabolites
Antonia Periclou, Ph.D.

P8-105
Changing Trends in Child and Adolescent Inpatient Psychiatric Hospitalization: The Association Between Decreasing Length of Stay and Readmission Rate
Christopher A. Petersen, M.D.

P8-106
A Multicenter, Eight-Week Study to Assess Usability of a Digital Health Feedback System in Adults With Schizophrenia Treated With Oral Aripiprazole
John Docherty, M.D.

P8-107
East Versus West: Cultural Variations in Video Game Play Among Adolescents and Associated Violence
Diana Mungall Robinson, M.D.

P8-108
The Influence of Slept Hours on Functioning and Quality of Life in Bipolar Disorder
Garcia Portilla, Ph.D.

P8-109
Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Encenicline as Procognitive Treatment in Patients With Schizophrenia
Steven Potkin, M.D.

P8-110
Efficacy of Lurasidone in Patients With Schizophrenia With Prominent Positive Symptoms: A Pooled Analysis of Short-Term Placebo-Controlled Studies
Steven Potkin, M.D.

P8-111
Stress Reactivity in the Context of Trauma Exposure and Marijuana Use
Vanja Radoncic, B.A.

P8-112
Does Metabolic Monitoring of Patients on Antipsychotic Medication Improve Management?
Mahdi Razafsha, M.D.

P8-113
Long-Term Safety and Durability of Effect of Aripiprazole Lauroxil in a One-Year Schizophrenia Extension Study
Robert Risinger, M.D.

P8-114
Symptom Stability in a 52-Week Schizophrenia Extension Study of Treatment With Long-Acting Injectable Aripiprazole Lauroxil
Robert Risinger, M.D.

P8-115
The Effect of Social Connectedness and Controllability on Suicidal Thoughts on Near-Term Suicidal Ideation and Behavior
Raquel E. Rose, B.S.

P8-116
Anti-Inflammatory Agents in the Treatment of Bipolar Depression: A Meta-Analysis
Joshua D. Rosenblat, M.D.

P8-117
Predictors of Response of a Comparative Trial of Six-Month Buprenorphine Implants and Sublingual Buprenorphine in Stable Opioid Dependent Patients
Richard N. Rosenthal, M.D., M.A.

P8-118
A Concierge Model of CAE Plus Long-Acting Injectable Antipsychotic in Individuals With Schizophrenia at Risk for Nonadherence and Homelessness
Martha Sajatovic, M.D.

P8-119
Neurological and Psychiatric Comorbidities Assessment in the PRISM II Study of Dextromethorphan/Quinidine for Treatment of Pseudobulbar Affect
William Sauve, M.D.

P8-120
Total Cholesterol Is Positively Correlated With Scores on the NIH Toolbox Cognitive Test Battery in Patients With Schizophrenia
Ashwini Saxena, M.D., Ph.D.

P8-121
Treatment of Addition in Alzheimer’s Disease: The Efficacy of Rationale for Combination Therapy With Galantamine and Memantine
Luisa C. Schmidt, M.D.
P8-122
Gender Differences in Mental Health Among 10- to 14-Year-Old Children Who Were Very Low Weight at Birth
Maria Serrano-Villar, M.S.

P8-123
Privacy Denied: Exploring the Tensions Between Procedural Justice and Respect for Privacy at the Consent and Capacity Board
Janooshsha Balasundaram, M.D.

P8-124
Factors Affecting Psychiatric Disorders in Offspring of Parents With Bipolar Disorder in South Korea
Se-Hoon Shim, M.D., Dr.P.H.

P8-125
The Normalization of Brain F-18-FDG Hypometabolism Following Electroconvulsive Therapy in a Woman With Treatment-Resistant Depression: A Case Report
Se-Hoon Shim, M.D., Dr.P.H.

P8-126
WITHDRAWN

P8-127
Transcranial Magnetic Stimulation Treatment of Depression Using a 20 Hertz Theta Burst Pulse Pattern: A Consecutive Case Series
William F. Stubbeman, M.D.

P8-128
Comparable Neuropsychiatric Safety Observed With Deutetrabenazine Treatment and Placebo in Patients With Huntington Disease (First-HD)
Victor Sung, M.D.

P8-129
Depression and Social Cognition in Schizophrenia
Jung Sung Il

P8-130
Lurasidone for Major Depressive Disorder With Mixed Features: Effect of Irritability
Alan C. Swann, M.D.

P8-131
Use of Repetitive Transcranial Magnetic Stimulation in ECT-Resistant Major Depression: A Case Series
Daniel Drew Tarman, M.D., M.Eng.

P8-132
Case Series of Deep Repetitive Transcranial Magnetic Stimulation to the Medial Prefrontal and Anterior Cingulate Cortices After HI Failure
Aron Tendler, M.D.

P8-133
Andrew N. Tuck, B.Sc.

P8-134
Correlates of Clozapine Use After a First Episode of Schizophrenia Compared to Patients Not Prescribed Clozapine: A Long-Term Prospective Study
Alp Ucok, M.D.

P8-135
A Look at Implementation of TeamSTEPPS on an Acute Inpatient Psychiatric Unit
Hiren Umrania, M.D.

P8-136
Factors Associated With Assaultive Behavior of Men and Women With Psychosis: The Importance of Victimization
Jan Vevera, M.D., Ph.D.

P8-137
“We Don’t Talk About That Stuff”: A Toolkit for Integrating Sexual and Reproductive Health Services Into Outpatient Psychiatric Practice
Martha C. Ward, M.D.

P8-138
Efficacy of Cariprazine in Bipolar Depression: Post-Hoc Band-Pass Analyses of Two Randomized, Double-Blind, Placebo-Controlled Trials
Lakshmi Yatham, M.B.B.S.

P8-139
Mild Cognitive Disorder and Depression: Treatment With and Association Between Donepezil and Escitalopram
Julio C. Zarra, M.D., Dr.P.H.

P8-140
Do Direct Survivors of Terrorism Remaining in the Disaster Community Show More Resilience Than Survivors Who Relocate?
Phebe Tucker, M.D.

P8-141
Minimal Clinically Important Difference and Treatment Response Determination for UCSD Performance-Based Skills Assessment Post Hoc Analysis
William Jacobson, Ph.D.

P8-142
Impact of Vortioxetine on Functional Capacity in MDD Patients With Cognitive Dysfunction: A UCSD Performance-Based Skills Assessment Post Hoc Analysis
William Jacobson, Ph.D.
New Research Topic Index

Abuse and Neglect Victims
P4-016, P7-013

Academic Psychiatry and Psychiatric Education
P3-014, P4-008, P4-009, P4-028, P5-009, P5-011, P5-016, P5-048, P6-120, P7-035, P8-026, P8-038, P8-075, P8-076

Addiction Psychiatry/Substance Use and Addictive Disorders
P1-001, P3-002, P3-007, P3-009, P3-015, P4-017, P4-020, P4-033, P4-038, P5-003, P5-010, P5-040, P5-044, P5-057, P5-065, P5-066, P5-069, P5-079, P5-081, P5-085, P6-013, P6-038, P6-039, P6-059, P6-075 through P6-077, P6-085, P6-097, P6-122, P6-125, P6-139, P7-006, P7-072, P7-078, P7-080, P7-087, P8-009, P8-031, P8-065, P8-068, P8-112, P8-118, P8-128

ADHD
P5-061, P5-070, P6-018, P6-024, P6-040, P6-041, P6-084, P6-086, P6-137, P7-033, P8-001, P8-024, P8-040, P8-042, P8-059, P8-062

Administrative Psychiatry (Public, Private and University)
P8-137

Aggressive Behaviors: Etiology, Assessment and Treatment
P5-059, P7-057, P8-138

AIDS and HIV
P5-019, P5-071, P7-003

Anxiety Disorders
P3-020, P4-003, P4-018, P5-031, P5-042, P6-019, P6-028, P6-065, P6-088, P6-093, P6-101, P7-017, P8-048, P8-090

Arts and Humanities (includes Historical Issues)
P8-135

Autism Spectrum Disorders
P3-008, P3-016, P6-126

Biological Psychiatry
P5-043, P5-047, P6-061, P6-070, P6-107, P7-052, P8-047

Bipolar and Related Disorders
P3-012, P3-017, P3-030, P3-37, P5-035, P5-075, P5-084, P6-014, P6-017, P6-026, P6-029, P6-030, P6-057, P6-108, P7-015, P7-021, P7-022, P7-029, P7-037, P7-040, P8-014, P8-027, P8-034, P8-049, P8-085, P8-105, P8-109, P8-117, P8-125, P8-144

Brain Imaging
P7-030, P8-052, P8-126

Child and Adolescent Psychiatry
P3-024, P3-026, P3-034, P5-046, P5-060, P6-009, P6-064, P6-081, P6-127, P7-028, P7-056, P7-076, P7-082, P8-058, P8-106, P8-108, P8-123

Clinical Case Studies (MS-RES)
P1-002 through P1-177

Cognitive Behavioral and Motivational Therapies
P5-082, P8-025

Combined Treatment (Pharmacotherapy and Psychotherapy)
P8-119

Community Development and Service Projects (MS-RES)
P2-001 through P2-013

Computers, Technology and the Internet
P4-039, P7-083, P8-043

Couples and Family Therapies
P7-050

Cultural Psychiatry and Diversity
P3-010, P4-013, P5-037, P5-076, P5-078, P6-103, P7-011, P7-031, P7-064

Curriculum Development and Educational Projects (MS-RES)
P2-014 through P2-034

Depressive Disorders
P3-027, P4-010, P5-030, P5-036, P5-067, P5-077, P6-004, P6-007, P6-027, P6-034, P6-035, P6-062, P6-067, P6-068, P6-091, P6-112, P6-128, P6-144, P7-025, P7-048, P7-055, P7-065, P8-008, P8-030, P8-035, P8-037, P8-050, P8-067, P8-070, P8-077,
# New Research Topic Index

P8-084, P8-086, P8-088, P8-097, P8-100, P8-129, P8-132, P8-140, P8-145, P8-146

**Diagnosis/Assessment**
P5-032, P5-045, P7-024, P8-051

**Disaster Psychiatry**
P3-021, P7-042, P8-016, P8-017

**Disaster/Assessment**
P7-049

**Dissociative Disorders**
P8-087

**Emergency Psychiatry**
P4-040, P5-052, P5-053, P5-080, P6-025, P8-007, P8-053

**Epidemiology**
P4-011, P6-022, P6-045, P6-051, P6-053, P6-079, P6-143, P8-018

**Ethics**
P7-007, P8-124

**Feeding and Eating Disorders**
P6-048, P6-136, P7-062, P7-063

**Forensic Psychiatry**
P3-011, P3-018, P5-064, P7-039

**Gender Dysphoria**
P7-059

**Genetics**
P7-075, P8-021

**Geriatric Psychiatry**
P4-021 through P4-024, P4-029, P6-072, P6-119, P6-124, P6-141, P8-102

**Global Mental Health and International Psychiatry**
P5-024, P5-026, P5-041, P8-015

**Group Therapies**
P6-111, P7-005

**Health Services Research**
P7-079, P7-086

**Integrated and Collaborative Care**
P5-022, P5-050, P6-010, P7-071

**Integrative Medicine (CAM)**
P6-087

**Military/Veterans and Their Families**
P7-051, P7-069

**Neurocognitive Disorders**
P3-031, P5-002, P6-015, P7-016, P7-053, P8-060, P8-130, P8-143

**Neurodevelopmental Disorders**
P4-002

**Neuropsychiatry**
P3-019, P4-004, P4-006, P4-019, P4-031, P4-036, P4-037, P5-018, P5-028, P5-086, P6-001, P7-058, P8-004

**Neuroscience**
P6-055, P8-005, P8-032, P8-120

**Non-Pharmacological Somatic Therapies (ECT, TMS)**
P6-021, P6-056, P7-014, P8-012, P8-133, P8-134

**Obsessive-Compulsive and Related Disorders**
P3-005, P4-026, P6-042, P6-044, P6-105, P6-131, P6-132, P7-046, P7-073, P8-036, P8-081

**Pain Management**
P5-029, P8-006

**Patient Oriented and Epidemiology (MS-RES)**
P2-035 through P2-083

**Patient Safety**
P7-077

**Personality Disorders**
P5-027, P6-133, P6-145, P7-001, P7-032, P8-104

**Post-Traumatic Stress Disorder (PTSD)**
P3-035, P5-058, P6-037, P6-121, P7-081, P8-041, P8-057
## New Research Topic Index

<table>
<thead>
<tr>
<th>Topic</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Psychiatric Rehabilitation and Recovery</strong></td>
<td>P6-134, P6-135</td>
</tr>
<tr>
<td><strong>Psychiatric Services: Organization and Delivery</strong></td>
<td>P6-043, P6-082, P6-095, P7-018, P7-045, P7-067, P7-085, P8-142</td>
</tr>
<tr>
<td><strong>Psychiatrists: Professional and Personal Issues</strong></td>
<td>P4-001</td>
</tr>
<tr>
<td><strong>Psychoimmunology</strong></td>
<td>P5-049, P7-023</td>
</tr>
<tr>
<td><strong>Psychopharmacology</strong></td>
<td>P4-027, P4-035, P5-004, P5-008, P5-014, P5-021, P5-023, P5-072, P6-003, P6-011, P6-049, P6-050, P6-054, P6-118, P7-002, P7-034, P7-038, P8-010, P8-020, P8-045, P8-063, P8-064, P8-074, P8-089, P8-103, P8-122, P8-145</td>
</tr>
<tr>
<td><strong>Psychosocial and Biomedical Research Projects (MS-RES)</strong></td>
<td>P2-084 through P2-108</td>
</tr>
<tr>
<td><strong>Psychosomatic Medicine</strong></td>
<td>P3-001, P3-003, P3-013, P3-029, P3-032, P4-032, P5-007, P5-055, P5-063, P5-073, P6-005, P6-036, P6-058, P6-069, P6-099, P6-140, P6-142, P7-061, P7-066, P7-088, P8-044, P8-095</td>
</tr>
<tr>
<td><strong>Religion, Spirituality and Psychiatry</strong></td>
<td>P7-060</td>
</tr>
<tr>
<td><strong>Research Design/Methodology</strong></td>
<td>P8-078, P8-079</td>
</tr>
<tr>
<td><strong>Resident, Fellows and Medical Student Concerns</strong></td>
<td>P3-028, P5-001, P5-051</td>
</tr>
<tr>
<td><strong>Schizophrenia Spectrum and Other Psychotic Disorders</strong></td>
<td>P2-109, P3-004, P3-006, P3-022, P3-025, P4-014, P5-006, P5-054, P5-062, P5-068, P5-074, P5-083, P6-020, P6-033, P6-060, P6-066, P6-071, P6-074, P6-078, P6-080, P6-083, P6-089, P6-090, P6-092, P6-098, P6-100, P6-102, P6-106, P6-109, P6-110, P6-113 through P6-115, P6-129, P6-146, P6-147, P7-004, P7-012, P7-019, P7-020, P7-027, P7-054, P7-068, P7-074, P7-084, P8-013, P8-022, P8-023, P8-028, P8-029, P8-033, P8-039, P8-046, P8-054, P8-055, P8-056, P8-066, P8-069, P8-072, P8-073, P8-080, P8-082, P8-083, P8-091, P8-094, P8-096, P8-098, P8-099, P8-107, P8-110, P8-111, P8-113 through P8-115, P8-121, P8-131, P8-136, P8-141</td>
</tr>
<tr>
<td><strong>Sleep-Wake Disorders</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Social and Community Psychiatry</strong></td>
<td>P4-007, P4-012, P4-025, P5-005, P5-020, P6-023, P7-008, P7-043, P8-061</td>
</tr>
<tr>
<td><strong>Somatic Symptom Disorders</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Suicide</strong></td>
<td>P3-033, P4-005, P4-015, P4-034, P5-017, P6-002, P6-008, P6-032, P6-047, P6-063, P6-073, P6-116, P6-130, P8-003, P8-011, P8-071, P8-092, P8-116</td>
</tr>
<tr>
<td><strong>Treatment Techniques and Outcome Studies</strong></td>
<td>P3-023, P6-031, P6-104</td>
</tr>
<tr>
<td><strong>Victims of Violence-Domestic/Combat/Crime/Terrorism/War</strong></td>
<td>P6-096</td>
</tr>
<tr>
<td><strong>Wellness</strong></td>
<td>P6-117</td>
</tr>
<tr>
<td><strong>Women's Health</strong></td>
<td>P4-030, P5-012, P5-033, P5-038, P6-012, P6-094, P6-123, P7-041, P7-047, P7-070, P8-093, P8-101, P8-139</td>
</tr>
</tbody>
</table>
Exhibits Guide

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exhibitor Sponsorship Acknowledgments</td>
<td>184</td>
</tr>
<tr>
<td>General Information</td>
<td>186</td>
</tr>
<tr>
<td>Product Theaters</td>
<td>188</td>
</tr>
<tr>
<td>Therapeutic Update</td>
<td>197</td>
</tr>
<tr>
<td>Exhibitors with Product/Service Descriptions</td>
<td>198</td>
</tr>
<tr>
<td>Exhibitors by Product/Service Listing</td>
<td>240</td>
</tr>
<tr>
<td>Career Fair and Publishers’ Book Fair Exhibitors</td>
<td>244</td>
</tr>
<tr>
<td>Numerical List of Exhibitors by Booth Number</td>
<td>246</td>
</tr>
<tr>
<td>Exhibit Hall Floor Plan</td>
<td>250</td>
</tr>
</tbody>
</table>
Exhibits Guide

The APA thanks our exhibitors for their sponsorship of the Exhibit Hall and for providing additional support for activities and services at the APA Annual Meeting. Their sponsorship supports the Annual Meeting and enriches the meeting experience for attendees. The APA deeply appreciates their support and encourages you to visit the Exhibit Hall.

Sponsorships and Support

APA Cafés (including coffee, charging stations and Wi-Fi):
- Takeda Pharmaceuticals USA, Inc. and Lundbeck

APA Doctor’s Bag Pocket:
- Sunovion Pharmaceuticals, Inc.

Exhibit Hall Charging Stations:
- Acadia Pharmaceuticals, Inc.
- Assurex Health

Hotel Key Cards:
- Alkermes, Assurex Health and Sunovion Pharmaceuticals, Inc.

Annual Meetings App:
- Alkermes

List of Exhibitors

- Acadia Healthcare
- ACADIA Pharmaceuticals
- Admera Health
- Air Force Recruiting Services
- Align International Recruitment Ltd.
- Alkermes, Inc.
- All Star Recruiting
- Allergan
- Allina Health
- AltheaDx
- American Academy of Addiction Psychiatry
- American Board of Psychiatry and Neurology, Inc.
- American Physician Institute—Beat the Boards
- American Professional Agency, Inc.
- Arbor Pharmaceuticals, LLC
- Arcadian Telepsychiatry
- Army Medical Recruiting
- Association & Meeting Solutions
- Association of Gay and Lesbian Psychiatrists (AGLP)
- Assurex Health
- Atlanta Center for Medical Research
- Aureus Medical Group
- Aurora Health Care
- Austen Riggs Center
- Barton Associates
- Bassett Healthcare Network
- Behavioral Health Recruitment Services
- Billings Clinic
- Braeburn Pharmaceuticals, Inc.
- Brainsway USA Inc.
- Brookhaven Retreat
- California Correctional Health Care Services (CCHCS)
- Cambridge University Press
- Captive Risk Planners/Perfect Tax & Finance
- CareClix
- Carilion Clinic
- Carolinas Healthcare System
- The Center for Eating Disorders at Sheppard Pratt
- Central Intelligence Agency
- Christian Medical & Dental Associations, Psychiatry Section
- Clinical Psychiatry News
- Community Health Systems
- Community Psychiatry
- CompHealth
- Compulink Business Systems, Inc.
- Correct Care Solutions, LLC
- CoverMyMeds
- Current Psychiatry
- Delta Companies
- Department of Behavioral Health & Developmental Disabilities
- Department of Veterans Affairs
- Destination Hope
- Diamond Healthcare Recruitment Division
- DR Wanted
- Electromedical Products International, Inc.
- Elsevier, Inc.
- EmCare
- FCS, Inc.
- Federal Bureau of Prisons (BOP)
- Focus: The Journal of Lifelong Learning in Psychiatry
- Fraser Health
- Genomind
- Georgia Association of Community Service Boards, Inc.
- Georgia Ketamine
- Glens Falls Hospital
- Global Medical Staffing
- Gould Farm
- Greater Hudson Valley Health System
- Group Health Physicians
- Guilford Publications
- Harmonex Neuroscience Research, Inc.
- HCPLive
- Hillside, Inc.
- Hogrefe Publishing Corp.
- Horizon Health
- Hospital Corporation of America (HCA)
- Humana Inc.
- IASIS Healthcare
- Indivior Inc.
- Infinite Trading, Inc.
Exhibits Guide

Informa Health Care Journals
InSight Telespsychiatry, LLC
Intermountain Healthcare
International Congress on Dual Disorders
Intra-Cellular Therapies Inc.
IPC Healthcare
Iris Telehealth
Ironshore Pharmaceuticals and Development, Inc.
Jackson & Coker
The JAMA Network
Janssen Pharmaceuticals, Inc.
JPE Healthcare Staffing, Inc.
Kaiser Permanente, The Permanente Medical Group, Inc.
Liberty Healthcare Corporation
LifePoint Health
Locum Source, Inc.
LocumTenens.com
Magstim
Magventure, Inc.
Maxim Physician Resources
Mayo Clinic
McLean Hospital
MD.com
MECTA Corporation
Medical Billing Professionals
Medical Search
Medicus Healthcare Solutions
MedPartners Locum Tenens
Memorial Hospital of Sweetwater County
Menninger Clinic
Merck & Co.
Metabolic Maintenance
MMH Services, Inc.
Millennium Health
Ministry Health Care
Minnesota Department of Human Services
Mount Sinai Health System
Muse: The Brain Sensing Headband
National Institute of Mental Health (NIMH)
Neba Health, LLC
NEOS Therapeutics
Neurocrine Biosciences, Inc.
NeuroNetrix
NeuroScience, Inc.
NeuroStar TMS Therapy
New York-Presbyterian Hospital
North Carolina Office of Rural Health
North GA Partnership (NoGAP)
Northeast Georgia Health System, Inc.
Northern Light Technologies
Novant Health
OmegABrite
Oregon Health & Science University, Department of Psychiatry
Oregon State Hospital
Otsuka America Pharmaceutical, Inc.
Otto Trading, Inc.
Oxford University Press
Physicians for a National Health Program
PracticeLink.com
Providence Health & Services
Psychiatric Times
PsychU
Quotient ADHD System by Pearson
Rhodes Pharmaceuticals L.P.
Riverside Health System
Rochester Regional Health
Rogers Behavioral Health System
Rogers Memorial Hospital
Routledge Journals
Routledge/CRC Press
Rutgers Center of Alcohol Studies
Saint Francis Health System/Laureate Psychiatric Clinic and Hospital
SARDAA-Schizophrenia & Related Disorders Alliance of America
Sheppard Pratt Health System
Shire
Shire U.S., Inc.
Sierra Tucson
Skyland Trail
Somatics LLC
Sotera Medical, Inc.
Southwest Behavioral Health Services
Spartanburg Regional Healthcare System
Springer
Springstone Inc.
Sun Behavioral Health
Sunovion Pharmaceuticals Inc.
Takeda Pharmaceuticals U.S.A., Inc./Lundbeck
Tallahassee Memorial Healthcare
TeiSage, Inc.
Tenet Health
The TOVA Company
Tris Pharma
TrueLearn
Tséhootsooí Medical Center
U.S. Department of State, Office of Medical Services
Unity Center for Behavioral Health
Universal Health Services, Inc.
University of Florida Department of Psychiatry
Valant Medical Solutions
Vanda Pharmaceuticals Inc.
Vanderbilt Behavioral Health
Veritas Collaborative
Via Christi Health System
Virtual Medical Staff
VISTA Staffing Solutions, Inc.
Weatherby Healthcare
Wellington Retreat
Westchester Medical Center
Wexford Health Sources
Wiley
Wolters Kluwer Health
World Health Information Network
WPA World Congress of Psychiatry 2017 Berlin
General Information

The APA exhibits program is an integral component of the overall Annual Meeting and provides an excellent opportunity for meeting registrants to obtain the latest information on products and services related to the psychiatric profession.

The meeting would not be possible without the generous support of our exhibitors, so please allow adequate time in your daily schedule to visit the exhibits, which are located in Exhibit Hall B3-B4, Level 1, Building B, in the Georgia World Congress Center. When you explore the exhibits, you will have the opportunity to participate in interactive computer programs and speak with the representatives of companies who provide services and products related directly to your professional and personal interests.

To assist in locating a particular company or product, a floor plan of the Exhibit Hall is included in this section, along with a list of: 1) alphabetical list of exhibitors with product/service description; 2) exhibitors listed by product/service; and 3) exhibitors listed numerically by booth number. Exhibit information will also be available on the Interactive Wayfinding Exhibit Hall Monitor in the exhibit hall, within the registration area.

Hospitality Lounges

Two APA Cafés, serving complimentary coffee (Locations #236 and #1837) are located in the rear of the Exhibit Hall. Please utilize these areas to relax and network with colleagues. Charging stations for cell phones and laptops, as well as free Wi-Fi, are also available in each café.

Publishers’ Book Fair

Major publishers and book sellers, including American Psychiatric Association Publishing, are located in this designated area. Participating companies are selling and taking orders for new and current professional books in the field of psychiatry.

Career Fair

Exhibitors in this area include government agencies, hospitals, locum tenens, mental health clinics, psychiatric facilities and recruiters seeking psychiatrists to fill open positions. Find APA JobCentral, the career hub for psychiatry and ultimate recruitment tool for employers and job seekers alike, located in APA Central, next to the American Psychiatric Association Publishing Bookstore.

International Pavilion

This area in the Exhibit Hall is comprised of international organizations and associations that will be holding international meetings outside of the United States.

Endorsements

Products and services displayed in the Exhibit Hall occur by the contractual arrangement between the American Psychiatric Association and participating companies. This arrangement does not constitute or imply an endorsement by the American Psychiatric Association of these products or services.

Exhibit Hall Food Voucher

Save money and use your $10 food voucher (attached to your meeting badge, for paid attendees only) redeemable for food/beverage at the concession areas inside the Exhibit Hall only. Note: There is no cash value/cash back, no replacement on vouchers and they are for one-time use only, Sunday, May 15 – Tuesday, May 17, 10:00 a.m. – 4:00 p.m.

Exhibit Hall Activities

All Exhibit Hall activities will take place in Exhibit Hall B3-B4, Level 1, Building B, in the Georgia World Congress Center:

- APA Cafés with daily coffee service, along with free Wi-Fi and charging stations for cell phones and laptops.
- Check the schedule in this Guide and plan to attend Poster Sessions, which will be held Saturday–Tuesday, and Product Theaters, which will be held Sunday–Tuesday.

Exhibit Dates and Hours

SATURDAY, MAY 14

APA Bookstore, APA Central, Publishers’ Book Fair and Career Fair open:

9:00 a.m. – 4:00 p.m.

SUNDAY, MAY 15

All commercial and educational exhibits, the International Pavilion, the APA Bookstore, APA Central, Publishers’ Book Fair and the Career Fair are open Sunday, Monday and Tuesday.

10:00 a.m. – 4:00 p.m.

MONDAY, MAY 16

10:00 a.m. – 4:00 p.m.

TUESDAY, MAY 17

10:00 a.m. – 4:00 p.m.
General Information

- The APA Bookstore, APA Central, Publishers’ Book Fair and Career Fair will open on Saturday, May 14.
- Commercial and educational exhibits and the International Pavilion will open on Sunday, May 15.

The Sunshine Act and How It Affects You

The Physician Payment Sunshine Act is a federal law that requires pharmaceutical and device manufacturers under certain circumstances to publicly report any complimentary gift, food, beverage, non-CME certified education or other items of value given to physicians. Some of the food, product theaters and trinkets that may be available to you at this meeting have been sponsored by companies that may be required to report your receipt of that gift. APA recommends that you ask the person providing the complimentary item whether your name will be reported under the Act before accepting complimentary products or food so that you can make an independent and educated decision to accept or not accept it.

Badge Color Codes

<table>
<thead>
<tr>
<th>Color</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>BLUE</td>
<td>Members</td>
</tr>
<tr>
<td>YELLOW</td>
<td>Nonmembers</td>
</tr>
<tr>
<td>RED</td>
<td>Exhibitors</td>
</tr>
<tr>
<td>GREEN</td>
<td>APA Administration</td>
</tr>
<tr>
<td>SILVER</td>
<td>Press</td>
</tr>
<tr>
<td>BLACK</td>
<td>Temporary Staff</td>
</tr>
</tbody>
</table>
APA Product Theaters are for informational and promotional purposes only and do not offer CME credit. The information presented is provided by the supporting companies and does not represent any endorsement by the American Psychiatric Association of any company or product. The sessions will take place in a separate theater area built in the Exhibit Hall. There are a total of 13, 60-minute promotional product presentation sessions. Sessions will seat 250 participants on a first-come, first-served basis. The 60-minute sessions are held Sunday, May 15 – Tuesday, May 17, with five sessions each day at 11:00 a.m., Noon, 1:00 p.m., 2:00 p.m. and 3:00 p.m. Only registered meeting participants may attend the presentations, and your meeting badge is required for admittance. Boxed lunches and beverages are provided by the APA for the programs. Supporters of these sessions include Acadia Pharmaceuticals Inc., Alkermes, Allergan, Janssen Pharmaceuticals Inc., NEOS Therapeutics, Inc., Otsuka America Pharmaceutical Inc., Shire Pharmaceuticals Inc., Rhodes Pharmaceuticals L.P., Sunovion Pharmaceuticals Inc., Takeda Pharmaceuticals, U.S.A., Inc. and Lundbeck, and Tris Pharma. Plan to attend!

These sessions are covered by the Physician Payment Sunshine Act, and physicians attending will be required to provide their identifying information for public reports.

**SUNDAY, MAY 15**

**11:00 a.m. – Noon**

*Product Theater 1*

Supported by Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck

Assessing Major Depressive Disorder and an Option for Treatment

**Presenter:**

Rakesh Jain, M.D., M.P.H.
Clinical Professor, Department of Psychiatry, Texas Tech University School of Medicine, Midland, Texas

**Noon – 1:00 p.m.**

*Product Theater 2*

Supported by Allergan

A New Antipsychotic Clinical Overview

**Presenter:**

Andrew Cutler, M.D.
Chief Medical Officer, Meridien Research Group, Tampa, Fla.; CEO and Chief Medical Officer, Florida Clinical Research Center, Bradenton, Fla.

**1:00 p.m. – 2:00 p.m.**

*Product Theater 1*

Supported by Acadia Pharmaceuticals Inc.

Understanding Parkinson’s Disease Psychosis and Its Treatment

**Presenters:**

Daniel E. Kremens, M.D., J.D.
Associate Professor of Neurology, Co-Director of the Parkinson’s Disease and Movement Disorders Division, Neurology Clerkship Director, Sidney Kimmel Medical College at Thomas Jefferson University

Henry A. Nasrallah, M.D.
The Sydney W. Souers Endowed Chair, Chairman and Professor, Department of Neurology and Psychiatry, Saint Louis University School of Medicine, Chief of Neurology and Psychiatry, University Hospital, Saint Louis University, St. Louis, Mo.

**2:00 p.m. – 3:00 p.m.**

*Product Theater 2*

Supported by Otsuka America Pharmaceutical, Inc.

Injecting a Once-Monthly Long-Acting Injectable Into the Schizophrenia Treatment Conversation

**Presenters:**

Henry A. Nasrallah, M.D.
Sydney W. Souers Endowed Chair, Chairman and Professor, Department of Neurology and Psychiatry, Saint Louis University, St. Louis, Mo.

Rebecca S. Roma, M.D.
Medical Director, Community Treatment Team Program, Assertive Community Treatment Teams, Mercy Behavioral Health and UPMC Mercy, Pittsburgh, Pa.
Product Theaters

3:00 p.m. – 4:00 p.m.
Product Theater 1
Supported by Shire Pharmaceuticals, Inc.
Beyond Childhood: Recognizing the Impact of ADHD in Adults
Presenter:
Rakesh Jain, M.D., M.P.H.
Clinical Professor, Department of Psychiatry, Texas Tech University School of Medicine, Midland, Texas

Noon – 1:00 p.m.
Product Theater 2
Supported by Sunovion Pharmaceuticals Inc.
Clinical Experts in Bipolar Depression: A Collaborative Approach to Care
Presenters:
Vladimir Maletic, M.D.
Clinical Professor, Department of Neuropsychiatry and Behavioral Science, University of South Carolina Columbia, S.C.; Consultant of Sunovion Pharmaceuticals Inc.
James Sloan Manning, M.D.
Adjunct Associate Professor, Department of Family Medicine, University of North Carolina at Chapel Hill, Chapel Hill, N.C.; Co-Director, Mood Disorders Clinic, Moses Cone Family Practice Center, Greensboro, N.C.; Consultant of Sunovion Pharmaceuticals Inc.

2:00 p.m. – 3:00 p.m.
Product Theater 2
Supported by Otsuka America Pharmaceutical, Inc. and Lundbeck LLC
Make Way for Possibilities of an Adjunctive Therapy for Major Depressive Disorder
Presenter:
Rakesh Jain, M.D., M.P.H.
Clinical Professor, Department of Psychiatry and Behavioral Sciences, Texas Tech University School of Medicine, Midland, Texas

MONDAY, MAY 16

11:00 a.m. – Noon
Product Theater 1
Supported by Alkermes
Schizophrenia: Treating a Complex Condition with a New Long-Acting Injectable (LAI)
Presenters:
Gustavo Alva, M.D., DFAPA
Medical Director, ATP Clinical Research, Pacific Neuropsychiatric Specialists, Costa Meca, Calif.
Henry A. Nasrallah, M.D.
Professor and Chairman, Department of Neurology and Psychiatry, St. Louis University School of Medicine, St. Louis, Mo.

TUESDAY, MAY 17

11:00 a.m. – Noon
Product Theater 1
Supported by Janssen Pharmaceuticals Inc.
A Review of the Safety and Efficacy of Janssen Long-Acting Atypical Antipsychotics: A Sequential Dosing for the Treatment of Schizophrenia
Presenter:
Jason C. Bermak, M.D., Ph.D.
Medical Director/Psychiatrist, SF-CARE, Inc., San Francisco, Calif.

APA product theaters are for informational and promotional purposes only, and do not offer CME credit. The information presented is provided by the supporting companies and does not represent any endorsement by the American Psychiatric Association of any company or product.
<table>
<thead>
<tr>
<th>Noon – 1:00 p.m.</th>
<th>1:00 p.m. – 2:00 p.m.</th>
<th>2:00 p.m. – 3:00 p.m.</th>
</tr>
</thead>
</table>
| **Product Theater 2**  
Supported by Otsuka America Pharmaceutical, Inc.  
**Is It Depression or Something More? Patient Identification, Diagnosis and Treatment of Pseudobulbar Affect**  
*Presenters:*  
Gerald A. Maguire, M.D., DFAPA  
Professor and Chair, Psychiatry and Neuroscience, UC Riverside School of Medicine, Riverside, Calif.  
Stephen M. Stahl, M.D., Ph.D.  
Adjunct Professor, Department of Psychiatry, University of California, San Diego School of Medicine, San Diego, Calif., Honorary Visiting Senior Fellow, University of Cambridge, Cambridge, UK, Director of Psychopharmacology, California Department of State Hospitals, Chairman, Neuroscience Education Institute (NEI)  
| **Product Theater 1**  
Supported by NEOS Therapeutics, Inc.  
**A New Product for the Treatment of ADHD**  
*Presenter:*  
Gregory W. Mattingly, M.D.  
Associate Clinical Professor, Department of Psychiatry, Washington University School of Medicine, St. Louis, Mo.; President, Midwest Research Group, St. Charles, Mo.  
| **Product Theater 2**  
Supported by Tris Pharma  
**An Update on ADHD and New Developments from Tris Pharma**  
*Presenter:*  
Ann Childress, M.D.  
President of the Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas, Nev.  
|
We are a recognized leader in delivering high-quality clinical care, advancing knowledge in the field and educating the next generation. A diversity of interests can be accommodated and positions can be tailored to emphasize clinical service delivery, teaching, and/or research. Clinical service opportunities span the ambulatory, inpatient and consultative settings. Subspecialty areas of growth include addictions, child and adolescent, forensics, geriatrics, neuropsychiatry and psychosomatic medicine.

Join Us

We are a recognized leader in delivering high-quality clinical care, advancing knowledge in the field and educating the next generation. A diversity of interests can be accommodated and positions can be tailored to emphasize clinical service delivery, teaching, and/or research. Clinical service opportunities span the ambulatory, inpatient and consultative settings. Subspecialty areas of growth include addictions, child and adolescent, forensics, geriatrics, neuropsychiatry and psychosomatic medicine.

For consideration, please email your CV and cover letter to: Kam Carlberg
Faculty Recruiter
The Ohio State University Wexner Medical Center
kamala.carlberg@osumc.edu

Ohio State is an Equal Opportunity/Affirmative Action Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability status or protected veteran status.
Early Morning Functioning in Stimulant-Treated Children and Adolescents with Attention-Deficit/Hyperactivity Disorder, and its Impact on Caregivers

Floyd R. Sallee, MD, PhD

“Conclusions: Control of EMF impairments from inadequately controlled ADHD symptoms is a significant unmet need in children and adolescents with ADHD treated with stable morning doses of stimulant medications. Current orally administered stimulant treatment options have not addressed this challenge.”
Helping People Live the Healthiest Lives Possible.

Utah has no shortage of outdoor adventure. It’s also home to one of the best healthcare networks in the nation. We are recruiting for those looking for better opportunities and a better life.

PSYCHIATRY – ADULT
Logan | Ogden | Provo | Salt Lake City | St. George

MEDICAL HEALTH INTEGRATION MEDICAL DIRECTOR
Salt Lake City

Employment position with the Intermountain Medical Group. Competitive salary and additional income for meeting quality goals. Stipend, signing bonus and student loan repayment. Full Intermountain benefits that include defined pension, 401K match, and CME. Relocation provider, up to 15K.

physicianrecruit@imail.org
800.888.3134
PhysicianJobsIntermountain.org

Unless otherwise specified, visa sponsorship is not available.
Therapeutic Update

One Therapeutic Update will be held on Monday, May 16. The update is a two-hour informational program supported by Otsuka America Pharmaceutical, Inc. The promotional program is being held as an extension of the Exhibit Hall. It features a presentation by thought leaders in therapeutic areas. CME credit is not provided for the session. Attendees must be registered for the Annual Meeting, and the meeting badge is required for admittance.

The Therapeutic Update is for informational and promotional purposes only and does not offer CME credit. The information presented is provided by the supporting companies and does not represent any endorsement by the American Psychiatric Association of any company or product. Plan to attend!

The Therapeutic Update is covered by the Physician Payment Sunshine Act, and physicians attending will be required to provide their identifying information for public reports.

MONDAY, MAY 16

6:45 p.m. – 9:00 p.m.
Omni Atlanta Hotel at CNN Center International D-F, M2, North Tower
Supported by Otsuka America Pharmaceutical, Inc.

Reception and Dinner: 6:45 p.m.
Documentary screening to begin at 7:15 p.m.

Join Otsuka for a screening of the first-ever documentary about Pseudobulbar Affect (PBA):
Beyond Laughter & Tears: A Journey of Hope

Program Host:
Stephen M. Stahl, M.D., Ph.D.,
Adjunct Professor, Department of Psychiatry, University of California, San Diego School of Medicine, San Diego, Calif.,
Honorary Visiting Senior Fellow, University of Cambridge, Cambridge, UK, Director of Psychopharmacology, California Department of State Hospitals, Chairman, Neuroscience Education Institute (NEI)

Food service begins at 6:45 p.m.
Program begins at 7:15 p.m.

The Therapeutic Update is for informational and promotional purposes only and does not offer CME credit. The information presented is provided by the supporting companies and does not represent any endorsement by the American Psychiatric Association of any company or product.
Exhibitors with Product/Service Descriptions

**Acadia Healthcare**

*Booth #1922*

6100 Tower Cir Ste 1000
Franklin, TN 37067
physiciancareerline.com

We are happy to introduce Acadia Healthcare powered by Physician Career Line. Physician Career Line is dedicated solely to physicians. Its purpose is to provide information on current events related to physicians as well as the conferences we will be attending and educational programs we have to offer. Physicians will also be able to find the latest psychiatrist positions on this site. Visit our website for more information.

**ACADIA Pharmaceuticals**

*Booth #1437*

11085 Torreyana Rd Ste 100
San Diego, CA 92121-1104
acadiapharm.com

ACADIA Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related central nervous system disorders.

**Admera Health**

*Booth #1800*

126 Corporate Blvd
South Plainfield, NJ 07080-2411
admerahealth.com

Admera Health is a CLIA-certified, CAP accredited laboratory, utilizing next-generation sequencing technology to advance the field of personalized medicine. Our expertise includes pharmacogenomics, cardiovascular disease and noninvasive cancer screening. Diagnostic test results are delivered to physicians and patients in a distilled and manageable report, giving them the relevant information to make the most informed treatment decisions.

**Air Force Recruiting Services**

*Booth #608*

550 D St W Ste 1
Randolph AFB, TX 78150
airforce.com

Air Force Recruiting Service—The world’s greatest Air Force powered by airmen, fueled by innovation. Looking for unique challenges, professional growth, and a desire to make a difference in your life as well as others? Consider a career as an Air Force biomedical sciences corps officer. Few firms can match the perks we offer: competitive salary; funded, advanced, and continuing education; comprehensive medical and dental; 30 days paid vacation each year; tax-free food and housing allowances.

**Align International Recruitment Ltd.**

*Booth #619*

429 Durham St N
Christchurch, New Zealand
alignrecruitment.com

Align International Recruitment Ltd, recruits board certified psychiatrists for full-time, direct hire positions in New Zealand. Call 1-800-511-6976 or email larry@alignrecruitment.com to explore the adventure and opportunity of a lifetime to live and work in beautiful New Zealand. New Zealand and our fabulous Kiwi lifestyle are closer than you think!

**Alkermes, Inc.**

*Booth #1623, 1811*

852 Winter St
Waltham, MA 02451-1420
alkermes.com

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include
Exhibitors with Product/Service Descriptions

schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R & D center in Waltham, Mass., a research and manufacturing facility in Athlone, Ireland, and a manufacturing facility in Wilmington, Ohio.

All Star Recruiting
Booth #617
4400 W Sample Rd Ste 250
Coconut Creek, FL 33073-3476
allstarrecruiting.com

All-Star Recruiting has been providing professional placement services and proven results to hospitals, physician groups and practice management organizations since 2003. We currently service both physician and advance practice needs for both locum and permanent medical positions. Our managing partners have over 30 years of experience, and our recruiters over 100 years of combined experience. We pride ourselves on being a recruitment firm that can provide swift, professional and reliable service without the cost, multiple contacts and headaches of a larger company. All-Star Recruiting is headquartered in Coconut Creek, Fla., and provides strategic staffing solutions for clients in numerous medical specialties.

Allergan
Booth #1337, 1546
400 Interpace Pkwy
Parsippany, NJ 07054-1120
actavis.com

Allergan is a global pharmaceutical company focused on developing, manufacturing and commercializing generic and innovative branded pharmaceutical products for patients around the world.

Allina Health
Booth #602
2925 Chicago Ave
Minneapolis, MN 55407-1321
allinahealth.org

As the largest provider of mental health and addiction services in Minnesota, Allina Health has a long and proud history of providing care to our communities. More than 150 mental health and addiction providers care for more than 100,000 patients each year at 35 primary care clinics, five specialty care clinics and eight hospitals. Services range from hospital inpatient, partial hospitalization, assessment and referral, day treatment, addiction, clinic visits, eConsultation and telemedicine. Stop by our booth or visit our website for information.

AltheaDx
Booth #1410
10578 Science Center Dr
San Diego, CA 92121-1143
altheadx.com

We are a commercial stage molecular diagnostics company specializing in the field of pharmacogenetics, or PGx. IDgenetix, our PGx product testing portfolio, enables personalized therapeutic decisions for patients suffering from some of the most prevalent clinical conditions in the United States, including neuropsychiatric disorders, cardiovascular disease and pain. Our proprietary algorithm-based bioinformatic platform and PGx product testing portfolio are intended to serve as a tool to assist healthcare providers in identifying optimal drugs for their patients as well as dosing guidelines based on a patient’s genetic make-up, current prescription regimen and other key factors. IDgenetix is designed to enable healthcare providers to make timely and evidence-based decisions, which we believe can reduce the overall cost of patient care by reducing adverse events, optimizing patients’ overall therapeutic regimen and helping to achieve a faster therapeutic response.
Exhibitors with Product/Service Descriptions

**American Academy of Addiction Psychiatry**

Booth #1603  
400 Massasoit Ave Ste 307  
East Providence, RI 02914-2012  
aap.org

The American Academy of Addiction Psychiatry is the professional membership organization for learning and sharing about the art and science of addiction psychiatry research and clinical treatment.

**American Board of Psychiatry and Neurology, Inc.**

Booth #1429  
2150 E Lake Cook Rd Ste 900  
Buffalo Grove, IL 60089-1875  
abpn.com

The American Board of Psychiatry and Neurology serves the public interest and the professions of psychiatry and neurology by promoting excellence in practice through its certification and maintenance of certification processes. ABPN also oversees the certification process for physicians seeking certification in child and adolescent psychiatry.

**American Physician Institute—Beat the Boards**

Booth #1419  
125 Windsor Dr Ste 111  
Oak Brook, IL 60523-4081  
anamericanphysician.com

American Physician Institute (API) provides dynamic medical education, CME and self-assessment credits to thousands of physicians every year. Each course provides high-yield, laser-focused content for the purpose of effectively passing their board exam or to keep up-to-date on the latest advancements. API features CME-accredited learning materials, resident director and physician dashboards, webinars, a comprehensive Q bank and board-style practice exams.

**American Professional Agency, Inc.**

Booth #1217  
95 Broadway  
Amityville, NY 11701-2718  
apmalpractice.com

Our company is a leading provider of psychiatrists medical professional liability insurance and is the only program endorsed by the American Psychiatric Association. Our policyholders receive comprehensive protection, many discounts and exceptional risk management services, which include a 24-hour daily hotline in the event of an emergency.

**Arbor Pharmaceuticals, LLC**

Booth #1717  
6 Concourse Pkwy Ste 1800  
Atlanta, GA 30328-5353  
arborpharma.com

Arbor Pharmaceuticals is an Atlanta, Ga. based specialty pharmaceutical company devoted to the treatment of diseases and disorders affecting pediatric patients. Arbor is dedicated to improving the lives of patients and caregivers by bringing improved treatments to market with an intense focus on quality and effectiveness.

**Arcadian Telepsychiatry**

Booth #1810  
7241 Hollywood Road  
Ft. Washington, PA 19034-1204  
arciadantelepsychiatry.com

Founded in 2012, Arcadian has grown to become one of the nation’s leading providers of telepsychiatry services. With more than 30 years of behavioral health and management experience, Arcadian is the clear choice among qualified care providers. Psychiatrists can work from home or established office locations, establishing reliable revenue streams without additional logistics or travel times.
Exhibitors with Product/Service Descriptions

**Army Medical Recruiting**
Booth #716
1307 3rd Ave Bldg 1307
Fort Knox, KY 40121-2725
goarmy.com

Please visit the Army Medical Recruiting booth to speak to learn more about rewarding careers in the Army Reserves or active duty Army.

**Association & Meeting Solutions**
Booth #1505
6900 Grove Road
Thorofare, NJ 08086-9447
helio.com/psychannals

Please visit the Association & Meeting Solutions exhibit for more information about products and services that will be of interest to you.

**Association of Gay and Lesbian Psychiatrists (AGLP)**
Booth #1601
4514 Chester Ave
Philadelphia, PA 19143-3707
aglp.org

The AGLP is a professional organization of psychiatrists, psychiatry residents and medical students, which serves as a voice for the concerns of lesbians and gay men within the psychiatric community. The Association is committed to fostering an accurate understanding of homosexuality, opposing discriminatory practices against gay men and lesbians, and promoting supportive, well-informed psychiatric care for lesbian and gay patients. The organization provides opportunities for affiliation and collaboration among psychiatrists who share these concerns.

**Assurex Health**
Booth #845
6030 S Mason Montgomery Rd
Mason, OH 45040-3706
assurexhealth.com

Assurex Health is the leading personalized medicine company dedicated to helping healthcare providers determine the right medication for patients with behavioral health conditions and chronic pain. We help people achieve mental wellness with advanced genomics technology providing individualized treatment support for neuropsychiatric condition.

**Atlanta Center for Medical Research**
Booth #1827
501 Fairburn Rd SW
Atlanta, GA 30331-2012
acmr.org

The Atlanta Center for Medical Research (ACMR) is a 150,000 square foot facility that accommodates up to 300 overnight participants and employs over 100 full-time research personnel. ACMR has been a national leader in research studies for more than three decades. The organization’s innovations and expertise have led the entire industry to higher standards of precision and safety. Sponsors trust ACMR to conduct the highest quality research and provide them with reliable data. Participants trust ACMR to honor their contribution with obsessive attention to their safety and comfort.

**Aureus Medical Group**
Booth #706
13609 California St Ste 500
Omaha, NE 68154-5245
aureusmedical.com

Aureus Medical is a nationwide leader in healthcare staffing and recruitment. With decades of experience, extensive resources and a nationwide network of client healthcare organizations, Aureus connects physicians in a wide spectrum of specialties with rewarding locum tenens and direct hire (full-time) opportunities across the country.
Exhibitors with Product/Service Descriptions

Aurora Health Care
Booth #506
PO Box 343930
Milwaukee, WI 53234-3930
aurora.org

Aurora Health Care is the largest integrated health system in Wisconsin providing patient care in 90 communities. Nationally recognized as a leader in quality health care and innovation, our integrated delivery model allows our physicians to support their patients, connect with colleagues and offer state-of-the-art, top tier quality care.

Austen Riggs Center
Booth #1530
25 Main St
Stockbridge, MA 01262-9701
austenriggs.org

The Austen Riggs Center holds patient authority and its completely open, voluntary and therapeutic community setting as core values in the treatment of psychiatrically complex adults. Austen Riggs is a not-for-profit, private residential treatment program and psychiatric hospital with a continuum of care. Patients receive individual psychotherapy four times weekly with a doctoral level clinician, supported by an interdisciplinary treatment team. Visit our website for information, resources, online CME/CE courses and more.

Barton Associates
Booth #1600
300 Jubilee Dr
Peabody, MA 01960-4030
bartonassociates.com

Barton Associates is a leading national locum tenens physician staffing and recruiting firm. Every day, our team engages with hospitals, medical practices and companies across the country in need of locum tenens physicians, dentists, nurse practitioners and physician assistants in a wide variety of medical specialties. You can trust that Barton Associates has the resources, scale and dedication to your career needed to help you find the perfect locum tenens job. This is all we do. We’re the locum tenens experts.

Bassett Healthcare Network
Booth #1309
1 Atwell Rd
Cooperstown, NY 13326-1394
bassett.org

Bassett Medical Center, located in beautiful Cooperstown, N.Y., is seeking well-trained BC/BE adult-psychiatrists to join our progressive multidisciplinary team. The Department of Psychiatry has a 10-bed, inpatient unit and an outpatient facility. Practice opportunities include a director of inpatient psychiatry and outpatient psychiatrist positions. Visit us at our website.

Behavioral Health Recruitment Services
Booth #1446
250 North Ave
Athens, GA 30601-2244
advantagebhs.org

Behavioral Health Recruitment Services is a division of Advantage Behavioral Health System. We are focused on the recruitment and placement of physicians, nurse practitioners, physician assistants as well as other behavioral health professionals for several Community Service Boards in Georgia. A career working for a community service board is rewarding on many levels. We provide comprehensive mental health, substance abuse and developmental disabilities services. We offer our employees medical, dental, legal and vision insurance, tuition reimbursement, CME credits and a matching 401(k). In addition to these benefits, we also participate in the Federal Loan Forgiveness Program.
Exhibitors with Product/Service Descriptions

**Billings Clinic**
*Booth #603*
801 N 29th St
Billings, MT 59101
billingsclinic.com

Billings Clinic offers psychiatric opportunities—outpatient, hospitalist seeking BE/BC adult psychiatrists to join a collegial team of 12 psychiatrists. We offer a top tier salary and student loan repayment with hours from 8 a.m. – 5 p.m., Monday through Friday, with a 1:11 weekday backup call, residency teaching opportunities, 44 inpatient beds and a tertiary referral center. Billings Clinic is a multi-specialty, physician-led organization and a proud member of the Mayo Clinic Care Network. Located in the magnificent Rocky Mountains in Billings, Mont., this friendly college community has great schools, safe neighborhoods and family activities. Exciting outdoor recreation minutes from home with 300 days of sunshine!

**Brainsway USA Inc.**
*Booth #1617*
2 Bala Plz Ste 300
Bala Cynwyd, PA 19004-1512
brainsway.com

Brainsway offers an effective, safe and noninvasive treatment for psychiatric and neurological disorders. Brainsway’s revolutionary deep TMS (transcranial magnetic stimulation) is indicated by the Food and Drug Administration for treatment of depressive episodes in adult patients diagnosed with major depressive disorder who failed to achieve satisfactory improvement from antidepressant medication in the current episode. Brainsway’s unique technology is based on patents registered by the National Institute of Health and by the company.

**Brookhaven Retreat**
*Booth #1513*
1016 Ic King Rd
Seymour, TN 37865-3150
brookhavenretreat.com

Please visit the Brookhaven Retreat, LLC exhibit for more information about The Lily Program®, an individualized mental health program for women.

**California Correctional Health Care Services (CCHCS)**
*Booth #301*
8280 Longleaf Dr Bldg D2
Elk Grove, CA 95758
changingprisonhealthcare.org

We are improving our organization’s health care services measurably by hiring exceptional, dedicated clinicians like you. Our psychiatrists have rewarding careers providing first-rate mental health care to inmate patients in each of our 35 institutions. Please visit us at Booth 301 for additional information on our great pay and benefits, qualification requirements and the application process. While there, ask us about our Visa Sponsorship Program.

**Braeburn Pharmaceuticals, Inc.**
*Booth #1405*
47 Hulfish St
Princeton, NJ 08542-3713
porettaorr.com

Braeburn Pharmaceuticals, an Apple Tree Partners company, develops and commercializes innovative medical products. The company’s first product will be Probuphine®, a buprenorphine implant currently under FDA priority review for the maintenance treatment of opioid dependence. Braeburn’s executive team has decades of experience successfully bringing blockbuster pharmaceuticals and medical devices to market, as well as a deep understanding of clinical development and quality assurance processes. Apple Tree Partners is a venture capital firm that seeks to in-license and/or acquire products to build complementary pharmaceutical, medical device and technology-enabled healthcare services companies.
Exhibitors with Product/Service Descriptions

Cambridge University Press
Booth #417
32 Avenue Of The Americas
New York, NY 10013-2473
cambridge.org

Cambridge University Press is a leading publisher of professional books and journals in psychiatry. With dozens of new books in the past year, including important new titles from Dr. Stephen M. Stahl, author of *Stahl’s Essential Psychopharmacology*. Cambridge has cutting-edge material for all mental health professionals and is pleased to announce the reconfiguration and relaunch of the journal *CNS Spectrums*, with Dr. Stahl as its Editor-in-Chief.

Captive Risk Planners/Perfect Tax & Finance
Booth #1404
6850 Tpc Dr Ste 112
McKinney, TX 75070-3145
captiveriskplanners.com

Please visit the Captive Risk Planners/Perfect Tax & Finance exhibit for more information about products and services that will be of interest to you.

CareClix
Booth #1700
1934 Old Gallows Rd Ste 350
Vienna, VA 22182-4050
careclix.com

CareClix is a comprehensive telehealth software as a service solution that combines our online medical suite with clinical patients and doctors to perform consultation similar to face-to-face consultations. Our secure HIPAA-compliant platform enables remote consultations between patients and physicians and allows for the sharing and collaboration of clinical data between all parties involved. CareClix is transforming healthcare worldwide.

Carilion Clinic
Booth #405
213 S Jefferson St Ste 1401
Roanoke, VA 24011
carilionclinic.org

The Virginia Tech Carilion School of Medicine in Roanoke, Va., has an opening for an adult psychiatrist to join the faculty of the Department of Psychiatry and Behavioral Medicine at the physician-led Carilion Clinic. The training program in general psychiatry has 34 residents and there are fellowships in child, geriatric, and addiction psychiatry. This inpatient/outpatient faculty position in psychiatry is associated with Carilion Roanoke Memorial Hospital, a 700-bed teaching/tertiary referral center with 35 acute adult psychiatric beds, and several community partner organizations. Responsibilities include direct clinical services, teaching medical students, supervising residents and fellows in psychiatry, and integrating research with clinical practice. There are opportunities for research collaboration with world-renowned neuroscientists at the Virginia Tech Carilion School of Medicine and Research Institute. Submit CV and cover letter to Amy Silcox, Physician Recruiter, amsilcox@carilionclinic.org or call 540-224-5187.

Carolinas Healthcare System
Booth #609
4135 S Stream Blvd Ste 300
Charlotte, NC 28217-4555
carolinashealthcare.org

Please visit the Carolinas Healthcare System—Behavioral Health exhibit for more information about exciting job opportunities for psychiatrists in beautiful Charlotte, N.C., and surrounding areas.
Exhibitors with Product/Service Descriptions

The Center for Eating Disorders at Sheppard Pratt
Booth #1403
6535 N Charles St Fl 3
Baltimore, MD 21204-5826
eatingdisorder.org

The Center for Eating Disorders at Sheppard Pratt offers comprehensive care for children, adolescents and adults with eating disorders. A national leader in evidence-based treatment since 1989, we provide highly specialized individual, group, family, occupational, art and nutritional therapies. Our continuum of care includes an inpatient program, partial hospital program, intensive outpatient program and free support groups and collaborative care workshops for caregivers.

Central Intelligence Agency
Booth #415
Recruitment Center
Washington, DC 20505
cia.gov

The CIA is the premier agency responsible for providing global intelligence on the ever-changing political, social, economic, technological and military environment. Here, your paramount goal and mission will be to protect the national security of the United States. Virtually any job you can imagine is available at the CIA—plus, some you can’t even imagine.

Christian Medical & Dental Associations, Psychiatry Section
Booth #1510
PO Box 7500
Bristol, TN 37621-7500
cmda.org

Christian Medical Association, Psychiatry Section is a ministry of the Christian Medical and Dental Associations. We are a 15,000 member organization providing resources, networking, education and a public voice for Christian healthcare professionals and students. The psychiatry section offers a forum for the interface of psychiatric practice and the Christian faith. APA participants are welcome to attend our concurrent programs. Visit our website for more information.

Clinical Psychiatry News
Booth #1412
7 Century Dr Ste 302
Parsippany, NJ 07054-4609
clinicalpsychiatrynews.com

Clinical Psychiatry News is an independent newspaper that provides the practicing psychiatrist with timely and relevant news and commentary about clinical developments in the field and about the impact of health care policy on the specialty and the physician’s practice.

Community Health Systems
Booth #601
4000 Meridian Blvd
Franklin, TN 37067-6325
chs.net

Community Health Systems, Inc., is one of the nation’s leading operators of general acute care hospitals. The organization’s affiliates own, operate or lease 207 hospitals in 29 states with approximately 31,100 licensed beds. Affiliated hospitals are dedicated to providing quality healthcare for local residents and contribute to the economic development of their communities. Based on the unique needs of each community served, these hospitals offer a wide range of diagnostic, medical and surgical services in inpatient and outpatient settings.

Community Psychiatry
Booth #503
3825 N Freeway Blvd Ste 100
Sacramento, CA 95834-1928
communitypsychiatry.com

Community Psychiatry began 20 years ago with one primary objective - improving patient access to psychiatric care by creating collaborative relationships with hospitals, physicians, psychotherapists and insurers. Our goal is to provide patients with knowledgeable,
Exhibitors with Product/Service Descriptions

Compassionate treatment and our doctors with the support they need to deliver the best possible care. Our group has grown to over 22 offices and over 50 psychiatrists in small group practices throughout Northern California and two offices near Ann Arbor, Mich. For our physicians, we manage the paperwork so that they can focus on their work with integrity and autonomy.

**CompHealth**

**Booth #1501**

6440 S Millrock Drive
Suite 175
Salt Lake City, UT 84121-5892
comphealth.com

CompHealth is a national leader in healthcare staffing, serving providers in more than 100 specialties. Founded in 1979, CompHealth is the largest locum tenens staffing agency in the United States. CompHealth also specializes in permanent physician placement and both temporary and permanent allied healthcare staffing. CompHealth is part of the CHG Healthcare Services family of companies, which is ranked No. 16 on *Fortune* magazine’s list of “100 Best Companies to Work For.” To learn more, visit our website.

**Compulink Business Systems, Inc.**

**Booth #1424**

1100 Business Center Cir
Thousand Oaks, CA 91320-1129
compulinkadvantage.com

A proven leader for over 30 years, Compulink is a recognized leader in ONC-certified, EHR and practice management systems for psychiatry. Offering the industry’s most flexible, most complete, and best supported system, our Psych Advantage is designed to help improve patient care and practice profitability.

**Correct Care Solutions, LLC**

**Booth #1814**

1283 Murfreesboro Pike Ste 500
Nashville, TN 37217-2421
correctcaresolutions.com

At Correct Care Solutions (CCS), we have the opportunity to serve patients who have traditionally been underserved. Mental Health in jails, prisons, psychiatric hospitals and residential treatment facilities offers an exciting and fulfilling career to psychiatrists. At CCS, we offer psychiatrists flexible career opportunities, competitive pay and benefits, and a support team that is one of the best in the industry. Join us today and grow your career with a company that values patient’s health.

**CoverMyMeds**

**Booth #1825**

2 Miranova Place
Columbus, OH 43215-5078
covermymeds.com

CoverMyMeds is the nation’s largest electronic prior authorization (ePA) platform and one of the fastest growing healthcare technology companies in the U.S. Our technology easily integrates with pharmacy systems, EHRs and PBMs to create the industry’s most efficient ePA solution, helping patients receive the medications they need, faster. With more than 1 million PA requests processed each month, we are the only vendor using the NCPDP ePA standard at scale. Over 500,000 providers currently use CoverMyMeds to submit PA requests to PBMs electronically, eliminating timely phone calls and faxes. Providers, on average, save 15 minutes per PA request by using CoverMyMeds’ secure web portal. Visit our website for more information or call 866-452-5017 to get started.
Exhibitors with Product/Service Descriptions

**Current Psychiatry**
**Booth #1414**
7 Century Dr Ste 302  
Parsippany, NJ 07054-4609  
currentpsychiatry.com

Sign up for a free subscription to *Current Psychiatry*, a leading monthly review publication and its website that provide timely, practical, peer-reviewed education and advice from leading authorities on common clinical problems, edited by Henry A. Nasrallah, M.D., and published in an educational partnership with Saint Louis University. *Current Psychiatry* is available in print to all practicing U.S. psychiatrists (in private and group settings and in hospitals), psychiatry residents, program faculty and advanced-practice mental health practitioners.

**Delta Companies**
**Booth #1928**
1755 Wittington Pl Ste 175  
Dallas, TX 75234  
thedeltacompanies.com

The Delta Companies offer permanent and temporary staffing solutions nationwide for physicians, physician extenders, allied and therapy healthcare professionals. Physician staffing services are represented by Delta physician placement and Delta locum tenens. All other allied healthcare staffing services are represented by Delta healthcare providers.

**Department of Behavioral Health and Developmental Disabilities**
**Booth #1305**
Representing Georgia’s Community Service Boards  
c/o Gateway Behavioral Health Services  
700 Coastal Village Drive  
Brunswick, GA 31520  
dbhdd.ga.gov

The Department of Behavioral Health and Developmental Disabilities, through partnership with its Community Service Boards throughout Georgia, provides a safety-net network of providers focused on offering easy access to high-quality care that leads to a life of recovery and independence for those with behavioral health challenges, substance abuse issues, and intellectual and developmental disabilities.

**Department of Veterans Affairs**
**Booth #411**
1250 Poydras St Ste 1000  
New Orleans, LA 70113-1810  
vacareers.va.gov

Please visit the Department of Veterans Affairs exhibit for more information about products and services that will be of interest to you.

**Destination Hope**
**Booth #1806**
6555 Powerline Road  
Ft. Lauderdale, FL 33309-2067  
destinationhope.net

Please visit the Destination Hope exhibit for more information about products and services that will be of interest to you.

**Diamond Healthcare Recruitment Division**
**Booth #708**
PO Box 85050  
Richmond, VA 23285-5050  
diamondhealth.com

Diamond Healthcare is a fully integrated population health management organization with a special concentration on Behavioral Health. We own or operate over 80 psychiatric programs in 31 states across the country. Whether you are just starting out or have many years practice experience, physicians of all backgrounds will find many rewarding positions within our very collegial organization.
Exhibitors with Product/Service Descriptions

**DR Wanted**

**Booth #514**

950 E Paces Ferry Rd NE Ste 2160
Atlanta, GA 30326-1384
drwanted.com

DR Wanted is a national leader in the locum tenens industry. Our areas of focus include jobs in primary care hospital, emergency medicine and anesthesiology, as well as allied health. We offer A++ malpractice insurance, bi-weekly pay and other great benefits! Best-of-Class technology and an individual high-touch philosophy, these are the cornerstones of the DR Wanted recruitment process. Our seasoned team of staffing professionals provide a personal and unique search experience with an obsessive devotion to finding the right fit. At DR Wanted, we focus on shortening the search process while also providing a precise match for both client and candidate every time. Contact us today to find out more about the resources and candidates currently available.

**Electromedical Products International, Inc.**

**Booth #1211**

2201 Garrett Morris Pkwy
Mineral Wells, TX 76067-9034
alpha-stim.com

Overwhelmed by patients with mood and sleep disorders? Alpha-Stim® can help you melt away their anxiety, depression and insomnia so they can experience life again. Alpha-Stim is supported by more research than any other prescription device in its class. Read over 55 studies and reviews revealing robust effect sizes at our website. Side effects are rare, minor and self-limiting. Pocket-sized Alpha-Stim medical devices work through ear clip electrodes that send a weak current directly into the brain for 20-minute sessions. This alters the EEG by increasing Alpha frequencies and decreasing Delta frequencies. Electromedical Products International, Inc., was founded in 1981 and is the world leader in cranial electrotherapy stimulation. Come by our booth to try it for yourself. You will be amazed at how good you will feel. Request a free 60-day loan by visiting our website or contact us at info@alpha-stim.com or 1-940-328-0788.

**Elsevier, Inc.**

**Booth #525**

1600 John F Kennedy Blvd Ste 1800
Philadelphia, PA 19103-2398
elsevier.com

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health and technology professionals, empowering them to make better decisions, deliver better care and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions—among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey—and publishes nearly 2,200 journals, including *The Lancet* and *Cell* and over 26,000 book titles, including a number of iconic reference works.

**EmCare**

**Booth #407**

13737 Noel Road, Suite 1600
Dallas, TX 75240-1331
emcare.com

EmCare is the nation’s largest multispecialty group with fantastic inpatient psychiatric opportunities in Florida, New Hampshire, Indiana and expanding across the nation. Block schedules, plenty of time off, competitive pay and comprehensive, administrative support, leadership jobs are available! Contact us at 1-214-712-2465 or visit our website for more information.

**FCS, Inc.**

**Booth #605**

1711 Ashley Cir Ste 6
Bowling Green, KY 42104-5801
fcspsy.com

Helping psychiatrists find a place to call home for over 30 years, FCS, Inc., is the leader in psychiatric recruitment, and is quickly becoming the primary source for psychiatry Locum Tenens assignments.
Exhibitors with Product/Service Descriptions

Federal Bureau of Prisons (BOP)
Booth #403
320 1st St NW
Washington, DC 20534-0002
bop.gov

Join the Leader in correctional health care! The Federal Bureau of Prisons (BOP) values your unique contribution to our collaborative team medicine approach of providing health care. Experience a level of clinical diversity and continuity of care not commonly available in the private sector. BOP has 122 federal prisons nationwide with full-time physician, dentist, physician assistant, nurse practitioner and nurse vacancies. For more information, contact BOP at 1-800-800-2676 or via email at BOP-HSD/Recruitment@bop.gov.

Focus: The Journal of Lifelong Learning in Psychiatry
Booth #1528
1000 Wilson Blvd Ste 1825
Arlington, VA 22209-3924
psychiatry.org

Focus: The Journal of Lifelong Learning in Psychiatry is the complete system for lifelong learning, maintenance of certification, self-assessment, performance in practice and CME.

Fraser Health
Booth #610
400-13450 102 Ave
Surrey, BC V3T 0H1
Canada
physicians.fraserhealth.ca

Located in the Metro Vancouver and Fraser Valley region of British Columbia, Fraser Health has 20 culturally and geographically diverse communities—from urban to rural. As the fastest-growing region in the province, we provide health services to 1.6 million people with 12 acute care hospitals, tertiary teaching hospitals and services in public health, home health, mental health and residential care facilities. Fraser Health’s mental health and substance use program provides a range of services including child, youth/adolescent, adult, geriatric psychiatry at eight of our 12 University of British Columbia affiliated hospitals and through 12 community mental health teams. Successful applicants with have their FRCPC designation (or equivalent) and be eligible for licensure with the College of Physicians and Surgeons of British Columbia. Visit us at our website.

Genomind
Booth #1227
2200 Renaissance Blvd
King Of Prussia, PA 19406-2755
genomind.com

Genomind is a personalized medicine company bringing innovation to mental healthcare through genetic testing. Genomind is comprised of pioneering researchers and thought leaders in psychiatry and neurology who specialize in pharmacogenetic laboratory testing for psychiatry. Genomind is committed to partnering with clinicians to improve their patients’ lives. Learn more at our website.

Georgia Association of Community Service Boards, Inc.
Booth #1425
3150 Golf Ridge Blvd Ste 202
Douglasville, GA 30135-1930
gacsb.org

Georgia Association of Community Service Boards, Inc. (GACSB) leads the development and operations of mental health, developmental disabilities and addictive diseases services, community-based and comprehensive in range, provided by the 26 community service boards (CSB), Georgia’s public safety net. Advocating, initiating and supporting actions designed to improve services, the GACSB serves its member organizations by speaking with one voice on matters involving CSBs.
Exhibitors with Product/Service Descriptions

**Georgia Ketamine**  
*Booth #1710*  
1370 Thompson Bridge Road, Suite 101  
Gainesville, GA 30501  
georgiaketamine.com

Georgia Ketamine offers IV Ketamine infusion treatments for clinical depression. We focus on treatment resistant depression and other MDD that do not respond adequately to appropriate courses of at least two antidepressants but not limited to treatment resistant depression, major depressive disorders, post-partum depression, bipolar depression and severe anxiety. Having been treated with at least two or more classes with no results, choose Ketamine infusions.

**Glens Falls Hospital**  
*Booth #408*  
100 Park Street  
Glens Falls, NY 12801-4431  
glensfallshospital.org

Glens Falls Hospital, in Glens Falls N.Y., is an integrated health care system, serving a six-county region of the southern Adirondacks. With 2,700 employees, 400+ credentialed providers and 28 locations, it has the region’s longest-established employed physician group. Specializations include primary care, cardiology, endocrinology, hematology/oncology, internal medicine, nephrology, otolaryngology, psychiatry, emergency and inpatient medicine, thoracic surgery and wound healing. Patients are offered a wide range of services and community health improvement programs.

**Global Medical Staffing**  
*Booth #613*  
3995 S 700 E Ste 100  
Salt Lake City, UT 84107-2536  
gmedical.com

We offer extraordinary locum tenens assignments that last from a few days, to a month, to a year or longer in locations around the globe. We handle all the details so you’re free to treat patients, free to boost your expertise, free to earn a competitive living and enjoy practicing medicine - without worrying about the business of medicine. Let us help you find your perfect place to practice!

**Gould Farm**  
*Booth #1411*  
PO Box 157  
Monterey, MA 01245-0157  
gouldfarm.org

Within the spectrum of Axis I disorders, those in recovery come to Gould Farm to gain skills to responsibly manage disruptive symptoms and construct a more useful framework for a sustainable sense of positive place in this world. Medication management, counseling, cognitive therapy, open dialogue and practical skills training are integrated into a structured work week. Spending six to 12 months in this normative, thriving community can be life changing.

**Greater Hudson Valley Health System**  
*Booth #409*  
707 E Main Street  
Middleton, NY 10940-2650  
ormc.org

We are a three hospital, not-for-profit health system coming to recruit psychiatrists for employment with our group.

**Group Health Physicians**  
*Booth #504*  
320 Westlake Ave N  
Seattle, WA 98109-5232  
grouphealthphysicians.org

Group Health Physicians is one of the nation’s largest and most honored multispecialty medical groups. This group of more than 1,400 doctors and clinicians is responsible for clinical quality and care at Group Health, a consumer-governed health system in Washington State and North Idaho with more than 600,000 plan members. In 2010, Group Health Physicians received the prestigious American Medical
Exhibitors with Product/Service Descriptions

Group Association’s Acclaim Award for physician-led innovations that have transformed care at Group Health Medical Centers. As a practitioner at Group Health Physicians, you will join a collaborative team in a professionally satisfying, patient-centered environment. Please come by our booth to learn more about the great opportunities awaiting you today at Group Health!

Guilford Publications
Booth #420
370 7th Ave Ste 1200
New York, NY 10001
guilford.com

Harmonex Neuroscience Research, Inc.
Booth #1514
408 Healthwest Dr
Dothan, AL 36303-2054
clinicom.com
CliniCom is a secure, intuitive, web-based intake and assessment tool developed by Harmonex Neuroscience Research and has been used in mental health settings for the past ten years. CliniCom generates clinical reports by gathering information directly from patients, parents and/or guardians prior to the initial office visit. Users can complete the assessment from any computer, tablet, smart phone or any other mobile devices.

HCPLive
Booth #1311
666 Plainsboro Rd Ste 300
Plainsboro, NJ 08536-3000
hcplive.com
MD Magazine is a comprehensive clinical news and information portal that provides physicians with up-to-date specialty- and disease-specific resources designed to help them provide better care to patients. At MD Magazine, you will find breaking news, video interviews with physician experts, in-depth conference coverage, finance and practice management updates, insight and analysis from physician contributors and more.

Hillside, Inc.
Booth #1521
690 Courtenay Dr NE
Atlanta, GA 30306-3421
hsdie.org
Hillside is one of Atlanta’s oldest not-for-profit organizations. Our mission is to help children and families thrive by providing outstanding residential and community mental health services. Our programs focus on the strengths of our kids and encourage the growth and improvement they need to navigate through life. Hillside is currently the only Dialectical Behavior Therapy (DBT) adherent residential treatment facility in the Southeast providing specialized cutting edge behavioral treatment and education to children and their families. We offer a continuum of care ranging from outpatient DBT clinic to residential treatment. Please visit Hillside’s exhibit for more information about our continuum of care.

Hogrefe Publishing Corp.
Booth #522
38 Chauncy St Ste 1002
Boston, MA 02111-2318
hogrefe.com
Hogrefe Publishing has been publishing books, periodicals, and assessment tools in the fields of psychiatry, medicine and psychology for over 60 years. Visit us at Booth 522! We will be presenting the latest print and online editions
Exhibitors with Product/Service Descriptions

of the Clinical Handbook of Psychotropic Drugs (CHPD) for adults and for children and adolescents. Take advantage of special offers for combining CHPD print editions and online versions.

Horizon Health
Booth #1400
1965 Lakepointe Dr Ste 100
Lewisville, TX 75057
horizonhealth.com

Founded in 1981, Horizon Health Behavioral Health Services is the leading manager and provider of hospital-based behavioral health programs. We have provided services in 47 states, working with hospitals of all types and sizes to manage their behavioral health programs, providing an additional revenue stream and helping to ease the strain on their emergency departments.

Hospital Corporation of America (HCA)
Booth #1328
2 Maryland Farms Ste 210
Brentwood, TN 37027
practicewithus.com

Hospital Corporation of America (HCA) owns and operates 160 healthcare facilities in 20 states with opportunities coast to coast. HCA was one of the nation’s first hospital companies. We are committed to the care and improvement of human life, and we strive to deliver quality healthcare that meets the needs of the communities we serve.

Humana Inc.
Booth #1812
500 W Main St Ste 300
Louisville, KY 40202-4268
humana.com

Please visit the Humana exhibit for more information about products and services that will be of interest to you.

IASIS Healthcare
Booth #505
117 Seaboard Ln Bldg E
Franklin, TN 37067-2855
iasishealthcare.com

IASIS Healthcare is a healthcare services company that seeks to deliver high-quality, cost-effective healthcare through a board and differentiated set of capabilities and assets that include acute care hospitals with related patient access points and a diversified manage care risk platform. With a total annual revenue of approximately $2.6 billion, IASIS, headquartered in Franklin, Tenn., owns and operates 16 acute care hospitals, one behavioral hospital and multiple other access points in high-growth urban and suburban markets throughout the United States, including Arizona, Arkansas, Colorado, Louisiana, Texas and Utah. This encompasses 132 physician clinics, multiple outpatient surgical units, imaging centers and investments in urgent care centers and onsite employer-based clinics, that serve more than a combined 1.1 million patients.

Indivior Inc.
Booth #1409, 1547, 1713
10710 Midlothian Turnpike
Richmond, VA 23235-4722
indivior.com

Indivior Inc. is a specialty pharmaceutical company at the forefront of providing educational resources and treatment options to physicians and patients dealing with opioid dependence. Please visit the company’s medical booth where Indivior medical personnel will be standing by.

Infinite Trading, Inc.
Booth #1614
3651 Lindell Rd Ste D120
Las Vegas, NV 89103
hidow.com

Please visit the Infinite Trading exhibit for more information about products and services that will be of interest to you.
Exhibitors with Product/Service Descriptions

**Informa Health Care Journals**
Booth #526
4 Park Square, Milton Park
Abington, OX14 4R United Kingdom
tandfonline.com

Please visit the Informa Health Care Journals exhibit for more information about products and services that will be of interest to you.

**InSight Telepsychiatry, LLC**
Booth #1616
765 E Route 70 Bldg A-100
Marlton, NJ 08053-2341
insighttelepsychiatry.com

InSight is the leading national telepsychiatry service provider organization with a mission to increase access to quality behavioral health care through telehealth. InSight’s behavioral health providers bring care into any setting on an on-demand or scheduled basis. InSight has over 16 years of telepsychiatry experience and is an industry thought-leader.

**Intermountain Healthcare**
Booth #501
36 S State St Fl 21
Salt Lake City, UT 84111-1630
physicianjobsintermountain.org

Visit Intermountain Healthcare to learn about exciting physician job opportunities (named by Forbes as one of nation’s top 25 employers in 2015). Intermountain Healthcare, a Utah-based, nonprofit system of 22 hospitals, 185 clinics, a medical group of over 1,000 employed physicians, a health plans division (Select Health), and other health services, is widely recognized as a leader in clinical quality improvement and efficient healthcare delivery.

**International Congress on Dual Disorders**
Booth #327
Londres 17
Madrid, 28028 Spain
cipd2015.com

Dual disorder is a mental disorder and an addiction, whether to substance, sex, game, electronic devices or other, is growing exponentially all over the world. The addictions can differ from continent to continent, or from culture to culture, but the disorders themselves and the increase of addictions are there. We wish to address this unsettling reality with rigor, methodology and professionalism, giving a floor for experts, peers, clinicians and mental professionals facing daily these challenges, to share a disquieting reality.

**Intra-Cellular Therapies Inc.**
Booth #644
430 E 29th St
New York, NY 10016-8367
intracellulartherapies.com

Intra-Cellular Therapies, Inc. (ITCI) is a biopharmaceutical company that is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson’s and Alzheimer’s disease. Building on the science generated from the Nobel Prize winning laboratory of Dr. Paul Greengard at The Rockefeller University, ITCI develops compounds that have the potential to treat a wide range of diseases associated with the central nervous system. The company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in dementia, depression and other neuropsychiatric and neurological disorders. ITI-007, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia and bipolar depression. The company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders.
Exhibitors with Product/Service Descriptions

**IPC Healthcare**
**Booth #401**
4605 Lankershim Blvd
North Hollywood, CA 91602-1818
hospitalist.com

IPC is the nation’s leading physician group practice company focused on the delivery of hospitalist and facility-based services. IPC’s clinicians and affiliated providers practice in hospitals and other inpatient facilities including acute, post-acute and long-term care settings.

**Iris Telehealth**
**Booth #1203**
1944 E Pembroke Ave Ste A
Hampton, VA 23663-1326
iristelehealth.com

Iris Telehealth is an innovative telepsychiatry company with a mission to provide underserved communities with access to the best mental health care possible. We have earned a reputation for providing outstanding customer service and excellent clinical care. Iris values building strong professional relationships with our partners and their staff. We are dedicated to understanding your organization’s needs and operational goals because we recognize that your success is critical to our own. At Iris, we believe that everyone deserves access to mental health services and we are proud to help provide this care where it is needed most!

**Ironshore Pharmaceuticals and Development, Inc.**
**Booth #1637**
10 Market St Ste 715
Camana Bay, KY1-9006 Cayman Islands
highlandtherapeutics.com

Ironshore Pharmaceuticals and Development, Inc., is leveraging its proprietary DELEXIS® drug delivery platform to optimize the delivery of stimulant medications for the treatment of ADHD. Ironshore seeks to fulfill a significant unmet medical need in the treatment of ADHD—inadequate symptom control during the early morning routine. Dosed in the evening, DELEXIS® provides a consistent delay in initial release of the active drug, followed by controlled, extended-release, to target meaningful control of ADHD symptoms immediately upon wakening and throughout the day.

**Jackson & Coker**
**Booth #1622**
3000 Old Alabama Rd Ste 119-608
Alpharetta, GA 30022-8555
jacksoncoker.com

At Jackson & Coker, we focus on you—the patient’s true hero. When you are looking for flexibility, Jackson & Coker’s concierge level service makes it convenient to work locum tenens. Our credentialing department, privileging assistance, and travel coordinators will handle all the details. When you are ready to settle down, our permanent recruiting consultants can help you find the job of a lifetime.

**The JAMA Network**
**Booth #624**
330 N Wabash Ave Ste 39300
Chicago, IL 60611-5885
jamanetwork.com

Building on a tradition of editorial excellence, The JAMA Network brings JAMA together with 11 specialty journals to offer enhanced access to the research, viewpoints and medical news shaping medicine today and into the future. JAMA Cardiology, a new peer-reviewed journal will publish in early 2016.

**Janssen Pharmaceuticals, Inc.**
**Booth #637**
1000 Route 202
Raritan, NJ 08869-1425
janssen.com

Janssen Pharmaceuticals, Inc., a pharmaceutical company of Johnson & Johnson, provides medicines for an array of health concerns in several therapeutic areas, including diabetes, mental health, pain management and cardiovascular disease.
Exhibitors with Product/Service Descriptions

**JPE Healthcare Staffing, Inc.**

**Booth #404**

5665 Atlanta Hwy Ste 103-102
Alpharetta, GA 30004-3932
jpehealth.com

Please visit the JPE Healthcare Staffing, Inc. exhibit for more information about Locum Tenens and permanent placement that will be of interest to you.

**Kaiser Permanente, The Permanente Medical Group, Inc.**

**Booth #614**

1800 Harrison St Fl 7
Oakland, CA 94612-3466
physiciancareers.kp.org

Within the Permanente Medical Groups, physicians find recognition, stability, opportunity and independence. Through our leadership in the use of advance technology, creation of innovative solutions, and our influence on health policy and reform efforts, Kaiser Permanente is helping to shape the future of health care in the nation. Contact us today to discover how you can become a part of our innovative model of practice.

**Liberty Healthcare Corporation**

**Booth #612**

401 E City Ave Ste 820
Bala Cynwyd, PA 19004-1155
libertyhealthcare.com

Liberty Healthcare Corporation is a Joint Commission-certified and physician-owned health care services organization that provides outpatient, residential, ACT, inpatient, and telepsychiatry services throughout the U.S. Liberty currently seeks psychiatrists who are interested in general/adult, geriatric, child/adolescent and forensic psychiatry for positions in California, Maine, and South Carolina.

**LifePoint Health**

**Booth #606**

330 Seven Springs Way
Brentwood, TN 37027-5098
lifepointgoodlife.com

LifePoint Health is a dynamic system of hospitals, private practice groups and academic partnerships focused on providing the best possible healthcare to our 72 communities. Our growth and quality initiatives are unmatched, and so are LifePoint’s physician opportunities. We are committed to our behavioral health initiatives and to offering excellent career growth, compensation and lifestyle options for both inpatient and outpatient psychiatrists. Whether your interest is in geriatrics, addiction or general psychiatry, LifePoint has a community that needs your training and experience. Come see us in Booth 606 for details on our opportunities across the United States.

**Locum Source, Inc.**

**Booth #1420**

1275 Glenlivet Dr Ste 100
Allentown, PA 18106-3107
locum-source.com

Locum Source, Inc., is a locum tenens and permanent placement agency for physicians, physician assistants and nurse practitioners. Our company was founded by two board-certified surgeons who have significant locum tenens experience. Their experience and expertise offer a unique advantage in the locum tenens market that is not available elsewhere. Our goal is to exceed your expectations with our level of customer service. If you are a hospital or a provider, we look forward to being “The Source” for all your locum tenens needs.
Exhibitors with Product/Service Descriptions

**LocumTenens.com**

**Booth #1323**

2655 Northwinds Pkwy
Alpharetta, GA 30009-2280
locumtenens.com

Founded in 1995, LocumTenens.com is a full-service staffing firm serving physicians, advanced practice professionals and healthcare facilities looking to solve employment shortage. The operator of the largest online job board for the locum industry, LocumTenens.com provides job-seeking providers direct access to thousands of jobs, in all specialties, posted directly by facilities and agencies nationwide.

**Magstim**

**Booth #1518**

633 Davis Drive
Suite 200
Morrisville, NC 27560
magstim.com

The company that developed the first magnetic stimulator is pleased to present the Magstim Therapy System. Stop by our exhibit to see how the Therapy System can provide you with the rTMS device you need in a more cost effective manner.

**Magventure, Inc.**

**Booth #1707**

303 Perimeter Ctr N Ste 300
Atlanta, GA 30346-3401
magventure.com

MagVenture Inc. offers a complete line of magnetic stimulation solutions for a broad range of research and clinical applications. MagVenture's FDA-cleared MagVita TMS depression treatment system is simple, effective and easy to use for psychiatrists wishing to provide an alternative to patients who are not responding to antidepressants. The system, which is offered with no per-use fee, was FDA cleared in 2015 (510(k)), indicated for the treatment of major depressive disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.

**Maxim Physician Resources**

**Booth #1225**

5001 Lyndon B Johnson Freeway
Ste 900
Dallas, TX 75244-6151
maximphysicians.com

Maxim Physician Resources (MPR) is an industry leader in nationwide physician staffing services, specializing in placing physicians in locum tenens opportunities. Maxim realizes the key to quality is in the details, and as such, MPR focuses on the unique needs that are inherent to physician staffing. Maxim handles the recruitment, screening, credentialing and the eventual placement of highly-qualified physicians in various clinical environments.

**Mayo Clinic**

**Booth #1313**

200 1st St SW
Rochester, MN 55905-0002
mayoclinic.org

The Mayo Clinic mission is to inspire hope and contribute to health and well-being by providing the best care to every patient through integrated clinical practice, education and research. Our neuroscience and genomic research in mood and addictive disorders continues to guide cutting edge progressive clinical care to meet the need of our patients. Multidisciplinary teams are constantly seeking innovation in clinical care and sharing it with the psychiatric community. Visit Booth 1313 to meet our psychiatrists and learn more about our research, clinical practice and CME courses.
McLean Hospital

Booth #1300

115 Mill St
Belmont, MA 02478-1048
mclean.harvard.edu

McLean Hospital is an international center for psychiatric treatment, teaching, research and education. McLean offers state-of-the-art diagnostic and treatment services across a full continuum that includes inpatient, residential, partial hospital and outpatient care. McLean is also home to an expanded array of specialized academic programs for children and adolescents as well as dedicated services for older adults with Alzheimer’s and other dementias. McLean houses the largest research program of any private psychiatric hospital in the world and as a major teaching affiliate of Harvard Medical School, McLean educates the best and brightest mental health providers.

MD.com

Booth #1602

1908 Marlton Pike E
Cherry Hill, NJ 08003-2118
MD.com

We offer every physician in the U.S. their own virtual clinic to provide secure video visits to their patients. We help doctors attract new patients by promoting these virtual clinics to more than 1 million U.S. consumers visiting MD.com each month. Consumers can find a doctor through the MD.com search engine populated with more than 880,000 doctors. Book or request an appointment online.

MECTA Corporation

Booth #1301

19799 SW 95th Ave Ste B
Tualatin, OR 97062-7584
mectacorp.com

For over 40 years, MECTA has set the standard for unparalleled innovation, based on research through four generations of ECT devices used for the treatment of depression. New optimized ECT includes new, more efficient parameters, resulting in greater efficacy and the minimization of cognitive side effects. This is combined with the newest, easy-to-use optimized titration methodology, and four treatment menus for Ultrabrief, Near Ultrabrief, Brief Pulse and Full spECTrum dosing. The new MECTA EMR stores treatment data and monitoring that can be saved onto hospital servers and EHRs as pdfs! Up to 700 data points can be viewed in clinician offices, and exported into spreadsheets. The newest form of ECT, FEAST, patented by MECTA, is in clinical trials and promises to change the treatment markedly! MECTA—Evidence Based ECT!

Medical Billing Professionals

Booth #1223

P.O. Box 560
Royersford, PA 19468
mbpros.com

Medical Billing Professionals, with over 18 years of behavioral health billing experience, will submit your claims for as little as $1.59 per claim. Stop by our booth for information on our free iPad offer.

Medical Search

Booth #412

23 Vreeland Rd Ste 210
Florham Park, NJ 07932-1510
medsearchint.com

Medical Search is a premier Locum Tenens and permanent placement agency, specializing in placing all levels of medical professional into the most opportunistic assignments nationwide. The psychiatry division is solely dedicated to their clients and physicians to ensure the highest level of quality and service in the industry.
Exhibitors with Product/Service Descriptions

**Medicus Healthcare Solutions**
**Booth #604**
7 Industrial Way Unit 5  
Salem NH 03079-2817  
medicushcs.com
Medicus Healthcare Solutions provides nationwide locum and permanent career opportunities for physicians, CRNAs and advanced practitioners. We offer our providers opportunities to work as consultants, interim leaders and specialists on teams assembled for projects such as new program launches. For healthcare facilities and groups, Medicus provides permanent placement, supplemental physician staffing and locum tenens management services.

**MedPartners Locum Tenens**
**Booth #1523**
5810 Coral Ridge Dr Ste 250  
Coral Springs, FL 33076-3381  
medpartnerslt.com
MedPartners Locum Tenens was established to build the best possible staffing organization in the locum tenens industry. Our founders have a simple vision—build a company that never loses sight of taking care of all its highly-talented employees. With more than 25 years of combined healthcare and physician staffing experience, MedPartners Locum Tenens has the knowledge, resources and proven industry commitment to help facilities execute the increasing demands of today’s rapidly changing healthcare landscape.

**Memorial Hospital of Sweetwater County**
**Booth #508**
1200 College Dr  
Rock Springs, WY 82901-5868  
sweetwatermemorial.com
Please visit the Memorial Hospital of Sweetwater County exhibit to inquire about their current positions available.

**Menninger Clinic**
**Booth #1317**
12301 Main St  
Houston, TX 77035-6207  
menningerclinic.com
The Menninger Clinic, Houston, is a specialty psychiatric hospital for assessment and treatment of adolescents and adults with difficult-to-treat psychiatric disorders, as well as co-occurring conditions. Inpatient care integrates evidence-based and biopsychosocial therapies with rehabilitation. Outpatient and intensive outpatient services and a psychosocial clubhouse are also offered. Menninger trains clinicians, conducts research and is affiliated with Baylor College of Medicine.

**Merck & Co.**
**Booth #837**
2000 Galloping Hill Rd  
Kenilworth, NJ 07033-1310  
merck.com
Today’s Merck is working to help the world be well. Through our medicines, vaccines, biologic therapies and consumer and animal products, we work with customers and operate in more than 140 countries to deliver innovative health solutions.

**Metabolic Maintenance**
**Booth #1347**
601 N Larch St  
Sisters, OR 97759-9320  
methylpro.com
Metabolic Maintenance, the parent company of MethylPro®, has been a pioneer in the field of personal nutrition for over 30 years by collaborating with healthcare professionals and delivering quality supplements. With a foundation in medical research, good manufacturing practices, and personalized customer service, we are proud to offer custom formulas, a complete supplement line, and the MethylPro® line of professional strength L-methylfolate supplements.
Exhibitors with Product/Service Descriptions

**MHM Services, Inc.**
*Booth #712*
1593 Spring Hill Rd Ste 610
Vienna, VA 22182-2249
mhm-services.com

MHM Services is a leading provider of specialized healthcare services to correctional facilities, state hospitals and community mental health centers nationwide. Today we employ more than 6,000 healthcare professionals in 16 states.

**Millennium Health**
*Booth #1044*
15330 Avenue of Science
San Diego, CA 92128
millenniumhealth.com

Millennium Health is a leading health solutions company that delivers accurate, timely, clinically actionable information to inform the right treatment decisions for each patient at the right time. Millennium offers a comprehensive suite of services to better tailor patient care. More information is available at our website.

**Ministry Health Care**
*Booth #410*
900 Illinois Ave
Stevens Point, WI 54481-3114
ministryhealth.org

Ministry Health Care is an integrated system of hospitals and clinics serving patients across Wisconsin. We are widely recognized as a top-rated health care system with 15 hospitals, 47 clinics and more than 650 physicians and advanced practice clinicians. We are actively seeking both adult and child/adolescent psychiatrists in both metropolitan and rural areas. Why choose Ministry Health Care? Our physicians say it best! Visit our website to hear why our physicians chose Ministry Health Care and, more importantly, why they stay!

**Minnesota Department of Human Services**
*Booth #512*
PO Box 64997
Saint Paul, MN 55164-0997
dhs.state.mn.us

Make a difference working for DHS. Our clinical staff is made up of very talented, dedicated people and we want you to be part of our team. Current opportunities include: adult psychiatrist, forensic psychiatrist, psychologist, psychiatric nurse practitioner and clinician. Programs include: mental health inpatient treatment facility, community behavioral health hospitals, forensic services and the Minnesota sex offender program. Contact us at 651-431-3672 or email to lena.garcia@state.mn.us.

**Mount Sinai Health System**
*Booth #1701*
1 Gustave L Levy Pl
New York, NY 10029-6504
icahn.mssm.edu

The Mount Sinai Behavioral Health System is a comprehensive network of psychiatric clinical and addiction services. Through its dynamic integration of clinical care, leading-edge science and education, the Behavioral Health System is able to deliver new models of treatment and support a large-scale research infrastructure—providing patients with unparalleled psychiatric treatments and advancing the field of mental health and substance abuse care.

**Muse: The Brain Sensing Headband**
*Booth #1511*
511 King Street West, Suite 303
Toronto, ON, Canada, MSV 1K4
choosemuse.com

Muse: the brain sensing headband, the world’s first wearable brain sensing platform, allows clinicians, health professionals and coaches to easily deploy cloud- and app-based meditation and neurofeedback to clients and consumers.
Exhibitors with Product/Service Descriptions

**National Institute of Mental Health (NIMH)**  
**Booth #1607**  
6001 Executive Boulevard  
Bethesda, MD 20892-9663  
nimh.nih.gov

The National Institute of Mental Health (NIMH) is the lead federal agency for research on mental disorders. NIMH is one of the 27 Institutes and Centers that make up the National Institutes of Health (NIH), the nation’s medical research agency. NIH is part of the U.S. Department of Health and Human Services. The mission of NIMH is to transform the understanding and treatment of mental illnesses through basic and clinical research, paving the way for prevention, recovery and cure.

**Neba Health, LLC**  
**Booth #1503**  
753 Broad Street, Suite 701  
Augusta, GA 30901-1380  
nebahealth.com

For kids presented with ADHD-like symptoms, Neba assists in crafting your treatment plan by helping answer the question: Is it ADHD or something else? FDA-cleared Neba is the first brainwave-based neuropsychiatric interpretive aid to integrate with a clinician’s traditional ADHD evaluation. Surveys show parents think Neba provides help they are looking for, that NEBA provides useful information and they would recommend Neba to others. Neba is $79 per month, supplies included. You may cancel anytime.

**NEOS Therapeutics**  
**Booth #1049**  
2940 N Hwy 360 Ste 400  
Grand Prairie, TX 75050-6424  
neostx.com

Please visit the NEOS Therapeutics exhibit for more information about Adzenys XR-ODT.

**Neurocrine Biosciences, Inc.**  
**Booth #1618**  
12780 El Camino Real  
San Diego, CA 92130-2042  
neurocrine.com

Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals utilizing our novel R&D platform. Neurocrine’s efforts are focused on conditions with high unmet medical needs, specifically in neurological and endocrine based diseases and disorders.

**Neuronetrix**  
**Booth #1823**  
1044 E Chestnut St  
Louisville, KY 40204-6033  
neuronetrix.com

Neuronetrix is transforming the diagnosis of patients with cognitive disorders by providing accurate and meaningful diagnostic information to health care professionals early in the disease process. This information is critical to clinicians who wish to provide optimal care for their patients and to scientists who are searching for ways to treat these devastating disorders.

**NeuroScience, Inc.**  
**Booth #1207**  
373 280th St  
Osceola, WI 54020-4120  
neuroscienceinc.com

NeuroScience Inc., is committed to personalized health care solutions. We provide sophisticated neurologic, immune and hormone laboratory testing, as well as proprietary nutraceuticals that target identified imbalances. We bring everything together for the practitioner with our “assess and address” approach.
Exhibitors with Product/Service Descriptions

**NeuroStar TMS Therapy**

Booth #1529  
3222 Phoenixville Pike  
Malvern, PA 19355-9615  
neurostar.com  

NeuroStar TMS Therapy is a proven non-drug option for treatment resistant depression. Over half of those treated with NeuroStar achieve durable response, and over one third reach full remission. Visit us in Booth 1529 to learn why NeuroStar is the market leader in transcranial magnetic stimulation, and what’s new in 2016.

**New York-Presbyterian Hospital**

Booth #1522  
525 E 68th St # 51  
New York, NY 10065-4870  
nyp.org  

The psychiatry programs of NewYork-Presbyterian, Columbia University College of Physicians and Surgeons and Weill Cornell Medicine, ranked #1 in the nation by *U.S. News and World Report*, offer innovative clinical care from early development through older adulthood. Our teams provide individualized psychiatric, neurobehavioral and psychopharmacological services to acute, sub-acute and recovering patients in discreet and compassionate settings.

**North Carolina Office of Rural Health**

Booth #413  
311 Ashe Ave  
Raleigh, NC 27606-2102  
ncdhhs.gov/orhcc  

Please visit the North Carolina Office of Rural Health Community Care exhibit for more information about their products and services that will be of interest to you.

**North GA Partnership (NoGAP)**

Booth #509  
175 Gwinnett Dr Ste 260  
Lawrenceville, GA 30046-8444  
northgapartnership.org  

North Georgia Partnership for Behavioral Health is a collaborative network ensuring high-quality, accessible integrated services.

**Northeast Georgia Health System, Inc.**

Booth #710  
743 Spring St NE  
Gainesville, GA 30501-3715  
practicemedicinehere.com  

Located on the Gainesville campus of Northeast Georgia Medical Center (NGMC), in Gainesville, Ga., Laurelwood (54 beds) provides a broad range of services for adolescents and adults experiencing mental health or substance abuse problems. Laurelwood offers a variety of treatment options including: detoxification, inpatient treatment, day partial treatment, intensive outpatient treatment and aftercare support. NGMC is a two-hospital system with a 557-bed regional referral center located in Gainesville and a 120-bed hospital located in Braselton. The medical staff of over 650 members represents a vast range of primary care and subspecialty physicians. NGMC is one of the Nation’s 100 Top Hospitals according to a study by CareChex. NGMC has been named one of “Metro Atlanta’s Top 100 Workplaces” by the *Atlanta Journal Constitution* for 2011-2015.

**Northern Light Technologies**

Booth #1201  
8971 Henri Bourassa West  
St. Laurent, QC H4S1P7  
Canada  
northernlighttechnologies.com  

Produced in North America the 10,000 Lux Northern Light Desk Lamp, the Travelite, Flamingo Floor Lamp, Boxelite, ceiling track-
Exhibitors with Product/Service Descriptions

mounted Showoff, the Luxor, and the New Mini-Luxor table lamp are preferred by thousands of healthcare professionals. We are the supplier of choice for affordable, versatile, powerful and adjustable bright light sources that are UV-clean, flicker-free and operate on a 110V to 220V current. Contact us at 1-800-263-0066 or at our website.

Novant Health
 Booth #511
2000 Fronlis Plaza Blvd
Winston-Salem, NC 27103
novanthealth.org

Please visit the Novant Health exhibit for more information about products and services that will be of interest to you.

OmegaBrite
 Booth #1319
8275 S Eastern Ave Ste 121
Las Vegas, NV 89123-2544
omegabrite.com

The mission of OmegaBrite is to develop natural products of the highest quality that promote health and well-being based on scientific evidence. We are proud of the overwhelming positive response we have received for our flagship product, OmegaBrite 100% Natural Advance Omega-3 Formula.

Oregon Health & Science University, Department of Psychiatry
 Booth #502
3181 SW Sam Jackson Park Rd
UHN80
Portland, OR 97239
ohsu.edu

The Department of Psychiatry at Oregon Health & Science University (OHSU) has outstanding opportunities for BC/BE psychiatrists. We are an acclaimed academic health center. We invite you to stop by our exhibit in the Career Fair for more information about psychiatry opportunities in the beautiful Northwest.

Oregon State Hospital
 Booth #500
2600 Center St NE
Salem, OR 97301-2682
osh.oregon.gov

Oregon State Hospital is actively recruiting psychiatrists. We are surrounded by ocean beaches, snow-covered mountains and world-famous wineries all within an hour’s drive. What more could you ask for? Come by our booth and meet our Superintendent and our Chief of Psychiatry. They are ready to answer your questions.

Otsuka America Pharmaceutical, Inc.
 Booth #937, 1037, 1324, 1926
508 Carnegie Center Dr
Princeton, NJ 08540-6492
otsuka-us.com

Otsuka America Pharmaceutical, Inc. is an innovative, fast-growing healthcare company that commercializes Otsuka discovered and in-licensed products in the United States, with a strong focus on neuroscience, oncology, cardio-renal and medical devices. For more information visit our website.

Otto Trading, Inc.
 Booth #1308
1921 Carnegie Ave Ste C
Santa Ana, CA 92705
unimedmassager.com

Please visit the Otto Trading, Inc., exhibit for more information about our digital massager and TENs unit.

Oxford University Press
 Booth #423
198 Madison Ave
New York, NY 10016-4308
oup.com

Oxford University Press is proud to publish some of the world’s premier books, journals and online resources in psychiatry. Visit our booth for a discount on new and classic titles, free journal samples and demos of our online products!
Exhibitors with Product/Service Descriptions

**Physicians for a National Health Program**

**Booth #1613**

29 E Madison St Ste 1412  
Chicago, IL 60602-4404  
pnhp.org

Physicians for a National Health Program is a non-profit research and education organization of 20,000 physicians, medical students and health professionals who support single-payer national health insurance. PNHP performs groundbreaking research and contributes scholarly articles to peer-reviewed medical journals, coordinates speakers and forums, participates in town hall meetings and debates, and appears regularly on national television and news programs advocating for a single-payer system.

**Psychiatric Times**

**Booth #431**

535 Connecticut Ave Ste 300  
Norwalk, CT 06854-1713  
psychiatrictimes.com

For over 17 years, *Psychiatric Times* has provided accurate, objective and unbiased coverage of the most clinically relevant issues in psychiatry. Each issue features a special report, a collection of several physician authored articles on a topic of broad interest, as well as an article providing readers the opportunity to earn continuing medical education credits. Read more about these hot topics on our website.

**PracticeLink.com**

**Booth #515**

415 2nd Ave  
Hinton, WV 25951-2427  
practicelink.com

Physicians searching for their first or next practice rely on PracticeLink—the career advancement resource for physicians. PracticeLink helps physicians find the practice opportunities that best suit their personal and professional needs and provides helpful career development and job-search information. Find your next practice by visiting our website.

**PsychU**

**Booth #1714**

163 York St  
Gettysburg, PA 17325-1933  
psychu.org

PsychU.org is the online community and knowledge center dedicated to understanding, sharing and evolving best practices in mental health treatment. Through the exchange of information, experience and ideas, PsychU members aim to shift the current trajectory of mental health care and improve the future outlook for individuals with mental illnesses. The PsychU community brings together physicians, clinicians, care managers, nurses, recovery coaches, pharmacists, payers, advocates, researchers and all professionals involved in providing, financing, or regulating mental health services.

**Providence Health & Services**

**Booth #700**

1201 NE Lloyd Blvd Ste 510  
Portland, OR 97232-1202  
providence.org

Providence Health & Services, rated among the most integrated health systems in the nation, recruits nearly 1,000 physicians and advanced practice providers each year into its network of hospitals, medical groups and private practice partners in Alaska, California, Montana, Oregon and Washington. Join us and help create healthier communities together.

**Quotient® ADHD System by Pearson**

**Booth #1304**

239 Littleton Rd Ste 6A  
Westford, MA 01886-3545  
quotient-adhd.com

The Quotient® ADHD System is an innovative device that objectively measures three core symptom domains of ADHD: hyperactivity, inattention and impulsivity. Based on research from McLean Hospital, a Harvard Medical School Affiliate, this easy-to-administer tool uses advanced motion tracking technology to track
Exhibitors with Product/Service Descriptions

a child or adult’s micro-movements while they complete a computerized test that takes less than half an hour. Visit Quotient® at Booth 1304.

Rhodes Pharmaceuticals L.P.
Booth #1447
498 Washington St
Coventry, RI 02816-5467
rhopharma.com
Rhodes Pharmaceuticals L.P. is a specialty pharmaceutical company based in Coventry, RI. Rhodes’ vision for success is based on a sustainable business platform, competitive costs, high-quality products, reliable supply, excellent customer service and a vertically integrated and robust pipeline. For more information, visit our website and our exhibit at Booth #1447.

Riverside Health System
Booth #313
2 Eaton St Ste 705
Hampton, VA 23669-4073
riversideonline.com
Established in 1915, Riverside was founded by the community as a single hospital. One hundred years later, Riverside has evolved into a large regional healthcare system with multiple hospitals and affiliates throughout the region and more than 550 providers in a full range of specialties. Riverside is proud to be a physician led, not-for-profit, fully integrated, health organization. The Riverside difference is the dedication we give to fully serving the needs of the community, the attention we give to partnering with our patients to improve outcomes and our commitment to caring for our patients and team members as we would care for those we love. For more information regarding opportunities please contact Nicole Laroch at nicole.laroche@rivhs.com.

Rochester Regional Health
Booth #607
1425 Portland Ave
Rochester, NY 14621-3001
rochesterregional.org
Rochester Regional Health is an integrated health services organization serving the people of Western New York, the Finger Lakes and beyond. The system provides care from 150 locations, including five hospitals, more than 100 primary and specialty practices, rehabilitation centers and ambulatory campuses; innovative senior services, facilities and independent housing; a wide range of behavioral health services and ACM Medical Laboratory, a global leader in patient and clinical trials. With 16,000 employees, Rochester Regional Health was named one of “America’s Best Employers” by Forbes in 2015. The Rochester region’s suburbs feature excellent public and private schools and a variety of housing options. The Rochester region offers diverse cultural and recreational opportunities year-round, including the Rochester Philharmonic Orchestra, GeVa Theater Center, Rochester International Jazz Festival as well as easy access.

Rogers Behavioral Health System
Booth #1829
34700 Valley Rd
Oconomowoc, WI 53066-4500
rogersbh.org
Rogers Behavioral Health is a leader in comprehensive and effective behavioral health treatment for children, teens and adults with OCD and anxiety disorders, eating disorders, depression and mood disorders, and addiction. Rogers creates an environment where patients and their families know what tomorrow will bring—Life. Worth. Living. For more information, please visit our website.
**Exhibitors with Product/Service Descriptions**

**Rogers Memorial Hospital**  
**Booth #1712**  
34700 Valley Rd  
Oconomowoc, WI 53066-4599  
rogershospital.org

Wisconsin-based Rogers Behavioral Health System is a private, not-for-profit system nationally recognized for its specialized psychiatry and addiction services. Anchored by Rogers Memorial Hospital, Rogers offers multiple levels of evidence-based treatment for adults, children, and adolescents with depression and mood disorders, eating disorders, addiction, obsessive-compulsive and anxiety disorders, and posttraumatic stress disorder in multiple locations. For more information, visit our website.

**Rutgers Center of Alcohol Studies**  
**Booth #527**  
607 Allison Rd  
Piscataway, NJ 08854-8001  
alcoholstudies.rutgers.edu

The Rutgers Center of Alcohol Studies publishes the *Journal of Studies on Alcohol and Drugs*, the oldest substance-related journal in the United States (est. 1940). The Center’s education and training division offers cutting-edge education for health, mental health and public health professionals working in the addictions field. All programs, including the historic summer school, offer practical, evidence-based education designed to enhance outcomes. Visit our website at jsad.com.

**Saint Francis Health System/Laureate Psychiatric Clinic and Hospital**  
**Booth #406**  
6161 South Yale Avenue  
Tulsa, OK 74136-1902  
saintfrancis.com

Please visit the Saint Francis Health System/Laureate Psychiatric Clinic and Hospital exhibit for more information about products and services that will be of interest to you.

**SARDAA—Schizophrenia & Related Disorders Alliance of America**  
**Booth #747**  
PO Box 941222  
Houston, TX 77094-8222  
SARDAA.org

Please visit the SARDAA-Schizophrenia and Related Disorders Alliance of America exhibit for more information about products and services that will be of interest to you.

**Routledge Journals**  
**Booth #528**  
530 Walnut St Ste 850  
Philadelphia, PA 19106-3604  
tandfonline.com

Routledge Journals, a division of Taylor and Francis, is a leading international publisher of scholarly research in behavioral science and mental health. Visit the Routledge Journals booth to learn about our wide range of products and services and to request free sample copies of our essential publications in the field of psychiatry.

**Routledge/CRC Press**  
**Booth #530**  
711 3rd Ave Fl 8  
New York, NY 10017-9209  
routledge.com

Routledge and CRC Press publish a comprehensive portfolio of textbooks, professional books, monographs and journals on psychiatry, clinical psychology, and more. Visit our website at Routledge or crcpress.com to keep up-to-date on the newest developments in the field.
Exhibitors with Product/Service Descriptions

Sheppard Pratt Health System
Booth #1401
PO Box 6815
Baltimore, MD 21285-6815
sheppardpratt.org

Sheppard Pratt Health System is dedicated to improving quality of life through mental health, special education and addiction services for children, adolescents and adults. Our patient-centered treatment approach, combined with our legacy of clinical excellence, sets us apart from other health systems on a national level. We have been ranked among the nation’s top psychiatric hospitals for 25 years by U.S. News & World Report.

Shire
Booth #1209
300 Shire Way
Lexington, MA 02421-2101
shire.com

Shire enables people with life-altering conditions to lead better lives. Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs. Please visit our website.

Shire U.S., Inc.
Booth #1329
725 Chesterbrook Blvd
Chesterbrook, PA 19087-5649
shire.com

Shire enables people with life-altering conditions to lead better lives. Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

Sierra Tucson
Booth #1413
39580 S Lago Del Oro Pkwy
Tucson, AZ 85739-1091
SierraTucson.com

For over 32 years, Sierra Tucson has held a longstanding legacy of clinical excellence and compassionate care. A multidisciplinary team of professionals utilizes the Sierra Tucson Model®, a bio-psycho-social-spiritual approach for individualized treatment. Sierra Tucson combines integrative and experiential therapies with evidence-based practices to provide a full range of treatment modalities. Residents receive the resources, support and tools necessary for long-term change, including one full year of continuing care and a lifetime of alumni services. Call 800-842-4487 or visit our website.

Skyland Trail
Booth #1416
1961 N Druid Hills Rd NE
Atlanta, GA 30329-1842
skylandtrail.org

Skyland Trail is a nationally recognized, not for profit, evidenced based, JCAHO accredited residential and day treatment facility for adults seeking recovery from mental illness located in Atlanta. Skyland Trail treats adults with bipolar disorder, major depression, schizophrenia, anxiety disorders and dual diagnosis. We accept private insurance. Recovery communities include DBT, dual diagnosis, CBT, young adult and social integration. Please visit our website or call 678-686-5931.

Somatics LLC
Booth #1431
720 Commerce Dr Suite 101
Venice, FL 34292-1750
thymatron.com

Somatics is the manufacturer of the Thymatron® ECT instrument, which is faster and easier than ever to use. Unique benefits include maximum ultrabrief response, age-based stimulus titration, EEG seizure intensity and duration, higher stimulus current, greater cerebral stimulation, best seizure generalization and efficacy by peak heart rate. Unique features include EctoBrain® Stimulus Assurance Analyzer, remote treat handle, automatic optimal stimulus selection at 0.3 and 0.5 ms, 4-channel monitor-printer, postictal suppression index, automatic EEG seizure endpoint detection and digital heart rate printout.
Exhibitors with Product/Service Descriptions

Soterix Medical, Inc.  
**Booth #1402**  
237 W 35th St Ste 1401  
New York, NY 10001-1950  
soterixmedical.com

Soterix Medical, Inc., was formed to develop and deploy innovative medical treatments focused on neuropsychiatric and neurological disorders and rehabilitation. SMI is the world leader in clinical trials for non-invasive neuromodulation working with over 250 medical centers in the United States and worldwide. Multiple, ongoing trials are currently underway ranging from depression, ADHD, PTSD, schizophrenia, stroke, chronic pain, and epilepsy. Soterix Medical tDCS-LTE is currently CE approved for major depressive disorder.

Southwest Behavioral Health Services  
**Booth #402**  
3450 N 3rd St  
Phoenix, AZ 85012-2331  
sbhservices.org

Please visit the Southwest Behavioral Health Services exhibit for more information about products and services that will be of interest to you.

Spartanburg Regional Healthcare System  
**Booth #510**  
101 E Wood St  
Spartanburg, SC 29303  
spartanburgregional.com

The Spartanburg Regional booth will be recruiting board certified and/or board eligible psychiatrists for Spartanburg Medical Center, located in the beautiful upstate of South Carolina.

Specialists On Call  
**Booth #1711**  
1503 Edwards Ferry Road, NE, Suite 310  
Leesburg, VA 20176-6692  
specialistsoncall.com

Specialists On Call is the nation’s leading provider of clinical telemedicine services. We help hospitals deliver effective care to psychiatric patients with immediate, 24/7 access to board certified psychiatrists via a robust and secure telemedicine platform. Our telepsychiatry service reduces the costs associated with such resource intensive patients and improves overall efficiency for hospital emergency departments as well as psychiatric inpatient units.

Springer  
**Booth #524**  
233 Spring St Fl 6  
New York, NY 10013-1578  
springer.com

Springer Science+Business Media is a leading global scientific, technical and medical publisher offering high-quality products across all media. Springer publishes more than 2,000 journals and 8,000 new books per year and is home to the world’s largest STM eBook collection as well as the most comprehensive portfolio of open access journals. Make sure to visit our booth or find out more online at our website.

Springstone Inc.  
**Booth #400**  
101 S 5th St Ste 3850  
Louisville, KY 40202-3127  
springstone.com

At Springstone, we develop and operate private behavioral healthcare hospitals. We bring progressive, cutting-edge health and state-of-the-art facilities to underserved communities. Our mission is to deliver compassionate, high-quality treatment for mental health and addiction disorders using innovative, evidence-based approaches. Our levels of service include inpatient, partial hospitalization and intensive outpatient care. We are always seeking psychiatric practitioners who enjoy working in a team-driven atmosphere.
Exhibitors with Product/Service Descriptions

Sun Behavioral Health
Booth #1306
12 Broad St Ste 403
Red Bank, NJ 07701-1938
sunbehavioral.com

Inpatient and outpatient psychiatric hospital services for all ages. Specialized programs to meet the unique needs of each community. Opportunities for psychiatrists and psychiatric and substance abuse registered nurses.

Sunovion Pharmaceuticals Inc.
Booth #1237, 1247
84 Waterford Dr
Marlborough, MA 01752-7010
sunovion.com

Sunovion Pharmaceuticals Inc., is a leading pharmaceutical company dedicated to discovering, developing and commercializing therapeutic products that advance the science of medicine in the central nervous system and respiratory disease areas to improve the lives of patients and their families. Visit us online at our website.

Takeda Pharmaceuticals U.S.A., Inc./Lundbeck
Booth #1817
1 Takeda Pkwy
Deerfield, IL 60015-5713
takeda.us & lundbeck.com

Takeda Pharmaceuticals Company Limited and Lundbeck formed a strategic alliance in 2007 to co-develop and co-commercialize in the U.S. and Japan several compounds in Lundbeck’s pipeline for the treatment of mood and anxiety disorders. Together, both companies are deeply committed to supporting the needs of the mental health community.

Tallahassee Memorial Healthcare
Booth #1519
1300 Miccosukee Rd
Tallahassee, FL 32308
tmh.org

Tallahassee Memorial HealthCare (TMH) is a private, not-for-profit, 501 C3 hospital located in the Florida panhandle. TMH is seeking a general, child and adolescent and addictions psychiatrist to serve both in-patient and out-patient populations. We offer full benefits, malpractice and competitive salaries.

TeleSage, Inc.
Booth #1512
PO Box 750
Chapel Hill, NC 27514-0750
telkesage.com

Please visit theTeleSage, Inc., exhibit for more information about products and services that will be of interest to you.

Tenet Health
Booth #513
1445 Ross Ave Ste 1400
Dallas, TX 75202-2703
tenethealth.com

Tenet Healthcare is one of the largest healthcare corporations in the United States. Our hospitals and clinics are constantly looking for psychiatrists to join them. We have very desirable locations and practice types.

The TOVA Company
Booth #1417
3321 Cerritos Ave
Los Alamitos, CA 90720-2105
tovatest.com

T.O.V.A. (Test of Variables of Attention) is a computerized assessment that measures inattention, impulsivity, response time, variance of response time and d prime. LD and languages do not confound results. Its objective and accurate data can provide important necessary information for evaluations and monitoring of treatments of attention related disorders.
Exhibitors with Product/Service Descriptions

**Tris Pharma**  
**Booth #1149**  
2033 US Highway 130 Ste D  
Monmouth Junction, NJ 08852-3003  
trispharma.com  
Please visit the Tris Pharma exhibit for more information about products and services that will be of interest to you.

**TrueLearn**  
**Booth #1715**  
2 Penn Ctr W Ste 220  
Pittsburgh, PA 15276-0110  
truelearn.com  
TrueLearn offers question banks used by thousands of medical students and residents, including those preparing for the ABPN's PRITE, Board Exam and the MOC Exam. Prepare with psychiatry board review questions specifically crafted by board-certified psychiatrists to mirror those tested on ABPN exams. Learn from the most comprehensive assessment platform available to physicians seeking board certification in psychiatry.

**Tséhootsooi Medical Center**  
**Booth #1415**  
PO Box 649  
Fort Defiance, AZ 86504-0649  
fdihb.org  
Tséhootsooi Medical Center (TMC) serves 47,000 American Indian beneficiaries in northeastern Arizona. As an acute care hospital, TMC provides comprehensive inpatient and outpatient health services to 16 communities with expansion of specialty services, including construction of a new clinic in Sanders, Ariz., Nahat'á Dziil Health Center.

**U.S. Department of State, Office of Medical Services**  
**Booth #1322**  
2401 E St NW  
Washington, DC 20522-0001  
careers.state.gov  
The U.S. Department of State, our country’s lead foreign policy agency, provides a rich international experience whether at home or abroad and opportunities to become responsible leaders. Each day, our employees make a difference as they contribute to our global society and defend and advance our country’s interests and values. They work on the business of diplomacy and high priority issues that impact the safety, security and prosperity of our world—human rights, environment, energy, food security, public health and technology—all while experiencing a unique career. Our talented and inclusive workforce reflects and champions all of our strengths and diversity—personal, professional and educational. We offer a workplace that values and rewards leadership, collaboration and innovation, and personal and professional development.

**Unity Center for Behavioral Health**  
**Booth #507**  
3181 SW Sam Jackson Park Rd  
c/o OHSU Mail Code: UHN80  
Portland, OR 97239-3011  
ohsu.edu/unity  
Please visit the Unity Center for Behavioral Health exhibit. Unity is an unprecedented collaborative between Legacy Health, Oregon Health & Science University (OHSU), Adventist Health and Kaiser Permanente—an innovative patient and family-centered care environment for adults and adolescents experiencing a mental or behavioral health crisis in Portland, Ore.
Universal Health Services, Inc.

Booth #1418
3295 River Exchange Dr Ste 190
Norcross, GA 30092-4221
uhsinc.com

Universal Health Services, Inc., is the largest facilities-based behavioral health provider in the country. The Behavioral Health Division operates through subsidiaries over 220 facilities nationwide offering services that touch more than 420,000 lives each year—from youth and adult programs to dedicated services for military personnel and their families. In addition to our behavioral health facilities, we operate 25 acute care hospitals and three surgery centers. We have locations in 37 states, the District of Columbia, Puerto Rico, the U.S. Virgin Islands and the United Kingdom, and employ more than 70,000 people. UHS is actively recruiting psychiatrists nationwide for practice opportunity positions at our behavioral health facilities.

University of Florida
Department of Psychiatry

Booth #1310
1149 Newell Dr
Gainesville, FL 32610-3011
psychiatry.ufl.edu

The Department of Psychiatry in the College of Medicine at the University of Florida is the leader in the Southeast for innovative evidence-based treatment programs for mental health disorders, addiction, obsessive compulsive disorder, eating disorders and obesity. Providing a wide variety of services, including inpatient hospital care and detox to outpatient clinics, ECT, TMS, DTMS, DBS, Parent-Child Interaction Therapy (PCIT), and adult, child and adolescent treatment and evaluation.

Uskudar University Npistanbul Neuropsychiatry Hospital

Booth #1406
Uskudar University Npistanbul Neuropsychiatry Hospital
Inkilap Mah. Siteyolu Sokak. No:29/B
Umraniye, Istanbul
Turkey
npistanbul.com

Please visit the Uskudar University Npistanbul Neuropsychiatry Hospital exhibit for more information about its products and services that will be of interest to you.

Valant Medical Solutions

Booth #1423
2033 6th Ave Ste 500
Seattle, WA 98121-2591
valant.com

Valant was founded in 2005 to provide behavioral health practices, agencies and clinicians with cloud-based software to streamline administration and empower what’s most important—improving outcomes. Inspired by the fact that technology has transformed all of our lives in meaningful ways, Valant has reinvented the behavioral health platform.

Vanda Pharmaceuticals Inc.

Booth #537
2200 Pennsylvania Ave NW Ste 300E
Washington, DC 20037-1754
vandapharmaceuticals.com

Vanda Pharmaceuticals Inc., is a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs. Vanda is committed to providing education and awareness for schizophrenia and Non-24-Hour Sleep-Wake Disorder (Non-24), a chronic circadian rhythm disorder.
Exhibitors with Product/Service Descriptions

**Vanderbilt Behavioral Health**
**Booth #1500**
1601 23rd Ave S
Nashville, TN 37212-3133
vanderbiltbehavioralhealth.com

Vanderbilt Behavioral Health is comprised of Vanderbilt Psychiatric Hospital, an 88-bed inpatient facility, the adult and adolescent partial hospitalization programs; the psychiatry outpatient clinics, which provide more than 60,000 outpatient visits annually; the neuromodulation program, which includes transcranial magnetic stimulation, electroconvulsive therapy and deep brain stimulation; and the Center of Excellence, which provides services for children in state custody or who are at risk of a custodial situation. As a part of Vanderbilt University Medical Center, we provide world-class care for our patients, setting the standard for excellence while advancing our field through education and research.

**Veritas Collaborative**
**Booth #1615**
615 Douglas St Ste 500
Durham, NC 27705-6616
veritascollaborative.com

Veritas Collaborative is a Specialty Hospital System for the Treatment of Eating Disorders. Accredited by The Joint Commission, Veritas delivers multidisciplinary, evidence-based care for patients and their families in a warm, inviting and gender-inclusive environment. Located in Durham, N.C., and Richmond, Va., Veritas Collaborative provides inpatient, acute residential, partial hospitalization, and intensive outpatient levels of care for individuals with eating disorder diagnoses (ages 10 and over). For more information, visit our website or call 855-875-5812.

**Via Christi Health System**
**Booth #611**
1 Mount Carmel Way
Pittsburg, KS 66762
viachristi.org

Please visit the Via Christi Health System exhibit for more information about products and services that will be of interest to you.

**Virtual Medical Staff**
**Booth #1422**
2655 Northwinds Pkwy
Alpharetta, GA 30009-2280
locumtenens.com

Virtual Medical Staff is a telemedicine solution providing physician staffing, telemedicine technology and the technical support needed to provide patients with specialty care and consults.

**VISTA Staffing Solutions, Inc.**
**Booth #600**
275 E 200 S
Salt Lake City, UT 84111-2002
vistastaff.com

VISTA Staffing Solutions offers you a full range of job options. We help you work when and where you want, meeting your needs today and in the future. Every time you call, you get a decision-maker empowered to take care of you. Tell us where you’d like to go! Visit our website or call us at 800-366-1884.

**Weatherby Healthcare**
**Booth #1517**
6451 N Federal Hwy Ste 800
Ft Lauderdale, FL 33308-1409
weatherbyhealthcare.com

As part of its signature Red Ribbon Service, staffing company Weatherby Healthcare provides healthcare professionals a personal consultant whose priority is to find them the ideal locum tenens or permanent job and negotiate the best terms on their behalf. Enjoy premium services and excellent pay. Call 800-586-5022 or visit our website.
Exhibitors with Product/Service Descriptions

**Wellington Retreat**  
**Booth #1408**  
7051 Seacrest Blvd  
Lantana, FL 33462-5139  
welingtonretreat.com

Wellington Retreat is located in Lantana, Fla., offering sunshine and warm weather to visitors and inhabitants. Wellington Retreat is the only addiction and psychiatric rehabilitation center in the state that is run by an addiction psychiatrist involved in all treatment decisions. Wellington Retreat is more than proud of its expert staff who are firmly dedicated to the healing process of each and every one of their patients. Using research-backed, cutting-edge practices, our patients receive the state-of-the-art treatment they deserve. Our leading neuropsychiatrist and addictionologist, Robert A. Moran, M.D., welcomes each patient, spending quality time with them in order to achieve a correct diagnosis and an appropriate, effective treatment plan that will fit their individual needs. Oftentimes, individuals who suffer from substance abuse disorders will have an unknown co-occurring psychiatric disorder as well.

**Westchester Medical Center**  
**Booth #704**  
100 Woods Road  
Valhalla, NY 10595  
westchestermedicalcenter.com

Please visit the Westchester Medical Center exhibit for more information about products and services that will be of interest to you.

**Wexford Health Sources**  
**Booth #945**  
501 Holiday Dr Foster Plaza 4  
Pittsburgh, PA 15220  
wexfordhealth.com

Wexford Health Sources, one of the nation’s leading innovative correctional health care companies, provides clients with experienced management and technologically advanced services combined with programs that control costs while ensuring quality. For the past two decades, Wexford Health has consistently delivered proven staffing expertise and a full range of medical, behavioral health, pharmacy, utilization management, provider contracting, claims processing and quality management services.

**Wiley**  
**Booth #626**  
350 Main St  
Malden, MA 02148-5089  
wiley.com

Wiley is a global provider of knowledge and knowledge-enabled services that improve outcomes in areas of research, professional practice and education. Visit our website or Booth 626 for more information.

**Wolters Kluwer Health**  
**Booth #416**  
2001 Market St  
Philadelphia, PA 19103-7044  
lww.com

Wolters Kluwer Health is a global provider of information, business intelligence, and point-of-care solutions for the healthcare industry. Major brands include Lippincott Williams & Wilkins, Lippincott Solutions, medical books, journals, and electronic media. Please visit our booth to browse our comprehensive product selection including the newly published *Kaplan and Sadock’s Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry*. 
The Department of Psychiatry at Dartmouth-Hitchcock is a large academic department. We actively create new knowledge in our field, teach and train others in the knowledge, and apply that knowledge in the care of individuals and populations. Our primary clinical training sites include Dartmouth-Hitchcock Medical Center in Lebanon, NH, the VA Medical Center in White River Junction, VT, and New Hampshire Hospital in Concord, NH. Other important clinical sites include Hanover Psychiatry in Hanover, NH, Cheshire Medical Center in Keene, NH, and Riverview Psychiatric Center in Augusta, ME.

Consistently in the top 5 most livable states (CQ Press), New Hampshire boasts four-season living with year-round recreation, a myriad of cultural events and venues and highly-ranked schools. Amenities associated with urban areas in Boston MA, Burlington VT, and Montreal, QC are all within a short drive.

Learn more and apply at: DHproviders.org/Psychiatry or by contacting Jeffrey.S.Wooten.Jr@hitchcock.org

Dartmouth-Hitchcock is an equal opportunity employer and all qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, disability status, veteran status, gender identity or expression, or any other characteristic protected by law.
BRING BALANCE TO YOUR CAREER
We offer our psychiatrists the work-life balance they deserve.

PSYCHIATRIST
$273,000 - $385,073
$294,128 - $391,340
email your resume today!
email your resume today!

Enjoy a flexible work schedule with all of the security and benefits of our employment.

- Nights shifts/Weekend rotations available
- All Hour work week
- Welcome Bonus of $15,000 cash or cash equivalent
- Generous yearly paid time off
- Outstanding benefits
- Retirement plan after 5 years
- License reimbursement
- DEA fee reimbursement
- Annual pass/UEP with paid time off to attend your sponsorship opportunities

4th Annual Showcase: May 18/19, 2018
VISIT US AT BOOTH 301
Exhibitors with Product/Service Descriptions

World Health Information Network
Booth #1516
2738 Camino Capistrano Ste 4
San Clemente, CA 92672
whin.com
Please visit the World Health Information Network exhibit for more information about providing tele-mental health services to your clients or to earn extra income treating patients in your free time.

WPA World Congress of Psychiatry 2017 Berlin
Booth #329
Paulsborner Strabe 44
Berlin, 14193 Germany
wpamadrid2014.com
Please visit the WPA World Congress of Psychiatry exhibit for more information about products and services that will be of interest to you.
NewYork-Presbyterian’s expertise in accurate diagnosis and comprehensive psychiatric care is incomparable, providing services for all ages – from children and adolescents through older adults. Our psychiatry programs offer subspecialty clinical care in the full range of psychiatric diagnoses, provide a continuum of care from outpatient therapy through partial and inpatient hospitalization, and conduct neurobehavioral and psychopharmacological research that is advancing the field.

**Come visit us** at Booth #1522 to learn more
Antidepressants not working? Let NeuroStar TMS Therapy® help.

NeuroStar TMS Therapy® is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.

Long term durability of effect has not been established in a randomized controlled trial.

In an NIMH-funded, independent, randomized controlled trial, patients treated with TMS using a clinical-trial version of the NeuroStar TMS System were four times more likely to achieve remission compared to patients receiving sham treatment ($P = 0.0173$; odds ratio = 4.05).³

For more information on how NeuroStar TMS may work for you and your patients contact us at 877-600-7555 or visit us at NeuroStar.com

Visit our booth to see NeuroStar® demonstrations and get the latest Reimbursement updates.

Booth #1529

NeuroStar TMS Therapy® is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.

Long term durability of effect has not been established in a randomized controlled trial.

In an NIMH-funded, independent, randomized controlled trial, patients treated with TMS using a clinical-trial version of the NeuroStar TMS System were four times more likely to achieve remission compared to patients receiving sham treatment ($P = 0.0173$; odds ratio = 4.05).³

## Exhibitors by Product/Service Listing

### Association/NonProfit
- American Academy of Addiction Psychiatry .......................... 1603
- Physicians for a National Health Program .......................... 1613
- SARDAA—Schizophrenia & Related Disorders Alliance of America ........ 747

### Behavioral Healthcare
- Community Psychiatry ................................................. 503
- Diamond Healthcare Recruitment Division .................................. 708
- Georgia Association of Community Service Boards, Inc. ............ 1425
- Horizon Health ......................................................... 1400
- Mount Sinai Health System ............................................. 1701
- Muse: The Brain Sensing Headband .................................... 1511
- North GA Partnership (NoGAP) ....................................... 509
- Novant Health .......................................................... 511
- Riverside Health System ............................................... 313
- Rogers Behavioral Health System .................................... 1829
- Sierra Tucson .......................................................... 1413
- Springstone Inc ......................................................... 400
- Sun Behavioral Health ................................................... 1306
- Vanderbilt Behavioral Health .......................................... 1500

### Clinical Decision Support
- Assurex Health .......................................................... 845
- TeleSage, Inc. ........................................................... 1512

### Computer Software
- TrueLearn .............................................................. 1715

### Correctional Mental Health
- California Correctional Health Care Services (CCHCS) .................. 301
- MHM Services, Inc ..................................................... 712
- Wexford Health Sources ................................................. 945

### Diagnostic Laboratory
- Admera Health .......................................................... 1800
- AltheaDx .............................................................. 1410
- Millennium Health ....................................................... 1044

### Diagnostic Testing
- NeuroScience, Inc ....................................................... 1207

### Diagnostic Tool
- Harmonex Neuroscience Research, Inc ................................ 1514
- Quotient® ADHD System by Pearson .................................. 1304
- The TOVA Company .................................................... 1417

### Dietary Supplement
- OmegaBrite ............................................................ 1319

### Drug and Alcohol Treatment
- Destination Hope .......................................................... 1806

### Dual Diagnosis Treatment
- Wellington Retreat .......................................................... 1408

### ECT
- MECTA Corporation ..................................................... 1301
- Somatics LLC ............................................................ 1431

### Educational
- American Physician Institute—Beat the Boards ....................... 1419
- National Institute of Mental Health (NIMH) ......................... 1607
- PsychU ................................................................. 1714

### Electronic Health Record
- Compulink Business Systems, Inc .................................... 1424
- Valant Medical Solutions ............................................... 1423
- World Health Information Network .................................... 1516

### Financial Service
- Captive Risk Planners/Perfect Tax & Finance ......................... 1404

### Health Care
- Acadia Healthcare ....................................................... 1922
- Community Health Systems ............................................. 601
Exhibitors by Product/Service Listing

Correct Care Solutions, LLC ..........................1814
Humana Inc.............................................1812
IPC Healthcare ...........................................401
LifePoint Health ..........................................606

Health Care Technology
CoverMyMeds ..............................................1825

Hospital
Aurora Health Care ......................................506
Austen Riggs Center .....................................1530
The Center for Eating Disorders
at Sheppard Pratt .........................................1403
Glens Falls Hospital .....................................408
McLean Hospital ..........................................1300
Menninger Clinic .........................................1317
New York-Presbyterian Hospital ....................1522
Oregon Health & Science
University, Department of Psychiatry ................502
Oregon State Hospital ..................................500
Sheppard Pratt Health System ........................1401
Unity Center for Behavioral Health .................507
University of Florida Department of Psychiatry ........1310
Uskudar University Npistanbul
Neuropsychiatry Hospital ................................1406
Veritas Collaborative ....................................1615
Westchester Medical Center ............................704

Insurance
American Professional Agency, Inc. ..................1217

International Organization
International Congress on Dual Disorders ........327
WPA Wold Congress of Psychiatry 2017 Berlin ....329

Locum Tenens
Aureus Medical Group ..................................706
Barton Associates .........................................1600
CompHealth .............................................1501
DR Wanted ...............................................514
Global Medical Staffing ................................613
Locum Source, Inc. .......................................1420
LocumTenens.com ........................................1323
Maxim Physician Resources .........................1225
Medical Search ..........................................1225
VISTA Staffing Solutions, Inc. .........................600
Weatherby Healthcare ..................................1517

Medical Billing
Medical Billing Professionals ........................1223

Medical Device
Brainsway USA Inc. .......................................1617
Electromedical Products International, Inc. 1211
Magventure, Inc. ..........................................1707
Neba Health, LLC .........................................1503
Neuronetrix .............................................1823
NeuroStar TMS Therapy .................................1529
Otto Trading, Inc. .........................................1308
Soterix Medical, Inc. ......................................1402

Medical Device, Therapy
Infinite Trading, Inc. ......................................1614
Magstim ..................................................1518

Medical Education
Focus: The Journal of Lifelong Learning in Psychiatry ........1528

Mental Health Treatment
Genomind ...........................................1227
Georgia Ketamine ........................................1710
Hillside, Inc. .............................................1521

Nutritional Products
Metabolic Maintenance ..................................1347
Exhibitors by Product/Service Listing

### Pharmaceutical
- ACADIA Pharmaceuticals ............. 1437
- Allergan .................................. 1337, 1546
- Arbor Pharmaceuticals, LLC ........... 1717
- Braeburn Pharmaceuticals, Inc......... 1405
- Indivior Inc. ............................. 1409, 1547, 1713
- Intra-Cellular Therapies Inc .......... 644
- Ironshore Pharmaceuticals and Development, Inc......... 1637
- Janssen Pharmaceuticals, Inc .......... 637
- Merck & Co. ............................. 837
- NEOS Therapeutics ..................... 1049
- Otsuka America Pharmaceutical, Inc 937, 1037, 1324, 1926
- Rhodes Pharmaceuticals L.P. .......... 1447
- Shire .................................... 1209
- Shire U.S., Inc. ......................... 1329
- Sunovion Pharmaceuticals Inc ........ 1237, 1247
- Takeda Pharmaceuticals U.S.A., Inc./Lundbeck . 1817
- Tris Pharma ................................ 1149
- Vanda Pharmaceuticals Inc .......... 537

### Phototherapy
- Northern Light Technologies .......... 1201

### Professional Support/Organization
- American Board of Psychiatry and Neurology, Inc .......................... 1429
- Association of Gay and Lesbian Psychiatrists (AGLP) ................... 1601
- Christian Medical & Dental Associations, Psychiatry Section ........ 1510

### Psychiatric Facility
- Gould Farm ................................ 1411
- Mayo Clinic ................................ 1313
- Skyland Trail ............................. 1416
- Southwest Behavioral Health Services .... 402
- Veritas Collaborative .................... 1615

### Publisher/Bookseller
- Association & Meeting Solutions ...... 1505
- Cambridge University Press .......... 417
- Clinical Psychiatry News ............... 1412
- Current Psychiatry ....................... 1414
- Elsevier, Inc. ........................... 525
- Guilford Publications .................... 420
- HCPLive .................................. 1311
- Hogrefe Publishing Corp ................ 522
- Informa Health Care Journals ........ 526
- The JAMA Network ...................... 624
- Oxford University Press ............... 423
- Psychiatric Times ....................... 431
- Routledge Journals ...................... 528
- Routledge/CRC Press .................... 530
- Rutgers Center of Alcohol Studies ... 527
- Springer .................................. 524
- Wiley ..................................... 626
- Wolters Kluwer Health .................. 416

### Recruitment
- Air Force Recruiting Services .......... 608
- Align International Recruitment Ltd ... 619
- All Star Recruiting ...................... 617
- Allina Health . .......................... 602
- Army Medical Recruiting .............. 716
- Aureus Medical Recruiting ............. 706
- Bassett Healthcare Network ........... 1309
- Behavioral Health Recruitment Services 1446
- Billings Clinic ........................... 603
- Carilion Clinic ........................... 405
- Carolinas Healthcare System .......... 609
- Central Intelligence Agency .......... 415
Exhibitors by Product/Service Listing

<table>
<thead>
<tr>
<th>Product/Service Listing</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delta Companies</td>
<td>1928</td>
</tr>
<tr>
<td>Department of Behavioral Health and Developmental Disabilities</td>
<td>1305</td>
</tr>
<tr>
<td>Department of Veterans Affairs</td>
<td>411</td>
</tr>
<tr>
<td>EmCare</td>
<td>407</td>
</tr>
<tr>
<td>FCS, Inc.</td>
<td>605</td>
</tr>
<tr>
<td>Federal Bureau of Prisons (BOP)</td>
<td>403</td>
</tr>
<tr>
<td>Fraser Health</td>
<td>610</td>
</tr>
<tr>
<td>Glens Falls Hospital</td>
<td>408</td>
</tr>
<tr>
<td>Greater Hudson Valley Health System</td>
<td>409</td>
</tr>
<tr>
<td>Group Health Physicians</td>
<td>504</td>
</tr>
<tr>
<td>Hospital Corporation of America (HCA)</td>
<td>1328</td>
</tr>
<tr>
<td>IASIS Healthcare</td>
<td>505</td>
</tr>
<tr>
<td>Intermountain Healthcare</td>
<td>501</td>
</tr>
<tr>
<td>Jackson &amp; Coker</td>
<td>1622</td>
</tr>
<tr>
<td>JPE Healthcare Staffing, Inc.</td>
<td>404</td>
</tr>
<tr>
<td>Kaiser Permanente, The Permanente Medical Group, Inc.</td>
<td>614</td>
</tr>
<tr>
<td>Liberty Healthcare Corporation</td>
<td>612</td>
</tr>
<tr>
<td>Medicus Healthcare Solutions</td>
<td>604</td>
</tr>
<tr>
<td>MedPartners Locum Tenens</td>
<td>1523</td>
</tr>
<tr>
<td>Memorial Hospital of Sweetwater County</td>
<td>508</td>
</tr>
<tr>
<td>Ministry Health Care</td>
<td>410</td>
</tr>
<tr>
<td>Minnesota Department of Human Services</td>
<td>512</td>
</tr>
<tr>
<td>North Carolina Office of Rural Health</td>
<td>413</td>
</tr>
<tr>
<td>Northeast Georgia Health System, Inc.</td>
<td>710</td>
</tr>
<tr>
<td>PracticeLink.com</td>
<td>515</td>
</tr>
<tr>
<td>Providence Health &amp; Services</td>
<td>700</td>
</tr>
<tr>
<td>Rochester Regional Health</td>
<td>607</td>
</tr>
<tr>
<td>Rogers Memorial Hospital</td>
<td>1712</td>
</tr>
<tr>
<td>Saint Francis Health System/ Laureate Psychiatric Clinic and Hospital</td>
<td>406</td>
</tr>
<tr>
<td>Spartanburg Regional Healthcare System</td>
<td>510</td>
</tr>
<tr>
<td>Tallahassee Memorial Healthcare</td>
<td>1519</td>
</tr>
<tr>
<td>Tenet Health</td>
<td>513</td>
</tr>
<tr>
<td>Tsehootsooi Medical Center</td>
<td>1415</td>
</tr>
<tr>
<td>U.S. Department of State, Office of Medical Services</td>
<td>1322</td>
</tr>
<tr>
<td>Universal Health Services, Inc.</td>
<td>1418</td>
</tr>
<tr>
<td>Via Christi Health System</td>
<td>611</td>
</tr>
</tbody>
</table>

Research

<table>
<thead>
<tr>
<th>Research</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atlanta Center for Medical Research</td>
<td>1827</td>
</tr>
<tr>
<td>Neurocrine Biosciences, Inc.</td>
<td>1618</td>
</tr>
</tbody>
</table>

Retreat

<table>
<thead>
<tr>
<th>Retreat</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brookhaven Retreat</td>
<td>1513</td>
</tr>
</tbody>
</table>

Telehealth

<table>
<thead>
<tr>
<th>Telehealth</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arcadian Telepsychiatry</td>
<td>1810</td>
</tr>
<tr>
<td>CareClix</td>
<td>1700</td>
</tr>
<tr>
<td>InSight Telepsychiatry, LLC</td>
<td>1616</td>
</tr>
<tr>
<td>Iris Telehealth</td>
<td>1203</td>
</tr>
<tr>
<td>MD.com</td>
<td>1602</td>
</tr>
<tr>
<td>Specialists On Call</td>
<td>1711</td>
</tr>
<tr>
<td>Virtual Medical Staff</td>
<td>1422</td>
</tr>
</tbody>
</table>
Career Fair and Publishers’ Book Fair Exhibitors

Career Fair Exhibitors
Air Force Recruiting Services .......................... 608
Align International Recruitment Ltd. .............. 619
All Star Recruiting ................................. 617
Allina Health ........................................ 602
Army Medical Recruiting .......................... 716
Aureus Medical Group ............................. 706
Aurora Health Care ................................. 506
Billings Clinic ........................................ 603
Carilion Clinic ....................................... 405
Carolinas Healthcare System ....................... 609
California Correctional Health Care Services (CCHCS) .......................... 301
Central Intelligence Agency ......................... 415
Community Health Systems ......................... 601
Community Psychiatry ............................ 503
Department of Veterans Affairs .................. 411
Diamond Healthcare Recruitment Division ........... 708
DR Wanted .......................................... 514
EmCare ............................................. 407
FCS, Inc. ........................................... 605
Federal Bureau of Prisons (BOP) .................. 403
Fraser Health ....................................... 610
Glens Falls Hospital ................................. 408
Greater Hudson Valley Health System .......... 409
Group Health Physicians .......................... 504
Global Medical Staffing ........................... 613
IASIS Healthcare ........................................ 505
Intermountain Healthcare ......................... 501
IPC Healthcare ..................................... 401
JPE Healthcare Staffing, Inc ......................... 404
Kaiser Permanente, The Permanente Medical Group, Inc. ........... 614
Liberty Healthcare Corporation .................... 612
LifePoint Health ..................................... 606
Medical Search ...................................... 412
Medicus Healthcare Solutions ..................... 604
Memorial Hospital of Sweetwater County .......... 508
MHM Services, Inc. .................................. 712
Ministry Health Care ................................. 410
Minnesota Department of Human Services .......... 512
North Carolina Office of Rural Health ............. 413
North GA Partnership (NoGAP) .................... 509
Northeast Georgia Health System, Inc .......... 710
Novant Health ....................................... 511
Oregon Health & Science University, Department of Psychiatry .......... 502
Oregon State Hospital ............................. 500
PracticeLink.com ................................... 515
Providence Health & Services ...................... 700
Riverside Health System ............................ 313
Rochester Regional Health ......................... 607
Saint Francis Health System/ Laureate Psychiatric Clinic and Hospital ........... 406
Spartanburg Regional Healthcare System .......... 510
Southwest Behavioral Health Services ............. 402
Springstone Inc. .................................... 400
Tenet Health ......................................... 513
Unity Center for Behavioral Health ................. 507
Via Christi Health System ........................... 611
VISTA Staffing Solutions, Inc ....................... 600
Westchester Medical Center ....................... 704

Publishers’ Book Fair Exhibitors
Cambridge University Press .......................... 417
Elsevier, Inc. ....................................... 525
Guilford Publications ............................... 420
Hogrefe Publishing Corp. .......................... 522
Informa Health Care Journals ....................... 526
The JAMA Network .................................. 624
Oxford University Press ............................. 423
Psychiatric Times ..................................... 431
Routledge Journals .................................. 528
Routledge/CRC Press ................................ 530
Rutgers Center of Alcohol Studies ................ 527
Springer ............................................ 524
Wiley .................................................. 626
Wolters Kluwer Health ................................ 416
For more information regarding Faculty benefits, please visit www.psychiatry.ufl.edu

The Department of Psychiatry at Oregon Health & Science University (OHSU) has an outstanding opportunity for a BC/BE psychiatrist. The position offers an option of four days of clinical work and one day of protected time to pursue community service and academic interests, and is central to a University-State partnership at the Oregon State Hospital. It offers a unique career path opportunity in a creative environment at a time of historic and progressive change in State mental health.

Academic rank begins at the level of Assistant Professor and may be higher depending on credentials. All applicants must be board certified or board-eligible in Psychiatry. Completion of a fellowship training in forensics, addictions, geriatrics and/or public psychiatry provides additional practice opportunities within the hospital. The position offers very competitive pay and benefits, including a relocation allotment.

Oregon Health & Science University is a nationally prominent research university and Oregon’s only public academic health center. It educates health professionals and scientists and provides leading-edge patient care, community services and biomedical research.

When you join OHSU, you join a dedicated team of caregivers, educators, researchers and administrative professionals who diligently pursue the advancement and application of knowledge to directly benefit the individuals and communities we serve. Each day at OHSU brings a chance to further your learning, discover something new and touch the lives of people in Oregon and beyond.

We look forward to hearing from you.

Jonathan Betinski, M.D.
Associate Professor of Clinical Medicine at Oregon Health Sciences University
Director, Division of Public Psychiatry
Medical Director, OHSU ECHO
Chief Medical Officer, Cascadia Behavioral Healthcare, Inc.
psychjob@ohsu.edu

Be sure to stop by our booth at the APA Career Fair

The University of Florida is an equal opportunity institution dedicated to building a broadly diverse and inclusive faculty & staff.

www.psychiatry.ufl.edu

2015 • 227 pages • ISBN 978-1-58562-547-5 • eBook • $55.00 • Item #62547

2015 • 227 pages • ISBN 978-1-58562-547-5 • eBook • $55.00 • Item #62547

www.appi.org
Email: appi@psych.org
Phone: 1-800-368-5777

2015 • 227 pages • ISBN 978-1-58562-547-5 • eBook • $55.00 • Item #62547

First prize in psychiatry at the 2015 British Medical Association Medical Book Awards

Helping Kids in Crisis
Managing Psychiatric Emergencies in Children and Adolescents
Edited by Fadi Haddad, M.D., and Ruth Gerson, M.D.

This is a practical, easy-to-use guide for clinicians working with child and adolescent psychiatric emergencies across a range of settings. This book provides clinical case examples with concrete tools for assessment, de-escalation, and diagnosis, to help clinicians quickly stabilize the crisis and determine when a trip to the emergency room is necessary.

The College's Gainesville campus is composed of 28 clinical and basic science departments staffed by more than 1,200 faculty members. Both UF and UF Health have again made the national honor roll as one of America's Best Employers, according to Forbes magazine's annual listing that is featured in the April 2016 edition. This year, UF Health rose nine spots to No. 16 among all health care providers and No. 89 out of the top 500 companies. UF ranked No. 13 among public universities and No. 90 overall. Highly motivated and compassionate psychiatrists are encouraged to join our team.

We are currently recruiting for the following specialties:

- Assistant/Associate/Full Professor—Adult Psychiatrist (Inpatient and Outpatient) —Gainesville, FL.
- Assistant/Associate/Professor—2 Community Psychiatrists—Jacksonville, FL.
- Assistant/Associate/Professor—Adult Psychiatrist—Ocala, FL.
- Assistant/Associate/Full Professor—Adult & Child Psychiatrist in the Community Psychiatry Division—Vero Beach, FL.
- Assistant/Associate/Professor—Consult Liaison Child and Adult Psychiatrist —Gainesville, FL.
- Assistant/Associate/Professor—Psychologist in the Addiction Medicine Division—Gainesville, FL.

Must be Board Certified and/or Board Eligible M.D. in Psychiatry and able to obtain a Florida Medical License. Demonstrated record of clinical excellence, research or teaching interest in an academic medical center. Additional Board Certifications in Addiction Psychiatry, Gero-Psychiatry or other Psychiatric subspecialties are of particular interest.

For more information regarding Faculty benefits, please visit http://adminaffairs.med.ufl.edu/fringe-benefits/faculty-benefits/

Applicants must apply through the Careers at UF website http://jobs.ufl.edu/
# Numerical List of Exhibitors by Booth Number

<table>
<thead>
<tr>
<th>Booth</th>
<th>Company Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>301</td>
<td>California Correctional Health Care Services (CCHCS)</td>
</tr>
<tr>
<td>313</td>
<td>Riverside Health System</td>
</tr>
<tr>
<td>327</td>
<td>International Congress on Dual Disorders</td>
</tr>
<tr>
<td>329</td>
<td>WPA World Congress of Psychiatry 2017 Berlin</td>
</tr>
<tr>
<td>400</td>
<td>Springstone Inc.</td>
</tr>
<tr>
<td>401</td>
<td>IPC Healthcare</td>
</tr>
<tr>
<td>402</td>
<td>Southwest Behavioral Health Services</td>
</tr>
<tr>
<td>403</td>
<td>Federal Bureau of Prisons (BOP)</td>
</tr>
<tr>
<td>404</td>
<td>JPE Healthcare Staffing, Inc.</td>
</tr>
<tr>
<td>405</td>
<td>Carilion Clinic</td>
</tr>
<tr>
<td>406</td>
<td>Saint Francis Health System/Laureate Psychiatric Clinic and Hospital</td>
</tr>
<tr>
<td>407</td>
<td>EmCare</td>
</tr>
<tr>
<td>408</td>
<td>Glens Falls Hospital</td>
</tr>
<tr>
<td>409</td>
<td>Greater Hudson Valley Health System</td>
</tr>
<tr>
<td>410</td>
<td>Ministry Health Care</td>
</tr>
<tr>
<td>411</td>
<td>Department of Veterans Affairs</td>
</tr>
<tr>
<td>412</td>
<td>Medical Search</td>
</tr>
<tr>
<td>413</td>
<td>North Carolina Office of Rural Health</td>
</tr>
<tr>
<td>415</td>
<td>Central Intelligence Agency</td>
</tr>
<tr>
<td>416</td>
<td>Wolters Kluwer Health</td>
</tr>
<tr>
<td>417</td>
<td>Cambridge University Press</td>
</tr>
<tr>
<td>420</td>
<td>Guilford Publications</td>
</tr>
<tr>
<td>423</td>
<td>Oxford University Press</td>
</tr>
<tr>
<td>431</td>
<td><em>Psychiatric Times</em></td>
</tr>
<tr>
<td>500</td>
<td>Oregon State Hospital</td>
</tr>
<tr>
<td>501</td>
<td>Intermountain Healthcare</td>
</tr>
<tr>
<td>502</td>
<td>Oregon Health &amp; Science University, Department of Psychiatry</td>
</tr>
<tr>
<td>503</td>
<td>Community Psychiatry</td>
</tr>
<tr>
<td>504</td>
<td>Group Health Physicians</td>
</tr>
<tr>
<td>505</td>
<td>IASIS Healthcare</td>
</tr>
<tr>
<td>506</td>
<td>Aurora Health Care</td>
</tr>
<tr>
<td>507</td>
<td>Unity Center for Behavioral Health</td>
</tr>
<tr>
<td>508</td>
<td>Memorial Hospital of Sweetwater County</td>
</tr>
<tr>
<td>509</td>
<td>North GA Partnership (NoGAP)</td>
</tr>
<tr>
<td>510</td>
<td>Spartanburg Regional Healthcare System</td>
</tr>
<tr>
<td>511</td>
<td>Novant Health</td>
</tr>
<tr>
<td>512</td>
<td>Minnesota Department of Human Services</td>
</tr>
<tr>
<td>513</td>
<td>Tenet Health</td>
</tr>
<tr>
<td>514</td>
<td>DR Wanted</td>
</tr>
<tr>
<td>515</td>
<td>PracticeLink.com</td>
</tr>
<tr>
<td>522</td>
<td>Hogrefe Publishing Corp.</td>
</tr>
<tr>
<td>524</td>
<td>Springer</td>
</tr>
<tr>
<td>525</td>
<td>Elsevier, Inc.</td>
</tr>
<tr>
<td>526</td>
<td>Informa Health Care Journals</td>
</tr>
<tr>
<td>527</td>
<td>Rutgers Center of Alcohol Studies</td>
</tr>
<tr>
<td>528</td>
<td>Routledge Journals</td>
</tr>
<tr>
<td>530</td>
<td>Routledge/CRC Press</td>
</tr>
<tr>
<td>537</td>
<td>Vanda Pharmaceuticals Inc.</td>
</tr>
<tr>
<td>600</td>
<td>VISTA Staffing Solutions, Inc.</td>
</tr>
<tr>
<td>601</td>
<td>Community Health Systems</td>
</tr>
<tr>
<td>602</td>
<td>Allina Health</td>
</tr>
<tr>
<td>603</td>
<td>Billings Clinic</td>
</tr>
<tr>
<td>604</td>
<td>Medicus Healthcare Solutions</td>
</tr>
<tr>
<td>605</td>
<td>FCS, Inc.</td>
</tr>
<tr>
<td>606</td>
<td>LifePoint Health</td>
</tr>
<tr>
<td>607</td>
<td>Rochester Regional Health</td>
</tr>
<tr>
<td>608</td>
<td>Air Force Recruiting Services</td>
</tr>
<tr>
<td>609</td>
<td>Carolinas Healthcare System</td>
</tr>
<tr>
<td>610</td>
<td>Fraser Health</td>
</tr>
<tr>
<td>611</td>
<td>Via Christi Health System</td>
</tr>
<tr>
<td>612</td>
<td>Liberty Healthcare Corporation</td>
</tr>
<tr>
<td>613</td>
<td>Global Medical Staffing</td>
</tr>
<tr>
<td>614</td>
<td>Kaiser Permanente, The Permanente Medical Group, Inc.</td>
</tr>
<tr>
<td>617</td>
<td>All Star Recruiting</td>
</tr>
<tr>
<td>619</td>
<td>Align International Recruitment Ltd.</td>
</tr>
<tr>
<td>624</td>
<td>The <em>JAMA</em> Network</td>
</tr>
<tr>
<td>626</td>
<td>Wiley</td>
</tr>
<tr>
<td>637</td>
<td>Janssen Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>644</td>
<td>Intra-Cellular Therapies Inc.</td>
</tr>
<tr>
<td>700</td>
<td>Providence Health &amp; Services</td>
</tr>
<tr>
<td>704</td>
<td>Westchester Medical Center</td>
</tr>
<tr>
<td>706</td>
<td>Aureus Medical Group</td>
</tr>
<tr>
<td>Booth Number</td>
<td>Company Name</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------</td>
</tr>
<tr>
<td>708</td>
<td>Diamond Healthcare Recruitment Division</td>
</tr>
<tr>
<td>710</td>
<td>Northeast Georgia Health System, Inc.</td>
</tr>
<tr>
<td>712</td>
<td>MHM Services, Inc.</td>
</tr>
<tr>
<td>716</td>
<td>Army Medical Recruiting</td>
</tr>
<tr>
<td>747</td>
<td>SARDA—Schizophrenia &amp; Related Disorders Alliance of America</td>
</tr>
<tr>
<td>837</td>
<td>Merck &amp; Co.</td>
</tr>
<tr>
<td>845</td>
<td>Assurex Health</td>
</tr>
<tr>
<td>937</td>
<td>Otsuka America Pharmaceutical, Inc.</td>
</tr>
<tr>
<td>945</td>
<td>Wexford Health Sources</td>
</tr>
<tr>
<td>1037</td>
<td>Otsuka America Pharmaceutical, Inc.</td>
</tr>
<tr>
<td>1044</td>
<td>Millennium Health</td>
</tr>
<tr>
<td>1049</td>
<td>NEOS Therapeutics</td>
</tr>
<tr>
<td>1149</td>
<td>Tris Pharma</td>
</tr>
<tr>
<td>1201</td>
<td>Northern Light Technologies</td>
</tr>
<tr>
<td>1203</td>
<td>Iris Telehealth</td>
</tr>
<tr>
<td>1207</td>
<td>NeuroScience, Inc.</td>
</tr>
<tr>
<td>1209</td>
<td>Shire</td>
</tr>
<tr>
<td>1211</td>
<td>Electromedical Products International, Inc.</td>
</tr>
<tr>
<td>1217</td>
<td>American Professional Agency, Inc.</td>
</tr>
<tr>
<td>1223</td>
<td>Medical Billing Professionals</td>
</tr>
<tr>
<td>1225</td>
<td>Maxim Physician Resources</td>
</tr>
<tr>
<td>1227</td>
<td>Genomind</td>
</tr>
<tr>
<td>1237</td>
<td>Sunovion Pharmaceuticals Inc.</td>
</tr>
<tr>
<td>1247</td>
<td>Sunovion Pharmaceuticals Inc.</td>
</tr>
<tr>
<td>1300</td>
<td>McLean Hospital</td>
</tr>
<tr>
<td>1301</td>
<td>MECTA Corporation</td>
</tr>
<tr>
<td>1304</td>
<td>Quotient® ADHD System by Pearson</td>
</tr>
<tr>
<td>1305</td>
<td>Department of Behavioral Health and Developmental Disabilities</td>
</tr>
<tr>
<td>1306</td>
<td>Sun Behavioral Health</td>
</tr>
<tr>
<td>1308</td>
<td>Otto Trading, Inc.</td>
</tr>
<tr>
<td>1309</td>
<td>Bassett Healthcare Network</td>
</tr>
<tr>
<td>1310</td>
<td>University of Florida Department of Psychiatry</td>
</tr>
<tr>
<td>1311</td>
<td>HCPLive</td>
</tr>
<tr>
<td>1313</td>
<td>Mayo Clinic</td>
</tr>
<tr>
<td>1317</td>
<td>Menninger Clinic</td>
</tr>
<tr>
<td>1319</td>
<td>OmegaBrite</td>
</tr>
<tr>
<td>1322</td>
<td>U.S. Department of State, Office of Medical Services</td>
</tr>
<tr>
<td>1323</td>
<td>LocumTenens.com</td>
</tr>
<tr>
<td>1324</td>
<td>Otsuka America Pharmaceutical, Inc.</td>
</tr>
<tr>
<td>1328</td>
<td>Hospital Corporation of America</td>
</tr>
<tr>
<td>1329</td>
<td>Shire U.S., Inc.</td>
</tr>
<tr>
<td>1337</td>
<td>Allergan</td>
</tr>
<tr>
<td>1347</td>
<td>Metabolic Maintenance</td>
</tr>
<tr>
<td>1400</td>
<td>Horizon Health</td>
</tr>
<tr>
<td>1401</td>
<td>Sheppard Pratt Health System</td>
</tr>
<tr>
<td>1402</td>
<td>Soterix Medical, Inc.</td>
</tr>
<tr>
<td>1403</td>
<td>The Center for Eating Disorders at Sheppard Pratt</td>
</tr>
<tr>
<td>1404</td>
<td>Captive Risk Planners/Perfect Tax &amp; Finance</td>
</tr>
<tr>
<td>1405</td>
<td>Braeburn Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>1406</td>
<td>Uskudar University Npistanbul Neuropsychiatry Hospital</td>
</tr>
<tr>
<td>1408</td>
<td>Wellington Retreat</td>
</tr>
<tr>
<td>1409</td>
<td>Indivior Inc.</td>
</tr>
<tr>
<td>1410</td>
<td>AltheaDx</td>
</tr>
<tr>
<td>1411</td>
<td>Gould Farm</td>
</tr>
<tr>
<td>1412</td>
<td>Clinical Psychiatry News</td>
</tr>
<tr>
<td>1413</td>
<td>Sierra Tucson</td>
</tr>
<tr>
<td>1414</td>
<td>Current Psychiatry</td>
</tr>
<tr>
<td>1415</td>
<td>Tsehootsooi Medical Center</td>
</tr>
<tr>
<td>1416</td>
<td>Skyland Trail</td>
</tr>
<tr>
<td>1417</td>
<td>The TOVA Company</td>
</tr>
<tr>
<td>1418</td>
<td>Universal Health Services, Inc.</td>
</tr>
<tr>
<td>1419</td>
<td>American Physician Institute — Beat the Boards</td>
</tr>
<tr>
<td>1420</td>
<td>Locum Source, Inc.</td>
</tr>
<tr>
<td>1422</td>
<td>Virtual Medical Staff</td>
</tr>
<tr>
<td>1423</td>
<td>Valant Medical Solutions</td>
</tr>
<tr>
<td>1424</td>
<td>Compulink Business Systems, Inc.</td>
</tr>
<tr>
<td>1425</td>
<td>Georgia Association of Community Service Boards, Inc.</td>
</tr>
<tr>
<td>1429</td>
<td>American Board of Psychiatry and Neurology, Inc.</td>
</tr>
</tbody>
</table>
### Numerical List of Exhibitors by Booth Number

<table>
<thead>
<tr>
<th>Booth Number</th>
<th>Company Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>1431</td>
<td>Somatics LLC</td>
</tr>
<tr>
<td>1437</td>
<td>ACADIA Pharmaceuticals</td>
</tr>
<tr>
<td>1446</td>
<td>Behavioral Health Recruitment Services</td>
</tr>
<tr>
<td>1447</td>
<td>Rhodes Pharmaceuticals L.P.</td>
</tr>
<tr>
<td>1500</td>
<td>Vanderbilt Behavioral Health</td>
</tr>
<tr>
<td>1501</td>
<td>CompHealth</td>
</tr>
<tr>
<td>1503</td>
<td>Neba Health, LLC</td>
</tr>
<tr>
<td>1505</td>
<td>Association &amp; Meeting Solutions</td>
</tr>
<tr>
<td>1510</td>
<td>Christian Medical &amp; Dental Associations, Psychiatry Section</td>
</tr>
<tr>
<td>1511</td>
<td>Muse: The Brain Sensing Headband</td>
</tr>
<tr>
<td>1512</td>
<td>TeleSage, Inc.</td>
</tr>
<tr>
<td>1513</td>
<td>Brookhaven Retreat</td>
</tr>
<tr>
<td>1514</td>
<td>Harmonex Neuroscience Research, Inc.</td>
</tr>
<tr>
<td>1516</td>
<td>World Health Information Network</td>
</tr>
<tr>
<td>1517</td>
<td>Weatherby Healthcare</td>
</tr>
<tr>
<td>1518</td>
<td>Magstim</td>
</tr>
<tr>
<td>1519</td>
<td>Tallahassee Memorial Healthcare</td>
</tr>
<tr>
<td>1521</td>
<td>Hillside, Inc.</td>
</tr>
<tr>
<td>1522</td>
<td>New York-Presbyterian Hospital</td>
</tr>
<tr>
<td>1523</td>
<td>Medpartners Locum Tenens</td>
</tr>
<tr>
<td>1528</td>
<td>Focus: The Journal of Lifelong Learning in Psychiatry</td>
</tr>
<tr>
<td>1529</td>
<td>NeuroStar TMS Therapy</td>
</tr>
<tr>
<td>1530</td>
<td>Austen Riggs Center</td>
</tr>
<tr>
<td>1546</td>
<td>Allergan</td>
</tr>
<tr>
<td>1547</td>
<td>Indivior Inc.</td>
</tr>
<tr>
<td>1600</td>
<td>Barton Associates</td>
</tr>
<tr>
<td>1601</td>
<td>Association of Gay and Lesbian Psychiatrists (AGLP)</td>
</tr>
<tr>
<td>1602</td>
<td>MD.com</td>
</tr>
<tr>
<td>1603</td>
<td>American Academy of Addiction Psychiatry</td>
</tr>
<tr>
<td>1607</td>
<td>National Institute of Mental Health (NIMH)</td>
</tr>
<tr>
<td>1613</td>
<td>Physicians for a National Health Program</td>
</tr>
<tr>
<td>1614</td>
<td>Infinite Trading, Inc.</td>
</tr>
<tr>
<td>1615</td>
<td>Veritas Collaborative</td>
</tr>
<tr>
<td>1616</td>
<td>InSight Telepsychiatry, LLC</td>
</tr>
<tr>
<td>1617</td>
<td>Brainsway USA Inc.</td>
</tr>
<tr>
<td>1618</td>
<td>Neurocrine Biosciences, Inc.</td>
</tr>
<tr>
<td>1622</td>
<td>Jackson &amp; Coker</td>
</tr>
<tr>
<td>1623</td>
<td>Alkermes, Inc.</td>
</tr>
<tr>
<td>1637</td>
<td>Ironshore Pharmaceuticals and Development, Inc.</td>
</tr>
<tr>
<td>1700</td>
<td>CareClix</td>
</tr>
<tr>
<td>1701</td>
<td>Mount Sinai Health System</td>
</tr>
<tr>
<td>1707</td>
<td>Magventure, Inc.</td>
</tr>
<tr>
<td>1710</td>
<td>Georgia Ketamine</td>
</tr>
<tr>
<td>1711</td>
<td>Specialists On Call</td>
</tr>
<tr>
<td>1712</td>
<td>Rogers Memorial Hospital</td>
</tr>
<tr>
<td>1713</td>
<td>Indivior Inc.</td>
</tr>
<tr>
<td>1714</td>
<td>PsychU</td>
</tr>
<tr>
<td>1715</td>
<td>TrueLearn</td>
</tr>
<tr>
<td>1717</td>
<td>Arbor Pharmaceuticals, LLC</td>
</tr>
<tr>
<td>1800</td>
<td>Admera Health</td>
</tr>
<tr>
<td>1806</td>
<td>Destination Hope</td>
</tr>
<tr>
<td>1810</td>
<td>Arcadian Telepsychiatry</td>
</tr>
<tr>
<td>1811</td>
<td>Alkermes, Inc.</td>
</tr>
<tr>
<td>1812</td>
<td>Humana Inc.</td>
</tr>
<tr>
<td>1814</td>
<td>Correct Care Solutions, LLC</td>
</tr>
<tr>
<td>1817</td>
<td>Takeda Pharmaceuticals U.S.A., Inc./Lundbeck</td>
</tr>
<tr>
<td>1823</td>
<td>Neuronetrix</td>
</tr>
<tr>
<td>1825</td>
<td>CoverMyMeds</td>
</tr>
<tr>
<td>1827</td>
<td>Atlanta Center for Medical Research</td>
</tr>
<tr>
<td>1829</td>
<td>Rogers Behavioral Health System</td>
</tr>
<tr>
<td>1922</td>
<td>Acadia Healthcare</td>
</tr>
<tr>
<td>1926</td>
<td>Otsuka America Pharmaceutical, Inc.</td>
</tr>
<tr>
<td>1928</td>
<td>Delta Companies</td>
</tr>
</tbody>
</table>
Exhibit Hall Floor Plan
For the treatment of schizophrenia

Evidence of autonomic instability (irregular pulse or blood pressure), NMS include hyperpyrexia, muscle rigidity, altered mental status, and other symptoms of autonomic instability. NMS may also be accompanied by fever and a blood pressure increase. Immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; 2) intensive symptomatic treatment and medical monitoring; and 3) treatment of any concomitant serious medical problems for which specific treatments are available.

Tardive Dyskinesia (TD): The risk of developing TD (a syndrome of abnormal, involuntary movements) and the potential for it to become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic increase. The syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses. Prescribing should be consistent with the need to minimize TD. Discontinue ARISTADA if clinically appropriate. There is no known treatment for established TD, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn.

Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that include:

- **Hyperglycemia/Diabetes Mellitus**: Hyperglycemia, in some cases extreme and associated with ketoacidosis, coma, or death, has been reported in patients treated with atypical antipsychotics. There have been reports of hyperglycemia in patients treated with oral aripiprazole. Patients with diabetes should be regularly monitored for worsening of glucose control; those with risk factors for diabetes should undergo baseline and periodic fasting blood glucose testing. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia, including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients require continuation of antidiabetic treatment despite discontinuation of the suspect drug.

- **Dyslipidemia**: Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.

- **Weight Gain**: Weight gain has been observed with atypical antipsychotic use. Clinical monitoring of weight is recommended.
ARISTADA helps you match your patients with the efficacy and options they need

Delivering proven efficacy and flexibility for individualized care

- Significantly improved Positive and Negative Syndrome Scale (PANSS) total score at day 85 vs placebo
- The 882-mg dose provides extended coverage with monthly or 6-week dosing interval
- The 441-mg and 662-mg doses are given monthly
- ARISTADA® (aripiprazole lauroxil) is only to be administered as an intramuscular injection by a healthcare professional. For patients who have never taken aripiprazole, establish tolerability with oral aripiprazole prior to initiating treatment with ARISTADA
- Administer treatment with oral aripiprazole for 21 consecutive days in conjunction with the first ARISTADA injection
- Dose may be adjusted as needed. When making dose and dosing interval adjustments, the pharmacokinetics and prolonged-release characteristics of ARISTADA should be considered
- Missed doses: If time elapsed since last injection exceeds 6 weeks (441 mg) or 8 weeks (662 mg and 882 mg), supplement next injection with oral aripiprazole. Please see full Prescribing Information for more instructions for missed doses

Learn more at Booth 1623

Orthostatic Hypotension: Aripiprazole may cause orthostatic hypotension which can be associated with dizziness, lightheadedness, and tachycardia. Monitor heart rate and blood pressure, and warn patients with known cardiovascular or cerebrovascular disease and risk of dehydration and syncope.

Leukopenia, Neutropenia, and Agranulocytosis: Leukopenia, neutropenia, and agranulocytosis have been reported. Patients with a history of clinically significant low white blood cell count (WBC)/absolute neutrophil count (ANC) and history of drug-induced leukopenia/ neutropenia should have frequent complete blood count (CBC) during the first few months of receiving ARISTADA. Consider discontinuation of ARISTADA at the first sign of a clinically significant decline in WBC count in the absence of other causal factors. Monitor patients with clinically significant neutropenia for fever or other symptoms or signs of infection and treat promptly if such symptoms or signs occur. Discontinue ARISTADA in patients with severe neutropenia (absolute neutrophil count <1000/mm³) and follow their WBC until recovery.

Seizures: ARISTADA should be used with caution in patients with a history of seizures or with conditions that lower the seizure threshold.

Potential for Cognitive and Motor Impairment: ARISTADA may impair judgment, thinking, or motor skills. Patients should be cautioned about operating hazardous machinery, including automobiles, until they are certain ARISTADA does not affect them adversely.

Body Temperature Regulation: Disruption of the body’s ability to reduce core body temperature has been attributed to antipsychotic agents. Advise patients regarding appropriate care in avoiding overheating and dehydration. Appropriate care is advised for patients who may exercise strenuously, may be exposed to extreme heat, receive concomitant medication with anticholinergic activity, or are subject to dehydration.

Dysphagia: Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Use caution in patients at risk for aspiration pneumonia.

Concomitant Medication: Decreasing the ARISTADA dosage is recommended in patients taking strong CYP3A4 inhibitors and/or strong CYP2D6 inhibitors for longer than 2 weeks. Increasing the ARISTADA dosage is recommended in patients taking CYP3A4 inducers for longer than 2 weeks. No ARISTADA dosage changes are recommended for patients taking CYP450 modulators for less than 2 weeks.

Most Commonly Observed Adverse Reaction: The most common adverse reaction (≥25% incidence and at least twice the rate of placebo in patients treated with ARISTADA) was akathisia.

Injection-Site Reactions: Injection-site reactions were reported by 4%, 5%, and 2% of patients treated with 441 mg ARISTADA, 882 mg ARISTADA, and placebo, respectively. Most of these were injection-site pain and associated with the first injection and decreased with each subsequent injection. Other injection-site reactions (induration, swelling, and redness) occurred at less than 1%.

Dystonia: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first days of treatment and at low doses.

Pregnancy/Nursing: May cause extrapyramidal and/or withdrawal symptoms in neonates with third trimester exposure. Advise patients to notify their healthcare provider of a known or suspected pregnancy. Inform patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ARISTADA during pregnancy. Aripiprazole is present in human breast milk. The benefits of breastfeeding should be considered along with the mother’s clinical need for ARISTADA and any potential adverse effects on the infant from ARISTADA or from the underlying maternal condition.

Please see Brief Summary of full Prescribing Information, including Boxed Warning, on the following pages.


©2016 Alkermes, Inc. All rights reserved. ARI-001462 Printed in the U.S.A.
ARISTADA® (aripiprazole lauroxil) extended-release injectable suspension, for intramuscular use

**BRIEF SUMMARY OF PRESCRIBING INFORMATION**

(For complete details, please see full Prescribing Information and Medication Guide.)

**WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSES**

- Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death
- ARISTADA is not approved for the treatment of patients with dementia-related psychosis

**INDICATIONS AND USAGE:** ARISTADA is an atypical antipsychotic indicated for the treatment of schizophrenia.

**CONTRAINDICATIONS:** ARISTADA is contraindicated in patients with a known hypersensitivity reaction to aripiprazole. Hypersensitivity reactions have ranged from pruritus/urticaria to anaphylaxis.

**WARNINGS AND PRECAUTIONS**

Increased Mortality in Elderly Patients With Dementia-related Psychosis: Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group.

Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributable to the antipsychotic drug as opposed to other characteristic(s) of the patient is not clear. ARISTADA is not approved for the treatment of patients with dementia-related psychosis.

Cerebrovascular Adverse Reactions, Including Stroke: In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly patients with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks) including fatalities compared to placebo-treated patients. ARISTADA is not approved for the treatment of patients with dementia-related psychosis.

Neuroleptic Malignant Syndrome: A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) may occur in association with antipsychotic drugs, including ARISTADA. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.

The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify cases in which the clinical presentation includes both serious medical illness (e.g., pneumonia, systemic infection, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology.

The management of NMS should include (1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; (2) intensive symptomatic treatment and medical monitoring; and (3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for uncomplicated NMS.

If a patient appears to require antipsychotic drug treatment after recovery from NMS, reintroduction of drug therapy should be closely monitored, since recurrences of NMS have been reported.

Tardive Dyskinesia: A syndrome of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be higher among the elderly, especially elderly women, it is impossible to predict which patients will develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown.

The risk of developing tardive dyskinesia and the likelihood that it will become irreversible appear to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase, but the syndrome can develop after relatively brief treatment periods at low doses, although this is uncommon.

There is no known treatment for established tardive dyskinesia, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment itself may suppress (or partially suppress) the signs and symptoms of the syndrome and may thus mask the underlying process. The effect of symptomatic suppression on the course of the syndrome is unknown.

Given these considerations, ARISTADA should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that is known to respond to antipsychotic drugs. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically. If signs and symptoms of tardive dyskinesia appear in a patient treated with ARISTADA, drug discontinuation should be considered. However, some patients may require treatment with ARISTADA despite the presence of the syndrome.

Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that include hyperglycemia/diabetes mellitus, dyslipidemia, and weight gain. While all drugs in the class have been shown to produce some metabolic changes, each drug has its own specific risk profile.

**Hyperglycemia/Diabetes Mellitus:** Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics. There have been reports of hyperglycemia in patients treated with oral aripiprazole. Assessment of the relationship between antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and hyperglycemia-related adverse reactions is not completely understood. However, epidemiological studies suggest an increased risk of hyperglycemia-related adverse reactions in patients treated with the atypical antipsychotics.

Patients with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients require continuation of anti-diabetic treatment despite discontinuation of the suspect drug.

In the long-term, open-label schizophrenia study with ARISTADA, 14% of patients with normal hemoglobin A1c (>5.7%) at baseline developed elevated levels (>5.7%) post-baseline.

**Dyslipidemia:** Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.

In the long-term, open-label schizophrenia study with ARISTADA, shifts in baseline fasting total cholesterol from normal (<200 mg/dL) to high (≥240 mg/dL) were reported in 1% of patients; shifts in baseline fasting LDL cholesterol from normal (<100 mg/dL) to high (≥160 mg/dL) were reported in 1% of patients; and shifts in baseline fasting triglycerides from normal (<150 mg/dL) to high (≥200 mg/dL) were reported in 8% of patients. In the same study, shifts in baseline fasting total cholesterol from borderline (200-240 mg/dL) to high (≥240 mg/dL) were reported in 15% of patients; shifts in baseline fasting LDL cholesterol from borderline (100-160 mg/dL) to high (≥160 mg/dL) were reported in 8% of patients; and shifts in baseline fasting triglycerides from borderline (150 mg/dL and <200 mg/dL) to high (≥200 mg/dL) were reported in 35% of patients. In addition, the proportion of patients with shifts in fasting HDL cholesterol from normal (>40 mg/dL) to low (≤40 mg/dL) was reported in 15% of patients.

**Weight Gain:** Weight gain has been observed with atypical antipsychotic use. Clinical monitoring of weight is recommended.

The proportion of adult patients with weight gain ≥7% of body weight is presented in Table 1.

*Table 1: Proportion of Adult Patients With Shifts in Weight in the 12-Week, Placebo-Controlled, Fixed-Dose Schizophrenia Trial*

<table>
<thead>
<tr>
<th>Placebo</th>
<th>ARISTADA</th>
</tr>
</thead>
<tbody>
<tr>
<td>441 mg</td>
<td>882 mg</td>
</tr>
<tr>
<td>N = 207</td>
<td>N = 207</td>
</tr>
<tr>
<td>N = 208</td>
<td>N = 208</td>
</tr>
</tbody>
</table>

**Weight gain**

<table>
<thead>
<tr>
<th>N (%)</th>
<th>N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>10</td>
</tr>
<tr>
<td>9</td>
<td>0</td>
</tr>
</tbody>
</table>

**Orthostatic Hypotension:** Aripiprazole may cause orthostatic hypotension, perhaps due to its α₁-adrenergic receptor antagonism. Associated adverse reactions related to orthostatic hypotension can include dizziness, lightheadedness, and tachycardia. Generally, these risks are greatest at the beginning of treatment and during dose escalation. Patients at increased risk of these adverse reactions or at increased risk of developing complications from hypotension include those with dehydration, hypovolemia, treatment with antihypertensive medication, history of cardiovascular disease (e.g., heart failure, myocardial infarction, ischemia, or conduction abnormalities), history of cerebrovascular disease, as well as patients who are antipsychotic-naïve. In such patients, consider using a lower starting dose, and monitor for orthostatic vital signs.

Orthostatic hypotension was reported for 1 patient in the ARISTADA 882 mg group (0.5%) and no patients in the 441 mg group. In the long-term open-label schizophrenia efficacy study, orthostatic hypotension was reported for 1 (0.2%) patient treated with ARISTADA. Orthostatic hypotension was defined as a decrease in systolic blood pressure ≥20 mmHg accompanied by an increase in heart rate ≥25 bpm when comparing standing to supine values.
Leukopenia, Neutropenia, and Agranulocytosis: In clinical trials and/or postmarketing experience, events of leukopenia and neutropenia have been reported temporally related to antipsychotic agents. Agranulocytosis has also been reported. Possible risk factors for leukopenia/neutropenia include pre-existing low white blood cell count (WBC)/absolute neutrophil count (ANC) and history of drug-induced leukaemia/neutropenia. In patients with a history of a clinically significant low WBC/ANC or drug-induced leukemia/neutropenia, perform a complete blood count (CBC) frequently during the first few months of therapy. In such patients, consider discontinuation of ARISTADA at the first sign of a clinical significant decline in WBC in the absence of other causative factors. Monitor patients with clinically significant neutropenia for fever or other symptoms or signs of infection and treat promptly if such symptoms or signs occur. Discontinue ARISTADA in patients with severe neutropenia (absolute neutrophil count <1000/mm^3) and follow their WBC until recovery.

Seizures: As with other antipsychotic drugs, use ARISTADA cautiously in patients with a history of seizures or with conditions that lower the seizure threshold. Conditions that lower the seizure threshold may be more prevalent in a population of 65 years or older.

Potential for Cognitive and Motor Impairment: ARISTADA, like other antipsychotics, has the potential to impair judgment, thinking, or motor skills. Patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that therapy with ARISTADA does not affect them adversely.

Body Temperature Regulation: Disruption of the body’s ability to reduce core body temperature has been attributed to antipsychotic agents. Appropriate care is advised when prescribing ARISTADA for patients who will be experiencing conditions which may contribute to an elevation in core body temperature (e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration).

Dysphagia: Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. ARISTADA and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia.

ADVERSE REACTIONS

Clinical Studies Experience: Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Patient Exposure: ARISTADA has been evaluated for safety in 880 adult patients in clinical trials in schizophrenia.

Commonly Observed Adverse Reactions: The most common adverse reaction (incidence >5% and at least twice the rate of placebo in patients treated with ARISTADA) was akathisia.

Adverse Reactions Occurring at an Incidence of 2% or More in ARISTADA-Treated Patients. Adverse reactions associated with the use of ARISTADA (incidence of 2% or greater, rounded to the nearest percent and ARISTADA incidence greater than placebo) that occurred at a rate equal to or less than placebo are listed in Table 1.

Table 1: Incidence of EPS Compared to Placebo

<table>
<thead>
<tr>
<th>Adverse Reaction Term</th>
<th>Placebo N = 207 (%)</th>
<th>441 mg N = 207 (%)</th>
<th>882 mg N = 208 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Akathisia</td>
<td>4</td>
<td>11</td>
<td>11</td>
</tr>
<tr>
<td>Restlessness</td>
<td>1</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Other EPS</td>
<td>4</td>
<td>5</td>
<td>7</td>
</tr>
<tr>
<td>Dystonia</td>
<td>1</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Parkinsonism</td>
<td>3</td>
<td>4</td>
<td></td>
</tr>
</tbody>
</table>

Dyskinesia: Symptoms of dyskinesia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dyskinetic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first-generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups.

Other Adverse Reactions Observed in Clinical Studies: The following listing does not include reactions: 1) already listed in previous tables or elsewhere in labeling, 2) for which a drug cause was remote, 3) which were so general as to be uninformative, 4) which were not considered to have significant clinical implications, or 5) which occurred at a rate equal to or than placebo.

Cardiac – angina pectoris, tachycardia, palpitations
Gastrointestinal disorders – constipation, dry mouth
General disorders – asthenia
Musculoskeletal – muscular weakness
Nervous system disorders – dizziness
Psychiatric disorders – anxiety, suicide

Adverse Reactions Reported in Clinical Trials with Oral Aripiprazole: The following is a list of additional adverse reactions that have been reported in clinical trials with oral aripiprazole and not reported above for ARISTADA.

Blood and Lymphatic System Disorders: thrombocytopenia
Cardiac Disorders: bradycardia, atrial flutter, cardiorespiratory arrest, atrioventricular block, atrial fibrillation, myocardial ischemia, myocardial infarction, cardiopulmonary failure
Eye Disorders: photophobia, diplopia
Gastrointestinal Disorders: gastroesophageal reflux disease
General Disorders and Administration-Site Conditions: peripheral edema, chest pain, face edema
Hepatobiliary Disorders: hepatitis, jaundice
Immune System Disorders: hypersensitivity
Injury, Poisoning, and Procedural Complications: fall, heat stroke
Investigations: weight decreased, hepatic enzyme increased, blood glucose increased, lactate dehydrogenase increased, gamma glutamyl transferase increased, blood prolactin increased, blood urea increased, blood creatinine increased, blood bilirubin increased, electrocardiogram QT prolonged, glycosylated hemoglobin increased
Metabolism and Nutrition Disorders: anorexia, hypokalemia, hyposthenia, hypoglycemia
Musculoskeletal and Connective Tissue Disorders: muscle tightness, rhabdomyolysis, mobility decreased
Nervous System Disorders: memory impairment, cogwheel rigidity, hypokinesia, myoclonus, bradykinesia, akinesia, myoclonus, coordination abnormal, speech disorder, choreoathetosis
Psychiatric Disorders: aggression, loss of libido, delirium, libido increased, anorgasmia, tic, homicidal ideation, catatonia, sleep walking
Renal and Urinary Disorders: urinary retention, nocturia
Reproductive System and Breast Disorders: erectile dysfunction, gynecomastia, menstruation irregular, amenorrhea, breast pain, priapism
Respiratory, Thoracic, and Mediastinal Disorders: nasal congestion, dyspnea
Skin and Subcutaneous Tissue Disorders: rash, hyperhidrosis, pruritus, photosensitivity reaction, alopecia, urticaria
Vascular Disorders: hypotension, hyperventilation

Postmarketing Experience: The following adverse reactions have been identified during post-approval use of oral aripiprazole. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or to establish a causal relationship to drug exposure: occurrences of allergic reaction (anaphylactic reaction, angioedema, laryngospasm, pruritus/urticaria, or oropharyngeal spasm), pathological gambling, hiccups, and blood glucose fluctuation.

DRUG INTERACTIONS

Drugs Having Clinically Important Interactions With ARISTADA

Table 4: Clinically Important Drug Interactions With ARISTADA

<table>
<thead>
<tr>
<th>Concomitant Drug Name or Drug Class</th>
<th>Clinical Rationale</th>
<th>Clinical Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strong CYP3A4 Inhibitors (e.g., lurasidone, clozapine) or CYP2D6 inhibitors (e.g., quinidine, fluoxetine, paroxetine)</td>
<td>The concomitant use of oral aripiprazole with inducing CYP3A4 or CYP2D6 inhibitors increased the exposure of aripiprazole compared to the use of oral aripiprazole alone.</td>
<td>With concomitant use of ARISTADA with a strong CYP3A4 inhibitor or CYP2D6 inhibitor for more than 2 weeks, reduce the ARISTADA dose.</td>
</tr>
</tbody>
</table>
In pregnant rabbits treated with oral doses of 10, 30, and 100 mg/kg/day, which are 2 to 11 times human exposure at the oral MRHD based on AUC and 6 to 65 times the oral MRHD on mg/m² basis of aripiprazole during the period of organogenesis, decreased maternal food consumption and increased abortions were seen at the highest dose as well as increased fetal mortality. Decreased fetal weight and increased incidence of fused sternebrae were observed at 3 and 11 times the oral MRHD based on AUC. In rats treated with oral doses of 3, 10, and 30 mg/kg/day which are 1 to 10 times the oral MRHD on mg/m² basis of aripiprazole perinatally and postnatally (from day 17 of gestation through day 21 postpartum), slight maternal toxicity and slightly prolonged gestation were seen at the highest dose. An increase in stillbirths and decreases in pup weight (persisting into adulthood) and survival were also seen at this dose.

**Lactation: Risk Summary:** Aripiprazole is present in human breast milk; however, there are insufficient data to assess the amount in human milk, the effects on the breastfed infant, or the effects on milk production. The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for ARISTADA and any potential risks to the infant from ARISTADA or from the underlying maternal condition.

**Pediatric Use:** Safety and effectiveness of ARISTADA in patients <18 years of age have not been evaluated.

**Geriatric Use:** Safety and effectiveness of ARISTADA in patients >65 years of age have not been evaluated.

**Hepatic and Renal Impairment:** No dosage adjustment for ARISTADA is required based on a patient’s hepatic function (mild to severe hepatic impairment, Child-Pugh score between 5 and 15), or renal function (mild to severe renal impairment, glomerular filtration rate between 15 and 90 mL/minute).

**Other Specific Populations:** No dosage adjustment for ARISTADA is required on the basis of a patient’s sex, race, or smoking status.

**OVERDOSAGE**

**Human Experience:** The largest known case of acute ingestion with a known outcome involved 1260 mg of oral aripiprazole (42 times the maximum recommended daily dose) in a patient who fully recovered. Common adverse reactions (reported in at least 5% of all overdose cases) reported with oral aripiprazole overdosage (alone or in combination with other substances) include vomiting, somnolence, and tremor. Other clinically important signs and symptoms observed in one or more patients with aripiprazole overdoses (alone or with other substances) include acidosis, aggression, aspartate aminotransferase increased, atrial fibrillation, bradycardia, coma, confusional state, convulsion, blood creative phosphokinase increased, decreased level of consciousness, hypertension, hypokalemia, hypotension, lethargy, loss of consciousness, QRS complex prolonged, QT prolonged, pneumonia aspiration, respiratory arrest, status epilepticus, and tachycardia.

**Management of Overdose:** In case of overdose, call the Poison control center immediately at 1-800-222-1222.

To report SUSPECTED ADVERSE REACTIONS, contact Alkermes, Inc. at 1-866-274-7623 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

**PATIENT COUNSELING INFORMATION**

Physicians are advised to discuss the FDA-approved patient labeling (Medication Guide) with patients for whom they prescribe ARISTADA.

This Brief Summary is based on ARISTADA Full Prescribing Information Rev January 2016

Manufactured and marketed by Alkermes, Inc., Wattham, MA 02451-1420

Alkermes® is a registered trademark of Alkermes, Inc. and ARISTADA® is a registered trademark of Alkermes Pharma Ireland Limited, used by Alkermes, Inc. under license.

©2016 Alkermes, Inc. All rights reserved. ARI-001477

---

**Table 4: Clinically Important Drug Interactions With ARISTADA (cont)**

<table>
<thead>
<tr>
<th>Concomitant Drug Name or Drug Class</th>
<th>Clinical Rationale</th>
<th>Clinical Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Strong CYP3A4 Inducer</strong> (e.g., carbamazepine, rifampin)</td>
<td>The concomitant use of oral aripiprazole and carbamazepine decreased the exposure of aripiprazole compared to the use of oral aripiprazole alone.</td>
<td>With concomitant use of ARISTADA with a strong CYP3A4 inducer for more than 2 weeks consider increasing the ARISTADA dose.</td>
</tr>
<tr>
<td><strong>Antihypertensive Drugs</strong></td>
<td>Due to its alpha adrenergic antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents.</td>
<td>Monitor blood pressure and adjust dose accordingly.</td>
</tr>
<tr>
<td>Benzodiazepines (e.g., lorazepam)</td>
<td>The intensity of sedation was greater with the combination of oral aripiprazole and lorazepam as compared to that observed with aripiprazole alone. The orthostatic hypotension observed was greater with the combination as compared to that observed with lorazepam alone.</td>
<td>Monitor sedation and blood pressure. Adjust dose accordingly.</td>
</tr>
</tbody>
</table>

**USE IN SPECIFIC POPULATIONS**

**Pregnancy**

**Pregnancy Exposure Registry:** There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ARISTADA during pregnancy. For more information, contact the National Pregnancy Registry for Atypical Antipsychotics at 1-866-961-2388 or visit [http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/](http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/).

**Risk Summary:** Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. Limited published data on aripiprazole use in pregnant women are not sufficient to inform any antipsychotic-associated risks for birth defects or miscarriage. No teratogenicity was observed in animal reproductive studies with intramuscular administration of aripiprazole lauroxil to rats and rabbits during organogenesis at doses up to 6 and 18 times, respectively, the maximum recommended human dose (MRHD) of 882 mg based on body surface area (mg/m²). However, aripiprazole caused developmental toxicity and possible teratogenic effects in rats and rabbits [see Data in full Prescribing Information]. The background risk of major birth defects and miscarriage for the indicated population are unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively. Advise pregnant women of the potential risk to a fetus.

**Clinical Considerations:** Fetal/Newborn Adverse Reactions: Extrapyramidal and/or withdrawal symptoms, including agitation, hyperactivity, hypotonia, tremor, somnolence, respiratory distress, and feeding disorder have been reported in neonates who were exposed to antipsychotic drugs during the third trimester of pregnancy. These symptoms have varied in severity. Monitor neonates for extrapyramidal and/or withdrawal symptoms and manage symptoms appropriately. Some neonates recover within hours or days without specific treatment; others required prolonged hospitalization.

**Data:**

**Animal Data for Aripiprazole Lauroxil:** Aripiprazole lauroxil did not cause adverse developmental or maternal effects in rats or rabbits when administered intramuscularly during the period of organogenesis at doses of 18, 49, or 144 mg/animal in pregnant rats which are approximately 0.7 to 6 times the maximum recommended human dose (MRHD) of 882 mg ARISTADA on a mg/m² basis and at doses of 241, 723, and 2893 mg/animal in pregnant rabbits which are approximately 1 to 18 times the MRHD for ARISTADA on a mg/m² basis. However, aripiprazole caused developmental toxicity and possible teratogenic effects in rats and rabbits.

**Animal Data for Aripiprazole:** Pregnant rats were treated with oral doses of 3, 10, and 30 mg/kg/day, which are approximately 1 to 10 times the oral maximum recommended human dose (MRHD) of 30 mg/day on mg/m² basis of aripiprazole during the period of organogenesis. Treatment at the highest dose caused a slight prolongation of gestation and delay in fetal development, as evidenced by decreased fetal weight, and undescended testes. Delayed skeletal ossification was observed at 3 and 10 times the oral MRHD on mg/m² basis. At 3 and 10 times the oral MRHD on mg/m² basis, delivered offspring had decreased body weights. Increased incidences of hepatodiphragmatic nodules and diaphragmatic hernia were observed in offspring from the highest dose group (the other dose groups were not examined for these findings). A low incidence of diaphragmatic hernia was also seen in the fetuses exposed to the highest dose. Postnatally, delayed vaginal opening was seen at 3 and 10 times the oral MRHD on mg/m² basis and impaired reproductive performance (decreased fertility rate, corpora lutea, implants, live fetuses, and increased post-implantation loss, likely mediated through effects on female offspring) along with some maternal toxicity were seen at the highest dose; however, there was no evidence to suggest that these developmental effects were secondary to maternal toxicity.
Presenters Index
## Presenters Index

### A

<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aaronson, Alexandra L., M.D.</td>
<td>163</td>
</tr>
<tr>
<td>Abbey, Susan, M.D.</td>
<td>143</td>
</tr>
<tr>
<td>Abdel Gawad, Noha, M.D.</td>
<td>159</td>
</tr>
<tr>
<td>Aboara, Ahmed, M.D., D.Ph.</td>
<td>79</td>
</tr>
<tr>
<td>Aboueid, Lilas, D.O.</td>
<td>152</td>
</tr>
<tr>
<td>Acar, Selin, B.S.</td>
<td>137</td>
</tr>
<tr>
<td>Acharya, Bibhav, M.D.</td>
<td>100</td>
</tr>
<tr>
<td>Acosta-Uribé, Juliana</td>
<td>163</td>
</tr>
<tr>
<td>Adams, Caitlin, M.D.</td>
<td>152</td>
</tr>
<tr>
<td>Adams, Samantha, Ph.D.</td>
<td>131</td>
</tr>
<tr>
<td>Adelsheim, Steven, M.D.</td>
<td>69, 108</td>
</tr>
<tr>
<td>Adelsky, Sol, M.D., M.P.H.</td>
<td>85</td>
</tr>
<tr>
<td>Adelson, Stewart L., M.D.</td>
<td>132</td>
</tr>
<tr>
<td>Adi, Ahmad, M.B.B.S., M.P.H.</td>
<td>115</td>
</tr>
<tr>
<td>Adler, Amy B., Ph.D.</td>
<td>132</td>
</tr>
<tr>
<td>Aeschbach-Jachmann, Crispa, M.D.</td>
<td>152</td>
</tr>
<tr>
<td>Aftab, Awais, M.B.B.S.</td>
<td>137, 152</td>
</tr>
<tr>
<td>Afzal, Fariha, M.B.B.S.</td>
<td>152</td>
</tr>
<tr>
<td>Afzal, Saba, M.D.</td>
<td>152</td>
</tr>
<tr>
<td>Agarwal, Vishesh, M.D.</td>
<td>171</td>
</tr>
<tr>
<td>Agashe, Mohan</td>
<td>67</td>
</tr>
<tr>
<td>Aga, Vimal M., M.D.</td>
<td>65</td>
</tr>
<tr>
<td>Agbonvitor, Mawuen, M.D., M.Sc.</td>
<td>117</td>
</tr>
<tr>
<td>Aggarwal, Neil K., M.D., M.B.A.</td>
<td>105, 115</td>
</tr>
<tr>
<td>Aggarwal, Rashid, M.D.</td>
<td>101</td>
</tr>
<tr>
<td>Ahmad, Ammar Y., M.D.</td>
<td>152</td>
</tr>
<tr>
<td>Ahmedani, Brian K., Ph.D., M.S.W.</td>
<td>166</td>
</tr>
<tr>
<td>Ahmed, Iqbal, M.D.</td>
<td>108</td>
</tr>
<tr>
<td>Ahmed, Mohammed W., M.D.</td>
<td>172</td>
</tr>
<tr>
<td>Ahmed, Mohsina, M.D.</td>
<td>116</td>
</tr>
<tr>
<td>Ahmed, Saeed, M.D.</td>
<td>152</td>
</tr>
<tr>
<td>Ahuja, Amir, M.D.</td>
<td>75</td>
</tr>
<tr>
<td>Aminwewu, Osarhiemen Ruth, M.B.B.S.</td>
<td>172</td>
</tr>
<tr>
<td>Akerele, Evristo, M.D.</td>
<td>145</td>
</tr>
<tr>
<td>Akhtar, Sameerah, M.D.</td>
<td>152</td>
</tr>
<tr>
<td>Akil, Mayada, M.D.</td>
<td>113</td>
</tr>
<tr>
<td>Akinsanya, Adefolake, M.D.</td>
<td>163</td>
</tr>
<tr>
<td>Akiyama, Tsuyoshi, M.D., D.PHIL.</td>
<td>113</td>
</tr>
<tr>
<td>Akin, Will M., Ph.D.</td>
<td>115</td>
</tr>
<tr>
<td>Akpinar, Abdullah, M.D., M.Ed.</td>
<td>174</td>
</tr>
<tr>
<td>Aksoy Poyraz, Cana, M.D.</td>
<td>166</td>
</tr>
<tr>
<td>Alarcón, Renato D., M.D., M.PH.</td>
<td>104, 115</td>
</tr>
<tr>
<td>Alavi, Nazanin, M.D.</td>
<td>84, 146</td>
</tr>
<tr>
<td>Albassam, Ahmed, M.D.</td>
<td>152</td>
</tr>
<tr>
<td>Albright, Brittany B., M.D., M.PH.</td>
<td>166</td>
</tr>
<tr>
<td>Alegria, Margarita, Ph.D.</td>
<td>77</td>
</tr>
<tr>
<td>Alexander, Ricky</td>
<td>104</td>
</tr>
<tr>
<td>Alexopoulos, George S., M.D.</td>
<td>102</td>
</tr>
<tr>
<td>Alhadi, Ahmed, M.D., M.B.B.S.</td>
<td>161</td>
</tr>
<tr>
<td>Al-Hassani, Ghanem, M.D.</td>
<td>69</td>
</tr>
<tr>
<td>Ali, Arshand, M.D.</td>
<td>152</td>
</tr>
<tr>
<td>Ali, Shahtah, M.D.</td>
<td>71</td>
</tr>
<tr>
<td>Alkis, Andrew R., M.D.</td>
<td>158</td>
</tr>
<tr>
<td>Allen, Rebecca M., M.D., M.PH.</td>
<td>174</td>
</tr>
<tr>
<td>Almas, Aysha, M.B.B.S., M.Sc.</td>
<td>166</td>
</tr>
</tbody>
</table>

### Alosaimi, Fahad D., M.D. | 161          |
### Alphs, Larry D., M.D., Ph.D. | 174          |
### Alptekin, Koksan, M.D. | 161          |
### Al-Rubeay, Safa, M.D.   | 152          |
### Alva, Gustavo M., DFAPA | 189          |
### Alvarez, Kiara, Ph.D.   | 77           |
### Alwahibi, Abdulrahman, M.D. | 166         |
### Aly, Tarek, M.D.        | 152          |
### Amadio, Jordan          | 86           |
### Amann, Birgit, M.D.     | 189          |
### Amin, Abdel F., M.D., M.PH. | 69          |
### Amin, Ritesh, M.D.     | 152          |
### Amin, Rohul, M.D.      | 61, 65       |
### Ananthamoorthy, Renuka, M.D. | 107        |
### Andersen, Aaron K., D.O. | 152         |
### Anderson, Frederick, M.D. | 145         |
### Anderson, Jeffrey, Sc.D. | 170          |
### Anderson, Karen E., M.D. | 174         |
### Anderson, Otis, M.D.   | 101, 108     |
### Andruskevicius, Sergejus, M.D. | 166       |
### Anees, Muhammad A., M.D. | 159         |
### Anglero Diaz, Yohanis L., M.D. | 152      |
### Annamalai, Aniyazhi, M.D. | 62          |
### An, Seung-Min, M.D.    | 163          |
### Anthony, James C., M.Sc., Ph.D. | 69           |
### Anzia, Daniel, M.D.    | 85           |
### Anzia, Joan, M.D.      | 85, 113, 130 |
### Aoun, Elie, M.D.       | 75, 132      |
### Appelbaum, Kenneth     | 88           |
### Appelbaum, Paul S., M.D. | 82, 86, 100, 104, 108, 127, 131, 135 |
### Apter, Gisele, M.D., Ph.D. | 79, 129     |
### Aragon, Darinka, M.D.  | 152          |
### Arbuckle, Melissa, M.D., Ph.D. | 132        |
### Ardalan, Firouz, B.A.  | 166          |
### Arditti, Joyce, Ph.D.  | 101          |
### Arroyo, William, M.D.  | 104, 137     |
### Artigas, Francesc, Ph.D. | 175         |
### Aschbacher, Kirstin, Ph.D. | 70          |
### Ashai, Ayesha, M.D.    | 177          |
### Ash, David M., M.D., M.B.A., M.S. | 175     |
### Asherson, Philip, Ph.D., M.B.B.S. | 143  |
### Ashley, Kenneth, M.D.  | 101          |
### Ash, Peter, M.D.       | 87, 104      |
### Asif, Muhammad, M.D.   | 161          |
### Athiru, Aparna, M.D.   | 71           |
### Attia, Evelyn, M.D.    | 80, 90, 102  |
### Auchtinloss, Elizabeth L., M.D. | 67, 86, 169 |
### Auger, R. Robert, M.D. | 64           |
### Avery, Jonathan, M.D.  | 66           |
### Ayaz, Sumayya B., M.D. | 161          |
### Aycock, Jean E., M.D.  | 117          |
### Ayub, Shahana, M.D.    | 152          |
### Ayub, Shehzad, D.O.    | 152          |
### Ayuel, Atong, M.D.     | 128          |
### Azam, Mohammed A., M.D. | 172          |
### Azizi, Hafizullah, M.D. | 175          |
Babalola, Ronke L., M.D., M.P.H. ............................................. 146
Babatope, Taiwo, M.D., M.B.A., M.P.H. ............................... 163
Bachem, Rachel C., D.Phil. .................................................. 127
Baer, Wendy, M.D. ............................................................. 112, 132
Bagwadi Ellur, Mallikarjun, M.D. ........................................ 152
Baggott, Matthew J., Ph.D. .................................................... 108
Bailey, John, D.O. ............................................................. 126
Bailey, Rahn K., M.D. .......................................................... 85, 108
Baier, Mimi ................................................................. 61
Baker, Megan E., M.D. ......................................................... 126
Baker, Ross A. ................................................................. 175
Balasundaram, Janooshsheya, M.D. .................................... 164, 179
Baler, Ruben, Ph.D. ............................................................ 130
Balieas, Julio, M.D. .............................................................. 83
Balon, Richard, M.D. .......................................................... 126, 136
Bantu, Sophia, M.D. ........................................................... 61
Baranoski, Madelon, Ph.D. .................................................. 106
Barber, Keila D., M.H.S. ...................................................... 71
Barber, Mary, M.D. ............................................................ 80, 132
Barkil-Oteo, Andres, M.D., M.S. ........................................ 66, 83
Barnea, Yael, M.D., L.L.B. .................................................... 161
Barnhill, John W., M.D. ........................................................ 132
Barry, Declan, Ph.D. ........................................................... 115
Barry, John, M.D. ............................................................... 60
Basal, Gaston, M.D. ............................................................. 60, 66
Basel, Bruce, M.D., M.S. ...................................................... 61
Bassirnia, Anahita ............................................................. 171
Bateman, Anthony, M.D. .................................................... 66
Bath, Eraka, M.D., L.L.B. ...................................................... 143
Batista, Sharon, M.D. .......................................................... 86
Batta, Priya ............................................................ 164
Baum, Antonio L., M.D. ...................................................... 77
Baweja, Raman, M.D., M.S. .................................................. 167
Baynor, Jessica S., M.D. ....................................................... 152
Bazzi, Lama, M.D. .............................................................. 132
Beahs, John O., M.D. ........................................................... 66
Bean, Jennifer, Pharm.D. .................................................... 71
Becker, Anne, M.D., Ph.D. ................................................. 80, 100
Becker, Daniel F., M.D. ......................................................... 145
Beck, Judith S., Ph.D. ......................................................... 61, 65, 67, 82, 85, 105
Begel, Daniel, M.D. ............................................................. 77
Belhadj-Tahar, Hafid, M.D., Ph.D. ....................................... 110, 161
Bell, Carl C., M.D. ............................................................... 76
Bell, Holly S. ................................................................. 102
Bell, Tiffani, M.D. ............................................................... 127
Bellnap, Barri, M.D. ............................................................ 80
Benassi, Paul V., M.D. ......................................................... 158
Benedek, Elissa P., M.D. ....................................................... 102
Benjamin, Sheldon, M.D. ................................................. 67, 113
Bennett, Jeffrey I., M.D. ...................................................... 87, 102
Benson, Carmela, M.S. ......................................................... 169
Benson, R. Scott, M.D. ......................................................... 137
Benson, Timothy, M.D. ....................................................... 108
Bentman, Adrienne L., M.D. .................................................. 113
Bera, Kevin R., B.S. ............................................................ 178
Beresin, Eugene V., M.D., M.A. ........................................... 146
Berlin, Jon, M.D. ................................................................ 85, 99
Bermak, Jason C., M.D., Ph.D. ............................................ 189
Berman, Ellen, M.D. ............................................................ 118
Bermeo-Ovalle, Adriana, M.D. ............................................. 60
Bermudes, Richard A., M.D. ............................................... 127
Bernardi, Silvia, M.D. .......................................................... 101
Bernstein, Carol A., M.D. ..................................................... 136
Bhandari, Stuti, M.D. ........................................................... 173
Bhatia, Subhash C., M.D. ....................................................... 82
Bhugra, Dinesh ............................................................... 109, 136
Bierut, Laura J., M.D. ............................................................ 106
Binder, Reneé, M.D. ............................................................ 75, 85, 91, 119, 102, 130
Bisaga, Adam, M.D. ............................................................ 129
Biskin, Robert, M.D., M.Sc .................................................. 128
Blair, Thomas, M.D., M.S. .................................................... 164
Blanch, Jordi ................................................................. 137
Blanco, Carlos, M.D. ............................................................ 62
Bland, Anton, M.D. ............................................................ 102
Blank Jr., Arthur S., M.D. ...................................................... 86
Blazer, Daniel G., M.D., M.P.H. ............................................ 76
Blevins, Derek, M.D. ............................................................ 160
Blier, Pierre ................................................................. 127
Bloom, Mia M., Ph.D. ........................................................... 116
Blumenfield, Michael, M.D. ............................................... 86
Blyta, Afrim A., M.D. ........................................................... 145
Boland, Robert J., M.D. ....................................................... 82, 106
Bonilla-Silva, Eduardo, Ph.D. .............................................. 110
Bonnie, Richard J., J.D. ....................................................... 98, 107, 119, 132
Borchering, Breck, M.D. ...................................................... 76
Bordoloi, Meelie, M.D. ........................................................ 164
Borenstein, Jeffrey, M.D. ..................................................... 127
Bostwick, J, Michael, M.D. .................................................. 83, 88
Bota, Robert G., M.D. ........................................................... 152
Boursiquot, Philippe-Edouard, M.D., B.Sc. ......................... 69
Boutros, Nashaat, M.D. ........................................................ 101
Bowen, Lynneice, M.D., M.Ed. ............................................. 71
Bowering, Tricia, M.D. ........................................................ 60
Bowes, Michael Reid, D.O. .................................................. 175
Boyce, Cheryl A., Ph.D. ......................................................... 136
Boyce, Niall, Ph.D., M.B. ...................................................... 143
Boyd, Carol J., Ph.D., R.N. ...................................................... 136
Boyd, J, Wesley, M.D., Ph.D. ................................................ 67, 83
Boyer, Matthew, B.A ........................................................... 152
Braaten, Ellen, Ph.D. ........................................................... 67
Bradley, John, M.D. ............................................................. 112
Brady, Kathleen, M.D., Ph.D. ............................................... 62
Brandstetter, Jennifer M., M.D. ............................................ 88
Brannan, Stephen, M.D. ..................................................... 176
Braun, Ilana M., M.D. ............................................................ 134
Bravata, Dena ............................................................... 86
Breen, Ellen K., R., M.D. ....................................................... 134
Brenner, Adam ............................................................... 113
Breur, Jorien Gemma, M.D. ............................................... 104
Breyer, Stephen ............................................................... 132, 133
Brichtant-Petitjean, Clara, M.D. ............................................ 79
# Presenters Index

<table>
<thead>
<tr>
<th>Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Briggs, Jessica, B.A.</td>
<td>175</td>
</tr>
<tr>
<td>Brock, David G., M.D.</td>
<td>175</td>
</tr>
<tr>
<td>Brody, Benjamin, M.D.</td>
<td>65</td>
</tr>
<tr>
<td>Brooks, James</td>
<td>60, 77</td>
</tr>
<tr>
<td>Brooks, John</td>
<td>80</td>
</tr>
<tr>
<td>Brown, Adam, Ph.D.</td>
<td>142</td>
</tr>
<tr>
<td>Brown, Brianne, Psy.D.</td>
<td>175</td>
</tr>
<tr>
<td>Brown, Frank W., M.D.</td>
<td>85, 110</td>
</tr>
<tr>
<td>Brown, Gregory K., Ph.D.</td>
<td>144</td>
</tr>
<tr>
<td>Brown, Kevin</td>
<td>78</td>
</tr>
<tr>
<td>Brown, Millard, M.D.</td>
<td>145</td>
</tr>
<tr>
<td>Brown, Richard P., M.D.</td>
<td>106, 128</td>
</tr>
<tr>
<td>Brown, Thomas, Ph.D.</td>
<td>106, 133</td>
</tr>
<tr>
<td>Brozyna, Caroline D., M.D.</td>
<td>101, 108</td>
</tr>
<tr>
<td>Bubli, Emanual, M.D.</td>
<td>146</td>
</tr>
<tr>
<td>Buckley, Peter, M.B.B.S.</td>
<td>129</td>
</tr>
<tr>
<td>Busch, Alisa B., M.D., M.S.</td>
<td>107</td>
</tr>
<tr>
<td>Busch, Fredric N., M.D.</td>
<td>67</td>
</tr>
<tr>
<td>Busis, Deborah Beck, L.C.S.W.</td>
<td>67</td>
</tr>
<tr>
<td>Bussing, Regina, M.D.</td>
<td>61</td>
</tr>
<tr>
<td>Buwalda, Victor J. A., M.D., Ph.D.</td>
<td>105,112</td>
</tr>
<tr>
<td>Byne, William M., M.D.</td>
<td>64</td>
</tr>
<tr>
<td>Bysani, Sailaja, M.D.</td>
<td>172</td>
</tr>
<tr>
<td>Caban-Aleman, Carissa, M.D.</td>
<td>145</td>
</tr>
<tr>
<td>Cadenhead, Kristin, M.D.</td>
<td>83, 88</td>
</tr>
<tr>
<td>Cai, Stella, M.D.</td>
<td>88</td>
</tr>
<tr>
<td>Calabrese, Joseph, M.D.</td>
<td>175</td>
</tr>
<tr>
<td>Caligor, Eve, M.D.</td>
<td>67, 79, 105, 118, 127</td>
</tr>
<tr>
<td>Calkins, Monica E., Ph.D.</td>
<td>65</td>
</tr>
<tr>
<td>Campbell, Marc L., D.O., Ph.D.</td>
<td>172</td>
</tr>
<tr>
<td>Camps-Romero, Eduardo, M.D.</td>
<td>145</td>
</tr>
<tr>
<td>Candiulis, Philip, M.D.</td>
<td>84, 88, 104, 118</td>
</tr>
<tr>
<td>Cano, Miguel Angel, Ph.D., M.P.H.</td>
<td>161</td>
</tr>
<tr>
<td>Canton, Ali, M.D.</td>
<td>164</td>
</tr>
<tr>
<td>Canuso, Amy A., D.O.</td>
<td>138</td>
</tr>
<tr>
<td>Capaldi, Vincent F. II, M.D., M.Sc.</td>
<td>134</td>
</tr>
<tr>
<td>Caplan, Rochelle, M.D.</td>
<td>66</td>
</tr>
<tr>
<td>Carlo, Andrew D., M.D.</td>
<td>101, 102</td>
</tr>
<tr>
<td>Carlson, Stephan M., M.D.</td>
<td>62</td>
</tr>
<tr>
<td>Carnall, Amy B., D.N.P., N.P.</td>
<td>167</td>
</tr>
<tr>
<td>Carrothers, Timothy J., Sc.D.</td>
<td>167</td>
</tr>
<tr>
<td>Carter, Arthur Thomas, M.D.</td>
<td>172</td>
</tr>
<tr>
<td>Carter, Dakota, M.D.</td>
<td>152</td>
</tr>
<tr>
<td>Carter, Debbie R., M.D.</td>
<td>136</td>
</tr>
<tr>
<td>Caruso, Keith A., M.D.</td>
<td>142</td>
</tr>
<tr>
<td>Carvalhal, Adriana, M.D., Ph.D.</td>
<td>143</td>
</tr>
<tr>
<td>Casey, Patricia R., M.D.</td>
<td>127</td>
</tr>
<tr>
<td>Cassimatis, Emmanuel, M.D.</td>
<td>124, 125</td>
</tr>
<tr>
<td>Cassin, Stephanie, Ph.D.</td>
<td>66</td>
</tr>
<tr>
<td>Castellanos, Daniel, M.D.</td>
<td>83</td>
</tr>
<tr>
<td>Castilla-Puentes, Ruby C., M.D., Dr.P.H.</td>
<td>126</td>
</tr>
<tr>
<td>Castilla-Puentes, Wilma Ines, M.D.</td>
<td>60</td>
</tr>
<tr>
<td>Castro, Carl, Ph.D.</td>
<td>145</td>
</tr>
<tr>
<td>Caudill, Robert, M.D.</td>
<td>102</td>
</tr>
<tr>
<td>Cazares, Paulette, M.D., M.P.H.</td>
<td>70, 138</td>
</tr>
<tr>
<td>Certa, Kenneth M., M.D.</td>
<td>126</td>
</tr>
<tr>
<td>Chae, Jeong-Ho</td>
<td>175</td>
</tr>
<tr>
<td>Chaimowitz, Gary, M.D., M.B.</td>
<td>161</td>
</tr>
<tr>
<td>Chakraburty, Amarsha, M.D.</td>
<td>152</td>
</tr>
<tr>
<td>Chan, Carlyle</td>
<td>99</td>
</tr>
<tr>
<td>Chaney, Michelle, M.D., M.Sc.</td>
<td>71, 75</td>
</tr>
<tr>
<td>Chang, Grace, M.D., M.P.H.</td>
<td>115</td>
</tr>
<tr>
<td>Chang, Kiki, M.D.</td>
<td>80</td>
</tr>
<tr>
<td>Chang, Sung Man, M.D., Ph.D.</td>
<td>175</td>
</tr>
<tr>
<td>Chan, Stephanie H., M.D.</td>
<td>69, 164</td>
</tr>
<tr>
<td>Chan, Steven</td>
<td>99</td>
</tr>
<tr>
<td>Chase, Daria, Ed.M.</td>
<td>167</td>
</tr>
<tr>
<td>Chatigny, Ashley H., D.O.</td>
<td>136</td>
</tr>
<tr>
<td>Chaudhry, Monika, M.D.</td>
<td>152</td>
</tr>
<tr>
<td>Cheema, Raminder Pal, M.D.</td>
<td>153</td>
</tr>
<tr>
<td>Chen, Alexander, B.A.</td>
<td>172</td>
</tr>
<tr>
<td>Chen, Donna, M.D., M.P.H.</td>
<td>83</td>
</tr>
<tr>
<td>Chen, Justin, M.D., M.P.H.</td>
<td>87</td>
</tr>
<tr>
<td>Chen, Pao-Huan, M.D.</td>
<td>161</td>
</tr>
<tr>
<td>Chen, Wan-Yi, Ph.D., M.S.W.</td>
<td>75</td>
</tr>
<tr>
<td>Cheong, Josepha A., M.D.</td>
<td>82, 108, 130</td>
</tr>
<tr>
<td>Cheon, Joohah</td>
<td>172</td>
</tr>
<tr>
<td>Cheung, Stephanie, M.D.</td>
<td>83</td>
</tr>
<tr>
<td>Chien, I-Chia, M.D., Ph.D.</td>
<td>161</td>
</tr>
<tr>
<td>Chikvashvili, Irina, D.O.</td>
<td>155</td>
</tr>
<tr>
<td>Childress, Ann C., M.D.</td>
<td>167</td>
</tr>
<tr>
<td>Childress, Ann, M.D.</td>
<td>190</td>
</tr>
<tr>
<td>Childs, Ed</td>
<td>90</td>
</tr>
<tr>
<td>Chilton, Julie A., M.D.</td>
<td>112</td>
</tr>
<tr>
<td>Chi, Su Hyuk</td>
<td>172</td>
</tr>
<tr>
<td>Chiu, Simon, M.D., Ph.D.</td>
<td>175</td>
</tr>
<tr>
<td>Choi, Hee Yeon, M.D.</td>
<td>176</td>
</tr>
<tr>
<td>Choi-Kain, Lois W., M.D., M.Ed.</td>
<td>113, 135</td>
</tr>
<tr>
<td>Chong, Yon J., M.D., M.P.H.</td>
<td>153</td>
</tr>
<tr>
<td>Chopra, Mehek, D.O.</td>
<td>153</td>
</tr>
<tr>
<td>Chotalia, Jigar K., M.B.B.S., M.P.H.</td>
<td>158</td>
</tr>
<tr>
<td>Choudhry, Zia, M.D., Ph.D., M.Sc.</td>
<td>175</td>
</tr>
<tr>
<td>Christensen, Aleta, M.P.H.</td>
<td>104</td>
</tr>
<tr>
<td>Chudal, Roshan, Ph.D., M.B.B.S., M.P.H.</td>
<td>167</td>
</tr>
<tr>
<td>Chukwuweke, Priscilla N., M.D., M.P.H.</td>
<td>153, 158, 161</td>
</tr>
<tr>
<td>Chukwu, Ijeoma, M.D., M.P.H.</td>
<td>88</td>
</tr>
<tr>
<td>Chumley, Frank Breckenridge, M.D.</td>
<td>153</td>
</tr>
<tr>
<td>Chung, In-Won, M.D., Ph.D.</td>
<td>167, 175</td>
</tr>
<tr>
<td>Chung, Moon Yong, M.D.</td>
<td>162</td>
</tr>
<tr>
<td>Chung, Sang-Keun</td>
<td>167</td>
</tr>
<tr>
<td>Chung, Seungwon, M.D.</td>
<td>161</td>
</tr>
<tr>
<td>Chung, Wilson, D.O.</td>
<td>153</td>
</tr>
<tr>
<td>Chwastlak, Lydia, M.D., M.P.H.</td>
<td>143</td>
</tr>
<tr>
<td>Ciottoli, Carlo, M.D.</td>
<td>136</td>
</tr>
<tr>
<td>Citrome, Leslie, M.D., M.P.H.</td>
<td>127</td>
</tr>
<tr>
<td>Clarke, Diana E., Ph.D., M.Sc.</td>
<td>71, 84, 128, 129, 146</td>
</tr>
<tr>
<td>Clayton, Anita</td>
<td>102</td>
</tr>
<tr>
<td>Clemon, David B., Ph.D.</td>
<td>167</td>
</tr>
<tr>
<td>Coccaro, Emil, M.D.</td>
<td>105</td>
</tr>
<tr>
<td>Coffin, Phillip O., M.D., M.A.</td>
<td>87</td>
</tr>
<tr>
<td>Coghill, David, M.D.</td>
<td>143</td>
</tr>
<tr>
<td>Cohen, Carl I., M.D.</td>
<td>137</td>
</tr>
</tbody>
</table>
Presenters Index

Cohen, Jenna, B.A. .......................................................... 172
Cohen, Lisa J., Ph.D. .................................................. 70
Cohen, Mary Ann A., M.D. ........................................ 107
Cohen, Mitchell J., M.D. ............................................. 143
Cole, Steven, M.D., M.A. ............................................. 133
Collins, Ashley D., D.O. ............................................. 159
Colombo, Francesca .................................................... 105
Colom, Omar A., M.D. ............................................... 153
Colón-Rivera, Hector, M.D. ....................................... 75, 101
Compton, Wilson M., M.D. ........................................ 106, 115
Conant-Norville, David O., M.D. ......................... 77, 158
Conrad, Rachel, M.D. ................................................ 104
Conroy, Michelle .......................................................... 106
Conway, Kevin P., Ph.D. ........................................... 106
Correa da Costa, Sabrina, M.D. ......................... 161, 167
Correale, Jennifer, J.D., Esq. .............................. 134, 145
Coryell, William, M.D. ............................................... 145
Costello, Caitlin, M.D. ............................................... 104
Cournois, Francine, M.D. ........................................ 117, 133
Coverdale, John H., M.D. ......................................... 113
Cox, Lara J., M.D., M.S. ........................................... 65, 110, 126
Coyle, Colleen ............................................................. 116
Craig, Thomas J., M.D. ............................................. 77
Craig, Thomas K. J., Ph.D., M.B.B.S. ..................... 129
Crawford, Allison, M.D., M.A. ............................ 118, 143
Creed, Jamie O., B.S. ............................................... 167
Cress, Kim K., M.D. .................................................. 127, 167
Crone, Catherine, M.D. ........................................... 108, 135
Crumlish, Jennifer A., Ph.D. .................................... 108
Cruz Alvarez, Beatriz, M.D. ................................. 164, 167
Cubells, Joseph F., M.D., Ph.D. .............................. 78
Cukor, Judith, Ph.D. .................................................. 132
Cullen, Bernadette M.B. ......................................... 71, 132
Cummings, Hugh, M.D. ........................................... 62
Curseen, Kim, M.D. ................................................... 132
Cutler, Andrew J., M.D. ............................................ 175
Cutler, Andrew, M.D. ................................................ 188
Cyrrus, Kali, M.D., M.P.H. ....................................... 136

D

Dager, Alecia D., Ph.D. .............................................. 64
Dakwar, Elias, M.D. .................................................. 129
D’Aquila, Carolyn, L.C.S.W., M.P.H. ..................... 134
Darby, William C., M.D. ......................................... 101, 114
Dar, Syma, M.D. .......................................................... 145
Das, Smita, M.D., Ph.D. ........................................... 88, 116, 117, 158
Datta, Vivek, M.D., M.P.H. ......................................... 136
Dave, Ana, M.D. .......................................................... 76
Dave, Shalini D., D.O. ............................................. 153
Dave, Subodh, M.D. .................................................. 76
Davidoff, Donald A., Ph.D. .................................... 60, 66
Davidowitz, Andrew M.S. ...................................... 153
Davidson, Deepak M., M.D. .................................... 153
Davine, Jon S., M.D. ................................................. 61
Davis, Steven Roy, M.D. ......................................... 102
Deans, Emily C., M.D. .............................................. 128
Deas, Deborah, M.D., M.P.H. .............................. 78
Deas, Consuelo, M.D., Ph.D. ................................. 167
De Erasquín, Gabriel, M.D., Ph.D. ....................... 75, 134
De Faria, Ludmila, M.D. ........................................... 78
DeGraba, Thomas J., M.D. ....................................... 143
De Guzman, Earl Andrew B., M.D. .................. 157, 164
Deirdre M. Ryan ....................................................... 60
De Jong, Sando, M.D. ................................................ 113
de Julio, Adriana B., M.D., M.Sc. ....................... 164, 167
Dela Cruz, Milania, M.D., M.P.H. ....................... 158, 167
dela Gandara, Jose E., M.D. .................................. 83
Dell, Mary Lynn, D.Min., M.D. ......................... 62, 134
Dell’Ossio, Bernardo, M.D. .................................... 167, 167
De Mille, Steven M., Ph.D. ...................................... 167
DePaolo, Antonio, Ph.D. ......................................... 71
DePaulo Jr., J. Raymond, M.D. ............................ 79, 153
DeReczyk, Aimee, M.D. ........................................... 157
Derish, Nicole E., M.D. ............................................. 167
DeRubeis, Laura, B.A. .............................................. 164
Desai, Pratik Kumar, M.D., M.P.H. ...................... 159, 164
Detweiler, Mark Budd, M.D., M.S. ..................... 142
Devanand, Davangere P., M.D. ............................ 86, 134
Devavasy, Cindy, M.D. ............................................. 80
Devlin, Michael, M.D. .............................................. 105
Dewan, Mantosh, M.D. ........................................... 105
Dhillon, Arashinder, M.D. ...................................... 153, 153
Dhillon, Kanwaldeep, M.D. .................................. 164, 167
Diamond, Diana, Ph.D. ........................................... 79, 105
Díaz, Esperanza, M.D. ............................................. 83
DiBenedetto, Allitia, M.D. ....................................... 170
Dickstein, Leah, M.D. ............................................. 82, 134
Di Giacomo, Ester, M.D. ......................................... 161
Dike, Charles C., M.D. ............................................. 144
Dilley, James, M.D. .................................................. 80
Dimsdale, Joel E., M.D. ............................................ 114
Dineen Wagner, Karen, M.D., Ph.D. ................... 77, 118
Di Nicola, Vincenzo, M.D., Ph.D. ..................... 153, 153
Divakarla, Swati, M.D. ............................................. 69
Dixon, Lisa B., M.D., M.P.H. .................................... 175
D’Mello, Dale, M.D. ................................................. 108
Do, Linda, D.O. .......................................................... 143
Dominguez, Matthew L., M.D., M.P.H. ............... 65, 71, 78, 132, 136
Dong, Hyunseok, M.D., Psy.D. ............................. 172
Dooley, Erin, M.D. ................................................... 153
Douaihy, Antoine, M.D. ......................................... 107, 137
Douglas, John, M.D. ............................................... 84
Doumas, Stacy J., M.D. ............................................ 175
Downing, Laura M., M.D. ....................................... 157
Dragatsi, Dianna, M.D. .......................................... 134
Dracu, Luiž, M.D., Ph.D. ........................................ 167
Dress, Eric, M.B.S. ..................................................... 65
Dreyer, Benard, M.D. ............................................. 108
Druss, Benjamin G., M.D. ....................................... 135
D’Souza, Deepak Cyril, M.D., M.B.B.S. ............... 64, 85

psychiatry.org/annualmeeting

Guide to the 2016 Annual Meeting
## Presenters Index

<table>
<thead>
<tr>
<th>Name</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dube, Anish R., M.D., M.PH.</td>
<td>65, 101, 126</td>
</tr>
<tr>
<td>Duckworth, Ken, M.D.</td>
<td>69</td>
</tr>
<tr>
<td>Duda, Roger, M.D.</td>
<td>138</td>
</tr>
<tr>
<td>Duffy, Farifteh F., Ph.D.</td>
<td>71, 146</td>
</tr>
<tr>
<td>Dukakis, Kitty</td>
<td>99</td>
</tr>
<tr>
<td>Dumas, Noel B.</td>
<td>102</td>
</tr>
<tr>
<td>Dunlap, Constance E., M.D.</td>
<td>105</td>
</tr>
<tr>
<td>Durgam, Suresh, M.D.</td>
<td>175</td>
</tr>
<tr>
<td>Dusad, Asha, M.D.</td>
<td>161</td>
</tr>
<tr>
<td>Du, Ye B., M.D., M.PH.</td>
<td>61</td>
</tr>
<tr>
<td>Earley, Willie, M.D.</td>
<td>175</td>
</tr>
<tr>
<td>El lend er, Pamela, Psy.D.</td>
<td>112</td>
</tr>
<tr>
<td>Eisen, Jane L., M.D.</td>
<td>132</td>
</tr>
<tr>
<td>Elefant, Erica, M.S.W., R.N.</td>
<td>175</td>
</tr>
<tr>
<td>Elias, Alby, M.D., M.B.B.S.</td>
<td>71</td>
</tr>
<tr>
<td>Elkady, Rasha, M.D.</td>
<td>153</td>
</tr>
<tr>
<td>Ellison, James M., M.D., M.PH.</td>
<td>60, 66</td>
</tr>
<tr>
<td>El-Mallah, Rif S., M.D.</td>
<td>142</td>
</tr>
<tr>
<td>Elmi, Sarah, M.D.</td>
<td>172</td>
</tr>
<tr>
<td>El Sara, Ammar, M.D.</td>
<td>153</td>
</tr>
<tr>
<td>Elswick, Daniel, M.D.</td>
<td>79</td>
</tr>
<tr>
<td>Enomoto, Kana</td>
<td>86</td>
</tr>
<tr>
<td>Epstein, Igor, D.O.</td>
<td>157</td>
</tr>
<tr>
<td>Epstein, Steve E., M.D.</td>
<td>135</td>
</tr>
<tr>
<td>Erb, Alexis, M.D.</td>
<td>167</td>
</tr>
<tr>
<td>Erickson, Jennifer M., D.O.</td>
<td>164</td>
</tr>
<tr>
<td>Erickson-Schroth, Laura</td>
<td>75</td>
</tr>
<tr>
<td>Eriksson, Hans</td>
<td>175</td>
</tr>
<tr>
<td>Erlich, Matthew D., M.D.</td>
<td>66, 101, 126</td>
</tr>
<tr>
<td>Ernst, Carrie L., M.D.</td>
<td>102</td>
</tr>
<tr>
<td>Escamilla, Kristin V., M.D.</td>
<td>167</td>
</tr>
<tr>
<td>Espi Forcen, Fernando, M.D.</td>
<td>126</td>
</tr>
<tr>
<td>Eswonia, LeRoy C., B.S.</td>
<td>112</td>
</tr>
<tr>
<td>Etwaroo, Narissa R.</td>
<td>153, 159</td>
</tr>
<tr>
<td>Eun, Tae Kyung, M.D.</td>
<td>160</td>
</tr>
<tr>
<td>Everett, Anita, M.D.</td>
<td>110, 112</td>
</tr>
<tr>
<td>Everett, Mia, M.D.</td>
<td>101</td>
</tr>
<tr>
<td>Evren, Cuneyt, M.D.</td>
<td>167, 168</td>
</tr>
<tr>
<td>Eyler, Evan, M.D.</td>
<td>64</td>
</tr>
<tr>
<td>Faggen, Alec</td>
<td>153</td>
</tr>
<tr>
<td>Fairbairn, Jonathan, M.D.</td>
<td>157</td>
</tr>
<tr>
<td>Fairman, Nathan, M.D., M.PH.</td>
<td>125</td>
</tr>
<tr>
<td>Falcone, Tatiana, M.D.</td>
<td>66, 109, 126</td>
</tr>
<tr>
<td>Faller, Angelo, M.D.</td>
<td>168</td>
</tr>
<tr>
<td>Famador, Mark, M.D.</td>
<td>117</td>
</tr>
<tr>
<td>Fan, Qing, M.D., Ph.D.</td>
<td>168</td>
</tr>
<tr>
<td>Fareed, Ayma n</td>
<td>112</td>
</tr>
<tr>
<td>Farooq, Mobeen</td>
<td>153</td>
</tr>
<tr>
<td>Farrell, Helen, M.D.</td>
<td>90</td>
</tr>
<tr>
<td>Faulkner, Larry R., M.D.</td>
<td>119, 124, 125</td>
</tr>
<tr>
<td>Fauman, Beverly, M.D.</td>
<td>71</td>
</tr>
<tr>
<td>Fawcett, Jan, M.D.</td>
<td>82, 144</td>
</tr>
<tr>
<td>Fayad, Sarah M., M.D.</td>
<td>67</td>
</tr>
<tr>
<td>Feldman, Jacqueline M., M.D.</td>
<td>69</td>
</tr>
<tr>
<td>Feldman, Lara W., D.O.</td>
<td>145</td>
</tr>
<tr>
<td>Fernandez, Carlos, M.D.</td>
<td>164</td>
</tr>
<tr>
<td>Ferranti, Jessica, M.D.</td>
<td>146</td>
</tr>
<tr>
<td>Ferrer, Daphne, M.D.</td>
<td>129</td>
</tr>
<tr>
<td>Feusner, Jamie, M.D.</td>
<td>117</td>
</tr>
<tr>
<td>Figee, Martijn, M.D., Ph.D.</td>
<td>69</td>
</tr>
<tr>
<td>Fils-Aimé, Joseph Reginald, M.D., M.Sc.</td>
<td>100</td>
</tr>
<tr>
<td>Fineberg, Naomi A., M.B.B.S.</td>
<td>69</td>
</tr>
<tr>
<td>Fink, Sabina, M.D.</td>
<td>152</td>
</tr>
<tr>
<td>Fink, Victoria, M.D.</td>
<td>171</td>
</tr>
<tr>
<td>Finlayson, A. J., Reid, M.D.</td>
<td>99</td>
</tr>
<tr>
<td>First, Michael B., M.D.</td>
<td>100, 108, 130</td>
</tr>
<tr>
<td>Fisher, Carl</td>
<td>127</td>
</tr>
<tr>
<td>Fiskin, Anna, M.D., M.Sc.</td>
<td>172</td>
</tr>
<tr>
<td>Fitelson, Elizabeth, M.D.</td>
<td>78, 114</td>
</tr>
<tr>
<td>Fjukstad, Katrine Kvell, M.D.</td>
<td>164</td>
</tr>
<tr>
<td>Flinton, Christopher, M.D.</td>
<td>143</td>
</tr>
<tr>
<td>Flora, Charles M., L.C.S.W.</td>
<td>86</td>
</tr>
<tr>
<td>Flynn, David, M.D.</td>
<td>80</td>
</tr>
<tr>
<td>Fochtmann, Laura J., M.D.</td>
<td>77</td>
</tr>
<tr>
<td>Fogelson, David L., M.D.</td>
<td>116</td>
</tr>
<tr>
<td>Foglesong, Dana, B.S.</td>
<td>117</td>
</tr>
<tr>
<td>Foidel, Sarah, O.T.R./L.</td>
<td>79</td>
</tr>
<tr>
<td>Fong, Tim, M.D.</td>
<td>79, 85, 116</td>
</tr>
<tr>
<td>Foo, Kalvin, B.Sc.</td>
<td>175</td>
</tr>
<tr>
<td>Ford, Elizabeth, M.D.</td>
<td>115</td>
</tr>
<tr>
<td>Fore, Peter, M.D.</td>
<td>145</td>
</tr>
<tr>
<td>Forester, Brent, M.D., M.Sc.</td>
<td>60</td>
</tr>
<tr>
<td>Formella, Andrea, Pharm.D.</td>
<td>175</td>
</tr>
<tr>
<td>Forrester, Anique, M.D.</td>
<td>134</td>
</tr>
<tr>
<td>Forstein, Marshall, M.D.</td>
<td>82, 101, 117, 132, 137</td>
</tr>
<tr>
<td>Forster, Janice, M.D.</td>
<td>87, 145</td>
</tr>
<tr>
<td>Fortuna, Lisa R., M.D., M.PH.</td>
<td>77</td>
</tr>
<tr>
<td>Foster, Norman L., M.D.</td>
<td>76</td>
</tr>
<tr>
<td>Fournis, Gael, M.D.</td>
<td>161</td>
</tr>
<tr>
<td>Fowler, J. Christopher, Ph.D.</td>
<td>87</td>
</tr>
<tr>
<td>Franco Cadet, Suhey G., M.D.</td>
<td>153</td>
</tr>
<tr>
<td>Franco, Kathleen</td>
<td>109</td>
</tr>
<tr>
<td>Frangou, Sophia, M.D., Ph.D.</td>
<td>129</td>
</tr>
<tr>
<td>Frasch, Karel J., M.D.</td>
<td>168</td>
</tr>
<tr>
<td>Freedman, Robert, M.D.</td>
<td>91, 134</td>
</tr>
<tr>
<td>Freidi, Eve Khlyavich, M.D.</td>
<td>80</td>
</tr>
<tr>
<td>Frieden, Tom, M.D., M.PH.</td>
<td>118, 119</td>
</tr>
<tr>
<td>Fritz, Gregory K., M.D.</td>
<td>77</td>
</tr>
<tr>
<td>Fromson, John A., M.D.</td>
<td>65</td>
</tr>
<tr>
<td>Frueh, B. Christopher, Ph.D.</td>
<td>87</td>
</tr>
<tr>
<td>Frye, Elizabeth A., M.D., M.PH.</td>
<td>61, 104</td>
</tr>
<tr>
<td>Fryml, Leah D., M.D.</td>
<td>153</td>
</tr>
<tr>
<td>Fu, Dong-Jing, M.D., Ph.D.</td>
<td>175</td>
</tr>
<tr>
<td>Fuehrlein, Brian S., M.D.</td>
<td>104</td>
</tr>
<tr>
<td>Fu, Emily, M.D.</td>
<td>153</td>
</tr>
<tr>
<td>Fuller, Linda, D.O.</td>
<td>143</td>
</tr>
<tr>
<td>Fung, Kenneth P., M.D.</td>
<td>62, 78, 90</td>
</tr>
<tr>
<td>Fung, Wai Lun Alan, M.D., Sc.D.</td>
<td>62</td>
</tr>
<tr>
<td>Funk, Margo, M.D., M.A.</td>
<td>109, 126, 145</td>
</tr>
<tr>
<td>Furuta, Michelle, M.D.</td>
<td>143</td>
</tr>
</tbody>
</table>
Presenters Index

G

Gabbard, Glen O., M.D. .................................. 75, 104, 107, 113, 126, 136
Gache, Chris, M.D. ........................................ 175
Gage, Fred H., Ph.D. ...................................... 74, 80
Galanter, Marc, M.D. ...................................... 65
Gallagher, Keith, M.D. ..................................... 82
Galles, Elyse, B.A. .......................................... 164
Galyanker, Igor, M.D., Ph.D. ......................... 70, 144
Gandhi, Raghu, M.D., M.B.B.S. .................... 158
Gandhi, Tanuja, M.D. .................................... 101, 109, 158, 160
Gao, Keming, M.D., Ph.D. .............................. 175
Garavan, Hugh, Ph.D. ................................... 64
Garrick, Marshall L., M.D. .............................. 142
Gatchel, Jennifer, M.D., Ph.D. ....................... 66
Gawande, Atul, M.D., M.P.H. ......................... 91
Gaytan Jr., Osvaldo, M.D., Ph.D. ................... 76
Genova, Nicholas J., M.D. .............................. 164
George, Mark ............................................. 99
George, Tony P., M.D. .................................... 106
Gerberg, Patricia L., M.D. .............................. 106, 128
Gershengoren, Liliya, M.D., M.P.H. ............... 158
Ghabrash, Maykel F., M.D., M.Sc. ................. 176
Ghairatmal, Mohammad A. ............................ 172
Ghani, Shareh O., M.D. ................................ 88
Ghignone, Erica, M.D., M.A. .......................... 153
Ghimiire, Shree Ram, M.D. ............................ 161
Ghiya, Deepjyoti, M.D. ................................. 153
Gibbs, Ayana, M.D., Ph.D. ............................ 176
Gilbert, Mary, J.D. ....................................... 86
Gillihan, Seth J., Ph.D. ................................ 105
Gillman, Megan L., M.D. .............................. 159
Ginory, Almari, M.D. .................................... 67, 71, 75, 90, 100
Ginory, Laura, M.D. ...................................... 90
Gipson, Shih Yee-Marie Tan, M.D. ................. 138
Giri, Aditi, M.B.B.S. .................................... 164
Gise, Leslie H., M.D. ................................... 67
Glancy, Graham D., M.B. .............................. 128
Glick, Ira, M.D. ........................................... 90
Glick, Rachel, M.D. ...................................... 69, 85
Glower, Juliet A., M.D. ................................. 164
Goddu, Sumana, M.D., M.P.H. ..................... 172
Goedken, Rebecca E., M.D. ........................... 160
Goelitz, Melissa, M.D. ................................ 86
Goethe, John W., M.D. ................................ 100
Goff, Donald C., M.D. .................................. 64
Gogineni, Rama Rao, M.D. .......................... 78, 80, 109
Goldbach, Jeremy, Ph.D. ............................. 145
Goldberg, Joseph F., M.D. ............................ 102
Goldenberg, Matthew N., M.D., M.Sc. .......... 143, 176
Gold, Liza H., M.D. ..................................... 135
Goldman, Matthew L., M.D., M.S. ................. 136
Goldwaser, Alberto M., M.D. ....................... 117
Gomez, Chaska, Psy.D. ................................ 70
Gomez Fuentes, Amy C., M.D. ...................... 153
Gomez, Juan Carlos, Eq. .............................. 137
Gomez-Trigo Baldominos, Jesus, M.D. .......... 161
Goniewicz, Maciej L., Ph.D., Pharm.D. ......... 106
Goode, Kimberly D., A.A.S. ........................ 70
Goodman, Marianne, M.D. ........................ 84, 90, 128
Goodwin, Ericka, M.D. ............................... 108
Gopal, Srihari, M.D., M.H.S. ......................... 170, 176
Gordon, Kimberly, M.D. ............................. 67
Gorelick, David, M.D., Ph.D. ....................... 133
Gorrindo, Tristan, M.D. ............................... 110, 116
Goschin, Simona ......................................... 83
Goswami Banerjee, Arpita, M.D. ................. 153
Goyal, Dharmendra K., M.B.B.S. .................. 153
Grace, Anthony A., Ph.D. ............................ 62
Graham, Yolanda P., M.D. ........................... 143
Gralnik, Leonard M., M.D., Ph.D. ................. 143
Grammer, Geoffrey, M.D. ........................... 143
Grant, Cynthia, Ph.D., L.C.S.W. ................... 101
Grassi, Giacomo, M.D. ................................. 69, 168
Gray, Kyle J., M.D., M.A. ............................ 112
Gray, Sheila Hafter, M.D. ............................ 108
Grebla, Regina, Ph.D., M.P.H. ...................... 176
Green, Alan L., M.D. .................................... 130
Greenbaum, Jordan, M.D. ........................... 143
Greer, Tracy, Ph.D. ..................................... 144
Gregoire, Phillip, M.Sc. ............................... 160
Griffith, Ezra, M.D. ..................................... 87, 106, 114, 138
Griffith, James, M.D. ................................. 62, 100
Grob, Charles, M.D. ................................... 83, 88
Gross, Raz, M.D., M.P.H. ............................. 176
Gruenberg, Linda F., D.O. ............................ 145
Gspandl, Scott, M.D. ................................... 160
Guanci, Nicole ........................................... 101
Guerra, Paloma Andrea, M.D. ....................... 164
Gularte, Valeria Soares ............................... 161
Gunderson, John, M.D. ............................ 79, 84, 90, 113, 128
Gunturu, Sasidhar, M.D., M.B.B.S. ............... 159
Guo, Qi, Ph.D. ........................................... 168
Gupta, Neha, M.D. ...................................... 153
Gupta, Nitin, M.D. ...................................... 146
Gur, Raquel, M.D. ....................................... 65
Gurski, John, D.O. ....................................... 161
Guttikonda, Sameera, M.D. ......................... 152
Guzman, Margarita, J.D., M.B. ..................... 114

H

Habeych, Miguel, M.D., M.P.H. .................... 167
Habl, Samar, M.D. ..................................... 80, 132
Hackman, Ann, M.D. .................................. 82
Hagan, Jarred, D.O. ..................................... 65
Hah, Jennifer, M.D., M.S. ............................. 115
Hairson, Danielle, M.D. .............................. 71, 117
Hales, Robert E., M.D. ............................... 113
Haller, Ellen, M.D. ...................................... 75
Hall, Ryan, M.D. ......................................... 109, 137
Halperin Rosen, Anna, M.D. ....................... 131
Haltzman, Scott, M.D. ................................. 101
Hamdani, Najma F., M.D., M.H.A. ............... 153
Hameed, Ahmad, M.D. ............................... 173
<table>
<thead>
<tr>
<th>Presenters Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hamidovic, Ajna, Pharm.D. ...........................................</td>
</tr>
<tr>
<td>Hammanieh, Rasha, Ph.D., Pharm.D. ................................</td>
</tr>
<tr>
<td>Han, Doug Hyun, M.D., Ph.D. ...........................................</td>
</tr>
<tr>
<td>Hanif, Amina, M.D. ....................................................</td>
</tr>
<tr>
<td>Hann, Michael, M.D., M.S. ..............................................</td>
</tr>
<tr>
<td>Hanrathan, Mary, L.C.S.W. .............................................</td>
</tr>
<tr>
<td>Haque, Shariq, M.D. ....................................................</td>
</tr>
<tr>
<td>Hardaway, Rashad, M.D. ..................................................</td>
</tr>
<tr>
<td>Hardeman, Suzanne M., N.P. ..............................................</td>
</tr>
<tr>
<td>Harding, Richard K., M.D. ..............................................</td>
</tr>
<tr>
<td>Harewood, Meredith, M.D. ..............................................</td>
</tr>
<tr>
<td>Harrigan, Michael R., M.D., M.B.A. ..................................</td>
</tr>
<tr>
<td>Harris, Christopher, D.O. .............................................</td>
</tr>
<tr>
<td>Harris, Gregory G., M.D., M.P.H. .....................................</td>
</tr>
<tr>
<td>Harrison, Nzinga, M.D. ................................................</td>
</tr>
<tr>
<td>Harrison, Patrice, M.D. ................................................</td>
</tr>
<tr>
<td>Hart, Joseph, B.A. ........................................................</td>
</tr>
<tr>
<td>Harvey, Margaret, Psy.D. ..............................................</td>
</tr>
<tr>
<td>Harvey, Philip D., Ph.D. .................................................</td>
</tr>
<tr>
<td>Hasan, Rabiya, M.D. .....................................................</td>
</tr>
<tr>
<td>Hasnain, Mehrul, M.D. ...................................................</td>
</tr>
<tr>
<td>Hassamal, Sameer, M.D. ................................................</td>
</tr>
<tr>
<td>Hassan, Tariq .............................................................</td>
</tr>
<tr>
<td>Hatch, Ainslie, Ph.D. ....................................................</td>
</tr>
<tr>
<td>Hatters-Friedman, Susan Joy, M.D. ....................................</td>
</tr>
<tr>
<td>Hauser, Peter, M.D. .....................................................</td>
</tr>
<tr>
<td>Hawa, Raed, M.D. ..........................................................</td>
</tr>
<tr>
<td>Hawes, Maniah, B.S. .....................................................</td>
</tr>
<tr>
<td>Hazlett, Erin, Ph.D. .....................................................</td>
</tr>
<tr>
<td>Hedrick, Saima, M.P.H. .................................................</td>
</tr>
<tr>
<td>Heeramun, Vineka, M.D. ..................................................</td>
</tr>
<tr>
<td>Hemani, Umair M., D.O., M.S. ...........................................</td>
</tr>
<tr>
<td>Hendren, Robert L., D.O. ..............................................</td>
</tr>
<tr>
<td>Hendry, Travis, M.D. ....................................................</td>
</tr>
<tr>
<td>Henein, Fady, M.D. ........................................................</td>
</tr>
<tr>
<td>Henh, Fritz A., M.D., Ph.D. ............................................</td>
</tr>
<tr>
<td>Herman, Barry K., M.D. ................................................</td>
</tr>
<tr>
<td>Hermida, Adriana, M.D. ................................................</td>
</tr>
<tr>
<td>Hernandez, Sergio, M.D. ...............................................</td>
</tr>
<tr>
<td>Herrera, Cristian Y., M.D., Ph.D. ....................................</td>
</tr>
<tr>
<td>Herrman, Helen, M.D., M.B. ..........................................</td>
</tr>
<tr>
<td>Hershey, Benjamin R., M.D. ...........................................</td>
</tr>
<tr>
<td>Hersh, Richard, M.D. ..................................................</td>
</tr>
<tr>
<td>Heru, Alison M., M.D. ..................................................</td>
</tr>
<tr>
<td>Hidalgo, Marla, D.O. ...................................................</td>
</tr>
<tr>
<td>Higgins Jr, Napoleon B., M.D. .......................................</td>
</tr>
<tr>
<td>Hildebrandt, Tom, Psy.D. ..............................................</td>
</tr>
<tr>
<td>Hill, Kevin, M.D., M.H.S. .............................................</td>
</tr>
<tr>
<td>Hill, Wesley, M.D. .....................................................</td>
</tr>
<tr>
<td>Hilt, Dana, M.D. ..........................................................</td>
</tr>
<tr>
<td>Hilty, Donald M., M.D. ................................................</td>
</tr>
<tr>
<td>Hoang, Julia L., M.D. ................................................</td>
</tr>
<tr>
<td>Hobbs, Jacqueline A., M.D., Ph.D. ..................................</td>
</tr>
<tr>
<td>Ho, Cyrus S., M.B.B.S. ................................................</td>
</tr>
<tr>
<td>Hodgson, Richard E., M.D., M.B.B.S., M.Sc. ......................</td>
</tr>
<tr>
<td>Hodson, David S., Ed.D. ...............................................</td>
</tr>
<tr>
<td>Hoffman, Christopher, M.D. ..........................................</td>
</tr>
<tr>
<td>Hoffman, Perry, Ph.D. ................................................</td>
</tr>
<tr>
<td>Hoge, Charles, M.D. ....................................................</td>
</tr>
<tr>
<td>Hoge, Steven, M.D., M.B.A. ...........................................</td>
</tr>
<tr>
<td>Hoirisch-Clapau, Silvia, M.D. .......................................</td>
</tr>
<tr>
<td>Holbert, Richard, M.D. ................................................</td>
</tr>
<tr>
<td>Hollander, Eric, M.D. ..................................................</td>
</tr>
<tr>
<td>Holland, Peter J., M.D. .................................................</td>
</tr>
<tr>
<td>Holloway, Ian W., Ph.D., M.P.H. ....................................</td>
</tr>
<tr>
<td>Holsey, M. Daniel, D.O. ...............................................</td>
</tr>
<tr>
<td>Hong, Victor, M.D. .....................................................</td>
</tr>
<tr>
<td>Hooshmand, Farnaz, M.D. .............................................</td>
</tr>
<tr>
<td>Horgan, John, Ph.D. ....................................................</td>
</tr>
<tr>
<td>Horowitz, Mardi, M.D. ..................................................</td>
</tr>
<tr>
<td>Horvath, Thomas B., M.D. .............................................</td>
</tr>
<tr>
<td>Horwath, Ewald, M.D. ..................................................</td>
</tr>
<tr>
<td>Horwitz, Josh, M.D. ....................................................</td>
</tr>
<tr>
<td>Howe III, Edmund G., M.D. ...........................................</td>
</tr>
<tr>
<td>Hoxha, Avjola, M.D. ....................................................</td>
</tr>
<tr>
<td>Hreish, Mark N., M.D. ................................................</td>
</tr>
<tr>
<td>Hsiung, Robert, M.D. ...................................................</td>
</tr>
<tr>
<td>Hsu, Kean J., Ph.D. ...................................................</td>
</tr>
<tr>
<td>Huang, Yueqin, M.D., Ph.D., M.P.H. ................................</td>
</tr>
<tr>
<td>Hugh Cummings ..........................................................</td>
</tr>
<tr>
<td>Hughes-Feltenberger, Megan, Ph.D. ................................</td>
</tr>
<tr>
<td>Hunzeker, Adam, M.D. ..................................................</td>
</tr>
<tr>
<td>Huremovic, Damir, M.D., M.P.P. ....................................</td>
</tr>
<tr>
<td>Hurley, Brian, M.D., M.B.A. ..........................................</td>
</tr>
<tr>
<td>Hurwitz, Thomas D., M.D. .............................................</td>
</tr>
<tr>
<td>Hu, Sai, D.O. ............................................................</td>
</tr>
<tr>
<td>Husain, Nusrat, M.D. ...................................................</td>
</tr>
<tr>
<td>Hussain, Filza C., M.D. .................................................</td>
</tr>
<tr>
<td>Hutton, Todd, M.D. .....................................................</td>
</tr>
<tr>
<td>Huynh, Martin K., B.S. ................................................</td>
</tr>
<tr>
<td>Hwang, Michael, M.D. ................................................</td>
</tr>
<tr>
<td>Hyde, Lee S., M.D. .....................................................</td>
</tr>
<tr>
<td>Hyler, Steven E., M.D. ................................................</td>
</tr>
<tr>
<td>Iarvici, Doris, M.D. ....................................................</td>
</tr>
<tr>
<td>Ibeziko, Patricia, M.D. ................................................</td>
</tr>
<tr>
<td>Ibrahim, Lobna, M.D. ...................................................</td>
</tr>
<tr>
<td>Iheagwara, Chioma Linda, D.O. .......................................</td>
</tr>
<tr>
<td>Iheanacho, Theddeus, M.D. ............................................</td>
</tr>
<tr>
<td>Ikekwere, Joseph C., M.D., M.P.H. ..................................</td>
</tr>
<tr>
<td>Ilipilia, Geeta S., M.D. ................................................</td>
</tr>
<tr>
<td>Immanuel, Josepha, M.D. .............................................</td>
</tr>
<tr>
<td>Imran, Sheema, M.D. ...................................................</td>
</tr>
<tr>
<td>Ingram, Douglass H., M.D. ...........................................</td>
</tr>
<tr>
<td>Iosifescu, Dan V., M.D., M.Sc. .......................................</td>
</tr>
<tr>
<td>Iqbal, Muhammad Naved, M.D., M.B.B.S. .........................</td>
</tr>
<tr>
<td>Irfan, Muhammad, M.B.B.S., M.S. ..................................</td>
</tr>
<tr>
<td>Irwin, Scott A., M.D., Ph.D. .........................................</td>
</tr>
<tr>
<td>IsHak, Waguih William, M.D. .......................................</td>
</tr>
<tr>
<td>Isinguzo, Chidinna, M.D. .............................................</td>
</tr>
<tr>
<td>Islam, Zahid, M.D. .....................................................</td>
</tr>
<tr>
<td>Ivanova, Danielle, D.O. ................................................</td>
</tr>
<tr>
<td>Ivany, Christopher, M.D. .............................................</td>
</tr>
</tbody>
</table>
Presenters Index

Iyer, Sharat P., M.D., M.S. ........................................ 66, 107
Iyer, Veeraraghavan J., M.D., M.B.B.S. ................. 154

J

Jabari, Lamis, M.D. .................................................. 164
Jackson, Timothy .................................................. 66
Jacobs, Karen L., Ph.D. ........................................ 113
Jacob Mathai, Ashwin, M.D. .............................. 172
Jacobs, Karen, D.O. ............................................. 109
Jacobson, William, Ph.D. .................................. 179
Jadi, Maryam, M.D., M.P.H. ................................. 160
Jain, Abhishek, M.D. ........................................ 117, 137, 142
Jain, Lakshit, M.D. ............................................... 158
Jain, Rakesh, M.D., M.P.H. ................................ 188, 189
James, Christopher ............................................. 159
Janda, Kim D., Ph.D. ........................................... 87
Janicak, Philip G., M.D. ..................................... 64, 127
Jayaram, Geetha, M.D. ...................................... 82
Jenkins, Thomas, Ph.D. ...................................... 87
Jennings, Keith W., Ph.D. .................................. 70
Jeon, Junwon, M.D. ............................................ 172
Jessica, Moore, M.D. .......................................... 132
Jeste, Dilip V., M.D. ........................................... 76, 86, 104
Jett, Marti, Ph.D. ................................................. 70
Jha, Manish K., M.B.B.S. .................................. 144, 146, 172, 176
Ji, Ning .......................................................... 168
Joe, Soohyun ..................................................... 172
Johnson, David, M.D. ...................................... 84, 127
Johnson, Sarah, M.D. ....................................... 67
Johnston, Robert J. H., M.D. ............................ 154
Joiner, Thomas, Ph.D. ....................................... 70
Jones, Jana, Ph.D. .............................................. 66
Jones, Megan, Pharm.D., M.P.A. ....................... 171
Jones, Meissa M., M.S. ...................................... 176
Jones, Travis W., M.D. ...................................... 154
Jordan, Ayana, M.D., Ph.D. .............................. 71
Jose, Divya E., M.D. ........................................ 176
Joseph, Courtney, D.O. ................................... 154
Joseph, Robert C., M.D., M.S. .......................... 82
Josephson, Allan, M.D. .................................. 144
Joshi, Astik, M.D. .............................................. 154, 159
Joshi, Kaustubh G., M.D. .................................. 61
Joshi, Kruti, M.P.H. ........................................... 170, 176
Joshi, Pallavi, M.A. ........................................... 158
Joshi, Paramjit, M.D. ....................................... 77
Josiasse, Richard C., Ph.D. ............................ 176
Joy, Michelle, M.D. .......................................... 128
Judge, Sheila, M.D. ........................................... 129
Jung, Chan Hyun, M.D. ................................... 164
Jun, Tae-Youn, M.D., Ph.D. .............................. 110, 162

K

Kakhi, Sara, M.D. .................................................. 162
Kallivayalil, Roy Abraham, M.D. ....................... 129
Kalnik, Matthew W., Ph.D. ............................... 114
Kanba, Shigenobu, M.D., Ph.D. ......................... 113, 134
Kang, Jee In .......................................................... 176
Kang, Suk-Hoon, M.D. ..................................... 162
Kannali, Rajasekhar, M.D. .............................. 154
Kantor, Edward, M.D. ................................... 85
Kaplish, Dheeraj, M.D. ..................................... 164
Kapoor, Shweta, Ph.D., M.B.B.S. ....................... 132
Karasic, Dan H., M.D. ........................................ 64
Karim, Reef, D.O. .............................................. 79
Karlsson, Per-Axel L., Ph.D. ......................... 168, 169
Karnik, Niranjan, M.D., Ph.D. .......................... 75
Kaster, Tyler, M.D. ............................................. 168
Kathol, Roger, M.D. .......................................... 135
Kato, Takahiro A., M.D., Ph.D. ......................... 134
Kaur, Amanjot, M.B.B.S. ................................ 172, 176
Kazmi, Ajmal, M.D., D.P.M. .............................. 144
Keefe, Richard, Ph.D. ..................................... 113
Keenan, Walker Daniel, B.S. .......................... 159
Keith, Asheena, M.D. ......................................... 117
Kemble, Stephen B., M.D. ............................ 67, 154
Kendler, Kenneth, M.D. ................................... 106, 108
Kennedy, Patrick .................................................. 105
Kennedy, Robert, M.D. ..................................... 99, 112
Kennedy, Sidney H., M.B.B.S. .......................... 129
Kent, Justine M., M.D. .......................................... 82
Kernberg, Otto F., M.D. .................................. 79, 105, 135
Kern, John, M.D. ........................................ 79, 106, 130, 132
Kertzner, Robert M. ....................................... 132
Ketchen, Bethany, Ph.D. .................................. 112
Kethini, Vandana, M.D. .................................. 154
Ketter, Terence A., M.D. .................................... 80, 168
Khairalla, Hanan, M.D. .................................... 160
Khairy, Nahed, M.D. ......................................... 162
Khalfayan, Andrey, M.D. .................................. 168
Khalid-Khan, Sarosh, M.D. ............................. 146
Khalil, Afaf Hamed, M.D., Ph.D. ...................... 69
Khan, Christina Tara, M.D., Ph.D. ....................... 82
Khan, Jaffar, M.D. .................................................. 112
Khan, Mohammed A., M.D. ............................ 117
Khan, Mohsin, M.D. .......................................... 154
Khan, Muhammad, M.D. .................................. 162
Khan, Surbhi, M.B.B.S. ...................................... 154
Khan, Qaiser S., M.D. ......................................... 159
Khan, Sheema, M.D. ........................................... 167
Khattak, Sohail, M.D. ....................................... 176
Khawaja, Imran S., M.B.B.S. .............................. 64
Khawam, Elias, M.D. ......................................... 145
Khosh-Chashm, Darrow, M.D. ......................... 160
Khusbalani, Sunil, M.D. .................................. 71, 76, 83, 142
Khusid, Marina, M.D. ......................................... 83
Kidd, Jeremy D., M.D., M.P.H. ......................... 131, 158
Kilani, Jyotsna, M.D. .......................................... 154
Kim, Chaeri .......................................................... 176
Kim, Chan-Hyung, M.D., Ph.D. ....................... 170
Kim, Chul-Eung, M.D., Ph.D. ........................... 168
Kim, Daniel, M.D. ............................................. 109
Kim, Daseul, M.D. ............................................. 164
Kim, Eun Young, M.D., Ph.D. ......................... 168
Presenters Index

Kim, Ga Eun, M.D. ........................................ 176
Kim, Han-Joon, M.D. ..................................... 168
Kim, Helena K., Ph.D. .................................... 168
Kim, Hyun, M.D., Ph.D. .................................. 168
Kim, Jung W., M.D. ....................................... 138
Kim, Kahlen Hong Seon, B.A. ......................... 172
Kim, Keun You, M.D. ..................................... 164
Kim, Kyungwon, M.D. .................................... 172
Kim, Minsu .................................................. 164
Kim, Seong Hwan, M.D., Ph.D. ....................... 168
Kim, Siekyeong, M.D., Ph.D. ......................... 168
Kim, Taeho, M.D. .......................................... 164
Kim, Won .................................................... 162
Kim, Yong-Ku, M.D., Ph.D. ............................. 168
Kim, Young Hoon, M.D., Ph.D. ....................... 168
Kim, Young Shin, M.D., Ph.D. ......................... 78
Kingdon, David, M.D. .................................... 60
Kiong, Timothy, M.D. .................................... 172
Kirsch, Daniel, M.D. ................................. 71, 136
Kiss, Béla, M.Sc. ........................................... 176
Kjaer, Jesper N. ............................................ 172
Klass, Benjamin O., M.D. .............................. 154
Kleber, Herbert D., M.D. ............................... 129
Kleiman, Mark, Ph.D., M.P.P. ......................... 69
Kleiner, Oliver, Ph.D. ..................................... 176
Klin, Arni, Ph.D. ........................................... 78
Knable, Michael B., D.O. ............................... 75
Knoll IV, James L., M.D. ................................. 135
Koenig, Jessica A., M.D. ................................. 172
Koenigsberg, Harold W., M.D. ....................... 105
Kogan, Richard, M.D. ................................... 71
Koh, Steve H., M.D., M.P.H. .......................... 80, 84, 91, 100, 125
Kolli, Venkata B., M.B.B.S. ............................ 82
Kolodner, George, M.D. .................................. 83
Ko, Mancia, Pharm.D. ................................... 177
Komrad, Mark, M.D. ................................. 61, 84, 118, 142
Koniaris, Christine M.D. ............................... 88
Kor, Ariel, M.S. ............................................ 101
Koss, Debra, M.D. ......................................... 126
Kosten, Thomas, M.D. ................................... 114
Kothari, Kavita, M.B.B.S. ............................... 154
Kott, Alan, M.D. ........................................... 177
Koyuncu, Ahmet, M.D. .................................. 162
Krakowski, Menahem I., M.D. ....................... 117
Kramer, Kenneth, Ph.D. ............................... 177
Kratovil, Christopher, M.D. ......................... 64
Kraus, Louis, M.D. ........................................ 76
Kremens, Daniel E., M.D., J.D. ....................... 188
Krishna, Swathi, M.D. ................................... 71, 108
Kroeger Ptakowski, Kristin ......................... 112
Krueger, Robert, Ph.D. ................................. 129
Krystal, John, M.D. ....................................... 83, 88
Kudler, Harold, M.D. ..................................... 86
Kudva, Ganesh, M.B.B.S. ............................... 162
Kumari, Meena, M.D. .................................... 158
Kumar, Reena, M.D. ..................................... 159
Kum, Seon, M.D. ......................................... 136
Kung, Simon, M.D. ....................................... 112
Kurdyak, Paul, M.D., Ph.D. ......................... 110, 118
Kurkjian, Natalie, M.D. ............................... 169
Kurtz, Kristina E., D.O. ................................. 154
Kuvischansky, Jaime M., M.D. ....................... 162

L

LaChance, Laura R., M.D. ............................ 128
Lackamp, Jeanne, M.D. .................................. 88
LaFrance Jr., W. Curt, M.D., M.P.H. ............ 60
Lagman, Jasmin G., M.D. ............................. 109, 154
Lahera, Guillermo, M.D., Ph.D. ..................... 169
Lai, Hank, M.D. .......................................... 154
Lakshmin, Pooja, M.D. .................................. 154
Lambert, Kristen M., J.D., M.S.W. ................. 102
Lambrese, Jason V., M.D. ............................. 172
Lam, June, M.D. .......................................... 164
Lam, Raymond, M.D. ................................... 177
La Noce, Audrey, D.O. ................................. 154
Lavender, Ted .............................................. 102
Lavretska, Helen, M.D. ................................. 76, 169
Lazarus, Arthur, M.D., M.B.A. ...................... 118
Lazarus, Joash T., M.D. ................................. 112
Leal, Camilo, M.D. ....................................... 154
Lee, Byeonghee, M.D. .................................... 173
Lee, Chuan-Mei, M.D., M.A. ......................... 127
Lee, Deokjong, M.D. ..................................... 165
Lee, Elliott K., M.D. ....................................... 64
Lee, Hochang B., M.D. ................................... 135
Lee, Hyuk, M.D. ........................................... 169
Lee, Hyun-Ah, M.D. ...................................... 173
Lee, Kyoung-UK, M.D. ................................... 169
Lee, Li-Wen Grace, M.D. ............................... 101
Lee, Richard J., M.D. ..................................... 172
Lee, Sang Kyu, M.D., Ph.D. ......................... 169
Lee, Sang Yeol, Ph.D. ................................... 162
Lee, Seung-Hwan, M.D., Ph.D. ................. 169, 169
Lee, Sooyeon, M.D. ..................................... 164
Lee, Woo Hyung, M.D. ................................. 165
Lee, Yena ..................................................... 177
Lee, Young Sik, M.D., Ph.D. ......................... 177
Lefebvre, Patrick, M.A. ................................. 177
Le, Hoa, D.O. ............................................. 134
Leistedt, Samuel J., M.D., Ph.D. ................. 118
Levent, Jacob, M.D. ....................................... 155
Lemieux, Anthony, Ph.D., M.A. ................ 115
Lerner, Debra, Ph.D., M.Sc. ......................... 110
Levine, Henry S., M.D. ................................. 133
Levine, Stephen B., M.D. ............................. 60
Levin, Frances R., M.D. ............................... 69, 129
Levin, Saul, M.D., M.P.A. ............................ 85, 105, 113
Levitt, William, M.D. ................................... 155, 157, 160
Levounis, Petros, M.D. ............................... 60, 75, 84, 101
Lev-Ran, Shaul, M.D. ................................... 130
Levy, Sharon, M.D., M.P.H. ......................... 90
Lewandowski, Cathleen A., Ph.D., M.S.W .......... 86
Presenters Index

Lewis, Edward Thomas, M.D. ........................................ 158
Lewis-Fernandez, Roberto, M.D. .......................... 78, 83, 88, 101
Lewy, Alfred J., M.D. ............................................. 66
Lichtenstein, Max A., M.D. ..................................... 155
Licinio, Julio, M.D. .................................................. 116
Li, Dongmei .......................................................... 62, 88, 113
Li, Eun Jung, M.D. ............................................... 165
Li, Kevin J. ............................................................. 155
Li, Luming, M.D. .................................................... 165
Lima, Ateaya, M.D. ................................................. 112
Lim, Jongseok ....................................................... 165
Lim, Russell F., M.D., M.Ed. ................................. 88, 113
Lindenmayer, Jean-Pierre, M.D. ......................... 118, 169, 177
Lin, Joy E., B.S. ..................................................... 160
Links, Paul ............................................................... 79
Lipsitt, Don, M.D., M.A. ........................................ 82
Li, Shuang, M.D., Ph.D. ........................................... 177
Lisotto, Maria Jose, M.D. ..................................... 78
Liu, Lusha .............................................................. 87
Liu, Shiyuan .......................................................... 165
Liu, Zhaorui, M.D., Ph.D., M.P.H. ..................... 169
Lizano, Paulo L., M.D., Ph.D. ............................. 169
Lliberes Rincon, Nubia, M.D. ................................. 142
Lochhead, Jeannie, M.D. ..................................... 160
Loehr, Colleen, M.D. ................................................ 67
Loewen, Gordon R., Ph.D. .................................. 177
Lohitsa, Akshay, M.D. ............................................ 131
Lokko, Hermioni, M.D., M.P.P. ............................ 158
Lolak, Sermak, M.D. ................................................. 132
Lomax, James W., M.D. ......................................... 130
López-Jaramillo, Carlos, M.D., Ph.D. ................. 169
Lowenthal, David, M.D., J.D. ............................. 83
Lowy, Daniel L., L.C.S.W. .................................. 134
Lubarda, Jovana, Ph.D. ......................................... 177
Lubin, Molly, M.D. ................................................... 85
Lu, Francis, M.D. ....................................................... 83
Luo, John, M.D. ...................................................... 112
Lusskin, Shari I., M.D. ........................................... 60
Lynch, Alison J., Esq. .......................................... 128
Lytle, Sarah M., M.D. ............................................. 169

M

MacDonald, Kelly, M.D. ...................................... 165
MacKenzie, James G., D.O. .................................... 145
Mackey, Sean, M.D., Ph.D. ................................ 115
MacLeod, Stephanie, M.Sc. ................................ 100
Madan, Alok, Ph.D., M.P.H. .................................. 87
Mathusoodanan, Subramoniam, M.D. ............. 169
Madsen, Helle, M.D. .............................................. 177
Maeng, Se-Ri, M.D. ............................................... 169
Mago, Rajnish, M.D. ............................................. 177
Maguire, Gerald A., M.D., DFAPA ....................... 190
Mahdianian, Artin, M.D. ................................... 65, 155
Mahendran, Rathi, M.Ed., M.Med. ................ 162
Maher, John, M.D. .................................................... 84
Maheshwari, Subani, M.D. .................................... 159
Mahoney, Nicholas, D.O. .................................... 165
Maj, Mario, M.D., Ph.D. ........................................... 128
Makani, Ramkrishna D., M.D., M.P.H. ............. 160
Makanjuola, Titilayo, M.D. .................................. 165
Maldonado, Jose R., M.D. ..................................... 131
Maletic, Vladimir, M.D. .................................... 189
Malik, Arsalan, M.D. ............................................. 143
Malik, Mahgul, M.D. ............................................. 137
Maloy, Katherine, M.D. ....................................... 69
Maltz, Brenda, M.A., R.N. ...................................... 66
Malveaux, Wilsa M. S. Charles, M.D., M.A. ....... 127
Manalai, Partam, M.D. .......................................... 177
Mancevski, Branislav, M.D. ................................. 110
Mangal, Jed P., M.D. .............................................. 61
Mangiardi, Mario, M.D. ........................................... 155
Mann, Gurtej S., M.D. ............................................. 177
Manning, James Sloan, M.D. .............................. 189
Manocha, Pankaj, M.D. ......................................... 173
Mao, Alice R., M.D. ................................................. 77
Marazziti, Donatella, M.D. .................................. 177
Marcus, Adeyemi, M.D. ....................................... 155
Marder, Stephen R., M.D. .................................... 64, 83, 88
Mariani, John J., M.D. .......................................... 129
Marino, Leslie, M.D., M.P.H. ............................... 66
Marino, Patricia, Ph.D. ........................................... 126
Markkula, Niina, M.D., M.Sc. .............................. 177
Markowitz, Paul J., M.D., Ph.D. .......................... 117
Markowitz, John C., M.D. ..................................... 79
Markx, Sander, M.D. .............................................. 102
Marlin, Robert P., M.D., Ph.D., M.P.H. ............. 83
Marmar, Charles R., M.D. .................................. 70
Martinez, Richard .................................................. 118
Martin, Glenn, M.D. .............................................. 85
Martino, Steve, Ph.D. ............................................ 105
Martz, Gloria, M.D. ................................................. 155
Marumoto, Megan, M.D. ................................... 146
Maruyama, Nancy, M.D. ..................................... 83
Mashiana, Amanpreet K., B.S. ......................... 158
Maskel, Lynn, M.D. .............................................. 102
Mathur, Anu, M.D. .................................................... 71
Mattingly, Greg, M.D. ........................................... 169
Mattingly, Gregory W., M.D. ............................... 190
Maududi, Syed E., M.D. ....................................... 155
Mayberg, Helen, M.D. ............................................ 130
May, Catharine S., M.D. ........................................ 85
Mazhar, Mir N., M.D. ............................................. 169
McBurnett, Keith, Ph.D. ....................................... 169
McCabe, Sean Esteban, Ph.D. ......................... 136
McCarron, Robert M., D.O. ................................. 67, 80, 86, 137
McCure, Deimante, B.A. ................................... 173
McCracken, James T., M.D. .................................. 83, 88
McDonald, William M., M.D. .......................... 86
McCougall, Matthew A., M.D. ......................... 160
McDuff, David R., M.D. ....................................... 65
McGinnis, MegAnn Kay, B.S. ............................ 177
McGlynn, Lawrence, M.D., M.S. .................... 82, 107, 137
McGovern, Amanda, Ph.D. ............................ 126
McGraw, Kate, Ph.D. ............................................ 138

Guide to the 2016 Annual Meeting  |  269
<table>
<thead>
<tr>
<th>Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>McHugh, Paul, M.D.</td>
<td>77</td>
</tr>
<tr>
<td>McIntyre, Roger S., M.D.</td>
<td>77, 177</td>
</tr>
<tr>
<td>McKenzie, Kwarne, M.D.</td>
<td>62</td>
</tr>
<tr>
<td>McLeod, Megan, M.D.</td>
<td>165</td>
</tr>
<tr>
<td>McMickens, Courtney L., M.D., M.P.H.</td>
<td>61, 101</td>
</tr>
<tr>
<td>McNeil, Shawn E., M.D.</td>
<td>155</td>
</tr>
<tr>
<td>McNiel, Dale E., Ph.D.</td>
<td>74, 88</td>
</tr>
<tr>
<td>McVoy, Molly, M.D.</td>
<td>67</td>
</tr>
<tr>
<td>Medici, Clara Reece, B.S.</td>
<td>165</td>
</tr>
<tr>
<td>Medlock, Morgan, M.D.</td>
<td>102</td>
</tr>
<tr>
<td>Melicher, Tomas, M.D.</td>
<td>155</td>
</tr>
<tr>
<td>Mellon, Synthia H., Ph.D.</td>
<td>70</td>
</tr>
<tr>
<td>Meltzer, Herbert Y., M.D.</td>
<td>115</td>
</tr>
<tr>
<td>Mendiola, Andrea, M.D.</td>
<td>177</td>
</tr>
<tr>
<td>Merlo, Lisa J., Ph.D.</td>
<td>71</td>
</tr>
<tr>
<td>Metzner, Jeffrey L., M.D.</td>
<td>88, 98, 100, 119, 126</td>
</tr>
<tr>
<td>Meyer-Bahlburg, Heino F. L., Ph.D.</td>
<td>64</td>
</tr>
<tr>
<td>Meyer, Donald J., M.D.</td>
<td>82</td>
</tr>
<tr>
<td>Meyer, Eric, M.D.</td>
<td>166</td>
</tr>
<tr>
<td>Miccio, Steve, B.A.</td>
<td>85</td>
</tr>
<tr>
<td>Miday, Karen K., M.D.</td>
<td>131</td>
</tr>
<tr>
<td>Mihalijovic, Aida Spahic, M.D., M.S.</td>
<td>71, 173</td>
</tr>
<tr>
<td>Millard, Hun, M.D.</td>
<td>134</td>
</tr>
<tr>
<td>Millegan, Jeffrey, M.D., Ph.D.</td>
<td>169</td>
</tr>
<tr>
<td>Miller, Adam, M.D.</td>
<td>69</td>
</tr>
<tr>
<td>Miller, Andrew, M.D.</td>
<td>99</td>
</tr>
<tr>
<td>Miller, Gregory, M.D., M.B.A.</td>
<td>101</td>
</tr>
<tr>
<td>Miller, Shefalli, M.D.</td>
<td>80</td>
</tr>
<tr>
<td>Mills, Jacob, B.S.</td>
<td>131</td>
</tr>
<tr>
<td>Milrod, Barbara, M.D.</td>
<td>67</td>
</tr>
<tr>
<td>Minhas, Hassan M., M.D., M.B.B.S.</td>
<td>126</td>
</tr>
<tr>
<td>Mintz, David L., M.D.</td>
<td>80, 106</td>
</tr>
<tr>
<td>Mischoulon, David, M.D., Ph.D.</td>
<td>115</td>
</tr>
<tr>
<td>Misri, Shaila, M.D.</td>
<td>60</td>
</tr>
<tr>
<td>Mistry, Amit, M.D.</td>
<td>155</td>
</tr>
<tr>
<td>Mitra, Paroma, M.D., M.P.H.</td>
<td>155</td>
</tr>
<tr>
<td>Moamai, Javad, M.D., M.Sc.</td>
<td>169</td>
</tr>
<tr>
<td>Moffic, H. Steven, M.D.</td>
<td>78, 86, 105, 118</td>
</tr>
<tr>
<td>Mogallapu, Raja, M.D.</td>
<td>155</td>
</tr>
<tr>
<td>Moghimi, Yavar, M.D.</td>
<td>137</td>
</tr>
<tr>
<td>Mohite, Satyajit, M.D., M.P.H.</td>
<td>169, 177</td>
</tr>
<tr>
<td>Mohyuddin, Farooq, M.D., M.B.B.S.</td>
<td>105</td>
</tr>
<tr>
<td>Mohyuddin, Hira</td>
<td>173</td>
</tr>
<tr>
<td>Mokrani, Marie-Claude, Ph.D.</td>
<td>167, 169</td>
</tr>
<tr>
<td>Molaei, Ali M., B.A.</td>
<td>177</td>
</tr>
<tr>
<td>Moller, Hans-Jurgen, M.D.</td>
<td>114</td>
</tr>
<tr>
<td>Monahan, John, Ph.D.</td>
<td>98, 110</td>
</tr>
<tr>
<td>Montalvo, Cristina, M.D.</td>
<td>101</td>
</tr>
<tr>
<td>Montano Arteaga, Pamela C., M.D.</td>
<td>78</td>
</tr>
<tr>
<td>MontazeriHem, Douna, M.D.</td>
<td>173</td>
</tr>
<tr>
<td>Montenegro, Roberto E., M.D., Ph.D.</td>
<td>90</td>
</tr>
<tr>
<td>Montoya, Ivan D., M.D., M.P.H.</td>
<td>114</td>
</tr>
<tr>
<td>Montoya, Ivan D., M.D., Ph.D.</td>
<td>86</td>
</tr>
<tr>
<td>Mooney, Larissa</td>
<td>79</td>
</tr>
<tr>
<td>Moore, Kevin D., M.D.</td>
<td>102, 142</td>
</tr>
<tr>
<td>Moore, Lauren E., M.D.</td>
<td>155</td>
</tr>
<tr>
<td>Moosor, Matthew, M.S.</td>
<td>136</td>
</tr>
<tr>
<td>Moreira-Almeida, Alexander, M.D., Ph.D.</td>
<td>144</td>
</tr>
<tr>
<td>Moreno, Maria E., M.D.</td>
<td>155</td>
</tr>
<tr>
<td>Morgan, Theresa A., Ph.D.</td>
<td>126</td>
</tr>
<tr>
<td>Morris, Sapna B., M.D., M.B.A.</td>
<td>104</td>
</tr>
<tr>
<td>Morse, Michael D., M.P.A.</td>
<td>100</td>
</tr>
<tr>
<td>Moscicki, Eve, Sc.D., M.P.H.</td>
<td>71</td>
</tr>
<tr>
<td>Mosier, Jessica, M.D.</td>
<td>126</td>
</tr>
<tr>
<td>Moukaddam, Nidal, M.D., Ph.D.</td>
<td>118</td>
</tr>
<tr>
<td>Moussaou, Driess, M.D.</td>
<td>69, 78, 129</td>
</tr>
<tr>
<td>Moutier, Christine, M.D.</td>
<td>136</td>
</tr>
<tr>
<td>Mruthyunjaya, Pranathi, M.D.</td>
<td>153</td>
</tr>
<tr>
<td>Mudgway, Ross J.</td>
<td>173</td>
</tr>
<tr>
<td>Munjal, Sahil, M.D.</td>
<td>80, 155, 165</td>
</tr>
<tr>
<td>Munzani, Lakshmi Priya, M.D.</td>
<td>162</td>
</tr>
<tr>
<td>Murphy, Dewey S., M.D.</td>
<td>155</td>
</tr>
<tr>
<td>Murphy, James, M.D.</td>
<td>76, 136</td>
</tr>
<tr>
<td>Murray, Robin M., M.D.</td>
<td>69</td>
</tr>
<tr>
<td>Muser, Erik, Pharm.D., M.P.H.</td>
<td>170</td>
</tr>
<tr>
<td>Muskin, Philip R., M.D., M.A.</td>
<td>82, 83, 116</td>
</tr>
<tr>
<td>Muszynski, Irvin L., J.D.</td>
<td>112, 116</td>
</tr>
<tr>
<td>Myers, Michael F., M.D.</td>
<td>118, 131, 136</td>
</tr>
<tr>
<td>Myers, Trenton, M.D.</td>
<td>155</td>
</tr>
<tr>
<td>Myers, Wade C., M.D.</td>
<td>104</td>
</tr>
</tbody>
</table>

N

<table>
<thead>
<tr>
<th>Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nadelson, Carol C., M.D.</td>
<td>129</td>
</tr>
<tr>
<td>Naeem, Farooq, Ph.D., M.Sc.</td>
<td>62, 134</td>
</tr>
<tr>
<td>Nagalla, Madhavi, M.D.</td>
<td>112</td>
</tr>
<tr>
<td>Nagurney, Michelle, M.D.</td>
<td>78</td>
</tr>
<tr>
<td>Nam, Yoonmin</td>
<td>173</td>
</tr>
<tr>
<td>Narasimhan, Meera, M.D.</td>
<td>102</td>
</tr>
<tr>
<td>Nardi, Antonio E., M.D., Ph.D.</td>
<td>169</td>
</tr>
<tr>
<td>Nascimento, Antonio L., M.D., M.Sc.</td>
<td>178</td>
</tr>
<tr>
<td>Nash, Maureen C., M.D., M.S.</td>
<td>79</td>
</tr>
<tr>
<td>Nasrallah, Henry A., M.D.</td>
<td>79, 99, 127, 178, 188, 189</td>
</tr>
<tr>
<td>Nasrulla, Insiya, M.B.B.S.</td>
<td>165</td>
</tr>
<tr>
<td>Nassan, Malik, M.B.B.S.</td>
<td>115, 173</td>
</tr>
<tr>
<td>Navarro, Aniceto, M.D.</td>
<td>61</td>
</tr>
<tr>
<td>Naveen, M. M., M.D.</td>
<td>159</td>
</tr>
<tr>
<td>Neff, Daniel, M.D.</td>
<td>126</td>
</tr>
<tr>
<td>Ngebenebor, Nicolle, B.S.</td>
<td>169</td>
</tr>
<tr>
<td>Neller, Robert B., Gen.</td>
<td>130, 131</td>
</tr>
<tr>
<td>Nelson, Christopher, M.D.</td>
<td>88</td>
</tr>
<tr>
<td>Nelson, Sally, M.Ed., R.N.</td>
<td>146</td>
</tr>
<tr>
<td>Nemerooff, Charles B., M.D., Ph.D.</td>
<td>77</td>
</tr>
<tr>
<td>Nepal, Hitekshya, M.D.</td>
<td>173</td>
</tr>
<tr>
<td>Neramball, Malini, M.D.</td>
<td>165</td>
</tr>
<tr>
<td>Netherton, Elisabeth, M.D.</td>
<td>61</td>
</tr>
<tr>
<td>Neufeld, Ron, Ph.D.</td>
<td>99</td>
</tr>
<tr>
<td>New, Antonia S., M.D.</td>
<td>105</td>
</tr>
<tr>
<td>Newmark, Thomas, M.D.</td>
<td>78</td>
</tr>
<tr>
<td>Ng-Mak, Daisy S., Ph.D.</td>
<td>178</td>
</tr>
<tr>
<td>Nguyen, Sarah A., M.D.</td>
<td>173</td>
</tr>
<tr>
<td>Nicolas, Samuel A., M.D.</td>
<td>173</td>
</tr>
<tr>
<td>Nielsen, Rebecca Z., M.Sc.</td>
<td>178</td>
</tr>
<tr>
<td>Nijjar, Gursharon, M.D.</td>
<td>173</td>
</tr>
<tr>
<td>Nikiforov, Ivan, M.D.</td>
<td>169</td>
</tr>
</tbody>
</table>
## Presenters Index

<table>
<thead>
<tr>
<th>Page</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>114</td>
<td>Nikzad, Vahid, M.D.</td>
</tr>
<tr>
<td>115</td>
<td>O'Brien, Virginia, M.D.</td>
</tr>
<tr>
<td>117</td>
<td>O'Gorman, Cedric, M.D.</td>
</tr>
<tr>
<td>119</td>
<td>Okereke, Olivia I., M.D., S.M.</td>
</tr>
<tr>
<td>122</td>
<td>Okoronkwo, Joshua</td>
</tr>
<tr>
<td>124</td>
<td>Olsson, David P., M.D., Ph.D.</td>
</tr>
<tr>
<td>125</td>
<td>Olupona, Tolu, M.D.</td>
</tr>
<tr>
<td>127</td>
<td>Ong, Christopher F., M.D.</td>
</tr>
<tr>
<td>129</td>
<td>Oquendo, Maria A., M.D.</td>
</tr>
<tr>
<td>130</td>
<td>O'Reardon, John P., M.D.</td>
</tr>
<tr>
<td>138</td>
<td>Orr, Matt, Ph.D.</td>
</tr>
<tr>
<td>142</td>
<td>O'Shaughnessy, Roy, M.D.</td>
</tr>
<tr>
<td>143</td>
<td>Osher, Fred C., M.D.</td>
</tr>
<tr>
<td>144</td>
<td>Osman, Ekatherina, D.O.</td>
</tr>
<tr>
<td>146</td>
<td>Osman, Ossama Tawakol, M.D.</td>
</tr>
<tr>
<td>147</td>
<td>Ososky, Howard J., M.D., Ph.D.</td>
</tr>
<tr>
<td>149</td>
<td>Osório, Flávia L.</td>
</tr>
<tr>
<td>150</td>
<td>Ospina Duque, Jorge, M.D.</td>
</tr>
<tr>
<td>153</td>
<td>Ouanes, Sami, M.D.</td>
</tr>
<tr>
<td>154</td>
<td>Ouellette, P. Lynn, M.D.</td>
</tr>
<tr>
<td>155</td>
<td>Owen, Andrew, M.S.</td>
</tr>
<tr>
<td>159</td>
<td>Owens, Samuel M., Ph.D.</td>
</tr>
<tr>
<td>163</td>
<td>Ozbayrak, R. Kaan, M.D., M.B.A.</td>
</tr>
<tr>
<td>165</td>
<td>Ozdemir, Armagan</td>
</tr>
<tr>
<td>168</td>
<td>Ozel-Kizil, Erguvan T., M.D.</td>
</tr>
<tr>
<td>169</td>
<td>Padilla Candelario, Auralyd, M.D.</td>
</tr>
<tr>
<td>172</td>
<td>Padilla, Vanessa, M.D.</td>
</tr>
<tr>
<td>174</td>
<td>Pai, Nagesh, M.D.</td>
</tr>
<tr>
<td>176</td>
<td>Palazzolo, Jerome, M.D., Ph.D.</td>
</tr>
<tr>
<td>178</td>
<td>Pallanti, Stefano, M.D., Ph.D.</td>
</tr>
<tr>
<td>179</td>
<td>Palmer, Brian, M.D., M.P.H.</td>
</tr>
<tr>
<td>180</td>
<td>Pandey, Ghanshyam N., Ph.D.</td>
</tr>
<tr>
<td>181</td>
<td>Pao, Maryland, M.D.</td>
</tr>
<tr>
<td>183</td>
<td>Pardes, Herbert, M.D.</td>
</tr>
<tr>
<td>184</td>
<td>Parekh, Ranna, M.D., M.P.H.</td>
</tr>
<tr>
<td>185</td>
<td>Parikh, Niketa, B.S.</td>
</tr>
<tr>
<td>186</td>
<td>Parikh, Tapan, M.D., M.P.H.</td>
</tr>
<tr>
<td>187</td>
<td>Park, Bhinja Pearl, M.D.</td>
</tr>
<tr>
<td>188</td>
<td>Park, Dongchan, M.D.</td>
</tr>
<tr>
<td>189</td>
<td>Park, Hyemi, M.D.</td>
</tr>
<tr>
<td>191</td>
<td>Park, Jiyeeon (Regina)</td>
</tr>
<tr>
<td>192</td>
<td>Park, Jong-II, M.D., Ph.D.</td>
</tr>
<tr>
<td>193</td>
<td>Park, Sa Eun, M.D.</td>
</tr>
<tr>
<td>194</td>
<td>Park, Seon-Cheol</td>
</tr>
<tr>
<td>195</td>
<td>Parks, Joseph, M.D.</td>
</tr>
<tr>
<td>196</td>
<td>Parmar, Arpit, M.D., M.B.B.S.</td>
</tr>
<tr>
<td>197</td>
<td>Parsaik, Ajay, M.D., M.S.</td>
</tr>
<tr>
<td>198</td>
<td>Pary, Robert J., M.D.</td>
</tr>
<tr>
<td>199</td>
<td>Pashko, Steven, Ph.D.</td>
</tr>
<tr>
<td>200</td>
<td>Pasternak, Gavril, M.D., Ph.D.</td>
</tr>
<tr>
<td>201</td>
<td>Patel, Ankur, M.D.</td>
</tr>
<tr>
<td>202</td>
<td>Patel, Ervin L., Psy.D.</td>
</tr>
<tr>
<td>203</td>
<td>Patel, Mitesh, M.D.</td>
</tr>
<tr>
<td>204</td>
<td>Patel, Rachit, M.D.</td>
</tr>
<tr>
<td>205</td>
<td>Patel, Rahul Kumar, M.D., M.P.H.</td>
</tr>
<tr>
<td>206</td>
<td>Patel, Ronak, M.D.</td>
</tr>
<tr>
<td>207</td>
<td>Patel, Ruchikumar Arvind, M.B.B.S.</td>
</tr>
<tr>
<td>208</td>
<td>Patel, Rupal, M.B.B.S.</td>
</tr>
<tr>
<td>209</td>
<td>Patel, Shama, M.D.</td>
</tr>
<tr>
<td>210</td>
<td>Patel, Shirali S., M.D.</td>
</tr>
<tr>
<td>211</td>
<td>Pate, R. Jill, M.D.</td>
</tr>
<tr>
<td>212</td>
<td>Pato, Michele T., M.D.</td>
</tr>
<tr>
<td>213</td>
<td>Patriquin, Michelle, Ph.D.</td>
</tr>
<tr>
<td>214</td>
<td>Paudel, Shreedhar, M.D., M.P.H.</td>
</tr>
<tr>
<td>215</td>
<td>Pazuniak, Markian, M.D.</td>
</tr>
<tr>
<td>216</td>
<td>Pearson, Godfrey D., M.D.</td>
</tr>
<tr>
<td>217</td>
<td>Pelka, Bryan M., M.D.</td>
</tr>
<tr>
<td>218</td>
<td>Pender, Vivian, M.D.</td>
</tr>
<tr>
<td>219</td>
<td>Pendler, Paul, Psy.D.</td>
</tr>
<tr>
<td>220</td>
<td>Penesetti, Deepak, M.D.</td>
</tr>
<tr>
<td>221</td>
<td>Pengrin, Lauren, D.C.</td>
</tr>
<tr>
<td>222</td>
<td>Penninix, Brenda W., Ph.D.</td>
</tr>
<tr>
<td>223</td>
<td>Penn, Joseph V., M.D.</td>
</tr>
<tr>
<td>224</td>
<td>Pensa, Keith, M.D.</td>
</tr>
<tr>
<td>225</td>
<td>Penumetcha, Varma, M.D.</td>
</tr>
<tr>
<td>226</td>
<td>Penzner, Julie B., M.D.</td>
</tr>
<tr>
<td>227</td>
<td>Pereira, Luis, M.D.</td>
</tr>
<tr>
<td>228</td>
<td>Perez-Rodriguez, M, Mercedes, M.D., Ph.D.</td>
</tr>
<tr>
<td>229</td>
<td>Periclou, Antonia, Ph.D.</td>
</tr>
<tr>
<td>230</td>
<td>Perkins, Matthew B., M.D., M.P.H.</td>
</tr>
</tbody>
</table>

**P**

<table>
<thead>
<tr>
<th>Page</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>67</td>
<td>Padilla Candelario, Auralyd, M.D.</td>
</tr>
<tr>
<td>90</td>
<td>Padilla, Vanessa, M.D.</td>
</tr>
<tr>
<td>169</td>
<td>Pai, Nagesh, M.D.</td>
</tr>
<tr>
<td>163</td>
<td>Palazzolo, Jerome, M.D., Ph.D.</td>
</tr>
<tr>
<td>69</td>
<td>Pallanti, Stefano, M.D., Ph.D.</td>
</tr>
<tr>
<td>79</td>
<td>Palmer, Brian, M.D., M.P.H.</td>
</tr>
<tr>
<td>84</td>
<td>Pandey, Ghanshyam N., Ph.D.</td>
</tr>
<tr>
<td>77</td>
<td>Pao, Maryland, M.D.</td>
</tr>
<tr>
<td>102</td>
<td>Pardes, Herbert, M.D.</td>
</tr>
<tr>
<td>90</td>
<td>Parekh, Ranna, M.D., M.P.H.</td>
</tr>
<tr>
<td>167</td>
<td>Parikh, Niketa, B.S.</td>
</tr>
<tr>
<td>160</td>
<td>Parikh, Tapan, M.D., M.P.H.</td>
</tr>
<tr>
<td>134</td>
<td>Park, Bhinja Pearl, M.D.</td>
</tr>
<tr>
<td>85</td>
<td>Park, Dongchan, M.D.</td>
</tr>
<tr>
<td>163</td>
<td>Park, Hyemi, M.D.</td>
</tr>
<tr>
<td>178</td>
<td>Park, Jiyeeon (Regina)</td>
</tr>
<tr>
<td>167</td>
<td>Park, Jong-II, M.D., Ph.D.</td>
</tr>
<tr>
<td>157</td>
<td>Park, Sa Eun, M.D.</td>
</tr>
<tr>
<td>170</td>
<td>Park, Seon-Cheol</td>
</tr>
<tr>
<td>135</td>
<td>Parks, Joseph, M.D.</td>
</tr>
<tr>
<td>163</td>
<td>Parmar, Arpit, M.D., M.B.B.S.</td>
</tr>
<tr>
<td>160</td>
<td>Parsaik, Ajay, M.D., M.S.</td>
</tr>
<tr>
<td>87</td>
<td>Pary, Robert J., M.D.</td>
</tr>
<tr>
<td>170</td>
<td>Patel, Ankur, M.D.</td>
</tr>
<tr>
<td>71</td>
<td>Patel, Ervin L., Psy.D.</td>
</tr>
<tr>
<td>170</td>
<td>Patel, Mitesh, M.D.</td>
</tr>
<tr>
<td>170</td>
<td>Patel, Rachit, M.D.</td>
</tr>
<tr>
<td>161</td>
<td>Patel, Rahul Kumar, M.D., M.P.H.</td>
</tr>
<tr>
<td>155</td>
<td>Patel, Ronak, M.D.</td>
</tr>
<tr>
<td>173</td>
<td>Patel, Ruchikumar Arvind, M.B.B.S.</td>
</tr>
<tr>
<td>163</td>
<td>Patel, Rupal, M.B.B.S.</td>
</tr>
<tr>
<td>143</td>
<td>Patel, Shama, M.D.</td>
</tr>
<tr>
<td>61</td>
<td>Patel, Shirali S., M.D.</td>
</tr>
<tr>
<td>71</td>
<td>Pate, R. Jill, M.D.</td>
</tr>
<tr>
<td>110</td>
<td>Pato, Michele T., M.D.</td>
</tr>
<tr>
<td>87</td>
<td>Patriquin, Michelle, Ph.D.</td>
</tr>
<tr>
<td>165</td>
<td>Paudel, Shreedhar, M.D., M.P.H.</td>
</tr>
<tr>
<td>155</td>
<td>Pazuniak, Markian, M.D.</td>
</tr>
<tr>
<td>129</td>
<td>Pearson, Godfrey D., M.D.</td>
</tr>
<tr>
<td>108</td>
<td>Pelka, Bryan M., M.D.</td>
</tr>
<tr>
<td>134</td>
<td>Pender, Vivian, M.D.</td>
</tr>
<tr>
<td>137</td>
<td>Pendler, Paul, Psy.D.</td>
</tr>
<tr>
<td>71</td>
<td>Penesetti, Deepak, M.D.</td>
</tr>
<tr>
<td>158</td>
<td>Pengrin, Lauren, D.C.</td>
</tr>
<tr>
<td>82</td>
<td>Penninix, Brenda W., Ph.D.</td>
</tr>
<tr>
<td>77</td>
<td>Penn, Joseph V., M.D.</td>
</tr>
<tr>
<td>70</td>
<td>Penska, Keith, M.D.</td>
</tr>
<tr>
<td>158</td>
<td>Penumetcha, Varma, M.D.</td>
</tr>
<tr>
<td>100</td>
<td>Penzner, Julie B., M.D.</td>
</tr>
<tr>
<td>155</td>
<td>Pereira, Luis, M.D.</td>
</tr>
<tr>
<td>105</td>
<td>Perez-Rodriguez, M, Mercedes, M.D., Ph.D.</td>
</tr>
<tr>
<td>178</td>
<td>Periclou, Antonia, Ph.D.</td>
</tr>
<tr>
<td>101</td>
<td>Perkins, Matthew B., M.D., M.P.H.</td>
</tr>
</tbody>
</table>
## Presenters Index

<table>
<thead>
<tr>
<th>Name</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peroski, Michael S., D.O.</td>
<td>134, 153</td>
</tr>
<tr>
<td>Perrin, Andrew, M.D., Ph.D.</td>
<td>158</td>
</tr>
<tr>
<td>Pesa, Jacqueline, Ph.D., M.P.H.</td>
<td>170</td>
</tr>
<tr>
<td>Peseschkian, Hamid, M.D., D.M.Sc.</td>
<td>145</td>
</tr>
<tr>
<td>Pestana Knight, Elia M., M.D.</td>
<td>66</td>
</tr>
<tr>
<td>Peteet, John, M.D.</td>
<td>62, 78, 144</td>
</tr>
<tr>
<td>Petersen, Christopher A., M.D.</td>
<td>178</td>
</tr>
<tr>
<td>Petersen, Daena L., M.D., M.P.H.</td>
<td>84, 90, 107</td>
</tr>
<tr>
<td>Peters-Strickland, Timothy, M.D.</td>
<td>176</td>
</tr>
<tr>
<td>Petitjean, Francois, M.Psy.</td>
<td>78</td>
</tr>
<tr>
<td>Petrides, Georgios</td>
<td>99</td>
</tr>
<tr>
<td>Pettigrew, Roderic, B.S.</td>
<td>173</td>
</tr>
<tr>
<td>Pflanz, Steven E., M.D.</td>
<td>137</td>
</tr>
<tr>
<td>Phillips, Katharine A., M.D.</td>
<td>110, 117, 132, 170</td>
</tr>
<tr>
<td>Piddoubny, Walter, M.D.</td>
<td>159</td>
</tr>
<tr>
<td>Pi, Edmond Hsin T., M.D.</td>
<td>87, 113</td>
</tr>
<tr>
<td>Pi, Edmond Hsin T., M.D.</td>
<td>113</td>
</tr>
<tr>
<td>Pierce, Andrew, M.D.</td>
<td>157</td>
</tr>
<tr>
<td>Pier, Katherine, M.D.</td>
<td>134</td>
</tr>
<tr>
<td>Pilla, Malathi, M.D.</td>
<td>159</td>
</tr>
<tr>
<td>Pinals, Debra, M.D.</td>
<td>69, 114, 135</td>
</tr>
<tr>
<td>Pinninti, Narasimha, M.D., D.P.M.</td>
<td>117</td>
</tr>
<tr>
<td>Plakun, Eric M., M.D.</td>
<td>106, 132, 138</td>
</tr>
<tr>
<td>Pleak, Richard R., M.D.</td>
<td>64</td>
</tr>
<tr>
<td>Pogarell, Oliver, M.D.</td>
<td>101</td>
</tr>
<tr>
<td>Pollack, Mark H., M.D.</td>
<td>75</td>
</tr>
<tr>
<td>Poon, Amy, M.D.</td>
<td>90, 142</td>
</tr>
<tr>
<td>Porche, Michelle V., Ed.D.</td>
<td>77</td>
</tr>
<tr>
<td>Porter-O’Grady, Tim, Ed.D., R.N.</td>
<td>104</td>
</tr>
<tr>
<td>Portilla, Garcia, Ph.D.</td>
<td>178</td>
</tr>
<tr>
<td>Posner, Jonathan, M.D.</td>
<td>143</td>
</tr>
<tr>
<td>Potkin, Steven, M.D.</td>
<td>177, 178</td>
</tr>
<tr>
<td>Potter, Nancy N., Ph.D.</td>
<td>142</td>
</tr>
<tr>
<td>Pourrezaei, Kimia, D.O.</td>
<td>156</td>
</tr>
<tr>
<td>Powsner, Seth, M.D.</td>
<td>99, 112</td>
</tr>
<tr>
<td>Prabhakar, Deepak, M.D., M.P.H.</td>
<td>130, 134</td>
</tr>
<tr>
<td>Preti, Emanuele, Ph.D.</td>
<td>127</td>
</tr>
<tr>
<td>Price, Marilyn, M.D.</td>
<td>135</td>
</tr>
<tr>
<td>Pririm, Annelle, M.D., M.P.H.</td>
<td>127</td>
</tr>
<tr>
<td>Puchakayala, Nandita, M.B.B.S.</td>
<td>173</td>
</tr>
<tr>
<td>Pula, Jack, M.D.</td>
<td>64, 75</td>
</tr>
<tr>
<td>Pumariega, Andres J., M.D.</td>
<td>129, 137</td>
</tr>
<tr>
<td>Purcell, David W., J.D., Ph.D.</td>
<td>101</td>
</tr>
<tr>
<td>Puri, M., Rehan, M.D., M.P.H.</td>
<td>158</td>
</tr>
<tr>
<td>Rahmani, Rumana, M.D.</td>
<td>156</td>
</tr>
<tr>
<td>Rai, Abhishek, M.D.</td>
<td>157</td>
</tr>
<tr>
<td>Rajewska-Rager, Aleksandra, M.D., Ph.D.</td>
<td>170</td>
</tr>
<tr>
<td>Raj, Pritham, M.D.</td>
<td>67</td>
</tr>
<tr>
<td>Rakesh, Gopalkumar, M.D.</td>
<td>165</td>
</tr>
<tr>
<td>Rakofsky, Jeffrey J., M.D.</td>
<td>90</td>
</tr>
<tr>
<td>Rally, Sanjeev K., M.D.</td>
<td>173</td>
</tr>
<tr>
<td>Ramaswamy, Sriman, M.D.</td>
<td>82</td>
</tr>
<tr>
<td>Ramsey, Drew, M.D.</td>
<td>128</td>
</tr>
<tr>
<td>Raney, Lori, M.D.</td>
<td>79, 106, 112, 130, 132, 135</td>
</tr>
<tr>
<td>Ranganathan, Mohini, M.B.B.S.</td>
<td>101</td>
</tr>
<tr>
<td>Rao, Nyapati R., M.D.</td>
<td>76, 90, 112</td>
</tr>
<tr>
<td>Rao, Vani, M.D.</td>
<td>82</td>
</tr>
<tr>
<td>Rapaport, Mark H., M.D.</td>
<td>110, 116</td>
</tr>
<tr>
<td>Rasgon, Natalie</td>
<td>80</td>
</tr>
<tr>
<td>Rathod, Shanaya, M.D.</td>
<td>62</td>
</tr>
<tr>
<td>Ratnakaran, Badr, D.P.M., M.B.B.S.</td>
<td>163</td>
</tr>
<tr>
<td>Ratzliff, Anna, M.D., Ph.D.</td>
<td>79, 106, 130, 132, 143</td>
</tr>
<tr>
<td>Rauch, Sheila A. M., Ph.D.</td>
<td>75</td>
</tr>
<tr>
<td>Razafsha, Mahdi, M.D.</td>
<td>178</td>
</tr>
<tr>
<td>Razdan, Anupriya, M.B.B.S.</td>
<td>156</td>
</tr>
<tr>
<td>Reddy, Abhishek, M.D.</td>
<td>156</td>
</tr>
<tr>
<td>Reese, LeRoy, Ph.D.</td>
<td>87</td>
</tr>
<tr>
<td>Regenbogen, Alexandra, M.D.</td>
<td>85</td>
</tr>
<tr>
<td>Regincos, Rosa, L.C.S.W.</td>
<td>114</td>
</tr>
<tr>
<td>Rehim, Ainy, M.D., M.P.H.</td>
<td>173</td>
</tr>
<tr>
<td>Reich, James H., M.D., M.P.H.</td>
<td>66, 105</td>
</tr>
<tr>
<td>Reid, Czerne M., Ph.D.</td>
<td>61</td>
</tr>
<tr>
<td>Reid, Racquel E., M.D.</td>
<td>117, 127, 132</td>
</tr>
<tr>
<td>Remington, Gary, M.D.</td>
<td>170</td>
</tr>
<tr>
<td>Resnick, Phillip J., M.D.</td>
<td>99, 109, 125, 133, 142</td>
</tr>
<tr>
<td>Ressler, Kerry, M.D., Ph.D.</td>
<td>70</td>
</tr>
<tr>
<td>Reus, Victor I., M.D.</td>
<td>77</td>
</tr>
<tr>
<td>Reyes, Maria M., M.D.</td>
<td>158</td>
</tr>
<tr>
<td>Reynolds III, Charles F., M.D.</td>
<td>86, 115</td>
</tr>
<tr>
<td>Riba, Michelle B., M.D.</td>
<td>69, 82, 104, 113, 136</td>
</tr>
<tr>
<td>Ribeiro Caldas Domingues, Isabel, M.D.</td>
<td>171</td>
</tr>
<tr>
<td>Rice, Alexandra K., M.D., M.A.</td>
<td>158</td>
</tr>
<tr>
<td>Richards, Lawrence K., M.D.</td>
<td>86</td>
</tr>
<tr>
<td>Richards, Misty, M.S.</td>
<td>67, 131</td>
</tr>
<tr>
<td>Richardson, Elizabeth Jane, M.D.</td>
<td>82</td>
</tr>
<tr>
<td>Richardson, Rita R., M.D.</td>
<td>134</td>
</tr>
<tr>
<td>Richter, Matthew, M.D.</td>
<td>165, 166</td>
</tr>
<tr>
<td>Ridout, Kathryn K., M.D., Ph.D.</td>
<td>132, 173</td>
</tr>
<tr>
<td>Ridout, Samuel J., M.D., Ph.D.</td>
<td>132, 173</td>
</tr>
<tr>
<td>Ripperger-Suhler, Jane, M.D., M.A.</td>
<td>84, 144</td>
</tr>
<tr>
<td>Risinger, Robert, M.D.</td>
<td>178</td>
</tr>
<tr>
<td>Ritchie, Elspeth C., M.D., M.P.H.</td>
<td>88, 138, 142</td>
</tr>
<tr>
<td>Rivelli, Sarah, M.D.</td>
<td>67</td>
</tr>
<tr>
<td>Rivera, Margo</td>
<td>146</td>
</tr>
<tr>
<td>Rivolta, Juan A., M.D.</td>
<td>158</td>
</tr>
<tr>
<td>Riyaz, Sonia, M.D.</td>
<td>156</td>
</tr>
<tr>
<td>Robert P. Marlin</td>
<td>83</td>
</tr>
<tr>
<td>Roberts, Laura, M.D., M.A.</td>
<td>90, 102, 104, 118, 127, 131, 146</td>
</tr>
<tr>
<td>Robertson, Katherine, M.D.</td>
<td>157, 158</td>
</tr>
<tr>
<td>Robinson, Diana Mungall, M.D.</td>
<td>156, 173, 178</td>
</tr>
</tbody>
</table>

### Q

<table>
<thead>
<tr>
<th>Name</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quin, Dyanna Leolani Ah, M.S.W.</td>
<td>112</td>
</tr>
<tr>
<td>Quintanilla, Maria Beatriz, M.D., Ph.D.</td>
<td>163</td>
</tr>
<tr>
<td>Qureshi, Naema, M.D.</td>
<td>173</td>
</tr>
</tbody>
</table>

### R

<table>
<thead>
<tr>
<th>Name</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raad, Raymond, M.D.</td>
<td>100</td>
</tr>
<tr>
<td>Rachakonda, Saumya, M.D.</td>
<td>173</td>
</tr>
<tr>
<td>Radhakrishnan, Rajiv, M.D., M.B.B.S.</td>
<td>85, 134</td>
</tr>
<tr>
<td>Rado, Jeffrey T., M.D., M.P.H.</td>
<td>86, 107</td>
</tr>
<tr>
<td>Radoncic, Vanja, B.A.</td>
<td>178</td>
</tr>
<tr>
<td>Raheja, Uttam, M.B.B.S.</td>
<td>170</td>
</tr>
</tbody>
</table>
Presenters Index

Robinson, Gail Erlick, M.D. .................................. 79, 110, 129  
Robles Martinez, Maria ........................................ 165  
Robles-Ramamurthy, Barbara, M.D. ...................... 101, 126  
Roca, Robert, M.D., M.P.H. .................................. 71, 118  
Rodin, Rebecca, M.Sc. ......................................... 165  
Rodriguez-Cabzas, Lisette, M.D. ................................ 90  
Rodriguez-Guzman, Juan, B.S. .......................... 173  
Rodriguez, Lorena, M.D. ...................................... 165  
Rodriguez-Roman, Laura, M.D. ............................ 156  
Roman, Daniel O., M.D. ....................................... 156  
Roma, Rebecca S., M.D. ...................................... 188  
Romba, Courtney Ann, M.D. .................................. 165  
Ronningstam, Elsa F., Ph.D. ................................. 61  
Roof, Jason, M.D. ............................................... 146  
Rosenbaum, Jerrol F., M.D. ................................... 101, 102  
Rosenblat, Joshua D., M.D. .................................... 178  
Rosenheck, Robert, M.D. ...................................... 144  
Rosenquist, Peter B., M.D. .................................... 125  
Rosenthal, Richard N., M.D., M.A. ....................... 104, 178  
Rose, Raquel E., B.S. .......................................... 178  
Roskes, Erik, M.D. .............................................. 128  
Rostain, Anthony, M.D. ....................................... 106, 133  
Rothbaum, Barbara, Ph.D. .................................... 75  
Rothe, Eugenio M., M.D. ....................................... 137  
Rothenberg, Kasia Gustaw, M.D., Ph.D. .................. 163  
Rotter, Merrill, M.D. ........................................... 114  
Rovner, Barry, M.D. ........................................... 115  
Roy, Arunima, M.B.B.S. ....................................... 165  
Roy III, Alphonse Kenison, M.D. ......................... 65, 76  
Roy, Kamalika, M.D. ........................................... 126, 156  
Rozel, John S., M.D. ........................................... 104, 142  
Ruedrich, Stephen, M.D. ..................................... 87  
RuiZ, Amanda, M.D. ............................................ 132  
RuiZ, Pedro, M.D. ............................................... 109, 137  
Rumbaugh, William D. Jr., M.D. ......................... 136  
Russ, Mark J., M.D. ............................................ 100  
Ryan, Deirdre M., M.B. ....................................... 60  
S  
Sabatello, Maya, Ph.D., LL.B. .............................. 135  
Sachdeva, Shilpa, M.D. ........................................ 173  
Saeed, Aliya, M.D. ............................................. 115, 116  
Saeed, Sy A., M.D., M.S. ...................................... 105  
Safar, Laura, M.D. ............................................... 110  
Safin, Daniel, M.D. ............................................. 83  
Sahu, Geetanjali, M.B.B.S. .................................... 165  
Sajatovic, Martha, M.D. ...................................... 170, 178  
Salerno, Karen E., M.S.W. .................................... 145  
Salgado, Cassandra, M.D., M.S. .......................... 85  
Samalin, Ludovic, M.D. ....................................... 78  
Sampathgiri, Kruthika, M.D. .................................. 156  
Samsel, Chase, M.D. .......................................... 146  
Samuels, Susan, M.D. ........................................ 66  
Sánchez-Gómez, Pedro M., M.D. ......................... 163  
Sanchez, Katherine, Ph.D., L.C.S.W. ..................... 144  
Sanchez-Rivero, Yuliet, M.D. .............................. 90  
Sanislow, Charles A., Ph.D. .............................. 128  
Santiago, Vincent A., B.Sc. ................................. 163  
Santos, Eric, M.D. ............................................. 156  
Sapiieha, Michal, M.D. ....................................... 137  
Saragoussi, Delphine, M.D., M.P.H. ..................... 170  
Sarhan, Walid, M.D. .......................................... 144  
Sarikaya Varlik, Dilek, M.D. .............................. 174  
Satcher, David, M.D., Ph.D. .............................. 105  
Sattar, Ayesha, M.D., M.B.B.S. ......................... 156  
Sauve, William, M.D. ....................................... 178  
Savu, Vasile, M.D. ............................................. 159  
Saxena, Ashwini, M.D., Ph.D. ............................ 178  
Saxon, Andrew J., M.D. .................................... 88, 106, 116  
Schaill, Lawrence, Ph.D., M.S.N. ......................... 78  
Schaaf, Kathy, B.Sc., R.N. ................................... 104  
Schatzberg, Alan F., M.D. ................................... 77, 105, 125  
Scheiber, Stephen C., M.D. ............................... 104  
SchiFF, Miriam, Ph.D. ....................................... 145  
Schindzielorz, Adam H., M.D. ............................ 156  
Schlozman, Steven, M.D. .................................... 67  
Schmahl, Christian, M.D. ................................... 135  
Schmidt, Luisa C., M.D. ..................................... 178  
Schmidt, Scott, D.O. ......................................... 112  
Schneider, Brett, M.D. ....................................... 112  
Schneideman, Barbara S., M.D., M.P.H. ............... 75  
Schnellbacher, Sebastian, D.O. .......................... 66, 82  
Schott, Meghan, D.O. ....................................... 165  
Schuermeyer, Isabel, M.D., M.S. ......................... 109  
Schulz, S. Charles, M.D. .................................... 107  
Schwartz, Ann, M.D. ......................................... 112, 132  
Schwartz, Patricia, M.D. .................................. 69, 134  
Schwartz, Thomas L., M.D. ............................... 143  
Schwartz, Victor, M.D. ...................................... 76, 136  
Scoggin, Steven, Psy.D. .................................... 62  
Scott, Charles, M.D. .......................................... 146  
Scully, Stephenie A., M.D. .................................. 174  
Secarea, Cristina M., M.D. ............................... 165  
Sederer, Lloyd I., M.D. ...................................... 113  
Seegan, Alexis A., M.D. ..................................... 129, 156  
Segal, Andrea G., M.S. .................................... 65  
Seibell, Phillip J., M.D. ....................................... 65  
Seibyl, John, M.D. ............................................ 76  
Seo, Wan-Seok, M.D., Ph.D. ............................ 170  
Serfaty, Marc A., M.D., M.B.B.S. ....................... 100  
Serhal, Eva, M.B.A. ........................................... 118  
Serrano, Patricia, M.D. ..................................... 156  
Serrano-Villar, Maria, M.S. ................................ 179  
Sethi Dalai, Shebani, M.D., M.S. ......................... 160  
Seth, Saagar, B.S. ............................................. 167  
Setlow, Barry, Ph.D. .......................................... 61  
Severe, Jennifer, M.D. ..................................... 71, 101, 157  
Shah, Apeksha, M.B.B.S. .................................... 156  
Shah, Asim, M.D. ............................................. 61, 118  
Shah, Pooja, M.D. ............................................ 161, 165  
Shah, Ravi N., M.D., M.B.A. .............................. 136  
Shah, Saloni, B.S. ............................................. 162  
Shahzadi, Ulfat, M.D., M.B.B.S. ......................... 163  
Shakeri, Jalal, M.D. .......................................... 170  

psychiatry.org/annualmeeting

Guide to the 2016 Annual Meeting | 273
## Presenters Index

<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shao, Wanda, D.O.</td>
<td>156</td>
</tr>
<tr>
<td>Shapiro, Anna P., B.A.</td>
<td>156</td>
</tr>
<tr>
<td>Shapiro, Edward R., M.D., M.A.</td>
<td>106</td>
</tr>
<tr>
<td>Shapiro, Gabrielle L., M.D.</td>
<td>76</td>
</tr>
<tr>
<td>Sharfstein, Steven S., M.D., M.P.A.</td>
<td>61, 67, 71, 76, 105, 110, 116, 119</td>
</tr>
<tr>
<td>Sharma, Ashish, M.D.</td>
<td>156</td>
</tr>
<tr>
<td>Sharma, Shridhar, M.D., D.P.M.</td>
<td>78</td>
</tr>
<tr>
<td>Sharon, Haggl, M.D.</td>
<td>165</td>
</tr>
<tr>
<td>Sharp, Carla, Ph.D.</td>
<td>87, 128</td>
</tr>
<tr>
<td>Shayanpour, Mahrokh, M.D.</td>
<td>174</td>
</tr>
<tr>
<td>Shear, Matthew, M.D.</td>
<td>66, 90</td>
</tr>
<tr>
<td>Sheehan, David V., M.D.</td>
<td>69</td>
</tr>
<tr>
<td>Sheehan, Kathleen, M.D., Ph.D.</td>
<td>143</td>
</tr>
<tr>
<td>Sheehan, Matthew M., B.A.</td>
<td>156</td>
</tr>
<tr>
<td>Sheikh, Sarah, M.D.</td>
<td>156</td>
</tr>
<tr>
<td>Sheline, Yvette, M.S.</td>
<td>75, 76</td>
</tr>
<tr>
<td>Shenava, Manisha, M.D.</td>
<td>156</td>
</tr>
<tr>
<td>Sher, Leo, M.D.</td>
<td>88, 130, 170</td>
</tr>
<tr>
<td>Sherman-Stokes, Sarah R., J.D.</td>
<td>83</td>
</tr>
<tr>
<td>Sher, Yelizaveta, M.D.</td>
<td>64, 82</td>
</tr>
<tr>
<td>Shim, Ruth, M.D., M.P.H.</td>
<td>112, 127</td>
</tr>
<tr>
<td>Shim, Se-Hoon, M.D., D.P.H.</td>
<td>179</td>
</tr>
<tr>
<td>Shindler, Maria L., M.S.N.</td>
<td>79</td>
</tr>
<tr>
<td>Shivanekar, Sharvari P., M.D.</td>
<td>174</td>
</tr>
<tr>
<td>Shore, Jay, M.D., M.P.H.</td>
<td>102</td>
</tr>
<tr>
<td>Short, Jessica M., D.O.</td>
<td>159</td>
</tr>
<tr>
<td>Shrivastava, Amresh, M.D.</td>
<td>77, 146, 170</td>
</tr>
<tr>
<td>Shtasel, Derri, M.D., M.P.H.</td>
<td>102</td>
</tr>
<tr>
<td>Shuara, Saoda, M.D.</td>
<td>156</td>
</tr>
<tr>
<td>Shulman, Barbara, M.D.</td>
<td>60</td>
</tr>
<tr>
<td>Sidoros, Rafik, M.D.</td>
<td>159</td>
</tr>
<tr>
<td>Siegela, Harry, B.S.</td>
<td>77</td>
</tr>
<tr>
<td>Sierzchula, Jessica J., D.O.</td>
<td>174</td>
</tr>
<tr>
<td>Silk, Kenneth R., M.D.</td>
<td>84, 90, 130, 135</td>
</tr>
<tr>
<td>Silverman, Joel J., M.D.</td>
<td>77</td>
</tr>
<tr>
<td>Simkin, Deborah R., M.D.</td>
<td>109</td>
</tr>
<tr>
<td>Simon, Kevin M., M.D.</td>
<td>61</td>
</tr>
<tr>
<td>Sirnpson, Annabelle K., M.D.</td>
<td>71</td>
</tr>
<tr>
<td>Singh, Balwinder, M.D., M.S.</td>
<td>158, 159, 160, 165</td>
</tr>
<tr>
<td>Singh, Gurjot, M.D.</td>
<td>156</td>
</tr>
<tr>
<td>Singh, Harvinder, M.D.</td>
<td>163</td>
</tr>
<tr>
<td>Singh, Jasbir, M.D.</td>
<td>156</td>
</tr>
<tr>
<td>Sinha, Preeti, M.D.</td>
<td>100</td>
</tr>
<tr>
<td>Siragusa, Joseph, M.D.</td>
<td>158</td>
</tr>
<tr>
<td>Sisti, Dominic, Ph.D.</td>
<td>65, 88, 108</td>
</tr>
<tr>
<td>Sivrioglu, Yusuf, M.D.</td>
<td>60</td>
</tr>
<tr>
<td>Sjöstrand, Hanna, M.D.</td>
<td>165</td>
</tr>
<tr>
<td>Skolnick, Phil, Ph.D.</td>
<td>86, 114</td>
</tr>
<tr>
<td>Small, Gary W., M.D.</td>
<td>86</td>
</tr>
<tr>
<td>Smith, Mary Kay, M.D.</td>
<td>82</td>
</tr>
<tr>
<td>Smith, Paula Marie, M.D.</td>
<td>90</td>
</tr>
<tr>
<td>Snyder, Elise, M.D.</td>
<td>86</td>
</tr>
<tr>
<td>Sockalingam, Sanjeev, M.D.</td>
<td>66, 118, 135, 143</td>
</tr>
<tr>
<td>Sohn, Sungyun, M.D.</td>
<td>174</td>
</tr>
<tr>
<td>Sola, Christopher, D.O.</td>
<td>145</td>
</tr>
<tr>
<td>Soldinger, Steve, M.D.</td>
<td>143</td>
</tr>
<tr>
<td>Soloway, Scott, M.D.</td>
<td>134</td>
</tr>
<tr>
<td>Song, Jaemin, M.D.</td>
<td>170</td>
</tr>
<tr>
<td>Sood, Shabnam, M.D.</td>
<td>171</td>
</tr>
<tr>
<td>Sorel, Eliot, M.D.</td>
<td>105</td>
</tr>
<tr>
<td>Sorrentino, Renee, M.D.</td>
<td>117, 137</td>
</tr>
<tr>
<td>Sosunmolu, Shoyinka O., M.D.</td>
<td>144</td>
</tr>
<tr>
<td>Spencer, Andrea E., M.D.</td>
<td>166</td>
</tr>
<tr>
<td>Sperber, Jacob, M.D.</td>
<td>71, 90</td>
</tr>
<tr>
<td>Sperry, Len, M.D.</td>
<td>144</td>
</tr>
<tr>
<td>Spiegel, David, M.D.</td>
<td>126</td>
</tr>
<tr>
<td>Spokes, Laima, M.D.</td>
<td>156</td>
</tr>
<tr>
<td>Spollen, John, M.D.</td>
<td>143</td>
</tr>
<tr>
<td>Spoth, Richard, Ph.D.</td>
<td>136</td>
</tr>
<tr>
<td>Sreepathi, Ananya R., M.D.</td>
<td>156</td>
</tr>
<tr>
<td>Sreshna, Nina E., M.D.</td>
<td>83</td>
</tr>
<tr>
<td>Srinivasan, Shilpa, M.D.</td>
<td>108, 142</td>
</tr>
<tr>
<td>Srinivasaragahvan, Jagannathan, M.D.</td>
<td>113</td>
</tr>
<tr>
<td>Stahl, Stephen M., M.D., Ph.D.</td>
<td>98, 100, 114, 127, 190, 197</td>
</tr>
<tr>
<td>State, Matthew, M.D.</td>
<td>74, 84</td>
</tr>
<tr>
<td>Stein, Aliza T., B.A.</td>
<td>126</td>
</tr>
<tr>
<td>Steinberg, Leah R., M.D.</td>
<td>166</td>
</tr>
<tr>
<td>Steinberg, Louisa J., M.D., Ph.D.</td>
<td>132</td>
</tr>
<tr>
<td>Stepp, Stephanie, Ph.D.</td>
<td>128</td>
</tr>
<tr>
<td>Sterling, Stacy, M.P.H., M.S.W.</td>
<td>90</td>
</tr>
<tr>
<td>Stern, Barry L., Ph.D.</td>
<td>127</td>
</tr>
<tr>
<td>Stern, Stephen L., M.D.</td>
<td>170</td>
</tr>
<tr>
<td>Stewart, Altha J., M.D.</td>
<td>85, 126</td>
</tr>
<tr>
<td>Stokes, Wesley N., Psy.D.</td>
<td>70</td>
</tr>
<tr>
<td>Stone, Alan, M.D.</td>
<td>113</td>
</tr>
<tr>
<td>Stone, Alice E., M.D.</td>
<td>174</td>
</tr>
<tr>
<td>Stotland, Nada L., M.D., M.P.H.</td>
<td>80, 107, 108, 129</td>
</tr>
<tr>
<td>Strain, James J., M.D.</td>
<td>127</td>
</tr>
<tr>
<td>Stratton, Tyler E., M.D.</td>
<td>138</td>
</tr>
<tr>
<td>Stubbeman, William F., M.D.</td>
<td>179</td>
</tr>
<tr>
<td>Stupinski, John, B.A.</td>
<td>156</td>
</tr>
<tr>
<td>St. Victor, Guitelle, M.D.</td>
<td>90, 112</td>
</tr>
<tr>
<td>Subedi, Jagannath, M.D.</td>
<td>170</td>
</tr>
<tr>
<td>Subhash, Ajith</td>
<td>174</td>
</tr>
<tr>
<td>Subramaniam, Geetha A., M.D.</td>
<td>90</td>
</tr>
<tr>
<td>Sudak, Donna M., M.D.</td>
<td>82, 117</td>
</tr>
<tr>
<td>Sugumaran, Archanai, M.B.B.S.</td>
<td>158</td>
</tr>
<tr>
<td>Suh, HwaGyu, M.D.</td>
<td>172</td>
</tr>
<tr>
<td>Sultan, Ryan S., M.D.</td>
<td>166</td>
</tr>
<tr>
<td>Summergrad, Paul, M.D.</td>
<td>80, 91, 108, 114, 135</td>
</tr>
<tr>
<td>Summers, Richard F., M.D.</td>
<td>113, 125</td>
</tr>
<tr>
<td>Sung, Dawn, M.D.</td>
<td>174</td>
</tr>
<tr>
<td>Sung II, Jung</td>
<td>179</td>
</tr>
<tr>
<td>Sung, Victor, M.D.</td>
<td>179</td>
</tr>
<tr>
<td>Suo, Shannon, M.D.</td>
<td>67</td>
</tr>
<tr>
<td>Suryadevara, Uma, M.D.</td>
<td>61</td>
</tr>
<tr>
<td>Susaimanickam, Bibiana M., M.B.B.S.</td>
<td>174</td>
</tr>
<tr>
<td>Susser, Leah, M.D.</td>
<td>156</td>
</tr>
<tr>
<td>Suzuki, Amanda, M.D.</td>
<td>159</td>
</tr>
<tr>
<td>Swann, Alan C., M.D.</td>
<td>179</td>
</tr>
<tr>
<td>Swanson, Jeff O., M.D.</td>
<td>110</td>
</tr>
<tr>
<td>Swartz, Marvin S., M.D.</td>
<td>82, 114, 132</td>
</tr>
</tbody>
</table>
Presenters Index

Swiggart, William H., M.S. ................................................. 99
Syed, Sharif ................................................................. 158
Szerman, Nestor, M.D. .................................................... 130

T

Tafet, Gustavo E., M.D., Ph.D. ........................................ 77
Takahashi, Hideotoshi, M.D., Ph.D. .............................. 170
Takayasu, Alexandra, M.D., M.P.H. ............................ 169
Talbott, John A., M.D. ..................................................... 78
Tamburello, Anthony ..................................................... 128
Tampi, Rajesh R., M.D., M.S. ......................................... 64, 160, 163
Tandon, Rajiv, M.D. ....................................................... 64
Tapia, Rafael E., M.D. ...................................................... 159
Tardelli, Vitor S., M.D. ..................................................... 174
Tarman, Daniel Drew, M.D., M.Eng. ............................. 179
Tarshis, Thomas P., M.D., M.P.H. ............................... 171
Taub-Schiff, Marlene, Ph.D. ......................................... 66
Taylor-Desir, Monica, M.D., M.P.H. ............................ 112
Taylor, Doug, M.B.A. ..................................................... 174
Taylor, Geoffrey P., M.D. ............................................... 83
Taylor, Jared K., M.D. ..................................................... 132
Taylor, Jerome H., M.D. ............................................... 101
Tegin, Cuneit, M.D. ....................................................... 156
Tendler, Aron, M.D. ...................................................... 179
Teo, Alan R., M.D., M.S. ............................................... 134
Thakrar, Tina S., M.D., M.B.A. ..................................... 174
Thangaraj, Swaminathan, D.O. .................................... 156
Thase, Michael E., M.D. ............................................... 60, 171
Thelen, Mindi ............................................................. 143
Thelen, Tim ................................................................. 143
Thiam, Melinda A., M.D. .............................................. 70
Thiara, Gurneet, S., M.D. .............................................. 60, 166
Thielman, Samuel, M.D., Ph.D. ................................. 144
Thomas, Anil A., M.D. ............................................... 62
Thomas, Christopher R., M.D. .................................... 113
Thomas, Connie, M.D. ............................................... 84
Thomas, Jean M., M.D. .................................................. 108
Thompson, Kenneth, M.D. ........................................ 80, 108, 129
Thompson, Sonda, M.S.N. ......................................... 70
Thompson, William W., Ph.D. .................................... 117
Tillman, Jane G., Ph.D. ............................................... 138
Timmons-Mitchell, Jane C., Ph.D. ............................... 126
Titcombe-Parekh, Roseann F., M.D., Ph.D. ................ 174
Tobkes, Taylor, M.D. ................................................... 157
Toledo, Theresa ......................................................... 134
Toll, Alba, M.D. .......................................................... 166
Torbey, Souraya, M.D. ................................................. 157, 159
Torous, John, M.D. ..................................................... 99, 112, 138
Torres Vilamaj, Imma, Psy.D., M.B.A., M.Sc. .............. 166
Trager, Evan J., M.D. .................................................... 174
Tran, David, M.D., M.P.P. ........................................... 166
Tran, Shelly T., M.D. .................................................... 159
Trestman, Robert L., M.D., Ph.D. ............................. 66, 88, 114, 128
Trevisan, Louis, M.D., M.Ed. ...................................... 64
Trimble, Michael, M.D. .............................................. 74, 75
Trivedi, Madhukar, M.D. ............................................. 144
Truong, Anh L., M.D. ................................................... 174

Tseng, Mei-Chih M., M.D., Ph.D. .................................. 171
Tsuang, John W., M.D. .............................................. 79
Tucci, Veronica, M.D., J.D. ......................................... 118
Tuck, Andrew N., B.Sc. ............................................. 179
Tucker, Phebe M., M.D. .............................................. 75, 179
Turkingdon, Douglas, M.D. ....................................... 60
Turner, Ana, Ph.D. ....................................................... 61
Turner, Andia H., B.Sc. ................................................. 160

U

Ucok, Alp, M.D. ........................................................... 179
Ulaj, Jusuf S., M.D. ..................................................... 145
Umrania, Hiren, M.D. .................................................. 179
Unützer, Jürgen, M.D., M.P.H. ................................. 135
Uzal Fernandez, Cristina, M.D. ................................ 163

V

Vaaler, Arne E., M.D., Ph.D. ......................................... 70
Van Ameringen, Michael, M.D. .................................. 171
Vanderlip, Erik, M.D., M.P.H. ...................................... 107, 132, 143
Vannucci, Adriana, M.D. .......................................... 171
Vargas Cruz, Cindy, M.D., M.B.A. .............................. 67
Varghese, Celia, M.D. .................................................. 157
Varlik, Cenk, M.D. ...................................................... 171
Vasan, Nina, M.D. ......................................................... 86
Vaughn, Rubaihna, M.D., M.P.H. .............................. 117
Vela, Ricardo M., M.D. ............................................... 109
Velliz, Philip, Ph.D. ..................................................... 136
Vemuri, Divya, M.D. .................................................... 157
Venigalla, Hema, M.B.B.S. ......................................... 174
Verdun, Marcia L., M.D. ............................................ 82
Vergare, Michael J., M.D. .......................................... 77
Verma, Chitrnanjan B., M.D. ....................................... 157
Vermetten, Eric, M.D., Ph.D. ..................................... 70
Vevera, Jan, M.D., Ph.D. .............................................. 179
Vieta, Eduard, M.D., Ph.D. ...................................... 131
Vijapura, Sagar, M.D. ................................................. 166
Vinacour, Carlos, M.D. ............................................. 171
Vinogradov, Sophia, M.D. ....................................... 107, 115
Vinson, Sarah Y., M.D. ............................................. 87, 127
Viswanathan, Ramaswamy, M.D. ............................ 113
Vito, Jose, M.D. .......................................................... 62
Vo, Lan Chi Krysti L., M.D. ....................................... 78
Volkow, Nora, M.D. ................................................... 69, 127
Volman, Susan F., Ph.D. ................................ .......... 62
von Hafften, Alexander H., M.D. ............................. 102
Vora, Ankita, M.D., M.P.H. ..................................... 157

W

Wager, Tor, Ph.D. ......................................................... 115
Wainberg, Milton, M.D. .......................................... 100
Waits, Wendi, M.D. ................................................... 82, 136, 146
Walszak, Art, M.D. ...................................................... 113
Waldman, Randee, M.D. ......................................... 87
Walker, Anita, L.C.S.W. ............................................. 104
Walker, Melissa, M.A. ............................................... 143
Walker, Sandra C., M.D. ............................................. 132

psychiatry.org/annualmeeting
Guide to the 2016 Annual Meeting
### Presenters Index

<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wallack, Joel J., M.D.</td>
<td>83</td>
</tr>
<tr>
<td>Walsh, B. Timothy, M.D.</td>
<td>80</td>
</tr>
<tr>
<td>Wang, Dana, M.D.</td>
<td>87</td>
</tr>
<tr>
<td>Wang, Dora, M.D., M.A.</td>
<td>107</td>
</tr>
<tr>
<td>Wang, Jack, D.O.</td>
<td>159</td>
</tr>
<tr>
<td>Wang, Paul, M.D.</td>
<td>78</td>
</tr>
<tr>
<td>Wang, Philip, M.D., Dr.P.H.</td>
<td>112, 128, 128, 86</td>
</tr>
<tr>
<td>Wang, Po, M.D.</td>
<td>80</td>
</tr>
<tr>
<td>Wang, Shao-Cheng, M.D., Ph.D.</td>
<td>166</td>
</tr>
<tr>
<td>Ward, Herbert, M.D.</td>
<td>100</td>
</tr>
<tr>
<td>Ward, Martha C., M.D.</td>
<td>112, 132, 179</td>
</tr>
<tr>
<td>Warner, Christopher H., M.D.</td>
<td>145</td>
</tr>
<tr>
<td>Warnick Jr., Stephen J., M.D.</td>
<td>126</td>
</tr>
<tr>
<td>Wasser, Tobias, M.D.</td>
<td>106, 118</td>
</tr>
<tr>
<td>Watson, Clarence</td>
<td>128</td>
</tr>
<tr>
<td>Webb, Allison, M.D.</td>
<td>65</td>
</tr>
<tr>
<td>Weber, Jenine, D.O.</td>
<td>158</td>
</tr>
<tr>
<td>Weililer, Emmanuelle</td>
<td>179</td>
</tr>
<tr>
<td>Wei, Mike, B.S.</td>
<td>146, 157</td>
</tr>
<tr>
<td>Weinberg, Igor</td>
<td>61</td>
</tr>
<tr>
<td>Weiner, Richard</td>
<td>99</td>
</tr>
<tr>
<td>Weine, Stevan M., M.D.</td>
<td>115, 116</td>
</tr>
<tr>
<td>Weinstock, Robert, M.D.</td>
<td>101, 114</td>
</tr>
<tr>
<td>Weintraub Brendel, Rebecca, M.D., J.D.</td>
<td>85, 104, 109</td>
</tr>
<tr>
<td>Weisensel, Nicolette, M.D.</td>
<td>145</td>
</tr>
<tr>
<td>Weiss, Catherine</td>
<td>179</td>
</tr>
<tr>
<td>Weisser, Lydia E., D.O., M.B.A.</td>
<td>105</td>
</tr>
<tr>
<td>Weiss, Kenneth J., M.D.</td>
<td>128</td>
</tr>
<tr>
<td>Weissman, Anna, M.D.</td>
<td>102</td>
</tr>
<tr>
<td>Weissman, Sidney, M.D.</td>
<td>145</td>
</tr>
<tr>
<td>Weiss, Roger D., M.D.</td>
<td>115, 130, 134</td>
</tr>
<tr>
<td>Weiss, Susan R. B., Ph.D.</td>
<td>69</td>
</tr>
<tr>
<td>Welch, Stephen, M.D.</td>
<td>61</td>
</tr>
<tr>
<td>Wendt, Burdette</td>
<td>179</td>
</tr>
<tr>
<td>Wertheimer, Moira, J.D., B.S.N.</td>
<td>132</td>
</tr>
<tr>
<td>Westermeyer, Joseph J., M.D., Ph.D.</td>
<td>65</td>
</tr>
<tr>
<td>West, Joyce C., Ph.D., M.P.P.</td>
<td>71, 107, 112, 116</td>
</tr>
<tr>
<td>West Jr., James C., M.D.</td>
<td>112</td>
</tr>
<tr>
<td>Westreich, Laurence, M.D.</td>
<td>104</td>
</tr>
<tr>
<td>White, Christopher, M.D.</td>
<td>174</td>
</tr>
<tr>
<td>White, Leigh, M.D.</td>
<td>76, 136</td>
</tr>
<tr>
<td>Wick, Paul H., M.D.</td>
<td>75, 107, 108</td>
</tr>
<tr>
<td>Wiechers, Ilse, M.D., M.H.S.</td>
<td>64</td>
</tr>
<tr>
<td>Wiegand, Hauke F., M.D., Ph.D.</td>
<td>174</td>
</tr>
<tr>
<td>Wigal, Sharon, Ph.D.</td>
<td>171</td>
</tr>
<tr>
<td>Wilcox, Marsha Ann, Ed.D., Sc.D.</td>
<td>82</td>
</tr>
<tr>
<td>Wilens, Timothy, M.D.</td>
<td>136</td>
</tr>
<tr>
<td>Wiles, Preston, M.D.</td>
<td>71, 136</td>
</tr>
<tr>
<td>Wilkins, Kirsten, M.D.</td>
<td>64</td>
</tr>
<tr>
<td>Wilkinson, Samuel, M.D.</td>
<td>85</td>
</tr>
<tr>
<td>Wilkins, Victoria, Ph.D.</td>
<td>126</td>
</tr>
<tr>
<td>Williams, Jill M., M.D.</td>
<td>88, 116</td>
</tr>
<tr>
<td>Williamson, Johnny, M.D.</td>
<td>108</td>
</tr>
<tr>
<td>Wills, Cheryl, M.D.</td>
<td>135</td>
</tr>
<tr>
<td>Winfrey, Chris, M.D.</td>
<td>78</td>
</tr>
<tr>
<td>Wininger, Bryce, M.D.</td>
<td>157</td>
</tr>
<tr>
<td>Winsberg, Mirene, M.D.</td>
<td>86</td>
</tr>
<tr>
<td>Winstead, Daniel K., M.D.</td>
<td>119</td>
</tr>
<tr>
<td>Winter, Christine A., D.O., M.B.A.</td>
<td>134</td>
</tr>
<tr>
<td>Wise, Thomas N., M.D.</td>
<td>135</td>
</tr>
<tr>
<td>Wiste, Anna K., M.D., Ph.D.</td>
<td>166</td>
</tr>
<tr>
<td>Wittenberg, Gayle M., Ph.D.</td>
<td>82</td>
</tr>
<tr>
<td>Witter, Daniel, M.D., Ph.D.</td>
<td>157</td>
</tr>
<tr>
<td>Wnuk, Susan, Ph.D.</td>
<td>66</td>
</tr>
<tr>
<td>Wolf, Jonathan P., M.D.</td>
<td>143</td>
</tr>
<tr>
<td>Wolf, Kari M., M.D.</td>
<td>84, 144</td>
</tr>
<tr>
<td>Wong, Donovan</td>
<td>86</td>
</tr>
<tr>
<td>Wonodi, Ikwunwa, M.B.B.S.</td>
<td>144</td>
</tr>
<tr>
<td>Woo, Benjamin, M.D.</td>
<td>144</td>
</tr>
<tr>
<td>Wood, Keith, M.D.</td>
<td>166</td>
</tr>
<tr>
<td>Woolley, Stephen, D.Sc.</td>
<td>84</td>
</tr>
<tr>
<td>Works, Lindsay, D.O.</td>
<td>166</td>
</tr>
<tr>
<td>Worley, Linda L., M.D.</td>
<td>99</td>
</tr>
<tr>
<td>Wrenn, Glenda, M.D.</td>
<td>61</td>
</tr>
<tr>
<td>Wright, Jesse H., M.D., Ph.D.</td>
<td>110, 166</td>
</tr>
<tr>
<td>Wu, Hanjing E., M.D., Ph.D.</td>
<td>160</td>
</tr>
<tr>
<td>Wynn, Gary H., M.D.</td>
<td>112</td>
</tr>
<tr>
<td>Xiang, Shuo, M.D.</td>
<td>163</td>
</tr>
<tr>
<td>Yager, Joel, M.D.</td>
<td>116</td>
</tr>
<tr>
<td>Yakov, Svetlana, M.D., Ph.D.</td>
<td>159</td>
</tr>
<tr>
<td>Yamamura, Kazuhiko, M.D., Ph.D.</td>
<td>170, 171</td>
</tr>
<tr>
<td>Yam, Philip Michael, M.D.</td>
<td>134</td>
</tr>
<tr>
<td>Yanovitch, Alan C., M.D.</td>
<td>171</td>
</tr>
<tr>
<td>Yang, Fang, M.D., Ph.D.</td>
<td>110, 166</td>
</tr>
<tr>
<td>Yang, Jong-Chul, M.D., Ph.D.</td>
<td>179</td>
</tr>
<tr>
<td>Yao, Lihua, M.Psy</td>
<td>126</td>
</tr>
<tr>
<td>Yap, Yen Ling, M.Sc.</td>
<td>163</td>
</tr>
<tr>
<td>Yaseen, Zimri S., M.D.</td>
<td>144</td>
</tr>
<tr>
<td>Yatham, Lakshmi, M.B.B.S.</td>
<td>179</td>
</tr>
<tr>
<td>Yeaw, Jennifer, Psy.D.</td>
<td>84</td>
</tr>
<tr>
<td>Ye, Chuanzhong, M.D., Ph.D.</td>
<td>171</td>
</tr>
<tr>
<td>Yehia, Baligh R.</td>
<td>142</td>
</tr>
<tr>
<td>Yehuda, Rachel, Ph.D.</td>
<td>70, 129</td>
</tr>
<tr>
<td>Yellowles, Peter, M.D.</td>
<td>102</td>
</tr>
<tr>
<td>Yeroms, Frank E., M.D.</td>
<td>79, 105, 118</td>
</tr>
<tr>
<td>Yin, Yingying, M.Med.</td>
<td>100</td>
</tr>
<tr>
<td>Yohanan, Monique, M.D., M.P.H.</td>
<td>110</td>
</tr>
<tr>
<td>Yohanna, Daniel, M.D.</td>
<td>145</td>
</tr>
<tr>
<td>Young, Allan H., M.D., Ph.D.</td>
<td>129</td>
</tr>
<tr>
<td>Young, John Q., M.D., M.P.H.</td>
<td>76, 90</td>
</tr>
<tr>
<td>Yousuf, Mohammad, M.D.</td>
<td>157</td>
</tr>
<tr>
<td>Yuen, Laura D., B.A.</td>
<td>166</td>
</tr>
<tr>
<td>Yue, Yingying, M.Med.</td>
<td>126</td>
</tr>
<tr>
<td>Yurgelen-Todd, Deborah, Ph.D.</td>
<td>62, 69</td>
</tr>
<tr>
<td>Yur’yev, Andriy, M.D., Ph.D.</td>
<td>134, 159</td>
</tr>
<tr>
<td>Zafar, Jawad, D.O.</td>
<td>160</td>
</tr>
<tr>
<td>Zafer, Maryam, M.S.</td>
<td>174</td>
</tr>
<tr>
<td>Zakers, Aleema, M.D., M.P.H.</td>
<td>117</td>
</tr>
</tbody>
</table>

---

Guide to the 2016 Annual Meeting
Presenters Index

Zalpuri, Isheeta, M.D. ....................................................... 76
Zanarini, Mary C., Ed.D. ........................................... 128, 135
Zarra, Julio C., M.D., Dr.PH ..................................... 179
Zeid, Dana ................................................................. 166
Zeller, Scott, M.D. ......................................................... 99
Zeng, Mary C., M.D. ....................................................... 102
Zerrate, Maria Carolina, M.D., M.H.S. .......................... 102
Zeshan, Muhammad, M.D. ......................................... 157
Zhan, Chang-Guo, Ph.D., M.Sc. ................................. 114
Zhang, Layan, M.B.B.S., M.S. ..................................... 166
Zhang, Tingting ............................................................. 171
Zhang, Yuqun ................................................................. 174
Zhong, Jun, M.D. ............................................................. 160
Zimmerman, Mark, M.D. ............................................. 76, 100, 107, 171
Zinns, Rachel, M.D., Ed.M. ....................................... 101
Zisook, Sidney, M.D. ....................................................... 70, 90, 129, 136
Zohar, Joseph, M.D. ....................................................... 127
Zonana, Howard, M.D. ................................................. 82
Zonana, Jess, M.D. ......................................................... 76
Zun, Leslie, M.D. ............................................................. 85, 99
Zuschlag, Zachary D., D.O. .......................................... 160
Women’s Brown Bag & Networking Lunch

**Sunday, May 15, 2016**
11:30 a.m. - 1:30 p.m.
Grand Ballroom B, M4, North Tower
Omni Atlanta Hotel at CNN Center

Women psychiatrists attending the APA Annual Meeting are cordially invited to join the Women’s Caucus for fellowship and conversation with a wonderful group of women colleagues from around the world and all career stages!

- Get advice from over fifteen prominent women psychiatrists on:
  - Building your career
  - Balancing your personal and professional roles
  - Taking your career in a different direction or to a new level
  - Negotiating salary, title, and more
  - Seeking national leadership in psychiatry
  - Building your practice
  - And more!

- Share your opinions with current and recently elected APA officials

- Meet residency and fellowship program directors from around the country

- Network with other women in your area who are looking for women colleagues to refer clients to

- Or just come by to relax, talk and make friends

*Be sure to bring your brown bag lunch!*
Introducing the New APA Meetings App.

Features:

- View sessions, schedule and speaker information
- Access an interactive exhibitor list and exhibit hall map
- View schedules for Component Meetings and Allied Professional Meetings
- Plan your time by selecting sessions and viewing “My Agenda”
- View an entire feed of event activity, including attendee updates, photos and more

Download: psychiatry.org/App

Apple and Google App Stores: Search for APA Meetings

App presented by: Alkermes™

Patient inspired®
FACING SCHIZOPHRENIA
VISIT BOOTH 937 TO ADVANCE THE CONVERSATION